

---

---

## **Therapeutic Class Overview**

### **Oral Atypical (Second-Generation) Antipsychotics**

#### **Therapeutic Class Overview/Summary:**

This overview will focus on the atypical antipsychotics, which are also known as second-generation antipsychotics (SGAs).<sup>1-14</sup> While several atypical antipsychotics are formulated as long-acting injections, these formulations will not be covered in this review. Antipsychotic medications have been used for over fifty years to treat schizophrenia and a variety of other psychiatric disorders.<sup>15</sup> Schizophrenia is believed to be caused by an increase in the cerebral activity of dopamine D<sub>2</sub> in the mesolimbic and/or mesocortical regions of the brain. Antipsychotic medications exert their effect in part by blocking D<sub>2</sub> receptors. It is the blockade of these receptors in the mesolimbic pathway that is believed to contribute to desired antipsychotic effects, especially improvement of positive symptoms associated with the disorder.<sup>16</sup>

In addition to blocking D<sub>2</sub> receptors in the mesolimbic pathway, FGAs also block D<sub>2</sub> receptors in the mesocortical, tuberoinfundibular, and nigrostriatal pathways.<sup>16</sup> D<sub>2</sub> blockade in these other pathways is thought to be responsible for the hyperprolactinemia and extrapyramidal symptoms (EPS) associated with this class.<sup>17</sup> FGAs may be characterized according to their affinity for the D<sub>2</sub> receptor. Low potency antipsychotics, such as chlorpromazine and thioridazine, are more sedating and associated with a higher incidence of anticholinergic side effects. Fluphenazine, haloperidol, pimozide, thiothixene, and trifluoperazine are high potency antipsychotics that are less sedating but associated with a higher incidence of EPS. The medium potency antipsychotics (loxapine, molindone, and perphenazine) possess a moderate risk of EPS and anticholinergic side effects.<sup>18</sup> With the exception of pimozide, all FGAs are indicated for use in the treatment of schizophrenia. FGAs are effective in the treatment of positive symptoms of schizophrenia, which include agitation, aggression, delusions, and hallucinations. Negative symptoms of schizophrenia which include avolition, anhedonia, alogia, affective flattening, and social withdrawal, do not respond as well to this antipsychotic class.<sup>17</sup> Pimozide is indicated only for the suppression of motor and phonic tics in patients with Tourette's disorder.

The term "atypical antipsychotic" was introduced in 1989 when clozapine was approved for use by the Food and Drug Administration (FDA). Originally, this term referred to an antipsychotic with a low risk of EPS.<sup>18</sup> As a class, SGAs or atypical antipsychotics are more selective in targeting the mesolimbic D<sub>2</sub> pathway. They also block or partially block serotonin (5-HT)<sub>2A</sub> and 5-HT<sub>1A</sub> receptors and have a greater affinity for 5-HT<sub>2</sub> receptors than D<sub>2</sub> receptors.<sup>16,18</sup> These differences in neuropharmacologic activity are associated with a lower risk of EPS and tardive dyskinesia; the risks vary with the specificity of each agent for D<sub>2</sub> and serotonin receptors.<sup>16,18</sup> Atypical antipsychotics have a more favorable outcome in the treatment of the negative symptoms of schizophrenia.<sup>16</sup> The SGAs are comprised of nine separate chemical entities, each with a unique neuropharmacologic and adverse event profile, mechanism of action, and chemical structure. The SGAs are aripiprazole, asenapine, brexpiprazole, clozapine, iloperidone, lurasidone, olanzapine, paliperidone, quetiapine, risperidone and ziprasidone.

Although in some respects the SGAs are safer and better tolerated than the FGAs, they are still associated with a number of serious risks and side effects. For this reason, the FDA has required various warnings to be inserted in the manufacturers' product information for these agents. All bear a warning that alerts prescribers and patients to the risk of hyperglycemia and other metabolic changes.<sup>1-14</sup> Ziprasidone also has a warning concerning QTc interval prolongation; however, all of the SGAs can increase the QTc interval to some degree.<sup>1-14</sup> Aripiprazole, brexpiprazole, lurasidone and quetiapine carry a black box warning regarding suicidality and antidepressant drugs.<sup>1,3,8,11,12</sup> All SGAs carry a black box warning noting that they are associated with an increased risk of death when used in the treatment of psychosis and behavioral problems in elderly patients with dementia. Most of the deaths that prompted the addition of the warning were due to cardiac-related events (e.g., heart failure or sudden death) or infection.<sup>21</sup> Of note, this last black box warning is directed at using antipsychotics in a manner that is not FDA-approved.

Due to the potential side-effect risks associated with these medications, any off-label use deserves close attention. Data published in peer-reviewed journals and in national and international guidelines support the use of SGAs as a treatment option for certain off-label uses. In many of these scenarios, SGAs are reserved for patients who are refractory to other first-line treatment modalities, including both pharmacotherapy and psychotherapy, and used in adjunction to mainstream therapies, as part of a multimodal approach.

Over the past 20 years, antipsychotic use in children and adolescents has grown. In the United States, the frequency of prescribing an antipsychotic agent increased from 8.6 per 1000 children in 1996 to 39.4 per 1000 children in 2002. According to a survey of national trends in the outpatient use of antipsychotics in children and adolescents, only 14.2% of antipsychotic prescriptions in children were for patients diagnosed with psychotic disorders.<sup>22</sup> Indications commonly associated with antipsychotic prescribing in pediatric patients include psychosis, schizophrenia, bipolar disorder, aggressive and disruptive behavior, and tic disorders. Off-label indications with limited available evidence for the use of atypical antipsychotics in children and adolescents include autistic spectrum disorders, major depressive disorder, anxiety disorders, and eating disorders. At this time, risperidone and aripiprazole are FDA-approved for the management of children and adolescents with autism (aged 5 to 16 and 6 to 17 years, respectively). Moreover, the following agents are indicated for the treatment of schizophrenia in adolescents: aripiprazole, olanzapine, paliperidone, quetiapine, and risperidone. Aripiprazole, asenapine, olanzapine, quetiapine and risperidone are FDA-approved for the treatment of manic or mixed bipolar I disorder in children and adolescents. None of the other available atypical antipsychotic agents are currently indicated for use in pediatric patients.<sup>1-14</sup>

Concerns have also been raised about the risks of combination therapy with the antipsychotics, which can multiply the risks of dangerous adverse events. The practice of polypharmacy is not supported by well-designed clinical trials published in the peer-reviewed literature. However, national and international consensus guidelines consider this approach in patients with treatment-refractory illness.

**Table 1. Current Medications Available in Therapeutic Class<sup>1-14</sup>**

Generic Name (Trade name)	Food and Drug Administration Approved Indications	Dosage Form/Strength	Generic Availability
Aripiprazole (Abilify <sup>®</sup> *, Abilify Discmelt <sup>®</sup> )	Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults; acute or maintenance treatment of manic or mixed episodes associated with bipolar I disorder in children and adolescents aged 10 to 17 years; adjunctive therapy to either lithium or valproate for the acute treatment of manic and mixed episodes associated with bipolar I disorder with or without psychotic features in adults and in pediatric patients aged 10 to 17 years; maintenance treatment of manic or mixed episodes associated with bipolar I disorder in adults; treatment of agitation associated with bipolar I disorder, manic or mixed in adults; acute and maintenance treatment of schizophrenia in adults; treatment of agitation associated with schizophrenia in adults; treatment of schizophrenia in adolescents aged 13 to 17; treatment of schizophrenia in adults; adjunctive treatment to antidepressants for major depressive disorder in adults; irritability associated with autistic disorder in children and adolescents aged six to 17 years	<u>Injection:</u> 7.5 mg/mL  <u>Orally disintegrating tablet:</u> 10 mg 15 mg  <u>Oral solution:</u> 1 mg/mL  <u>Tablet:</u> 2 mg 5 mg 10 mg 15 mg 20 mg 30 mg	a

Generic Name (Trade name)	Food and Drug Administration Approved Indications	Dosage Form/Strength	Generic Availability
Asenapine (Saphris®)	Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults or adolescents (10 to 17 years of age); adjunctive therapy to either lithium or valproate for the acute treatment of manic and mixed episodes associated with bipolar I disorder; acute and maintenance treatment of schizophrenia in adults	<u>Sublingual tablet:</u> 5 mg 10 mg	-
Brexpiprazole (Rexulti®)	Adjunctive treatment to antidepressants for major depressive disorder in adults; treatment of schizophrenia in adults	<u>Tablet:</u> 0.25 mg 0.5 mg 1 mg 2 mg 3 mg 4 mg	-
Clozapine (Fazaclo ODT®*, Clozaril®*, Versacloz®)	Reduction in the risk of recurrent suicidal behavior in schizophrenia or schizoaffective disorder in adults; treatment-resistant schizophrenia in adults	<u>Orally disintegrating tablet:</u> 12.5 mg 25 mg 100 mg 150 mg 200 mg  <u>Tablet:</u> 25 mg 50 mg 100 mg  <u>Suspension:</u> 50 mg/mL	a
Iloperidone (Fanapt®)	Treatment of schizophrenia in adults	<u>Tablet:</u> 1 mg 2 mg 4 mg 6 mg 8 mg 10 mg 12 mg	-
Lurasidone (Latuda®)	Treatment of schizophrenia in adults, treatment of depressive episodes associated with bipolar disorder in adults	<u>Tablet:</u> 20 mg 40 mg 80 mg 60 mg 120 mg	-
Olanzapine (Zyprexa®*, Zyprexa IM®*, Zyprexa Zydis®)	Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults; acute or maintenance treatment of manic or mixed episodes associated with bipolar I disorder in children and adolescents aged 10 to 17 years; adjunctive therapy to either lithium or valproate for the acute treatment of manic and mixed	<u>Injection:</u> 10 mg vials  <u>Orally disintegrating tablet:</u> 5 mg	a

Generic Name (Trade name)	Food and Drug Administration Approved Indications	Dosage Form/Strength	Generic Availability
	episodes associated with bipolar I disorder; maintenance treatment of manic or mixed episodes associated with bipolar I disorder in adults; treatment of agitation associated with bipolar I disorder, manic or mixed in adults; treatment of agitation associated with bipolar I mania in adults; treatment of depressive episodes associated with bipolar disorder in adults; acute and maintenance treatment of schizophrenia in adults; treatment of agitation associated with schizophrenia in adults; treatment of schizophrenia in adolescents aged 13 to 17; adjunctive treatment to antidepressants for major depressive disorder in adults	10 mg 15 mg 20 mg  <u>Tablet:</u> 2.5 mg 5 mg 7.5 mg 10 mg 15 mg 20 mg	
Paliperidone (Invega®*)	Acute and maintenance treatment of schizophrenia in adults; treatment of schizophrenia in adolescents aged 12 to 17; treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers and/or antidepressants in adults	<u>Extended-release tablet:</u> 1.5 mg 3 mg 6 mg 9 mg  <u>Suspension for IM injection:</u> 39 mg 78 mg 117 mg 156 mg 234 mg	a
Quetiapine (Seroquel®*, Seroquel XR®)	Maintenance treatment of bipolar I disorder as adjunct therapy to lithium or divalproex in adults; treatment of acute manic episodes associated with bipolar I disorder as either monotherapy or adjunct therapy to lithium or divalproex in adults; treatment of acute manic episodes associated with bipolar I disorder as either monotherapy or adjunct therapy to lithium or divalproex in children and adolescents aged 10 to 17 years; treatment of manic or mixed episodes associated with bipolar I disorder as either monotherapy or adjunct therapy to lithium or divalproex in adults; treatment of depressive episodes associated with bipolar disorder in adults; acute and maintenance treatment of schizophrenia in adults; treatment of schizophrenia in adolescents aged 13 to 17; treatment of schizophrenia in adults; adjunctive treatment to antidepressants for major depressive disorder in adults	<u>Extended-release tablet:</u> 50 mg 150 mg 200 mg 300 mg 400 mg  <u>Tablet:</u> 25 mg 50 mg 100 mg 200 mg 300 mg 400 mg	a
Risperidone (Risperdal®*, Risperdal M-Tab®*)	Adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder; maintenance treatment of bipolar I disorder as adjunct therapy to lithium or valproate in adults; short-term treatment of acute manic or mixed	<u>Orally disintegrating tablet:</u> 0.25 0.5 mg	a

Generic Name (Trade name)	Food and Drug Administration Approved Indications	Dosage Form/Strength	Generic Availability
	episodes associated with bipolar I disorder in adults and in children and adolescents aged 10 to 17 years; short-term treatment of acute mixed or manic episodes associated with bipolar I disorder in combination with lithium or valproate in adults; acute and maintenance treatment of schizophrenia in adults; treatment of schizophrenia in adolescents aged 13 to 17; irritability associated with autistic disorder in children and adolescents aged five to 16 years	1 mg 2 mg 3 mg 4 mg  <u>Oral solution:</u> 1 mg/mL  <u>Tablet:</u> 0.25 mg 0.5 mg 1 mg 2 mg 3 mg 4 mg	
Ziprasidone (Geodon®*)	Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults; maintenance treatment of bipolar I disorder as adjunct therapy to lithium or valproate in adults; treatment of acute manic or mixed episodes associated with bipolar disorder; treatment of agitation associated with schizophrenia in adults; treatment of schizophrenia in adults	<u>Capsule:</u> 20 mg 40 mg 60 mg 80 mg  <u>Injection:</u> 20 mg/mL	a

\*Generic available in at least one dosage form and/or strength.

### Evidence-based Medicine

- The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) was a large, multi-center study initiated by the National Institute of Mental Health to examine the effectiveness of second generation antipsychotics (SGAs) compared to first generation antipsychotics (FGAs) in patients with chronic schizophrenia.<sup>43-45</sup> Among the unexpected outcomes was the finding that, with the exception of clozapine, the SGAs did not separate out as robustly from the FGAs with respect to overall efficacy and times to treatment discontinuation.
  - Due to relatively high discontinuation rates across all treatment arms, potential biases regarding optimal dosing of individual drugs, and clear differences in treatment-emergent side effect profiles, the implications of CATIE are subject to interpretation which may preclude definitive guidance in developing pharmacotherapy guidelines for patients with schizophrenia as a whole.
- The role of the SGAs has been clearly established in the treatment of bipolar disorder and schizophrenia (and, in the case of aripiprazole, quetiapine extended-release and olanzapine/fluoxetine combination therapy, as adjunctive treatment of major depressive disorder).
- Meta-analyses evaluating the roles of available atypical antipsychotics in the treatment of schizophrenia suggest that all agents are significantly more effective than placebo.<sup>46-58,68-72</sup> The trends for respective efficacy suggest that clozapine is the most effective agent in the class, followed by olanzapine and risperidone. Aripiprazole tended to exhibit lower efficacy than the other agents.<sup>46-58,68-72</sup>
- A meta-analysis in adult patients with bipolar disorder found risperidone to be the most effective treatment option (taking into account both efficacy and tolerability).<sup>68</sup> The next best treatment options, in order of decreased efficacy, were olanzapine, haloperidol, quetiapine, carbamazepine, aripiprazole, valproate, lithium, and ziprasidone. Lamotrigine, topiramate and gabapentin were found to be less effective than placebo.
- In the management of major depressive disorder, aripiprazole, quetiapine, and risperidone augmentation therapies were associated with improved outcomes.<sup>77</sup>

- The efficacy and safety of brexpiprazole in the treatment of schizophrenia was demonstrated by two pivotal multicenter, randomized, double-blind, placebo controlled six week trials, VECTOR and BEACON.<sup>27,28</sup> Positive and Negative Syndrome Scale (PANSS) scores were significantly improved with brexpiprazole when compared to placebo. Treatment differences were -8.72 ( $P<0.0001$ ), -7.64 ( $P=0.0006$ ) and -6.47 ( $P=0.0022$ ) for brexpiprazole 2 mg, 4 mg, and 4 mg respectively.<sup>27,28</sup>
- The efficacy of asenapine in the treatment of schizophrenia in adults has been evaluated in four, published, randomized, double-blind, placebo-controlled, and active-controlled (haloperidol, risperidone, and olanzapine) trials, ranging in duration from six weeks to one year<sup>29-32</sup>. The efficacy and safety of asenapine in the treatment of manic or mixed bipolar I disorder were evaluated in five placebo-controlled, and active-controlled (olanzapine) studies in adult patients, with or without psychotic features.<sup>59-63</sup>
  - In a direct-comparison study, asenapine was less effective than olanzapine in terms of changes from baseline in PANSS and Clinical Global Impression-Severity of Illness (CGI-S) scores.<sup>32</sup> Study discontinuation due to inadequate efficacy was noted in 14% of patients receiving olanzapine compared to 25% of patients in the asenapine group. Mean weight gain was 0.9 kg with asenapine and 4.2 kg with olanzapine.<sup>32</sup> In another study, clinically significant weight gain was noted in 17% of patients receiving risperidone and 9% of patients in the asenapine group.<sup>29</sup>
  - In a pooled analysis of patients experiencing bipolar mania, asenapine and olanzapine were comparable in terms of reduction from baseline in Young Mania Rating Scale (YMRS) scores at week-52 of therapy.<sup>63</sup>
  - A meta-analysis of various antimanic therapy options, found that asenapine was associated with a statistically significant improvement in YMRS scores from baseline compared to placebo (mean difference, -0.30; -0.53 to -0.07), though it was less effective compared to olanzapine (0.22; 0.08 to 0.37).<sup>68</sup>
- Iloperidone has been studied as monotherapy for the treatment of adult patients with an acute or subacute exacerbation of schizophrenia.
  - Three six-week, randomized, double-blind, placebo- and active comparator (risperidone and haloperidol)-controlled studies found iloperidone to be significantly more effective than placebo.<sup>34</sup>
  - One four-week, placebo- and active- comparator (ziprasidone)-controlled study found a significant improvement in PANSS scores with iloperidone therapy compared to placebo.<sup>33</sup>
- Lurasidone has been investigated for the treatment of adult patients with acute and chronic symptoms of schizophrenia in two six-week, placebo-controlled studies and two 21-day studies directly comparing the safety and efficacy of lurasidone 120 mg once daily with ziprasidone 80 mg twice daily.<sup>39-42</sup>
  - Lurasidone and ziprasidone were comparable in terms of reduction in total PANSS, PANSS positive symptom, PANSS general symptom, CGI-S scores and several cognition scales.<sup>41-42</sup> In addition, both drugs were comparable in terms of rates of discontinuation for any reason rate and discontinuation due to adverse events.<sup>40,41</sup> Both therapies were associated with a small weight loss from baseline and neither therapy was associated with a clinically significant ECG abnormality.
  - Of note, lurasidone was more effective in improving negative symptom PANSS scores compared to ziprasidone ( $P=0.046$ ).<sup>41</sup>
- Available evidence suggests that, except for clozapine, olanzapine is associated with greater weight gain compared to all other atypical antipsychotic agents. In contrast, ziprasidone is associated with a low incidence of weight gain.<sup>214</sup>
- Data from the Food and Drug Administration Adverse Reporting System (AERS) indicates that the risk of experiencing a diabetes-related adverse event is greatest with olanzapine, followed by risperidone, and least with ziprasidone and aripiprazole, across all age groups.<sup>243</sup>
- Risperidone is associated with the greatest risk of prolactin elevation-related adverse events.<sup>46-58,68-72,260</sup>

- Risperidone, aripiprazole and ziprasidone are associated with a high incidence of extrapyramidal adverse events.<sup>222</sup> Quetiapine is associated with the least risk of extrapyramidal adverse events.<sup>222</sup>
- The incidence of sexual dysfunction was noted to be higher with the use of olanzapine, risperidone, and clozapine than with quetiapine, ziprasidone or aripiprazole.<sup>226</sup>
- The Agency of Healthcare Research and Quality (AHRQ) is the lead federal agency for research on healthcare quality, costs, outcomes and patient safety. In 2011, AHRQ had issued an update to a prior 2007 review of scientific evidence on the safety and effectiveness of atypical antipsychotics for off-labeled use.<sup>78, 189</sup>
  - Indications associated with moderate/high strength of evidence for the use of atypical antipsychotics included general anxiety disorder (quetiapine), dementia (aripiprazole, olanzapine, risperidone), depression (aripiprazole, quetiapine, risperidone), augmentation of selective serotonin reuptake inhibitors for obsessive compulsive disorder [OCD] (risperidone), and post-traumatic stress disorder [PTSD] (risperidone).<sup>89</sup> Refer to Appendices IIa and IIb for additional details.
- The AHRQ had conducted a systematic review of literature on the safety and efficacy of antipsychotics in children and adolescents.<sup>95,96</sup> For details, refer to Appendices IIIa and IIIb.
  - Indications associated with moderate strength evidence for the use of atypical antipsychotics included disruptive behavior disorder, bipolar disorder, schizophrenia, and Tourette's syndrome.
  - No significant differences between the different atypical antipsychotics were noted in the identified head-to-head comparisons.
  - The risks of weight gain (weight gain: 4.6 kg) and dyslipidemia were highest with olanzapine. Weight gain with ziprasidone was not significantly different from placebo. The other atypical antipsychotics were associated with intermediate weight gain.
  - Risperidone was associated with the greatest incidence of prolactin-related adverse events (consistent with adult data).
  - Extrapyramidal adverse events were significantly more common with risperidone and aripiprazole compared to placebo.
- According to a systematic review by Safer et al, weight gain secondary to atypical antipsychotics is greater in children and adolescents than in adults.<sup>257</sup>

### Key Points within the Medication Class

- According to Current Clinical Guidelines:
  - Antipsychotics are a mainstay in therapy for schizophrenia.<sup>306-308</sup>
  - Lithium, valproate and/or antipsychotics are recommended as initial therapy of bipolar disorder.<sup>293-296</sup>
  - The American Psychiatric Association guideline recommends the use of antipsychotics for the management of psychosis or agitation in patients with dementia.<sup>297</sup>
  - For the treatment of anxiety disorders, sertraline is recommended as a first-line pharmacotherapeutic agent.<sup>291,292</sup> Second-line treatment options include serotonin norepinephrine reuptake inhibitors (SNRIs) or switching to alternative selective serotonin reuptake inhibitors (SSRIs). Augmentation therapy with antipsychotics is an option in treatment-refractory patients but the guidelines recommend that initiation of combination therapy be limited to specialists.
  - In major depressive disorder, first-line treatment options include SSRIs, SNRIs, bupropion or mirtazapine.<sup>300-302</sup> Antipsychotic augmentation therapy is an option for patients who have failed antidepressant monotherapy.
  - In obsessive compulsive disorder, SSRIs and cognitive behavioral therapy are recommended as first-line treatment options.<sup>303</sup> Patients who have failed an SSRI trial may be offered augmentation therapy with an antipsychotic or cognitive behavioral therapy. Similarly, SSRIs and SNRIs are considered to be first-line treatment options for the treatment of post-traumatic stress disorder (PTSD).<sup>304,305</sup>
  - Atypical antipsychotics may be used as adjunctive therapy for the management of treatment-refractory PTSD.

- The European Society for the Study of Tourette Syndrome guideline recommends risperidone as a first-line agent for the treatment of tics.<sup>319</sup> Aripiprazole has a role in treatment-refractory patients.
- The American Academy of Child and Adolescent Psychiatry (AACAP) guideline acknowledges that atypical antipsychotics are the most commonly prescribed class of drugs for the treatment of maladaptive aggression, regardless of diagnosis; yet emphasize that pharmacotherapy should not be used as the only intervention in children with oppositional defiant disorder.<sup>314</sup>
- Although the antipsychotics are not addressed in national and international insomnia treatment guidelines, the National Institute of Health (NIH) Consensus and State-of-the-Science Statement on Manifestations and Management of Chronic Insomnia in Adults state that due to the lack of evidence supporting the short and long term efficacy of antipsychotics, in addition to their significant risks, their use in the treatment of chronic insomnia cannot be recommended.<sup>321</sup>
- In a practice guideline on the use of atypical antipsychotics in children and adolescents, issued by the AACAP in 2011, the panel recommends that prior to initiation of antipsychotic therapy patients should undergo a thorough diagnostic assessment, evaluation for comorbid medical conditions and concomitant medications.<sup>319</sup> Furthermore, a multidisciplinary plan that includes education and psychotherapy should be established. The prescriber should also have a thorough discussion of the risks and benefits of psychotropic medication.
- Of the atypical antipsychotics, risperidone is recognized as an agent with the most substantial amount of methodologically stringent evidence for use in pediatric patients.<sup>319</sup>
- There is almost no data to support the use of atypical antipsychotics in pre-school aged children.<sup>319</sup> The guideline recommends a marked amount of caution before using these agents in pre-schoolers.
- Given the risk of metabolic side-effects, pediatric patients receiving atypical antipsychotic therapy should be closely monitored for changes in weight, blood pressure, fasting plasma glucose and lipid profile.<sup>319</sup>

**Table 2. Evidence for the Use of Atypical Antipsychotics in Pediatrics (2011 AACAP guideline)<sup>308</sup>**

	Clozapine	Risperidone	Olanzapine	Quetiapine	Ziprasidone	Aripiprazole
Schizophrenia/ Psychosis	+++	+++*	++++*	++++*	+	++++*
Bipolar Disorder	++	+++*	+++*	++++*	+++	+++*
Disruptive behavior disorders/ Aggression	++	+++	+++	++	+	+
Autism/ PDD irritability	+	++++*	+++	+	+	++++*
Tourette's/tics		++++	+		+++	
PTSD	+					
Eating Disorder			+			
Long-term safety studies		+		+		

PDD=pervasive developmental disorder; PTSD=post-traumatic stress disorder

++++ Multiple randomized controlled studies

+++ One randomized controlled study

++ Uncontrolled study

+ Case studies

\* FDA approved in children and/or adolescents

· Other Key Facts:



- Paliperidone is an active metabolite of risperidone and therefore carries some similarity in chemical structure and pharmacologic effects with the parent drug.
- The use of clozapine is limited due to a risk of agranulocytosis.
- Aripiprazole, clozapine, olanzapine, paliperidone, quetiapine, risperidone and ziprasidone are available generically.

**Appendix I: Summary of the Strength of Evidence for Off-Label Efficacy Outcomes (adopted from 2011 AHRQ systematic review)<sup>189</sup>**

Indication	Strength of Evidence	Findings	Conclusions
<b>Dementia</b>	<b>High</b>	<p>The 2011 meta-analysis of PCTs, aripiprazole, olanzapine, and risperidone were superior to placebo as treatment of behavioral symptoms as measured by total scores on BEHAVE-AD, BPRS, and NPI. Effect sizes were generally considered to be “small” in magnitude.</p> <p>Psychosis –risperidone was superior to placebo, as measured by the psychosis subscales of the BEHAVE-AD, BPRS, and NPI. Results for aripiprazole did not meet conventional levels of statistical significance.</p> <p>Agitation – Aripiprazole, olanzapine and risperidone were superior to placebo, as measured by the agitation subscales of the BEHAVE-AD, BPRS, NPI, and CMAI.</p> <p>Three head to head trials compared atypicals; none was found superior.</p>	Aripiprazole, olanzapine, and risperidone <b>have efficacy</b> as treatment for behavioral symptoms of dementia.
<b>Depression</b> <i>Augmentation of SSRI/SNRI</i>	<p><b>Moderate</b> (risperidone, aripiprazole, quetiapine)</p> <p><b>Low</b> (olanzapine, ziprasidone)</p>	The meta-analysis used “response” to treatment and remission as outcome. Pooling trials that reported the HAM-D as outcome, the relative risk of responding for participants taking quetiapine or risperidone was significantly higher than for placebo. Other trials reported MADRS scores; the relative risk of responding for participants taking aripiprazole was significantly higher than those taking placebo. Risperidone was included in two trials. These reported the drug	Aripiprazole, quetiapine, and risperidone <b>have efficacy</b> as augmentation to SSRIs/SNRIs for major depressive disorder.  Olanzapine and ziprasidone <b>may also have efficacy</b> .

Indication	Strength of Evidence	Findings	Conclusions
		<p>superior to placebo. The relative risk of responding for participants taking aripiprazole was significantly higher than those taking placebo.</p> <p>Olanzapine had only two trials, so pooling was not performed; the trials reported olanzapine superior to placebo.</p> <p>In one available ziprasidone trial, the drug was superior to placebo in terms of MADRS scores. One trial compared ziprasidone at differing levels augmenting sertraline to sertraline alone. This trial found a greater improvement in CGI-S and MADRS scores augmenting with ziprasidone at 160mg than either augmentation with ziprasidone at 80mg or sertraline alone. However, there was no significant difference in HAMD-17, CGI-I or HAM-A scores.</p>	
<b>Monotherapy</b>	<b>Moderate</b>	<p>Olanzapine alone was no better than placebo in improving symptoms at six or 12 weeks in three trials. Outcomes were too heterogeneous to allow pooling.</p> <p>In five PCTs, quetiapine was superior according to relative risk of both responding and remitted as measured by MADRS.</p>	<p>Olanzapine <b>does not have efficacy</b> as monotherapy for major depressive disorder.</p> <p>Quetiapine <b>has efficacy</b> as monotherapy for major depressive disorder</p>
<b>Obsessive Compulsive Disorder (OCD)</b>			
<b>Augmentation of SSRIs</b>	<p><b>Moderate</b> (risperidone)</p> <p><b>Low</b> (olanzapine)</p>	<p>The 2006 meta-analysis pooled results of nine trials of risperidone, olanzapine, or quetiapine as augmentation therapy in patients who were resistant to treatment with SSRI. Atypical antipsychotics had a clinically important benefit, (measured by the Yale-Brown Obsessive-Compulsive Scale (YBOCS), when used as augmentation therapy. Relative risk of “responding” significant for augmentation with quetiapine and risperidone.</p>	<p>Risperidone <b>has efficacy</b> in improving OCD symptoms when used as an adjunct to SSRI in treatment refractory patients.</p> <p>Olanzapine <b>may have efficacy</b>.</p> <p>Quetiapine is more <b>efficacious</b> than ziprasidone and clomipramine.</p>

Indication	Strength of Evidence	Findings	Conclusions
		<p>The updated 2011 meta-analysis found risperidone superior to placebo, as measured by changes in the Y-BOCS.</p> <p>There were too few studies (two) of olanzapine augmentation to permit separate pooling of this drug. Both trials reported olanzapine superior to placebo.</p> <p>One new head to head trial found no difference in effect between olanzapine and risperidone as SSRI augmentation. One new head to head trial found quetiapine more effective than ziprasidone as SSRI augmentation. In one new trial, quetiapine produced a significant reduction in Y-BOCS score, while clomipramine did not.</p>	
<b>Augmentation of citalopram</b>	<p><b>Low</b> (quetiapine)</p> <p><b>Very low</b> (risperidone)</p>	<p>One trial of risperidone reported no differences between groups in achieving a response to therapy, but patients maintained on risperidone had a significantly longer period of time to relapse compared to placebo (102 vs 85 days).</p> <p>Two trials found quetiapine superior to placebo as augmentation for citalopram, according to Y-BOCS and CGI-I scores.</p>	<p>Quetiapine and risperidone <b>may be efficacious</b> as augmentation to citalopram in OCD patients.</p>
<b>Post-Traumatic Stress Disorder</b>	<p><b>Moderate</b> (risperidone)</p> <p><b>Low</b> (Olanzapine)</p> <p><b>Very Low</b> (Quetiapine)</p>	<p>Three trials enrolled men with combat-related PTSD; these showed a benefit in sleep quality, depression, anxiety, and overall symptoms when risperidone or olanzapine was used to augment therapy with antidepressants or other psychotropic medication.</p> <p>Three trials of olanzapine or risperidone as monotherapy for abused women with PTSD were inconclusive regarding efficacy.</p> <p>One trial found a three-fold decline in PTSD Scale (CAPS) scores in</p>	<p>Risperidone is <b>efficacious</b> in reducing combat-related PTSD symptoms when used as an adjunct to primary medication.</p>

Indication	Strength of Evidence	Findings	Conclusions
		<p>patients treated with quetiapine monotherapy compared to placebo.</p> <p>There were too few olanzapine studies (two) to pool; one reported olanzapine superior to placebo, while one did not.</p> <p>A meta-analysis of risperidone, using CAPS scores as outcome, found risperidone to be superior to placebo.</p> <p>In a meta-analysis by condition, atypical antipsychotics were efficacious for combat-related PTSD but not PTSD in abused women.</p>	
<b>Personality Disorders</b>			
<b>Borderline</b>	<p><b>Low</b> (aripiprazole)</p> <p><b>Very low</b> (quetiapine, olanzapine)</p>	<p>Four trials provide evidence that olanzapine is superior to placebo and may be superior to fluoxetine. The benefit of adding olanzapine to dialectical therapy in one trial was small. Two trials of olanzapine found no difference from placebo in any outcomes compared to placebo.</p> <p>Aripiprazole was superior to placebo in one small trial. Another trial found aripiprazole superior to placebo in improving SCL-90, HAM-D, and HAM-A scores at 8 months and less self-injury at 18 months.</p> <p>A trial of ziprasidone found no significant difference in CGI-BPD, depressive, anxiety, psychotic or impulsive symptoms compared to placebo at 12 weeks.</p> <p>One trial found quetiapine to be superior to placebo on BPRS and PANSS scales.</p> <p>Due to heterogeneity of outcomes, a meta-analysis could not be performed.</p>	<p>Olanzapine had <b>mixed results</b> in seven trials, aripiprazole was found <b>efficacious</b> in two trials, quetiapine was found <b>efficacious</b> in one trial, and ziprasidone was found <b>not efficacious</b> in one trial.</p>
<b>Schizotypal</b>	<b>Low</b>	Risperidone was superior to	Risperidone had <b>mixed</b>

Indication	Strength of Evidence	Findings	Conclusions
		placebo in one small trial. In another trial risperidone was found to be no different from placebo on a cognitive assessment battery.	<b>results</b> when used to treat schizotypal personality disorder in two small trials.
<b>Tourette's Syndrome</b>	<b>Low</b>	Risperidone was superior to placebo in one small trial, and it was at least as effective as pimozide or clonidine for eight to 12 weeks of therapy in the three other trials. One trial of ziprasidone showed variable efficacy compared to placebo.	Risperidone <b>is at least as efficacious as pimozide or clonidine</b> for Tourette's syndrome.
<b>Anxiety</b>	<b>Moderate</b>	Three placebo-controlled trials of quetiapine as monotherapy for Generalized Anxiety Disorder (GAD) could be pooled; relative risk of responding on HAM-A favored the quetiapine group.  One head to head trial showed no difference between risperidone and paroxetine on HAM-A score improvement. One trial each found quetiapine equally effective as paroxetine and escitalopram.	Quetiapine <b>has efficacy</b> as treatment for Generalized Anxiety Disorder.
<b>Attention Deficit/Hyperactivity Disorder</b>			
<b>No comorbidity</b>	<b>Low</b>	One trial showed risperidone superior to placebo in reducing scores on the Children's Aggression Scale-Parent version (CAS-P).	Risperidone <b>may be efficacious</b> in treating children with ADHD with no serious co-occurring disorders.
<b>Mental retardation</b>	<b>Low</b>	One trial showed risperidone led to greater reduction in SNAP-IV (Swanson, Nolan, and Pelham teacher & parent rating scale) scores than methylphenidate.	Risperidone <b>may be superior to methylphenidate</b> in treating ADHD symptoms in mentally retarded children.
<b>Bipolar</b>	<b>Low</b>	Two trials of aripiprazole showed no effect on SNAP-IV (Swanson, Nolan, and Pelham teacher & parent rating scale) scores than placebo.	Aripiprazole is <b>inefficacious</b> in reducing ADHD symptoms in children with bipolar disorder.
<b>Eating Disorders</b>	<b>Moderate</b> (olanzapine)  <b>Low</b> (quetiapine)	In a pooled analysis of three trials, there was no difference in change in BMI at either one or three months with olanzapine compared to placebo.  One trial of quetiapine reported no statistical difference from placebo in BMI increase at three months.	Olanzapine and quetiapine <b>have no efficacy</b> in increasing body mass in eating disorder patients.

Indication	Strength of Evidence	Findings	Conclusions
<b>Insomnia</b>	<b>Very Low</b>	In one small trial (N=13) of quetiapine, sleep outcomes were not statistically different from placebo.	Quetiapine may be <b>inefficacious</b> in treating insomnia.
<b>Substance Abuse</b>			
<b>Alcohol</b>	<b>Moderate</b> (aripiprazole)  <b>Low</b> (quetiapine)	Two trials of aripiprazole and one of quetiapine reported percentage of patients completely abstinent during follow-up. In a pooled analysis, the effect vs placebo was insignificant.	Aripiprazole is <b>inefficacious</b> in treating alcohol abuse/dependence. Quetiapine may also be <b>inefficacious</b> .
<b>Cocaine</b>	<b>Low</b>	Two trials of olanzapine and one of risperidone reported there was no difference in efficacy vs placebo as measured by the Addiction Severity Index (ASI).	Olanzapine is <b>inefficacious</b> in treating cocaine abuse/dependence. Risperidone may also be <b>inefficacious</b> .
<b>Methamphetamine</b>	<b>Low</b>	One trial found aripiprazole inefficacious in reducing use of intravenous amphetamine, as measured by urinalysis. Another trial found aripiprazole inefficacious in reducing craving for methamphetamine.	Aripiprazole is <b>inefficacious</b> in treating methamphetamine abuse/dependence.
<b>Methadone</b>	<b>Low</b>	One trial of methadone-treated patients found no difference between risperidone and placebo in reduction of cocaine or heroin use.	Risperidone is an <b>inefficacious</b> adjunct to methadone maintenance

ADHD=attention-deficit hyperactivity disorder; BEHAVE-AD=Behavioral Pathology in Alzheimer's Disease Scale; BPRS=Brief Psychiatric Rating Scale; CGI-BPD=Clinical Global Impression Scale for Borderline Personality Disorder; CGI-I=Clinical Global Impression Improvement; CGI-S=Clinical Global Impression-Severity; CMAI =Cohen-Mansfield Agitation Inventory; HAM-A = Hamilton Anxiety Scale; HAM-D=Hamilton Depression Rating Scale; MADRS=Montgomery-Asberg Depression Rating Scale; MDD=major depressive disorder; NPI=Neuropsychiatric Inventory; OCD=obsessive-compulsive disorder; PANSS=Positive and Negative Syndrome Scale; PCT=placebo-controlled trial; PTSD=post-traumatic stress disorder; SSRI=selective serotonin reuptake inhibitor; SNRI=serotonin-norepinephrine reuptake inhibitors; ZAN-BPD=Zanarini Rating Scale for Borderline Personality Disorder

#### Appendix II: Summary of Adverse Events of Atypical Antipsychotics for Off-Label Use (adopted from 2011 AHRQ systematic review)<sup>189</sup>

Adverse Event	Head-to-Head Studies	Active Comparator Studies	Placebo-Controlled Studies
<b>Weight Gain</b>			
<b>Elderly</b>	In one large trial (CATIE-AD) patients who were treated with olanzapine, quetiapine, or risperidone averaged a monthly gain of 1.0, 0.7, and 0.4 lbs respectively,	More common in patients taking olanzapine than risperidone or conventional antipsychotics, particularly if their BMI was less than 25 at baseline, according to	According to the meta-analysis, more common in patients taking olanzapine and risperidone than placebo.

Adverse Event	Head-to-Head Studies	Active Comparator Studies	Placebo-Controlled Studies
	compared to a monthly weight loss of 0.9 lbs for placebo patients.	a large cohort study.	
<b>Adults</b>	More common in olanzapine patients than ziprasidone patients in one trial.	More common among patients taking olanzapine than patients taking conventional antipsychotics in three trials. More common in patients taking aripiprazole than patients taking conventional antipsychotics in one trial. More common among patients taking olanzapine than patients taking mood stabilizers in two trials.	According to the meta-analysis, more common in patients taking aripiprazole, olanzapine, quetiapine, and risperidone than placebo.
<b>Children/Adolescents</b>	No head to head studies	No difference between clonidine and risperidone in one trial.	More common in patients taking risperidone in two PCTs. No difference in one small PCT of ziprasidone.
<b>Mortality-in the elderly</b>	No difference between olanzapine and risperidone according to a meta-analysis of six trials of olanzapine published in 2006.	Six large cohort studies compared mortality in elderly patients taking atypical and conventional antipsychotics. Four of these studies found a significantly higher rate of death with conventional antipsychotics, while two found no statistical difference in mortality between the drug classes.	The difference in risk for death was small but statistically significant for atypicals, according to a 2006 meta-analysis which remains the best available estimate. Sensitivity analyses found no difference between drugs in the class. Patients taking atypicals had higher odds of mortality than those taking no antipsychotics in the two cohort studies that made that comparison. There are no trials or large observational studies of ziprasidone in this population.
<b>Endocrine</b>			
<b>Elderly</b>	No evidence reported	No evidence reported	No difference in endocrine events in

Adverse Event	Head-to-Head Studies	Active Comparator Studies	Placebo-Controlled Studies
			risperidone patients in one PCT. Regarding diabetes, risk was elevated but not statistically significant in one industry-sponsored cohort study of olanzapine patients.
<b>Adults</b>	Diabetes more common in patients taking olanzapine than patients taking risperidone in one trial.	No evidence reported	<p>Endocrine events more common in patients taking quetiapine, risperidone, and ziprasidone in one PCT each. More common in olanzapine in two pooled PCTs.</p> <p>Diabetes more common in patients taking quetiapine in six pooled PCTs; however, the pooled odds ratio was elevated at 1.47 but not statistically significant. More common in olanzapine patients in one PCT; the odds ratio of 5.14 was not statistically significant, with very wide confidence intervals (0.6 to 244). Lower odds of diabetes in risperidone patients in one large observational study.</p>
<b>Cerebrovascular Accident (CVA)</b>	No evidence reported	Hospitalization for CVA was increased in the first week after initiation of typical antipsychotics, but not for initiation of atypicals in a large cohort study.	More common in risperidone patients than placebo according to four PCTs pooled by the manufacturer. In a meta-analysis of PCTs, risperidone was the only drug associated with an increase. More common in olanzapine than placebo according to five PCTs pooled by the manufacturer.
<b>Extrapyramidal Symptoms (EPS)</b>			
<b>Elderly</b>	More common in patients taking aripiprazole and	No evidence reported	More common in patients taking risperidone, according to the meta-



Adverse Event	Head-to-Head Studies	Active Comparator Studies	Placebo-Controlled Studies
	risperidone patients than patients taking quetiapine in one large trial (CATIE-AD).		analysis. Quetiapine and aripiprazole were not associated with an increase.  More common in olanzapine in one PCT.
<b>Adults</b>	No evidence reported	Less likely in patients taking quetiapine than mood stabilizers in one small trial. Less likely in patients taking olanzapine or aripiprazole than patients taking conventional antipsychotics in one trial each.	More common in patients taking aripiprazole, quetiapine, and ziprasidone than placebo according to the meta-analysis.
<b>Sedation</b>			
<b>Elderly</b>	More common in elderly patients taking olanzapine or quetiapine than risperidone according to the meta-analysis, but not statistically significant.	No difference in one trial of olanzapine vs benzodiazepines. No difference in three trials of olanzapine and three of risperidone vs conventional antipsychotics.	More common in patients taking aripiprazole, olanzapine, quetiapine, and risperidone than placebo according to the meta-analysis.
<b>Adults</b>	More common in patients taking quetiapine than risperidone in two trials.  No difference in one trial of risperidone vs olanzapine.	Olanzapine patients had higher odds than mood stabilizer patients in two trials.  More common in olanzapine and quetiapine patients than SSRIs patients in three and two trials respectively.  Olanzapine patients had lower odds than patients taking conventional antipsychotics in the pooled analysis of three trials.	More common in patients taking aripiprazole, olanzapine, quetiapine, risperidone, and ziprasidone than placebo in the meta-analysis.
<b>Children/Adolescents</b>	No head-to-head trials	No difference in one small trial of clonidine vs risperidone. More patients on haloperidol than risperidone reported sleep	Less common in aripiprazole patients than placebo patients in one PCT. No difference from placebo in one small PCT of ziprasidone.

Adverse Event	Head-to-Head Studies	Active Comparator Studies	Placebo-Controlled Studies
		problems in one trial.	

BMI=body mass index; CATIE-AD=Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer's Disease; CVA=cerebrovascular accident; EPS=extrapyramidal symptoms; PCT=placebo-controlled trial; SSRI=serotonin selective reuptake inhibitor

### Appendix III: Summary of the Strength of Evidence for Efficacy Outcomes in Children and Adolescents (adopted from the 2012 AHRQ systematic review)<sup>96</sup>

Outcome	Comparison (# of studies)	Strength of Evidence	Summary
<b><i>Pervasive developmental disorder</i></b>			
Autistic symptoms	FGA vs SGA (2 RCTs)	Low	No significant difference
	SGA vs placebo (7 RCTs)	Low	Significant effect in favor of SGA on ABC (MD, 218.3; 95% CI, 227.1 to 29.5; I2, 79.6%); CARS (MD, 24.9; 95% CI, 28.5 to 21.4; I2, 64%).
CGI	SGA vs placebo (3 RCTs)	Low	No significant difference
OC symptoms	SGA vs placebo (3 RCTs)	Low	Significant effect in favor of SGA (MD, 21.7; 95% CI, 23.2 to 20.3; I2, 49%).
Medication adherence	SGA vs placebo (2 RCTs)	Low	No significant difference
<b><i>Disruptive behavior disorder</i></b>			
Aggression	SGA vs placebo (5 RCTs)	Low	No significant difference
Anxiety	SGA vs placebo (4 RCTs)	Low	No significant difference
Behavior symptoms	SGA vs placebo (7 RCTs)	Moderate	Significant effect in favor of SGA for ABC (MD, 221.0; 95% CI, 231.1 to 210.8; I2, 62%); BPI (MD, 23.8; 95% CI, 26.2 to 21.4; I2, 0%); NCBRF (MD, 26.9; 95% CI, 210.4 to 23.5; I2, 62%).
CGI	SGA vs placebo (7 RCTs)	Moderate	Significant effect in favor of SGA for CGI-I (MD, 21.0; 95% CI, 21.7 to 20.3; I2, 45%); CGI-S (MD, 21.3; 95% CI, 22.2 to 20.5; I2, 78%).
Medication adherence	SGA vs placebo (5 RCTs)	Low	No significant difference
<b><i>Bipolar Disorder</i></b>			
CGI	SGA vs placebo (7 RCTs)	Moderate	Significant effect in favor of SGA (MD, 20.7; 95% CI, 20.8 to 20.5; I2, 36%).
Depression	SGA vs	Low	No significant difference

Outcome	Comparison (# of studies)	Strength of Evidence	Summary
	placebo (7 RCTs)		
Manic Symptoms	SGA vs placebo (7 RCTs)	Low	All except one study significantly favored SGA (studies not pooled due to high heterogeneity).
Medication adherence	SGA vs placebo (7 RCTs)	Low	Significant effect in favor of placebo (RR, 2.0; 95% CI, 1.0 to 4.0; I2, 0%).
Suicide-related behavior	SGA vs placebo (7 RCTs)	Moderate	No significant difference for suicide-related deaths, attempts, or ideation.
<b>Schizophrenia</b>			
CGI	FGA vs SGA (3 RCTs)	Low	Significant effect in favor of SGA (MD, 20.8; 95% CI, 21.3 to 20.3; I2, 0%).
	Clozapine vs olanzapine (2 RCTs)	Low	No significant difference
	Olanzapine vs risperidone (3 RCTs)	Low	No significant difference
	SGA vs placebo (6 RCTs)	Moderate	Significant effect in favor of SGA (MD, 20.5; 95% CI, 20.7 to 20.3; I2, 28%).
Positive and negative symptoms	FGA vs SGA (3 RCTs)	Low	No significant difference
	Clozapine vs olanzapine (2 RCTs, 1 PCS)	Low	No significant difference
	Olanzapine vs risperidone (3 RCTs, 1 PCS)	Low	No significant difference
	SGA vs placebo (6 RCTs)	Moderate	Significant effect in favor of SGA (MD, 28.7; 95% CI, 211.8 to 25.6; I2, 38%).
Medication adherence	FGA vs SGA (2 RCTs, 1 PCS)	Low	No significant difference
	Clozapine vs quetiapine (2 RCTs)	Low	No significant difference
	Olanzapine vs risperidone (4 RCTs, 1 PCS)	Low	No significant difference
	SGA vs	Low	No significant difference

Outcome	Comparison (# of studies)	Strength of Evidence	Summary
	placebo (2 RCTs)		
Suicide-related behaviors	SGA vs placebo (5 RCTs)	Low	No significant difference
<b>Tourette syndrome</b>			
Tics	SGA vs placebo (2 RCTs)	Moderate	Significant effect in favor of SGA (MD, 27.0; 95% CI, 210.3 to 23.6; I <sup>2</sup> , 0%)
<b>Behavioral symptoms</b>			
Autistic symptoms	Risperidone vs placebo (2 RCTs)	Low	Significant effect in favor of risperidone in one study; NR in second study.

ABC=Aberrant Behavior Checklist, BPI=Behavior Problem Inventory, CARS=Childhood Autism Rating Scale, CGI-I=Clinical Global Impressions-Improvement, CGI-S=Clinical Global Impressions-Severity, NCBRF=Nisonger Child Behavior Rating Scale, NR=not reported, OC=obsessive-compulsive, PCS=prospective cohort study, RR=relative risk

### Appendix IIIb: Summary of Evidence for Adverse Events in Children and Adolescents (adopted from 2012 AHRQ systematic review)<sup>96</sup>

Outcome	Strength of Evidence	SGA vs SGA	Placebo-Controlled Studies
<b>Dyslipidemia</b>	Low	Aripiprazole was significantly favored over olanzapine (RR, 0.25; 95% CI, 0.08 to 0.8) <sup>a</sup> and 95% CI, 271.3 to 27.4). <sup>a</sup> No significant differences were observed for clozapine vs olanzapine, olanzapine vs quetiapine and quetiapine vs risperidone.	Significant effect in favor of placebo over aripiprazole (RR, 2.5; 95% CI, 1.4, 4.4) <sup>a</sup> , olanzapine (RR, 2.4; 95% CI, 1.2 to 4.9; I <sup>2</sup> , 45%), and quetiapine (RR, 2.4; 95% CI, 1.1 to 5.4; I <sup>2</sup> , 0%).
	Moderate	Significant effect in favor of risperidone compared with olanzapine for cholesterol (MD, 10.2 mg/dL; 95% CI, 3.1 to 17.2; I <sup>2</sup> , 0%) and triglycerides (MD, 17.3 mg/dL; 95% CI, 3.5 to 31.1; I <sup>2</sup> , 0%).	NA
<b>EPS</b>	Low	No significant difference for clozapine vs olanzapine, clozapine vs risperidone, olanzapine vs quetiapine, olanzapine vs risperidone, quetiapine vs risperidone.	No significant differences for placebo compared to olanzapine or quetiapine.
	Moderate	NA	Significant effect in favor of placebo over aripiprazole (RR, 4.2; 95% CI, 2.4 to 7.2; I <sup>2</sup> , 0%) and risperidone (RR, 2.7; 95% CI, 1.4 to 4.9; I <sup>2</sup> , 0%).

Outcome	Strength of Evidence	SGA vs SGA	Placebo-Controlled Studies
<b>Insulin Resistance</b>	Low	No significant difference for olanzapine vs quetiapine, olanzapine vs risperidone or quetiapine vs risperidone.	No significant difference between aripiprazole and placebo or olanzapine and placebo.
<b>Prolactin-related sexual side effects</b>	Low	Significant effect in favor of clozapine over olanzapine (MD, 210.8 ng/dL; 95% CI, 216.7 to 24.8; I <sup>2</sup> , 21%). No significant difference for quetiapine vs risperidone.	Significant effect in favor of placebo over risperidone in seven or eight studies (not pooled due to heterogeneity). No significant difference for quetiapine compared to placebo.
	Moderate	Significant effect in favor of olanzapine over risperidone (RR, 0.4; 95% CI, 0.2 to 0.6; I <sup>2</sup> , 0%).	Significant effect in favor of aripiprazole over placebo (MD, 24.1 ng/mL; 95% CI, 26.3 to 21.8; I <sup>2</sup> , 0%). Significant effect in favor of placebo over olanzapine (MD, 11.5 ng/mL; 95% CI, 8.8 to 14.1; I <sup>2</sup> , 0%).
<b>Sedation</b>	Low	No significant differences for clozapine vs olanzapine, olanzapine vs quetiapine, olanzapine vs risperidone, quetiapine vs risperidone.	Significant effect in favor of placebo over aripiprazole (RR, 2.7; 95% CI, 1.1 to 6.5; I <sup>2</sup> , 76%). No significant difference in placebo comparisons with olanzapine and quetiapine.
	Moderate	NA	Significant effect in favor of placebo over risperidone (RR, 2.9; 95% CI, 1.5 to 5.5; I <sup>2</sup> , 32%) and ziprasidone (RR, 3.0; 95% CI, 1.7 to 5.2; I <sup>2</sup> , 0%).
<b>Weight gain</b>	Low	Significant effect in favor of aripiprazole over olanzapine (MD, 24.1 kg; 95% CI, 25.5 to 22.7), a quetiapine (MD, 21.6 kg; 95% CI, 23.0 to 20.3) <sup>a</sup> and risperidone (MD, 22.3 kg; 95% CI, 23.9 to 20.7). <sup>a</sup> No significant difference for clozapine vs olanzapine, clozapine vs risperidone, and quetiapine vs risperidone.	No significant difference for ziprasidone compared to placebo.
	Moderate	Significant effect in favor of quetiapine over olanzapine (RR,	Significant effect in favor of placebo over

Outcome	Strength of Evidence	SGA vs SGA	Placebo-Controlled Studies
		1.5; 95% CI, 1.1 to 2.0; I <sup>2</sup> , 0%) and risperidone over olanzapine (MD, 2.4 kg; 95% CI, 1.5 to 3.3; I <sup>2</sup> , 72%).	aripiprazole (MD, 0.8 kg; 95% CI, 0.4 to 1.2; I <sup>2</sup> , 13%), olanzapine (MD, 4.6 kg; 95% CI, 3.1 to 6.1; I <sup>2</sup> , 70%), quetiapine (MD, 1.8 kg; 95% CI, 1.1 to 2.5; I <sup>2</sup> , 49%), and risperidone (MD, 1.8 kg; 95% CI, 1.5 to 2.1; I <sup>2</sup> , 0%).

AE=adverse event; EPS=extrapyramidal symptom; RR=relative risk.

a=Only 1 study contributed to this estimate; therefore, an I<sup>2</sup> value could not be calculated.

**References**

Please refer to the full therapeutic class review on atypical antipsychotics for a list of references.

---

---

## ***Therapeutic Class Review Atypical (Second-Generation) Antipsychotics***

### **Overview/Summary**

This review will focus on the atypical antipsychotics, which are also known as second-generation antipsychotics (SGAs).<sup>1-14</sup> While several atypical antipsychotics are formulated as long-acting injections, these formulations will not be covered in this review. Antipsychotic medications have been used for over fifty years to treat schizophrenia and a variety of other psychiatric disorders.<sup>15</sup> Schizophrenia is believed to be caused by an increase in the cerebral activity of dopamine D<sub>2</sub> in the mesolimbic and/or mesocortical regions of the brain. Antipsychotic medications exert their effect in part by blocking D<sub>2</sub> receptors. It is the blockade of these receptors in the mesolimbic pathway that is believed to contribute to desired antipsychotic effects, especially improvement of positive symptoms associated with the disorder.<sup>16</sup>

In addition to blocking D<sub>2</sub> receptors in the mesolimbic pathway, FGAs also block D<sub>2</sub> receptors in the mesocortical, tuberoinfundibular, and nigrostriatal pathways.<sup>16</sup> D<sub>2</sub> blockade in these other pathways is thought to be responsible for the hyperprolactinemia and extrapyramidal symptoms (EPS) associated with this class.<sup>17</sup> FGAs may be characterized according to their affinity for the D<sub>2</sub> receptor. Low potency antipsychotics, such as chlorpromazine and thioridazine, are more sedating and associated with a higher incidence of anticholinergic side effects. Fluphenazine, haloperidol, pimozide, thiothixene, and trifluoperazine are high potency antipsychotics that are less sedating but associated with a higher incidence of EPS. The medium potency antipsychotics (loxapine, molindone, and perphenazine) possess a moderate risk of EPS and anticholinergic side effects.<sup>18</sup> With the exception of pimozide, all FGAs are indicated for use in the treatment of schizophrenia. FGAs are effective in the treatment of positive symptoms of schizophrenia, which include agitation, aggression, delusions, and hallucinations. Negative symptoms of schizophrenia which include avolition, anhedonia, alogia, affective flattening, and social withdrawal, do not respond as well to this antipsychotic class.<sup>17</sup> Pimozide is indicated only for the suppression of motor and phonic tics in patients with Tourette's disorder.

The term "atypical antipsychotic" was introduced in 1989 when clozapine was approved for use by the Food and Drug Administration (FDA). Originally, this term referred to an antipsychotic with a low risk of EPS.<sup>18</sup> As a class, SGAs or atypical antipsychotics are more selective in targeting the mesolimbic D<sub>2</sub> pathway. They also block or partially block serotonin (5-HT)<sub>2A</sub> and 5-HT<sub>1A</sub> receptors and have a greater affinity for 5-HT<sub>2</sub> receptors than D<sub>2</sub> receptors.<sup>16,18</sup> These differences in neuropharmacologic activity are associated with a lower risk of EPS and tardive dyskinesia; the risks vary with the specificity of each agent for D<sub>2</sub> and serotonin receptors.<sup>16,18</sup> Atypical antipsychotics have a more favorable outcome in the treatment of the negative symptoms of schizophrenia.<sup>16</sup> The SGAs are comprised of nine separate chemical entities, each with a unique neuropharmacologic and adverse event profile, mechanism of action, and chemical structure. The SGAs are aripiprazole, asenapine, brexpiprazole, clozapine, iloperidone, lurasidone, olanzapine, paliperidone, quetiapine, risperidone and ziprasidone.

The neuropharmacology of aripiprazole differs from other SGAs, as it is a partial D<sub>2</sub> and 5-HT<sub>1A</sub> agonist and a 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> antagonist. It is referred to as a D<sub>2</sub>-serotonin system stabilizer since the partial agonist activity allows for blockade of an overstimulated receptor and stimulation of a receptor when activity is needed.<sup>16</sup> EPS rates comparable to placebo may be attributable to the partial-agonist activity of this agent. Aripiprazole is FDA-approved for use in schizophrenia in adults and adolescents, acute manic and mixed episodes associated with bipolar disorder in adults and adolescents, agitation associated with schizophrenia or bipolar disorder in adults, irritability associated with autistic disorder in children and adolescents and major depressive disorder in adults.<sup>1</sup>

Asenapine is the first antipsychotic agent that is solely available in the United States as a sublingual tablet formulation. It is approved for the treatment of schizophrenia in adults and acute treatment of manic or mixed episodes associated with bipolar I disorder in adults, either as monotherapy or adjunctive therapy.<sup>2</sup> It is also approved for acute use in children 10 to 17 years of age for the treatment of manic or

mixed episodes of bipolar I disorder. It has a distinctive receptor binding profile in that it displays high affinity binding and antagonistic activity at a wide range of dopamine, serotonin, norepinephrine, and histamine receptors (H<sub>1</sub>).<sup>2</sup>

Brexpiprazole is FDA-approved for the adult treatment of schizophrenia and as an adjunctive treatment in major depressive disorder. It is hypothesized that the efficacy of brexpiprazole may be mediated through a combination of partial agonist activity at serotonin 5-HT<sub>1A</sub> and dopamine D<sub>2</sub> receptors, and antagonist activity at serotonin 5-HT<sub>2A</sub> receptors.<sup>3</sup>

Clozapine has a high affinity for 5-HT receptors and a lower, transient affinity for D<sub>2</sub> receptors. Its use is limited by its risk of agranulocytosis. In addition to a boxed warning for agranulocytosis, clozapine also carries a boxed warning for cardiac toxicity, seizures, orthostatic hypotension, and respiratory and cardiac arrest.<sup>4-6</sup> Clozapine is effective in patients who do not respond to conventional or other atypical antipsychotics. It is approved for use in severely ill patients with schizophrenia or those with schizophrenia or schizoaffective disorder at risk for suicidal behavior.<sup>4-6</sup> Clozapine is now also formulated as an oral solution.<sup>6</sup>

Iloperidone is indicated for the acute treatment of adults with schizophrenia. Iloperidone is thought to exert its pharmacological effects via antagonism of the D<sub>2</sub> and 5-HT<sub>2</sub> receptors, with high affinity for 5-HT<sub>2A</sub>, D<sub>2</sub> and D<sub>3</sub> receptors and low affinity for 5-HT<sub>1A</sub>, D<sub>1</sub> and H<sub>1</sub> receptors. Iloperidone treatment may be associated with QTc prolongation. Iloperidone must be titrated to an effective dose which may delay symptom control during the first two weeks of therapy; therefore, this must be considered when choosing an agent for the acute treatment of schizophrenia.<sup>7</sup>

Lurasidone is indicated for the treatment of adults with schizophrenia and for the treatment of depressive episodes associated with bipolar disorder. It is a high affinity antagonist at D<sub>2</sub> receptors and 5-HT<sub>2A</sub>/5-HT<sub>7</sub> receptors, a moderate affinity antagonist at alpha<sub>2C</sub> adrenergic receptors, a partial agonist at 5-HT<sub>1A</sub> receptors and is an antagonist at alpha<sub>2A</sub> adrenergic receptors. Lurasidone has little to no affinity for histamine<sub>1</sub> and muscarinic receptors. To insure optimal absorption and distribution, the drug should be taken with food (at least 350 calories). Lurasidone is primarily metabolized in the liver via the CYP3A4 enzyme. Consequently, coadministration with strong CYP3A4 inducers or inhibitors is contraindicated.<sup>8,19</sup>

Olanzapine is approved for use in the treatment of adults and adolescents with schizophrenia, manic or mixed episodes associated with bipolar I disorder in adults and adolescents, and agitation associated with schizophrenia or bipolar disorder. Olanzapine has a dose-dependent risk of EPS and hyperprolactinemia related to higher D<sub>2</sub> receptor occupancy.<sup>9</sup>

Quetiapine is approved for use in the treatment of adults and adolescents with schizophrenia, adults and adolescents with acute manic episodes, and adults with depressive episodes associated with bipolar disorders.<sup>11,12</sup> Likely due to its low and transient occupancy of D<sub>2</sub> receptors, quetiapine is associated with a low incidence of EPS and has not been shown to significantly elevate prolactin levels.

Risperidone is approved by the FDA for the treatment of schizophrenia and acute manic or mixed episodes associated with bipolar disorder in adults and adolescents.<sup>13</sup> Risperidone is also indicated for the management of irritability associated with autism. Compared to other SGAs, risperidone results in a higher incidence of prolactin level elevation and EPS, particularly at doses above 6 mg per day. Paliperidone, the active metabolite of risperidone, is also approved by the FDA for the treatment of schizophrenia in adults and adolescents. Moreover, paliperidone is indicated for the treatment of schizoaffective disorder as an adjunct to mood stabilizers and/or antidepressants. This medication is available in an extended-release formulation and has been shown to have an incidence of EPS similar to placebo at daily doses up to 6 mg.<sup>10,20</sup>

Ziprasidone is indicated for the treatment of schizophrenia and manic or mixed episodes associated with bipolar disorder (with or without psychotic features).<sup>14</sup> Ziprasidone differs from other medications in its



class as it has a high affinity for D<sub>2</sub> receptors but a greater affinity for 5-HT<sub>2</sub> receptors. The higher affinity for the 5-HT<sub>2</sub> receptors may reduce the incidence of EPS, but this risk is dose dependent.<sup>16,18</sup> It also possesses potent serotonin and norepinephrine reuptake blocking effects.<sup>14</sup>

Although in some respects the SGAs are safer and better tolerated than the FGAs, they are still associated with a number of serious risks and side effects. For this reason, the FDA has required various warnings to be inserted in the manufacturers' product information for these agents. All bear a warning that alerts prescribers and patients to the risk of hyperglycemia and other metabolic changes.<sup>1-14</sup> Ziprasidone also has a warning concerning QTc interval prolongation; however, all of the SGAs can increase the QTc interval to some degree.<sup>1-14</sup> Aripiprazole, brexpiprazole, lurasidone and quetiapine carry a black box warning regarding suicidality and antidepressant drugs.<sup>1,3,8,11,12</sup> All SGAs carry a black box warning noting that they are associated with an increased risk of death when used in the treatment of psychosis and behavioral problems in elderly patients with dementia. Most of the deaths that prompted the addition of the warning were due to cardiac-related events (e.g., heart failure or sudden death) or infection.<sup>21</sup> Of note, this last black box warning is directed at using antipsychotics in a manner that is not FDA-approved.

Due to the potential side-effect risks associated with these medications, any off-label use deserves close attention. Data published in peer-reviewed journals and in national and international guidelines support the use of SGAs as a treatment option for certain off-label uses. In many of these scenarios, SGAs are reserved for patients who are refractory to other first-line treatment modalities, including both pharmacotherapy and psychotherapy, and used in adjunction to mainstream therapies, as part of a multimodal approach.

Over the past 20 years, antipsychotic use in children and adolescents has grown. In the United States, the frequency of prescribing an antipsychotic agent increased from 8.6 per 1000 children in 1996 to 39.4 per 1000 children in 2002. According to a survey of national trends in the outpatient use of antipsychotics in children and adolescents, only 14.2% of antipsychotic prescriptions in children were for patients diagnosed with psychotic disorders.<sup>22</sup> Indications commonly associated with antipsychotic prescribing in pediatric patients include psychosis, schizophrenia, bipolar disorder, aggressive and disruptive behavior, and tic disorders. Off-label indications with limited available evidence for the use of atypical antipsychotics in children and adolescents include autistic spectrum disorders, major depressive disorder, anxiety disorders, and eating disorders. At this time, risperidone and aripiprazole are FDA-approved for the management of children and adolescents with autism (aged 5 to 16 and 6 to 17 years, respectively). Moreover, the following agents are indicated for the treatment of schizophrenia in adolescents: aripiprazole, olanzapine, paliperidone, quetiapine, and risperidone. Aripiprazole, asenapine, olanzapine, quetiapine and risperidone are FDA-approved for the treatment of manic or mixed bipolar I disorder in children and adolescents. None of the other available atypical antipsychotic agents are currently indicated for use in pediatric patients.<sup>1-14</sup>

Concerns have also been raised about the risks of combination therapy with the antipsychotics, which can multiply the risks of dangerous adverse events. The practice of polypharmacy is not supported by well-designed clinical trials published in the peer-reviewed literature. However, national and international consensus guidelines consider this approach in patients with treatment-refractory illness.

**Medications**

The second-generation antipsychotics that are included in this review are listed in Table 1. This review encompasses all oral dosage forms and immediate release injections.

**Table 1. Medications Included Within Class Review**

Generic Name (Trade name)	Medication Class	Generic Availability
Aripiprazole (Abilify <sup>®*</sup> , Abilify Discmelt <sup>®</sup> )	Atypical antipsychotic	a
Asenapine (Saphris <sup>®</sup> )	Atypical antipsychotic	-
Brexipiprazole (Rexulti <sup>®</sup> )	Atypical antipsychotic	-
Clozapine (Fazaclo ODT <sup>®*</sup> , Clozaril <sup>®*</sup> , Versacloz <sup>®</sup> )	Atypical antipsychotic	a
Iloperidone (Fanapt <sup>®</sup> )	Atypical antipsychotic	-
Lurasidone (Latuda <sup>®</sup> )	Atypical antipsychotic	-
Olanzapine (Zyprexa <sup>®*</sup> , Zyprexa IM <sup>®*</sup> , Zyprexa Zydis <sup>®*</sup> )	Atypical antipsychotic	a
Paliperidone (Invega <sup>®*</sup> )	Atypical antipsychotic	a
Quetiapine (Seroquel <sup>®*</sup> , Seroquel XR <sup>®</sup> )	Atypical antipsychotic	a
Risperidone (Risperdal <sup>®*</sup> , Risperdal M-Tab <sup>®*</sup> )	Atypical antipsychotic	a
Ziprasidone (Geodon <sup>®*</sup> )	Atypical antipsychotic	a

IM=intramuscular, ODT=orally disintegrating tablet, XR=extended release

\*Generic is available in at least one dosage form or strength.

**Indications**

**Table 2. Food and Drug Administration (FDA)-Approved Indications-Single-Entity Products<sup>1-14</sup>**

Indications	Aripiprazole	Asenapine	Brexipiprazole	Clozapine	Iloperidone	Lurasidone	Olanzapine	Paliperidone	Quetiapine	Risperidone	Ziprasidone
<b>Bipolar Disorders</b>											
Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults	a *	a					a *				a *
Acute or maintenance treatment of manic or mixed episodes associated with bipolar I disorder in children and adolescents aged 10 to 17 years	a *	a									
Acute or maintenance treatment of manic or mixed episodes associated with bipolar I disorder in children and adolescents aged 13 to 17 years							a ***				
Adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder										a †	
Adjunctive therapy to either lithium or valproate for the acute treatment of manic and mixed episodes associated with bipolar I disorder with or without psychotic features in adults and in pediatric patients aged 10 to 17 years	a *										
Adjunctive therapy to either lithium or valproate for the acute treatment of manic and mixed episodes associated with bipolar I disorder		a					a *				
Maintenance treatment of manic or mixed episodes associated with bipolar I disorder in adults	a *						a *				
Maintenance treatment of bipolar I disorder as adjunct therapy to lithium or divalproex in adults									a *		
Maintenance treatment of bipolar I disorder as adjunct therapy to lithium or valproate in adults										a †	a *
Short-term treatment of acute manic or mixed episodes associated with bipolar I disorder in adults and in children and adolescents aged 10 to 17 years										a *	
Short-term treatment of acute mixed or manic episodes associated with bipolar I disorder in combination with lithium or valproate in adults										a *	

Indications	Aripiprazole	Asenapine	Brexipiprazole	Clozapine	Iloperidone	Lurasidone	Olanzapine	Paliperidone	Quetiapine	Risperidone	Ziprasidone
Treatment of acute manic or mixed episodes associated with bipolar disorder											a *
Treatment of acute manic episodes associated with bipolar I disorder as either monotherapy or adjunct therapy to lithium or divalproex in adults									a *		
Treatment of acute manic episodes associated with bipolar I disorder as either monotherapy or adjunct therapy to lithium or divalproex in children and adolescents aged 10 to 17 years									a *		
Treatment of manic or mixed episodes associated with bipolar I disorder as either monotherapy or adjunct therapy to lithium or divalproex in adults									a		
Treatment of agitation associated with bipolar I disorder, manic or mixed in adults	a †						a †				
Treatment of agitation associated with bipolar I mania in adults							a †				
Treatment of depressive episodes associated with bipolar disorder in adults						a	a ¶		a *		
<b>Schizophrenia</b>											
Acute and maintenance treatment of schizophrenia in adults	a *	a					a *†	a *†	a *	a	
Reduction in the risk of recurrent suicidal behavior in schizophrenia or schizoaffective disorder in adults				a							
Treatment of agitation associated with schizophrenia in adults	a †						a †				a †
Treatment of schizophrenia in adolescents aged 13 to 17	a *						a **		a *	a	
Treatment of schizophrenia in adolescents aged 12 to 17								a *			
Treatment of schizophrenia in adults	a *		a		a §	a			a *	a †	a *
Treatment-resistant schizophrenia in adults				a							
<b>Miscellaneous Disorders</b>											
Adjunctive treatment to antidepressants for major depressive disorder in adults	a *		a				a #¶		a		
Irritability associated with autistic disorder in children and adolescents aged five to 17 years										a *	

Indications	Aripiprazole	Asenapine	Brexiprazole	Clozapine	Iloperidone	Lurasidone	Olanzapine	Paliperidone	Quetiapine	Risperidone	Ziprasidone
Irritability associated with autistic disorder in children and adolescents aged six to 17 years	a *										
Treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers and/or antidepressants in adults								a *			

\*Oral dosage form(s).

†Intramuscular dosage form.

‡ Approved for acute treatment only.

§ In choosing among treatments, prescribers should consider the ability of Fanapt® to prolong the QT interval and the use of other drugs first. Prescribers should also consider the need to titrate Fanapt® slowly to avoid orthostatic hypotension, which may lead to delayed effectiveness compared to some other drugs titration.

|| Oral extended-release dosage form.

¶ Only approved when used in combination with fluoxetine

# Indicated for the treatment depression in patients who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode.

\*\* Medical treatment of both pediatric schizophrenia and bipolar I disorder should be part of a total treatment program that includes psychological, educational, and social interventions. The increased potential for weight gain and hyperlipidemia, in adolescents compared to adults, may lead clinicians to consider prescribing other drugs first in adolescents.

A number of the atypical antipsychotics have been studied and used off-label for a variety of treatments.

**Pharmacokinetics****Table 3. Pharmacokinetics**<sup>1-14</sup>

Drugs(s)	Bioavailability (%)	Protein Binding (%)	Renal Excretion (%)	Active Metabolites	Serum Half-Life (hours)
Aripiprazole	87*; 100†	>99	25	Dehydroaripiprazole	75 to 146
Asenapine	35 (<2 if swallowed)	95	50	None identified	24
Brexpiprazole	95	>99	25	None identified	91
Clozapine	50 to 60	97	50	Desmethyl metabolite, limited activity	8 to 12
Iloperidone	96	~95	58.2 to 45.1	Two predominant; P88 and P95	18 (iloperidone), 26 (P88) and 23 (P95) in extensive metabolizers  33 (iloperidone), 37 (P88) and 31 (P95) in poor metabolizers
Lurasidone	9-19	99	9	Two (ID-14283 and ID-14326)	18
Olanzapine	Well absorbed	93	57	Not reported	21 to 54
Paliperidone	28	74	59	Not reported	23
Quetiapine	100	83	73	N-dealkylated quetiapine	7; 9 to 12‡
Risperidone	70	90	70	Not reported	20*
Ziprasidone	60*; 100†	>99	Not reported	Not reported	2 to 5

\*Oral dosage form.

†Intramuscular dosage form.

‡Active metabolite.

**Clinical Trials**

Numerous clinical studies evaluating the efficacy of antipsychotic medications have been conducted for both Food and Drug Administration (FDA)-approved and non-approved indications.<sup>23-290</sup> The available published literature describing the safety and efficacy of atypical antipsychotic agents for both off-label and FDA-approved indications in adults, children and adolescents are included in Table 4 to Table 9.

The efficacy and safety of brexpiprazole in the treatment of schizophrenia was demonstrated by two pivotal multicenter, randomized, double-blind, placebo controlled six week trials, VECTOR and BEACON.<sup>27,28</sup> In VECTOR, the average effect of brexpiprazole 2 mg and 4 mg on the primary efficacy endpoint (Positive and Negative Syndrome Scale [PANSS] scores) measure was statistically significant compared to placebo with greater mean improvements in PANSS total score at week six ( $P < 0.0001$ ). The treatment differences were  $-8.72$  ( $P < 0.0001$ ) and  $-7.64$  ( $P = 0.0006$ ) for brexpiprazole 2 mg and 4 mg, respectively.<sup>27</sup> BEACON also showed a significantly improved PANSS score with brexpiprazole 4 mg compared with placebo. The treatment difference was  $-6.47$  ( $P = 0.0022$ ).<sup>28</sup> Both studies showed

statistically significant improvements in Clinical Global Impressions-Severity (CGI-S) scores (P value not reported for VECTOR, P=0.0015 for BEACON).<sup>27,28</sup>

The efficacy and safety of brexpiprazole in the adjunctive treatment of major depressive disorder was demonstrated by two pivotal multicenter, randomized, double-blind, placebo controlled six week trials.<sup>290</sup> A pooled analysis of the two trials showed greater improvement with adjunctive brexpiprazole compared to placebo in Montgomery-Asberg Depression Rating Scale (MADRS) total score (least squares mean difference to placebo was brexpiprazole 1 mg, -2.02; P=0.0018, brexpiprazole 2 mg, -2.35; P=0.0007 and brexpiprazole 3 mg, -2.54; P=0.0001).<sup>290</sup>

The efficacy of asenapine in the treatment of schizophrenia in adults has been evaluated in four, published, randomized, double-blind, placebo-controlled, and active-controlled (haloperidol, risperidone, and olanzapine) trials, ranging in duration from six weeks to one year.<sup>29-32</sup> Asenapine was associated with statistically significant improvement in the PANSS scores from baseline compared to placebo, starting from week two of therapy. Clinical Global Impression-Improvement (CGI-I) and Clinical Global Impression-Severity of Illness (CGI-S) scores were also significantly improved with asenapine therapy, compared to placebo. Moreover, an extension study demonstrated a reduced risk of relapse associated with continuation of asenapine therapy.<sup>31</sup> However, a direct-comparison study suggests that asenapine is less effective than olanzapine in terms of changes from baseline in PANSS and CGI-S scores.<sup>32</sup> Furthermore, study discontinuation due to inadequate efficacy was noted in only 14% of patients receiving olanzapine compared to 25% of patients in the asenapine group. Mean weight gain was 0.9 kg with asenapine and 4.2 kg with olanzapine.<sup>32</sup> In another study, while 17% of patients receiving risperidone experienced a weight gain of at least 7% from baseline, 9% of patients in the asenapine were noted to exhibit clinically significant weight gain.<sup>29</sup> The efficacy and safety of asenapine in the treatment of manic or mixed bipolar I disorder were evaluated in five placebo-controlled, and active-controlled (olanzapine) studies in adult patients, with or without psychotic features.<sup>59-63</sup> Asenapine 5 to 10 mg twice daily was statistically more effective than placebo on the Young Mania Rating Scale (YMRS) and the Clinical Global Impression-Bipolar Scale (CGI-BS) in all studies. In a pooled analysis of patients experiencing bipolar mania, asenapine and olanzapine were comparable in terms of reduction from baseline in YMRS scores 5 weeks of therapy.<sup>63</sup> Likewise, another pooled analysis of patients experiencing bipolar depression episode found that olanzapine and asenapine were associated with comparable improvement in baseline Montgomery-Asberg Depression Rating Scale (MADRS) scores after 21 days of therapy.<sup>61</sup> A meta-analysis of various antimanic therapy options, found that asenapine was associated with a statistically significant improvement in YMRS scores from baseline compared to placebo (mean difference, -0.30; -0.53 to -0.07), though it was less effective compared to olanzapine (0.22; 0.08 to 0.37).<sup>68</sup> In addition, another meta-analysis calculated that six patients would be treated with asenapine for one to achieve a positive response, compared to placebo.<sup>46</sup> Most commonly reported adverse events reported with asenapine included sedation, dizziness, somnolence and weight gain.<sup>75</sup> Of note, it was calculated that for every nine patients treated with olanzapine over asenapine, one would experience a clinically significant weight gain.<sup>62</sup>

Iloperidone was studied as monotherapy for the treatment of adult patients with an acute or subacute exacerbation of schizophrenia. Three, six-week, randomized, double-blind, placebo- and active comparator (risperidone and haloperidol)-controlled studies found iloperidone to be significantly more effective than placebo.<sup>34</sup> Another four week, placebo- and active- comparator (ziprasidone)-controlled study found a significant improvement in PANSS scores with iloperidone therapy compared to placebo.<sup>33</sup> Two meta-analyses of these four studies corroborated earlier data, finding iloperidone more effective than placebo in terms of improvement from baseline in various subscales of the PANSS scale and BPRS scores.<sup>35,36</sup> The long-term efficacy and safety of iloperidone in the treatment of schizophrenia was evaluated in a meta-analysis that pooled the follow-up data (up to 52 weeks) from three prospective randomized clinical trials.<sup>37</sup> The meta-analysis found the long-term efficacy of iloperidone, assessed via the time to relapse endpoint, to be comparable to haloperidol (P=0.85), with a more favorable long-term safety profile.<sup>37</sup> Moreover, another meta-analysis designed to evaluate the short-term safety of iloperidone found the following dose-related adverse effects: dry mouth, dizziness, somnolence and dyspepsia.<sup>38</sup>

EPS adverse events were noted in association with iloperidone but were more common with haloperidol and risperidone therapies. Iloperidone was also associated with QTc prolongation and weight gain (1.5 kg to 2.1 kg).<sup>38</sup>

Lurasidone has been investigated for the treatment of adult patients with acute and chronic symptoms of schizophrenia in two six-week, placebo-controlled studies and two 21-day studies directly comparing the safety and efficacy of lurasidone 120 mg once daily with ziprasidone 80 mg twice daily.<sup>39-42</sup> In placebo controlled studies, lurasidone, dosed 40 mg, 80 mg, or 120 mg once daily was associated with significant improvements from baseline in PANSS and the Brief Psychiatric Rating Scale (BPRSd) scores, compared to placebo.<sup>39,42</sup> The two direct-comparison studies demonstrated comparable improvements in the lurasidone and ziprasidone groups in terms of the reduction in total PANSS, PANSS positive symptom, PANSS general symptom, CGI-S scores and several cognition scales.<sup>40,41</sup> Likewise, the two groups were comparable in terms of rates of discontinuation for any reason rate and discontinuation due to adverse events.<sup>40,41</sup> Of note, lurasidone was more effective in improving negative symptoms PANSS scores compared to ziprasidone (P=0.046).<sup>41</sup> Both therapies were associated with a small weight loss from baseline and neither therapy was associated with a clinically significant ECG abnormality. EPS adverse events were noted in 3.3% of patients in the ziprasidone group and in 3.3% of patients receiving lurasidone.<sup>41</sup> Two studies conducted evaluated the effectiveness of lurasidone for bipolar depression. The least squares mean change from baseline to week six in MADRS and Clinical Global Impression–Bipolar Illness (CGI-BP depression score after six weeks (P<0.001 for both trials). Median time to response was also significantly shorter for the lurasidone group compared with placebo (P<0.001 for both trials).<sup>285,286</sup>

Evaluation of the atypical antipsychotics as a whole for the treatment of schizophrenia was done via a systemic review and a meta-analysis. Asmal et al directly compared quetiapine to other atypical in a systemic review, while Leucht et al reviewed oral atypical antipsychotics compared to placebo or another atypical antipsychotic in a meta-analysis. Both found generally the atypical antipsychotics were efficacious with minor differences between studies on what which is more effective.<sup>282,283</sup> It is important to note that both trials noted distinct differences in side effects. Quetiapine may produce fewer parkinsonian effects than paliperidone, aripiprazole, ziprasidone, risperidone and olanzapine. Quetiapine appears to have a similar weight gain profile to risperidone, as well as clozapine and aripiprazole (although data are very limited for the latter two comparators). Quetiapine may produce greater weight gain than ziprasidone and less weight gain than olanzapine and paliperidone.<sup>282</sup>

A systematic review evaluating the use of atypical antipsychotics in patients aged 13 to 17 years for the short term management of schizophrenia was done by Kumar et al. No convincing evidence suggests that atypical antipsychotic medications are “superior” to typical medications for the treatment of adolescents with psychosis. However, atypical antipsychotic medications may be more acceptable to young people because fewer symptomatic adverse effects are seen in the short term. Little evidence is available to support the “superiority” of one atypical antipsychotic medication over another, but side effect profiles are different for different medications.<sup>284</sup>

The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) was a large, multi-center study initiated by the National Institute of Mental Health to examine the effectiveness of SGAs compared to first generation antipsychotics (FGAs) in patients with chronic schizophrenia. It was intended to include patients treated in typical clinical settings and to reflect typical clinical practice in which individuals with schizophrenia may require multiple medication trials before finding one that is adequately both efficacious and tolerable. The study design allowed for patients who discontinued one study antipsychotic drug to enter subsequent phases of the study to receive additional antipsychotic medications.<sup>43-45</sup> Among the unexpected outcomes was the finding that, with the exception of clozapine, the SGAs did not separate out as robustly from the FGAs with respect to overall efficacy and times to treatment discontinuation. However, because of relatively high discontinuation rates across all treatment arms, potential biases regarding optimal dosing of individual drugs, and clear differences in treatment-emergent side effect profiles, the implications of CATIE are subject to interpretation which may preclude definitive guidance in developing pharmacotherapy guidelines for patients with schizophrenia as a whole.



Risperidone oral solution or oral aripiprazole compared to placebo was evaluated for the use in irritability associated with autism. Kent et al evaluated irritability and CGI-S scores, and found they were significantly improved after six weeks with only high-dose risperidone (1.25 to 1.75 mg/day;  $P < 0.001$  and  $P = 0.004$ , respectively) compared to placebo and not low-dose risperidone (0.125 to 0.175 mg/day;  $P = 0.164$  and  $P = 0.817$ , respectively) compared to placebo.<sup>287</sup> Findling et al evaluated relapse rates for patients who had irritability associated with autism. Relapse rates at week 16 were 35% for aripiprazole and 52% for placebo, for a hazard ratio (aripiprazole/placebo) of 0.57 (95% confidence interval [CI], 0.28 to 1.12). The mean time until 25% of patients treated with aripiprazole relapsed was 56 days (95% CI, 31 to undefined), and, for placebo, it was 29 days (95% CI, 25 to 45), representing a difference that was not statistically significant ( $P = 0.097$ ). A post hoc analysis demonstrated a number needed to treat of six (95% CI, 2.58 to not approached) to prevent one additional relapse.<sup>288</sup>

The Agency of Healthcare Research and Quality (AHRQ) is the lead federal agency for research on healthcare quality, costs, outcomes and patient safety. Under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, the AHRQ is required to conduct and support research into the clinical effectiveness, comparative effectiveness, and appropriateness of pharmaceuticals, medical devices and healthcare services for the recipients of Medicare, Medicaid, and the State Children's Health Insurance Program.<sup>95,198</sup>

In 2011, AHRQ had issued an update to a prior 2007 review of scientific evidence on the safety and effectiveness of atypical antipsychotics for off-labeled use.<sup>78, 198</sup> Specifically, asenapine, aripiprazole, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone were evaluated for off-labeled uses, such as anxiety disorders, attention deficit hyperactivity disorder (ADHD), dementia and severe geriatric agitation, depression, eating disorder, insomnia, obsessive-compulsive disorder, posttraumatic stress disorder, personality disorders, substance abuse, Tourette's syndrome and autism. Efficacy analyses included controlled trials of at least six weeks in duration. Results from efficacy studies judged clinically similar were pooled in a meta-analysis. For trials judged not clinically similar, a narrative synthesis was performed. Adverse events analysis included trials of any duration, case series or cohort studies with a comparison group of  $> 1,000$  patients. Following analysis and synthesis of data, the draft report was reviewed by a technical expert panel consisting of scientists and clinicians with expertise in psychiatric conditions. Of note, no pertinent studies with asenapine, iloperidone or paliperidone met the inclusion criteria and were thus not included in the final evaluation of results.

The overall strength of evidence was assessed using a grading method developed by the Grade Working Group. The classification criteria are as follows<sup>198</sup>:

- High= High confidence that the evidence reflects the true effect. Further research is very unlikely to change the confidence on the estimate of effect.
- Moderate= Moderate confidence that the evidence reflects the true effect. Further research may change the confidence in the estimate of effect and may change the estimate.
- Low= Low confidence that the evidence reflects the true effect. Further research is likely to change the confidence in the estimate of effect and is likely to change the estimate.

The AHRQ evidence grading system took into account the following factors: risk of bias, consistency, directness, precision, dose-response, potential confounders that would decrease the observed effect, strength of association, and publication bias. In summary, indications associated with moderate/high strength of evidence for the use of atypical antipsychotics included general anxiety disorder (quetiapine), dementia (aripiprazole, olanzapine, risperidone), depression (aripiprazole, quetiapine, risperidone), augmentation of SSRIs for obsessive compulsive disorder [OCD] (risperidone), and post-traumatic stress disorder [PTSD] (risperidone).<sup>89</sup> In addition, the AHRQ had conducted a systematic review of literature on the safety and efficacy of antipsychotics in children and adolescents.<sup>95,96</sup> The review included studies of atypical antipsychotics (aripiprazole, clozapine, olanzapine, quetiapine, risperidone, paliperidone, and ziprasidone), conducted in patients 24 years of age or younger, used for the following FDA-approved and off-label indications: pervasive developmental disorder, ADHD/disruptive behavior disorders, bipolar

disorder, schizophrenia, psychosis, Tourette's syndrome, OCD, PTSD, anorexia nervosa, and miscellaneous behavioral issues. In summary, indications associated with moderate strength evidence for the use of atypical antipsychotics included disruptive behavior disorder, bipolar disorder, schizophrenia, and Tourette's syndrome. No significant differences between the different atypical antipsychotics were noted in the identified head-to-head comparisons. The risks of weight gain (weight gain: 4.6 kg) and dyslipidemia were highest with olanzapine. Weight gain with ziprasidone was not significantly different from placebo. The other atypical antipsychotics were associated with intermediate weight gain. Risperidone was associated with the greatest incidence of prolactin-related adverse events (consistent with adult data). EPS adverse events were significantly more common with risperidone and aripiprazole compared to placebo. For details of these findings, refer to Table 6 and Appendices IIa and IIB.

**Table 4. Efficacy Clinical Trials Using the Antipsychotics**

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
<b>Acute Psychotic Symptoms</b>				
Hatta et al <sup>23</sup>  Olanzapine orally disintegrating tablet 10 mg  vs  risperidone oral solution 3 mg	MC, OL  Acutely agitated psychotic patients with a score $\geq 15$ on the PANSS-EC when visiting or brought to the psychiatric emergency department	N=87  2 months	Primary: PANSS-EC, CGI-C, patient satisfaction, blood pressure, heart rate and EPS  Secondary: Not reported	Primary: There were no significant main effects on treatment (P=0.09), and no significant interaction was seen between time course and treatment on PANSS-EC (P=0.41).  There were no differences in patient satisfaction found between treatment groups (P=0.91).  There were no significant differences in mean CGI-C scores between treatment groups (P=0.22).  There were no significant differences in mean changes in systolic and diastolic blood pressure between groups (P=0.41 and P=0.71, respectively).  Mean change in heart rate was significantly greater in the olanzapine orally disintegrating tablet group (-9.2 beats/minute) compared to the risperidone oral solution group (1.1 beats/minute; P=0.03).  There were no significant differences between groups in percent of patients experiencing EPS (P=0.28).  Secondary: Not reported
Verma et al <sup>24</sup>  Risperidone 2.2 mg/day (mean dose)  vs  olanzapine 13.2 mg/day (mean dose)	MC, OL, OS  Male patients admitted to a veterans affairs medical center geropsychiatric inpatient unit for the treatment of	N=34  21 months	Primary: Differences in effectiveness, side effect profiles, and cost between the two cohorts based on PANSS, CMAI, GAF, ESRS, and RSSE scores	Primary: CMAI, GAF, and PANSS scoring showed that both groups performed significantly better following their stay in the veterans affairs medical center from baseline scoring at admission (P<0.001). There were no significant differences between risperidone and olanzapine on any measure, including CMAI and PANSS (P values not significant).  Upon discharge, the mean ESRS score was 23.46 with risperidone-treated patients and 20.54 with olanzapine-treated patients (P=0.557).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
	behavioral disturbances, physical aggression, verbal threats, wandering, general confusion		Secondary: Not reported	The RSSE was 8.14 with risperidone-treated patients and 7.71 with olanzapine-treated patients (P=0.557).  Secondary: Not reported
Currier et al <sup>25</sup>  Risperidone liquid concentrate 2 mg plus lorazepam oral 2 mg  vs  haloperidol intramuscular 5 mg plus lorazepam intramuscular 5 mg	PRO  Psychotic patients aged 18 to 65 years who required emergency medication for the control of agitation and/or violence	N=60  3 months	Primary: PANSS, CGI scale, time to sleep, need for repeat doses, and adverse events  Secondary: Not reported	Primary: Both treatments lead to significant improvements in PANSS measures (P<0.0001) and there were no differences found between treatment groups (P=0.42).  Both treatment groups lead to significant improvements in CGI scores (P<0.0001) and there were no differences found between treatment groups (P=0.419).  There were no significant differences between treatment groups regarding time to sleep (P value not reported).  One patient in the risperidone group required subsequent treatment with haloperidol for ongoing agitation compared to none in the haloperidol group (P value not reported).  One patient in the haloperidol group reported one adverse event (dystonia) compared to no reports of side effects in the risperidone group (P value not reported).  Secondary: Not reported
San et al <sup>26,27</sup>  Haloperidol 1.5 to 8.5 mg daily  vs	OL, RCT  Patients ≥18 years of age with the presence of psychotic symptoms on	N=114  1 year	Primary: Treatment discontinuation  Secondary: All-cause discontinuation	Primary: At 12 months, the proportion of patients who discontinued treatment was 40% with olanzapine, 56.6% with quetiapine, 64% with risperidone, 80% with ziprasidone and 85.7% with haloperidol. A comparison between antipsychotics demonstrated significantly lower discontinuation in patients taking olanzapine compared to haloperidol (P=0.000) or ziprasidone (P=0.001).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
olanzapine 7.5 to 40 mg daily vs quetiapine 100 to 1500 mg daily vs risperidone 1.5 to 7.0 mg daily vs ziprasidone 40 to 240 mg daily	admission ( $\geq 4$ on PANSS positive scale) and naïve to psychotropic medications		rates, symptom change measured by the PANSS and the CDSS and adverse event rates	Secondary: All-cause discontinuation of treatment occurred at $125 \pm 25.4$ days with haloperidol, $142.7 \pm 30.8$ days with ziprasidone, $187.1 \pm 32.7$ days with quetiapine, $206.2 \pm 27.8$ days with risperidone and $260.2 \pm 26.2$ days with olanzapine.  Significant improvements from baseline in PANSS scores were apparent at 12 months in the five treatment groups. Olanzapine treatment significantly improved PANSS total scores from baseline compared to treatment with haloperidol ( $P=0.019$ ).
<b>Early Psychosis</b>				
Marshall et al <sup>26</sup>  Atypical antipsychotics (olanzapine, risperidone) vs cognitive behavioral therapy vs specialized team providing needs-focused intervention vs adherence coping education	SR  Patients in the prodromal phase of psychosis or experiencing first-episode psychosis	N=1,808  2 months to 2 years	Primary: Prevention of psychosis, discontinuation, PANSS scores  Secondary: Not reported	Primary: Olanzapine used for the prevention of psychosis for people with prodromal symptoms was associated with a risk ratio for conversion to psychosis of 0.58 (95%CI, 0.3 to 1.2). Cognitive behavioral therapy was associated with a similar risk of conversion to psychosis (RR, 0.50; 95% CI, 0.2 to 1.7).  Risperidone in addition to cognitive behavioral therapy and specialized team was associated with a benefit over specialist team alone at six months of therapy (RR conversion to psychosis, 0.27; 95%CI, 0.1 to 0.9; NNT, 4). However, the benefit of risperidone augmentation was not sustained at 12 months (RR, 0.54; 95%CI, 0.2 to 1.3).  Omega 3 fatty acid was associated with a significant benefit over placebo in the risk of conversion to psychosis (RR, 0.13; 95%CI, 0.02 to 1.0; NNT, 6).  In patients with first-episode psychosis, specialized team involvement

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
vs standard care (at community mental health center)				<p>was associated with a lower risk of discontinuation (NNT=9), improved compliance (NNT=9) and a fewer number of patients not living independently at 5 years (NNT=19), compared to standard of care. There were no significant differences between groups in the mean number of days spent in hospital at one year or number of patients who were not hospitalized by 5 years.</p> <p>There were no significant differences between the group that received phase-specific treatment brief intervention and antipsychotics compared to the treatment as usual group either in discontinuation rate or number of hospital admissions.</p> <p>There were no significant differences between the group that received adherence coping education in addition to antipsychotic therapy and the treatment as usual group either in discontinuation rate, change in PANSS scores or quality of life measures.</p> <p>Secondary: Not reported</p>
<b>Schizophrenia</b>				
Correll et al <sup>27</sup> VECTOR Brexpiprazole 0.25 mg QD vs brexpiprazole 2 mg QD vs brexpiprazole 4 mg QD vs placebo	MC, DB, PB, RCT Patients 18 to 65 years of age with schizophrenia and who experienced an acute exacerbation of psychotic symptoms and would benefit from hospitalization or continued hospitalization for treatment	N=623 6 weeks	Primary: Change from baseline at week six in PANSS total score Secondary: Change from baseline at week six in CGI severity rating and treatment-emergent adverse events	Primary: Treatment with brexpiprazole 2 mg and 4 mg had statistically significantly greater mean improvements in PANSS total score than the placebo at week six. The treatment differences were -8.7 (P<0.0001) and -7.64 (P=0.0006) compared to placebo for brexpiprazole 2 mg and 4 mg, respectively. Secondary: Mean change from baseline at week six in CGI severity total score was statistically significantly greater with brexpiprazole 2 mg and 4 mg compared to placebo (P=0.0006). Overall incidence of treatment-emergent adverse events was lower in the three brexpiprazole groups (48.9% to 56.7%) compared to placebo (62.0%). Akathisia more frequently reported with brexpiprazole 2 mg and

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>4 mg compared to placebo (4.4% and 7.2% vs 2.2%, respectively). Increased body weight was more frequently reported with brexpiprazole 2 mg and 4 mg compared to placebo (2.7% and 3.9% vs 1.6%, respectively). Mean body weight change at week 6 was 1.45 kg and 1.28 kg for brexpiprazole 2 mg and 4 mg and 0.42 kg for the placebo group. Least squares (LS) mean differences from placebo were 1.03 kg for the brexpiprazole 2mg (P=0.03) and 0.86 kg for 4 mg (P=0.07). An increase in body weight of <math>\geq 7\%</math> from baseline at any visit was seen more frequently with brexpiprazole 2 mg and 4 mg compared to placebo (8.8% vs 9.0% vs 4.4%, respectively). No clinically significant changes in physical and laboratory measurements or between treatment groups.</p>
<p>Kane et al<sup>28</sup> BEACON</p> <p>Brexpiprazole 1 mg QD vs brexpiprazole 2 mg QD vs brexpiprazole 4 mg QD vs placebo</p>	<p>MC, DB, PC, RCT</p> <p>Patients 18 to 65 years of age with schizophrenia and who experienced an acute exacerbation of psychotic symptoms, defined by meeting all of the following criteria at screening and baseline visits: BPRS total score <math>\geq 40</math>, score of <math>\geq 4</math> on two or more BPRS items, and CGI-S score <math>\geq 4</math>. Patients were also eligible there was perceived benefit from hospitalization or continued</p>	<p>N=674</p> <p>6 weeks</p>	<p>Primary: Change from baseline to week six in PANSS Total Score</p> <p>Secondary: Change from baseline at week six in CGI-S and treatment-emergent adverse events</p>	<p>Primary: Statistically significant improvement in PANSS Total Score with brexpiprazole 4 mg compared to placebo with a treatment difference of -6.47 (P=0.0022). Brexpiprazole 1 mg and 2 mg had numerical improvements in in PANSS Total Score compared to placebo.</p> <p>Secondary: Improvement in CGI-S score with brexpiprazole 4 mg compared to placebo (LS mean difference: -0.38; P=0.0015). Treatment with brexpiprazole 1 and 2 mg had improvement compared to placebo; however, it was not statistically significant (P&gt;0.05).</p> <p>Most common treatment-emergent adverse events were headache, insomnia and agitation. Reports of akathisia were lower with brexpiprazole (4.2% to 6.5%) compared to placebo (7.1%). Patients treated with brexpiprazole had moderate weight gain from baseline to week six compared to placebo (1.23 to 1.89 kg vs 0.35 kg, respectively). An increase in body weight of <math>\geq 7\%</math> from baseline was greater with brexpiprazole (10% to 12.2%) compared to placebo (3.9%). There were no clinically significant changes in physical and laboratory measurements or EPS between treatment groups.</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
	hospitalization for an acute relapse at trial entry, and had a history of relapse and/or symptom exacerbation when not receiving antipsychotics.			
<p>Potkin et al<sup>29</sup></p> <p>Asenapine 5 mg sublingual twice daily</p> <p>vs</p> <p>risperidone 3 mg orally twice daily</p> <p>vs</p> <p>placebo</p>	<p>AC, DB, DD, FD, MC, PC, PG, RCT</p> <p>Patients ≥18 years of age with a DSM-IV diagnosis of schizophrenia with acute exacerbation of symptoms defined by a CGI-S score ≥4 (at least moderately ill) and a PANSS total score ≥60 (with baseline scores ≥4 required on ≥2 items of the PANSS positive subscale [delusions, conceptual disorganization, hallucinatory behavior, grandiosity, and suspiciousness / persecution]);</p>	<p>N=182 (174, ITT population)</p> <p>6 weeks</p>	<p>Primary: Change from baseline in PANSS total score at end point</p> <p>Secondary: Changes in CGI-S score and PANSS positive, negative, and general psycho-pathology subscale scores; safety analyses (performed in those who received ≥1 dose of study medication)</p>	<p>Primary: Mean changes from baseline in PANSS total score were -15.9 with asenapine vs -5.3 with placebo (P&lt;0.005); the change with risperidone (-10.9) was nonsignificant vs placebo (P value not reported).</p> <p>Asenapine produced significantly greater decreases in PANSS total scores from week 2 onward compared to placebo.</p> <p>Secondary: At end point, mean changes from baseline in CGI-S were -0.74 for asenapine vs -0.28 for placebo (P&lt;0.01); the change with risperidone (-0.75) was also significant vs placebo (P&lt;0.005). Both active treatments were associated with significantly greater decreases in CGI-S scores from week 4 onward compared to placebo.</p> <p>At end point, mean changes from baseline in PANSS positive subscale score were -5.5 for asenapine vs -2.5 for placebo (P=0.01); the change with risperidone (-5.1) was also significant vs placebo (P&lt;0.05). Compared to placebo, there were significantly greater decreases in PANSS positive subscale scores with asenapine from week 3 onward, and with risperidone at weeks 1, 3, 5, and 6.</p> <p>At end point, mean changes from baseline in PANSS negative subscale score were -3.20 for asenapine vs -0.60 for placebo (P=0.01); the change with risperidone (-1.05) was nonsignificant vs placebo. Asenapine produced significantly greater decreases in PANSS negative subscale scores from week 3 onward compared to placebo.</p>



Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
	<p>patients who had previously taken an antipsychotic (other than clozapine) were required to have had a history of a clinically meaningful response to that agent; current antipsychotic medication was discontinued <math>\geq 3</math> days before baseline, current mood stabilization therapy was discontinued <math>\geq 5</math> days before baseline</p>			<p>At end point, mean changes from baseline in PANSS general psychopathology subscale score were -7.2 for asenapine vs -2.2 for placebo (<math>P &lt; 0.005</math>); the change with risperidone (-4.8) was nonsignificant vs placebo. Asenapine produced significantly greater decreases in PANSS general psychopathology subscale scores from week 2 onward compared to placebo.</p> <p>The overall frequency of adverse events was comparable across both treatment groups and placebo. All patients with adverse events recovered without sequelae.</p> <p>There were no significant between-group differences on the SAS, BAS, and AIMS scales, although risperidone-treated patients were more likely to use antiparkinsonian drugs.</p> <p>Incidence of clinically significant weight gain (<math>\geq 7.0\%</math> increase from baseline) was 17.0% with risperidone vs 4.3% with asenapine and 1.9% with placebo.</p> <p>Proportion of patients with post-baseline prolactin levels at end point <math>\geq 2</math> times the laboratory upper limit of normal was higher in the risperidone group (79%) than in the asenapine (9%) or placebo (2%) groups.</p> <p>There were no clinically important between-group differences with respect to treatment effects on blood pressure or heart rate during the study; also, there were no reports of QT interval prolongation <math>&gt; 500</math> ms in any treatment group.</p>
<p>Kane et al<sup>30</sup></p> <p>Asenapine sublingual 5 mg to 10 mg twice daily continued therapy</p> <p>vs</p>	<p>DB, PC, MC, RCT</p> <p>Patients, 18 years of age and older, diagnosed with schizophrenia, history of at least 1 prior acute schizo-</p>	<p>N=700</p> <p>28 weeks (DB phase); 28 weeks (OL phase)</p>	<p>Primary: Time to relapse/impending relapse</p> <p>Secondary: Time to discontinuation for</p>	<p>Primary: Asenapine continued therapy was associated with a significantly lower risk of/impending relapse compared to placebo (12.1 vs 47.4%; <math>P &lt; 0.001</math>). The relative risk of relapse/relative relapse with asenapine vs placebo was 0.26 over 6 months.</p> <p>Secondary: Significantly less patients continuing asenapine therapy discontinued the</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
switching to placebo sublingual from asenapine  Note: prior to double-blind phase, patients were stabilized on 26 weeks of open-label asenapine therapy	phrenia episode in the past 3 years, and schizophrenia requiring continuous antipsychotic therapy for at least 1 year prior to study entry		any reason, changes from baseline in PANSS total, PANSS Marder factors, CGI-S, CGI-I, Calgary Depression Scale for Schizophrenia (CDSS) scores, adverse events	drug early compared to those who switched to placebo (30.4 vs 62.5%; RR, 0.47; P<0.0001).  During the double-blind phase of the study, patients continuing asenapine therapy experienced significant improvements from baseline in the following efficacy measures: PANSS total score, Marder factors (positive, negative, disorganized thought, hostility/excitement, and anxiety/depression symptoms), CGI-S scores, and CDSS total scores (P<0.0001 for all, except CDSS, P=0.027).  During the double-blind phase, the incidence of adverse events considered serious with asenapine and placebo was 3.1% and 9.9%, respectively. The incidence of EPS events with asenapine and placebo was 3.1% and 4.7%, respectively. The most frequently reported adverse events with asenapine vs placebo were anxiety (8.2 vs 10.9%), increased weight (6.7 vs 3.6%), and insomnia (6.2 vs 13.5%). The incidence of weight gain of at least 7% was 3.7% and 0.5% with asenapine and placebo, respectively.
Kane et al <sup>31</sup>  Asenapine 5 mg twice daily vs asenapine 10 mg twice daily vs haloperidol 4 mg twice daily vs placebo	DB, MC, PC, RCT  Adult patients, 18 years of age or older, diagnosed with schizophrenia with an acute exacerbation of psychotic symptoms at study entry	N=458  6 weeks	Primary: Change from baseline in the total PANSS score  Secondary: PANSS Subscale scores, PANSS Marder factors, CGI-S, CDSS, percentage of PANSS responders, percentage of CGI-I responders	Primary: Asenapine 5 mg and haloperidol were both associated with a significant improvement in PANSS total score from baseline, compared to placebo (P<0.05). Asenapine 10 mg was not associated with a significant change from baseline in PANSS total scores.  Secondary: At study endpoint, all treatment groups exhibited significant improvements from baseline compared to placebo in PANSS subscale scores (P<0.05).  All treatment groups were more efficacious than placebo in terms of the positive Marder factor, but none showed advantage on the negative factor. Only haloperidol was more effective than placebo in improving Marder hostility/excitement factor and asenapine 5 mg was the only group who exhibited improvement in Marder anxiety/depression and disorganized thought factors.

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>Significantly more patients in the asenapine 5 mg and 10 mg groups were classified as PANSS responders, compared to placebo (55 vs 49 vs 33%, respectively, P&lt;0.05).</p> <p>Significantly more patients in the asenapine 5 mg group were classified as CGI-I responders, compared to placebo (48 vs 34%, respectively, P&lt;0.05).</p> <p>At study endpoint, asenapine 5 mg and haloperidol groups experienced significant improvement in CGI-S scores from baseline, compared to placebo (P&lt;0.05).</p> <p>At study endpoint, asenapine 5 mg group experienced significant improvement in CDSS scores from baseline, compared to placebo (P&lt;0.05).</p> <p>Treatment-related adverse events were noted in 44%, 52%, 57%, and 41% of the asenapine 5 mg, 10 mg, haloperidol, and placebo groups, respectively. The incidence of EPS was 15%, 18%, 34%, and 10% in the asenapine 5 mg, 10 mg, haloperidol, and placebo groups, respectively. The incidence of clinically significant weight gain was 5%, 4%, 2%, and 4% in the asenapine 5 mg, 10 mg, haloperidol, and placebo groups, respectively. The mean weight gain in patients assigned to asenapine 5 mg, asenapine 10 mg, and placebo groups was 0.7 kg, 0.6 kg, and -0.4 kg, respectively.</p>
<p>Schoemaker et al<sup>32</sup></p> <p>Asenapine 5 mg to 10 mg twice daily</p> <p>vs</p> <p>olanzapine 10 mg to 20 mg once daily</p>	<p>DB, DD, MC, RCT</p> <p>Adult patients, 18 years of age and older, diagnosed with schizophrenia or schizoaffective disorder, PANSS total score ≥60,</p>	<p>N=1,225</p> <p>1 year</p>	<p>Primary: PANSS total score, PANSS Marder factors, CGI-S, discontinuation rate, adverse events</p> <p>Secondary:</p>	<p>Primary: In the last observation carried forward analysis, at 1 year, olanzapine was significantly more effective than asenapine in terms of the following outcome measures: PANSS total score, PANSS Marder factors, and CGI-S (P&lt;0.001). However, there were no significant differences between groups when evaluated by an observed cases analysis.</p> <p>Study completion rates were 38% with asenapine and 57% with olanzapine. Discontinuation due to inadequate response occurred in 25%</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
	including scores $\geq 4$ on at least 2 of 5 items on the PANSS positive subscale, and a CGI-S score of $\geq 4$		Not reported	and 14% of patients receiving asenapine and olanzapine, respectively.  The incidence of adverse events was comparable between the two groups (60% for asenapine and 61% for olanzapine). Mean weight gain was 0.9 kg with asenapine and 4.2 kg with olanzapine ( $P < 0.0001$ ). EPS events were reported by 18% of asenapine-treated patients compared to 8% of patients receiving olanzapine.  Secondary: Not reported
Cutler et al <sup>33</sup>  Iloperidone 24 mg daily  vs  ziprasidone 160 mg daily  vs  placebo daily	AC, DB, MC, PC, PG, RCT  Men and women 18 to 65 years of age diagnosed with acute exacerbations of schizophrenia by DSM-IV criteria, had BMI 18-35 kg/m <sup>2</sup> , CGI-S scores $\geq 4$ at baseline, overall PANSS total scores $\geq 70$ at screening and baseline, a rating of $\geq 4$ (moderate) on at least 2 of the following PANSS Positive Subscale symptoms at screening and baseline: delusions,	N=593  4 weeks	Primary: Change from baseline in PANSS total scores  Secondary: Change from baseline on the PANSS-derived BPRS, PANSS subscales (PANSS-P, PANSS-N, and PANSS-GP), Calgary Depression Scale for Schizophrenia (CDSS), CGI-S, and the Clinical Global Impression of Change  Safety endpoints included: Incidence of treatment-emergent adverse events	Primary: The iloperidone and ziprasidone groups achieved significantly greater improvement in PANSS total scores vs those receiving placebo (iloperidone: -12.0, ziprasidone: -12.3, placebo -7.1; $P < 0.01$ and $P < 0.05$ , respectively).  Secondary: The iloperidone and ziprasidone groups showed significantly greater improvement from baseline to end of study vs placebo in BPRS, PANSS-P, and PANSS-N scores ( $P < 0.05$ for BPRS, PANSS-N; $P < 0.01$ for PANSS-P); no significant difference was observed in reduction of PANSS-GP scores ( $P$ not reported).  Significantly more patients receiving iloperidone (72% [143/200]) than placebo (52% [48/93]) experienced improvement ( $\geq 20\%$ reduction from baseline) in PANSS-P scores ( $P = 0.005$ ).  The iloperidone group showed a significantly greater reduction in CGI-S scores vs placebo (-0.65 and -0.39, respectively; $P = 0.007$ ), as did the ziprasidone group (-0.67; $P = 0.013$ ).  Significantly more patients receiving iloperidone (65% [183/283]) than placebo (52% [73/140]) achieved CGI-C improvement ( $P < 0.05$ ). Both the iloperidone and the ziprasidone did not demonstrate any improvement in CDSS scores vs placebo.

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
	conceptual disorganization, hallucinations, suspiciousness / persecution			<p>Safety: Most adverse events were mild to moderate. Compared to ziprasidone, iloperidone was associated with lower rates of sedation (13 vs 27%), somnolence (4 vs 6%), EPS (3 vs 9%), akathisia (1 vs 7%), agitation (3 vs 7%), and restlessness (4 vs 5%). However, iloperidone demonstrated higher rates of weight gain (11 vs 5%), tachycardia (9 vs 2%), orthostatic hypotension (7 vs 0), dizziness (17 vs 13%), and nasal congestion (8 vs 3%) compared to ziprasidone.</p> <p>The incidence of clinically relevant changes in laboratory parameters was comparable between iloperidone and ziprasidone including total cholesterol, triglycerides, glucose, and prolactin.</p>
<p>Potkin et al<sup>34</sup></p> <p>Study 1: iloperidone 4, 8 or 12 mg daily or haloperidol 15 mg daily  vs  placebo daily</p> <p>Study 2: iloperidone 4 to 8 mg daily or iloperidone 10 to 16 mg daily or risperidone 4 to 8 mg daily  vs  placebo daily</p>	<p>3 AC, DB, MC, PC, RCT,  Adults aged 18 to 65 years with acute or subacute exacerbation of schizophrenia and PANSS total score of <math>\geq 60</math> at screening and at baseline</p>	<p>N=1943  6 weeks</p>	<p>Primary: Study 1: Change in PANSS total score  Study 2 &amp; 3: Change in BPRS scores  Secondary: PANSS-P scale, PANSS-N scale, PANSS-GP, BPRS and CGI-S (in studies 2 &amp; 3)</p>	<p>Primary: Study 1: PANSS-T scores significantly improved from baseline with, iloperidone 12 mg daily and with haloperidol 15 mg (iloperidone 12 mg: -9.0, haloperidol 15 mg: -13.9; placebo: P=0.047 and P&lt;0.001, respectively). However, in the iloperidone 4 mg daily, and the iloperidone 8 mg groups (4 mg: -9.0; 8 mg: -7.8, placebo -4.6; P=0.097 and P=0.047 respectively), PANSS improvements were not significantly different.</p> <p>Study 2: Significant improvement in BPRS scores were demonstrated in all of iloperidone doses and with risperidone when compared to placebo. The decrease in BRPS-TS for the iloperidone 4 mg to 8 mg dose was -6.2 (P=0.012), iloperidone 10 mg/day to 16 mg/day dose was -7.2 (P=0.001) and risperidone 4 mg to 8 mg dose was -10.3 (P&lt;0.001).</p> <p>Study 3: Significant improvement in BPRS scores were demonstrated with iloperidone 20 mg/day to 24 mg/day (-8.6; P=0.010) and risperidone 6 mg to 8 mg (-11.5; P&lt;0.001) compared to placebo (-5.0). Improvement in BPRS score for the iloperidone 12 mg/day to 16 mg/day (-7.1; P=0.09) group was not significantly different compared to placebo.</p> <p>Secondary: Study 1: Iloperidone 12 mg along with haloperidol 15 mg was significantly</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
<p>Study 3:                      iloperidone 12 to 16 mg daily                      or                      iloperidone 20 to 24 mg/day                      or                      risperidone 6 to 8 mg daily                      vs                      placebo daily</p>				<p>more effective than placebo at improving BPRS scores (iloperidone: -6.8, haloperidol: -9.0, placebo: -3.6; P=0.042 and P&lt;0.001 respectively). Iloperidone 4 mg and 8 mg were not statistically significant in reducing BPRS scores compared to placebo (4 mg: -6.4, 8 mg: -3.8; P=0.070 and P=0.095 respectively).</p> <p>Study 2: Iloperidone 4 mg to 8 mg significantly improved PANSS-T (-9.5 vs -3.5 with placebo; P=0.017), PANSS-P (-3.5 vs -1.6 with placebo; P=0.020), PANSS-GP (-4.2 vs -1.1 with placebo; P=0.017), and CGI-S (-0.6 vs -0.2 with placebo; P=0.003) scores. Iloperidone 10 mg to 16 mg significantly decreased PANSS-T (-11.1 vs -3.5 with placebo; P=0.002), PANSS-P (-4.1 vs -1.6 with placebo; P=0.002), PANSS-N (-2.4 vs -1.0 with placebo; P=0.021), PANSS-GP (-4.8 vs -1.1 with placebo; P=0.003), and CGI-S (-0.5 vs -0.2 with placebo; P=0.006) scores.</p> <p>Study 3: Iloperidone 12 mg to 16 mg significantly improved CGI-S (-0.6 vs -0.4 with placebo; P=0.028) scores, whereas iloperidone 20 mg to 24 mg significantly decreased PANSS-T (-14.0 vs -7.6 with placebo; P=0.005), PANSS-P (-5.1 vs -3.1 with placebo; P=0.008), PANSS-N (-2.8 vs -3.4 with placebo; P=0.023), PANSS-GP (-5.9 vs -2.8 with placebo; P=0.007), and CGI-S (-0.6 vs -0.4 with placebo; P=0.037) scores.</p>
<p>Cutler et al (abstract)<sup>268</sup>                      Iloperidone 24 mg daily                      Patients could be reduced to 12 mg daily any time after day 35 at the investigators discretion.</p>	<p>ES                      Patients with schizophrenia who had previous been treated with iloperidone for ≥4 weeks</p>	<p>N=173                      25 weeks</p>	<p>Primary:                      Treatment-emergent adverse events, PANSS total score                      Secondary:                      Not reported</p>	<p>Primary:                      Treatment-emergent adverse events were mostly mild to moderate in severity and included headache (13.9%), weight increase (9.2%), dizziness (6.9%), nausea (6.4%), sedation (6.4%), and insomnia (5.2%). The only notable dose-related treatment-emergent adverse events were increased weight and headache. Levels of serum glucose, lipids, and prolactin were essentially unchanged or decreased during treatment.</p> <p>In general, akathisia and EPS improved or were unchanged during treatment.</p> <p>There was no signal of worsening of efficacy based on changes from</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				baseline in the PANSS total score.  Secondary: Not reported
Citrome et al <sup>35</sup>  Iloperidone 4 mg to 8 mg daily  vs  iloperidone 10 mg to 16 mg daily  vs  iloperidone 20 mg to 24 mg daily  vs  active controls (haloperidol 15 mg daily, risperidone 4 mg to 8 mg daily, or ziprasidone 160 mg daily)  vs  placebo	MA, PH  Patients, aged 18 to 65 years, diagnosed with schizophrenia or schizoaffective disorder	N=3,580  4 to 6 weeks	Primary: PANSS subscales (excitement/hostility, depression/anxiety, cognition, positive and negative symptoms)  Secondary: Not reported	Primary: Compared to placebo, iloperidone 10-16 mg and 20-24 mg groups exhibited improvement from baseline in excitement/hostility scores of the PANSS subscale (P<0.001).  Compared to placebo, iloperidone 10-16 mg and 20-24 mg groups exhibited improvement from baseline in depression/anxiety scores of the PANSS subscale (P<0.05).  Compared to placebo, iloperidone 10-16 mg and 20-24 mg groups exhibited improvement from baseline in cognition scores of the PANSS subscale (P<0.05).  Compared to placebo, iloperidone 10-16 mg and 20-24 mg groups exhibited improvement from baseline in terms of positive scores of the PANSS subscale (P<0.05).  Compared to placebo, iloperidone 10-16 mg group exhibited a significant improvement from baseline in terms of negative scores of the PANSS subscale (P<0.05).  Compared to placebo, risperidone group exhibited statistically significant improvements from baseline in all five PANSS subscales (P<0.05).  Compared to placebo, ziprasidone group exhibited improvements from baseline in the cognition, excitement/hostility, and positive symptom PANSS subscales (P<0.05).  Secondary: Not reported
Citrome et al <sup>36</sup>	MA, PH	N=2,401	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
Iloperidone 4 mg to 8 mg daily vs iloperidone 10 mg to 16 mg daily vs iloperidone 20 mg to 24 mg daily vs active controls (haloperidol 15 mg daily, risperidone 4 mg to 8 mg daily, or ziprasidone 160 mg daily) vs placebo	Patients, aged 18 to 65 years, diagnosed with schizophrenia or schizoaffective disorder	4 to 6 weeks	Change from baseline in BPRS derived scores, total PANSS scores, PANSS positive, and PANSS negative scores  Secondary: Not reported	Compared to placebo, iloperidone 10-16 mg and 20-24 mg groups exhibited improvement from baseline in BPRS derived scores, total PANSS scores, PANSS positive, and PANSS negative scores (P<0.05).  Compared to placebo, haloperidol, risperidone and ziprasidone treatment groups exhibited improvements from baseline in BPRS derived scores, total PANSS scores, PANSS positive, and PANSS negative scores (P<0.05).  The most commonly reported adverse events with iloperidone which occurred more frequently than with placebo were dizziness, dry mouth, somnolence, nasal congestion, fatigue, sedation, and tachycardia. The NNH value for dizziness in patients receiving iloperidone was calculated as 8. The incidence of EPS events was comparable to the placebo group.  Secondary: Not reported
Kane et al <sup>37</sup> Iloperidone 4-16 mg daily vs haloperidol 5-20 mg daily	MA Adults 18 to 65 years of age diagnosed with schizophrenia or schizoaffective disorder based on DSM-IV criteria, a PANSS score of >60, normal vital	N=489 52 weeks (6 week phase, followed by a 46-week phase)	Primary: Time to relapse during long-term phase  Secondary: Change in PANSS total score, Brief Psychiatric Rating scale, CGI-C, adverse events, lab	Primary: Relapse rates were similar between the groups with 43.5% in the iloperidone group and 41.2% in the haloperidol group (HR, 1.030; 95% CI, 0.743 to 1.428; P=0.8596). The mean time to relapse was not significant with 89.8 days in the iloperidone group compared to 101.8 days in the haloperidol group (P=0.8411).  Secondary: There was no significant difference between treatment groups in mean change in PANSS total scores (-16.1 for iloperidone vs -17.4 for haloperidol; P=0.338).



Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
	<p>signs, no contraindication to study medications and an available caregiver to support treatment adherence</p>		<p>tests and 12-lead electrocardiogram</p>	<p>There was no significant difference between treatment groups in changes in Brief Psychiatric Rating scale (−9.0 for iloperidone vs −9.6 for haloperidol; P=0.390).</p> <p>Of the patients treated with iloperidone, 65.0% exhibited improvement in CGI-C scores compared to 66.0% treated with haloperidol (P value not reported).</p> <p>Overall, 73.3% of patients who received iloperidone experienced at least 1 adverse event compared to 68.6% of patients in the haloperidol group (P value not reported).</p> <p>At study end, iloperidone demonstrated significant improvement in overall ratings of EPS (−1.6) compared to haloperidol, which worsened from baseline (0.6; P&lt;0.001).</p> <p>Long-term treatment with iloperidone produced slight increases in total cholesterol (−0.26 to 0.89 mg/dL), triglycerides (0.31 to 6.82 mg/dL) and glucose levels (2.66 to 5.80 mg/dL; P values not reported). Haloperidol changes from baseline to endpoint were as follows: in total cholesterol (7.44 to 6.95 mg/dL), triglycerides (−0.11 to 12.08 mg/dL) and glucose levels (−0.41 to −0.49 mg/dL; P values not reported).</p> <p>Similar changes in QTc prolongation were noted between the groups (P value not reported).</p>
<p>Weiden et al<sup>38</sup></p> <p>Study 1: Iloperidone 4, 8 or 12 mg/day or haloperidol 15 mg daily</p> <p>vs</p>	<p>MA</p> <p>Adults aged 18 to 65 years with acute or subacute exacerbation of schizophrenia and PANSS total score of ≥60 at screening</p>	<p>N=1553</p> <p>6 weeks</p>	<p>Primary: Short term safety of iloperidone including dose related adverse events, QT prolongation, weight gain, and changes in</p>	<p>Primary: Across all doses of iloperidone the most common dose related adverse events were dry mouth, dizziness, somnolence, and dyspepsia. EPS disorders, tremor, akathisia, dystonia and somnolence also occurred with iloperidone; however, these symptoms occurred more often in the haloperidol group and the risperidone group. Other events that occurred more often in the risperidone group than the iloperidone groups included akathisia, tremor, and somnolence.</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
<p>placebo daily</p> <p>Study 2:                      iloperidone 4 to 8 mg daily                      or                      iloperidone 10 to 16 mg daily                      or                      risperidone 4 to 8 mg daily</p> <p>vs</p> <p>placebo daily</p> <p>Study 3:                      iloperidone 12 to 16 mg daily                      or                      iloperidone 20 to 24 mg daily                      or                      risperidone 6 to 8 mg daily</p> <p>vs</p> <p>placebo daily</p>	<p>and at baseline</p> <p>This trial reported the safety results for the trial by Potkin et al.</p>		<p>laboratory values.</p> <p>Secondary:                      Not reported</p>	<p>QTc prolongation increased in all iloperidone groups. QTcF increased from baseline to 2.9 msec with iloperidone 4 mg/day to 8 mg/day, 3.9 msec with iloperidone 10 mg/day to 16 mg/day, and 9.1 msec with iloperidone 20 mg/day to 24 mg/day (all P&lt;0.05). Patients in the haloperidol group also demonstrated a significant increase in QTcF from baseline of 5.0 msec (P&lt;0.05); however, patients in the risperidone groups showed a non-significant increase from baseline in QTcF interval of 0.6 msec (P= not significant)</p> <p>Weight gain experienced with iloperidone was statistically significant compared to placebo with an average increase of 1.5 kg with 4 mg/day to 8 mg/d, 2.1 kg with 10 mg/day to 16 mg/day and 1.7 kg with 20 mg/day to 24 mg/day (all P&lt;0.05). In the risperidone group, the average weight gain was 1.5 kg (P=0.05 vs placebo). The only group that did not experience weight gain was haloperidol (-0.4 kg; P value not reported).</p> <p>Similar changes were seen in all treatment groups in blood glucose levels, total cholesterol, and triglycerides. In the iloperidone group prolactin levels were generally decreased after treatment; while the haloperidol and risperidone groups demonstrated significantly increased levels of prolactin.</p> <p>Secondary:                      Not reported</p>
<p>Nasrallah et al<sup>269</sup></p> <p>Lurasidone 40 mg daily</p> <p>vs</p> <p>lurasidone 80 mg daily</p> <p>vs</p> <p>lurasidone 120 mg daily</p>	<p>DB, MC, PC, PG, RCT</p> <p>Patients 18 to 75 years of age with schizophrenia for ≥1 year and were currently experiencing an acute exacerbation of psychotic</p>	<p>N=500</p> <p>6 weeks</p>	<p>Primary:                      PANSS total score</p> <p>Secondary:                      CGI-S, PANSS subscale scores, MADRS and adverse events</p>	<p>Primary:                      Patients treated with lurasidone 80 mg experienced significantly greater improvements in PANSS total score compared to placebo (-23.4 vs -17.0; P&lt;0.05); however, there was no significant differences compared to placebo for the 40 mg or 120 mg groups (-19.2 and -20.5, respectively; P values not reported). Significantly greater improvement in PANSS total score was observed from week two onward for patients receiving lurasidone 80 mg compared to placebo.</p> <p>Secondary:                      Significant improvements in CGI-S scores were reported with lurasidone</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
vs placebo	symptoms (lasting ≤2 months), CGI-S ≥4, PANSS score ≥80, including a score ≥4 on 2 or more of the following five items: delusions, conceptual disorganization, hallucinations, unusual thought content, and suspiciousness			<p>80 mg compared to placebo (-1.4 vs -1.0; P&lt;0.05); however, no significant difference was reported among patients treated with the 40 mg or 120 mg doses (-1.1 and -1.2, respectively; P value not reported).</p> <p>Treatment with lurasidone 80 mg or 120 mg was associated with significant improvement in the PANSS positive symptoms subscale score at six weeks compared to placebo (P&lt;0.001 and P&lt;0.05, respectively).</p> <p>Changes in PANSS negative symptoms and general psychopathology subscales were not significantly different for any of the lurasidone groups compared to placebo.</p> <p>The change in MADRS scores were not statistically significant for any lurasidone group compared to placebo at six weeks.</p> <p>The proportion of patients receiving lurasidone 40 mg, 80 mg and 120 mg who experienced at least one adverse event was 77.4, 74.4 and 85.5%, respectively, compared to 66.9% for those receiving placebo. The most common adverse events reported with lurasidone were akathisia, headache, somnolence, nausea and sedation. The majority of adverse events were mild or moderate in intensity.</p> <p>The rate of discontinuation due to adverse events was 5.6, 9.1 and 12.9%, respectively, for patients receiving lurasidone and 8.7% for patients receiving placebo.</p> <p>The proportion of patients with clinically significant weight gain (≥7%) was greater for those receiving lurasidone 40 mg (9.0%), 80 mg (9.3%) and 120 mg (6.5%) compared to placebo (3.2%).</p> <p>Treatment with lurasidone, regardless of dose, was associated with minimal changes in median total cholesterol, LDL, HDL and TG. Median changes in fasting glucose and HbA<sub>1c</sub> were quite small and were similar between the lurasidone and placebo groups</p>
Nakamura et al <sup>39</sup>	DB, MC, PG, PC	N=180	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
<p>Lurasidone 80 mg daily</p> <p>vs</p> <p>placebo</p>	<p>RCT</p> <p>Patients aged 18-64 years who were hospitalized for an acute exacerbation of schizophrenia, with a minimum illness duration of 1 year, Brief psychiatric Rating Scale (BPRSd) total score (extracted from the positive and negative syndrome scale (PANSS) of at least 42 with a score of at least 4 on 2 or more positive symptom items, a Clinical Global Impressions-Severity of Illness Scale (CGI-S) score <math>\geq 4</math>, a Simpson-Angus Scale (SAS) score of <math>&lt; 2</math> and an Abnormal Involuntary Movement Scale (AIMS) score of <math>&lt; 3</math></p>	<p>6 weeks (patients were hospitalized until at least day 28)</p>	<p>BPRSd extracted from the PANSS</p> <p>Secondary: PANSS total, PANSS positive symptoms, PANSS negative symptoms, PANSS general psychopathology, PANSS cognitive, CGI-S, Montgomery-Asberg Depression Rating Scale (MADRS), adverse events</p>	<p>Patients in the lurasidone group experienced a statistically significant improvement from baseline in the BPRSd score over the placebo group (8.9 vs -4.2; P=0.0118).</p> <p>Secondary: Patients in the lurasidone group experienced a statistically significant improvement in total PANSS score over placebo (-14.1 vs -5.5; P=0.0040).</p> <p>Patients in the lurasidone group experienced a statistically significant improvement in positive PANSS score over placebo (-4.3 vs -1.7; P=0.0060).</p> <p>Patients in the lurasidone group experienced a statistically significant improvement in negative PANSS score over placebo (-2.9 vs -1.3; P=0.0250).</p> <p>Patients in the lurasidone group experienced a statistically significant improvement in general psychopathology PANSS score over placebo (-7.0 vs -2.7; P=0.0061).</p> <p>Patients in the lurasidone group experienced a statistically significant improvement in cognitive PANSS score over placebo (-2.1 vs -0.5; P=0.0015).</p> <p>Patients in the lurasidone group experienced a statistically significant improvement in CGI-S score over placebo (-0.6 vs -0.2; P=0.0072).</p> <p>Patients in the lurasidone group experienced a statistically significant improvement in MADRS score over placebo (-2.9 vs -0.1; P=0.0187).</p> <p>The change from baseline SAS score was not statistically different between the lurasidone and placebo groups (0.2 vs 0.1; P=0.58).</p> <p>The change from baseline BAS score was statistically different between</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>the lurasidone and placebo groups with more patients in the lurasidone group experiencing akathisia (0.2 vs -0.1; P=0.03).</p> <p>The change from baseline AIMS score was not statistically different between the lurasidone and placebo groups (0.3 vs 0.5; P=0.61).</p> <p>Treatment with lurasidone was not associated with any significant treatment-emergent ECG abnormalities.</p> <p>There were no clinically significant changes in heart rate or blood pressure.</p> <p>The incidence of clinically significant (&gt;7% increase from baseline) weight gain was slightly lower in the lurasidone group vs placebo (6.7 vs 7.8%, P value not reported).</p> <p>There were no significant differences between lurasidone and placebo with regard to cholesterol, triglycerides, high density lipoprotein, or fasting blood glucose (no P value given). There was a statistically significant increase in HbA<sub>1c</sub> in the lurasidone group vs placebo (0.1 vs 0.0%; P&lt;0.05). Treatment with lurasidone was associated with a statistically significant increase in prolactin levels over placebo (2.4 vs -0.3 ng/mL; P&lt;0.05).</p>
<p>Harvey et al<sup>40</sup></p> <p>Lurasidone 120 mg once daily</p> <p>vs</p> <p>ziprasidone 80 mg twice daily</p>	<p>DB, RCT</p> <p>Patients, aged 18 to 70 years, with chronic schizophrenia or schizoaffective disorder, without hospitalization or acute exacerbation of psychosis in the prior 3 months</p>	<p>N=301</p> <p>21 days</p>	<p>Primary:</p> <p>MATRICES Consensus Cognitive Battery (MCCB), Schizophrenia Cognition Rating Scale (SCoRS), Wechsler Memory Scale (WMS), Neuropsychological Assessment</p>	<p>Primary:</p> <p>There was no statistically significant difference between treatment groups in changes from baseline on the composite MCCB score (P=0.73).</p> <p>There was no statistically significant difference between treatment groups in changes from baseline in SCoRS scores (P=0.056).</p> <p>Compared to baseline, lurasidone therapy was associated with significant improvements in MCCB scores, BACS Symbol Coding scores, Trail Making Part A scores, and the WMS spatial span scores (P&lt;0.05).</p> <p>Compared to baseline, ziprasidone therapy was associated with</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
			Battery (NAB)  Secondary: Not reported	significant improvements in BACS Symbol Coding scores, animal naming, NAM Mazes, and Trail Making Part A scores (P<0.05).  Secondary: Not reported
Potkin et al <sup>41</sup>  Lurasidone 120 mg once daily  vs  ziprasidone 80 mg twice daily	DB, RCT  Patients, aged 18 to 70 years, with chronic schizophrenia or schizoaffective disorder, without hospitalization or acute exacerbation of psychosis in the prior 3 months	N=301  21 days	Primary: PANSS negative, PANSS positive, PANSS total, PANSS general psychopathology, CGI scores  Secondary: Not reported	Primary: Lurasidone was associated with significantly greater reduction in PANSS negative symptom scores compared to ziprasidone (-1.3 vs -0.6; P=0.046).  There were no statistically significant differences between the two groups in the reduction from baseline in PANSS total, PANSS positive symptom, PANSS general psychopathology, or CGI-S scores (P>0.05).  The percentage of patients who discontinued from the study due to any reason was comparable between the lurasidone and ziprasidone groups (32.5 vs 30.7%). The discontinuation rate due to adverse events was also similar in the lurasidone and ziprasidone groups (10.4 vs 11.1%).  Treatment with lurasidone and ziprasidone was associated with a small endpoint reduction in median weight (-0.65 kg vs -0.35 kg) and median total cholesterol (-6.4 mg/dl vs -44 mg/dl). Neither of the two groups experienced a change in median triglyceride levels. Likewise, neither of the two groups was associated with a clinically significant ECG abnormality. EPS events were noted in 3.3% of patients receiving lurasidone and 1.3% of patients in the ziprasidone group.  Secondary: Not reported
Meltzer et al <sup>42</sup>  Lurasidone 40 mg once daily  vs	DB, MC, PC, RCT  Patients aged 18-75 years who had experienced an	N=478  6 weeks	Primary: Change in PANSS total score at 6 weeks  Secondary:	Primary: All active treatment groups experienced a statistically significant improvement in the primary endpoint compared to the placebo group (P<0.05).  Secondary:

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
lurasidone 120 mg once daily vs olanzapine 15 mg once daily vs placebo	acute exacerbation of psychotic symptoms $\leq 2$ months and had marked deterioration of function from baseline or patients who had been hospitalized for the treatment of an acute psychotic exacerbation for $\leq 2$ weeks before screening, with a minimum illness duration of 1 year, PANSS total score of $\geq 80$ , with a score of at least 4 on 2 or more of select PANSS items, score of $\geq 4$ on the SGI-S at screening		PANSS positive symptoms, PANSS negative symptoms, PANSS, general psychopathology, CGI-S, MADRS, PANSS response rate ( $\geq 20\%$ improvement from baseline) at week-six, adverse events	<p>All active treatment groups experienced a statistically significant improvement in PANSS positive symptoms compared to the placebo group (<math>P &lt; 0.05</math>).</p> <p>All active treatment groups experienced a statistically significant improvement in PANSS negative symptoms compared to the placebo group (<math>P &lt; 0.05</math>).</p> <p>All active treatment groups experienced a statistically significant improvement in PANSS general psychopathology symptoms, compared to the placebo group (<math>P &lt; 0.05</math>).</p> <p>All active treatment groups experienced a statistically significant improvement in CGI-S compared to the placebo group (<math>P &lt; 0.05</math>).</p> <p>Compared to placebo, only patients receiving olanzapine experienced a statistically significant improvement in MADRS (<math>P = 0.003</math>).</p> <p>Compared to placebo, significantly more patients in the olanzapine group achieved PANSS response (<math>P &lt; 0.001</math>). While more patients in the lurasidone groups experienced response to therapy, statistically significant difference from placebo was not reached.</p> <p>The percentage of patients experiencing at least one treatment emergent adverse event was 78.9% with lurasidone, 82% with olanzapine and 72.4% with placebo. The most frequently reported adverse events associated with lurasidone therapy were headache, akathisia, somnolence, insomnia, and sedation. Change in EPS, measured by SAS, BAS, and AIMS was absent or mild in lurasidone-treated patients. ECG abnormalities were not observed.</p>
Ogasa et al <sup>270</sup> Lurasidone 40 mg once daily vs	DB, MC, PC, PG, RCT Patients 18 to 64 years of with	N=149 6 weeks	Primary: Mean change in BPRSd Secondary:	Primary: The LS mean change in BPRSd score from baseline was significantly greater with lurasidone 40 mg (-9.4; $P = 0.018$ ) and 120 mg (-11.0; $P = 0.004$ ) compared to placebo (-3.8).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
lurasidone 120 mg once daily vs placebo	schizophrenia for at least one year who were hospitalized for an acute exacerbation of symptoms and BPRS from the PANSS of $\geq 42$ , a score of $\geq 4$ on two or more items of the positive symptoms subscale on the PANSS, CGI-S score of $\geq 4$		Mean change from baseline in PANSS scores and CGI-S and adverse events	<p>Secondary:</p> <p>The PANSS total score was significantly improved with lurasidone 120 mg compared to placebo (-17.0; P=0.009); however, there was no statistically significant improvement with the 40 mg dose (-14.0; P=0.076).</p> <p>The PANSS positive symptom score was significantly improved from baseline with lurasidone 40 mg (-4.6; P=0.018) and 120 mg (-5.1; P=0.005) compared to placebo.</p> <p>The PANSS negative symptom score was significantly improved from baseline with lurasidone 120 mg compared to placebo (-4.0; P=0.011); however, there was no statistically significant improvement with the 40 mg dose (-2.7; P=0.177).</p> <p>The change from baseline in PANSS general psychopathology was significantly improved with lurasidone 120 mg compared to placebo (-7.8; P=0.023); however, the improvement with the 40 mg dose was not significant (-5.8; P=0.185).</p> <p>The mean changes in CGI-I and CGI-S were significantly greater with both doses of lurasidone compared to placebo (P&lt;0.05 for all).</p> <p>The most commonly reported adverse events for patients receiving lurasidone were nausea (16.2%), sedation (16.2%), akathisia (11.1%), dizziness (11.1%), and headache (11.1%). More patients receiving lurasidone 120 mg reported nausea and akathisia (22.4 and 14.3%, respectively) compared to those receiving lurasidone 40 mg (10 and 8%, respectively). The majority of adverse events were mild to moderate in intensity.</p> <p>There were minimal changes in mean body weight in any treatment group after six weeks of treatment. The change in median total cholesterol was comparable for patients treated with lurasidone (-13 mg/dL for lurasidone 40 mg and -3 mg/dL for lurasidone 120 mg) and patients in the placebo group (-11.0 mg/dL). Median triglyceride levels remained unchanged in</p>



Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>the lurasidone 40 mg group, increased by 16.5 mg/dL in the lurasidone 120 mg group, and decreased by -11 mg/dL in the placebo group. Median serum glucose levels were either unchanged or minimally decreased from baseline to six weeks. There were no clinically significant hematology laboratory test results or urinalysis results reported.</p>
<p>Lieberman et al<sup>43</sup>                      CATIE Phase 1                      Olanzapine 7.5-30 mg/day                      vs                      perphenazine 8-32 mg/day                      vs                      quetiapine 200-800 mg/day                      vs                      risperidone 1.5-6.0 mg/day                      vs                      ziprasidone 40-160 mg/day</p>	<p>DB, MC, RCT                      Patients 18 to 65 years old with a diagnosis of schizophrenia, a condition appropriate for treatment with an oral medication, and the decision-making capacity to make choices and provide informed consent</p>	<p>N=1,493                      Up to 18 months</p>	<p>Primary:                      Discontinuation of treatment for any cause                      Secondary:                      Specific reasons for the discontinuation of treatment, and adverse effects</p>	<p>Primary:                      Overall, 74% of patients discontinued treatment before 18 months (olanzapine, 64%; risperidone, 74%; perphenazine, 75%; ziprasidone, 79%; quetiapine, 82%). Time to treatment discontinuation for any cause was significantly longer with olanzapine compared to quetiapine (P&lt;0.001) and risperidone (P=0.002), but not compared to perphenazine (P=0.021)<sup>†</sup> or ziprasidone (P=0.028)<sup>†</sup>.                      Secondary:                      Treatment discontinuation due to lack of efficacy occurred in 28% of patients in the quetiapine group, 27% of the risperidone group, 25% of the perphenazine group, 24% of the ziprasidone group, and 15% of the olanzapine group. Time to discontinuation due to lack of efficacy was significantly longer with olanzapine than with all of the other groups (P&lt;0.001) except ziprasidone (P=0.026)<sup>†</sup>.                      Treatment discontinuation due to intolerability occurred in 19% of patients who received olanzapine, 16% of the perphenazine group, 15% of both the quetiapine and ziprasidone groups, and 10% of the risperidone group. Time to discontinuation due to intolerability was similar among the groups (P≥0.027)<sup>†</sup>.                      Thirty-four percent of patients in the ziprasidone group, 33% of the quetiapine group, 30% of both the risperidone and perphenazine groups, and 24% of the olanzapine group decided to discontinue treatment. Time to treatment discontinuation was significantly longer with olanzapine than with quetiapine (P&lt;0.001) and risperidone (P=0.008), but not compared to perphenazine (P=0.036)<sup>†</sup> or ziprasidone (P=0.018)<sup>†</sup>.                      Olanzapine was associated with the greatest discontinuation rates due to</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
<p>McEvoy et al<sup>44</sup></p> <p>CATIE Phase 2 (efficacy)</p> <p>Clozapine 200-600 mg/day</p> <p>vs</p> <p>olanzapine 7.5-30.0 mg/day</p> <p>or</p> <p>quetiapine 200-800 mg/day</p> <p>or</p> <p>risperidone 1.5-6.0 mg/day</p>	<p>DB, MC, OL (clozapine), RCT</p> <p>Patients 18 to 65 years old with a diagnosis of schizophrenia, a condition appropriate for treatment with an oral medication, and the decision-making capacity to make choices and provide informed consent who had discontinued the second generation antipsychotic given in CATIE Phase 1 due to lack of efficacy</p>	<p>N=99</p> <p>Up to 18 months</p>	<p>Primary: Time until discontinuation for any reason</p> <p>Secondary: Time to discontinuation for inadequate therapeutic benefit, intolerable side effects, or patient decision, psychopathology, and adverse events</p>	<p>weight gain or metabolic effects, while perphenazine had the greatest discontinuation rates due to EPS. Olanzapine also had the greatest adverse effects on HbA<sub>1c</sub>, total cholesterol, and triglycerides.</p> <p>Primary: Overall, 69% of patients discontinued treatment prior to study completion (clozapine, 56%; olanzapine, 71%; risperidone, 86%; quetiapine, 93%). Time to all-cause treatment discontinuation was significantly longer with clozapine (median 10.5 months) than with quetiapine (3.3 months; P=0.01), or risperidone (2.8 months; P&lt;0.03), but not with olanzapine (2.7 months; P=0.12).</p> <p>Secondary: Discontinuation for inadequate therapeutic benefit occurred in 43% of patients in the quetiapine and risperidone groups, 35% of the olanzapine group, and 11% for the clozapine group. Time to discontinuation for inadequate therapeutic benefit was significantly longer for clozapine compared to the other three agents (P&lt;0.02 for each comparison).</p> <p>There were no significant differences between treatments in time to discontinuation due to intolerable side effects or patient decision (P values not reported).</p> <p>Clozapine significantly reduced the PANSS total score (mean, -11.7) compared to quetiapine (2.5; P=0.02) and risperidone (4.1; P&lt;0.03), but not compared to olanzapine (-3.2; P=0.22). Significant reductions in CGI scale scores at 3 months were seen with clozapine (mean, -0.7) compared to olanzapine (0.1; P&lt;0.02) and quetiapine (0.2; P=0.003), but not compared to risperidone (0.0; P=6.18).</p> <p>Due to the small number of patients, adequate power was not reached to reasonably compare adverse events among the groups. Reported adverse events included anticholinergic events (highest with quetiapine, 47%), insomnia (risperidone, 31%), sialorrhea (clozapine, 33%), prolactin levels increased (risperidone, exposure-adjusted mean, 14.4 ng/mL).</p>
<p>Stroup et al<sup>45</sup></p>	<p>DB, MC, RCT</p>	<p>N=444</p>	<p>Primary:</p>	<p>Primary:</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
CATIE Phase 2 (tolerability) Ziprasidone 40-160 mg/day vs olanzapine 7.5-30.0 mg/day or quetiapine 200-800 mg/day or risperidone 1.5-6.0 mg/day	Patients 18 to 65 years old with a diagnosis of schizophrenia, a condition appropriate for treatment with an oral medication, and have the decision-making capacity to make choices and provide informed consent who had discontinued the SGA given in CATIE Phase 1 due to intolerability	Up to 18 months	Time until treatment discontinuation for any reason  Secondary: Time to treatment discontinuation for inadequate therapeutic benefit, intolerable side effects, or patient decision, PANSS scores, CGI ratings, safety and tolerability outcomes	Overall, 74% of patients discontinued treatment before completion of the study. Time to discontinuation for any reason was longer with olanzapine (median, 6.3 months) and risperidone (7.0 months) than with the quetiapine (4.0 months) and ziprasidone (2.8 months) groups (P=0.004 for overall group difference).  Secondary: There were no differences among treatment groups regarding discontinuation due to lack of efficacy or intolerable side effects.  In those patients who discontinued previous therapy due to inefficacy, olanzapine was more effective than quetiapine and ziprasidone, and risperidone was more effective than quetiapine (P=0.004 among groups). There were no significant differences between groups in those who discontinued previous treatment due to intolerability (P value not reported).  There were significantly greater improvements in PANSS scores with olanzapine than with quetiapine (estimated MD, -6.8; P=0.005) and ziprasidone (estimated MD, -5.9; P=0.005), but not with risperidone. There were no differences in changes in CGI scores between treatment groups (P values not reported).  Hospitalizations due to schizophrenia exacerbation were lower with olanzapine (0.28) than with risperidone (0.40), ziprasidone (0.48), and quetiapine (0.70). Common adverse events included sexual dysfunction (highest with risperidone, 29%), insomnia (ziprasidone, 31%), orthostatic faintness (quetiapine, 13%), weight gain (olanzapine, 1.3 lb/month), increases in total cholesterol (olanzapine, mean, -17.5 mg/dL), prolactin (risperidone, mean, 24.0 ng/mL), and triglycerides (mean, 94.1 mg/dL).
Stroup et al <sup>45</sup> CATIE Phase 3 Monotherapy with	OL Patients 18 to 65 years old with a diagnosis of	N=270 Up to 18 months	Primary: Time until treatment discontinuation for any reason	Primary: Overall, 39% of patients discontinued treatment prior to study completion. A similar number of patients within the commonly selected regimens (second generation antipsychotics) discontinued therapy for any reason (33%-46%). There were no substantial differences between treatments in

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
aripiprazole, clozapine, olanzapine, perphenazine, quetiapine, risperidone, or ziprasidone or fluphenazine decanoate or combination of any two of these treatments	schizophrenia, a condition appropriate for treatment with an oral medication, and have the decision-making capacity to make choices and provide informed consent who had discontinued treatment in CATIE Phase 2		Secondary: Reason for treatment discontinuation, PANSS scores, CGI ratings, safety and tolerability outcomes	the proportion of possible treatment time that patients stayed on treatment (67%-80%).  Secondary: A greater number of patients discontinued therapy with aripiprazole (18%), olanzapine (15%), and combination antipsychotic treatment (13%) for lack of efficacy compared to clozapine (5%), risperidone (3%), quetiapine (6%), and ziprasidone (8%).  In terms of efficacy measures, there were no differences among mean changes of the PANSS scores or the CGI scale scores between the treatment groups.  Side effects varied widely among the groups. Weight gain of at least 7 lb occurred most frequently with combination treatment (39%), clozapine (32%), and olanzapine (23%). Highest exposure-adjusted blood glucose increases were seen with aripiprazole, and risperidone caused substantial increases in prolactin levels.
Citrome et al <sup>46</sup>  Asenapine 5 to 10 mg twice daily  vs  atypical antipsychotics (olanzapine 5 to 20 mg daily, risperidone 3 mg twice daily)  vs  placebo	SR  Phase II or III clinical studies of asenapine in adult patients with schizophrenia and bipolar mania	Schizophrenia (N=1,778); Bipolar mania (N=473)  3 to 52 weeks	Primary: NNH, NNT  Secondary: Not reported	Primary: The NNT for a positive response with asenapine (defined as a minimum of 20% decrease in the PANSS total scores) vs placebo was 6. The NNT of 8 was calculated with asenapine vs placebo for a 30% reduction from baseline in PANSS total scores.  For the patients with schizophrenia, the NNH values for asenapine vs placebo for commonly observed adverse reactions were 17 for somnolence, 34 for EPS, 34 for akathisia, and 25 for oral hypoesthesia.  For patients with bipolar disorder, the NNH values for asenapine vs placebo were 6 for somnolence, 13 for dizziness, 20 for EPS other than akathisia and 25 for increased weight.  In schizophrenia trials, the NNH for weight gain of at least 7% from baseline were 35, 14, and 9 in asenapine, risperidone, and olanzapine groups, respectively.

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>In schizophrenia trials, the NNH for fasting glucose level 1.5 times the upper limit of normal were 452, 188, and 174 in asenapine, risperidone, and olanzapine groups, respectively.</p> <p>In schizophrenia trials, the NNH for LDL cholesterol &gt;50% upper limit of normal were 234 and 174 in asenapine and olanzapine groups, respectively.</p> <p>The NNH for prolactin level over 4 times the upper limit of normal were 19, 4, and 33 in asenapine, risperidone, and olanzapine groups, respectively.</p> <p>Secondary: Not reported</p>
<p>Souza et al (abstract)<sup>271</sup></p> <p>Olanzapine, doses not reported</p> <p>vs</p> <p>clozapine, doses not reported</p>	<p>MA</p> <p>Patients with treatment-resistant schizophrenia</p>	<p>N=648</p> <p>Duration not reported</p>	<p>Primary: Dropout rates, PANSS scales</p> <p>Secondary: Not reported</p>	<p>Primary: Olanzapine and clozapine had similar effects on dropout rates (RR, 0.93; 95% CI, 0.77 to 1.12), PANSS total endpoints (SMD, 0.21; 95% CI, -0.04 to 0.46) and PANSS total mean changes (SMD, 0.08; 95% CI, -0.01 to 0.027).</p> <p>Clozapine was “superior” to olanzapine for PANSS positive (SMD, 0.51; 95% CI, 0.17 to 0.86) and negative (SMD, 0.50; 95% CI, 0.16 to 0.85) subscales.</p> <p>Secondary: Not reported</p>
<p>Glick et al<sup>47</sup></p> <p>Atypical antipsychotics (olanzapine, risperidone, quetiapine, aripiprazole, ziprasidone, clozapine)</p> <p>vs</p>	<p>MA</p> <p>Randomized, double-blind studies with atypical antipsychotics in patients with</p>	<p>N=not reported</p> <p>at least 3 months</p>	<p>Primary: PANSS total score, relapse rate, discontinuation rate, adverse events</p> <p>Secondary:</p>	<p>Primary: Compared to placebo, olanzapine was associated with the greatest improvement in PANSS total scores from baseline, followed by risperidone (P&gt;0.05), quetiapine (P=10<sup>-4</sup>) and ziprasidone (P=0.004).</p> <p>Compared to olanzapine, the following risk ratios [RR] for relapse were determined: 0.87 for risperidone, 0.55 for ziprasidone and 0.39 for quetiapine (P value not reported).</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
placebo	schizophrenia or schizoaffective disorder		Not reported	<p>Compared to olanzapine, the following hazard ratios [HR] for relapse were determined: 0.84 for risperidone, 0.78 for ziprasidone and 0.60 for quetiapine (P value not reported).</p> <p>Compared to olanzapine, the following hazard ratios for all-cause discontinuations were determined: 0.77 for risperidone (P=0.005), 0.71 for quetiapine (P=0.02) and 0.68 for ziprasidone (P&lt;0.001).</p> <p>Compared to olanzapine, the following hazard ratios for discontinuation due to poor efficacy were noted in the EUFEST study: 0.39 for ziprasidone (P&lt;0.001) and 0.34 for quetiapine (P&lt;0.001).</p> <p>Conclusion: Clozapine is the most effective atypical antipsychotic. Olanzapine is more effective than risperidone; though both are more effective compared to the other atypical antipsychotics.</p> <p>EPS as measured by the use of antiparkinson drugs and compared to placebo were greatest in association with ziprasidone, followed by risperidone, olanzapine, aripiprazole and finally quetiapine (P value not reported).</p> <p>Akathisia as measured by the use of antiparkinson drugs and compared to olanzapine was most frequent in association with risperidone, followed by aripiprazole, olanzapine, ziprasidone and finally quetiapine (P value not reported).</p> <p>Weight gain, compared to olanzapine, was greatest in association with clozapine and olanzapine (comparable), followed by risperidone and quetiapine (2-4 lb weight gain), and least with ziprasidone and aripiprazole (P value not reported). Aripiprazole and ziprasidone caused approximately 4 kg less weight gain compared to olanzapine. Risperidone and quetiapine caused approximately 2.5-3 kg less weight gain compared to olanzapine.</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
<p>Jones et al<sup>48</sup></p> <p>Atypical antipsychotics (risperidone 4-8 mg daily, aripiprazole 10-30 mg daily, olanzapine 10-20 mg daily, quetiapine 150-750 mg daily, paliperidone ER 3-12 mg daily)</p> <p>vs</p> <p>placebo</p>	<p>SR</p> <p>Patients, mean age ranged from 37 to 39 years, diagnosed with schizophrenia</p>	<p>N=5,313</p> <p>4 to 8 weeks</p>	<p>Primary: PANSS, CGI-S scores, discontinuation rate, adverse events</p> <p>Secondary: Not reported</p>	<p>Secondary: Not reported</p> <p>Primary: All of the atypical antipsychotic drugs significantly improved total PANSS scores from baseline, compared to placebo (overall effect size -11.6; 95% CI, -13.3 to -10.0). Effect sizes (ES) for the individual agents ranged from -14.9 (95%CI, -17.6 to -12.3) for olanzapine to -9.5 (95%CI, -11.7 to -7.2) for aripiprazole.</p> <p>All of the atypical antipsychotic drugs were associated with a significant improvement in PANSS positive scores from baseline compared to placebo (overall ES, -3.7; 95%CI, -4.2 to -3.1). Effect sizes for individual agents ranged from -4.3 for risperidone and olanzapine (risperidone: 95%CI, -5.7 to -2.8 and olanzapine: 95%CI, -5.3 to -3.4) to -2.6 (95%CI, -3.4 to -1.7) for aripiprazole.</p> <p>All of the atypical antipsychotic drugs were associated with a significant improvement in PANSS negative scores compared to placebo (overall effect size, -2.4, 95%CI, -2.9 to -2.0). Effect sizes for individual agents ranged from -3.4 (95%CI, -4.2 to -2.7) for olanzapine to -1.3 (95%CI, -2.6 to -0.07) for quetiapine.</p> <p>Improvement on CGI-S score with atypical antipsychotic agents was -0.5 overall (95%CI, -0.6 to -0.4). Effect sizes for individual agents ranged from -0.8 (95%CI, -1.1 to -0.5) for risperidone to -0.3 (95%CI, -0.4 to -0.2) for aripiprazole.</p> <p>Paliperidone ER, olanzapine and risperidone tended to have lower discontinuation rates due to lack of efficacy compared to all atypical antipsychotics combined. Whereas, discontinuation rates tended to be greater among patients receiving aripiprazole and quetiapine compared to the mean rate for the atypical antipsychotics (P value not reported).</p> <p>There was no significant difference in discontinuation rates due to adverse events for all the atypical antipsychotic agents combined</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>compared to placebo. Results were similar for the individual agents except olanzapine, which had a higher discontinuation rate due to adverse effects.</p> <p>Atypical antipsychotics were associated with significant weight gain compared to placebo (OR, 2.84; 95%CI, 2.3 to 3.5). Odds of weight gain were lowest with paliperidone ER (OR, 1.75; 95%CI, 1.29 to 2.37) and highest with olanzapine (OR, 4.56; 95%CI, 3.46 to 6.01).</p> <p>Atypical antipsychotics were associated with increased odds of somnolence compared to placebo (OR, 1.7; 95%CI, 1.39 to 2.09). Odds of somnolence were lower than the mean with paliperidone ER and aripiprazole and higher than the mean with risperidone and olanzapine.</p> <p>Overall, there was no significant difference in agitation between atypical antipsychotics and placebo. Agitation tended to be lower than placebo for paliperidone ER and for quetiapine, but the significance of the result was uncertain.</p> <p>Secondary: Not reported</p>
<p>Klemp et al<sup>49</sup></p> <p>Atypical antipsychotics (aripiprazole, clozapine, olanzapine, risperidone)</p> <p>vs</p> <p>haloperidol</p> <p>vs</p> <p>placebo</p>	<p>MA</p> <p>Randomized controlled studies in patients with schizophrenia</p>	<p>N=7,743</p> <p>2 to 52 weeks</p>	<p>Primary: Response (defined as at least 20%-30% reduction in PANSS, BPRS or CGI scores, adverse events</p> <p>Secondary: Not reported</p>	<p>Primary: Compared to placebo, clozapine was associated with the greatest response ratio (1.99; 95%CI, 1.76 to 2.26), followed by olanzapine (1.86; 95%CI, 1.70 to 2.06), risperidone (1.85; 95%CI, 1.69 to 2.01), aripiprazole (1.55; 95%CI, 1.36 to 1.76) and finally haloperidol (1.40; 95%CI, 1.25 to 1.57).</p> <p>The probabilities that clozapine, olanzapine, and risperidone are better than aripiprazole are 1, 1, and 0.99, respectively.</p> <p>The probability that olanzapine is better than risperidone is 0.59. The probability that clozapine is better than olanzapine is 0.86. The probability that clozapine is better than risperidone is 0.88.</p>



Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>Compared to placebo, olanzapine was associated with the greatest weight gain as seen with a response ratio of 12.21 (95%CI, 10.22 to 15.05), followed by clozapine (11.28; 95%CI, 6.89 to 17.77), risperidone (6.42; 95%CI, 4.81 to 8.61), haloperidol (5.27; 95%CI, 4.17 to 6.71) and finally aripiprazole (4.57; 95%CI, 3.07 to 6.54).</p> <p>The probability that olanzapine causes less weight gain than either risperidone, haloperidol or aripiprazole is 0. The probability that risperidone causes less weight gain than aripiprazole is 0.03.</p> <p>Compared to placebo, haloperidol was associated with the greatest risk of EPS adverse events as seen with a response ratio of 2.33 (95%CI, 2.03 to 2.49), followed by risperidone (1.41; 95%CI, 1.20 to 1.64), clozapine (1.34; 95%CI, 0.96 to 1.78) and aripiprazole (1.34; 95%CI, 1.06 to 1.65).</p> <p>Olanzapine was associated with a lower risk of EPS adverse events, compared to placebo, with a response ratio of 0.91 (95%CI, 0.77 to 1.05).</p> <p>The probability that risperidone causes less EPS adverse events than aripiprazole is 0.32.</p> <p>Secondary: Not reported</p>
<p>Leucht et al<sup>50</sup></p> <p>Second generation antipsychotics (amisulpiride*, aripiprazole, clozapine, olanzapine, quetiapine, risperidone, sertindole*, ziprasidone, zotepine*)</p> <p>vs</p>	<p>MA</p> <p>Patients with schizophrenia or related psychotic disorders</p>	<p>N=21,533</p> <p>150 DB, randomized studies (OL studies excluded)</p> <p>FD studies selected generally</p>	<p>Primary: Overall efficacy</p> <p>Secondary: Positive, negative, and depressive symptoms, relapse, quality of life, EPS, weight gain and sedation</p>	<p>Primary: Four second-generation antipsychotic drugs were better than first-generation agents for overall efficacy, with small to medium effect sizes (amisulpiride, -0.31 [95% CI, -0.44 to -0.19; P&lt;0.0001], clozapine, -0.52 [95% CI, -0.75 to -0.29; P&lt;0.0001], olanzapine, -0.28 [95% CI, -0.38 to -0.18; P&lt;0.0001], and risperidone, -0.13 [95% CI, -0.22 to -0.05; P=0.002]).</p> <p>Secondary: Amisulpiride, clozapine, olanzapine, and risperidone were also more efficacious than first-generation agents for treatment of positive and</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
<p>first generation antipsychotics as comparator agents (including chlorpromazine, fluphenazine, haloperidol, perphenazine, thioridazine, thiothixene, trifluoperazine, plus others not available in the United States)</p>		<p>accepted optimal doses of each antipsychotic</p> <p>Duration of studies varied (from ≤12 weeks to &gt;6 months)</p>		<p>negative symptoms.</p> <p>Aripiprazole, quetiapine, sertindole, ziprasidone, and zotepine were not more effective than first-generation agents for treatment of negative symptoms.</p> <p>Aripiprazole, quetiapine, sertindole, ziprasidone, and zotepine were no more efficacious than first-generation agents for positive symptoms (and quetiapine was less efficacious).</p> <p>Amisulpiride, aripiprazole, clozapine, olanzapine, and quetiapine were significantly better in treating depressive symptoms than first-generation agents, whereas risperidone was not.</p> <p>Olanzapine, risperidone, and sertindole were found to be significantly better than first-generation agents in preventing relapse; amisulpiride, aripiprazole, and clozapine showed no significant difference (no studies were available for the other second-generation agents).</p> <p>Only amisulpiride, clozapine, and sertindole were better than first-generation agents for improving quality of life (which was reported in only 17 studies).</p> <p>All second-generation antipsychotics were associated with much fewer EPS effects than haloperidol.</p> <p>Amisulpiride, clozapine, olanzapine, quetiapine, risperidone, sertindole, and zotepine were associated with significantly more weight gain than haloperidol, whereas aripiprazole and ziprasidone were not.</p> <p>Clozapine, quetiapine, and zotepine were significantly more sedating than was haloperidol, whereas aripiprazole was significantly less sedating.</p>
<p>Khanna et al<sup>51</sup></p> <p>Aripiprazole, doses ranged</p>	<p>SR</p> <p>RCTs evaluating</p>	<p>N=6,389</p> <p>4 to 26 weeks</p>	<p>Primary:</p> <p>Global state (global impression less</p>	<p>Primary:</p> <p>Compared to olanzapine, no differences were apparent for global state (RR short-term, 1.00; 95% CI, 0.81 to 1.22; RR medium-term, 1.08; 95%</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
from 15 to 30 mg daily vs amisulpride, doses not reported vs clozapine, doses not reported vs olanzapine, doses not reported vs quetiapine, doses not reported vs risperidone, doses not reported vs sertindole, doses not reported vs ziprasidone, doses not reported	patients with schizophrenia and other types of schizophrenia-like psychosis		than 'much improved' or less than 50% reduction on a rating scale), general functioning (no clinically important change in general functioning) and adverse events  Secondary: Leaving the studies early	CI, 0.95 to 1.22) but mental state tended to favor olanzapine (MD, 4.68; 95% CI, 2.21 to 7.16).  Compared to risperidone, aripiprazole did not demonstrate an advantage in terms of global state (RR of no important improvement, 1.14; 95% CI, 0.81 to 1.60) or mental state (MD, 1.50; 95% CI, -2.96 to 5.96).  One study compared aripiprazole to ziprasidone and there was a similar change in the global state in both treatment groups (MD, -0.03; 95% CI, -0.28 to 0.22) and mental state (MD, -3.00; 95% CI, -7.29 to 1.29).  Compared to any one of several new generation antipsychotic drugs, aripiprazole demonstrated improvement in global state in energy (RR, 0.69; 95% CI, 0.56 to 0.84), mood (RR, 0.77; 95% CI, 0.65 to 0.92), negative symptoms (RR, 0.82; 95% CI, 0.68 to 0.99), somnolence (RR, 0.80; 95% CI, 0.69 to 0.93) and weight gain (RR, 0.84; 95% CI, 0.76 to 0.94).  There was no significant difference between treatments with regard to EPS (RR, 0.99; 95% CI, 0.62 to 1.59); however, fewer patients in the aripiprazole group had increased cholesterol levels (RR, 0.32; 95% CI, 0.19 to 0.54) or weight gain of ≥7% of total body weight (RR, 0.39; 95% CI, 0.28 to 0.54).  Significantly more patients treated with aripiprazole reported symptoms of nausea (RR, 3.13; 95% CI, 2.12 to 4.61) but weight gain (≥7% of total body weight) was less common in with aripiprazole (RR, 0.35; 95% CI, 0.19 to 0.64).  Secondary: The overall number of participants leaving studies early was 30 to 40%, limiting validity (no differences between groups).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
vs zotepine, doses not reported				
Soares-Weiser et al <sup>272</sup>  Olanzapine, doses not reported  vs  second generation antipsychotics	MA  Randomized and observational studies comparing olanzapine to other antipsychotics for the treatment of Schizophrenia and related disorders	N=235,591  12 weeks	Primary: Time to all-cause medication discontinuation  Secondary: All-cause discontinuation rate	Primary: On time to all-cause medication discontinuation, olanzapine was significantly better than aripiprazole (HR, 0.81; 95% CI, 0.71 to 0.93), quetiapine (HR, 0.68; 95% CI, 0.56 to 0.83), risperidone (HR, 0.77; 95% CI, 0.70 to 0.86), ziprasidone (HR, 0.73; 95% CI, 0.59 to 0.90) and perphenazine (HR, 0.68; 95% CI, 0.48 to 0.97) for RCTs and better than amisulpride (HR, 0.69; 95% CI, 0.53 to 0.90), risperidone (HR, 0.83; 95% CI, 0.75 to 0.92), haloperidol (HR, 0.56; 95% CI, 0.45 to 0.69), and perphenazine HR, 0.57; 95% CI, 0.37 to 0.87) for observational studies.  There were no significant differences between olanzapine and clozapine in RCTs or observational studies.  Secondary: In RCTs, olanzapine was associated with less treatment discontinuation compared to aripiprazole (RR, 0.87; 95% CI, 0.80 to 0.93), quetiapine (RR, 0.69; 95% CI, 0.58 to 0.82), risperidone (RR, 0.86; 95% CI, 0.81 to 0.92), ziprasidone (RR, 0.81; 95% CI, 0.78 to 0.83), haloperidol (RR, 0.75; 95% CI, 0.66 to 0.85), perphenazine (RR, 0.78; 95% CI, 0.64 to 0.95) and amisulpride (RR, 0.56; 95% CI, 0.32 to 0.96). No significant difference was observed between olanzapine and amisulpride (P=0.27) or clozapine (P=0.64). In the observational studies, olanzapine was associated with less treatment discontinuation compared to amisulpride (RR, 0.63; 95% CI, 0.46 to 0.87) and haloperidol (RR, 0.72; 95% CI, 0.63 to 0.81) and with a higher rate of discontinuation compared to clozapine (RR, 1.30; 95% CI, 1.03 to 1.64). No significant difference was observed between olanzapine and aripiprazole (P=0.48), quetiapine (P=0.08), risperidone (P=0.23), ziprasidone (P=0.29) and perphenazine (P=0.32).
Komossa et al <sup>52</sup>  Olanzapine, doses ranged from 2.5 to 50 mg daily	SR  Randomized, at least single-blind	N=9476 (50 studies)  6 to 26 weeks	Primary: Leaving the study early, re-hospitalization,	Primary: Olanzapine improved the general mental state (assessed via the PANSS total score) more than aripiprazole (WMD, -4.96; 95%CI, -8.06 to -1.85), quetiapine (WMD, -3.66; 95%CI, -5.39 to -1.93), risperidone (WMD, -

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
<p>vs</p> <p>amisulpride*, doses ranged from 150 to 800 mg daily</p> <p>vs</p> <p>aripiprazole, doses ranged from 15 to 30 mg daily</p> <p>vs</p> <p>clozapine, doses ranged from 25 to 900 mg daily</p> <p>vs</p> <p>quetiapine, doses ranged from 50 to 826.67 mg daily</p> <p>vs</p> <p>risperidone, doses ranged from 0.5 to 16 mg daily</p> <p>vs</p> <p>ziprasidone, doses ranged from 40 to 160 mg daily</p>	<p>design, comparing oral olanzapine with oral forms of amisulpride, aripiprazole, clozapine, quetiapine, risperidone, or ziprasidone in people with schizophrenia or schizophrenia-like psychosis</p>		<p>PANSS, adverse events</p> <p>Secondary: Not reported</p>	<p>1.94; 95%CI, -3.31 to -0.58) and ziprasidone (WMD, -8.32; 95%CI, -10.99 to -5.64), but not more than amisulpride or clozapine.</p> <p>Fewer patients in the olanzapine group left the study early due to inefficacy of treatment compared to quetiapine (RR, 0.56; 95%CI, 0.44 to 0.70, NNT=11), risperidone (RR, 0.78; 95%CI, 0.62 to 0.98, NNT=50 and ziprasidone (RR, 0.64; 95%CI, 0.51 to 0.79, NNT=17). Significantly fewer patients left the study early due to adverse events in the olanzapine group compared to clozapine (RR, 0.62; 95%CI, 0.43 to 0.92, NNT=20).</p> <p>Fewer patients required re-hospitalization in the olanzapine group compared to quetiapine (RR, 0.56; 95%CI, 0.41 to 0.77; NNT=11) and ziprasidone (RR, 0.65; 95%CI, 0.45 to 0.93; NNT=17); whereas, more patients in the olanzapine group were re-hospitalized compared to the clozapine group (RR, 1.28; 95%CI, 1.02 to 1.61, NNH not estimable).</p> <p>Except for clozapine, all comparators caused less weight gain than olanzapine (vs aripiprazole: WMD, 5.60kg, 95%CI, 2.15kg to 9.05kg; vs quetiapine: WMD, 2.68kg, 95%CI, 1.10kg to 4.26kg; vs risperidone: WMD, 2.61kg, 95%CI, 1.48kg to 3.74kg; vs ziprasidone: WMD, 3.82kg, 95%CI, 2.96kg to 4.69kg).</p> <p>Metabolic side effects such as glucose and cholesterol level increases were also more frequent in the olanzapine group compared to most comparators.</p> <p>Olanzapine may be associated with more EPS side effects than quetiapine, assessed by the use of antiparkinson medication (RR, 2.05; 95%CI, 1.26 to 3.32, NNH=25), but less than risperidone (RR, 0.78; 95%CI, 0.65 to 0.95, NNH=17) and ziprasidone (RR, 0.70;95%CI, 0.50 to 0.97, NNH not estimable).</p> <p>Olanzapine may increase prolactin level to a greater degree than aripiprazole, clozapine and quetiapine, but considerable less so than risperidone (WMD, -22.84; 95%CI, -27.98 to -17.69).</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>There was no significant difference between olanzapine and aripiprazole, ziprasidone or risperidone groups in change in QTc interval from baseline. Quetiapine was associated with significantly increased QTc interval from baseline, compared to olanzapine.</p> <p>Secondary: Not reported</p>
<p>Komossa et al<sup>53</sup></p> <p>Quetiapine, doses ranged from 50 to 800 mg daily</p> <p>vs</p> <p>clozapine, doses not reported</p> <p>vs</p> <p>olanzapine, doses not reported</p> <p>vs</p> <p>risperidone, doses not reported</p> <p>vs</p> <p>ziprasidone, doses not reported</p>	<p>SR</p> <p>Randomized, at least single-blind design, comparing oral quetiapine with oral forms of clozapine, olanzapine, risperidone or ziprasidone in people with schizophrenia or schizophrenia-like psychosis</p>	<p>N=4101 (21 studies)</p> <p>2 to 12 weeks</p>	<p>Primary: Leaving the study early, PANSS, adverse events</p> <p>Secondary: Not reported</p>	<p>Primary: Quetiapine was less effective in improving the general mental state (PANSS total score) compared to olanzapine (WMD, 3.66; 95%CI, 1.93 to 5.39) and risperidone (WMD, 3.09; 95%CI, 1.01 to 5.16). There were no significant differences in PANSS total scores between quetiapine and either clozapine or ziprasidone.</p> <p>Compared to olanzapine, quetiapine was associated with fewer movement disorders, assessed via the use of antiparkinson medication (RR, 0.49; 95%CI, 0.3 to 0.79, NNH=25 CI) and less weight gain (WMD, -2.81; 95%CI, -4.38 to -1.24) and glucose elevation (WMD, -9.32; 95%CI, -17.82 to -0.82), but more QTc prolongation (WMD, 4.81; 95%CI, 0.34 to 9.28). There was no significant difference in sedation between olanzapine and quetiapine. Likewise, cholesterol level changes from baseline were comparable between the groups.</p> <p>Compared to risperidone, quetiapine was associated with fewer movement disorders, assessed via the use of antiparkinson medication (RR, 0.5; 95%CI, 0.3 to 0.86; NNH=20), less prolactin increase (WMD, -35.28; 95%CI, -44.36 to -26.19) and some related adverse effects, but more cholesterol increase (WMD, 8.61; 95%CI, 4.66 to 12.56). Quetiapine was associated with significantly more sedation (RR, 1.21; 95%CI, 1.06 to 1.38; NNH=20), compared to risperidone. There was no significant difference in weight gain between the groups.</p> <p>Compared to ziprasidone, quetiapine was associated with fewer EPS adverse effects, assessed via the use of antiparkinson medication (RR,</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>0.43; 95%CI, 0.2 to 0.93, NNH not estimable) and prolactin increase. However, quetiapine was associated with significantly more sedation (RR, 1.36; 95%CI, 1.04 to 1.77; NNH=14) and weight gain (RR, 2.22; 95%CI, 1.35 to 3.63; NNH=13) and cholesterol (WMD, 16.01; 95%CI, 8.57 to 23.46) compared to ziprasidone. There was no significant difference in QTc prolongation between the groups.</p> <p>Secondary: Not reported</p>
<p>Suttajit et al<sup>273</sup></p> <p>Quetiapine, dose not reported</p> <p>vs</p> <p>typical antipsychotics</p> <p>Typical antipsychotics were considered any other antipsychotic excluding Amisulpride*, sulpiride*, zotepine*, olanzapine, risperidone, sertindole*, aripiprazole, ziprasidone and clozapine, at any dose.</p>	<p>SR</p> <p>Randomized, blinded studies comparing quetiapine typical antipsychotics in patients with schizophrenia or schizophrenia-like psychosis</p>	<p>N=7,217 (43 studies)</p> <p>Duration not reported</p>	<p>Primary: Global state</p> <p>Secondary: Leaving study early, relapse, mental state (positive and negative symptoms), general functioning, quality of life, cognitive function, service use (hospitalizations) and adverse events</p>	<p>The proportion of patients leaving the studies was not significantly different between patients treated with quetiapine or typical antipsychotics (36.5 vs 36.9%, respectively; RR, 0.91; 95% CI, 0.81 to 1.01). Fewer patients treated with quetiapine left the studies early due to adverse events (RR, 0.48; 95% CI, 0.30 to 0.77).</p> <p>Overall, global state was not significantly different between patients treated with quetiapine or typical antipsychotics (RR, 0.96; 95% CI, 0.75 to 1.23) and there was no significant difference in positive symptoms (PANSS positive subscore; MD, 0.02; 95% CI, -0.39 to 0.43). Similarly, general psychopathology was similar between the treatments (PANSS general psychopathology subscore; MD, -0.20; 95% CI, -0.83 to 0.42).</p> <p>Quetiapine treatment was significantly more effective for negative symptoms (PANSS negative subscore; MD, -0.82; 95% CI -1.59 to -0.04); however, this result was highly heterogeneous and driven by two small outlier studies with high effect sizes. Without these two studies, there was no heterogeneity and no statistically significant difference between quetiapine and typical antipsychotics.</p> <p>Quetiapine treatment may be associated with fewer adverse events (RR, 0.76; 95% CI, 0.64 to 0.90; NNH, 10), less abnormal ECG (RR, 0.38; 95% CI, 0.16 to 0.92; NNH, 8), fewer overall EPS effects (RR, 0.17; 95% CI, 0.09 to 0.32; NNH 3) and fewer specific EPS effects including akathisia, parkinsonism, dystonia and tremor.</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>Quetiapine may be associated with lower prolactin level (MD, -16.20; 95% CI, -23.34 to -9.07) and less weight gain compared to some typical antipsychotics in the short term (RR, 0.52; 95% CI, 0.34 to 0.80; NNH, 8).</p> <p>There was no significant difference between the two groups in suicide attempt, suicide, death, QTc prolongation, low blood pressure, tachycardia, sedation, gynecomastias, galactorrhea, menstrual irregularity and white blood cell count.</p>
<p>Komossa et al<sup>54</sup></p> <p>Risperidone, doses ranged from 0.5 to 12 mg daily</p> <p>vs</p> <p>amisulpride*, doses ranged from 100 to 1000 mg daily</p> <p>vs</p> <p>aripiprazole, doses ranged from 15 to 30 mg daily</p> <p>vs</p> <p>clozapine, doses ranged from 25 to 900 mg daily</p> <p>vs</p> <p>olanzapine, doses ranged from 2.5 to 40 mg daily</p> <p>vs</p>	<p>SR</p> <p>Randomized, blinded studies comparing risperidone with oral forms of amisulpride, clozapine, olanzapine, quetiapine, or ziprasidone in patients with schizophrenia or schizophrenia-like psychosis</p>	<p>N=7,760 (45 studies)</p> <p>up to 12 weeks (31 studies);</p> <p>13-26 weeks (6 studies);</p> <p>&gt;26 weeks (8 studies)</p>	<p>Primary: Leaving the study early, CGI, PANSS, BPRS, Quality of Life Scale (QLS), adverse events</p> <p>Secondary: Not reported</p>	<p>Primary: Based on data from two studies, compared to aripiprazole, risperidone was not associated with a significant change in global state, measured on the CGI scale (RR, 0.88; 95%CI, 0.62 to 1.24). There was no significant difference between risperidone and aripiprazole groups in leaving the study early (35 vs 34%; RR, 1.06; 95%CI, 0.79 to 1.41). Moreover, there was no significant difference between risperidone and aripiprazole groups in the mental state change from baseline, as measured on the PANSS total, negative and positive scales.</p> <p>Compared to clozapine, risperidone was not associated with a significant change in global state, measured on the CGI scale (RR, 1.07; 95%CI, 0.88 to 1.30). While the overall percentage of patients leaving the study early did not significantly differ between risperidone and clozapine groups (35 vs 31%; RR, 1.10; 95%CI, 0.86 to 1.41), risperidone was associated with a significantly greater discontinuation rate due to inadequate efficacy (14 vs 5%), but with a significantly lower rate of discontinuations due to side effects (7 vs 12%), compared to clozapine. There were no significant differences between groups in the changes from baseline in PANSS total scores (a measure of mental state), BPRS scores, positive and negative PANSS subscale scores, GAF scores of general functioning, or cognitive functioning scores.</p> <p>Compared to olanzapine, risperidone was not associated with a significant change in global state, measured on the CGI scale (RR, 0.98; 95%CI, 0.88 to 1.09). Fewer patients receiving olanzapine left the study early than patients in the risperidone group (48 vs 56%; RR, 1.14; 95%CI,</p>



Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
<p>quetiapine, doses ranged from 50 to 800 mg daily</p> <p>vs</p> <p>ziprasidone, doses ranged from 40 to 160 mg daily</p>				<p>1.07 to 1.21; NNH=13). There was a trend in more patients leaving in the risperidone group due to inadequate efficacy. Olanzapine therapy was associated with significantly greater improvement in the PANSS total scores (MD, 1.94; 95%CI, 0.58 to 3.31), negative symptoms as reflected by the SANS total scores (MD, 1.40; 95%CI, 0.37 to 2.43), and QLS total scores (MD, 5.10; 95%CI, 1.09 to 9.1).</p> <p>The percentage of patients leaving the study early did not significantly differ between risperidone and quetiapine groups (54 vs 57%; RR, 0.94; 95%CI, 0.87 to 1.02). Risperidone was associated with greater efficacy in the following outcome measures: PANSS total score (MD, -3.09; 95%CI, -5.16 to -0.40), PANSS positive scores (MD, -1.82; 95%CI, -2.48 to -1.16), BPRS positive scores (MD, -1.10; 95%CI, -2.02 to -0.18) and BPRS negative scores (MD, -0.57; 95%CI, -0.97 to -0.17).</p> <p>Based on data from three studies, the percentage of patients leaving the study early did not significantly differ between risperidone and ziprasidone groups (58 vs 65%; RR, 0.90; 95%CI, 0.83 to 0.98). Risperidone was associated with greater efficacy in the following outcome measures: PANSS total score (MD, -3.91; 95%CI, -7.55 to -0.27) and PANSS positive scores (MD, -2.50; 95%CI, -4.62 to -0.38). There were no significant differences between groups in the other efficacy endpoints.</p> <p>Risperidone produced more EPS side effects than a number of other atypical antipsychotics (use of antiparkinson medication vs clozapine RR, 2.57, 95%CI, 1.47 to 4.48, NNH=6; vs olanzapine RR, 1.28, 95%CI, 1.06 to 1.55, NNH=17; vs quetiapine RR, 1.98, 95%CI, 1.16 to 3.39, NNH=20; vs ziprasidone RR, 1.42; 95%CI, 1.03 to 1.96, NNH not estimable).</p> <p>Risperidone increased prolactin levels significantly more than all comparators (vs aripiprazole, MD, 54.71, 95%CI, 49.36 to 60.06; vs clozapine, MD, 38.50, 95%CI, 23.30 to 53.70; vs olanzapine, MD, 22.84; 95%CI, 17.69 to 27.98; vs quetiapine, MD, 35.28; 95%CI, 26.19 to 44.36; vs ziprasidone, MD, 21.97; 95%CI, 16.60 to 27.34).</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>There were no significant differences between risperidone and aripiprazole in glucose level or ECG changes. There were no significant differences between risperidone and olanzapine in ECG changes, glucose level, or seizures. There was no significant difference between risperidone and ziprasidone in ECG changes from baseline.</p> <p>Sedation (NNT=5) and seizures (NNT=14) occurred significantly less often with risperidone compared to clozapine. Sedation and somnolence occurred significantly less often with risperidone than with quetiapine (NNT=20 and NNT=13, respectively). Sedation was comparable between risperidone and the other drug comparisons.</p> <p>Risperidone was associated with significantly less weight gain compared to clozapine (MD, -3.30; 95%CI, -5.65 to -0.95) and olanzapine (MD, -0.61; 95%CI, -3.74 to -1.48). There were no significant differences in weight gain between risperidone and aripiprazole or quetiapine. Risperidone was associated with significantly more weight gain of &gt;7% of total body weight compared to ziprasidone (RR, 2.03; 95%CI, 1.35 to 3.06; NNH=14).</p> <p>Risperidone was associated with greater increases in cholesterol levels compared to aripiprazole (MD, 22.30; 95%CI, 4.91 to 39.69) and ziprasidone (MD, 8.58; 95%CI, 1.11 to 16.04), but less than olanzapine (MD -10.36; 95% CI -14.43 to -6.28) and quetiapine (MD, -8.49; 95%CI, -12.23 to -4.75).</p> <p>Secondary: Not reported</p>
<p>Komossa et al<sup>55</sup></p> <p>Ziprasidone, doses ranged from 40 to 160 mg daily</p> <p>vs</p>	<p>SR</p> <p>Randomized, at least single-blind studies comparing ziprasidone with oral forms of</p>	<p>N=3361</p> <p>18 to 78 weeks</p>	<p>Primary: Leaving the study early, PANSS, BPRS, Quality of Life Scale (QLS), adverse events</p>	<p>Primary: Based on one study comparing ziprasidone with clozapine, the two drugs were not shown to be significantly different in the number of patients leaving the study early due to any reason (RR, 1.0; 95%CI, 0.66 to 1.51). There was no significant difference between clozapine and ziprasidone in PANSS total score reduction from baseline (P value not reported).</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
<p>amisulpride*, doses not reported</p> <p>vs</p> <p>clozapine, doses not reported</p> <p>vs</p> <p>olanzapine, doses not reported</p> <p>vs</p> <p>quetiapine, doses not reported</p> <p>vs</p> <p>risperidone, doses not reported</p>	<p>amisulpride, clozapine, olanzapine, quetiapine, or risperidone in patients with schizophrenia or schizophrenia-like psychosis</p>		<p>Secondary: Not reported</p>	<p>Ziprasidone was a less acceptable treatment than olanzapine based on leaving the study early for any reason (RR, 1.26; 95%CI, 1.18 to 1.35; NNH=7). There was no significant difference between the groups in leaving the study early due to adverse events (RR, 1.12; 95%CI, 0.77 to 1.61), while olanzapine was preferred over ziprasidone in terms of leaving the study early due to inadequate efficacy (RR, 1.57; 95%CI, 1.27 to 1.94). Ziprasidone was less efficacious than olanzapine in the PANSS total score reduction from baseline (MD, 8.32 CI 5.64 to 10.99) and the positive PANSS subscore (RR, 3.11; 95%CI, 1.93 to 4.30). There were no significant changes between ziprasidone and olanzapine groups in BPRS total score, negative PANSS subscore, or the QLS total score.</p> <p>Based on the data from two studies comparison ziprasidone with quetiapine, there were no statistically significant differences between the groups in leaving the study early for any reason, improvement in PANSS total score, changes in PANSS positive and negative subscales (P value not reported).</p> <p>Ziprasidone was a less acceptable treatment than risperidone based on leaving the study early for any reason (RR, 1.11; 95%CI, 1.02 to 1.20; NNH=14), but not different from the other atypical antipsychotic drugs. Ziprasidone was less efficacious compared to risperidone in terms of improvement in PANSS total score from baseline (MD, 3.91; 95%CI, 0.27 to 7.55). PANSS positive subscale scores were significantly improved with risperidone compared to ziprasidone (MD, 2.50; 95%CI, 0.38 to 4.62); though there was no significant difference between the groups in the PANSS negative subscale score changes from baseline (MD, 0.04; 95%CI, -1.12 to 1.20). Neither was there a significant difference between groups in the BPRS total score (MD, 0.70; 95%CI, -2.93 to 4.33).</p> <p>Based on limited data there were no significant differences in tolerability between ziprasidone and amisulpride or clozapine.</p> <p>There were no significant differences between ziprasidone and olanzapine in the risk of QTc interval prolongation (MD, 2.19; 95%CI, -</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>0.58 to 4.96), prolactin level changes, or EPS side effects.</p> <p>Ziprasidone produced less clinically significant weight gain than olanzapine (MD, -3.82; 95CI, -4.69 to -2.96), quetiapine (RR, 0.45; 95% CI 0.28 to 0.74; NNT=13) or risperidone (3 RCTs, n=1063, RR 0.49 CI, 0.33 to 0.74).</p> <p>Ziprasidone was associated with significantly less sedation compared to quetiapine (RR, 0.73; 95%CI, 0.55 to 0.97; NNT=13). Sedation was comparable with ziprasidone, olanzapine, and risperidone therapies.</p> <p>Ziprasidone was associated with less cholesterol increase than olanzapine, quetiapine and risperidone.</p> <p>Ziprasidone was associated with slightly more EPS side-effects than olanzapine (RR, 1.43; 95%CI, 1.03 to 1.99).</p> <p>Ziprasidone produced a greater increase of prolactin level compared to quetiapine (MD, 4.77; 95% CI, 1.37 to 8.16).</p> <p>Ziprasidone was associated with less movement disorders (RR, 0.70; 95% CI, 0.51 to 0.97) and less prolactin level increases (MD, -21.97; 95% CI -27.34 to -16.60) than risperidone. There were no significant differences between ziprasidone and risperidone in QTc interval prolongation.</p> <p>Secondary: Not reported</p>
<p>Leucht et al<sup>56</sup></p> <p>Head-to-head comparisons of nine second-generation antipsychotic agents (amisulpiride*, aripiprazole, clozapine, olanzapine,</p>	<p>MA</p> <p>Patients with schizophrenia or other related psychotic disorders</p>	<p>N=13,558</p> <p>78 DB studies</p> <p>Duration of trials not specified</p>	<p>Primary: PANSS total score</p> <p>Secondary: Positive and negative symptoms</p>	<p>Primary: Amisulpiride was found to have no significant differences with olanzapine, risperidone, and ziprasidone (P values not reported).</p> <p>Aripiprazole was found less efficacious than olanzapine in two studies sponsored by aripiprazole's manufacturer (N=794; WMD, 5.0; P=0.002); two further studies found no significant difference compared to</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
quetiapine, risperidone, sertindole*, ziprasidone, and zotepine*)				<p>risperidone (P values not reported).</p> <p>Clozapine was found to not be significantly different from olanzapine, quetiapine, risperidone, and ziprasidone (P values not reported).</p> <p>Olanzapine was found to be significantly more efficacious than aripiprazole (N=794; WMD, -5.0; P=0.002), quetiapine (N=1,449; WMD, -3.7; P&lt;0.001), risperidone (N=2,404; WMD, -1.9; P=0.006), and ziprasidone (N=1,291; WMD, -8.3; P&lt;0.001); and not significantly different than amisulpiride or clozapine.</p> <p>Quetiapine was found to be significantly less efficacious than olanzapine (N=1,449; WMD, 3.7; P&lt;0.001) and risperidone (N=1,953; WMD, 3.2; P=0.003); and not significantly different than clozapine and ziprasidone.</p> <p>Risperidone was found to be significantly more efficacious than quetiapine (N=1,953; WMD, -3.2; P=0.003) and ziprasidone (N=1,016; WMD, -4.6; P=0.002); less efficacious than olanzapine (N=2,404; WMD, 1.9; P=0.006); and not significantly different than amisulpiride, aripiprazole, clozapine, and sertindole (P values not reported).</p> <p>Sertindole was found to not be significantly different than risperidone in two studies sponsored by sertindole’s manufacturer (P values not reported).</p> <p>Ziprasidone was found to be less efficacious than olanzapine (N=1,291; WMD, 8.3; P&lt;0.001) and risperidone (N=1,016; WMD, 4.6; P=0.002); and not significantly different than amisulpiride, clozapine, and quetiapine (P values not reported).</p> <p>Zotepine was found to be less efficacious than clozapine (N=59; WMD, 6.0; P=0.002).</p> <p>Secondary: Results for positive symptoms paralleled those found for overall</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>symptoms except that olanzapine was not significantly more efficacious than risperidone (P value not reported).</p> <p>No significant differences for negative symptoms were found, with the exception of a superiority of quetiapine compared to clozapine in two small studies of first-episode schizophrenia.</p> <p>The comparisons of quetiapine with risperidone and olanzapine with ziprasidone were heterogeneous, and the results did not change when outliers were excluded.</p> <p>The results were rather robust with regard to the effects of industry sponsorship, study quality, dosages, and trial duration.</p>
<p>Lobos et al<sup>57</sup></p> <p>Clozapine 207 mg to 642 mg daily</p> <p>vs</p> <p>olanzapine 16 mg to 30 mg daily</p> <p>vs</p> <p>quetiapine 362 mg to 536 mg daily</p> <p>vs</p> <p>risperidone 3.2 mg to 12 mg daily</p> <p>vs</p>	<p>SR</p> <p>Patients diagnosed with schizophrenia or schizoaffective disorder</p>	<p>N=3,099</p> <p>2 to 26 weeks</p>	<p>Primary: Discontinuation rate, BPRS total score, PANSS total score, negative symptoms, adverse events</p> <p>Secondary: Not reported</p>	<p>Primary: Clozapine was associated with a higher discontinuation rate than olanzapine (RR, 1.60; 95%CI, 1.07 to 2.40; NNT=25) and risperidone (RR, 1.88; 95%CI, 1.11 to 3.21; NNT=16). Fewer participants in the clozapine groups left the trials early due to inefficacy than risperidone (NNT=11).</p> <p>Clozapine was not significantly different from olanzapine, quetiapine, risperidone and ziprasidone in BPRS total score improvement from baseline (P&gt;0.05).</p> <p>There was no significant difference between clozapine and olanzapine or risperidone in improvement of PANSS total score from baseline (P&gt;0.05).</p> <p>According to two studies, quetiapine was more efficacious for negative symptoms compared to clozapine (MD, 2.23; 95%CI, 0.99 to 3.48).</p> <p>Clozapine was associated with less EPS side-effects, as estimated by the use of antiparkinson medication (RR, 0.39; 95%CI, 0.22 to 0.68; NNT=7) compared to risperidone.</p> <p>More participants in the clozapine group exhibited decreased white blood</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
ziprasidone 130 mg daily				<p>cells than those taking olanzapine, more hypersalivation and sedation than those on olanzapine, risperidone and quetiapine and more seizures than people on olanzapine and risperidone. In addition, clozapine was associated with a significant weight gain which was not observed with risperidone.</p> <p>Secondary: Not reported</p>
<p>Riedel et al<sup>58</sup></p> <p>Atypical antipsychotics (aripiprazole, olanzapine, quetiapine, and risperidone)</p>	<p>MA</p> <p>Patients, 18 to 65 years of age, diagnosed with schizophrenia</p>	<p>N=129</p> <p>8 weeks</p>	<p>Primary: Cognitive function, assessed via PANSS</p> <p>Secondary: Not reported</p>	<p>Primary: Compared to the other atypical antipsychotic, quetiapine was associated with the greatest cognitive improvement (P&lt;0.005). Quetiapine was found to improve working memory, verbal memory, reaction quality and visual memory.</p> <p>Olanzapine was associated with a significant improvement from baseline in working memory, verbal memory and visual memory (P value not reported).</p> <p>Risperidone was associated with a significant improvement from baseline in reaction time (P value not reported).</p> <p>Aripiprazole was associated with a significant improvement from baseline in reaction time and reaction quality (P value not reported).</p> <p>Secondary: Not reported</p>
<p>Leucht et al<sup>274</sup></p> <p>Antipsychotics (amisulpride, aripiprazole, asenapine, clozapine, chlorpromazine, haloperidol, iloperidone, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, sertindole,</p>	<p>MA</p> <p>Patients with schizophrenia or related disorders (schizoaffective, schizophreniform, or delusional disorder</p>	<p>N=43,049</p> <p>Duration not reported</p>	<p>Primary: Change in PANSS or BPRS</p> <p>Secondary: All-cause discontinuation, weight gain, use of antiparkinson</p>	<p>Primary: All drugs were “superior” to placebo, with clozapine being significantly more effective compared to other antipsychotics (SMD, -0.88; 95% CI, -1.03 to -0.73). Following clozapine, the overall change in symptoms was greatest with amisulpride (SMD, -0.66; 95% CI, -0.78 to -0.53), olanzapine (SMD, -0.59; 95% CI, -0.65 to -0.53), risperidone (SMD, -0.56; 95% CI, -0.63 to -0.50), paliperidone (SMD, -0.50; 95% CI, -0.60 to -0.39), zotepine (-SMD, -0.49; 95% CI, -0.66 to -0.31), haloperidol (SMD, -0.45; 95% CI, -0.51 to -0.39), quetiapine (SMD, -0.44; 95% CI, -0.52 to -</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
ziprasidone and zotepine) vs placebo			drugs as a measure of EPS adverse events, prolactin increase, QTc prolongation, and sedation	<p>0.35), aripiprazole (SMD, -0.43; 95% CI, -.052 to -0.34), sertindole (SMD, -0.39; 95% CI, -0.52 to -0.26), ziprasidone (SMD, -0.39; 95% CI, -0.49 to -0.30), chlorpromazine (SMD, -0.38; 95% CI, -0.54 to -0.23), asenapine (SMD, -0.38; 95% CI, -0.51 to -0.25), lurasidone (SMD, -0.33; 95% CI, -0.45 to -0.21) and iloperidone (SMD, -0.33; 95% CI, -0.43 to -0.22).</p> <p>Secondary: All-cause discontinuation was significantly better with antipsychotics compared to placebo, with the exception of zotepine. The ORs and NNTs ranged from 0.43 and 6 for amisulpride to 0.80 and 20 for haloperidol. Amisulpride (range of significant mean ORs 0.53 to 0.71; NNT 8 to 14), olanzapine (ORs, 0.58 to 0.76; NNT, 9 to 17), clozapine (ORs, 0.57 to 0.67; NNT 9 to 12), paliperidone (ORs, 0.60 to 0.71; NNT 9 to 14), and risperidone (OR, 0.66 to 0.78; NNT 11 to 18) had significantly lower all-cause discontinuation compared to several other drugs. Haloperidol was worse than quetiapine (OR, 1.32; NNT, 15) and aripiprazole (OR, 1.33; NNT, 15).</p> <p>Other than haloperidol, ziprasidone and lurasidone, all antipsychotics produced more weight gain compared to placebo. Olanzapine produced significantly more weight gain than most other drugs (SMD, 0.74; 95% CI, 0.67 to 0.81), followed by zotepine (SMD, 0.71 95% CI, 0.47 to 0.96). Clozapine (SMD, 0.65; 95% CI, 0.31 to 0.99), iloperidone (SMD, 0.62; 95% CI, 0.49 to 0.74), chlorpromazine (SMD, 0.55; 95% CI, 0.34 to 0.76), sertindole (SMD, 0.52; 95% CI, 0.38 to 0.68), quetiapine (SMD, 0.43; 95% CI, 0.34 to 0.53), risperidone (SMD, 0.42; 95% CI, 0.33 to 0.50), and paliperidone (SMD, 0.38; 95% CI, 0.27 to 0.48) produced significantly more weight gain than haloperidol, ziprasidone, lurasidone, aripiprazole, amisulpride, and asenapine (with the exception that asenapine did not differ significantly from paliperidone). Other differences were not statistically significant apart from iloperidone causing more weight gain than paliperidone, risperidone, and quetiapine.</p> <p>Clozapine, sertindole, olanzapine, quetiapine, aripiprazole, iloperidone, amisulpride and asenapine did not cause significantly more EPS adverse</p>



Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>events compared to placebo. Clozapine produced fewer EPS adverse events compared to all other drugs and placebo, and was followed in ranking by sertindole, olanzapine, and quetiapine. Haloperidol caused significantly more EPS adverse events compared to other drugs apart from zotepine and chlorpromazine. Zotepine, chlorpromazine, lurasidone, risperidone, and paliperidone were among the least well tolerated drugs, because they produced significantly more EPS adverse events compared to several other antipsychotics.</p> <p>Aripiprazole, quetiapine, asenapine, chlorpromazine and iloperidone did not cause significantly increased prolactin concentrations compared to placebo. Paliperidone and risperidone were associated with significantly more prolactin increase than all other drugs including haloperidol.</p> <p>Lurasidone, aripiprazole, paliperidone, and asenapine were not associated with significantly greater QTc prolongation compared to placebo. The greatest risk of QTc prolongation occurred with sertindole, amisulpride, ziprasidone and iloperidone.</p> <p>Amisulpride, paliperidone, sertindole and iloperidone were not significantly more sedating compared to placebo. The greatest risk of sedation occurred with clozapine, followed by zotepine, chlorpromazine, ziprasidone, quetiapine, olanzapine, asenapine, haloperidol, risperidone, lurasidone and aripiprazole.</p>
<p>Crespo-Facorro et al<sup>279</sup></p> <p>Aripiprazole 5 to 30 mg/day</p> <p>vs</p> <p>ziprasidone 40 to 160 mg/day</p> <p>vs</p> <p>quetiapine 100 to 600 mg/day</p>	<p>OL, PRO, RCT</p> <p>Patients 15 to 60 years of age living in the catchment area experiencing their first episode of psychosis with a diagnosis of psychotic disorder, schizophreniform</p>	<p>N=174</p> <p>3 months</p>	<p>Primary:</p> <p>Percentage of discontinuation of the initially assigned treatment at month three and the mean time to all-cause medication discontinuation</p>	<p>Primary:</p> <p>Mean (± SD) and median antipsychotic doses at three months were: aripiprazole, 6.8 ± 7.8 mg/day and 15.0 mg/day; ziprasidone, 87.7 ± 30.0 mg/day and 80.0 mg/day; and quetiapine, 358.3 ± 157.2 mg/day and 300.0 mg/day.</p> <p>The treatment discontinuation rate for any cause differed significantly between treatment groups (<math>\chi^2=21.334</math>; <math>P&lt;0.001</math>). Patients on quetiapine showed a higher rate (61.3%) of treatment discontinuation than aripiprazole (23.1%) and ziprasidone (37.1%) individuals. Insufficient efficacy in the quetiapine group was the main reason for discontinuation</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
	disorder, schizophrenia, or schizoaffective disorder		Secondary: Mean change in BPRS, SAPS and SANS, CGS, YMRS, and CDSS total scores at 3 months and the UKU rating scale	<p>rate differences (<math>\chi^2=20.223</math>; <math>P&lt;0.001</math>). The mean time (days) to all-cause discontinuation was 37.39 (95% CI, 27.71 to 47.07) for aripiprazole, 38.26 (95% CI, 29.19 to 47.33) for ziprasidone and 35.92 (95% CI, 28.44 to 43.40) for quetiapine. There was a significant difference between groups in time to discontinuation (Log Rank=23.467, <math>P&lt;0.001</math>).</p> <p>Secondary: There were no statistically significant differences in the severity of symptoms at baseline and at three months between the treatment groups. The univariate ANOVA analysis, after controlling by CDSS total score at baseline, also showed differences between treatments in reducing depressive symptoms (<math>F=4.404</math>; <math>P=0.014</math>). The post hoc pairwise analysis revealed a lower effect of ziprasidone compared to aripiprazole and quetiapine. The rate of responders (<math>\geq 40\%</math> BPRS &amp; <math>\leq 4</math> CGI) differed between groups (aripiprazole, 76.4%; ziprasidone, 55.8%; quetiapine 64.6%; <math>F=5.950</math>; <math>P=0.051</math>). This difference in the rate of responders between groups was statistically significant when the criteria of at least a 50% decrease in total BPRS at baseline was used as a cutoff (aripiprazole, 61.1%; ziprasidone, 36.5%; quetiapine, 50.0%; <math>F=7.303</math>; <math>P=0.026</math>).</p> <p>Intention-to-treat analyses showed no significant differences in the increment of extrapyramidal signs at three months (SARS total score) between treatments (<math>F=1.513</math>; <math>P=0.223</math>). The percentage of patients with treatment-emergent parkinsonism (a total score higher than three on the SARS at 6-weeks or/and 3-month assessments, given a total score of three or less at baseline) was not statistically different between treatment arms (aripiprazole, 13.9%; ziprasidone, 15.4%; quetiapine, 4.0%; <math>\chi^2=3.940</math>; <math>P=0.139</math>), although it could be of clinical relevance. Extrapyramidal signs were more severe and more frequent with aripiprazole and ziprasidone than with quetiapine.</p> <p>There was no significant difference between treatments in the severity of akathisia (BAS total score) at three months assessment (<math>F=2.616</math>; <math>P=0.076</math>). It is of note that a higher number of individuals in the</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>aripiprazole- and ziprasidone-treated groups (25.0% in both groups) experienced treatment-emergent akathisia (BAS global score of 2 or more at 6-week or/and 3-month evaluations, given a global score of less than 2 at baseline visit) compared to quetiapine-treated subjects (8.0%) (<math>\chi^2=6.408</math>; <math>P=0.041</math>).</p> <p>Intention-to-treat analyses revealed that quetiapine showed a marked increase in the prevalence of treatment-emergent somnolence (quetiapine, 34.0%; ziprasidone, 15.4%; and aripiprazole, 16.7%) (<math>\chi^2=6.827</math>; <math>P=0.033</math>) and an increased duration of sleep (quetiapine, 12.0%; ziprasidone, 3.8%; and aripiprazole, 1.4%) (<math>\chi^2=7.040</math>; <math>P=0.03</math>). Significant differences were also found in the frequency of body weight increase between treatments (<math>\chi^2=11.551</math>; <math>P=0.003</math>). One individual on ziprasidone (1.6%) showed a body weight increase compared to 23.6% of patients on aripiprazole and 14.0% of patients on quetiapine.</p> <p>Patients on quetiapine were taking significantly less hypnotics (lormetazepam) at the three month assessment compared to those patients on aripiprazole and ziprasidone (12.0%, quetiapine; 32.7% ziprasidone; 22.2%, aripiprazole; <math>\chi^2=6.279</math>; <math>P=0.043</math>). No significant differences were found between groups in the rate of anti-muscarinic agents, benzodiazepines, mood stabilizers and antidepressant use at three months.</p>
<p>Sanz-Fuentenebro et al<sup>280</sup></p> <p>Risperidone dose adjusted (2 to 10 mg once daily)</p> <p>vs</p> <p>clozapine dose adjusted (12.5 to 900 mg once daily)</p>	<p>AC, MC, RCT</p> <p>Patients &lt;35 (males) or &lt;40 (females) years of age with a primary diagnosis of schizophrenia or schizophreniform disorder, absence of any other</p>	<p>N=30</p> <p>12 months</p>	<p>Primary:</p> <p>Time to treatment, change in PANSS and UKU Side Effect Rating Scale at LOCF and at 12 months, and weight, glycemia and cholesterol changes</p> <p>Secondary:</p>	<p>Primary:</p> <p>Patients initially assigned to clozapine remained on this treatment for a significantly longer period of time (<math>41.1 \pm 15.9</math> weeks) than those initially assigned to the risperidone arm (<math>23.3 \pm 20.1</math> weeks; <math>U=58</math>, <math>Z=2.44</math>, <math>P=0.015</math>). Upon reaching the end of the 12<sup>th</sup> month, the number of cases with the same treatment prescribed initially (including drop-outs and switches) was higher for clozapine (9 out of 15) than for risperidone (5 out of 15). However, this difference was not statistically significant (<math>\chi^2=1.13</math>, <math>df=1</math>, <math>P=0.13</math>). If adherence to treatment after one year was considered as the outcome variable, the NNT is 4.16.</p> <p>Clinical changes with both drugs were similar, although the improvement</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
	<p>psychiatric disorder, absence of psychotropic drugs one month before start of study and absence of drug dependency (including alcohol; excluding nicotine and caffeine)</p>		<p>Not reported</p>	<p>was marginally better in the clozapine group by the time of the LOCF in positive (U=72, Z=1.65, P=0.10) and total scores (U=74, Z=1.61, P=0.10). Patients on clozapine significantly improved from baseline in positive (mean change <math>-14.4 \pm 7.4</math>, Z=-3.62, P&lt; 0.001), general (mean change <math>-17.3 \pm 12.4</math>, tz=-3.53, P&lt;0.001) and total (mean change <math>-35.5 \pm 26.6</math>, Z=-3.52, P&lt; 0.001) PANSS scores. Risperidone-treated patients significantly improved from baseline in positive (mean change <math>-9.5 \pm 7.21</math>, Z=-2.84 P=0.004) and total (mean change <math>-17.1 \pm 27.7</math>, Z=2.13, P=0.03) PANSS scores.</p> <p>In the 12-month comparison, there were no significant differences in the percent of change between clozapine (N=9) and risperidone (N=5) treated patients that never switched from their original treatment.</p> <p>The clozapine group (N=9) displayed a significant decrease in positive (mean change <math>-17.3 \pm 5.3</math>, Z=-2.67, P=0.008), general (mean change <math>-22.7 \pm 10.3</math>, Z=-2.67, P=0.008) and total (mean change <math>-48.0 \pm 24.7</math>, Z=-2.66, P=0.008) scores, as well as a marginal decrease (mean change <math>-8.2 \pm 10.3</math>, Z=-1.66, P=0.09) in negative symptom scores. The same comparisons for the risperidone group (N=5) displayed a significant decrease in positive (mean change <math>-15.8 \pm 6.0</math>, Z=-2.03, P=0.04) and general (mean change <math>-15.2 \pm 9.7</math>, Z=- 2.02, P=0.04) symptoms, and a non-significant increase in negative (mean change <math>-0.4 \pm 9.52</math>, Z=-0.27, P=0.78) PANSS scores.</p> <p>There were no significant differences in UKU scores at 12 months or by the time of the LOCF. In both groups, asthenia and somnolence were significantly more severe at LOCF than at baseline. In the clozapine group, concentration deficit and increased sleep time were also more severe at LOCF. In the between group comparisons, only increased sleep time was marginally more severe in the clozapine group (U=49.5, Z=2.34, P=0.087).</p> <p>There was a significant inverse association between subjective UKU scores and negative (Spearman's rho=-0.65, P=0.02), general</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>(Spearman's rho=-0.70, P=0.01), and total (Spearman's rho=-0.71, P=0.009) symptom improvement at 12 months. That association was also significant in both risperidone and clozapine treated patients considered alone.</p> <p>Both groups showed significant weight gain from baseline to endpoint, as well as increase in glycemia and cholesterol. Nevertheless, these changes were not significantly different between groups.</p> <p>Secondary: Not reported</p>
<p>Naber et al<sup>281</sup> (RECOVER)</p> <p>Quetiapine ER 400 to 800 mg once daily</p> <p>vs</p> <p>risperidone 2 to 6 mg once daily</p> <p>The use of concomitant antipsychotic therapy was not permitted throughout the study. A selective serotonin reuptake inhibitor, serotonin noradrenaline reuptake inhibitor, or a mood stabilizer was permitted if it had been maintained at a stable dose for at least at least two weeks prior to enrolment; the use of other antidepressants was not allowed.</p>	<p>OL, PG, PRO, RCT</p> <p>Outpatients 18 to 65 years of age with a diagnosis of schizoaffective disorder or schizophreniform disorder and a certain level of reduced subjective well-being</p>	<p>N=798</p> <p>12 months</p>	<p>Primary: SWN-K responder rate for the PP population at month six</p> <p>Secondary: Changes in SWN-K total score and SWN-K subscale scores at month 12 and rate of patients in subjective well-being remission, change in CGI-SCH severity of patient symptoms, change in CDSS depressive symptoms, change in CGI-SCH relapse rate, EQ-5D and functional outcomes</p>	<p>Primary: The SWN-K responder rate at month six in the PP was 64.8% (136/210) in the quetiapine ER group and 68.1% (158/232) in the risperidone group. The adjusted difference in responder rate between the groups was -5.7% (95% CI, -15.1 to 3.7); the lower 95% limit was below the predefined non-inferiority limit of -9.7%. Non-inferiority for quetiapine ER compared to risperidone could not, therefore, be established in terms of responder rate at month six. In the intention to treat analysis set, the SWN-K responder rate at month six was 62.6% (164/262) in the quetiapine ER group and 64.6% (184/285) in the risperidone group. The adjusted difference in responder rate between the groups was -3.4% (95% CI, -11.8 to 5.0).</p> <p>Secondary: The least squares mean change in SWN-K total score from baseline to month 12 was 23.2 points in the quetiapine ER group (n=173) and 21.1 points in the risperidone group (N=191) (difference, 2.1; 95% CI, -0.8 to 5.0). The lower 95% limit was above the predefined non-inferiority limit of -7.5 points, thereby indicating non-inferiority for quetiapine ER compared to risperidone in terms of change from baseline in SWN-K total score at month 12. In the intention to treat analysis set, the least squares mean change in SWN-K total score from baseline to month 12 was 22.7 points in the quetiapine XR group and 19.4 points in the risperidone group (difference, 3.3; 95% CI, 0.6 to 5.9).</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>There were no significant differences between the groups in terms of mean SWN-K subscale scores (physical functioning, social integration, mental functioning, self-control, or emotional regulation) at month 12 (quetiapine ER, N=210; risperidone, N=227).</p> <p>At month six, the SWN-K remission rate was 54.2% (142/262) in the quetiapine ER group compared with 48.1% (137/285) in the risperidone group, with no significant difference between the treatment groups (difference in SWN-K remission rate, 2.9%; 95% CI, -5.7 to 11.5). At month 12, the SWN-K remission rate was 66.2% (139/210) in the quetiapine ER group, compared with 56.4% (138/227) in the risperidone group (difference in SWN-K remission rate, 6.3%; 95% CI, -3.6, 16.2).</p> <p>The mean (SD) change in CGI-SCH overall severity score from baseline to Month 12 was similar in both treatment groups: -1.5 (1.1) in the quetiapine ER group and -1.3 (1.2) in the risperidone group.</p> <p>In total, 83.4% of patients (176/211) were classed as improved for CGI-SCH overall severity in the quetiapine ER group, compared with 78.4% of patients (178/227) in the risperidone group. At Month 12, mean (SD) change from baseline in CGI-SCH severity score for depressive symptoms was -1.3 (1.2) in the quetiapine ER group and -0.8 (1.3) in the risperidone group. The percentage of patients classed as improved for CGI-SCH depressive symptoms was higher in the quetiapine ER group (144/211; 68.2%) than in the risperidone group (131/227; 57.7%: OR for treatment effect, 1.65; 95% CI, 1.01, 2.70). There were no differences between the treatment groups for mean change from baseline to Month 12 in CGI-SCH positive symptom scores (quetiapine ER, -1.3; risperidone, -1.4), negative symptom scores (quetiapine XR, -1.4; risperidone, -1.3) and cognitive symptom scores (quetiapine XR, -1.2; risperidone, -1.1).</p> <p>The mean (SD) change in CGI-SCH overall severity score from baseline to Month 12 was similar in both treatment groups: -1.5 (1.1) in the quetiapine XR group and -1.3 (1.2) in the risperidone group.</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>In total, 83.4% of patients (176/211) were classed as improved for CGI-SCH overall severity in the quetiapine ER group, compared with 78.4% of patients (178/227) in the risperidone group. At month 12, mean (SD) change from baseline in CGI-SCH severity score for depressive symptoms was -1.3 (1.2) in the quetiapine ER group and -0.8 (1.3) in the risperidone group. The percentage of patients classed as improved for CGI-SCH depressive symptoms was higher in the quetiapine ER group (144/211; 68.2%) than in the risperidone group (131/227; 57.7%: OR for treatment effect, 1.65; 95% CI, 1.01 to 2.70). There were no differences between the treatment groups for mean change from baseline to month 12 in CGI-SCH positive symptom scores, negative symptom scores and cognitive symptom scores.</p> <p>Patient quality of life, measured by the EQ-5D health profile, was similar for both treatment groups at month six and month 12. The mean (SD) change from baseline to month 12 in EQ-5D index score was 0.21 (0.25) in the quetiapine ER group and 0.16 (0.24) in the risperidone group. In terms of functional improvement at month 12, 8/211 patients (3.8%) in the quetiapine ER group and 7/227 patients (3.1%) in the risperidone group reported a real improvement in both occupational and residential status from baseline; 160/211 patients (75.5%) in the quetiapine ER group and 171/227 patients (75.3%) in the risperidone group reported being in stable state for occupational and residential status as recorded at baseline.</p>
<p>Asmal et al<sup>282</sup></p> <p>Quetiapine flexible dosing (50 to 800 mg/day)</p> <p>vs</p> <p>other atypical antipsychotic flexible dosing</p>	<p>SR</p> <p>Randomized controlled studies that were at least single blinded that compared quetiapine to other atypical antipsychotics in</p>	<p>N varies by drug (35 studies)</p> <p>2 to 12 weeks (26 studies)</p> <p>Medium term (6 studies)</p>	<p>Primary: No clinically important response</p> <p>Secondary: Leaving the study early (for any reason), global state, mental state (with particular</p>	<p>Primary/secondary: Quetiapine compared to aripiprazole</p> <p>Four small short-term studies (N=293) fell into this comparison. Data were available for only one study for a number of outcomes.</p> <p>The overall rate of participants leaving studies early was 19.5%, with no clear difference between groups. However, this finding was based on only two small, short-term trials, limiting interpretation.</p> <p>Four studies of low-quality evidence found no significant difference in</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
<p>Other atypical antipsychotics could include: amisulpride*, aripiprazole, clozapine, olanzapine, risperidone, sertindole*, ziprasidone or zotepine*.</p>	<p>patients with schizophrenia and other types of schizophrenia-like psychosis</p>	<p>Long term (2 studies)</p>	<p>reference to the positive and negative symptoms of schizophrenia), general functioning, quality of life/satisfaction with treatment, cognitive function, service use, adverse effects</p>	<p>general mental state, positive symptoms or negative symptoms. Data from all studies measuring efficacy were potentially skewed and should be interpreted with caution.</p> <p>Quality of life was not measured and was not reported in these studies.</p> <p>Quetiapine compared to clozapine Five studies (N= 334) fell into this comparison.</p> <p>The overall rate of participants leaving studies early was remarkably low (8.4%) and showed no clear difference between groups. This finding was based on only two small (N=135), short-term trials, limiting any interpretation.</p> <p>No significant difference was noted in global state, general mental state or positive symptoms on the basis of studies of low-quality. A small reduction in negative symptoms was noted in those taking quetiapine, but this result must be interpreted with caution, as it was based on two small trials with low-quality evidence.</p> <p>Quality of life was not measured and was not reported in these studies.</p> <p><u>Quetiapine compared to olanzapine</u> Fourteen studies (N=1,953) contributed data to this comparison.</p> <p>Fewer people in the olanzapine group compared with the quetiapine group left studies early for 'any reason' or because of 'inefficacy of treatment'. This finding suggests that olanzapine is a more acceptable treatment than quetiapine, at least in the confines of clinical trials. Nevertheless, the overall rate of premature study discontinuations was high (61.7%), limiting the validity of all other results.</p> <p>Quetiapine is probably slightly less effective than olanzapine in reducing general mental state symptoms according to studies of moderate-quality evidence. No significant difference was noted in the reduction of negative</p>



Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>symptoms or positive symptoms. The latter findings should be interpreted with caution; studies measuring negative and positive symptoms were of low and very low quality, respectively.</p> <p>The number of participants re-hospitalized was significantly higher in the quetiapine group. This may reflect a certain efficacy advantage of olanzapine.</p> <p>Adverse effects were reported as at least one adverse effect, cardiac effects, QTc abnormalities and an increase in serum cholesterol, serum glucose and serum prolactin, as well as associated side effects, death, extrapyramidal symptoms, the occurrence of sedation, seizures and weight gain. Among these adverse effects, a benefit for quetiapine was found for the use of antiparkinson medication (a proxy measure for extrapyramidal adverse effects), weight, glucose, prolactin increase, and some prolactin-associated adverse effects. On the other hand, a certain superiority of olanzapine was noted in terms of QTc. Overall, it seems that quetiapine may be more tolerable than olanzapine, but this is weighed against slightly less efficacy.</p> <p>Very limited data on the important outcomes for quality of life are available. Olanzapine may improve general functioning (GAF total score) to a greater extent than quetiapine. One study of moderate quality reported no difference in quality of life measures between olanzapine and quetiapine.</p> <p><u>Quetiapine compared to paliperidone</u> Two studies (N=406) provided data on this comparison.</p> <p>The overall number of participants leaving the studies early was relatively low compared with other comparisons (14.0%). No significant difference was reported between groups or for reasons why participants left the studies.</p> <p>Paliperidone showed better efficacy than quetiapine in improving the</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>overall mental state score and in reducing positive and negative symptoms. However, this finding was based on only one small, short-term trial, thus limiting interpretation.</p> <p>In one small study, more participants reported at least one side effect while taking quetiapine compared with paliperidone. However, another study showed an advantage of quetiapine in terms of parkinsonian side effects, prolactin levels, sexual side effects and weight gain. Further studies are required to clarify the differences in adverse effect profiles between these two medications.</p> <p><u>Quetiapine compared to risperidone</u> Nineteen studies (N=3,123) met the inclusion criteria for this comparison.</p> <p>No clear difference was evident in the number of participants leaving the studies early, suggesting a similar overall acceptability of quetiapine and risperidone. Nevertheless, the overall discontinuation rate was high (51.8%), thus limiting the interpretation of all other results.</p> <p>Differences in efficacy were found for the general mental state, positive symptoms and, on exclusion of an outlier, negative symptoms. Quetiapine was less effective than risperidone in these aspects of psychopathology. Nevertheless, the differences were small (e.g., only three points on the PANSS total score).</p> <p>Adverse effects were reported as at least one adverse effect, cardiac effects, cholesterol increase, changes in serum glucose, increase in prolactin level and associated side effects, death, extrapyramidal adverse effects, sedation, weight gain and white blood cell count. Among these, quetiapine was better than risperidone in various measures of extrapyramidal adverse effects and prolactin-associated. On the other hand, quetiapine was associated with increased sedation and cholesterol compared with risperidone. These differences in the adverse effect profile and the slightly lower efficacy of quetiapine may be weighed in drug selection.</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>Three studies of moderate quality assessed quality of life. Participants treated with quetiapine reported significantly higher quality of life scores than those treated with risperidone.</p> <p><u>Quetiapine compared to ziprasidone</u> Two studies (N=722) provided data on this comparison.</p> <p>The overall number of participants leaving the studies early was very high (80.7%), clearly limiting the interpretation of any findings beyond the outcome of 'leaving the study early'. No significant difference was noted between groups, but the acceptability of both compounds seems to be poor.</p> <p>No significant difference in global state, general mental state or positive symptoms was noted in studies with evidence of very low (general state) or low (positive and negative symptoms).</p> <p>Adverse effects were reported as at least one adverse effect; cardiac effects; death; extrapyramidal side effects; changes in cholesterol, glucose and prolactin; the occurrence of sedation and weight gain. Quetiapine was advantageous in the use of antiparkinson medication and for prolactin levels, and two studies with moderate-quality evidence favored ziprasidone for weight gain and sedation.</p> <p>Quality of life was not measured in these studies.</p>
<p>Leucht et al<sup>283</sup></p> <p>Oral antipsychotic medications flexible-dose</p>	<p>MA</p> <p>Patients with a diagnosis of schizophrenia or related disorders</p>	<p>N=43,049 (212 studies)</p> <p>6 weeks (4 to 12 weeks used if 6 week data was unavailable)</p>	<p>Primary: Mean change in symptoms at end of the study</p> <p>Secondary: All-cause discontinuation, weight gain, use of</p>	<p>Primary: Most of the differences between drugs are gradual rather than discrete. All drugs had a greater effect compared to placebo (range of mean effect sizes -0.33 to -0.88), and clozapine was significantly more effective than all the other drugs. After clozapine, amisulpride, olanzapine, and risperidone were significantly more effective than the other drugs apart from paliperidone and zotepine. These effect sizes were small (range -0.11 to -0.33).</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
			antiparkinson drugs as a measure of extrapyramidal side-effects, prolactin increase, QTc prolongation, and sedation	<p>Secondary:</p> <p>All-cause discontinuation was used as a measure of acceptability. All drugs were significantly better than placebo apart from zotepine. ORs and NNTs ranged from 0.43 and 6 for amisulpride to 0.80 and 20 for haloperidol. Amisulpride (range of significant mean ORs 0.53 to 0.71; NNTs 8 to 14), olanzapine (0.58 to 0.76; 9 to 17), clozapine (0.57 to 0.67; 9 to 12), paliperidone (0.60 to 0.71; 9 to 14), and risperidone (0.66 to 0.78; 11 to 18) had significantly lower all-cause discontinuation than several other drugs. Haloperidol was worse than quetiapine (OR 1.32; NNT 15) and aripiprazole (OR 1.33; NNT 15).</p> <p>Apart from haloperidol, ziprasidone, and lurasidone, all drugs produced more weight gain than placebo. Olanzapine produced significantly more weight gain than most other drugs, followed by zotepine. Clozapine, iloperidone, chlorpromazine, sertindole, quetiapine, risperidone, and paliperidone produced significantly more weight gain than haloperidol, ziprasidone, lurasidone, aripiprazole, amisulpride, and asenapine (with the exception that asenapine did not differ significantly from paliperidone). Standardized mean differences for these comparisons ranged from -0.18 to -0.57. Other differences were not statistically significant apart from iloperidone causing more weight gain than paliperidone, risperidone, and quetiapine.</p> <p>Clozapine, sertindole, olanzapine, quetiapine, aripiprazole, iloperidone, amisulpride, and asenapine did not cause significantly more extrapyramidal side-effects than placebo. The range of mean ORs and NNHs for the other drugs were 1.61 to 4.76 and 3 to 11, respectively. Clozapine produced fewer extrapyramidal side-effects than all other drugs and placebo (mean ORs 0.06 to 0.40; NNTs 5 to 9), and was followed in ranking by sertindole, olanzapine, and. Haloperidol caused significantly more extrapyramidal side-effects than the other drugs apart from zotepine and chlorpromazine, for which the differences were not significant (mean ORs 0.06 to 0.52; NNHs 5 to 11; in favor of other drugs). Zotepine, chlorpromazine, lurasidone, risperidone, and paliperidone were among the least well tolerated drugs, because they</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>produced significantly more extrapyramidal side-effects than several others in the analysis.</p> <p>Aripiprazole, quetiapine, asenapine, chlorpromazine, and iloperidone did not cause significantly increased prolactin concentrations compared with placebo. Paliperidone and risperidone were associated with significantly more prolactin increase than all other drugs including haloperidol, and haloperidol was associated with significantly more than the rest apart from chlorpromazine and sertindole. Clozapine and zotepine could not be included in the analysis, because the one direct comparison between them (i.e., with each other) was not linked with any other drug in the network (standardized mean difference -1.23, 95% CI, -1.8 to -0.64, in favor of clozapine; n=52). No usable data were available for amisulpride.</p> <p>Lurasidone, aripiprazole, paliperidone, and asenapine were not associated with significant QTc prolongation compared with placebo. The standardized mean differences of the other drugs compared with placebo ranged from marginal (0.11, haloperidol) to large (0.90, sertindole).</p> <p>Amisulpride, paliperidone, sertindole, and iloperidone were not significantly more sedating than placebo. For the other drugs compared with placebo, mean ORs and NNHs ranged from 1.84 and 10 (aripiprazole) to 8.82 and 2 (clozapine).</p> <p>Results for efficacy and extrapyramidal side-effects were robust against the sensitivity and meta-regression analyses. The most notable exceptions were that the relative efficacy of asenapine increased from the 13th to the seventh rank when placebo comparisons were removed. A large, failed study had driven its primary result, so asenapine was also more effective (ninth rank) when such trials were excluded. Haloperidol doses lower than 12 mg per day (or 7.5 mg per day) caused significantly fewer extrapyramidal side-effects than did higher doses, but still more than any other antipsychotic drug; for the efficacy outcome, lower doses of haloperidol did not significantly differ from higher doses. Doses of Chlorpromazine higher than 600 mg per day (or 500 mg per day) were</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>associated with higher efficacy (sixth rank) than lower doses (14th rank), with little difference in extrapyramidal side-effects. Small studies tended to show higher efficacy of the active interventions compared with placebo (regression coefficient=1.31; 95% CI, 0.58 to 2.03). However this had only a small effect on the ranking of the treatments. None of the other meta-regression or sensitivity analyses led to any important changes in the efficacy and extrapyramidal side-effect hierarchies.</p>
<p>Kumar et al<sup>284</sup></p> <p>Atypical antipsychotics (risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole, amisulpiride, paliperidone, lurasidone and clozapine)</p>	<p>SR</p> <p>Randomized controlled studies that were DB and included patients 13 to 17 years of age with a diagnosis of schizophrenia or related disorders and were treated with atypical antipsychotics</p>	<p>N=1,112 (13 studies)</p> <p>12 weeks (12 studies)</p> <p>13 to 26 (one study)</p>	<p>Primary: Global state, clinical response, global functioning, adverse effects, service utilization outcomes</p> <p>Secondary: Global state, clinical response, social functioning, adverse effects, service utilization, economic outcomes and quality of life/satisfaction of care</p>	<p>Primary/secondary: <u>Atypical antipsychotics compared to placebo (only short term)</u> Global state as measured on the CGI-S showed no significant difference between olanzapine and placebo (1 RCT, N=107, RR 0.84, 95% CI, 0.65 to 1.10) with regard to the number of non-responders.</p> <p>The number of non-responders was not significantly different between participants receiving olanzapine and those given placebo (1 RCT, N=107, RR 0.84, 95% CI, 0.65 to 1.10). However, the number of non-responders receiving aripiprazole 10 mg/day was greater than the number given placebo (1 RCT, N=197, RR 0.72, 95% CI, 0.56 to 0.94).</p> <p>Significantly more people had weight gain &gt; 7% of their baseline pretreatment weight in the group receiving olanzapine over placebo (1 RCT, N=107, RR 3.56, 95% CI, 1.14 to 11.11). The mean weight gain for the group of young people receiving olanzapine was 4.3 kg as compared with 0.1 kg (P&lt;0.001) for the placebo group. Significantly more young people treated with olanzapine developed treatment-emergent serum high prolactin concentration at any time during treatment (81.0% vs 16.7%, P=0.008) as compared with the placebo group. The number of people with clinically significant high serum prolactin concentration at the end of the study was significantly higher for the olanzapine group (1 RCT, N=107, RR 4.70, 95% CI, 2.25 to 9.82).</p> <p>In another study the authors reported no significant difference in weight gain &gt; 5% between the group receiving aripiprazole and the group given placebo (1 RCT, N=202, RR 4.41, 95% CI, 0.98 to 19.91). Taken together, all adolescents treated in the aripiprazole arms of the trial, had</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>significantly lower serum prolactin concentration (1 RCT, N= 302, RR 3.77, 95% CI, 1.88 to 7.58) as compared with the placebo group.</p> <p>Significantly more (57% vs 32%) people left the study early (1 RCT, N=107, RR 0.56, 95% CI, 0.36 to 0.87) from the placebo group as compared with the olanzapine group. In the treatment arm, 10 of a total of 72 young people (14%) allocated to the olanzapine arm left the study because of lack of efficacy as compared with 18 of 35 young people (51%) allocated to the placebo arm, who left the study for the same reasons. In this trial, only 5 (7%) young people left the intervention arm (olanzapine) as the result of adverse effects. In the other study, no difference was noted between the intervention arm and the placebo arm with regard to leaving the study early (1 RCT, N=202, RR 1.76, 95% CI, 0.86 to 3.63).</p> <p>The mean end point of quality of life score was not included in the analysis, as the data were highly skewed.</p> <p><u>Atypical antipsychotics compared to typical antipsychotics (only short term)</u> Five studies compared atypical antipsychotic medications with typical antipsychotic medications.</p> <p>In one, the mean end point CGAS score clearly favored young people treated with clozapine (1 RCT, N=21, RR 17.00, 95% CI, 7.74 to 26.26) compared with haloperidol. However, the two groups did not differ in terms of the number of participants showing no improvement (1 RCT, N=21, RR 3.30, 95% CI, 0.41 to 26.81). Another study did not show significant improvement in the mean end point of CGI-I scores for adolescents treated with risperidone as compared with haloperidol (1 RCT, N=34, MD -0.60, 95% CI, -1.45 to 0.25) or for those treated with olanzapine as compared with haloperidol (1 RCT, N= 31, MD -0.70, 95% CI, -1.55 to 0.15).</p> <p>Mean end point BPRS score was reported by five studies included in the</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>analysis. No significant difference in the mean end point BPRS score was noted between atypical antipsychotic medications and typical antipsychotic medications (5 RCTs, N=236, MD -1.08, 95% CI, -3.08 to 0.93). Mean end point total PANSS score calculated from the figures reported by one trial showed significant improvement with olanzapine (1 RCT, N= 75, MD 27.00, 95% CI, 15.27 to 38.73) and risperidone (1 RCT, N=81, MD 32.90, 95% CI, 19.70 to 46.10) as compared with molindone. Although a different trial reported mean end point SANS and SAPS scores, the data were highly skewed and have not been included in the current analysis.</p> <p>No significant difference between atypical and typical antipsychotic medications was reported in two studies for extrapyramidal side effects such as tremors (2 RCTs, N=100, RR 0.46, 95% CI, 0.21 to 1.04) and restlessness (2 RCTs, N=100, RR 0.71, 95% CI, 0.24 to 2.10). One study reported that participants receiving clozapine were three times more likely to have drowsiness on treatment as compared with those given haloperidol (1 RCT, N=21, RR 3.30, 95% CI, 1.23 to 8.85, NNTH 2, 95% CI, 2 to 17). Although not reaching statistical significance, 50% of the participants (5 of 10 participants) receiving clozapine in the study had a drop in absolute neutrophil count to below 1500 per mm<sup>3</sup>. None of the participants in the haloperidol group experienced this adverse effect (1 RCT, N= 21, RR 12, 95% CI, 0.75 to 192.86). For the same study, 2 of 10 participants taking clozapine had seizures. This is clinically significant, although the risk ratio for seizures while taking clozapine as compared with haloperidol was not statistically significant (1 RCT, N= 21, RR 5.45, 95% CI, 0.29 to 101.55).</p> <p>The mean end point body weight was not greater for adolescents treated with risperidone (1 RCT, N= 81, MD 0.60, 95% CI, -8.31 to 9.51) or olanzapine (1 RCT, N= 75, MD 2.90, 95% CI, -6.30 to 12.10) as compared with molindone. In this study, mean serum cholesterol concentration showed a statistically significant increase at the end of the treatment period (1 RCT, N=75, MD 25.60, 95% CI, 5.84 to 45.36) for adolescents treated with olanzapine as compared with those given</p>



Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>molindone. The serum cholesterol concentration was not increased at the end of the study for adolescents treated with risperidone (1 RCT, N= 75, MD -1.50, 95% CI, -21.01 to 18.01). The mean end point serum prolactin concentration for all three groups (risperidone, olanzapine and molindone) in one study was much higher than the normal reference range, but no difference was reported for the mean end point serum prolactin concentration as compared with molindone for the group of adolescents receiving atypical antipsychotic medications.</p> <p>Although it did not reach statistical significance, 3 of the 10 young people treated with clozapine left the one as the result of adverse effects, of which two were due to a drop in neutrophil count (1 RCT, N=21, RR 3.30, 95% CI, 0.41 to 26.81). When all studies that reported reasons for leaving the study early were taken together, fewer adolescents receiving atypical antipsychotic medications left the study because of adverse effects (3 RCTs, N=187, RR 0.65, 95% CI, 0.36 to 1.15) or for any reason (3 RCTs, N=187, RR 0.62, 95% CI, 0.39 to 0.97).</p> <p><u>Atypical compared to atypical antipsychotic medication (only short term)</u>                      The numbers of participants with no improvement in CGI score were similar for the groups receiving risperidone and olanzapine (2 RCTs, N=111. RR 1.04, 95% CI, 0.70 to 1.54). In another study, which compared quetiapine and risperidone, no significant difference was reported in the numbers of participants showing no improvement in CGI score (1 RCT, N=22, RR 1.20, 95% CI, 0.52 to 2.79). The mean end point CAGS score was not significantly different (1 RCT, N= 39, MD 4.10, 95% CI, -6.71 to 14.91) for participants receiving clozapine and those taking olanzapine in a different study. However, the mean end point CGI-I score was significantly better for the group of adolescents receiving clozapine as compared with those given olanzapine (1 RCT, N= 39, MD -1.07, 95% CI -1.9 to -0.22).</p> <p>The mean end point BPRS score was not different in two studies that compared risperidone and olanzapine, which are not included in the analysis as the data were skewed. Similarly, another study reported that</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>similar numbers of participants in the groups receiving risperidone or quetiapine showed no response, as defined by less than 40% reduction in baseline PANSS score (1 RCT, N=19, RR 0.48, 95% CI, 0.17 to 1.31). When risperidone and quetiapine were compared in a study, no difference between the groups was noted regarding the number of participants who did not improve (1 RCT, N=29, RR 0.33, 95% CI 0.06 to 1.73). In a study which compared risperidone with quetiapine, similar numbers of participants in both groups did not show response on the PANSS score at the end of the study (1 RCT, N=22, RR 1.67, 95% CI 0.52 to 5.33). A study reported a similar mean end point score on BPRS for participants receiving clozapine and olanzapine (1 RCT, N=39, MD - 2.9, 95% CI, -10.13 to 4.33). However, categorical analysis of the data provided on the number of people who did not respond (defined as less than 30% reduction in BPRS score) showed that results favored clozapine over olanzapine (1 RCT, N=39, RR 0.14, 95% CI, 0.03 to 0.60).</p> <p>Not much difference was observed in some of the studies included in this review between medications used in the two arms of each trial (various atypical antipsychotics) regarding the mean end point body weight. Data reported by one study showed that the mean end point body weight was similar for adolescents treated with risperidone and those given olanzapine (1 RCT, N=76, MD -2.30, 95% CI, -9.97 to 5.37). However, the mean change in body weight showed that those treated with olanzapine had on average gained 6.1 + 3.6 kg by the end of treatment as compared with an average gain of 3.6 + 4 kg for those treated with risperidone. The mean change in body weight was statistically significant in this study.</p> <p>No significant difference in the number of people who gained ≥ 7% of baseline body weight between groups of adolescents treated with olanzapine and clozapine (1 RCT, N= 39, RR 1.75, 95% CI, 0.33 to 9.34). In one study, olanzapine had higher mean end point serum cholesterol concentration as compared with those taking risperidone (1 RCT, N= 76, MD -27.10, 95% CI, -50.13 to -4.07). The serum cholesterol concentration</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>for participants treated with olanzapine showed an average increase of 19.9 + 23.9 mg/dL at the conclusion of the study as compared with an average decrease of 10.2 + 26.7 mg/dL for those taking risperidone. .</p> <p>The serum prolactin concentration was increased much beyond the normal range by the end of the study for both groups of adolescents treated with atypical antipsychotic medications. However, no significant difference was noted between those who received risperidone and those who took olanzapine (1 RCT, N=76, MD -2.30, 95% CI, -9.97 to 5.37). Another study reported that a significantly greater number (10 of 11) of adolescents receiving risperidone as compared with quetiapine had raised serum prolactin concentration (1 RCT, N= 14, RR 4.44, 95% CI, 0.60 to 32.77).</p> <p>No difference in the number of participants reporting muscle stiffness or akathisia was noted between adolescents who received olanzapine and those who were given risperidone (1 RCT, N= 19, RR 2.22, 95% CI, 0.53 to 9.37) or quetiapine and risperidone (1 RCT, N= 19, RR 4.44, 95% CI, 0.60 to 32.77). In another study, no significant difference was reported between groups receiving risperidone versus quetiapine regarding their scores on the Barnes Akathisia Scale, the Simpson Angus Akathisia Scale and the Abnormal Involuntary Movement Scale.</p> <p>In one study, 11 of a total of 39 participants recruited left the study early. Of these 11 participants, six treated with olanzapine and one treated with clozapine left the study because of non-response, two left the clozapine arm of the trial because of weight gain and one left the olanzapine arm as a result of neutropenia.</p> <p>No difference in the number of people leaving the trial early because of side effects was reported for those treated with risperidone or olanzapine (3 RCTs, N=130, RR 1.21, 95% CI, 0.51 to 2.87). Two of 10 adolescents who were treated with quetiapine left the study because of non-response. In total, one of 10 young people from the risperidone group, four of 10 from the quetiapine group and four of 10 from the olanzapine group left</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				the study. In total, only one young person from the olanzapine group left the study because of weight gain.
<b>Bipolar Disorder</b>				
<p>McIntyre et al<sup>59</sup></p> <p>Asenapine 5 mg to 10 mg twice daily</p> <p>vs</p> <p>olanzapine 15 mg on day 1, followed by 5 mg to 20 mg once daily</p> <p>vs</p> <p>placebo</p>	<p>DB, PC, RCT</p> <p>Adult patients, 18 years of age or older, diagnosed with bipolar I disorder, experiencing manic or mixed episodes</p>	<p>N=488</p> <p>3 weeks (after 1 week placebo run-in period)</p>	<p>Primary: Change in YMRS total score from baseline</p> <p>Secondary: Change from baseline in Clinical Global Impression for Bipolar Disorder (CGI-BP), MADRS, percentage of responders (<math>\geq 50\%</math> reduction in YMRS total score), percentage of remitters (YMRS total score <math>\leq 12</math> at endpoint), adverse events</p>	<p>Primary: Asenapine was associated with a statistically significant reduction in YMRS total score from baseline, compared to placebo (-10.8 vs -5.5; <math>P &lt; 0.0001</math>). Statistically significant benefit with asenapine over placebo was noted as early as day-2 of therapy.</p> <p>Olanzapine was associated with a statistically significant reduction in YMRS total score from baseline, compared to placebo (-12.6 vs -5.5; <math>P &lt; 0.0001</math>).</p> <p>Secondary: Asenapine was associated with a statistically significant reduction in CGI-BP score from baseline, compared to placebo (-1.2 vs -0.7; <math>P \leq 0.01</math>).</p> <p>Olanzapine was associated with a statistically significant reduction in CGI-BP score from baseline, compared to placebo (-1.4 vs -0.7; <math>P \leq 0.0001</math>).</p> <p>Asenapine was not associated with significant difference in MADRS reduction at endpoint compared to placebo (-3.2 vs -1.8; <math>P &gt; 0.05</math>).</p> <p>Olanzapine was associated with a statistically significant reduction in MADRS score from baseline, compared to placebo (-4.2 vs -1.8; <math>P \leq 0.01</math>).</p> <p>Significantly greater percentage of patients in the asenapine group experienced a response (42.3%) or remission (40.2%) compared to patients receiving placebo (25.2% and 22.3%, respectively; <math>P &lt; 0.01</math> for both). The NNT values for YMRS response and remission were 6.</p> <p>Significantly greater percentage of patients in the olanzapine group experienced a response (50%) or remission (39.4%) compared to patients receiving placebo (25.2% and 22.3%, respectively; <math>P &lt; 0.005</math> for</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>both). The NNT values for YMRS response and remission were 5 and 6, respectively.</p> <p>Treatment-related adverse events were reported by 60.8%, 52.9%, and 36.2% of asenapine-, olanzapine-, and placebo-treated patients.</p> <p>Most common adverse events with asenapine that occurred at more than twice the frequency of placebo included sedation (18.6 vs 4.8%), dizziness (11.9 vs 3.8%), somnolence (8.8 vs 1.9%), fatigue (6.2 vs 1.9%), and oral hypoesthesia (5.2 vs 1%).</p> <p>Most common adverse events with olanzapine that occurred at more than twice the frequency of placebo included sedation (18.5%), dry mouth (14.3 vs 1%), dizziness (8.5%), somnolence (7.4%), and increased weight (6.9 vs 1%).</p> <p>The incidence of EPS events was 7.2% with asenapine, 7.9% with olanzapine and 2.9% with placebo.</p> <p>Asenapine, olanzapine, and placebo groups experienced the following weight gain: 1.6 kg, 1.9 kg, and 0.3 kg, respectively. NNH values vs placebo for the incidence of clinically significant weight gain were 17 and 8 in patients who received asenapine and olanzapine, respectively.</p>
<p>McIntyre et al<sup>60</sup></p> <p>Asenapine 5 mg to 10 mg twice daily</p> <p>vs</p> <p>olanzapine 15 mg on day 1, followed by 5 mg to 20 mg once daily</p> <p>vs</p>	<p>DB, MC, PC, RCT</p> <p>Adult patients, 18 years of age or older, diagnosed with bipolar I disorder, experiencing manic or mixed episodes, with YMRS total score <math>\geq 20</math></p>	<p>N=480</p> <p>3 weeks (after 1 week placebo run-in period)</p>	<p>Primary: Change in YMRS total score from baseline</p> <p>Secondary: Change from baseline in CGI-BP, MADRS, percentage of responders (<math>\geq 50\%</math> reduction in YMRS)</p>	<p>Primary: Asenapine was associated with a statistically significant reduction in YMRS total score from baseline, compared to placebo (-11.5 vs -7.8; <math>P &lt; 0.007</math>). Statistically significant benefit with asenapine over placebo was noted as early as day-2 of therapy.</p> <p>Olanzapine was associated with a statistically significant reduction in YMRS total score from baseline, compared to placebo (-14.6 vs -7.8; <math>P &lt; 0.0001</math>).</p> <p>Secondary: Asenapine was associated with a statistically significant reduction in CGI-</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
placebo			total score), percentage of remitters (YMRS total score $\leq 12$ at endpoint), adverse events	<p>BP score from baseline, compared to placebo (-1.2 vs -0.8; <math>P \leq 0.05</math>).</p> <p>Olanzapine was associated with a statistically significant reduction in CGI-BP score from baseline, compared to placebo (-1.5 vs -0.8; <math>P \leq 0.0001</math>).</p> <p>Asenapine was not associated with a significant difference in MADRS reduction at endpoint compared to placebo (-3.0 vs -1.9; <math>P &gt; 0.05</math>).</p> <p>Olanzapine was associated with a statistically significant reduction in MADRS score from baseline, compared to placebo (-4.1 vs -1.9; <math>P \leq 0.01</math>).</p> <p>The response (42.6 vs 34%) and remission (35.5 vs 30.9%) rates did not significantly differ between asenapine and placebo groups (<math>P &gt; 0.05</math>).</p> <p>Significantly greater percentage of patients in the olanzapine group experienced a response (54.7%) or remission (46.3%) compared to patients receiving placebo (34% and 30.9%, respectively; <math>P &lt; 0.05</math> for both). The NNT values for YMRS response and remission were 5 and 7, respectively.</p> <p>Treatment-related adverse events were reported by 55.1%, 46.8%, and 27.6% of asenapine-, olanzapine-, and placebo-treated patients.</p> <p>Most common adverse events with asenapine that occurred at more than twice the frequency of placebo included sedation (8.6 vs 3.1%), dizziness (10.3 vs 2.0%), somnolence (11.9 vs 3.1%), weight gain (6.5 vs 0.0%), and vomiting (5.4 vs 2%).</p> <p>Most common adverse events with olanzapine that occurred at more than twice the frequency of placebo included sedation (14.1%), dizziness (6.3%), somnolence (11.2%), increased appetite (6.3 vs 1%) and increased weight (9.3%).</p> <p>The incidence of EPS events was 10.3% with asenapine, 6.8% with</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>olanzapine and 3.1% with placebo.</p> <p>Asenapine, olanzapine, and placebo groups experienced the following weight gain: 0.9 kg, 2.6 kg, and 0.1 kg, respectively. NNH values vs placebo for the incidence of clinically significant weight gain were 19 and 7 in patients who received asenapine and olanzapine, respectively.</p>
<p>Szegediet al<sup>61</sup></p> <p>Asenapine 5 mg to 10 mg twice daily</p> <p>vs</p> <p>olanzapine 15 mg once daily on day 1, followed by 5 mg to 20 mg once daily</p> <p>vs</p> <p>placebo</p>	<p>MA, PH of 2 studies by McIntyre et al</p> <p>Adult patients, 18 years of age or older, diagnosed with bipolar I disorder, experiencing depressive symptoms, with YMRS total score <math>\geq 20</math> or CGI-BP-D score <math>\geq 4</math>, or mixed symptoms</p>	<p>N=977</p> <p>3 weeks (after 1 week placebo run-in period)</p>	<p>Primary: Change in MADRS, CGI-BP-D, and PANSS Marder anxiety/depression factor scores from baseline</p> <p>Secondary: Not reported</p>	<p>Primary: In patients with baseline MADRS scores <math>\geq 20</math>, CGI-BP-D scores <math>\geq 4</math>, or those experiencing a mixed episode, there was no statistically significant difference between asenapine and olanzapine (<math>P &gt; 0.05</math>) in terms of improvement in MADRS scores from baseline on day-21; though, asenapine was more effective than placebo (<math>P &lt; 0.05</math>).</p> <p>In patients with baseline MADRS scores <math>\geq 20</math>, significantly more patients in the asenapine group experienced remission compared to placebo on day-21 (70 vs 33%; <math>P = 0.012</math>); though, asenapine was not associated with a significantly greater remission rate compared to olanzapine (70 vs 48%; <math>P = 0.066</math>).</p> <p>In patients with baseline CGI-BP-D severity scores <math>\geq 4</math> or those exhibiting a mixed episode more patients in the asenapine group experienced remission compared to placebo on day-21 (<math>P &lt; 0.05</math>). In these patients, olanzapine was associated with significantly greater remission rate compared to placebo on day-21 (<math>P &lt; 0.05</math>).</p> <p>In patients with MADRS scores <math>\geq 20</math>, CGI-BP-D severity scores <math>\geq 4</math> or those exhibiting a mixed episode at baseline, there was no statistically significant difference between asenapine and olanzapine in terms of CGI-BP-D score reduction from baseline on day-21 (<math>P &gt; 0.05</math>).</p> <p>In patients with either CGI-BP-D severity scores <math>\geq 4</math> or those exhibiting a mixed episode at baseline, there was no statistically significant difference between asenapine and olanzapine in terms of PANSS Marder anxiety/depression factor score reduction from baseline on day-21 (<math>P &gt; 0.05</math>). Patients with baseline MADRS scores <math>\geq 20</math> who received</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>asenapine exhibited a statistically greater improvement in PANSS Marder anxiety/depression scores compared to olanzapine on day-7 (P=0.001).</p> <p>Secondary: Not reported</p>
<p>McIntyre et al<sup>62</sup></p> <p>Continuing asenapine 5 mg to 10 mg twice daily</p> <p>vs</p> <p>continuing olanzapine 5 mg to 20 mg once daily</p> <p>vs</p> <p>switching from placebo to asenapine in a blinded fashion</p>	<p>DB, ES</p> <p>Adult patients, 18 years of age or older, diagnosed with bipolar I disorder, experiencing manic or mixed episodes, with YMRS total score <math>\geq 20</math></p>	<p>N=480</p> <p>9 weeks</p>	<p>Primary: Change in YMRS scores from baseline</p> <p>Secondary: YMRS response and remission rates, CGI-BP, PANSS, MADRS, adverse events</p>	<p>Primary: At day-84, there was no statistically significant difference between asenapine and olanzapine in the YMRS score reduction from baseline (-24.4 vs -23.9; P value not reported).</p> <p>Secondary: At day-84, there were no statistically significant differences between asenapine and olanzapine in terms of YMRS response (77 vs 82%) and remission rates (75 vs 79%; P&gt;0.05 for both). The relative NNT values for olanzapine relative to asenapine in terms of YMRS response and remission were 40 and 48.</p> <p>At day-84, there was no statistically significant difference between asenapine and olanzapine in the CGI-BP score reduction from baseline (P&gt;0.05).</p> <p>At day-84, there were no statistically significant differences between asenapine and olanzapine in either the PANSS total score or MADRS score reduction from baseline (P&gt;0.05).</p> <p>There were no marked differences in the incidence of treatment-emergent or treatment-related adverse events between asenapine and olanzapine groups (P value not reported). The most frequently reported adverse events were sedation, dizziness, and insomnia with asenapine and sedation, headache, somnolence and weight gain with olanzapine. The incidence of EPS adverse events was 10% with placebo/asenapine, 15% with asenapine and 13% with olanzapine.</p> <p>Mean weight gain after 12 weeks of therapy was 0.5 kg with placebo/asenapine, 1.9 kg with asenapine, and 4.1 kg with olanzapine.</p>



Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
<p>McIntyre et al<sup>63</sup></p> <p>Continuing asenapine 5 mg to 10 mg twice daily</p> <p>vs</p> <p>continuing olanzapine 5 mg to 20 mg once daily</p> <p>vs</p> <p>switching from placebo to asenapine in a blinded fashion</p>	<p>DB, DD, MC, PG, ES of the 2 studies by McIntyre et al</p> <p>Adult patients, 18 years of age or older, diagnosed with bipolar I disorder, experiencing manic or mixed episodes, with YMRS total score <math>\geq 20</math></p>	<p>N=218</p> <p>40 weeks (in addition to the 3 week RCT and 12 week prior ES)</p>	<p>Primary: Adverse events</p> <p>Secondary: YMRS response at 52 weeks, YMRS remission at 52 weeks, change in YMRS scores, CGI-BP scores, and MADRS scores</p>	<p>The percentage of patients with clinically significant weight gain was greater with olanzapine (31%) than with asenapine (19%) after 12 weeks of therapy. The estimated NNH for clinically significant weight gain for olanzapine relative to asenapine was 9.</p> <p>Primary: The incidence of treatment-emergent adverse events was 71.9%, 86.1%, and 79.4% with placebo/asenapine, asenapine, and olanzapine, respectively.</p> <p>The most frequent treatment-emergent adverse events were headache and somnolence with placebo/asenapine, insomnia, sedation and depression with asenapine, and weight gain, somnolence and sedation with olanzapine.</p> <p>Prolactin levels &gt;4 times the upper limit of normal occurred in 0%, 6.5%, and 2.9% of patients receiving placebo/asenapine, asenapine and olanzapine, respectively.</p> <p>Shifts from normal to high fasting glucose levels occurred in 10%, 26%, and 22.2% of patients receiving placebo/asenapine, asenapine and olanzapine, respectively. The NNH value for asenapine relative to olanzapine was 27.</p> <p>Clinically significant weight gain occurred in 21.9%, 39.2%, and 55.1% of patients receiving placebo/asenapine, asenapine and olanzapine, respectively. The NNH value for olanzapine relative to asenapine was 7.</p> <p>Secondary: At week-52, there was no statistically significant difference between asenapine and olanzapine in the YMRS score reduction from baseline (-28.6 vs -28.2; P value not reported).</p> <p>At week-52, there was no statistically significant difference between asenapine and olanzapine in terms of YMRS remission and response rates (97.8 vs 98.4%; P value not reported).</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>At week-52, there was no statistically significant difference between asenapine and olanzapine in the CGI-BP mania severity score reduction from baseline (-3.5 vs -3.2; P value not reported).</p> <p>At week-52, there was no statistically significant difference between asenapine and olanzapine in the MADRS score reduction from baseline (-4.8 vs -4.4; P value not reported).</p>
<p>Calabrese et al<sup>64</sup></p> <p>Quetiapine 300 mg/day</p> <p>vs</p> <p>quetiapine 600 mg/day</p> <p>vs</p> <p>placebo</p>	<p>DB, MC, PC, PG, RCT</p> <p>Patients 18 to 65 years of age diagnosed with bipolar I or bipolar II disorder who were experiencing an acute depressive episode</p>	<p>N=838</p> <p>8 weeks</p>	<p>Primary: Mean change in MADRS total score from baseline to week 8</p> <p>Secondary: Changes in CGI-I, CGI-S and HAM-D scores from baseline to week 8, rates of and time to response (≥50% improvement in the total MADRS score from baseline) and remission (MADRS total score ≤12)</p>	<p>Primary: Quetiapine at either dose demonstrated statistically significant improvement in MADRS total scores compared to placebo from week 1 onward (P&lt;0.001 for all assessments).</p> <p>Secondary: Quetiapine-treated patients experienced a statistically significant improvement (P&lt;0.001) on the CGI-S as early as week 1 that was sustained till the end of the study for both doses; a larger percentage of patients improved on the CGI-I scale in the 600 mg/day (55.9%) and 300 mg/day (64.0%) quetiapine groups compared to the placebo group (34.3%) at the final assessment.</p> <p>The mean change from baseline in the HAM-D scores at week 8 was -13.84, -13.38, and -8.54 in the quetiapine 600 mg/day, quetiapine 300 mg/day, and placebo groups respectively (P&lt;0.001 for both quetiapine doses vs placebo).</p> <p>The proportions of patients meeting response criteria at the final assessment were 58.2% in the quetiapine 600 mg/day group, 57.6% in the quetiapine 300 mg/day group, and 36.1% in the placebo group.</p> <p>The proportion of patients meeting remission criteria were 52.9% in the quetiapine 600 mg/day and 300 mg/day groups, and 28.4% in the placebo group.</p> <p>Treatment-emergent mania rates were low and similar for the quetiapine</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
<p>Tohen et al<sup>65</sup></p> <p>Olanzapine 5-20 mg/day</p> <p>vs</p> <p>olanzapine-fluoxetine 6/25 mg</p> <p>vs</p> <p>olanzapine-fluoxetine 6/50 mg</p> <p>vs</p> <p>olanzapine-fluoxetine 12/50 mg</p> <p>vs</p> <p>placebo</p>	<p>DB, MC, PC, PG, RCT</p> <p>Patients 18 years or older diagnosed with bipolar I disorder, depressed</p>	<p>N=833</p> <p>8 weeks</p>	<p>Primary: Change in MADRS total score from baseline to week 8</p> <p>Secondary: Changes in CGI-BP, YMRS and HAM-A scores from baseline to week 8, rates of and time to response (≥50% improvement in the total MADRS score from baseline) and remission (MADRS total score ≤12 at an end point and completion of ≥4 weeks of study)</p>	<p>and placebo groups (3.2% and 3.9%, respectively).</p> <p>Primary: During all eight study weeks, the olanzapine and olanzapine-fluoxetine groups showed statistically significant improvement in depressive symptoms compared to the placebo group (olanzapine, -15.0; P=0.002; olanzapine-fluoxetine, -18.5; P&lt;0.001). The olanzapine-fluoxetine group showed statistically greater improvement than the olanzapine group at week 8 (P=0.01).</p> <p>Secondary: The olanzapine group showed greater mean improvement on the CGI-BP than the placebo group (P=0.004), and the olanzapine-fluoxetine group showed greater mean improvement than both the placebo (P&lt;0.001) and olanzapine (P=0.16) groups.</p> <p>Treatment-emergent mania (YMRS total score &lt;15 at baseline and ≥15 subsequently) did not differ among groups (placebo, 6.7%; olanzapine, 5.7%; olanzapine-fluoxetine, 6.4%).</p> <p>Remission criteria were met by 24.5% (87/355) of the placebo group, 32.8% (115/351) of the olanzapine group, and 48.8% (40/82) of the olanzapine-fluoxetine group.</p> <p>Adverse events for the olanzapine-fluoxetine group were similar to those in the olanzapine group, but also included higher rates of nausea and diarrhea.</p>
<p>Perlis et al<sup>66</sup></p> <p>Olanzapine 5-20 mg/day</p> <p>vs</p> <p>risperidone 1-6 mg/day</p>	<p>DB, MC, PG, RCT</p> <p>Hospitalized patients with bipolar I disorder, manic or mixed episode, without psychotic features</p>	<p>N=329</p> <p>3 weeks</p>	<p>Primary: Mean change in YMRS score from baseline to 3 weeks</p> <p>Secondary: Changes in CGI-BP severity of illness scale, improvement</p>	<p>Primary: Changes in YMRS scores from baseline to week 3 were not significantly different between treatment groups (olanzapine, -15.03; risperidone, -16.62; P&gt;0.05).</p> <p>Secondary: No significant differences between treatment groups for the HAM-D-21 (olanzapine, -6.06; risperidone, -5.20), MADRS (olanzapine, -6.22; risperidone, -5.40), or CGI-BP (olanzapine, -1.64; risperidone, -1.46)</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
			in depression by HAM-D-21 and MADRS scales, safety (assessed by the evaluation of treatment-emergent adverse events, discontinuations due to adverse events, vital sign measurements, and clinical laboratory tests)	<p>scores (all P&gt;0.05).</p> <p>With a response definition of ≥50% reduction in the YMRS score at endpoint, 62.1% of olanzapine-treated patients responded compared to 59.5% of the risperidone-treated patients.</p> <p>Olanzapine-treated patients experienced greater elevations in liver function enzymes (P&lt;0.05) and increase in weight (2.5 kg vs 1.6 kg; P=0.004); risperidone-treated patients were more likely to experience prolactin elevation (51.73 ng/mL vs 8.23 ng/mL; P&lt;0.001) and sexual dysfunction (total score increase of 1.75 vs 0.64; P=0.049).</p>
<p>Yatham et al<sup>67</sup></p> <p>Continuation of usual oral atypical antipsychotic (olanzapine, quetiapine, or risperidone)</p> <p>vs</p> <p>switching to long-acting risperidone 25 mg injection every 2 weeks</p>	<p>MC, OL, PRO, RCT</p> <p>Stable adults aged 18-65 years of age diagnosed with Bipolar I or Bipolar II according to DSM-IV criteria and currently on one oral atypical antipsychotic agent in combination with a maximum of two of lithium, valproate or lamotrigine; and, if applicable, one antidepressant</p>	<p>N=49</p> <p>6 months</p>	<p>Primary:</p> <p>Safety measures (adverse events, lab tests, vital signs, weight and movement disorders scales such as the BARS, SAS, and AIMS) and efficacy measures (CGI-S, YMRS, MADRS, HAM-A, EuroQol EQ-5D, VAS and time to intervention)</p> <p>Secondary:</p> <p>Not reported</p>	<p>Primary:</p> <p>At least one treatment emergent adverse event was reported by 16 (70%) of patients in the injection group and 19 (73%) in the oral group (P value not reported).</p> <p>There were no clinical significant changes in laboratory tests in either group (P value not reported).</p> <p>There were no significant changes in weight or heart rate within each group; however, diastolic blood pressure was significantly different at the study endpoint in the risperidone injection group (-5.2±11.0; P=0.033). There were significant between group differences in reduction of diastolic blood pressure favoring the injection group (P&lt;0.05).</p> <p>There were no significant differences between groups for mean changes in AIMS (P=0.95), SAS (P=0.11) or BARS (P=0.52) scores.</p> <p>The differences in changes in CGI-S and YMRS scores between the two groups was not significant (P=0.67 and P=0.31, respectively). There were also no significant differences in changes in MADRS or HAM-A scores between the groups (P values not reported).</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>There were no significant differences between the groups on changes in VAS, EuroQuol EQ-5D, or scores on the resource use questionnaire (P values not reported).</p> <p>There were no significant differences between groups on the number of interventions or time to intervention (P value not reported).</p> <p>Secondary: Not reported</p>
<p>Cipriani et al<sup>68</sup></p> <p>Atypical antipsychotics (aripiprazole, asenapine, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone)</p> <p>vs</p> <p>anticonvulsants (carbamazepine, valproate, gabapentin, lamotrigine, topiramate)</p> <p>vs</p> <p>haloperidol</p> <p>vs</p> <p>lithium</p> <p>vs</p> <p>placebo</p>	<p>MA</p> <p>Patients, 18 years of age or older, with a diagnosis of bipolar disorder (manic or mixed episode)</p>	<p>N=16,073</p> <p>3 weeks</p>	<p>Primary: Mean change in YMRS scores and dropout rates</p> <p>Secondary: Responder rate</p>	<p>Primary: Haloperidol (SMD, -0.56; 95%CI, -0.69 to -0.43), risperidone (-0.50; -0.63 to -0.38), olanzapine (-0.43; -0.54 to -0.32), lithium (-0.37; -0.63 to -0.11), quetiapine (-0.37; -0.51 to -0.23), aripiprazole (-0.37; -0.51 to -0.23), carbamazepine (-0.36; -0.60 to -0.11, asenapine (-0.30; -0.53 to -0.07), valproate (-0.20; -0.37 to -0.04), and ziprasidone (-0.20; -0.37 to -0.03) were significantly more effective than placebo in terms of mean change in YMRS scores from baseline.</p> <p>Gabapentin, lamotrigine, and topiramate were not significantly different from placebo in the mean change in YMRS scores from baseline (P value not reported).</p> <p>Risperidone was not significantly different from either olanzapine or quetiapine in the mean change in YMRS scores from baseline (P value not reported).</p> <p>Haloperidol had the highest number of significant differences and was significantly more effective than lithium (SMD, -0.19; 95% CI -0.36 to -0.01), quetiapine (-0.19; -0.37 to 0.01), aripiprazole (-0.19; -0.36 to -0.02), carbamazepine (-0.20; -0.36 to -0.01), asenapine (-0.26; -0.52 to 0.01), valproate (-0.36; -0.56 to -0.15), ziprasidone (-0.36; -0.56 to -0.15), lamotrigine (-0.48; -0.77 to -0.19), topiramate (-0.63; -0.84 to -0.43), and gabapentin (-0.88; -1.40 to -0.36).</p> <p>Risperidone and olanzapine exhibited a similar profile of comparative</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>efficacy to haloperidol, being more effective than valproate, ziprasidone, lamotrigine, topiramate, and gabapentin. Topiramate and gabapentin were significantly less effective compared to all other antimanic drugs. Olanzapine was associated with significantly greater improvement in YMRS scores from baseline compared to asenapine (-.22; -0.37 to -0.08).</p> <p>Olanzapine, risperidone, and quetiapine were associated with significantly lower dropout rate compared to lithium, lamotrigine, placebo, topiramate, and gabapentin (P value not reported). Aripiprazole was not statistically different from olanzapine, risperidone, and quetiapine in terms of the likelihood of discontinuing therapy (P value not reported).</p> <p>When the evaluated antimanic drugs were ordered by their probability to be the best treatment in terms of both efficacy (improvement on the YMRS) and tolerability (assessed via dropout rates), risperidone was found to be the most effective treatment option. In order of decreased efficacy, the next best treatment options were olanzapine, haloperidol, quetiapine, carbamazepine, aripiprazole, valproate, lithium, ziprasidone and asenapine. Lamotrigine, topiramate and gabapentin were found to be less effective than placebo.</p> <p>Secondary: Compared to placebo, aripiprazole (Odds Ratio [OR], 0.50; 0.38 to 0.66), asenapine (0.49; 0.29 to 0.83), carbamazepine (0.40; 0.22 to 0.77), valproate (0.50; 0.36 to 0.70), haloperidol (0.44; 0.33 to 0.58), lithium (0.55; 0.38 to 0.79), olanzapine (0.46; 0.36 to 0.58), quetiapine (0.50; 0.37 to 0.66), and risperidone (0.47; 0.35 to 0.61) were associated with better response rates.</p> <p>The difference in response rates between olanzapine and asenapine, olanzapine and risperidone, as well as quetiapine and risperidone were not statistically significant.</p>
Perlis et al <sup>69</sup> Aripiprazole, olanzapine,	MA of PC, randomized, trials	N=4,304 12 placebo-	Primary: Change in YMRS score at day 21 or	Primary: For the monotherapy studies all of the agents demonstrated significant efficacy; no differences were detected among any of the second

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
<p>quetiapine, risperidone or ziprasidone</p> <p>Monotherapy and adjunctive trial; no head-to-head comparative studies included.</p>	<p>Patients with a diagnosis of bipolar mania</p>	<p>controlled monotherapy trials; 6 placebo-controlled adjunctive or combination therapy trials</p> <p>Duration: 3-6 weeks</p>	<p>28 and rates of response at endpoint (defined as <math>\geq 50\%</math> decrease in YMRS score)</p> <p>Secondary: Proportion of patients achieving response</p>	<p>generation antipsychotics studied (the global F test for a main effect of drug was not significant [<math>P=0.38</math>], and no pairwise significant differences among drugs were found at the 0.05 level after adjustment for multiple comparisons using the Tukey HSD procedure).</p> <p>For the add-on therapy studies no differences in efficacy were detected among any of the drugs (the global F test for a main effect of drug was not significant [<math>P=0.25</math>], and no pairwise significant differences among drugs were found).</p> <p>Secondary: For the monotherapy trials overall response rates were 53% for second generation antipsychotics and 30% for placebo.</p> <p>For the add-on therapy studies only 3 trials reported data on response rates; the data set was too small to analyze.</p>
<p>Tarr et al<sup>70</sup></p> <p>Atypical antipsychotics (olanzapine, quetiapine, aripiprazole, risperidone)</p> <p>vs</p> <p>mood stabilizers (valproic acid, lithium)</p>	<p>MA</p> <p>Patients with manic or mixed type Bipolar I disorder</p>	<p>N=1,631</p> <p>3-4 weeks</p>	<p>Primary: Mean change from baseline in symptom severity, responder rate, drop-out rate</p> <p>Secondary: Not reported</p>	<p>Primary: Atypical antipsychotics were associated with significantly greater improvement in mania rating scales compared to mood stabilizers (SMD, -0.22; 95%CI, -0.33 to -0.11; <math>P&lt;0.0001</math>).</p> <p>Responder rates were 7% higher with atypical antipsychotics compared to mood stabilizers (<math>P=0.02</math>; NNT=17).</p> <p>Drop-out rates were 5% lower with atypical antipsychotics compared to mood stabilizers (<math>P=0.02</math>).</p> <p>Secondary: Not reported</p>
<p>Yildiz et al<sup>71</sup></p> <p>Atypical antipsychotics (aripiprazole, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone)</p>	<p>MA</p> <p>Adult patients with manic or mixed Bipolar I disorder</p>	<p>N=13,093</p> <p>Study duration not reported</p>	<p>Primary: Hedges' g scores, responder rate</p> <p>Secondary: Not reported</p>	<p>Primary: Compared to placebo, the following drugs were associated with a significant improvement from baseline in manic symptoms: aripiprazole, carbamazepine, haloperidol, lithium, olanzapine, paliperidone, quetiapine, risperidone, tamoxifen, valproate, and ziprasidone. The pooled effect size for these drugs was moderate (<math>P&lt;0.0001</math>). For categorical responder</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
vs Mood stabilizers (carbamazepine, lithium, valproate) vs haloperidol vs tamoxifen vs placebo				<p>rate, the pooled responder risk ratio was 1.52 (95%CI, 1.42 to 1.62; P&lt;0.0001). The responder rate difference between these drugs and placebo was 17% (drug: 48 vs placebo: 31%), with a NNT to produce a response of 6 (P&lt;0.0001).</p> <p>Among the atypical antipsychotics, risperidone was associated with the fewest number of patients needed to be treated to produce a positive response to therapy (NNT=4.2), followed by olanzapine (NNT=5), quetiapine (NNT=5.6), ziprasidone (NNT=5.9), aripiprazole (NNT=8.3), and finally paliperidone (NNT=12.5).</p> <p>Risperidone, haloperidol and tamoxifen were associated with large effect sizes compared to placebo (Hedges's g, 0.26 to 0.46).</p> <p>Lamotrigine, topiramate and verapamil were not associated with significantly greater efficacy in terms of the Hedges's g scores compared to placebo (P=0.62).</p> <p>Compared to placebo, atypical antipsychotics as a class were associated with a larger Hedges' g effect size (0.40; P&lt;0.0001) than the mood stabilizers (0.38; P&lt;0.0001). Atypical antipsychotics were also associated with greater categorical responder rate than the mood stabilizers (P=0.006). Antipsychotics were comparable or faster acting than the mood stabilizers in 7 trials (P=0.01).</p> <p>Secondary: Not reported</p>
Vieta et al <sup>72</sup> Atypical antipsychotics (quetiapine, olanzapine, aripiprazole) alone or as combination therapy vs	MA Patients, 18 years of age or older, with Bipolar I or II disorder and acute bipolar depression	N=6,731 6 to 12 weeks	Primary: MADRS, HAM-D, response, remission Secondary: Not reported	Primary: The greatest reduction in MADRS scores from baseline compared to placebo were noted with quetiapine 300 mg daily (-4.8; 95%CI, -6.18 to -3.49), quetiapine 600 mg (-4.8; 95%CI, -6.22 to -3.28) and olanzapine/fluoxetine combination therapy (-6.6; 95%CI, -9.59 to -3.61). Olanzapine was also associated with significant improvement in MADRS scores compared to placebo (P=0.004).



Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
<p>olanzapine/fluoxetine alone or as combination therapy</p> <p>vs</p> <p>paroxetine alone or as combination therapy</p> <p>vs</p> <p>mood stabilizers (lamotrigine, lithium, divalproex) alone or as combination therapy</p> <p>vs</p> <p>phenelzine alone or as combination therapy</p> <p>vs</p> <p>placebo</p>				<p>The greatest reduction in HAM-D scores from baseline compared to placebo was noted with quetiapine (-4.0 points; 95%CI, -5.0 to -2.9; P=0.000). The other study drugs were not associated with a significant change in HAM-D scores compared to placebo.</p> <p>Quetiapine, lamotrigine, olanzapine, olanzapine/fluoxetine, imipramine, and divalproex were associated with a significantly greater response rate compared to placebo (P&lt;0.05).</p> <p>Paroxetine, lithium, aripiprazole, and phenelzine were not associated with a significant difference in response rate compared to placebo.</p> <p>Quetiapine, olanzapine, olanzapine/fluoxetine were associated with significantly greater remission rates compared to placebo (P&lt;0.05). The other study medications were no significantly difference from placebo in terms of remission rate.</p> <p>Secondary: Not reported</p>
<p>Muradlidharan et al<sup>275</sup></p> <p>Atypical (second generation) antipsychotic</p> <p>Studies included monotherapy with atypical antipsychotics and in combination with mood stabilizers.</p>	<p>MA (of DB,PC, RCT)</p> <p>Patients 18 years of age or older with a primary diagnosis of manic or mixed episodes of bipolar disorder treated with an atypical (second generation antipsychotic)</p>	<p>N=1,289 (9 studies)</p>	<p>Primary: Mean change in YMRS or MRS to end of the study</p> <p>Secondary: Mean change in YMRS or MRS to end of the study in the mono- and adjunctive- therapy trials separately</p>	<p>Primary: The standardized mean differences [SMD] of the mean change in YMRS/MRS scores were determined using a random effects model. The SMD of mean change in mania scores in all trials combined was statistically significant in favor of the atypical antipsychotic group compared to placebo for acute mixed episodes of bipolar disorder (-0.41; 95% CI, -0.53 to -0.30). Test for overall effect was highly statistically significant (Z=7.11, P&lt;0.0001). There was no significant heterogeneity in the SMDs between the studies (Chi<sup>2</sup>=7.65, df=10, P=0.66, I<sup>2</sup>=0%).</p> <p>Secondary: The SMD for atypical antipsychotics as monotherapy was statistically</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>significant compared to placebo (-0.35; 95% CI, -0.49 to -0.22). The test for overall effect was <math>Z=5.07</math>; <math>P&lt;0.00001</math>. No significant heterogeneity was detected in the SMD between these studies (<math>\text{Chi}^2=3.42</math>, <math>\text{df}=7</math>, <math>P=0.84</math>, <math>I^2=0\%</math>).</p> <p>The test for overall effect of atypical antipsychotics in combination with mood stabilizers compared to placebo + mood stabilizers was also statistically significant (-0.55; 95% CI, -0.75 to -0.34). The test for overall effect was <math>Z=5.22</math>; <math>P&lt;0.00001</math>. There was no heterogeneity in the SMD between these studies (<math>\text{Chi}^2=1.85</math>, <math>\text{df}=2</math>, <math>P=0.40</math>, <math>I^2=0\%</math>).</p> <p>In order to ascertain if atypical antipsychotics have similar efficacy in treating manic symptoms in mixed episodes as in pure mania, the SMD for atypical antipsychotics was calculated separately for these two conditions. For this analysis, effect sizes of seven of the nine included RCTs that reported data for pure manic and mixed episodes separately were evaluated. The SMD for atypical antipsychotics compared to placebo was comparable in both pure mania (-0.56; 95% CI, -0.69 to -0.42; <math>N=1522</math>) and mixed episodes (-0.44; 95% CI, -0.59 to -0.29; <math>N=727</math>). Further, no significant differences were noted in the mean YMRS change scores for atypical antipsychotics between manic and mixed patients in each study (-0.00; 95% CI, -0.12 to 0.12; <math>Z=0.02</math>, <math>P=0.99</math>).</p> <p>The SMD of mean change in depression scores in two trials was statistically significant in favor of the atypical antipsychotics group compared to placebo (-0.30; 95% CI, -0.47 to -0.13). Test for overall effect was highly statistically significant (<math>Z=3.48</math>, <math>P&lt;0.001</math>). There was no significant heterogeneity in the SMDs between the two studies (<math>\text{Chi}^2=0.61</math>, <math>\text{df}=2</math>, <math>P=0.74</math>, <math>I^2=0\%</math>).</p>
<p>Loebel et al<sup>285</sup></p> <p>Each patient received therapeutic level of lithium or valproate.</p>	<p>DB, MC, PC, RCT</p> <p>Outpatients 18 to 75 years of age with a diagnosis of bipolar I disorder</p>	<p><math>N=348</math></p> <p>6 weeks</p>	<p>Primary: Change in MADRS from baseline to week 6</p> <p>Secondary:</p>	<p>Primary: The least squares mean change from baseline to week 6 in MADRS total score was significantly greater for the lurasidone group compared with the placebo group (-17.1 versus -13.5; <math>P=0.005</math> [effect size=0.34]). This was statistically improved compared to placebo starting week three, and was maintained at all subsequent study visits (weekly until week 6;</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
<p>Lurasidone 20 to 120 mg/day vs placebo once daily</p>	<p>who were experiencing a major depressive episode, with or without rapid cycling, without psychotic features, and with a history of at least one lifetime bipolar manic or mixed manic episode</p>		<p>Change in CGI-BP, 16-item Quick Inventory of Depressive Symptomatology self-rated version, HAM-A, Sheehan Disability Scale, and Quality of Life Enjoyment and Satisfaction Questionnaire–Short Form from baseline to week 6</p>	<p>P&lt;0.001, P&lt;0.001, P&lt;0.05, P&lt;0.01 for weeks 3, 4, 5 and six respectively).</p> <p>Secondary: Least squares mean change from baseline to week 6 in the CGI-BP depression severity score was significantly greater for the lurasidone group compared with the placebo group (–1.96 versus –1.51; P=0.003 [effect size=0.36]). This was statistically improved compared to placebo starting week two, and was maintained at all subsequent study visits (weekly until week 6; P&lt;0.05, P&lt;0.001, P&lt;0.001, P&lt;0.001, P&lt;0.01 for weeks 2, 3, 4, 5 and six respectively).</p> <p>There was a statistically significant reduction from baseline to week 6 in core depressive symptoms (MADRS-6 subscale score) in the lurasidone group compared with the placebo group (–11.6 versus –9.1; P=0.003).</p> <p>Treatment with lurasidone was associated with greater endpoint improvement compared with placebo on each of the 10 MADRS items, with a significant difference achieved on the following items: apparent sadness, reported sadness, reduced sleep, lassitude, inability to feel, and pessimistic thoughts (P-values varied all &lt;0.05).</p> <p>A significantly greater proportion of patients met a priori response criteria after 6 weeks of treatment with lurasidone compared with placebo (57% versus 42%; P=0.008 [number needed to treat=7]). Median time to response was significantly shorter for the lurasidone group compared with placebo (28 versus 42 days; log-rank P&lt;0.001). The proportion of patients achieving remission at endpoint was significantly greater in the lurasidone group compared with placebo (50% versus 35%; P=0.008 [number needed to treat=7]). The median time to remission was significantly shorter for the lurasidone group compared with placebo (35 versus 43 days, P=0.001).</p> <p>No significant treatment interactions by gender, race, ethnicity, or age were observed for either the MADRS total score or the CGI-BP</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>depression severity score. Least squares mean changes in scores from baseline to endpoint (lurasidone versus placebo) for secondary efficacy assessments were as follows: the Quick Inventory of Depressive Symptomatology (-8.1 versus -5.9; P&lt;0.001); the Hamilton anxiety scale (-8.0 versus -6.0; P=0.003); the Quality of Life, Enjoyment, and Satisfaction Questionnaire–Short Form (+22.2 versus +15.9; P=0.003); and the Sheehan Disability Scale (-9.5 versus -7.0; P=0.012).</p> <p>The incidence of extrapyramidal symptom-related adverse events was 15.3% in the lurasidone group and 9.8% in the placebo group; 11% of the lurasidone group and 4% of the placebo group received treatment with anticholinergic medication for acute extrapyramidal symptoms. Treatment with adjunctive lurasidone was associated with a small but significantly greater endpoint change compared with placebo in the Barnes Akathisia Rating Scale score global score (0.1 versus 0.0; P=0.009), and the Simpson-Angus Scale score (0.03 versus 0.01; P=0.018), but no difference for the Abnormal Involuntary Movement Scale total score (both groups, 0.0).</p>
<p>Loebel et al<sup>286</sup> Lurasidone 20 to 60 mg/day Or lurasidone 80 to 120 mg/day vs placebo</p>	<p>DB, MC, PC, PG, RCT  Outpatients 18 to 75 years of age with a diagnosis of bipolar I disorder who were experiencing a major depressive episode, with or without rapid cycling, without psychotic features, and with a history of at least one</p>	<p>N=485  6 weeks</p>	<p>Primary: Mean change in MADRS total score from baseline to week 6  Secondary: Change in CGI-BP, 16-item Quick Inventory of Depressive Symptomatology self-rated version, HAM-A, Sheehan Disability Scale, and Quality of Life</p>	<p>Primary: The least squares mean change from baseline to week 6 in MADRS total score was significantly greater than seen with placebo (-10.7) for the lurasidone 20 to 60 mg group (-15.4; P&lt;0.001 [effect size=0.51]) and the lurasidone 80 to 120 mg group (-15.4; P&lt;0.001 [effect size=0.51]). For both dosages this was statistically improved compared to placebo starting week two, and was maintained at all subsequent study visits (weekly until week 6; P&lt;0.05 for all).</p> <p>Secondary: The least squares mean change from baseline to week 6 in CGI-BP depression severity score was significantly greater than seen with placebo (-1.1) for the lurasidone 20 to 60 mg group (-1.8; P&lt;0.001 [effect size=0.61]) and the lurasidone 80 to 120 mg group (-1.7; P&lt;0.001 [effect size=0.50]). For the lurasidone 20 to 60 mg group and the 80 to</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
	lifetime bipolar manic or mixed manic episode		Enjoyment and Satisfaction Questionnaire– Short Form from baseline to week 6	<p>120 mg group, this was statistically improved compared to placebo starting weeks two and one respectively, and was maintained at all subsequent study visits (weekly until week 6; P&lt;0.05 for all).</p> <p>There was a statistically significant reduction from baseline to week 6 in core depressive symptoms (MADRS-6 subscale score) for the lurasidone 20 to 60 mg group (-10.4; P&lt;0.001) and the lurasidone 80 to 120 mg group (-10.4; P&lt;0.001) relative to the placebo group (-6.9). Lurasidone was associated with significantly greater improvement than placebo on seven of the 10 MADRS items in both the 20 to 60 mg and 80 to 120 mg groups.</p> <p>A significantly greater proportion of subjects met a priori response criteria after 6 weeks of treatment with lurasidone 20 to 60 mg (53%; P&lt;0.001 [number needed to treat=5]) and lurasidone 80 to 120 mg (51%; P&lt;0.001 [number needed to treat=5]) compared with placebo (30%). Median time to response was shorter in the lurasidone 20 to 60 mg group (34 days) and the 80 to 120 mg group (30 days) compared with the placebo group (42 days; log-rank P&lt;0.01 for both comparisons).</p> <p>The proportion of subjects achieving remission at endpoint was significantly greater in the lurasidone 20 to 60 mg group (42%; P=0.001 [number needed to treat=6]) and the lurasidone 80 to 120 mg group (40%; P=0.004 [number needed to treat=7]) compared with the placebo group (25%).</p> <p>No significant treatment interactions by gender, age, race, or ethnicity were observed for either the MADRS total score or the CGI-BP depression severity score.</p> <p>Treatment with both dosages of lurasidone was associated with significant improvement compared with placebo in anxiety symptoms, as measured by the clinician-rated Hamilton anxiety scale, the patient-rated Quick Inventory of Depressive Symptomatology, the Quality of Life, Enjoyment, and Satisfaction Questionnaire, and the Sheehan Disability</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>Scale.</p> <p>The incidence of extrapyramidal symptom-related adverse events was less than 10% in both lurasidone groups, with a modest dose-related increase in incidence. The proportion of patients who received treatment with anticholinergic medication for acute extrapyramidal symptoms was 3.7% in the lurasidone 20 to 60 mg group, 4.9% in the lurasidone 80 to 120 mg group, and 1.9% in the placebo group. Least squares mean changes from baseline to endpoint (lurasidone 20 to 60 mg and 80 to 120 mg versus placebo) were small for the Barnes Akathisia Scale (0.0 and 0.2 versus -0.1), and for the Simpson Angus Scale (0.02 and 0.02 versus 0.00). There were no significant changes from baseline to endpoint in the Abnormal Involuntary Movement Scale total score in any treatment group with no statistically significant differences between the lurasidone treatment groups and the placebo group.</p>
<b>Treatment-Resistant Depression</b>				
<p>Papakostas et al<sup>73</sup></p> <p>Aripiprazole 15 mg daily or 10 mg daily (if taken with fluoxetine or paroxetine) for 1 week, followed by upward titration up to 30 mg/day, clinical response or toxicity</p>	<p>OL, PRO</p> <p>Patients between the ages of 18 and 65 years, diagnosed to have MDD by the use of the Structured Clinical Interview for DSM-IV-Axis I disorders and with an initial 17-item HAM-D-17 score of 14 or greater; patients were required to have had an adequate trial of an SSRI (a minimum dose of</p>	<p>N=12</p> <p>8 weeks</p>	<p>Primary: Clinical response (defined as a 50% or greater reduction in HAM-D-17 score from baseline), remission (defined as a final HAM-D-17 score of less than or equal to 7)</p> <p>Secondary: Reduction in CGI score, reduction in HAM-D-17 score, adverse effects</p>	<p>Primary: Using an ITT analysis, 58.3% of patients responded to therapy (P value not reported).</p> <p>A remission rate of 41.7% was observed in the study population (P value not reported).</p> <p>Secondary: There was a significant reduction in mean CGI score from baseline (P=0.0002).</p> <p>There was a significant reduction in mean HAM-D-17 score from baseline (P&lt;0.0001).</p> <p>None of the evaluated patients experienced a severe side effect.</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
	10 mg/day for escitalopram, 20 mg/day for fluoxetine, paroxetine, and citalopram, or 50 mg/day for sertraline, for at least 6 weeks)			
<p>Maneeton et al<sup>276</sup></p> <p>Quetiapine XR, doses not reported</p> <p>vs</p> <p>placebo</p>	<p>MA</p> <p>Randomized, placebo-controlled trials of quetiapine monotherapy carried out in adults with MDD</p>	<p>N=1,497</p> <p>Duration not reported</p>	<p>Primary: Depression severity, response rate, overall discontinuation rate or discontinuation rate due to adverse events</p> <p>Secondary: Not reported</p>	<p>Primary: There was a significant reduction from baseline in MADRS scores for patients treated with quetiapine XR compared to placebo (WMD, -3.37; 95% CI, -3.95 to -2.79).</p> <p>Patients randomized to receive treatment with quetiapine XR experienced statistically significant reductions in HAM-D scores compared to patients randomized to receive placebo (WMD, -2.46; 95% CI, -3.47 to -1.45).</p> <p>More patients in the quetiapine XR treatment group were likely to respond to treatment (RR, 1.44; 95% CI, 1.26 to 1.64) and achieve remission (RR, 1.37; 95% CI, 1.12 to 1.68) compared to the placebo group.</p> <p>There was no statistically significant difference in the rate of discontinuation between the treatment groups (RR, 1.16; 95% CI, 0.97 to 1.39); however, patients treated with quetiapine XR were more likely to discontinue due to adverse events compared to the placebo group (RR, 2.90; 95% CI, 1.87 to 4.48).</p> <p>Secondary: Not reported</p>
<p>Papakostas et al<sup>74</sup></p> <p>Ziprasidone 20 mg twice a day for 1 week, followed by an upward titration up to 80</p>	<p>OL, PRO</p> <p>Patients between the ages of 18 and 65, diagnosed to</p>	<p>N=20</p> <p>6 weeks</p>	<p>Primary: Clinical response (defined as a 50% or greater reduction in HAM-D-17 total</p>	<p>Primary: Using an ITT analysis, 50.0% of patients responded to therapy (P value not reported).</p> <p>A remission rate of 38.5% was observed in the study population (P value</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
mg/day, clinical response or toxicity	have MDD by the use of the Structured Clinical Interview for DSM-IV-Axis I disorders and with an initial 17-item HAM-D-17 score of 14 or greater; patients were required to have had an adequate trial of an SSRI (a minimum dose of 10 mg/day for escitalopram, 20 mg/day for fluoxetine, paroxetine, and citalopram, or 50 mg/day for sertraline, for at least 6 weeks)		score from baseline), remission (defined as a final HAM-D-17 score of less than or equal to 7)  Secondary: Improvement in SQ-depression, - anxiety, - anger/hostility, somatic symptom, somatic well-being scale, adverse effects	not reported).  Secondary: At the end of the study, a significant improvement was observed in SQ-depression scores (17.5 vs 12.5, respectively; P=0.001), SQ-anxiety scores (14.1 vs 11.8, respectively; P=0.002), and SQ-anger/hostility scores (10.4 vs 6.9, respectively; P=0.021).  There was no significant improvement in SQ-somatic symptom scores (9.6 vs 10.6; P>0.05) or SQ-somatic well-being scores (1.5 vs 1.5, respectively; P>0.05).  None of the evaluated patients experienced a severe side effect.  There was no change in QTc from baseline to week 6 of the study (P>0.05). In addition, cholesterol level decreased compared to baseline (P>0.05).
Barbee et al <sup>5</sup>  Olanzapine, quetiapine, risperidone, ziprasidone started at a low dose and titrated up to the maximal tolerated dose	RETRO  Patients with treatment-resistant, nonpsychotic MDD, diagnosed based on the DSM-IV criteria, with an adequate trial of an SSRI at the highest tolerated dose for a minimum of 6 weeks	N=49  (Duration varied from 9.40 to 35.86 weeks)	Primary: Clinical response assessed via a CGI scale  Secondary: GAF score, rate of discontinuation	Primary: The overall response rate based on the CGI rating was 65%.  Individual rates of response were 57% for olanzapine, 50% for risperidone, 33% for quetiapine and 10% for ziprasidone. While the response rates noted with olanzapine, risperidone and quetiapine were significantly different from zero (P<0.001); the observed response rate for ziprasidone was not different from zero (P=0.47).  Secondary: There was an improvement in the GAF scores compared to baseline in the olanzapine (P<0.001) and risperidone (P=0.047) groups.



Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>There was no significant difference in the rate of discontinuation among patients receiving the four antipsychotic agents (P=0.13). Patients experienced only mild side effects with all of the evaluated antipsychotics.</p>
<p>Bauer et al<sup>76</sup></p> <p>Quetiapine XR 150 mg daily, in addition to ongoing antidepressant therapy</p> <p>vs</p> <p>quetiapine XR 300 mg daily, in addition to ongoing antidepressant therapy</p> <p>vs</p> <p>placebo, in addition to ongoing antidepressant therapy</p>	<p>MA</p> <p>Patients, aged 18 to 65 years, diagnosed with MDD based on the DSM-IV criteria, with HAM-D total score <math>\geq 20</math> and a HAM-D Item 1 (depressed mood) score <math>\geq 2</math> after an adequate trial (&gt;6 weeks of therapy at an adequate dose) of one of the following antidepressants: amitriptyline, bupropion, citalopram, duloxetine, escitalopram, fluoxetine, paroxetine, sertraline or venlafaxine</p>	<p>N=939</p> <p>6 weeks</p>	<p>Primary: Change in MADRS total score at week-6</p> <p>Secondary: MADRS response rate, MADRS remission rate, HAM-D, HAM-A, Pittsburgh Sleep Quality Index (PSQI), CGI-S scores, adverse events</p>	<p>Primary: Quetiapine XR 150 mg and 300 mg daily doses were associated with significant improvements in MADRS total scores from baseline, compared to placebo (-14.5 vs -14.8 vs -12.0, respectively; P&lt;0.001 for both). Significant benefit of quetiapine XR over placebo was noted as early as week-1 and was sustained through week-6.</p> <p>Secondary: Quetiapine XR 300 mg daily was associated with significantly greater MADRS response rate compared to placebo (58.3 vs 46.2%; P&lt;0.01). Quetiapine XR 150 mg daily was associated with marginal benefit over placebo in terms of MADRS response rate, but the difference did not reach statistical significance (53.7 vs 46.2%; P=0.063).</p> <p>Quetiapine XR 150 mg and 300 mg daily doses were associated with significantly greater remission rates compared to placebo (35.6 vs 36.5 vs 24.1%, respectively; P&lt;0.01 for both).</p> <p>Both quetiapine XR doses were associated with significant improvement from baseline, compared to placebo, in HAM-D, HAM-A, PSQI and CGI-S scores at week-6 of therapy (P&lt;0.05).</p> <p>Significantly more patients in the quetiapine XR 150 mg and 300 mg groups discontinued the study due to adverse events compared to the placebo group (8.9 vs 15.4 vs 1.9%, respectively). In the quetiapine XR groups, the most common adverse events leading to discontinuation were somnolence and sedation.</p> <p>The incidence of adverse events potentially related to EPS side effects was 3.8%, 6.4% and 4.2% of patients in the quetiapine XR 150 mg, 300 mg, and placebo groups.</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>The incidence of suicidality was 1.0%, 0.0% and 0.6% of patients in the quetiapine XR 150 mg, 300 mg, and placebo groups.</p> <p>Mean weight gain from baseline to week-6 in the quetiapine XR 150 mg, 300 mg, and placebo groups were 0.9 kg, 1.3 kg, and 0.2 kg, respectively.</p> <p>Secondary: Not reported</p>
<p>Komosa et al<sup>17</sup></p> <p>Atypical antipsychotics (aripiprazole, amisulpride*, olanzapine, quetiapine, risperidone) as monotherapy or augmentation therapy to antidepressants</p> <p>vs</p> <p>placebo or antidepressants</p>	<p>SR</p> <p>Patients with unipolar major depressive disorder or dysthymia</p>	<p>N=8,487 28 studies</p> <p>12 to 52 weeks</p>	<p>Primary: Treatment response (reduction of <math>\geq 50\%</math> on the HAM-D or the MADRS or at least much improved score on the CGI scale)</p> <p>Secondary: MADRS scores, HAM-D scores, HAM-A scores, remission (HAM-D <math>\leq 7</math> or MADRS <math>\leq 10</math>), adverse events</p>	<p>Primary: According to efficacy data from three available studies, aripiprazole augmentation therapy was associated with an odds ratio of a positive treatment response of 0.48 (95% CI, 0.37 to 0.63; P value not reported).</p> <p>There was no significant difference between olanzapine augmentation therapy and placebo in treatment response rate (P value not reported).</p> <p>According to efficacy data from three available studies, quetiapine monotherapy was associated with an odds ratio of a positive treatment response of 0.52 (95% CI, 0.41 to 0.66; P value not reported).</p> <p>According to efficacy data from two available studies, quetiapine augmentation therapy was associated with an odds ratio of a positive treatment response of 0.68 (95% CI, 0.52 to 0.90; P value not reported).</p> <p>According to efficacy data from two available studies, risperidone augmentation therapy was associated with an odds ratio of a positive treatment response of 0.57 (95% CI, 0.36 to 0.89; P value not reported).</p> <p>Secondary: According to efficacy data from three available studies, aripiprazole augmentation therapy was associated with a reduction in MADRS scores from baseline, compared to placebo (MD, -3.04; 95% CI, -4.09 to -2.00; P</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>value not reported). According to efficacy data from one available study, aripiprazole augmentation therapy was associated with a significant improvement in CGI scores from baseline, compared to placebo (OR, 0.51; 95% CI, 0.34 to 0.78; P value not reported). Compared to placebo, aripiprazole augmentation therapy was also associated with a significantly greater odds ratio of achieving remission (OR, 0.48; 95%CI, 0.36 to 0.64).</p> <p>Olanzapine augmentation therapy was associated with a lower discontinuation rate due to inefficacy compared to placebo. There were no significant differences in efficacy endpoints between the olanzapine monotherapy group and either placebo or antidepressant comparator groups. However, olanzapine augmentation therapy was associated with a significant reduction in MADRS scores from baseline, compared to placebo (MD, -2.84; 95% CI, -5.48 to -0.20; P value not reported). Olanzapine augmentation therapy was likewise associated with a significant improvement from baseline, compared to placebo in anxiety symptoms, as measured by the HAM-A scale (MD, -1.44; 95%CI, -2.81 to -0.06). There was no significant difference between olanzapine augmentation therapy and placebo in HAM-D score reduction from baseline (MD, -7.90; 95%CI, -16.63 to 0.83).</p> <p>According to efficacy data from two available studies, quetiapine augmentation therapy was associated with a significant improvement in CGI scores from baseline, compared to placebo (OR, 0.64; 95% CI, 0.49 to 0.84; P value not reported). Significantly more patients receiving quetiapine augmentation therapy, compared to placebo, experienced remission (OR, 0.52; 95%CI, 0.38 to 0.71). Likewise quetiapine augmentation therapy was associated with a significant improvement from baseline, compared to placebo in MADRS scores (OR, 6.80; 95%CI, 0.52 to 0.90) and HAM-A scores (OR, 0.23; 95%CI, 0.08 to 0.70).</p> <p>Significantly more patients receiving risperidone augmentation therapy, compared to placebo, experienced remission (OR, 0.39; 95%CI, 0.22 to 0.69). HAM-D scores were significantly improved from baseline,</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>compared to placebo with risperidone augmentation therapy (OR, 0.60; 95%CI, 0.38 to 0.95). There was no significant difference between risperidone and placebo augmentation groups in MADRS scores at endpoint (MD, -1.85; 95%ci, -9.71 to 5.47).</p> <p>Compared to placebo, aripiprazole augmentation therapy was associated with an increased risk of weight gain, akathisia, and EPS. Aripiprazole was not associated with an increased incidence of sedation or tremor. Olanzapine augmentation was associated with an increased risk of sedation and weight gain. Risperidone was associated with an increased risk of weight gain and prolactin release. Risperidone therapy was not associated with an increased risk of EPS events or sedation. Quetiapine was associated with an increased risk of sedation and weight gain. Quetiapine was not associated with an increased risk of EPS events or prolactin levels.</p>
<p>Kent et al<sup>287</sup></p> <p>Risperidone oral solution once daily (&lt;45 kg, 0.125 mg/day; ≥45 kg, 0.175 mg/day)</p> <p>vs</p> <p>Risperidone oral solution once daily (&lt;45 kg, 1.25 mg/day; ≥45 kg, 1.75 mg/day)</p> <p>vs</p> <p>placebo oral solution once daily</p>	<p>DB, MC, OL (phase 2) PC, RCT</p> <p>Patients 5 to 17 years of age with a diagnosis of autistic disorder, weighing at least 20 kg, with a mental age &gt;18 months</p>	<p>N=77</p> <p>6 week (DB phase)</p> <p>6 months (OL phase)</p>	<p>Primary: Mean change in the ABC-I at week six</p> <p>Secondary: Mean change in other ABC subscale scores at week 6, change in CGI-S score and CY_BOCS compulsion subscale score at week 6, response rate, and percentage of patients with CGI-I ratings of “much improved” or “very much improved” at</p>	<p>Primary: Irritability scores, as measured by the ABC-I, improved significantly in the risperidone high-dose group (P&lt;0.001), but not in the risperidone low-dose group (P=0.164) compared with placebo. Separation between the risperidone high-dose and placebo groups was observed from day eight.</p> <p>Secondary: Response rates were significantly higher in the risperidone high-dose group (83%; P=0.004), but not in the low-dose group (52%; P=0.817), compared with placebo (41%). Similarly, improvements on CGI-S were significant in the high-dose-, but not in the low-dose group, compared with placebo. The number of patients showing much or very much improvement on the CGI-I scores, was significantly higher in the risperidone high-dose group (63%, P&lt;0.001), but not in the low-dose group (17%, P=0.985), compared with placebo (15 %).</p> <p>For the ABC subscales, patients in the risperidone high-dose group showed significant improvement (P=0.019) on the hyperactivity subscale score, and patients in the risperidone low-dose group demonstrated significant improvement on the stereotypic behavior subscale scores</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
			week six	<p>(P=0.008), compared with placebo. Neither risperidone group showed significant improvement on the inappropriate speech or social withdrawal subscale scores (risperidone low-dose group, P=0.716, high-dose group, P=0.511), compared with placebo.</p> <p>Consistent with the other efficacy measurements, only patients in the risperidone high-dose group showed significant improvement compared with placebo in the CY-BOCS compulsions subscale scores (risperidone high-dose group, P=0.003; risperidone low-dose group, P=0.454 vs. placebo).</p>
<p>Findling et al<sup>288</sup></p> <p>Phase 1 (stabilization):</p> <p>All patients received aripiprazole 2 to 15 mg once daily until stabilized</p> <p>Phase 2 (randomization):</p> <p>Aripiprazole, dose adjusted from phase 1, once daily</p> <p>vs</p> <p>placebo once daily</p>	<p>DB (phase 2), MC, PC, PG, RCT</p> <p>Phase 1: Patients 6 to 17 years of age with a diagnosis of autistic disorder and who also had serious behavioral problems</p> <p>Phase 2: Patients whose symptoms of irritability demonstrated a stable response to aripiprazole therapy for 12 consecutive weeks in phase 1 were eligible for randomization into phase 2</p>	<p>Phase 1 N=157</p> <p>Phase 2 N=85</p> <p>Phase 1 13 to 26 weeks</p> <p>Phase 2 16 weeks</p>	<p>Primary: Time from randomization to relapse</p> <p>Secondary: Changes in other ABC subscales, CGI-S, PedsQL, and the Caregiver Strain Questionnaire evaluations</p>	<p>Primary: The Kaplan-Meier relapse rates at week 16 were 35% for aripiprazole and 52% for placebo, for an HR (aripiprazole/placebo) of 0.57 (95% CI, 0.28 to 1.12).</p> <p>The mean time until 25% of patients treated with aripiprazole relapsed was 56 days (95% CI, 31 to undefined), and, for placebo, it was 29 days (95% CI, 25 to 45), representing a difference that was not statistically significant (P=0.097).</p> <p>A post hoc analysis demonstrated a number needed to treat (NNT) of six (95% CI, 2.58 to not approached) to prevent one additional relapse.</p> <p>A treatment-by-race interaction was explored and among white patients (N=59), aripiprazole treatment resulted in a statistically significantly lower relapse rate than placebo (25.8% vs 60.7%, respectively), with an HR of 0.33 (95% CI, 0.14 to 0.78; P=0.011), whereas among nonwhite patients (N=26), the two treatment arms did not significantly differ (50.0% vs 31.3%, respectively), with an HR of 1.68 (95% CI, 0.49 to 5.83; P=0.410). An age interaction test found no statistically significant age interaction (P=0.243).</p> <p>Secondary: For, ABC-I, the mean increase from end of phase 1 to week 16 of phase 2 was 5.2 points among patients receiving aripiprazole and 9.6 points</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>among patients receiving placebo, for a treatment difference of -4.40 (95% CI, -8.82 to 0.02; P=0.051). The mean CGI-I score at week 16 of phase 2 was 4.2 for aripiprazole and 4.8 for placebo, for a treatment difference of -0.62 (95% CI, -1.35 to 0.10; P=0.090).</p> <p>In addition, differences between aripiprazole and placebo in mean change at week 16 of phase 2 were seen in the following ABC subscales: ABC-hyperactivity (P=0.041), ABC-stereotypy (P=0.018), and ABC-inappropriate speech (P=0.013). A difference was not seen in the ABC-social withdrawal subscale (P=0.205).</p> <p>The week 16 mean treatment difference in the Caregiver Strain Questionnaire global score was more beneficial for aripiprazole, with a treatment difference of -1.2 (95% CI, -2.0 to -0.3). Results from the objective strain, subjective externalized strain, and subjective internalized strain subscales similarly favored aripiprazole. However, the mean treatment difference at week 16 of 6.3 points (95% CI, -0.63 to 13.22) on the PedsQL was similar for aripiprazole and placebo. Differences between aripiprazole and placebo for the combined PedsQL scale within individual age groups, and on the emotional, social, and cognitive functioning subscales were also not statistically significant.</p>
<p>Study 1<sup>290</sup> (dossier)</p> <p>Brexpiprazole 2 mg QD with antidepressant therapy</p> <p>vs</p> <p>placebo</p>	<p>MC, DB, PC, RCT</p> <p>Adult patients with MDD, with or without symptoms of anxiety, who had an inadequate response to prior antidepressant therapy (one to three courses) in the current episode and who also demonstrated an</p>	<p>N=353</p> <p>6 weeks</p>	<p>Primary: Change in MADRS total score from baseline to week six and improvement in functioning as measured by the SDS mean score</p> <p>Secondary: Not reported</p>	<p>Primary: Brexpiprazole 2 mg with antidepressant therapy had a greater reduction in MADRS total scores compared to placebo. LS mean change from baseline was -8.4 with brexpiprazole compared to -5.2 with placebo. Placebo-subtracted difference was -3.2 (95% CI, -4.9 to -1.5). Brexpiprazole 2 mg had greater improvement in SDS scale compared to placebo.</p> <p>Secondary: Not reported.</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
	inadequate response throughout the eight weeks of prospective antidepressants.			
<p>Study 2<sup>290</sup> (dossier)</p> <p>Brexpiprazole 1 mg once daily with antidepressant therapy</p> <p>vs</p> <p>brexpiprazole 3 mg once daily with antidepressant therapy</p> <p>vs</p> <p>placebo</p>	<p>MC, DB, PC, RCT</p> <p>Adult patients with MDD, with or without symptoms of anxiety, who had an inadequate response to prior antidepressant therapy (one to three courses) in the current episode and who also demonstrated an inadequate response throughout the eight weeks of prospective antidepressants.</p>	<p>N=627</p> <p>6 weeks</p>	<p>Primary: Change in MADRS total score from baseline to week six and improvement in functioning as measured by the SDS mean score</p> <p>Secondary: Not reported</p>	<p>Primary: Brexpiprazole 3 mg with antidepressant therapy had a greater reduction in MADRS total scores compared to placebo. LS mean change from baseline was -7.6 with brexpiprazole 1 mg compared to -8.3 with brexpiprazole 3 mg vs -6.3 with placebo. Placebo-subtracted difference for brexpiprazole 1 mg was -1.3 (95%CI,-2.7 to 0.13) and for brexpiprazole 3 mg was -2.0 (95% CI, CI:-3.4 to -0.5). Brexpiprazole 3 mg had greater improvement in SDS scale compared to placebo.</p> <p>Secondary: Not reported.</p>

\* Agent is not available in the United States.

†Did not meet investigators' *a priori* standard of statistical significance, which adjusted for multiple comparisons.

Study design abbreviations: CI=confidence interval, DB=double-blind, DD=double dummy, ES=extension study, FD=fixed dose, HR=hazard ratio, LOCF=last observation carried forward, MA=meta-analysis, MC=multicenter, NNH=number needed to harm, NNT=number needed to treat, OL=open-label, OR=odds ratio, OS=observational, PC=placebo controlled, PH=post-hoc analysis, PG=parallel group, PRO=prospective, RCT=randomized controlled trial, RETRO=retrospective, RR=risk ratio, SMD=standardized mean difference, SR=systematic review

Other abbreviations: ABC=activities-specific balance confidence, AIMS=Abnormal Involuntary Movement Scale, BARS=Barnes Akathisia Rating Scale, BMI=body mass index, BPRS=brief psychiatric rating scale, CARS=Childhood Autism Rating Scale, CATIE=Clinical Antipsychotic Trials of Intervention Effectiveness, CDSS=Calgary depression rating scale for schizophrenia, CGAS=Children's Global Assessment Scale, CGI=clinical global impression, CGI-BP=clinical global impressions-bipolar version, CGI-I=clinical global impression of improvement, CGI-S=clinical global improvement-severity of illness, CMAI=Cohen-Mansfield agitation inventory, CPRS=children's psychiatric rating scale, CY-BOCS=children's Yale-Brown obsessive compulsive scale, DSM-IV-TR=Diagnostic and Statistical Manual of Mental Disorders, 4<sup>th</sup> edition-text revision, EPS=extrapyramidal symptoms, ER=extended release, ESR=extrapyramidal symptom rating scale, GAF=global assessment of functioning, HAM-A=Hamilton rating scale for anxiety, HAM-D=Hamilton rating scale for depression, HbA<sub>1c</sub>=glycosylated hemoglobin, ITT=intent-to-treat, LOCF=last observation carried forward,

LS=least squares, MADRS=Montgomery-Asberg depression rating scale, MCCB=Matricus consensus cognitive battery, MD=mean difference, MDD=major depressive disorder, NAB=neuropsychological assessment battery, PANSS=positive and negative syndrome scale, PANSS EC=positive and negative syndrome scale excited component, PedsQL=pediatric quality of life inventory, PP=per protocol, PSP=personal and social performance scale, PSQI=Pittsburgh sleep quality index, QLS=quality of life scale, RSSE=rating scale for side effects, SAS=Simpson-Angus scale, SCoRS=schizophrenia cognition rating scale, SD=standard deviation, SDS=schedule for deficit syndrome, SGA=second-generation antipsychotic, SGOT=serum glutamic oxaloacetic transaminase, SGPT= serum glutamic pyruvic transaminase, SMD=standardized mean difference, SSRI=selective serotonin-reuptake inhibitor, VAS=visual analog scale, WMS=Wenchsler memory scale, WMD=weighted mean difference, XR=extended-release, YMRS=Young mania rating scale

**Table 5. Off-Label Efficacy Clinical Trials Using the Antipsychotics for Adults**

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
<b>General</b>				
<p>Maheer et al<sup>78</sup> (AHRQ Review)</p> <p>Atypical antipsychotic (risperidone, olanzapine, quetiapine, aripiprazole, ziprasidone, asenapine, iloperidone, paliperidone)</p> <p>vs</p> <p>atypical antipsychotic, placebo, or other pharmacotherapy</p> <p>Note: no relevant studies of asenapine, iloperidone, or paliperidone were identified</p>	<p>SR</p> <p>Controlled studies comparing atypical antipsychotics with another atypical antipsychotic, placebo or other pharmacotherapy in patients with anxiety disorder, ADHD, dementia and severe geriatric agitation, major depressive disorder, eating disorder, insomnia, OCD, PTSD, personality disorders, substance abuse, and Tourette's syndrome</p>	<p>N=not reported (169 trials)</p> <p>Study duration varied</p>	<p>Primary: Dementia (improvement in psychosis, agitation and total global score), anxiety (HAM-A response), OCD (proportion of patients responding using the YBOCS scale), adverse events</p> <p>Secondary: Not reported</p>	<p>Primary: Psychosis, Agitation, Global Behavioral Symptoms in Dementia: Compared to placebo, aripiprazole (difference, 0.20; 95%CI, 0.04 to 0.35), olanzapine (difference, 0.12; 95%CI, 0.00 to 0.25), and risperidone (difference, 0.19; 95%CI, 0.00 to 0.38) were associated with small but statistically significant improvement in global symptoms from baseline. The pooled effect size for quetiapine was similar, but not statistically significant compared to placebo (difference, 0.13; 95%CI, -0.02 to 0.28).</p> <p>For the outcome of psychosis, only risperidone was associated with a statistically significant improvement from baseline, compared to placebo (difference, 0.20; 95%CI, 0.05 to 0.36). The pooled effect sizes for aripiprazole (difference, 0.14; 95%CI, -0.02 to 0.29), olanzapine (difference, 0.05; 95%CI, -0.07 to 0.17), and quetiapine (difference, 0.04; 95%CI, -0.11 to 0.19) were not significantly different from placebo.</p> <p>Risperidone, aripiprazole, and olanzapine were all associated with statistically significant improvement in agitation compared to placebo. The pooled effect sizes ranged from 0.19 to 0.31. The pooled effect size for quetiapine was not significantly different from placebo (difference, 0.05; 95%CI, -0.14 to 0.25).</p> <p>There were no statistically significant differences between risperidone and olanzapine or risperidone and quetiapine (P value not reported).</p> <p>Generalized Anxiety Disorder: Significantly more patients in the quetiapine group experienced response</p>



Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>to treatment, defined as at least a 50% improvement in HAMD-A scores from baseline, compared to placebo. The pooled result indicates a 26% increase in the risk of a positive response at 8 weeks of therapy (RR, 1.26; 95%CI, 1.02 to 1.56).</p> <p>Olanzapine (RR, 6.67; 95%CI, 0.93 to 47.59) and risperidone (RR, 0.99; 95%CI, 0.78 to 1.25) were not associated with a significantly increased risk of a positive treatment response, compared to placebo.</p> <p>In head-to-head studies, quetiapine was comparable to paroxetine and escitalopram at 8 weeks (P value not reported).</p> <p><b>Obsessive Compulsive Disorder:</b> Significantly more patients in the risperidone group experienced a positive response to treatment, compared to placebo (RR, 3.92; 95%CI, 1.26 to 12.13). Risperidone was associated with a 3.9-fold greater probability of responding compared to placebo; the NNT was estimated as 5.</p> <p>Olanzapine (RR, 1.00; 95%CI, 0.49 to 2.03) and quetiapine (RR, 2.36; 95%CI, 0.85 to 6.57) were not associated with significantly greater response rates compared to placebo.</p> <p><b>Other Conditions:</b> Available evidence (6 trials) indicated that atypical antipsychotics are not effective in causing significant weight gain in patients with eating disorders.</p> <p>The level of evidence is mixed regarding personality disorders and moderate for an association of risperidone with improving post-traumatic stress disorder.</p> <p>Evidence does not support efficacy of atypical antipsychotics for substance abuse.</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p><b>Safety:</b>                      In the elderly patients, aripiprazole was associated with significantly increased odds of experiencing sedation. Olanzapine was associated with significantly increased odds of experiencing a cardiovascular event, increased appetite/weight gain, anticholinergic events, sedation, EPS (NNH=10), and urinary tract symptoms. Quetiapine was associated with significantly increased odds of experiencing sedation and urinary tract symptoms. Risperidone was associated with significantly increased odds of experiencing sedation, cardiovascular event, cerebrovascular event (for stroke, NNH=53), EPS (NNH=20) and urinary tract symptoms.</p> <p>In the non-elderly adult patients, aripiprazole was associated with significantly increased odds of experiencing increased appetite/weight gain, sedation, fatigue, akathisia, and EPS. Olanzapine was associated with significantly increased odds of experiencing sedation, increased appetite/weight gain, and fatigue. Quetiapine was associated with significantly increased odds of experiencing sedation, increased appetite/weight gain, fatigue, and EPS. Risperidone was associated with significantly increased odds of experiencing increased appetite/weight gain, sedation. Ziprasidone was associated with significantly increased odds of experiencing sedation and EPS.</p> <p><b>Secondary:</b>                      Not reported</p>
<b>Anxiety Disorders</b>				
Depping et al <sup>79</sup>  Olanzapine, quetiapine, or risperidone as adjunctive therapy or monotherapy  vs  placebo	SR  Randomized controlled studies comparing olanzapine, quetiapine or risperidone with placebo, benzodiazepines,	N=4,144 (11 studies)  up to 52 weeks	Primary: Treatment response ( $\geq 50\%$ reduction in HAM-A scores), remission (HAM-A score $\leq 7$ ), relapse (recurrence of anxiety symptoms), HAM-A, HAM-D,	Primary: Quetiapine was associated with a significantly greater response rate compared to placebo in patients with generalized anxiety disorder (OR, 2.21; 95%CI, 1.10 to 4.45; P=0.03). Compared to placebo, quetiapine therapy was associated with a greater remission rate (OR, 1.83; 95%CI, 1.07 to 3.12; P=0.03). Compared to quetiapine, more patients experienced a relapse with placebo (OR, 0.18; 95%CI, 0.10 to 0.30). There was no statistically significant difference between quetiapine and placebo groups in clinically meaningful change in CGI from baseline (OR, 2.28; 95%CI, 1.01 to 5.14). Moreover, HAM-A and MADRS scores were

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
vs antidepressants	pregabalin or antidepressants in adult patients with generalized anxiety disorder, panic disorder, or phobias		MADRS, CGI, BSPS  Secondary: Not reported	<p>significantly improved in patients receiving quetiapine compared to placebo. Significantly more patients left the study early due to adverse events in the quetiapine group, compared to placebo (36.9 vs 5.4%). Compared to placebo, quetiapine therapy was associated with a significantly increased risk of EPS adverse effects (2.5 vs 4.4%), weight gain (MD, 0.63 kg), and sedation (6.7 vs 24.5%).</p> <p>There was no statistically significant difference between quetiapine monotherapy and antidepressant groups in response rate, remission, global state (assessed via CGI scores), change in HAM-A scores, or change in MADRS scores (P value not reported). However, a larger percentage of patients in the quetiapine vs antidepressant groups left the study early due to adverse events (17.6 vs 8.9%, respectively).</p> <p>Comparing quetiapine add-on therapy to antidepressants and placebo adjunctive therapy in patients with generalized anxiety disorder, there were no statistically significant differences between groups in response, remission, global state, change in HAM-A, MADRS scores or percentage of patients leaving the study early (P value not reported).</p> <p>Comparing quetiapine monotherapy and placebo in patients with social phobia, there were no statistically significant differences between groups in response rate or global state (P value not reported). However, patients in the quetiapine groups exhibited lower BPS scores at endpoint, indicating an improvement in anxiety symptoms (MD, 31.10; 95%CI, -85.41 to 147.61).</p> <p>Comparing olanzapine monotherapy and placebo in patients with social phobia, there were no statistically significant differences between groups in response rate, global state or percentage of patients leaving the study early (P value not reported). However, patients in the quetiapine groups exhibited lower BPS scores at endpoint, indicating an improvement in anxiety symptoms (MD, -22.50; 95%CI, -35.25 to -9.75). There were no significant differences between groups in weight gain.</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>Comparing olanzapine add-on therapy to antidepressants and placebo adjunctive therapy in patients with generalized anxiety disorder, there were no statistically significant differences between groups in response, remission, or percentage of patients leaving the study early (P value not reported). In contrast, olanzapine add-on therapy was associated with a significant improvement from baseline in anxiety symptoms (HAM-A scores) and depressive symptoms (HAM-D), compared to adjunctive placebo therapy. Significantly more patients in the olanzapine group experienced weight gain and sedation.</p> <p>Comparing risperidone add-on therapy to antidepressants and placebo adjunctive therapy in patients with generalized anxiety disorder, there were no statistically significant differences between groups in response, remission, CGI scores, MADRS scores, or percentage of patients leaving the study early (P value not reported). In contrast, risperidone add-on therapy was associated with a significant improvement from baseline in anxiety symptoms (HAM-A scores) compared to adjunctive placebo therapy. There were no significant differences between groups in weight gain, sedation or EPS adverse events from baseline.</p> <p>Secondary: Not reported</p>
<p>Lalonde et al<sup>80</sup></p> <p>Atypical antipsychotics (olanzapine, quetiapine, risperidone), used as monotherapy in patients with uncomplicated GAD or as augmentation therapy for refractory GAD</p> <p>Refractory GAD was defined as moderate symptoms despite 4-10 weeks of prior</p>	<p>MA</p> <p>Adults over the age of 18 treated with an atypical antipsychotic for generalized anxiety disorder (GAD)</p>	<p>N=2,459</p> <p>5 to 8 weeks</p>	<p>Primary:</p>	<p>Primary:</p> <p>Compared to placebo, augmentation with atypical antipsychotics was not associated with a significantly greater clinical response (RR, 1.14; 95%CI, 0.92 to 1.41; P=0.22).</p> <p>Patients receiving augmentation therapy with an antipsychotic were 43% more likely to discontinue therapy than those receiving placebo (RR, 1.43; 95%CI, 1.04 to 1.96; P=0.03). The NNH was 14.</p> <p>Compared to placebo, augmentation with atypical antipsychotics was not associated with a significantly greater remission rate (RR, 1.28; 95%CI, 0.96 to 1.71; P=0.09).</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
therapy with an evidence-based drug				<p>Compared to placebo, augmentation with atypical antipsychotics was not associated with a significant change in HAM-A scores from baseline (MD, -2.69; 95%CI, -5.90 to 0.52).</p> <p>Patients who received augmentation antipsychotic therapy did not experience a significantly greater weight gain than patients receiving placebo (P value not reported).</p> <p>Patients receiving quetiapine 150 mg monotherapy for the treatment of uncomplicated GAD were 31% more likely to experience a positive response than those receiving placebo (RR, 1.31; 95%CI, 1.20 to 1.44; P&lt;0.00001). The NNT was 7.</p> <p>Patients receiving quetiapine 150 mg monotherapy for the treatment of uncomplicated GAD were 44% more likely to achieve remission than those receiving placebo (RR, 1.44; 95%CI, 1.23 to 1.68; P&lt;0.00001). The NNT was 9.</p> <p>Patients receiving quetiapine 150 mg monotherapy experienced a significant 3.66 point reduction in HAM-A scores compared to placebo (95%CI, -5.13 to -2.19).</p> <p>Patients receiving quetiapine 150 mg monotherapy gained an average of 2.2 lbs (95%CI, 1.16 to 3.24) more than patients receiving placebo.</p> <p>Significantly more patients discontinued therapy in the quetiapine 150 mg monotherapy group compared to the placebo group (RR, 1.30; 95%CI, 1.09 to 1.54; P=0.004).</p> <p>Secondary: Not reported</p>
<b>Borderline Personality Disorder</b>				
Lieb et al <sup>81</sup> Atypical antipsychotics,	SR Randomized	N=1,714 5 to 24 weeks	Primary: Anger, impulsivity, psychotic	In one study (N=52), aripiprazole was found to have both significant effects on the reduction of the core symptoms of borderline personality (anger, impulsivity, psychotic symptoms, interpersonal problems) as well

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
antidepressants, or mood stabilizers  vs  placebo	controlled studies in adults patients with borderline personality disorder		symptoms, interpersonal problems, anxiety, depression  Secondary: Not reported	as in the treatment of comorbid conditions (depression, anxiety).  Pooled data from placebo-controlled studies with olanzapine (N=631) demonstrate significant reduction of affective instability (SMC, -0.16; 95%CI, -0.32 to -0.01), anger (SMC, -0.27; 95%CI, -0.43 to -0.12), and psychotic symptoms (SMC, -0.18; 95%CI, -0.34 to -0.03). Anxiety symptoms were also reduced in one study with olanzapine.  Ziprasidone was not demonstrated to exert significant effects on any outcome measure.  Among the mood stabilizers, beneficial effects were found with divalproex sodium, lamotrigine and topiramate. Carbamazepine was not associated with a benefit in patients with borderline personality disorder.  There was little evidence of efficacy with antidepressants. Only amitriptyline was associated with a significant reduction in depressive symptoms from baseline. No significant effect was found with fluoxetine and fluvoxamine.  Secondary: Not reported
Mercer et al <sup>82</sup>  Antipsychotics, antidepressants, or mood stabilizers	MA  Randomized, controlled, double-blind studies in patients with BPD	N=735  5 to 24 weeks	Primary: Anger, symptoms of depression  Secondary: Not reported	Primary: Mood stabilizers, with the exception of divalproic acid, were found to have the largest effect size for anger (-1.75; 95%CI, -2.77 to -0.74; P<0.001). The effect on anger was seen with lamotrigine, topiramate, and carbamazepine when used for up to 10 weeks. Divalproic acid and carbamazepine had a moderate effect on depression (-0.63; 95%CI, -0.99 to -0.27; P<0.001).  Antidepressants, with the exception of tricyclic antidepressants, had a moderate effect size for anger (-0.74; 95%CI, -1.27 to -0.21; P<0.001), but exhibited a small effect on depression (-0.37; 95%CI, -0.69 to -0.05; P<0.01).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>Antipsychotics had a moderate effect size for anger (-0.59; 95%CI, -1.04 to -0.15; P&lt;0.01), with aripiprazole associated with the largest effect size compared to other antipsychotics. Antipsychotics did not have a significant effect size for depression (-0.46; 95%CI, -0.94 to 0.03; P&gt;0.05).</p> <p>Secondary: Not reported</p>
<b>Dementia</b>				
<p>Cheung et al<sup>83</sup></p> <p>Quetiapine vs placebo</p>	<p>MA</p> <p>Patients receiving quetiapine or placebo for the treatment of behavioral and psychological symptoms of dementia</p>	<p>N=1,118</p> <p>6 to 12 weeks</p>	<p>Primary: Neuropsychiatric Inventory (NPI), Clinical Global Impression of Change Scale (CGI-C)</p> <p>Secondary: Not reported</p>	<p>Primary: Quetiapine-recipients experienced a significant improvement from baseline, compared to placebo, in NPI scores, with a WMD of -3.05 (95%CI, -6.10 to -1.01; P=0.05).</p> <p>Quetiapine-recipients experienced a significant improvement from baseline, compared to placebo, in CGI-C scores, with a WMD of -0.31 (95%CI, -0.54 to -0.08; P=0.008).</p> <p>Secondary: Not reported</p>
<p>Brody et al<sup>84</sup></p> <p>Risperidone vs placebo</p>	<p>DB, MC, PC, PG, RCT</p> <p>Patients residing in a nursing home aged ≥55 years with a diagnosis of dementia</p>	<p>N=345</p> <p>12 weeks</p>	<p>Primary: CMAI total aggression score</p> <p>Secondary: CMAI total nonaggression score, CMAI individual subscale scores, BEHAVE-AD total score, psychotic symptom subtotal and global rating scores, and the CGI-S and CGI-</p>	<p>Primary: There was a significantly greater improvement in CMAI rating scores in the risperidone group compared to the placebo group at each week of measure (P&lt;0.01), except week 12 (P=0.058).</p> <p>The least-squares mean of the CMAI total aggression score decreased by 4.4 more in the risperidone group than the placebo group (-7.5 vs -3.1; 95% CI, -6.75 to -2.07; P&lt;0.001), representing more than a 23% greater reduction in aggression in patients treated with risperidone. Both the differences in least-squares mean of the physical aggression and verbal aggression scores favored the risperidone group compared to placebo (-2.6; 95% CI, -4.45 to -0.67; P=0.008 and -1.8; 95% CI, -2.51 to -1.18; P&lt;0.001, respectively).</p> <p>Secondary:</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
			C scores	<p>The difference in least-squares mean between groups for the total nonaggression scale favored the risperidone group (-4.5; 95% CI, -7.39 to -1.70; P=0.002), with each of the subscale physical nonaggression and verbal nonaggression ratings also having a difference in least-squares mean which favored the risperidone group compared to placebo (-1.8; 95% CI, -3.75 to 0.15; P=0.071 and -2.8; 95% CI, -4.16 to -1.37; P&lt;0.001, respectively).</p> <p>Compared to baseline the least-squares mean scores for changes in BEHAVE-AD total and psychotic symptoms subscale were significantly more improved for the risperidone group at endpoint compared to placebo (-4.5; 95% CI, -6.45 to -2.46; P&lt;0.001 and -1.4; 95% CI, -2.26 to -0.44; P=0.004, respectively).</p> <p>Each of the BEHAVE-AD subscale scores favored the risperidone group compared to placebo at endpoint compared to baseline, as illustrated in the differences in least-squares mean between the groups [paranoid and delusional ideation (-0.8; 95% CI, -1.38 to -0.15; P=0.015), hallucinations (-0.6; 95% CI, -1.04 to -0.14; P=0.010), activity disturbances (-0.4; 95% CI, -0.89 to 0.03; P=0.067), aggressiveness (-1.5; 95% CI, -2.08 to -0.95; P&lt;0.001), diurnal rhythm disturbances (-0.2; 95% CI, -0.34 to 0.03; P=0.098), affective disturbance (-0.3; 95% CI, -0.57 to -0.02; P=0.034), and anxiety and phobias (-0.7; 95% CI, -1.12 to -0.21; P=0.004).</p> <p>Investigator and caregiver ratings of the CGI-S scale at endpoint showed statistically significant differences between the risperidone and placebo groups, with results favoring risperidone (P&lt;0.001).</p> <p>Serious adverse events defined as life-threatening, requiring hospitalization, or causing significant disability or incapacity, occurred in 16.8% of risperidone-treated patient's vs 8.8% of placebo-treated patients. The most commonly encountered serious adverse events overall were injury, cerebrovascular disorders and pneumonia.</p>
Brodady et al <sup>85</sup>	Post hoc analysis	N=93	Primary: Change in	Primary: Mean change in BEHAVE-AD psychosis subscale score was more



Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
Risperidone vs placebo	Patients with a diagnosis of Alzheimer's dementia or mixed Alzheimer's dementia with vascular dementia (analysis applied criteria for psychosis of Alzheimer's dementia to those with Alzheimer's dementia and mixed dementia) with a score of $\geq 2$ on any of the 12 items of the BEHAVE-AD psychosis subscale (paranoia/delusions and hallucinations subscales) at both screening and baseline	12 weeks	<p>BEHAVE-AD psychosis subscale and CGI-C at endpoint</p> <p>Secondary: Not reported</p>	<p>efficacious compared to placebo at endpoint (-5.2 vs -3.3; <math>P=0.039</math>; effect size, 0.31). After 2 weeks of treatment risperidone showed greater improvement in global functioning compared to placebo (28 vs 15%, respectively; <math>P&lt;0.05</math>).</p> <p>Distribution of CGI-C favored risperidone at the endpoint (<math>P&lt;0.001</math>). The number of patients classified as responders (defined as having a CGI-C of 'much' or 'very much' improved) was greater in the risperidone group (59%) than in the placebo group (26%).</p> <p>Secondary: Not reported</p>
De Deyn et al <sup>85</sup> Risperidone vs placebo	MA Institutionalized adults $\geq 55$ years of age diagnosed with dementia of the Alzheimer's type, vascular dementia, or a combination of the two	N=1,191 12 weeks	<p>Primary: CMAI frequency rating scale to assess agitated and aggressive behaviors including the CMAI total, total (verbal and physical) aggression, and total (verbal and physical)</p>	<p>Primary: Total mean CMAI score (change from baseline to endpoint) for the risperidone group showed greater improvement (5.4 points lower) than the placebo group (-11.8; 95% CI, -13.35 to -10.33 vs -6.4; 95% CI, -8.46 to -4.29; <math>P&lt;0.001</math>).</p> <p>Risperidone-treated patients (N=713) compared to the placebo group (N=426) also showed greater mean improvement at endpoint for total aggression (-5.0; 95% CI, -5.83 to -4.19 vs -1.8; 95% CI, -3.02 to -0.65; <math>P&lt;0.001</math>) and total nonaggression (-6.8; 95% CI, -7.78 to -5.88 vs -4.5; 95% CI, -5.79 to -3.29; <math>P&lt;0.001</math>), with the differences between group means (3.2 and 2.3 points, respectively) favoring risperidone.</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
			<p>nonaggression scores, the BEHAVE-AD severity rating scale to assess behavioral symptom clusters including BEHAVE-AD total and psychotic-symptom subscale scores (paranoid/delusional ideation and hallucinations)</p> <p>Secondary: CGI-C, CGI-S, safety assessments via adverse events, ESRS, MMSE, ECG and vital signs</p>	<p>The risperidone group had a significant mean improvement in total BEHAVE-AD score compared to the placebo group at the endpoint (-6.1; 95% CI, -6.72 to -5.42 vs -3.6; 95% CI, -4.43 to -2.76; P&lt;0.001). The total mean score for the psychotic-symptom subscale also favored the risperidone group compared to placebo at endpoint (-2.1; 95% CI, -2.40 to -1.79 vs -1.3; 95% CI, -1.68 to -0.81; P=0.003). The paranoid and delusional subset also had greater mean improvement (0.7 points lower) in the risperidone group than the placebo group (-1.7; 95% CI, -1.95 to -1.45 vs -1.0; 95% CI, -1.31 to -0.65; P=0.002) as did the hallucinations subset (-0.4; 95% CI, -0.53 to -0.27 vs -0.3; 95% CI, -0.45 to -0.09 respectively; P=0.191).</p> <p>Scores on the BEHAVE-AD total scale, at all evaluation points, were significantly more improved in risperidone-treated patients compared to the placebo.</p> <p>Secondary: Compared to baseline, there was a 17.7% increase in the number of risperidone-treated patients rated by investigators as “moderately ill or less” at endpoint vs an 8.3% increase in the placebo group (N=428) as measured with the CGI-S scale (P&lt;0.001). At endpoint, caregivers rated 22.9% more risperidone-treated patients vs 12.8% of placebo patients as “moderately ill or less” utilizing the CGI-S scale (P&lt;0.01).</p> <p>CGI-C scale ratings by investigators and caregivers also favored the risperidone group with significant results vs placebo at endpoint compared to baseline. Investigators at endpoint ranked 65.2% of risperidone and 45.2% of placebo-treated patients as improved, and fewer risperidone-treated patients were worse at endpoint compared to placebo (16.2 vs 25.1%, respectively; P&lt;0.001, difference in distribution at endpoint). Caregivers rated 61.7% of risperidone patients as improved and 23.7% as worse vs 42.7% of placebo patients as improved and 33.3% as worse at endpoint compared to baseline (P&lt;0.001, difference in distribution at endpoint).</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>Risperidone-treated patients improved significantly more compared to those on placebo on the mean CMAI total scores in both Alzheimer's disease and vascular dementia subgroups, but not in the mixed group (-12.4 vs -6.8; P&lt;0.001; -9.8 vs -5.4; P=0.019; and -11.6 vs -5.8; P=0.36; respectively). Similarly, more patients treated with risperidone had significantly better improvement in mean BEHAVE-AD total scores in both Alzheimer's disease and vascular dementia subgroups, but not in the mixed group (-6.3 vs -3.9; P&lt;0.001; -5.5 vs -3.2; P=0.020; and -5.3 vs -2.7; P=0.084, respectively). Significant differences in CMAI total and BEHAVE-AD total scores favored the risperidone group at endpoint regardless of severity of dementia.</p> <p>The incidence of adverse events was similar in the risperidone group (84.3%) and placebo group (83.9%) across risperidone dose groups. Most commonly reported adverse events were injury, fall, somnolence, purpura, and urinary tract infections all of which were comparable between groups (except somnolence). Somnolence occurred in 22.4% of risperidone patients and 13.9% of placebo patients.</p> <p>There was no significant increase in risk of death associated with risperidone (relative risk vs placebo, 1.17; 95% CI, 0.63 to -2.81).</p>
<p>Rocha et al<sup>87</sup></p> <p>Ziprasidone 40 mg twice a day for 7 weeks (dose adjusted throughout study according to patient response and investigator judgment)</p>	<p>OL</p> <p>Adults ≥60 years, medically stable with diagnosis of dementia and a clinically significant level of behavioral or psychotic symptoms (score ≥3 on any of the agitation/aggression, hallucinations, or</p>	<p>N=25</p> <p>7 weeks</p>	<p>Primary: Mean change from baseline to endpoint in NPI total score</p> <p>Secondary: CGI-S measures</p>	<p>Primary: The mean total NPI score declined from 47.1±17.1 at baseline to 25.8±17.9 at day 49 (P&lt;0.01). Additionally, the 12 NPI sub-item symptoms were reduced as follows: disinhibition, 76% reduction (3.16 to 0.76; P&lt;0.01), aberrant motor behavior, 60% reduction (5.56 to 2.24; P&lt;0.01), delusion, 53% reduction (4.88 to 2.28; P&lt;0.01), agitation, 51% reduction (8.00 to 3.96; P&lt;0.01), irritability, 56% reduction (5.6 to 2.44; P&lt;0.01), sleep problems, 50% reduction (4.72 to 2.36; P=0.01), appetite problems, 38% reduction (1.36 to 0.84; P=0.28), depression, 30.2% reduction (3.84 to 2.68; P=0.14), hallucination, 27% reduction (2.52 to 1.84; P=0.19), anxiety, 19% reduction (4.00 to 3.24; P=0.38), apathy, 4% reduction (3.32 to 3.2; P=0.88), euphoria, 100% reduction (0.12 to 0; P=0.19).</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
	delusions items of the NPI)			<p>Secondary: There was a 17% reduction in CGI-S severity score at day 49 compared to baseline (P&lt;0.01)</p> <p>An adverse event was reported in 76% of patients overall, with the most frequent side effects being somnolence (52%), gastrointestinal symptoms (20%), parkinsonism (20%), agitation (8%), insomnia (8%), dizziness (8%), and lip edema (8%). Five patients developed EPS.</p>
<p>Schneider et al<sup>88</sup></p> <p>Olanzapine vs quetiapine vs risperidone vs placebo</p> <p>Doses were initiated and adjusted as clinically needed based upon physician judgment.</p>	<p>DB, MC, PC, RCT</p> <p>Patients with dementia of the Alzheimer's type or probable Alzheimer's disease who were ambulatory and living at home or at an assisted-living facility; had delusions, hallucinations, aggression, or agitation that developed after dementia onset that was severe enough to disrupt their functioning; had signs and symptoms of psychosis, aggression, and agitation nearly daily the week prior to</p>	<p>N=421</p> <p>36 weeks</p>	<p>Primary: Time until discontinuation of treatment for any reason in phase I of study</p> <p>Secondary: Attainment of minimal or greater improvement on the CGI-C scale, safety as assessed by the occurrence of adverse events</p>	<p>Primary: There were no significant overall differences between treatment groups regarding time to discontinuation of treatment for any reason. The median time to discontinuation for the olanzapine, quetiapine, risperidone, and placebo groups was 8.1 weeks, 5.3 weeks, 7.4 weeks, and 8.0 weeks, respectively.</p> <p>Secondary: The median time to discontinuation of treatment due to lack of efficacy was 22.1 weeks for olanzapine, 26.7 weeks for risperidone, 9.1 weeks for olanzapine and 9.0 weeks for placebo.</p> <p>The HR for the discontinuation of treatment because of lack of efficacy was 0.51 for olanzapine compared to placebo (P&lt;0.001), and 0.61 for risperidone compared to placebo (P=0.01). Olanzapine and risperidone were equivalent to each other in time to discontinuation of treatment (HR, 0.84; 95% CI, 0.53 to 1.32) and olanzapine was more efficacious than quetiapine (HR, 0.63; 95% CI, 0.41 to 0.96; P=0.02).</p> <p>The time to discontinuation of treatment due to intolerance or death was favored by placebo with rates of discontinuation of 24%, 16%, 18%, and 5% for olanzapine, quetiapine, risperidone, and placebo, respectively (P=0.009 for overall comparison).</p> <p>At week 12, response rates (defined as a CGI-C score indicating at least minimal improvement with continued use of the study medication) were</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
	randomization or at least intermittently for 4 weeks			<p>32%, 26%, 29%, and 21% for olanzapine, quetiapine, risperidone, and placebo, respectively (P=0.22), with an overall rate of discontinuation of 63% at 12 weeks.</p> <p>There were higher rates of parkinsonism or EPS signs in the olanzapine and risperidone groups (12% in each group) compared to the quetiapine group (2%) and placebo (1%; P&lt;0.001). Sedation occurred more often with active drug treatment vs placebo (24%, 22%, 15% for the olanzapine, quetiapine, and risperidone groups vs 5% for the placebo group; P&lt;0.001). Confusion or changes in mental status were more frequent in the olanzapine group (18%) and risperidone group (11%) than reported in the quetiapine group (6%) or placebo group (5%) (P=0.03).</p>
<p>Verhy et al<sup>89</sup></p> <p>Olanzapine vs haloperidol</p>	<p>DB, MC, RCT</p> <p>Adults ≥60 years of age, diagnosed with dementia with a level of agitation clinically judged to represent a clinical problem requiring antipsychotic therapy, a score of ≥45 on the CMAI, and living in a nursing home or in their own homes</p>	<p>N=58</p> <p>5 weeks</p>	<p>Primary: Reduction in the mean total sum score on the CMAI scale from baseline to endpoint</p> <p>Secondary: Improvement of scores on the NPI Dutch version, the CGI scale and MMSE, and the UKU side-effect rating scale, the AIMS and the SAS were used to measure side effects and EPS</p>	<p>Primary: The mean reduction in total CMAI score at endpoint compared to baseline for patients treated with olanzapine was -10.07 vs -16.57 in the haloperidol-treated group (P=0.338).</p> <p>Repeated analysis on CMAI scores illustrated that agitation levels decreased in both groups (P&lt;0.001), but there were no statistically significant differences between the two groups (P=0.338).</p> <p>Secondary: The mean total NPI score showed an improvement for both the olanzapine and haloperidol groups (-11.09 vs -18.87; P=0.171) with the individual mean NPI scores for distress, psychosis, hyperactivity and mood also showing improvement at endpoint for the olanzapine and haloperidol groups (-3.4 vs -5.8; P=0.305; -1.0 vs -1.4; P=0.778; -6.9 vs -9.9; P=0.364; and -3.2 vs -2.7; P=0.823, respectively); however, none were able to reach a level of significance.</p> <p>The mean change at baseline on the CGI scale for the olanzapine group was -0.7 compared to -1.0 for the haloperidol group (P=0.917).</p> <p>Compared to baseline there were no statistically significant changes in</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>EPS defined by the SAS and AIMS scales. The mean change in AIMS score for the olanzapine group and haloperidol group had a mean increase by 0.42 (P=0.887). The mean change in SAS tended to show an improvement in the olanzapine group with a worsening trend in the haloperidol group (-1.44 vs 1.41; P=0.120).</p> <p>The mean change in MMSE score had a slight improvement in the olanzapine group but not in the haloperidol group (0.53 vs -0.13; P=0.481), while overall there were no statistically significant changes in the number of neurological side effects as shown by the mean change in UKU scores for the olanzapine and haloperidol groups (-0.7 vs -0.2; P=0.31).</p>
<p>Suh et al<sup>90</sup></p> <p>Risperidone</p> <p>vs</p> <p>haloperidol</p>	<p>Post hoc analysis of DB, RCT, XO, head-to-head trial</p> <p>Adults ≥ 65 years with a diagnosis of dementia of the Alzheimer's type, vascular dementia, or a combination of the two per DSM-IV criteria</p>	<p>N=114</p> <p>18 weeks</p>	<p>Primary: Korean version of BEHAVE-AD and CMAI scale</p> <p>Secondary: Not reported</p>	<p>Primary: Risperidone was more efficacious compared to haloperidol on various measures of the BEHAVE-AD-K scale, including: wandering (P=0.0496), agitation (P=0.0091), diurnal rhythm disturbances (P=0.0137), anxiety regarding upcoming events (P=0.0002) and other anxieties (P=0.0088).</p> <p>Risperidone was significantly more effective than haloperidol with various criteria of the CMAI-K scale including: physical sexual advances (P=0.0202), pacing and aimless wandering (P=0.0123), intentional falling (P=0.0398), hoarding (P=0.0499), performing repetitious mannerisms (P=0.0048), repetitive sentence or questions (P=0.0025), complaining (P=0.0101) and negativism (P=0.0027).</p> <p>A greater incidence of somnolence, insomnia and sialorrhea occurred in the haloperidol group compared to the risperidone group (P=0.0001). EPS were increased with haloperidol but were not increased with the risperidone group (P=0.0001).</p> <p>Secondary: Not reported</p>
<p>Fontaine et al<sup>91</sup></p>	<p>DB</p>	<p>N=39</p>	<p>Primary: NPI and CGI scales</p>	<p>Primary: The total NPI score for each group was significantly reduced at endpoint</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
Olanzapine vs risperidone	Patients diagnosed with dementia (medically stable and able to comply with oral medications), residing in an extended care facility, had a CGI score $\geq 4$ and an Alzheimer's Disease Cooperative Study agitation screening scale score $\geq 25$ with 6 points on the delusions, hallucinations, physical aggression, or verbal aggression subscales	14 days	Secondary: Empirical BEHAVE-AD, the PGDRS, the MOSES, the MMSE, and the QUALID; safety measures utilizing the AIMS scale, the BAS, and the SAS for EPS	<p>(<math>P &lt; 0.0001</math>), as were the subscale scores for depression/dysphoria (<math>P = 0.0277</math>), anxiety (<math>P = 0.0016</math>), the combined agitation, disinhibition, irritability, and aberrant motor behavior (<math>P &lt; 0.0001</math>), and delusions/hallucinations (<math>P = 0.0492</math>).</p> <p>Significant reduction on the CGI scale at endpoint was seen in both groups (<math>P &lt; 0.0001</math>); however, there was no difference between the groups.</p> <p>Secondary: Global E-BEHAVE-AD scores at endpoint showed a significant reduction within each group (<math>P = 0.001</math>), with a significant difference between groups for the sum of all subscale scores (<math>P = 0.021</math>).</p> <p>Behavioral scores on the PGDRS scale were significantly reduced at endpoint for each group (<math>P &lt; 0.001</math>); however, there was no difference between the groups.</p> <p>There was no significant change in MOSES scores for either treatment group.</p> <p>QUALID scores were significantly improved for each group (<math>P = 0.03</math>).</p> <p>SAS tended to rise over the course of the study, but did not reach statistical significance (<math>P = 0.08</math>). Both groups had similar responses on the AIMS scale (<math>P = 0.52</math>) when the none/normal categories were compared to the minimal and mild categories (no response were worse than "mild").</p> <p>The BAS resulted in 15 of 18 patients in the olanzapine group and 16 of 18 patients in the risperidone group rated "absent" responses, with no responses rated worse than "mild".</p>
<b>Obsessive Compulsive Disorder (OCD)</b>				
Komossa et al <sup>92</sup>	SR	N=396 (11 studies)	Primary: Treatment	Primary: There was no significant difference in response rates between olanzapine

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
<p>Olanzapine, quetiapine, or risperidone as adjunctive therapy to antidepressants</p> <p>vs</p> <p>placebo, in addition to antidepressants</p>	<p>Randomized controlled studies comparing adjunctive olanzapine, quetiapine or risperidone with placebo in adult patients with OCD</p>	<p>6 to 16 weeks</p>	<p>response (<math>\geq 25\%</math> reduction in Y-BOCS scores), Y-BOCS, HAM-A, HAM-D, MADRS, CGI</p> <p>Secondary: Not reported</p>	<p>and placebo adjunctive therapies (OR, 0.28; 95%CI, 0.01 to 6.45). Moreover, there were no significant differences between groups in mental state (assessed via Y-BOCS) scores, anxiety symptoms (assessed via HAM-A) or depressive symptoms (assessed via HAM-D). Fewer patients discontinued the study early due to inefficacy in the adjunctive olanzapine group, compared to placebo (OR, 0.10; 95%CI, 0.01 to 0.98; P=0.05). Olanzapine adjunctive therapy was associated with significantly greater weight gain compared to placebo (OR, 2.30; 95%CI, 0.80 to 3.80).</p> <p>There was no significant difference in response rates between quetiapine and placebo adjunctive therapies (OR, 0.53; 95%CI, 0.27 to 1.05). In addition, quetiapine was associated with greater improvement from baseline in Y-BOCS scores and HAM-A scores. There was no significant difference between the groups in depressive symptoms, assessed via MADRS and HAM-D. Significantly more patients discontinued from the study early due to adverse effects in the quetiapine group than in the placebo group (OR, 4.48; 95%CI, 1.43 to 14.04). Quetiapine therapy was associated with significantly more weight gain and sedation than placebo.</p> <p>Risperidone adjunctive therapy was associated with significantly greater response rate, improved global state (CGI) scores, reduction in anxiety (HAM-A) and depressive (HAM-D) symptoms compared to placebo. There was no significant difference in Y-BOCS scores between groups. Sedation occurred more frequently in the risperidone group. The other adverse events were comparable between groups.</p> <p>Secondary: Not reported</p>
<b>Post-Traumatic Stress Disorder</b>				
<p>Padala et al<sup>93</sup></p> <p>Risperidone</p> <p>vs</p>	<p>PC, PRO, RCT</p> <p>Females 19-64 years of age with Post-traumatic Stress Disorder</p>	<p>N=20</p> <p>Duration not specified</p>	<p>Primary: Outcomes Post-traumatic Stress Disorder Scale-8</p> <p>Secondary:</p>	<p>Primary: Significant improvements from baseline were seen at visit 6 through visit 11 for the risperidone treated group (P value not reported). No significant changes were seen in the placebo group.</p> <p>Secondary:</p>



Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
placebo Pivac et al <sup>94</sup>  Olanzapine, 5-10 mg/day administered once or twice a day for 6 weeks  vs  fluphenazine, 5-10 mg/day administered once or twice a day for 6 weeks	OL  Male war veterans, mean age 37.6 years, diagnosed with post-traumatic stress disorder, unresponsive to a 6-12 months trial of selective serotonin reuptake inhibitor	N=55  6 weeks	HAM-D  Primary: Arousal, trauma re-experiencing, avoidance, PANSS score, EPS, duration of therapy (3 weeks vs 6 weeks)  Secondary: Not reported	Scales showed results in line with the primary endpoint.  Primary: There was no significant difference between the study drugs in alleviating the symptoms, both groups experienced an improvement in arousal, trauma re-experiencing and avoidance (P<0.001).  Olanzapine was more effective in reducing symptoms in the PANSS negative, general psychopathology, supplementary items subscales, scores in CGI-S, CGI-I, and Patient Global Impression-Improvement scale (P<0.001). However, treatment for 3 or 6 weeks resulted in a similar decrease in the PANSS positive subscale scores (P>0.05).  EPS was more common with fluphenazine therapy (P<0.001).  Patients exhibited similar improvement in Post-traumatic Stress Disorder symptoms after 3 or 6 weeks of treatment (P value not reported).  Secondary: Not reported

Study abbreviations: CI=confidence interval, DB=double-blind, MC=multicenter, OL=open-label, PC=placebo-controlled, PG=parallel-group, PRO=prospective trial, R=randomized, RCT=randomized controlled trial, RETRO=retrospective, SR-systematic review, XO=cross-over

Miscellaneous abbreviations: AD=Alzheimer's Disease, ADHD=Attention Deficit Hyperactivity Disorder, AIMS=Abnormal Involuntary Movement Scale, BAS=Barnes Akathisia Scale, BEHAVE-AD=Behavioral Pathology in Alzheimer's Disease Rating Scale, BMI=body mass index, BPRS=Brief Psychiatric Rating Scale, CDRS=Children's Depression Rating Scale, CGAS=Children's Global Assessment Scale, CGI=Clinical Global Impressions Scale, CGI-C=Clinical Global Impression of Change, BSPS=Brief Social Phobia Scale, CGI-I=Clinical Global Impression of Change, CGI-I=Clinical Global Impression-Improvement, CGI-S=Clinical Global Impression Severity, CGI-SI=Clinical Global Impression—Severity of Illness, CMAI=Cohen-Mansfield Agitation Inventory, DOTES=Dosage Record Treatment Emergent Symptom Scale, DSM-IV=Diagnostic and Statistical Manual of Mental Disorders, 4<sup>th</sup> edition, ECG=electrocardiogram, EPS=EPS side effects, ESRs=EPS Symptom Rating Scale, GAD=generalized anxiety disorder, HAM-A=Hamilton Rating Scale for Anxiety, HAM-D=Hamilton Rating Scale for Depression, MADRS=Montgomery-Asberg Depression Rating Scale, MD=mean difference, MDD=major depressive disorder, MMSE=Mini-Mental State Examination, MOSES=Multidimensional Observational Scale for Elderly Subjects, NNH=number needed to harm, NNT=number needed to treat, NPI=Neuropsychiatric Inventory, OCD=Obsessive Compulsive Disorder, OR=Odds Ratio, PANSS=Positive and Negative Syndrome Scale, PTSD=Post Traumatic Stress Disorder, QUALID=Quality of Life in Late Stage Dementia Scale, SANS=Scale for the Assessment of Negative Symptoms, SAPS=Scale for the Assessment of Positive Symptoms, SAS=Simpson-Angus Scale, SMC=standardized mean changes, PGDRS=Psychogeriatric Dependency Rating Scales, TSH=thyroid stimulating hormone, UKU=Udvalg for Kliniske Undersøgelser, WMD=weighted mean difference, YBOCS=Yale-Brown Obsessive Compulsive Scale, YMRS=Young Mania Rating Scale

**Table 6. Clinical Trials Using Antipsychotics for Children and Adolescents (FDA-Approved and Off-Label)**

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
<p><b>General</b></p> <p>Seida et al<sup>95, 96</sup></p> <p>AHRQ Review</p> <p>Atypical (second-generation) antipsychotics (i.e. aripiprazole, clozapine, olanzapine, quetiapine, risperidone, paliperidone, ziprasidone)</p> <p>vs</p> <p>another atypical antipsychotic, first-generation antipsychotic (i.e. haloperidol), or placebo</p>	<p>SR</p> <p>Children and young adults 24 years of age or younger (mean age ranged from 4 to 21.5 years), diagnosed with pervasive developmental disorders, ADHD and disruptive behavior disorders, bipolar disorder, schizophrenia, or schizophrenia-related psychosis, Tourette syndrome, obsessive-compulsive disorder, post-traumatic stress disorder, anorexia nervosa, or behavioral issues;</p>	<p>N=not reported (140 studies)</p> <p>2 weeks to 18 months</p>	<p>Primary: Efficacy (various measures), adverse events</p> <p>Secondary: Not reported</p>	<p>Primary: Pervasive Developmental Disorders (PDD): Compared to placebo, aripiprazole and risperidone were associated with significantly greater improvement from baseline in autistic symptoms and fewer obsessive compulsive symptoms associated with these disorders. However, no significant difference was found between either aripiprazole or risperidone and placebo in terms of the Clinical Global Impressions (CGI) scale and medication adherence. The overall strength of evidence score for use of these drugs for PDD was low.</p> <p>Disruptive Behavioral Disorders: Risperidone was associated with significantly greater improvement from baseline in various measures of behavior symptoms and on CGI compared to placebo. The overall strength of evidence of this outcome was moderate.</p> <p>Atypical antipsychotics and placebo were comparable in terms of effects on aggression, anxiety, or medication adherence.</p> <p>Compared to placebo, aripiprazole, olanzapine, quetiapine, and risperidone were associated with significant improvement from baseline in the CGI-Bipolar scale scores in patients who primarily had mania or mixed Bipolar disorder. There was no significant difference between atypical antipsychotics and placebo in suicide-related behaviors. The overall strength of evidence of these outcomes was moderate.</p> <p>The evidence comparing different atypical antipsychotics (olanzapine, quetiapine, risperidone, and ziprasidone) and low vs high doses of aripiprazole, quetiapine, risperidone, and ziprasidone was insufficient to form conclusions.</p> <p>Aripiprazole, olanzapine, and quetiapine were not significantly different from placebo for depressive symptoms. However, aripiprazole,</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
	<p>randomized controlled trials, nonrandomized controlled trials, and cohort studies were included</p>			<p>olanzapine, quetiapine, risperidone, and ziprasidone were associated with significantly greater effect on manic symptoms compared to placebo. Medication adherence was significantly better with placebo compared to antipsychotic therapy. The overall strength of evidence of these outcomes was low.</p> <p>Schizophrenia: Aripiprazole, olanzapine, paliperidone, quetiapine, and risperidone were associated with statistically significant improvements in CGI, positive and negative symptoms compared to placebo (strength of evidence: low). For both outcomes, risperidone was associated with greater efficacy over placebo compared to the other atypical antipsychotics.</p> <p>Clozapine, olanzapine, and risperidone were significantly more effective than haloperidol for CGI improvement. Medication adherence was comparable between patients who received olanzapine vs quetiapine, olanzapine vs risperidone, and atypical antipsychotics vs placebo. There was no significant difference between atypical antipsychotics and placebo in terms of reduction of suicide-related behavior. The overall strength of evidence of these outcomes was low.</p> <p>Behavioral Symptoms: In two studies, patients receiving risperidone experienced greater improvement in Aberrant Behavior Checklist (ABC) scores compared to placebo (strength of evidence: low).</p> <p>Adverse Events: In head-to-head study comparison, risperidone caused less dyslipidemia vs olanzapine; olanzapine caused fewer prolactin-related events vs risperidone; quetiapine and risperidone caused less weight gain vs olanzapine (strength of evidence: moderate). Furthermore, aripiprazole caused less dyslipidemia vs olanzapine or quetiapine; aripiprazole caused less weight gain vs olanzapine, quetiapine, or risperidone. There were no significant differences between atypical antipsychotics with respect to EPS, insulin resistance, and sedation (strength of evidence:</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>low).</p> <p>In placebo-controlled study comparison, risperidone caused less dyslipidemia vs olanzapine; olanzapine caused fewer prolactin-related adverse events vs risperidone; quetiapine and risperidone caused less weight gain vs olanzapine (strength of evidence: moderate).</p> <p>Secondary: Not reported</p>
<b>Anorexia</b>				
<p>Leggero et al<sup>97</sup></p> <p>Olanzapine 1.25 mg to 12.5 mg daily as part of multimodal treatment (included psychotherapy, psychoeducation, assisted feeding, and prolonged control of somatic conditions)</p>	<p>PRO</p> <p>Girls, aged 9.6 to 16.3 years, diagnosed with anorexia</p>	<p>N=13</p> <p>6 months</p>	<p>Primary: Body Mass Index (BMI), Children's Global Assessment Scale (CGAS), Clinical Global Impressions-Severity (CGI-S), Child Behavior Checklist (CBCL), Eating Attitude Test (EAT), Eating Disorder Inventory (EDI-2), Structured Inventory for Anorexic and Bulimic Syndromes-Expert Form (Hyperactivity) (SIAB-EX)</p> <p>Secondary: Not reported</p>	<p>Primary:</p> <p>At six months, olanzapine therapy was associated with a statistically significant improvement from baseline in BMI (P&lt;0.001).</p> <p>At six months, olanzapine therapy was associated with a statistically significant improvement from baseline in CGAS (P&lt;0.001).</p> <p>At six months, olanzapine therapy was associated with a statistically significant improvement from baseline in CGI-S (P&lt;0.001).</p> <p>At six months, olanzapine therapy was associated with a statistically significant improvement from baseline in total CBCL scores (P=0.044).</p> <p>At six months, olanzapine therapy was associated with a statistically significant improvement from baseline in CBCL internalizing scores (P=0.034).</p> <p>At six months, olanzapine therapy was associated with statistically significant improvements from baseline in EAT-26 Total, Dieting, Bulimic, and Oral control scores (P&lt;0.05). An improvement in EAT-26 of at least 50% was achieved in 7 out of 13 patients (responders).</p> <p>At six months, olanzapine therapy was associated with statistically significant improvements from baseline in two areas of EDI-2: Interoceptive Awareness and Impulsivity (P&lt;0.05 for both).</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>At six months, olanzapine therapy was associated with a statistically significant improvement from baseline in SIAB-EX (P=0.005).</p> <p>Secondary: Not reported</p>
<p>Kafantaris et al<sup>98</sup></p> <p>Olanzapine 2.5 mg to 10 mg once daily at bedtime, in adjunct to a comprehensive eating disorder treatment program</p> <p>vs</p> <p>placebo once daily at bedtime, in adjunct to a comprehensive eating disorder treatment program</p>	<p>DB, PC, RCT</p> <p>Girls, aged 12 to 21, with a primary diagnosis of anorexia</p>	<p>N=20</p> <p>10 weeks</p>	<p>Primary: % of Median Body Weight (MBW)</p> <p>Secondary: Adverse events</p>	<p>Primary: Both olanzapine and placebo groups experienced statistically significant increase from baseline in %MBW (P=0.01); however there was no statistically significant difference between the two groups (P&lt;0.05).</p> <p>Secondary: At week 10, the olanzapine group had significantly higher glucose levels and insulin levels compared to patients receiving placebo (P≤0.05). There were no statistically significant differences between the groups in metabolic parameters or ECG.</p>
<b>Bipolar Disorder</b>				
<p>Findling et al<sup>99</sup></p> <p>Aripiprazole 10 mg daily</p> <p>vs</p> <p>aripiprazole 30 mg daily</p> <p>vs</p> <p>placebo</p>	<p>DB, MC, PC, RCT</p> <p>Children and adolescents, aged 10 to 17 years, diagnosed with bipolar I disorder with current manic or mixed episodes, with or without psychotic features, and a</p>	<p>N=296</p> <p>4 weeks</p>	<p>Primary: Change from baseline in YMRS total score</p> <p>Secondary: Change from baseline in the Children's Global Assessment Scale (CGAS), Clinical Global Impressions Scale-Bipolar Version (CGI-BP) severity of mania,</p>	<p>Primary: At four weeks, patients randomized to aripiprazole 10 mg daily therapy exhibited a statistically significant reduction from baseline on the YMRS total score, compared to placebo (14.2 vs 8.2; P&lt;0.0001).</p> <p>At four weeks, patients randomized to aripiprazole 30 mg daily therapy exhibited a statistically significant reduction from baseline on the YMRS total score compared to placebo (16.5 vs 8.2; P&lt;0.0001).</p> <p>Statistically significant improvements in the primary endpoint were observed in both aripiprazole dose groups compared to placebo as early as week one and were maintained throughout the study.</p> <p>Secondary: At four weeks, patients randomized to aripiprazole 10 mg daily therapy</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
	<p>Yong Mania Rating Scale (YMRS) total score <math>\geq 20</math> at baseline</p>		<p>depression, and overall bipolar illness, General Behavior Inquiry (GBI), CDRS-R, ADHD Rating Scale-Version IV (ADHD-RS-IV), response (defined as a reduction in baseline YMRS score of <math>\geq 50\%</math>), remission (defined as YMRS total score <math>\leq 12</math> and CGI-BP severity score <math>\leq 2</math>), adverse events</p>	<p>exhibited a statistically significant improvement from baseline in CGAS scores, compared to placebo (<math>P &lt; 0.0001</math>).</p> <p>At four weeks, patients randomized to aripiprazole 30 mg daily therapy exhibited a statistically significant improvement from baseline in the CGAS scores, compared to placebo (<math>P &lt; 0.0001</math>).</p> <p>At four weeks, patients randomized to aripiprazole 10 mg daily therapy exhibited a statistically significant reduction from baseline in the CGI-BP severity of mania scores, compared to placebo (1.6 vs 0.8; <math>P &lt; 0.0001</math>).</p> <p>At four weeks, patients randomized to aripiprazole 30 mg daily therapy exhibited a statistically significant reduction from baseline in the CGI-BP severity of mania scores, compared to placebo (2.1 vs 0.8; <math>P &lt; 0.0001</math>).</p> <p>At four weeks, patients randomized to aripiprazole 10 mg daily therapy exhibited a statistically significant reduction from baseline in the CGI-BP overall bipolar illness scores, compared to placebo (1.6 vs 0.8; <math>P &lt; 0.0001</math>).</p> <p>At four weeks, patients randomized to aripiprazole 30 mg daily therapy exhibited a statistically significant reduction from baseline in the CGI-BP overall bipolar illness scores, compared to placebo (2.0 vs 0.8; <math>P &lt; 0.0001</math>).</p> <p>Neither of the two aripiprazole treatment groups exhibited a statistically significant reduction from baseline in CGI-BP depression severity scores, compared to placebo (<math>P &gt; 0.05</math>). Changes from baseline in patient self-rated GBI-depression scores were likewise not significantly different from placebo in the two aripiprazole groups (<math>P &gt; 0.05</math>). The change from baseline in parent/guardian-rated CGI-depression scores was marginally significant compared to placebo, but only in the aripiprazole 10 mg daily group (<math>P = 0.04</math>).</p> <p>Neither of the two aripiprazole treatment groups exhibited a statistically</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>significant reduction from baseline in CDRS-R scores, compared to placebo (P&gt;0.05).</p> <p>At four weeks, patients randomized to aripiprazole 15 mg and 30 mg daily therapy groups exhibited a statistically significant reduction from baseline in the ADHD-RS-IV total scores, compared to placebo (P&lt;0.0001).</p> <p>Significantly more patients achieved treatment response after four weeks of therapy in the aripiprazole 10 mg (44.8%; P=0.0074) and 30 mg groups (63.6%; P&lt;0.0001), compared to placebo (26.1%).</p> <p>Significantly more patients achieved disease remission after four weeks of therapy in the aripiprazole 10 mg (25%; P=0.0002) and 30 mg groups (47.5%; P&lt;0.0001), compared to placebo (5.4%).</p> <p>At least one serious adverse event occurred in 5.1%, 2%, and 5.2% of patients receiving aripiprazole 10 mg, 30 mg, and placebo, respectively.</p> <p>No clinically significant trends in heart rate, blood pressure or ECG changes were observed among the groups.</p> <p>Mean weight gain from baseline was not statistically significant in the aripiprazole 10 mg daily (0.82 kg vs 0.56 kg; P=0.35) and aripiprazole 30 mg daily (1.08 kg vs 0.56 kg; P=0.13) groups, compared to placebo.</p> <p>There were no clinically significant changes from baseline in fasting serum glucose, total cholesterol, triglycerides, or HDL cholesterol (P value not reported).</p> <p>EPS events were reported by 23.5, 39.4, and 7.2% of the aripiprazole 10 mg daily, aripiprazole 30 mg daily, and placebo groups, respectively (P value not reported).</p>
Tramontina et al <sup>100</sup>	DB, PC, PG, RCT	N=710	Primary: Change from	Primary: Aripiprazole-treated patients demonstrated a statistically significant

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
<p>Aripiprazole 2-5 mg initially titrated up to 20 mg daily</p> <p>vs</p> <p>placebo</p>	<p>Children and adolescents, aged 8 to 17 years, with bipolar I or II disorder comorbid with ADHD, clear reports of ADHD symptom onset preceding mood symptoms, acutely manic or mixed state</p>	<p>6 weeks</p>	<p>baseline in Young Mania Rating Scale (YMRS), the Swanson, Nolan, and Pelham Scale-Version IV (SNAP-IV), weight</p> <p>Secondary: Change from baseline in the Child Mania Rating Scale- Parent Version (CMRS-P), Clinical Global Impressions Severity of Illness scale (CGI-S), Children's Depression Rating Scale-Revised (CDRS-R), Kutcher Adolescent Depression Scale (KADS), adverse events</p>	<p>reduction in YMRS scores from baseline compared to placebo (27.22 vs 19.52; effect size=0.80; 95% CI, 0.15 to 1.41; P=0.02).</p> <p>Aripiprazole was associated with significantly higher response rates compared to placebo (88.9 vs 52%; P=0.02; NNT=2.70).</p> <p>Aripiprazole was associated with significantly higher remission rates compared to placebo (72 vs 32%; P=0.01; NNT=2.50).</p> <p>There was no statistically significant difference in the change in SNAP-IV scores from baseline between aripiprazole and placebo groups (P=0.19).</p> <p>Weight gain was not significantly different between aripiprazole and placebo groups (1.2 kg vs 0.72 kg; P=0.25).</p> <p>Secondary: Aripiprazole-treated patients demonstrated a statistically significant reduction in CMRS-P scores from baseline compared to placebo (21.16 vs 15.52; effect size=0.54; P=0.02).</p> <p>Aripiprazole-treated patients demonstrated a statistically significant reduction in CGI-S scores from baseline compared to placebo (2.05 vs 1.64; effect size=0.28; P=0.04).</p> <p>There were no statistically significant differences in the change in CDRS-R and KADS scores from baseline between aripiprazole and placebo groups (P=0.59 and P=0.19, respectively).</p> <p>There were no statistically significant difference in the adverse event count between aripiprazole and placebo groups (3.76 vs 4.83; P=0.99).</p>
<p>Biederman et al<sup>101</sup></p> <p>Aripiprazole 5 to 40 mg daily</p>	<p>SCR</p> <p>Children and adolescents,</p>	<p>N=41</p> <p>up to 84 weeks</p>	<p>Primary: Change from baseline in CGI-severity scores</p>	<p>Primary: Patients receiving aripiprazole exhibited a reduction (improvement) in the mean mania CGI-severity score from 5.3 (marked/severe) to 3.4 (mild) (P&lt;0.001).</p>



Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
<p>Note: 39% of patients were receiving other antipsychotics concomitantly</p>	<p>aged 4 to 17, diagnosed with manic, hypomanic, or mixed bipolar disorder</p>		<p>Secondary: Not reported</p>	<p>Of the patients receiving aripiprazole, 15% were minimally improved, 15% exhibited no change, 27% were very much improved, and 43% were much improved from baseline.</p> <p>Aripiprazole therapy was not associated with serious adverse events. Common side effects included nausea, insomnia, vomiting, and agitation. Weight gain was not noted to occur.</p> <p>Secondary: Not reported</p>
<p>Frazier et al<sup>102</sup></p> <p>Olanzapine 2.5 mg/day to 20 mg/day, average 9.6 mg/day</p>	<p>OL, PRO</p> <p>Males and females, age 5-14 years, with bipolar (manic, mixed or hypomanic), with Young Mania Rating Scale (YMRS) total score <math>\geq 15</math></p>	<p>N=23</p> <p>8 weeks</p>	<p>Primary: YMRS, Clinical Global Impression Severity (CGI-S), Brief Psychiatric Rating Scale (BPRS)</p> <p>Secondary: Adverse events, laboratory values, EPS (monitored by Simpson-Angus Scale, Barnes Akathisia Scale, Abnormal Involuntary Movement Scale [AIMS])</p>	<p>Primary: Compared to baseline a statistically significant improvement in symptoms of mania, and all items on the YMRS scale was seen (<math>P &lt; 0.001</math>).</p> <p>Compared to baseline a significant improvement was seen in: elevated mood, increased motor activity-energy, sleep, irritability, speech, language-thought disorder, thought content and disruptive-aggressive behavior (<math>P &lt; 0.001</math> for all).</p> <p>Compared to baseline CGI-S scores improved significantly (<math>P &lt; 0.001</math>); however, there was no significant difference in the treatment response between bipolar youths with or without psychosis (P value not given).</p> <p>Secondary: No significant changes in Simpson-Angus, Barnes Akathisia or AIMS scores were reported.</p> <p>From baseline the average weight gain was 5.0 +/- 2.3 kg, mean change in BMI was 2.4 +/- 1.3 kg/m<sup>2</sup> (<math>P &lt; 0.001</math>).</p> <p>Prolactin levels changed significantly from baseline to endpoint (<math>P &lt; 0.002</math>); at endpoint 6 subjects had values above normal, one of which was twice the upper limit. However no subjects had signs or</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>symptoms associated with elevated prolactin.</p> <p>Pulse rates were significantly different at endpoint as compared to baseline for: supine pulse rate (P&lt;0.004), standing pulse rate (P&lt;0.001), and heart rate per EKG (P&lt;0.002).</p>
<p>Shaw et al<sup>103</sup></p> <p>Quetiapine 50 mg/day to 800 mg/day in divided doses, average dose was 467 mg/day</p>	<p>OL</p> <p>Patients 13-17 years of age with a psychotic disorder (schizophrenia, schizoaffective disorder, bipolar disorder, major depressive disorder with psychotic features, psychosis not otherwise specified)</p>	<p>N=15</p> <p>8 weeks</p>	<p>Primary: YMRS (Young Mania Rating Scale), BPRS (Brief Psychiatric Rating Scale), PANSS (Positive and Negative Syndrome Scale), CGI-SI (Clinical Global Impression - Severity of Illness), SAS (Simpson-Angus Scale), AIMS (Abnormal Involuntary Movement Scale) BAS (Barnes Akathisia Scale)</p> <p>Secondary: Adverse events</p>	<p>Primary: Significant improvement from baseline was seen in: BPRS, PANSS, positive symptoms, negative symptoms, YMRS, and CGI-SI scores (P&lt;0.001 for all).</p> <p>No significant change from baseline was seen for AIMS, BAS and SAS scores (P values not given).</p> <p>Secondary: Most frequently noticed adverse events were somnolence, headaches, and agitation.</p> <p>Total white blood cell count was less at the endpoint than discharge (P&lt;0.05).</p> <p>No significant change in TSH or T4 was seen (P&lt;0.008), or in total cholesterol or prolactin levels (P values not given).</p> <p>Significant changes in weight were observed from baseline to endpoint (P&lt;0.001).</p>
<p>Marchand et al<sup>104</sup></p> <p>Quetiapine 100-1,000 mg/day, average 400 mg/day</p>	<p>RETRO</p> <p>Patients 4-17 years of age with diagnosis of bipolar I, bipolar II, cyclothymia</p>	<p>N=32</p> <p>Chart review of patients from February 2000-April 2003 (length of</p>	<p>Primary: CGI-I, CGI-S</p> <p>Secondary: Body mass index (BMI)</p>	<p>Primary: Twenty four patients (80%) were responders with CGI-I ≤2. For patients receiving quetiapine as monotherapy (14 patients), 78.6% were responders.</p> <p>CGI-S score significantly improved from baseline (4.5) to endpoint (2.8) (P&lt;0.001).</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
	or bipolar disorder	treatment ranged from 1-32 months)		Secondary: 19/32 patient weights were available. Change in BMI from baseline (20.9) to endpoint (21.7) was not significant (P<0.115).
<p>DelBello et al<sup>105</sup></p> <p>Quetiapine 25 mg twice daily up to a maximum of 150 mg three times daily, in addition to divalproex 20 mg/kg initially and titrated up to a therapeutic level of 80-130 mg/dL (quetiapine group)</p> <p>vs</p> <p>placebo, in addition to divalproex 20 mg/kg initially and titrated up to a therapeutic level of 80-130 mg/dL (placebo group)</p>	<p>DB, PC, PG, RCT</p> <p>Adolescents, aged 12 to 18 years, with bipolar I disorder currently mixed or manic, YMRS score <math>\geq</math>20</p>	<p>N=30</p> <p>8 weeks</p>	<p>Primary: Change in Young Mania Rating Scale (YMRS) at 8 weeks</p> <p>Secondary: Change in PANSS-P, CDRS, CGAS, adverse events</p>	<p>Primary: At week six, both quetiapine and placebo groups exhibited statistically significant reductions in the YMRS scores from baseline (P&lt;0.05).</p> <p>However, quetiapine-treated patients exhibited a significantly greater reduction of YMRS scores from baseline compared to the group treated with divalproex alone (P=0.03). In addition, a significantly greater percentage of patients experienced treatment response, based on YMRS scores, in the quetiapine than in the placebo group (87 vs 53%; P=0.05).</p> <p>Secondary: CDRS scores were significantly improved from baseline in both treatment groups (P<math>\leq</math>0.01). However, there were no significant differences between groups in the change from baseline in CGAS scores (P=1.0)</p> <p>PANSS-P scores were significantly improved from baseline in both treatment groups (P&lt;0.01). However, there were no significant differences between groups in the change from baseline in CGAS scores (P=0.8)</p> <p>CGAS scores were significantly improved from baseline in both treatment groups (P&lt;0.01). However, there were no significant differences between groups in the change from baseline in CGAS scores (P=0.2)</p> <p>Patients randomized to the quetiapine group experienced a significantly greater reduction over time in YMRS scores compared to patients in the placebo group (P&lt;0.01).</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>There were no significant differences between treatment groups in the reduction over time in CDRS or PANSS-P scores (<math>P&gt;0.05</math>).</p> <p>The most common adverse events were sedation, nausea, headache, and gastrointestinal irritation. Sedation was significantly more common in patients receiving adjunctive quetiapine than placebo (<math>P=0.03</math>). There were no significant differences between the groups in change from baseline in QTc interval, platelet count, prolactin level, weight, EPS side effects, or liver function tests.</p>
<p>DelBello et al<sup>106</sup></p> <p>Quetiapine 300 to 600 mg daily</p> <p>vs</p> <p>placebo</p>	<p>DB, MC, PC, RCT</p> <p>Adolescents, aged 12 to 18 years, with a depressive episode associated with bipolar I disorder</p>	<p>N=32</p> <p>8 weeks</p>	<p>Primary: Change in Children's Depression Rating Scale-Revised Version (CDRS-R) at 8 weeks</p> <p>Secondary: Change in CDRS-R over the study period, change in Hamilton Anxiety Rating Scale (HAM-A), Young Mania Rating Scale (YMRS), Clinical Global Impression-Bipolar Version Severity (CGI-BP-S), response, remission rate, adverse events</p>	<p>Primary: At week six, both quetiapine and placebo groups exhibited statistically significant reductions in the CDRS-R scores from baseline (<math>P&lt;0.001</math>).</p> <p>However, the difference between the quetiapine and placebo groups in the reduction of CDRS-R from baseline was not statistically significant (19 vs 20; <math>P=0.89</math>).</p> <p>Secondary: There was no statistically significant difference between the groups in the average rate of change in CDRS-R scores over the eight weeks of the study (<math>P=0.11</math>).</p> <p>Response rates were 67% and 71% in the placebo and quetiapine groups, respectively (<math>P=1.0</math>).</p> <p>Remission rates were 40% and 35% in the placebo and quetiapine groups, respectively (<math>P=1.0</math>).</p> <p>At week-6, both quetiapine and placebo groups exhibited statistically significant reductions in the HAM-A scores from baseline (<math>P\leq 0.05</math>).</p> <p>However, the difference between the quetiapine and placebo groups in the reduction of HAM-A from baseline was not statistically significant (<math>P=0.74</math>).</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>Quetiapine was associated with a statistically significant reduction from baseline in the YMRS scores (P=0.03), while the change from baseline in the placebo group was not statistically significant (P=0.09). There was no statistically significant difference in the change in YMRS scores from baseline between quetiapine and placebo (P=0.76).</p> <p>At week six, both quetiapine and placebo groups exhibited statistically significant reductions in the CGI-BP-S scores from baseline (P&lt;0.005).</p> <p>However, the difference between the quetiapine and placebo groups in the reduction of CGI-BP-S from baseline was not statistically significant (P=0.9).</p> <p>The most commonly reported adverse events in the quetiapine group were gastrointestinal upset (65%), sedation (59%), and dizziness (41%). The only one of the above side effects that occurred at a significantly greater frequency in quetiapine-treated patients vs placebo was dizziness (P=0.04).</p> <p>Quetiapine-treated patients experienced significantly more frequent elevations in systolic, diastolic blood pressures, pulse and triglyceride level compared to placebo (P&lt;0.05). Significant differences in QTc interval between groups were not observed (P=0.8).</p> <p>Quetiapine-treated patients gained an average of 2.3 kg while those receiving placebo gained 0.9 kg (P=0.12).</p>
<p>Pathak et al<sup>277</sup></p> <p>Quetiapine 400 to 600 mg daily</p> <p>vs</p> <p>placebo</p>	<p>DB, MC, PC, PG, RCT</p> <p>Patients 10 to 17 years of age with bipolar I disorder with manic episodes, YMRS total</p>	<p>N=284</p> <p>3 weeks</p>	<p>Primary: Change from baseline in YMRS total score</p> <p>Secondary: Proportion of patients with clinical response</p>	<p>Primary:</p> <p>The reduction from baseline in YMRS total score was significantly greater with quetiapine 400 mg (LSM change, -14.25±0.96; 95% CI, -16.15 to -12.35) and 600 mg (LSM change, -15.60±0.97; 95% CI, -17.15 to -13.70) compared to placebo (LSM change, -9.04±1.12; 95% CI, -11.24 to -6.84). Significantly greater improvements were observed at day four with quetiapine 400 mg (P=0.015) and day seven with quetiapine 600 mg (P&lt;0.001).</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
	score $\geq 20$ at baseline		( $\geq 50\%$ reduction in YMRS total score), remission (YMRS total score $\leq 12$ ), CDRS-R, CGI-BP, CGAS and safety	<p>Secondary: The treatment response rates were significantly higher with 400 and 600 mg of quetiapine compared to placebo after three weeks of treatment (55 and 56 vs 28%; <math>P &lt; 0.001</math> for both compared to placebo).</p> <p>Remission rates were also significantly higher for patients treated with 400 mg (45%; <math>P &lt; 0.01</math>) or 600 mg (<math>P &lt; 0.001</math>) of quetiapine compared to placebo (23%).</p> <p>Overall, 23.7 and 19.8% of patients treated with quetiapine 400 or 600 mg rated themselves as 'very much improved' after three weeks compared to 13.2% of patients treated with placebo. Another 32.9, 45.7 and 20.6%, respectively, rated themselves as 'much improved'.</p> <p>Significant improvements in CGAS scores occurred in both quetiapine treatment groups compared to placebo (<math>P &lt; 0.001</math> for both compared to placebo).</p> <p>The most common adverse events in quetiapine-treated patients were somnolence, sedation, dizziness and headache. Most events were mild to moderate in severity. Treatment discontinuation due to adverse events occurred in 15.8, 7.1 and 4.4% of patients treated with quetiapine 400, 600 mg or placebo, respectively.</p> <p>The mean change in body weight was 1.7, 1.7 and 0.4 kg for patients treated with quetiapine 400, 600 mg and placebo, respectively. An increase in body weight of at least seven percent from baseline occurred in 14.5, 9.9 and 0% of patients randomized to receive quetiapine 400, 600 mg or placebo, respectively.</p> <p>Potentially clinically significant shifts in total cholesterol, LDL, and TG concentrations were more frequent in the quetiapine treatment groups compared to placebo.</p>
Delbello et al <sup>107</sup>	DB, RCT	N=50	Primary: Change from	Primary: Quetiapine-treated patients experienced a statistically significant

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
<p>Quetiapine 400 mg to 600 mg daily</p> <p>vs</p> <p>divalproex, dose was titrated up to serum level of 60 to 120 mcg/ml</p>	<p>Adolescents, aged 12 to 18 years, with bipolar I disorder (manic or mixed) and YMRS score of <math>\geq 20</math></p>	<p>28 days</p>	<p>baseline in YMRS</p> <p>Secondary: Change from baseline in CDRS, CGI-BP, Positive and Negative Syndrome Scale-Positive Subscale (PANSS-P), CDRS, response rate (CGI-BP-I <math>\leq 2</math>), remission rate (YMRS <math>\leq 12</math>), adverse events</p>	<p>improvement from baseline in YMRS scores (P&lt;0.0001).</p> <p>Divalproex-treated patients experienced a statistically significant improvement from baseline in YMRS scores (P&lt;0.0001).</p> <p>The difference between the two treatment groups in the change from baseline YMRS scores was not statistically significant (3.3; 95%CI, -3.5 to 10.1; P=0.3).</p> <p>Secondary: Both treatment groups were associated with a statistically significant improvement from baseline in CDRS scores (P&lt;0.0001 for both). However, the difference between the two groups in the change in CDRS scores from baseline was not statistically significant (1.6; 95%CI, -11.5 to 8.4; P=0.7).</p> <p>Both treatment groups were associated with a statistically significant improvement from baseline in PANSS-P scores (P&lt;0.00051 for both). However, the difference between the two groups in the change in CDRS scores from baseline was not statistically significant (3.5; 95%CI, -0.9 to 7.8; P=0.1).</p> <p>A significantly greater percentage of quetiapine-treated patients met the criteria for a CGI-BP-I overall response compared to patients randomized to divalproex therapy (72 vs 40%; P=0.02).</p> <p>A significantly greater percentage of quetiapine-treated patients met the criteria for a CGI-BP-I mania response compared to patients randomized to divalproex therapy (84 vs 56%; P=0.03).</p> <p>A significantly greater percentage of quetiapine-treated patients met the criteria for remission compared to patients randomized to divalproex therapy (60 vs 28%; P=0.02).</p> <p>Within a group of patients with psychosis, there was a significantly</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>greater CGI-BP-I overall response rate in those randomized to quetiapine compared to patients receiving divalproex therapy (55 vs 8%; P=0.03).</p> <p>Within a group of patients without psychosis, there was no significant difference in CGI-BP-I overall response rate between patients randomized to quetiapine compared to those receiving divalproex therapy (86 vs 69%; P=0.4).</p> <p>Within a group of patients with psychosis, there was no significant difference in YMRS remission rate between patients randomized to quetiapine compared to those receiving divalproex (55 vs 17%; P=0.09). Within a group of patients without psychosis, a statistically significant difference in YMRS remission rate between quetiapine and divalproex was not observed (64 vs 38%; P=0.3).</p> <p>There was no statistically significant difference between quetiapine and divalproex in weight gain from baseline (4.4 vs 3.6 kg; P=0.2).</p> <p>The most commonly reported adverse events in both groups were sedation, dizziness and gastrointestinal upset.</p>
<p>Haas et al<sup>108</sup></p> <p>Risperidone 0.5 to 2.5 mg daily vs risperidone 3 to 6 mg daily vs placebo</p>	<p>DB, PC, RCT</p> <p>Children and adolescents, aged 10 to 17 years, with a diagnosis of bipolar I disorder, experiencing a manic or mixed episode</p>	<p>N=169</p> <p>3 weeks</p>	<p>Primary: Change in YMRS total score from baseline</p> <p>Secondary: Clinical response rate (<math>\geq 50\%</math> reduction from baseline on the total YMRS), sustained YMRS response (<math>\geq 50\%</math> improvement at <math>\geq 2</math></p>	<p>Primary: Patients randomized to the risperidone 0.5-2.5 mg group experienced significantly greater reduction in mean YMRS total scores from baseline compared to placebo (18.5 vs 9.1; P&lt;0.001).</p> <p>Patients randomized to the risperidone 3-6 mg group experienced significantly greater reduction in mean YMRS total scores from baseline compared to placebo (16.5 vs 9.1; P&lt;0.001).</p> <p>Significantly greater changes in the primary endpoint were observed in both risperidone groups by day seven of therapy.</p> <p>Secondary: Clinical response was achieved by 59% of patients randomized to</p>



Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
			consecutive measurements and for the remainder of treatment), remission rate (YMRS score $\leq 12$ and CGI-BP score $\leq 2$ at the 21-day endpoint), CGI-BP, Brief Psychiatric Rating Scale for Children (BPRS-C), adverse events	<p>risperidone 0.5-2.5 mg group (P=0.002), 63% of patients receiving risperidone 3-6 mg group (P&lt;0.001), compared to 26% of patients in the placebo group. Statistically significant clinical response differences between risperidone and placebo, favoring risperidone, were noted starting day-14.</p> <p>Sustained clinical response was achieved by 44.9% of patients randomized to risperidone 0.5-2.5 mg group, 41.7% of patients receiving risperidone 3 to 6 mg group, compared to 15.8% of patients in the placebo group. Onset of sustained response was significantly more frequent and earlier in the risperidone 0.5 to 2.5 mg group (P=0.002) and risperidone 3 to 6 mg group (P&lt;0.001) than in the placebo group.</p> <p>Both risperidone groups had higher remission rates compared to placebo (43 vs 16%; P value not reported).</p> <p>Both risperidone groups exhibited a statistically significant improvement in CGI-BP scores from baseline compared to placebo (P&lt;0.001). No dose-response relationship was noted.</p> <p>Both risperidone groups exhibited a statistically significant improvement in overall BPRS-C total scores from baseline compared to placebo (P&lt;0.05). However, the change from baseline in the BPRS-C depression factor scores in the two risperidone groups was not significantly different from placebo (P&gt;0.05).</p> <p>The most commonly reported adverse events in patients receiving risperidone therapy were somnolence (42 to 56%), headache (38 to 40%), and fatigue (18 to 30%). Somnolence and fatigue were noted to be dose-dependent adverse events.</p> <p>The incidence of EPS adverse events was comparable between placebo and risperidone 0.5 to 2.5 mg group (5 and 8%, respectively); though, it was higher in the risperidone 3 to 6 mg group (25%).</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>Mean weight gain was 0.7 kg, 1.9 kg and 1.4 kg in the placebo, risperidone 0.5 to 2.5 mg, and risperidone 3 to 6 mg groups, respectively. The following percentages of patients had gained at least 7% of their baseline weight at study endpoint: 5.3% (placebo), 14.3% (risperidone 0.5 to 2.5 mg), and 10% (risperidone 3 to 6 mg), respectively.</p>
<p>Biederman et al<sup>109</sup></p> <p>Risperidone 0.25 mg/day to 2.0 mg/day</p> <p>vs</p> <p>olanzapine 1.25 mg/day to 10 mg/day</p>	<p>OL</p> <p>Children, aged 4 to 6 years, with bipolar I and bipolar disorder II</p>	<p>N=31</p> <p>8 weeks</p>	<p>Primary: YMRS (Young Mania Rating Scale) and CGI-I (Clinical Global Impression-Improvement) mania scales</p> <p>Secondary: CDRS (Children's Depression Rating Scale) and BPRS (Brief Psychiatric Rating Scale) at baseline, week 4, week 8 or study end point</p>	<p>Primary: Both groups experienced clinical improvement and statistically significant improvement from baseline (P&lt;0.05).</p> <p>No statistically significant difference between the treatments was seen. (P value not reported.)</p> <p>Secondary: Risperidone group had statistically significant improvement in depression as compared to olanzapine (P&lt;0.01)</p> <p>All lab values were similar between treatment groups with the exception of prolactin levels, which were statistically significantly higher for risperidone (P=0.009).</p> <p>Systolic blood pressure significantly increased from baseline in the risperidone group (P&lt;0.05). Both groups experienced significant weight gain as compared to baseline (P&lt;0.05).</p>
<p>Pavuluri et al<sup>110</sup></p> <p>Risperidone 0.5 to 2 mg daily</p> <p>vs</p> <p>divalproex, dose was titrated up to serum level of 60 to 120 mcg/ml</p>	<p>DB, RCT</p> <p>Children and adolescents, aged 8 to 18 years, with bipolar disorder I, medication-free or unstable on current medication</p>	<p>N=66</p> <p>6 weeks</p>	<p>Primary: Change from baseline in YMRS</p> <p>Secondary: Change from baseline in CDRS-R, CGIS-BP, Overt Aggression Scale (OAS), BPRS-C, response rate</p>	<p>Primary: Risperidone and divalproex therapies were both associated with a statistically significant reduction (-3.27 and -2.89, respectively) in the YMRS baseline scores at study endpoint (P&lt;0.01).</p> <p>A mixed-effects regression analysis, evaluated by active drug and time, demonstrated more rapid improvement in YMRS scores from baseline in the risperidone-treated group compared to patients receiving divalproex (P=0.01). However, final YMRS scores did not significantly differ between treatment groups (P value not reported).</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
			<p>(≥50% improvement on the YMRS), remission rate (YMRS score of ≤12 and CDRS-R score of &lt;28), adverse events</p>	<p>Secondary: Risperidone therapy was associated with statistically significant reductions in baseline CDRS-R, CGI-BP, BPRS-C, OAS-irritability, OAS-aggression, and CMRS-P scores (P&lt;0.01). OAS-suicidality was the only secondary endpoint that wasn't significantly improved from baseline at study endpoint (P&gt;0.05).</p> <p>Divalproex therapy was associated with statistically significant reductions in baseline CGI-BP, OAS-irritability, OAS-aggression, and CMRS-P scores (P&lt;0.01). In contrast, OAS-suicidality, CDRS-R, and BPRS-C scores were not significantly improved from baseline at study endpoint (P&gt;0.05).</p> <p>Reduction from baseline in CDRS-R scores was significantly greater among patients receiving risperidone compared to divalproex (P&lt;0.05).</p> <p>The response rates were 78.1% and 45.5% in risperidone and divalproex groups, respectively (P&lt;0.01).</p> <p>The remission rates were 62.5% and 33.3% in risperidone and divalproex groups, respectively (P&lt;0.05).</p> <p>At study endpoint, there were significantly more patients continuing risperidone therapy compared to the divalproex group (25 vs 17; P&lt;0.05).</p> <p>There were no statistically significant differences between the groups in weight gain, weight gain over 7% if baseline body weight, ECG changes, liver function tests, EPS, or thyroid function tests (P value not reported). Prolactin level was significantly elevated in patients receiving risperidone compared to the divalproex group (P&lt;0.05).</p>
<p>Biederman et al<sup>111</sup>  Ziprasidone 1 mg/kg titrated up to 2 mg/kg by week-3 and up to</p>	<p>OL, PRO  Children and adolescents,</p>	<p>N=21  8 weeks</p>	<p>Primary: Change from baseline in YMRS, BPRS, and CDRS-</p>	<p>Primary: Starting at week one through study endpoint, patients receiving ziprasidone exhibited a statistically significant reduction from baseline in the YMRS scores (P&lt;0.001).</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
the maximum daily dose of 80 mg twice daily	aged 6 to 17 years, with bipolar I disorder or bipolar disorder not otherwise specified (NOS), with a YMRS score of $\geq 15$		R scores, adverse events  Secondary: Not reported	<p>At week eight, 57% of patients had a 30% reduction in baseline YMRS scores, while 33% of patients experienced a 50% reduction in baseline YMRS scores.</p> <p>Of the patients with baseline symptoms of either depression or ADHD, 50% and 33%, respectively, exhibited improved symptoms.</p> <p>At week eight, patients receiving ziprasidone exhibited a statistically significant reduction from baseline in the BPRS-mania symptom scores (<math>P &lt; 0.02</math>).</p> <p>At week eight, patients receiving ziprasidone exhibited a statistically significant reduction from baseline in the BPRS-positive symptom scores (<math>P &lt; 0.02</math>).</p> <p>There were no statistically significant changes from baseline in the BPRS- negative symptom and psychological discomfort scores among patients receiving ziprasidone (<math>P = 0.1</math>).</p> <p>At week eight, patients receiving ziprasidone exhibited a statistically significant reduction from baseline in the CDRS-R scores (<math>P &lt; 0.02</math>).</p> <p>Ziprasidone therapy was not associated with a statistically significant weight gain (0.6 kg; <math>P = 0.2</math>) or QTc interval change (-3.7; <math>P = 0.5</math>) from baseline.</p> <p>Secondary: Not reported</p>
<b>Conduct Disorders/Disruptive Behavior Disorders (including aggression)</b>				
Ercan et al <sup>112</sup>  Aripiprazole 2.5 mg up to 10 mg daily	OL  Children and adolescents, aged 6 to 16	N=20  8 weeks	Primary: Change from baseline in Clinical Global Impressions-	Primary: The majority of patients (63.1%) receiving aripiprazole therapy were classified as treatment responders based on improvement on the CGI global improvement subscale (P value not reported).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
	years, with a conduct disorder		Severity and Improvement (CGI-S/CGI-S) scale, Turgay DSM-IV based child and adolescent behavior disorders screening and rating scale (T-DSM-IV), Child Behavior Checklist (CBCL), Teachers Report Form (TRF)  Secondary: Not reported	Risperidone therapy was associated with significant improvements from baseline in the following endpoints: inattention, hyperactivity/impulsivity, oppositional defiant disorder (ODD) and conduct disorder subscales of the T-DSM-IV (P value not reported). Aggression subscale on the CBCL and TRF also improved from baseline (P value not reported).  Secondary: Not reported
Findling et al <sup>113</sup>  Aripiprazole dosed based on patient weight (<25 kg: 1 mg/day; 25-50 kg: 2 mg/day; >50-70 kg: 5 mg/day; >70 kg: 10 mg/day)	OL, MC  Children and adolescents, aged 6 to 12 years, with conduct disorder, with or without comorbid ADHD	N=23  15 days (36 month extension)	Primary: Rapid Assessment and Action Planning Process (RAAPP), CGI-I, adverse events, pharmacokinetic data	Primary: RAAPP scores decreased from baseline by -1.00 and by -0.75 in children and adolescents, respectively, at month-36 of therapy (P value not reported).  By day-14, 63.6% and 45.5% of children and adolescents, respectively, were rated as much or very much improved on the CGI-I score. At month-36, 66.7% and 100% of children and adolescents, respectively, exhibited this level of improvement (P value not reported).  Serious adverse events were not reported. In addition, no one discontinued from the study due to adverse events.  At week-72, mean weight gain from baseline was 9 kg among children and 13.3 kg among adolescents (P value not reported).  Aripiprazole pharmacokinetics in children and adolescents are demonstrated to be linear and comparable with those in adults.

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
<p>Bastiaens et al<sup>114</sup></p> <p>Aripiprazole 2.5 mg daily (&lt;12 years of age) or 5 mg daily (12 years and older) titrated up</p> <p>vs</p> <p>ziprasidone 20 mg daily (&lt;12 years of age) or 40 mg daily (12 years and older) titrated up</p>	<p>OL</p> <p>Children and adolescents, aged 6 to 18 years, with clinically significant aggression</p>	<p>N=46</p> <p>2 months</p>	<p>Primary: Change from baseline in Overt Aggression Scale (OAS) scores</p> <p>Secondary: Parent Young Mania Rating Scale (PYMRS), Health and Life Functioning Scale (HALFS), Global Assessment of Functioning Scale (GAF), Clinical Global Impression-Improvement Scale (CGI), adverse events</p>	<p>Secondary: Not reported</p> <p>Primary: After two months of therapy, both treatment groups experienced a statistically significant improvement in OAS scores from baseline (P&lt;0.005). There was no statistically significant difference between treatment groups in the degree of OAS improvement (P=0.52). Aripiprazole- and ziprasidone-treated groups experienced a greater than 50% reduction in the OAS (70 and 71%, respectively).</p> <p>Secondary: After two months of therapy, both treatment groups experienced a statistically significant improvement in PYMRS scores from baseline (P&lt;0.005). There was no statistically significant difference between treatment groups in the degree of PYMRS improvement (P=0.78).</p> <p>After two months of therapy, aripiprazole group experienced a statistically significant improvement in HALFS scores from baseline (P=0.0013). Ziprasidone-treated patients also experienced an improvement in HALFS scores; however the change was not statistically significant. Never-the-less, there was no statistically significant difference between treatment groups in HALFS improvement from baseline after 2 months of therapy (P=0.43). As is indicated by the improvement in HALFS scores, quality of life improved by 41% in the treatment groups, combined.</p> <p>The CGI was rated as much improved in both treatment groups and there was no statistically significant difference between groups (P=0.68).</p> <p>After two months of therapy, both treatment groups experienced a statistically significant improvement in GAF scores from baseline (P&lt;0.005). There was no statistically significant difference between treatment groups in the degree of GAF improvement (P=0.42).</p> <p>Sedation was the most frequently reported side-effect in both groups,</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				followed by dizziness, nausea and headaches. The incidence of these side-effects was comparable between groups. EPS side effects were reported by two patients receiving aripiprazole and none in the ziprasidone group. Agitation was reported by two patients receiving ziprasidone and none in the aripiprazole group.
<p>Masi et al<sup>115</sup></p> <p>Olanzapine 5 mg to 20 mg daily</p> <p>Note: all patients were involved in psychotherapy, family therapy, or day-hospital group treatments.</p>	<p>RETRO</p> <p>Adolescents, aged 11 to 17.2 years, diagnosed with conduct disorder, treated with olanzapine, who had failed adequate doses of mood stabilizers (lithium or valproate)</p>	<p>N=23</p> <p>6 to 12 months</p>	<p>Primary: Modified Overt Aggression Scale (MOAS), CGI-I, Children Global Assessment Scale (CGAS), response rate (defined as an improvement of <math>\geq</math> 50% at MOAS and a score of 1 or 2 at CGI-I), weight gain</p> <p>Secondary: Not reported</p>	<p>Primary: At the end of follow-up period, 60.9% of patients were classified as responders.</p> <p>Patients were noted to have had a statistically significant improvement from baseline in MOAS scores (P&lt;0.001).</p> <p>Patients were noted to have had a statistically significant improvement from baseline in CGAS scores (P&lt;0.001).</p> <p>At the end of follow-up, mean weight gain among patients receiving olanzapine was 4.6 kg.</p> <p>Secondary: Not reported</p>
<p>Khan et al<sup>116</sup></p> <p>Olanzapine IM 5 to 10 mg daily, on average</p> <p>vs</p> <p>ziprasidone 20 mg daily, on average</p>	<p>NAT, RETRO</p> <p>Children and adolescents under 18 years of age, hospitalized for any mental illness and requiring an IM antipsychotic for acute agitation or aggression</p>	<p>N=100</p> <p>Study duration not reported</p>	<p>Primary: Mean length of stay, mean number of days on study agent, mean number of aggressive episodes, mean number of doses of emergency medication, mean number of doses of study agent, mean number of restraints, mean</p>	<p>Primary: There were no statistically significant differences between groups in the mean length of stay, mean number of days on study agent, mean number of aggressive episodes and the mean number of doses of study agent (P&gt;0.05).</p> <p>Ziprasidone therapy was associated with significantly more doses of emergency medication for acute aggression or agitation during their hospitalization compared to olanzapine (P=0.009).</p> <p>Ziprasidone-treated patients received significantly more IM injections of ziprasidone in combination with lorazepam or antihistaminic agents compared to patients in the olanzapine study group (P&lt;0.05).</p> <p>There was no statistically significant difference between treatment</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
			time in restraint, adverse events  Secondary: Not reported	groups in either the mean number of restraints or the mean time in restraint (P>0.05).  Somnolence was the most frequently reported adverse event in both ziprasidone and olanzapine treatment groups (16 and 20%, respectively). There were no clinically significant treatment-related adverse events in either of the two groups.
Kronenberger et al <sup>117</sup>  Quetiapine 50 to 300 mg twice daily, in addition to methylphenidate OROS 54 mg daily for 9 weeks (following treatment failure on a 3-week course of methylphenidate OROS monotherapy)	OL, PRO  Adolescents, aged 12 to 16 years, diagnosed with ADHD-combined type and disruptive behavior disorder, exhibiting aggressive or destructive conduct with at least 3 outbursts per month involving destruction of property, verbal aggression, or physical aggression during the past 2 months, and failure on methylphenidate OROS	N=24  13 weeks	Primary: Rating of Aggression Against People and Property (RAAP)  Secondary: Modified Overt Aggression Scale (MOAS), CGI-S, ADHD Rating Scale-IV-Parent Version (ADHD-RS-I), SNAP-IV, adverse events	Primary: RAAP scores were significantly improved during the methylphenidate OROS phase of the study (P<0.001) and were further significantly improved following combination therapy with quetiapine (P<0.001).  During the nine weeks of combined quetiapine and methylphenidate OROS therapy RAAP scores were improved in 75% of patients from the three week period when patients receiving methylphenidate OROS monotherapy.  Secondary: MOAS scores were significantly improved during the methylphenidate OROS phase of the study (P<0.001) and were further significantly improved following combination therapy with quetiapine (P<0.01).  SNAP-ODD scores were significantly improved during the methylphenidate OROS phase of the study (P<0.001) and were further significantly improved following combination therapy with quetiapine (P<0.01).  CGI-S scores were significantly improved during the methylphenidate OROS phase of the study (P<0.001) and were further significantly improved following combination therapy with quetiapine (P<0.001).  ADHD-RS scores were significantly improved during the methylphenidate OROS phase of the study (P<0.001) and were further significantly improved following combination therapy with quetiapine (P<0.001).



Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
	monotherapy			<p>SNAP-ADHD scores were significantly improved during the methylphenidate OROS phase of the study (P&lt;0.001) and were further significantly improved following combination therapy with quetiapine (P&lt;0.01).</p> <p>The only side effects reported at a significantly greater incidence during quetiapine administration than the methylphenidate OROS monotherapy phase were weight gain and increase in BMI (P&lt;0.05). No EPS adverse events were reported.</p>
<p>Connor et al<sup>118</sup></p> <p>Quetiapine 100 to 300 mg twice daily</p> <p>vs</p> <p>placebo</p>	<p>DB, PC, RCT</p> <p>Adolescents, aged 12 to 17, with a primary diagnosis of conduct disorder and exhibiting a moderate-to-severe degree of aggressive behavior, as documented by OAS score of <math>\geq 25</math> and CGI-S score <math>\geq 4</math></p>	<p>N=19</p> <p>7 weeks</p>	<p>Primary: CGI-S, CGI-I</p> <p>Secondary: Parent-assessed Q-LES-Q quality of life, Overt Aggression Scale (OAS), conduct problems subscale of the Conners' Parent Rating Scale (CPRS-CP)</p>	<p>Primary: Quetiapine-treated patients experienced a statistically significant improvement in CGI-S scores from baseline, compared to placebo-treated patients (P&lt;0.05).</p> <p>Quetiapine-treated patients experienced a statistically significant improvement in CGI-I scores from baseline, compared to placebo-treated patients (P=0.0006).</p> <p>Secondary: Quetiapine-treated patients were associated with a statistically significant improvement in Q-LES-Q quality of life scores from baseline, compared to placebo-treated patients (P=0.005).</p> <p>There were no statistically significant differences between groups in the change in OAS scores from baseline (P value not reported).</p> <p>There were no statistically significant differences between groups in the change in CPRS-CP scores from baseline (P value not reported).</p> <p>The only adverse events which were reported at a significantly greater frequency in the quetiapine group compared to placebo were decreased mental alertness, diminished emotional expression, and diminished facial expression (P&lt;0.05).</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>Weight gain of 2.3 kg was observed in the quetiapine group compared to a weight gain of 1.1 kg in patients receiving placebo (P=0.46). No significant differences in prolactin level was observed between groups (P=0.71).</p>
<p>Ercan et al<sup>119</sup></p> <p>Risperidone 0.125 mg (&lt;20 kg weight) or 0.25 mg daily (&gt;20 kg weight) initially up to a maximum of 1.50 mg daily</p>	<p>OL, PRO</p> <p>Preschool-aged children, 29 to 72 months of age, with conduct disorder and comorbid ADHD</p>	<p>N=8</p> <p>8 weeks</p>	<p>Primary: Change from baseline in CGI-I, CGI-S, T-DSM-IV-S, response (defined as 30% reduction on the T-DSM-IV-S or CGI-I score of <math>\leq 2</math>), adverse events</p> <p>Secondary: Not reported</p>	<p>Primary: Risperidone therapy was associated with a 78% reduction in CGI-S scores from baseline (P&lt;0.001) at week-8 of therapy. Statistically significant improvement was also seen at week four of the study (P&lt;0.001). All the children exhibited clinically significant improvements in CGI-S scores (much improved or very much improved) from baseline.</p> <p>At week eight, risperidone therapy was associated with a statistically significant reduction in CGI-I scores from baseline (P=0.002).</p> <p>The T-DSM-IV-S scores were significantly improved from baseline by 37.8 and 40.8 on both parental and clinical forms, respectively (P<math>\leq</math>0.001).</p> <p>All the patients were classified as responders, on both the CGI and T-DSM-IV scales.</p> <p>There was no statistically or clinically significant weight gain among children receiving risperidone therapy. The mean weight gain from baseline was 0.3 kg (P=0.061). There was a significant seven-fold increase in prolactin levels from baseline among risperidone-treated patients (P&lt;0.05).</p> <p>Except for one child who accidentally received a high dose, risperidone therapy was not associated with neurological side effects or EPS.</p> <p>Secondary: Not reported</p>
<p>Caldwell et al<sup>120</sup></p> <p>Risperidone 1 to 2.5 mg daily,</p>	<p>RETRO</p> <p>Adolescent,</p>	<p>N=129</p> <p>14-day</p>	<p>Primary: The Mendota Juvenile Treatment</p>	<p>Primary: Risperidone-treated group exhibited a statistically significant improvement from baseline in the MJTC behavioral assessment</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
<p>on average, in addition to cognitive behavioral therapy</p> <p>vs</p> <p>control (group prescribed other forms of pharmacotherapy)</p>	<p>boys who were delinquent and incarcerated, mean age of 16 years, admitted to a juvenile treatment center, diagnosed with childhood onset and persistent conduct disorder</p>	<p>treatment; 21-day baseline period</p>	<p>Center (MJTC) behavioral assessment</p> <p>Secondary: Weight gain</p>	<p>measure (effect size, 0.44; P&lt;0.0005).</p> <p>Risperidone-treated patients experienced an improvement in behavioral scores of 9.1%, on average, compared to 1.1% deterioration among patients receiving psychosocial therapy only.</p> <p>Secondary: The average weight gain among patients receiving risperidone therapy for an average of nine months was 15 lbs.</p>
<p>Croonenbergs et al<sup>121</sup></p> <p>Risperidone oral solution, 0.01 mg/kg/day to 0.02 mg/kg/day initially, titrated up to 0.06 mg/kg/day</p>	<p>MC, OL</p> <p>Children and adolescents 5 to 14 years of age, diagnosed with conduct disorder, oppositional defiant disorder or disruptive behavior disorder not otherwise specified, had a score of ≥24 on the Conduct Problem Subscale of the Nisonger Child Behavior Rating</p>	<p>N=504</p> <p>1 year</p>	<p>Primary: Change from baseline in Conduct Problem Subscale of the Nisonger Child Behavior Rating Form (N-CBRF)</p> <p>Secondary: Change from baseline in the other N-CBRF subscales, CGI Scale, Aberrant Behavior Checklist total and subscale scores, visual analog scale, cognition, adverse</p>	<p>Primary: Patients exhibited a 48% reduction from baseline in the mean N-CBRF conduct problem score at study endpoint (-15.8; P &lt;.001). Improvements were seen as early as weeks one through four, and the improvements were maintained during the subsequent 11 months.</p> <p>Secondary: Risperidone therapy was associated with significant improvements from baseline in the positive social behavior and problem behavior N-CBRF subscales (P&lt;0.001). Compliant/calm and adaptive/social both increased significantly from baseline (P&lt;0.001). Insecure/anxious, hyperactive, self-injury/stereotypic, self-isolated/ritualistic, and overly sensitive N-CBRF subscale scores decreased significantly from baseline (P&lt;0.001).</p> <p>Risperidone therapy was associated with a statistically significant improvement from baseline in the Mean Aberrant Behavior Checklist total scores (P&lt;0.001).</p> <p>Risperidone therapy was associated with a statistically significant improvement from baseline in CGI scores (P&lt;0.001).</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
	Form (N-CBRF) and mild-moderate mental retardation or borderline intellectual functioning, and a Vineland Adaptive Behavior Scale score of $\leq 84$		events	<p>Risperidone therapy was associated with a statistically significant improvement in tests of patients' cognitive function (<math>P &lt; 0.001</math>).</p> <p>At baseline, the most troublesome symptoms were aggression in 33% of patients, oppositional defiant behavior in 30%, and hyperactivity in 16%. The visual analog scale scores of the most troublesome symptom were significantly reduced by 40.3 (<math>P &lt; 0.001</math>).</p> <p>The most commonly reported adverse events were somnolence (30%), rhinitis (27%), and headache (22%). Adverse events leading to discontinuation of risperidone were weight gain (nine patients), increased appetite (four patients), gynecomastia (three patients), somnolence (three patients), and headache (three patients).</p> <p>The mean ESRS total score decreased by 0.3 from baseline at study endpoint (<math>P = .024</math>).</p> <p>Mean body weight by 7.0 kg from baseline; however, 50% of this weight gain was attributed to developmentally expected growth. Weight gain was greatest in the first six months of therapy, with little change between six and 12 months.</p>
<p>Reyes et al<sup>122</sup></p> <p>Risperidone oral solution, 1 to 3 mg daily (most patients)</p>	<p>ES, MC, OL</p> <p>Children and adolescents, aged 6 to 16 years with disruptive behavior disorder and subaverage intelligence, who had completed the original 1-</p>	<p>N=35</p> <p>2 years (total exposure to risperidone was 3 years)</p>	<p>Primary: CGI-S scores, adverse events</p> <p>Secondary: Not reported</p>	<p>Primary:</p> <p>The improvement in CGI-S scores observed at the end of the first year of therapy (original study) was maintained during the two-year extension study. At the end of the two-year extension study, 62% of patients had symptom ratings from not ill to mild severity, 20.6% were rated as moderately severe, 14.7% had a rating of marked, and only 2.9% of patients had a rating of severe.</p> <p>Mean ESRS scores were low throughout the study and most patients scored a zero on the total ESRS at each time point. There were no reports of tardive dyskinesia.</p> <p>During the two year extension, adverse events occurred more frequently</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
	year, open-label study by Croonenbergs et al			<p>during the first year of the extension, with the exception of headache, weight gain, somnolence, epistaxis, eosinophilia, and condition aggravated. There were no reports of adverse cognitive effects. Mean increases in weight and BMI were greatest during the first year of risperidone treatment, with measures stable during the two year extension.</p> <p>Secondary: Not reported</p>
<p>Pandina et al<sup>123</sup></p> <p>Risperidone 0.25 to 0.75 mg daily (&lt;50 kg) or 0.5 to 1.5 mg daily (≥50 kg)</p> <p>vs</p> <p>placebo</p>	<p>DB, I, MC, PC, RCT</p> <p>Children and adolescents, aged 5 to 17, without moderate or severe intellectual impairment (IQ≥54) with a disruptive behavior disorder</p>	<p>N=284</p> <p>6 months (6 weeks OL, 6 weeks single-blind, 6 months DB)</p>	<p>Primary: Continuous Performance Test (CPT), modified version of Verbal Learning Test-Children's Version (MVLTC)</p> <p>Secondary: Not reported</p>	<p>Primary: Statistically significant improvements from baseline were noted in risperidone-treated patients for CPT hard hit rates and discrimination ability (P&lt;0.05).</p> <p>Statistically significant improvements from baseline were noted in placebo-treated patients for CPT easy false alarms rates and hard hit rates and discrimination ability (P&lt;0.05). The easy and hard CPTs correct mean response time worsened with placebo compared to baseline.</p> <p>Compared to baseline, the MBLT-C short-delay free recall improved significantly in both risperidone-treated and placebo-treated groups (P&lt;0.05).</p> <p>After performing a multivariable analysis, no significant differences between risperidone and placebo were found in terms of cognition (P value not reported).</p> <p>Secondary: Not reported.</p>
<p>Reyes et al<sup>124</sup></p> <p>Risperidone oral solution, 0.50 mg once daily up to 0.75 mg daily (&lt;50 kg) or up to 1.5 mg</p>	<p>DB, I, MC, PC, RCT</p> <p>Children and adolescents,</p>	<p>N=335</p> <p>6 months</p> <p>6 weeks of OL</p>	<p>Primary: Time to symptom recurrence (defined as sustained deterioration</p>	<p>Primary: Time to symptom recurrence was significantly shorter with placebo compared to maintenance risperidone therapy (P&lt;0.001).</p> <p>Symptom recurrence occurred in 25% of patients after 119 days with</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
<p>daily (≥50 kg) vs placebo once daily</p> <p>Note: responders from the acute treatment phase entered into the continuation treatment phase</p>	<p>aged 5 to 17 years, without moderate or severe intellectual impairment (IQ ≥55), diagnosed with conduct disorder, oppositional defiant disorder, or disruptive behavior disorder not otherwise specified</p>	<p>risperidone (acute treatment); 6 weeks of single-blind risperidone (continuation treatment); 6 months of double-blind risperidone (maintenance)</p>	<p>on either the CGIS rating or the conduct problem subscale of the Nisonger Child Behavior Rating Form (NCBRS)</p> <p>Secondary: Rates of discontinuation due to symptom recurrence, disruptive behavior disorder symptoms, and general function, NCBRS, adverse events</p>	<p>risperidone and 37 days with placebo. Six-month Kaplan-Meier symptom recurrence estimates were 29.7% for risperidone and 47.1% for placebo. The hazard ratio for symptom recurrence was 2.24 (95% CI, 1.54 to 3.28) times higher after switching to placebo compared to continuing risperidone therapy.</p> <p>Secondary: Risperidone therapy was associated with a significantly lower rate of symptoms recurrence compared to placebo at the end of the maintenance period (27.3 vs 42.3%; P=0.002).</p> <p>At the end of the maintenance period, patients randomized to placebo, after receiving risperidone during the acute treatment phase experienced significantly greater deterioration in conduct problem scores compared to the risperidone treatment group (P&lt;0.001).</p> <p>Compared to placebo, patients receiving risperidone during the maintenance phase experienced statistically significant improvements in most NCBRS subscales (all except for the insecure/anxious, self-injury/stereotypic behavior, self-isolated/ritualistic, and overly sensitive subscales), the most troublesome symptom visual analogue subscales (aggression and oppositional defiant behavior), and the global measurements (CGI severity and Children’s Global Assessment Scale) (P≤0.01)</p> <p>Treatment-related adverse events were more frequently observed during acute treatment (54.8%) compared to the continuation phase (34.9%) and maintenance phase (47.7% with risperidone vs 36.2% with placebo).</p> <p>The most frequently reported treatment-related adverse events were headache, somnolence, fatigue, and increased appetite.</p> <p>Patients experienced a mean weight gain of 3.2 kg from study onset to the end of the continuation phase. Subsequently, risperidone-treated</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>patients experienced an additional weight gain of 2.1 kg, while placebo-treated patients exhibited a decrease in mean weight of 0.2 kg.</p> <p>There was no clinically significant change in mean fasting glucose levels during treatment (P value not reported).</p> <p>The only clinically significant change from baseline in lab values was an increase in prolactin level observed with risperidone use (P value not reported).</p> <p>The incidence of EPS adverse events was 1.7% in the risperidone group and 0.6% in the placebo group (P value not reported).</p>
<p>Haas et al<sup>125</sup></p> <p>Risperidone oral solution, 0.25 to 0.75 mg daily (&lt;50 kg) or 0.5 to 1.5 mg daily (≥50 kg)</p>	<p>OL, ES</p> <p>Children and adolescents, aged 5 to 17 years, without moderate or severe intellectual impairment, with disruptive behavior disorder, who had either successfully completed or experienced symptom recurrence during the DB study by Reyes</p>	<p>N=232</p> <p>1 year</p>	<p>Primary: Change in N-CBRF, CGI-S, Visual Analog Scale for the Most Troublesome Symptom (VAS-MS), CGAS, adverse events</p> <p>Secondary: Not reported</p>	<p>Primary:</p> <p>At one year of the open-label extension phase, both patients who had previously been randomized to placebo and those who had previously received risperidone experienced similar improvement in scores on the N-CBRF Conduct Problem Subscale, despite higher baseline values among patients previously receiving placebo (P value not reported).</p> <p>At one year of the open-label extension phase, patients who had experienced symptoms recurrence achieved greater improvement from baseline in scores on the N-CBRF Conduct Problem Subscale than patients who were not experiencing symptom recurrence during the double-blind study phase. The improvement was comparable between patients previously treated with risperidone and placebo (P value not reported).</p> <p>At one of the open-label extension phase, patients experienced improvements in the following efficacy measures: other N-CBRF subscales (with the exception of self-injury/stereotyped and self-isolated/ritualistic), CGI-S, VAS-MS, and CGAS (P value not reported).</p> <p>At one year of the open-label extension phase, improvements in N-</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
	et al <sup>135</sup>			<p>CBRF subscales, VAS-MS, and CGI-S scores were comparable in patients who previously receiving risperidone and those who previously received placebo.</p> <p>Patients had a weight gain of 4.3 kg over the course of the follow-up period. The expected normal weight gain for children between the ages of six and 12 is 3 to 3.5 kg per year.</p> <p>Weight gain and EPS side effects were reported in 4.3% of patients. There were no reports of tardive dyskinesia.</p> <p>Risperidone therapy was associated with increase in prolactin levels, though this effect decreased with prolonged use and was not commonly associated with adverse events.</p> <p>Secondary: Not reported</p>
<p>Van Bellinghen et al<sup>126</sup></p> <p>Risperidone oral solution 0.01 to 0.04 mg/kg/day initially up to 0.09 mg/kg/day</p> <p>vs</p> <p>placebo</p>	<p>DB, PC, PG</p> <p>Children and adolescents, aged 6 to 18 years, with IQs between 45 and 85 indicating persistent behavioral disturbances (e.g., hostility, aggressiveness, irritability, agitation, or hyperactivity)</p>	<p>N=13</p> <p>4 weeks</p>	<p>Primary: Change from baseline in Aberrant Behavior Checklist (ABC) scores, Clinical Global Impression scores (CGI), Visual Analogue Scale (VAS), Personal Assessment Checklist (PAC), and adverse events</p> <p>Secondary: Not reported</p>	<p>Primary: Compared to baseline, risperidone was associated with a significantly reduced ABC cluster scores for irritation (P&lt;0.01), hyperactivity (P=0.001), and inappropriate speech (P&lt;0.05). Placebo group experienced a statistically significant reduction in lethargy from baseline (P&lt;0.05), but not the other ABC cluster scores.</p> <p>The risperidone-treated group exhibited significant reductions in ABC irritation (-10.8 vs 0.1; P&lt;0.05) and hyperactivity scores (-14.8 vs 1.0; P&lt;0.01) at endpoint, compared to placebo-treated patients.</p> <p>CGI scores were “very much improved” or “much improved” from baseline in five of the six risperidone-treated patients, whereas all placebo-treated patients were either “unchanged” or “minimally improved”.</p> <p>Risperidone therapy was associated with a statistically significant reduction in symptom VAS scores from baseline (P&lt;0.05). Significant</p>



Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>differences in VAS score were noted between risperidone and placebo treatment groups throughout the study, beginning from week two (P&lt;0.05).</p> <p>Compared to placebo, PAC scores were significantly improved from baseline in patients receiving risperidone in the following subscales: social relationship (P&lt;0.05) and occupational attitudes (P&lt;0.05); while there was a non-significant trend toward improvement in adaptation (P=0.066), temperament (P=0.051), and dominance (P=0.059).</p> <p>The onset of therapeutic action of risperidone was rapid. Significant differences between the two treatment groups were observed at week one for the ABC hyperactivity score (P&lt;0.05), at week two for the VAS score (P&lt;0.01) and CGI score (P&lt; 0.05).</p> <p>While there was a weight gain of 7% from baseline in two risperidone-treated patients, the mean weight change was not significantly different compared to patients receiving placebo (11.8 kg vs 10.6 kg; P=0.319).</p> <p>There were no statistically significant differences between risperidone and placebo in ESRS scores.</p> <p>Secondary: Not reported</p>
<p>Aman et al<sup>127</sup></p> <p>Risperidone solution 0.01 to 0.06 mg/kg/day</p> <p>vs</p> <p>placebo</p>	<p>MA</p> <p>Children, aged 5 to 12 years, with or without comorbid ADHD, below average IQ scores, with either conduct disorder or</p>	<p>N=223</p> <p>6 weeks</p>	<p>Primary: N-CBRF Conduct Problem subscale</p> <p>Secondary: N-CBRF social competence and problem behavior subscales, N-CBRF problem behavior</p>	<p>Primary: Risperidone-treated patients experienced a statistically significant improvement from baseline in the Conduct Problem subscale compared to placebo-treated patients (P&lt;0.001).</p> <p>Secondary: Risperidone-treated patients experienced the most statistically significant improvements from baseline, compared to placebo, in the following N-CBRF social competence measures: “accepted redirection”, “initiated positive interactions”, “been patient, able to delay”, “expressed ideas clearly”, “participated in group activities”, and “shared with or</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
	<p>oppositional defiant disorder, who had participated in either of two 6-week, R, DB, PC trials</p>		<p>subscales, adverse events</p>	<p>helped others” (P&lt;0.001).</p> <p>Risperidone-treated patients also experienced statistically significant improvements from baseline, compared to placebo, in the following N-CBRF social competence measures: “followed rules” and “stayed on-task” (P&lt;0.01).</p> <p>Risperidone-treated patients experienced the most statistically significant improvements from baseline, compared to placebo, in the following N-CBRF problem behavior measures: “nervous or tense”, “says no one likes him or her”, “secretive, keeps things to self”, and “talks too much or too loud” (P&lt;0.001).</p> <p>Risperidone-treated patients also experienced statistically significant improvements from baseline, compared to placebo, in the following N-CBRF problem behavior measures: “exaggerates abilities or achievements”, “feels others are against him/her”, “lying or cheating”, “steals”, “too fearful or anxious”, and “sulks, is silent or moody (P&lt;0.01).</p> <p>There were no statistically significant differences between the groups in the following N-CBRF problem behavior measures: “overly anxious to please people”, “self-conscious or easily embarrassed” and “worrying” (P&gt;0.05).</p> <p>On the Hyperactivity N-CBRF problem behavior subscale, risperidone was associated with greater improvement from baseline compared to placebo in the following measures: “overactive, doesn’t sit still”, “restless, high energy level” (P&lt;0.001), “easily distracted”, “fails to finish things he/she starts”, and “short attention span” (P&lt;0.01).</p> <p>On the Self-Injury/Stereotypic N-CBRF problem behavior subscale, risperidone was associated with greater improvement from baseline compared to placebo in the following measures: “physically harms/hurts self on purpose” (P&lt;0.01).</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>On the Self-Isolated/Ritualistic N-CBRF problem behavior subscale, risperidone was associated with greater improvement from baseline compared to placebo in the following measures: “isolates self from others”, “refuses to talk”, and “odd repetitive behavior” (P&lt;0.01). There was no statistically significant improvement from baseline between the groups in “disinterested or unmotivated”, “rituals”, and “shy/timid” behavior (P&gt;0.05).</p> <p>On the Overly Sensitive subscale, the only significantly improved items was “easily frustrated” (P&lt;0.001).</p> <p>“Sudden changes in mood” and “irritable” measures were also improved in the risperidone group compared to placebo (P&lt;0.01).</p> <p>Headache and somnolence were the most frequently reported adverse events.</p>
<p>LeBlanc et al<sup>128</sup></p> <p>Risperidone solution 0.01 to 0.06 mg/kg/day</p> <p>vs</p> <p>placebo</p>	<p>MA</p> <p>Boys, aged 5 to 12 years, with or without comorbid ADHD, below average IQ scores, with either conduct disorder or oppositional defiant disorder, who had participated in either of two 6-week, R, DB, PC trials</p>	<p>N=163</p> <p>6 weeks</p>	<p>Primary: Change from baseline in aggression score</p> <p>Secondary: Not reported</p>	<p>Primary: Compared to placebo, risperidone-treated patients experienced significantly greater mean decreases from baseline in the aggression score week one through week six of the study (P&lt;0.001).</p> <p>At week six, aggression among risperidone-treated patients was reduced by 56.4% from baseline compared to a 21.7% reduction observed in the placebo group (P value not reported).</p> <p>Secondary: Not reported</p>
<p>Biederman et al<sup>129</sup></p>	<p>PHA</p>	<p>N=110</p>	<p>Primary:</p>	<p>Primary:</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
Risperidone solution 0.01 to 0.06 mg/kg/day vs placebo	Children, aged 5 to 12 years, with or without comorbid ADHD, below average IQ scores, with either conduct disorder or oppositional defiant disorder, who had participated in a 6-week, R, DB, PC trial (included in MAS by Aman et al and LeBlanc et al)	6 weeks	Affective measures of the N-CBRF (explosive irritability; agitated, expensive, grandiose; and depression)  Secondary: Not reported	Risperidone therapy was associated with a statistically significant improvement in all three affective measures of the N-CBRF subscale compared to placebo (P<0.03). The magnitude of effect was greatest for the non-affective measures (ES, 0.95), followed by “agitated, expansive, grandiose” (ES, 0.74), “explosive irritability” (ES, 0.69) and finally “depression” (ES, 0.44).  Secondary: Not reported
Scott et al <sup>130</sup>  Ziprasidone 0.6 mg/kg to 1.8 mg/kg for 3 to 8 days	CS  Pediatric patients, aged 9 months to 17 years, who developed severe agitation and/or aggression secondary to traumatic brain injury	N=20  18 months	Primary: Change in Riker Sedation-Agitation Scale (SAS) scores from baseline  Secondary: Not reported	Primary: Patients experienced a statistically significant improvement in SAS scores from baseline 24 hours after ziprasidone initiation (P<0.001).  Secondary: Not reported
<b>Delirium</b>				
Turkel et al <sup>131</sup>	RETRO	N=110	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
<p>Atypical antipsychotics (olanzapine 3 mg to 10 mg daily, quetiapine 25 mg to 75 mg daily, risperidone 0.5 mg to 1 mg daily) for up to 132 days</p>	<p>Children and adolescents, aged 1 to 18 years, diagnosed with delirium and given an antipsychotic</p> <p>Note: drug induced, infection and neoplasm were the most common causes of delirium.</p>	<p>2 years</p>	<p>Delirium Rating Scale Revised-98 (DRS-R98) scores, adverse events</p> <p>Secondary: Not reported</p>	<p>Children receiving any of the three studied atypical antipsychotics experienced a significant improvement in DRS-R98 scores from baseline (P&lt;0.001).</p> <p>There was no statistically significant difference in the final DRS-R98 scores among any of the three medication groups (P=0.17). Neither did the final DRS-R98 scores differ between children and adolescent patients (P=0.796).</p> <p>Other than one case of dystonia, no adverse events were observed during the study.</p> <p>Secondary: Not reported</p>
<p><b>Major Depressive Disorder (MDD)-Treatment Resistant</b></p>				
<p>Pathak et al<sup>132</sup></p> <p>Quetiapine 150 mg to 800 mg daily, in addition to an antidepressant</p>	<p>CS</p> <p>Adolescents, aged 13 to 18 years, with treatment resistant MDD, defined as a failure to respond to an adequate dose for at least 8 weeks of a selective serotonin reuptake inhibitor (SSRI),</p>	<p>N=10</p> <p>4-16 weeks</p>	<p>Primary: Treatment response (final CGI-I of 1 or 2)</p> <p>Secondary Not reported</p>	<p>Primary: Treatment response, based on the CGI-I score, was achieved by 70% of patients.</p> <p>Sedation was observed in 40% of patients, which usually resolved in the first few weeks of therapy.</p> <p>Average weight gain was 4.5 lbs, but varied from 0 to 23 lbs.</p> <p>Secondary: Not reported</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
<p>Spielmanns et al<sup>278</sup></p> <p>Atypical antipsychotics used as adjunctive treatment (aripiprazole, olanzapine/ fluoxetine combination, quetiapine and risperidone)</p> <p>vs</p> <p>placebo</p>	<p>and treated with adjunctive quetiapine</p> <p>MA</p> <p>Patients with current MDD and an inadequate response to at least one course of antidepressant medication treatment</p>	<p>N=3,549</p> <p>Up to 12 weeks</p>	<p>Primary: Remission (MADRS score <math>\leq</math>8, HAM-D score <math>\leq</math>7 or MADRS score of <math>\leq</math>10), treatment response (<math>\geq</math>50% improvement from baseline in MADRS or HAM-D), quality of life and adverse events</p> <p>Secondary: Not reported</p>	<p>Primary: All four treatments significantly improved remission rates compared to placebo: aripiprazole (OR, 2.01; 95% CI, 1.48 to 2.73), olanzapine/ fluoxetine (OR, 1.42; 95% CI, 1.01 to 2.0), quetiapine (OR, 1.79; 95% CI, 1.33 to 2.42) and risperidone (OR, 2.37; 95% CI, 1.31 to 4.30). The NNT was nine for all treatments except olanzapine/fluoxetine, for which the NNT was 19.</p> <p>The odds of a treatment response were significantly higher with aripiprazole (OR, 2.07; 95% CI, 1.58 to 2.72), olanzapine/fluoxetine (OR, 1.30; 95% CI, 0.87 to 1.93), quetiapine (OR, 1.53; 95% CI, 1.17 to 2.0) and risperidone (OR, 1.83; 95% CI, 1.16 to 2.88) compared to placebo.</p> <p>On measures of functioning and quality of life, atypical antipsychotics produced either no benefit or a very small benefit, with the exception of risperidone, which had a small-to-moderate effect on quality of life.</p> <p>Treatment was associated with several adverse events, including akathisia (aripiprazole), sedation (quetiapine, olanzapine/fluoxetine and aripiprazole), abnormal metabolic laboratory results (quetiapine and olanzapine/fluoxetine), and weight gain (all four drugs, especially olanzapine/fluoxetine).</p> <p>Secondary: Not reported</p>
<b>Obsessive Compulsive Disorder (OCD)-Treatment Resistant</b>				
<p>Masi et al<sup>133</sup></p> <p>Aripiprazole at a mean dose of 12.2 mg daily, in addition to a SSRI</p>	<p>CS</p> <p>Adolescents, aged 12 to 18 years, with OCD which did not</p>	<p>N=39</p> <p>Duration not reported</p>	<p>Primary: Treatment response (defined as CGI-I of 1 or 2 and CGI-S of <math>\leq</math>3 during 3</p>	<p>Primary: CGI-S scores significantly improved from baseline in patients receiving adjunctive aripiprazole therapy (P&lt;0.0001).</p> <p>Treatment response was achieved by 59% of patients.</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
	respond to 2 initial trials of SSRIs monotherapy, with CGI-S of $\geq 4$ and CGAS of $\leq 60$		consecutive months), CGI-S, CGAS, adverse events  Secondary: Not reported	CGAS scores significantly improved from baseline in patients receiving adjunctive aripiprazole therapy ( $P < 0.0001$ ).  Out of 16 patients with comorbid Tourette or tic disorder, 62.5% exhibited an improvement in tic symptoms after aripiprazole initiation.  Only three patients had a weight gain between 2 and 5 kg. Mild transitory agitation (10.3%), mild sedation (10.3%), and sleep disorders (7.7%) were reported; however, none of the patients discontinued due to adverse events.  Secondary: Not reported
<b>Pervasive Developmental Disorders (PDD) including Autistic Disorder, Asperger's Disorder, or PDD not otherwise specified (NOS)</b>				
Masi et al <sup>134</sup>  Aripiprazole, average dose of 8.1 mg daily	NAT, RETRO  Children and adolescents, aged 4.5 to 15 years, diagnosed with PDD and a severe behavioral disorder, such as aggression against self and/or others, hostility, hyperactivity, and severe impulsiveness	N=34  4 to 12 months	Primary: CGI-I, Children's Global Assessment Scale (C-GAS), Childhood Autism Rating Scale (CARS)  Secondary: Not reported	Primary: On the CGI-I scale, 32.4% of patients were rated as "much improved" or "very much improved", 35.3% were "minimally improved", and 29.4% were "unchanged" or "worsened" from baseline.  Patients experienced a statistically significant improvement in C-GAS scores from baseline with aripiprazole therapy ( $P < 0.0001$ ).  Patients experienced a statistically significant improvement in CARS scores from baseline with aripiprazole therapy ( $P < 0.0001$ ).  Therapy discontinuation due to lack of efficacy or adverse events occurred in 35.3% of patients.  Secondary: Not reported
Stigler et al <sup>135</sup>	OL, PRO	N=25	Primary: CGI-I, ABC-	Primary: Aripiprazole therapy was associated with a statistically significant

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
Aripiprazole 2.5 to 15 mg daily	Children and adolescents, aged 5 to 17 years, diagnosed with PDD not otherwise specified and Asperger's Disorder	14 weeks	irritability, treatment response (defined as a CGI-I score of 1 or 2 and a >25% improvement on the ABC-I)  Secondary: Vineland Adaptive Behavior Scales (VABS), Compulsion Subscale of the Children's Yale-Brown Obsessive Compulsive Scale Modified for PDDs (CY-BOCS-PDD)	improvement in CGI-I scores from baseline (P=0.0001).  Aripiprazole therapy was associated with a statistically significant improvement in ABC-I scores from baseline (P=0.001).  Treatment response was achieved in 88% of patients.  Secondary: Aripiprazole therapy was associated with a statistically significant improvement in the socialization domain of VABS (P=0.0001), but not the communication, motor skills, or daily living skills domains (P>0.05).  VABS composite scores significantly improved from baseline among aripiprazole-treated patients (P=0.036).  Aripiprazole therapy was also associated with statistically significant improvements in the maladaptive domains of VABS (P=0.0001).  Aripiprazole therapy was associated with a statistically significant improvement in CY-BOCS-PDD scores from baseline (P=0.0001).  Aripiprazole therapy was not associated with statistically significant changes in blood pressure, heart rate, ECG, or EPS from baseline (P value not reported).  Aripiprazole was associated with a weight gain of 2.7 kg, on average, and an increase in BMI by 0.8 from baseline (P<0.04).
Marcus et al <sup>136</sup>  Aripiprazole 5 mg, 10 mg, or 15 mg daily  vs  placebo	DB, MC, PG, PC, RCT  Children and adolescents, aged 6 to 17 years, diagnosed with	N=218  8 weeks	Primary: Aberrant Behavior Checklist Irritability (ABC-Irritability) subscale  Secondary: CGI-I scores, other	Primary: Aripiprazole-treated patients, at 5 mg through 15 mg daily dose, exhibited a statistically significant improvement from baseline in the ABC-Irritability score, compared to placebo (-12.4 to -14.4 vs -8.4, respectively; P<0.05).  Secondary: All aripiprazole doses were associated with a statistically significant



Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
	<p>autism and behavioral problems, such as irritability, agitation, self-injurious behavior, or a combination of the above, mental age <math>\geq 18</math> months, CGI-S score <math>\geq 4</math> and ABC Irritability subscale score <math>\geq 18</math></p>		<p>ABC subtypes, CY-BOCS, adverse events</p>	<p>improvement from baseline in the mean CGI-I scores compared to placebo (<math>P &lt; 0.005</math>).</p> <p>Compared to placebo, aripiprazole 15 mg daily was associated with statistically significant improvements in the following ABC subscales: ABC stereotype, ABC Hyperactivity, and ABC Inappropriate Speech (<math>P \leq 0.05</math>).</p> <p>Compared to placebo, aripiprazole 5 mg and 10 mg daily doses were associated with statistically significant improvements in the following ABC subscales: ABC stereotype and ABC Hyperactivity (<math>P \leq 0.05</math>).</p> <p>ABC Lethargy/Social Withdrawal subscale was not significantly changed in any of the three aripiprazole dose groups, compared to placebo (<math>P &gt; 0.05</math>).</p> <p>Compared to placebo, significant improvements in CGI-S were seen in aripiprazole 10 mg and 15 mg groups (<math>P \leq 0.05</math>). A significant improvement in CY-BOCS was only seen in the aripiprazole 15 mg group (<math>P \leq 0.05</math>).</p> <p>At week-8, response rate was significantly greater in the aripiprazole 5 mg group, compared to placebo (55.8 vs 34.7%; <math>P = 0.34</math>). However, there were no significant differences in response rate between patients receiving placebo and aripiprazole 10 mg or 15 mg daily.</p> <p>The most common adverse events leading to discontinuation were sedation, drooling, and tremor. No one in the aripiprazole groups discontinued due to inadequate efficacy.</p> <p>EPS adverse events were reported in 11.8% of the placebo group and 22-23% of the aripiprazole group.</p> <p>Significantly more patients in the aripiprazole groups experienced weight gain compared to the placebo group (1.3-1.5 vs 0.3 kg; <math>P &lt; 0.05</math>).</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
<p>Owen et al<sup>137</sup></p> <p>Aripiprazole 5 mg, 10 mg, or 15 mg daily</p> <p>vs</p> <p>placebo</p>	<p>DB, MC, PG, PC, RCT</p> <p>Children and adolescents, aged 6 to 17 years, diagnosed with autism and behavioral problems, such as irritability, agitation, self-injurious behavior, or a combination of the above, mental age <math>\geq 18</math> months, CGI-S score <math>\geq 4</math> and ABC Irritability subscale score <math>\geq 18</math></p>	<p>N=98</p> <p>8 weeks</p>	<p>Primary: ABC-Irritability subscale</p> <p>Secondary: CGI-I, treatment response (reduction in ABC irritability score of <math>\geq 25\%</math>, CGI-I score <math>&lt; 2</math>), CGI-S, CY-BOCS, adverse events</p>	<p>Primary: At week eight, aripiprazole-treated patients experienced a significantly greater improvement from baseline in ABC-irritability scores compared to placebo (-12.9 vs -7.9; <math>P &lt; 0.001</math>). Statistically significant benefit over placebo was seen as early as week one.</p> <p>Secondary: At week eight, aripiprazole-treated patients experienced a significantly greater improvement from baseline in CGI-I scores compared to placebo (<math>P &lt; 0.001</math>), beginning at week one.</p> <p>At week eight, significantly more patients randomized to aripiprazole experienced a treatment response compared to placebo (52.2 vs 14.3%; <math>P &lt; 0.001</math>).</p> <p>At week eight, aripiprazole-treated patients experienced significantly greater improvements from baseline in the following ABC subtypes compared to placebo: ABC hyperactivity, ABC stereotypy, ABC inappropriate speech (<math>P &lt; 0.001</math>). There was no statistically significant difference between aripiprazole and placebo in the change in ABC lethargy/social withdrawal subscale (<math>P &gt; 0.05</math>).</p> <p>At week eight, aripiprazole-treated patients experienced a significantly greater improvement from baseline in CGI-S scores compared to placebo (<math>P &lt; 0.001</math>).</p> <p>At week eight, aripiprazole-treated patients experienced a significantly greater improvement from baseline in CY-BOCS scores compared to placebo (<math>P &lt; 0.001</math>).</p> <p>Aripiprazole was associated with significantly greater weight gain from baseline compared to placebo (2.0 vs 0.8 kg; <math>P &lt; 0.005</math>). In addition, significantly more patients exposed to aripiprazole experienced clinically significant weight gain compared to placebo-treated patients (28.9 vs 6.1%; <math>P &lt; 0.01</math>).</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>EPS adverse events occurred in 14.9 and 8% of patients treated with aripiprazole and placebo, respectively.</p> <p>Aripiprazole was associated with a significant decrease in prolactin level from baseline, compared to placebo (-6.3 vs 1.6 ng/ml; P&lt;0.001).</p>
<p>Aman et al<sup>138</sup></p> <p>Aripiprazole 5 mg, 10 mg, or 15 mg daily</p> <p>vs</p> <p>placebo</p>	<p>PHA (Marcus et al/Owen et al.)</p> <p>Children and adolescents, aged 6 to 17 years, diagnosed with autism and behavioral problems, such as irritability, agitation, self-injurious behavior, or a combination of the above, mental age ≥18 months, CGI-S score ≥4 and ABC Irritability subscale score ≥18</p>	<p>N=316</p> <p>8 weeks</p>	<p>Primary: Line-item analysis of the ABC-Irritability subscale, ABC social withdrawal, ABC stereotypic behavior, ABC hyperactivity subscale and ABC inappropriate speech subscale</p> <p>Secondary: Not reported</p>	<p>Primary: Aripiprazole therapy was associated with statistically significant improvements from baseline compared to placebo in the following ABC-Irritability subscale measures: “mood changes quickly”, “cries/screams inappropriately”, “stamps feet/bangs objects”, “temper tantrums”, “aggressive toward others”, “yells, demands must be met immediately”, “cries over minor hurts” (P&lt;0.05).</p> <p>There were no statistically significant differences between groups in the following ABC-Irritability subscale measures: “injures self”, “physical violence” (P&gt;0.05).</p> <p>Aripiprazole therapy was associated with a statistically significant improvement from baseline compared to placebo in only one ABC-Social Withdrawal subscale measure: “difficult to reach” (P&lt;0.05).</p> <p>Aripiprazole therapy was associated with statistically significant improvements from baseline compared to placebo in the following ABC-Stereotypic Behavior subscale measures: “repetitive hand, body, or head movements”, “odd, bizarre behavior” and “waves or shakes extremities” (P&lt;0.05).</p> <p>Aripiprazole therapy was associated with statistically significant improvements from baseline compared to placebo in the following ABC-Hyperactivity subscale measures: “boisterous, constantly runs or jumps”, “tends to be excessively active”, “acts without thinking”, “restless”, “unable to sit still”, “disobedient”, “difficult to control”, “disrupts group activities”, “does not stay in seat”, “easily distractible”, “deliberately ignores direction”, “pays no attention when spoken to” (P&lt;0.05).</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>Aripiprazole therapy was associated with a statistically significant improvement from baseline compared to placebo in only one ABC-Inappropriate Speech subscale measure: “talks excessively” (P&lt;0.05).</p> <p>Secondary: Not reported</p>
<p>Marcus et al<sup>139</sup></p> <p>Aripiprazole 2 to 15 mg daily</p>	<p>OL, ES, MC</p> <p>Children and adolescents, aged 6 to 17 years, diagnosed with autism and behavioral problems, such as irritability, agitation, self-injurious behavior, or a combination of the above, mental age <math>\geq</math>18 months, CGI-S score <math>\geq</math>4 and ABC Irritability subscale score <math>\geq</math>18</p> <p>ES of patients enrolled in studies by Marcus et al or Owen et al.</p>	<p>N=330</p> <p>52 weeks</p>	<p>Primary: Adverse events</p> <p>Secondary: Not reported</p>	<p>Primary: Commonly reported adverse events included weight gain, vomiting, nasopharyngitis, increased appetite, pyrexia, upper respiratory tract infection, and insomnia.</p> <p>Discontinuations due to adverse events occurred in 10.6% of patients. Most frequent adverse events leading to discontinuation were aggression and weight gain.</p> <p>EPS adverse events were noted in 14.5% of patients and included tremor (3%), psychomotor hyperactivity (2.7%), akathisia (2.4%), and non-tardive dyskinesia (2.4%).</p> <p>The following metabolic abnormalities were noted in association with &gt;9 month risperidone therapy: glucose (2%), total cholesterol (5%), low-density cholesterol (7%), high-density cholesterol (30%), and triglycerides (5%).</p> <p>Aripiprazole therapy was associated with a decrease in serum prolactin level. The mean weight gain from baseline was 6.3 kg.</p> <p>Secondary: Not reported</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
<p>Hollander et al<sup>140</sup></p> <p>Olanzapine 2.5 every other day to 2.5 mg once daily (&lt;40 kg) or 2.5 to 5 mg daily (≥40 kg) initially up to a maximum of 20 mg daily</p> <p>vs</p> <p>placebo</p>	<p>DB, PC, RCT</p> <p>Children and adolescents, aged 6 to 14 years, with PDD</p>	<p>N=11</p> <p>8 weeks</p>	<p>Primary: CGI-I</p> <p>Secondary: CY-BOCS, MOAS irritability and aggression subscales, adverse events</p>	<p>Primary: Olanzapine therapy was associated with significantly improved CGI-I scores compared to placebo, with a significant linear trend x group interaction (P=0.012).</p> <p>Response rates were 50% and 20% for olanzapine-treated and placebo-treated patients, respectively (P value not reported).</p> <p>Secondary: There were no statistically significant difference between the groups in the change from baseline in CY-BOCS, MOAS irritability or MOAS aggression scores (P&gt;0.05).</p> <p>While patients receiving olanzapine experienced a weight gain of 7.5 lbs, placebo-treated patients gained an average of 1.5 lbs from baseline (P=0.028). Gain of more than 7% of baseline weight occurred in 66.6% olanzapine-treated patients and in 20% of placebo-treated patients.</p>
<p>Corson et al<sup>141</sup></p> <p>Quetiapine 25 to 600 mg daily</p>	<p>RETRO</p> <p>Patients, 12.1 years of age on average, with PDD, and therapy with quetiapine for at least 4 weeks</p>	<p>N=20</p> <p>4-180 weeks</p>	<p>Primary: Change from baseline in CGI-S, CGI-I, treatment response (CGI-I score of 1 or 2), adverse events</p> <p>Secondary: Not reported</p>	<p>Primary: Patients experienced a statistically significant improvement in CGI-S scores from baseline (P=0.002).</p> <p>While 40% of patients met the criteria for response on the CGI-I scale, the mean CGI-I score reported in the study was only 3.0, corresponding with minimal improvement.</p> <p>Adverse events occurred in 50% of patients and led to drug discontinuation in 15% of patients. Patients gained 5.7 kg, on average, at the end of the study.</p> <p>Secondary: Not reported</p>
<p>Hardan et al<sup>142</sup></p> <p>Quetiapine 200 to 800 mg daily</p>	<p>RETRO</p> <p>Patients, 5 to 19 years of age,</p>	<p>N=10</p> <p>10-48 weeks</p>	<p>Primary: Conner's Parent Scale (CPS) conduct,</p>	<p>Primary: Patients experienced a statistically significant improvement from baseline in conduct (P≤0.05), inattention (P≤0.01), and hyperactivity CPS subscales (P≤0.01).</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
	with PDD, treated with quetiapine for at least 18 months, failure with psychosocial interventions and at least two psychoactive agents		inattention, hyperactivity, psychosomatic, learning, and anxiety subscales, adverse events  Secondary: Not reported	There were no statistically significant improvements from baseline in the following CPS endpoints: psychosomatic, learning, and anxiety (P>0.05).  An average weight gain of 2.2 lbs was noted.  Secondary: Not reported
Golubchik et al <sup>143</sup>  Quetiapine 50 to 150 mg daily (low dose)	OL  Adolescents, aged 13 to 17 years, with high-functioning Autistic Spectrum Disorder (ASD) who exhibited agitation and/or aggressive behavior	N=11  8 weeks	Primary: CGI-S, OAS, Child Sleep Habits Questionnaire (CSHQ), adverse events  Secondary: Not reported	Primary: Low-dose quetiapine was associated with a statistically insignificant improvement in CGI-S scores from baseline (P=0.08), suggesting a modest effect on ASD global behavioral symptoms.  Low-dose quetiapine was associated with a statistically significant reduction in aggressive behavior from baseline, as indicated by OAS (P=0.028).  Low-dose quetiapine was associated with significant reduction in sleep disturbances from baseline, as indicated by CSHQ (P=0.014).  Only three patients experienced mild adverse events. They were nausea, decrease in appetite and sedation. There was no significant weight gain compared to baseline (P=0.075).  Secondary: Not reported
Martin et al <sup>144</sup>  Quetiapine 100 to 350 mg daily	OL  Boys, aged 6.2 to 15.3 years, with autistic disorder	N=6  16 weeks	Primary: ABC-Irritability, CY-BOCS, CGI-I, response (defined as CGI scores of "improved" or "very much improved",	Primary: There were no statistically significant changes from baseline in either ABC or the CY-BOCS scores (P value not reported).  Only two patients completed the study and exhibited a positive response to therapy on the CGI scale. Three patients discontinued the study due to lack of response and sedation limiting further dose increases, while

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
			adverse events  Secondary: Not reported	one patient experienced a possible seizure during the fourth week of therapy.  Additional significant adverse events included behavioral activation, increased appetite and weight gain (ranged from 0.9 to 8.2 kg).  Secondary: Not reported
Gagliano et al <sup>145</sup>  Risperidone at a starting dose of 0.25 mg/day which was increased gradually to 0.75-2 mg/day, given at bedtime or twice a day in tablets or oral solution	PRO  Children aged 3-10 years of age diagnosed with autism according to DSM-IV criteria	N=20  24 weeks  Phase 1: 12 weeks N=20  Phase 2: 12 weeks N=18 (responders at week 12 continued on Phase 2)	Primary: CGI, CPRS, relationship between plasma levels and efficacy  Secondary: EPS using the AIMS scale, adverse events	Primary: The CGI score in two of the 20 patients was four, which was considered a nonresponder and did not continue to Phase 2.  CPRS scores decreased significantly (improved) from baseline to week 12 (P<0.01).  There was no significant improvement in CPRS scores at week 24 compared to week 12 (P value not reported).  There was significant correlation between percent improvement in CPRS score and plasma levels of risperidone or its active fraction (P value not reported).  Secondary: No EPS were observed.  A mean increase of 2.6 kg and 3.7 kg was observed at weeks 12 and 24 respectively.  No major changes from baseline in electrocardiogram and laboratory tests.
Lemmon et al <sup>146</sup>  Risperidone (dose not specified)	RETRO  Children and adolescents, aged 3 to 15,	N=80  ≥6 months	Primary: Treatment success (based on CGI scores of improved), adverse	Primary: The most common indications for treatment included aggression (66%), impulsivity (14%), and stereotypies (4%).  Overall, 66% and 53% of patients met criteria for treatment success at

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
	with autism spectrum disorder		events  Secondary: Not reported	<p>six months and one year, respectively.</p> <p>Weight gain was the most frequently observed adverse event in both groups, followed by somnolence, aggression, and abnormal movements.</p> <p>Among patients five years of age or younger, 69% of patients met criteria for treatment success at 6 months. Risperidone was used as a first-line agent in 70% of patients in this age group. Prior medications included clonidine, guanfacine, and valproic acid.</p> <p>Somnolence was the most robust predictor of treatment failure.</p> <p>Secondary: Not reported</p>
<p>Aman et al<sup>147</sup></p> <p>Risperidone 0.5-3.5 mg/day in two divided doses</p> <p>vs</p> <p>placebo</p>	<p>DB, PC</p> <p>Individuals aged 5-17 diagnosed with autism according to DSM-IV criteria</p>	<p>N=101</p> <p>Double-blind comparison: 8 weeks</p> <p>Open label extension: 16 weeks</p>	<p>Primary: Laboratory values, vital signs, height and weight, adverse events</p> <p>Secondary: Not reported</p>	<p>Primary: After the eight week comparison, statistically significant changes in laboratory findings were found for red blood cell, neutrophil, and lymphocyte counts and for SGPT/SGOT (P values not reported).</p> <p>An elevated white blood cell count in a patient was the only abnormal laboratory findings reported at the four month extension.</p> <p>Tired during the day (P&lt;0.0001), excessive appetite (P&lt;0.0001), difficulty waking (P=0.05), excessive saliva or drooling (P=0.04), and dizziness or loss of balance (P=0.04) were reported significantly more frequently in the risperidone group.</p> <p>Difficulty falling asleep (P=0.02) and anxiety (P=0.05) were significantly less in the risperidone group compared to placebo.</p> <p>Significant weight gain was noted in the risperidone group (P&lt;0.001).</p> <p>There was no significant difference between placebo and risperidone in vital signs (P=0.15-0.65).</p>



Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
<p>Aman et al<sup>148</sup></p> <p>Risperidone 0.5-3.5 mg/day in two divided doses</p> <p>vs</p> <p>placebo</p>	<p>SA (study by Aman et al 2005)</p> <p>Individuals aged 5-17 diagnosed with autism according to DSM-IV criteria</p>	<p>N=38</p> <p>Double-blind comparison: 8 weeks</p>	<p>Primary: Cognition</p> <p>Secondary: Not reported</p>	<p>Secondary: Not reported</p> <p>Primary: Risperidone was not associated with a decline in performance. The following performance tasks were better executed by patients receiving risperidone than placebo: cancellation task and verbal learning task.</p> <p>There were no significant differences between groups in performance in the Pegboard (hand-eye coordination) or the Analog Classroom (timed math test) tasks (P value not reported).</p> <p>Secondary: Not reported</p>
<p>Aman et al<sup>149</sup></p> <p>Risperidone, 0.25-1.75 mg daily (14-20 kg), 0.5-2.5 mg daily (20-45 kg), 0.5-3.5 mg daily (&gt;45 kg)* (Medication group)</p> <p>vs</p> <p>combined treatment with risperidone, dosed same as above, and parent training in behavior management (COMB group)</p> <p>*Patients who did not exhibit a positive response to risperidone at 8 weeks were switched to aripiprazole</p>	<p>PG, MC, RCT</p> <p>Children, aged 4 to 13 years, with PDD, <math>\geq 18</math> on the Irritability subscale of parent-rated ABC, CGI severity score <math>\geq 4</math>, not taking psychotropic drugs for at least 2 weeks, IQ <math>\geq 35</math> or mental age <math>\geq 18</math> months</p>	<p>N=124</p> <p>24-week</p>	<p>Primary: Home Situations Questionnaire (HSQ) severity score</p> <p>Secondary: ABC Irritability, ABC Stereotypic, ABC Hyperactivity, ABC Social Withdrawal, ABC Inappropriate Speech, Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS), adverse events</p>	<p>Primary: After 24 weeks of therapy, HSQ scores significantly decreased by 71% in the COMB group compared to a 60% reduction from baseline observed in the medication group (P=0.006).</p> <p>Secondary: After 24 weeks of therapy, improvement in ABC Irritability subscale scores from baseline was significantly greater among patients randomized to COMB therapy compared to medication alone (P=0.01).</p> <p>After 24 weeks of therapy, improvement in ABC Stereotypic subscale scores from baseline was significantly greater among patients randomized to COMB therapy compared to medication alone (P=0.04).</p> <p>After 24 weeks of therapy, improvement in ABC Hyperactivity subscale scores from baseline was significantly greater among patients randomized to COMB therapy compared to medication alone (P=0.04).</p> <p>After 24 weeks of therapy, there were no statistically significant differences between groups in improvement from baseline in the following endpoints: ABC Social Withdrawal (P=0.78), ABC</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>Inappropriate Speech (P=0.20), and CY-BOCS (P=0.62).</p> <p>The only statistically significant difference between groups in terms of adverse events was with insomnia, which occurred more frequently in the medication alone group (P=0.04).</p>
<p>Luby et al<sup>150</sup></p> <p>Risperidone 0.5-1.5 mg in two divided doses per day</p> <p>vs</p> <p>placebo</p>	<p>DB, PC, RCT</p> <p>Preschool children 2.5 to 6 years of age with autism or pervasive developmental disorder not otherwise specified according to DSM-IV criteria</p>	<p>N=25</p> <p>6 months</p>	<p>Primary: CARS, GARS</p> <p>Secondary: Physiological measures, adverse events</p>	<p>Primary: No statistically significant difference was seen between the two treatment groups on any of the outcome measures of interest when differences in baseline developmental characteristics were accounted for.</p> <p>There was no significant difference between the two treatment groups in the effectiveness on anxiety (P=0.056).</p> <p>Secondary: There was a significant difference between risperidone and placebo in mean weight gain (2.96 kg compared to 0.61 kg; P=0.008) and prolactin change (33.38 ng/mL compared to 11.11 ng/mL; P=0.015).</p> <p>There was no significant difference in adverse events between groups (P value not reported).</p>
<p>McCracken et al<sup>151</sup></p> <p>Risperidone 0.5 to 3.5 mg daily</p> <p>vs</p> <p>placebo</p>	<p>DB, MC, PC, RCT</p> <p>Children and adolescents, aged 5 to 17 years, diagnosed with autistic disorder with tantrums, aggression, self-injurious behavior, or a combination of</p>	<p>N=101</p> <p>8 weeks</p>	<p>Primary: ABC Irritability score, response rate (defined as &gt;25% increase in ABC irritability score and a CGI-I rating of much improved or very much improved)</p> <p>Secondary: ABC Social Withdrawal, ABC</p>	<p>Primary: At week eight, risperidone-treated patients exhibited a 56.9% reduction in the mean ABC Irritability score from baseline, compared to a 14.1% reduction observed in the placebo group (P&lt;0.001).</p> <p>A positive response was noted in 69 and 12% of patients randomized to risperidone and placebo therapy, respectively (P&lt;0.001). In 2/3 of patients with a positive response at eight weeks, the benefit was maintained at six months.</p> <p>Secondary: At week eight, risperidone-treated patients exhibited a significantly greater improvement in the mean ABC Social Withdrawal score from baseline, compared to the placebo group (P=0.03).</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
	above, exhibiting a mental age of $\geq 18$ months, weighing $\geq 15$ kg		Stereotype, ABC Hyperactivity, ABC Inappropriate Speech, CGI-I, adverse events	<p>At week eight, risperidone-treated patients exhibited a significantly greater improvement in the mean ABC Stereotype score from baseline, compared to the placebo group (<math>P &lt; 0.001</math>).</p> <p>At week eight, risperidone-treated patients exhibited a significantly greater improvement in the mean ABC Hyperactivity score from baseline, compared to the placebo group (<math>P &lt; 0.001</math>).</p> <p>At week eight, risperidone-treated patients exhibited a significantly greater reduction in the mean ABC Inappropriate Speech score from baseline, compared to the placebo group (<math>P = 0.03</math>).</p> <p>At week eight, the proportion of patients whose behavior was rated as much improved on the CGI-I scale differed between the two groups by 64%, in favor of risperidone (<math>P &lt; 0.001</math>).</p> <p>Risperidone group gained significantly more weight compared to the placebo group (2.7 vs 0.8 kg; <math>P &lt; 0.001</math>). Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperidone group compared to placebo (<math>P &lt; 0.05</math>).</p>
<p>Miral et al<sup>152</sup></p> <p>Risperidone dosed 0.01 mg/kg up to 0.08 mg/kg daily</p> <p>vs</p> <p>haloperidol dosed 0.01 mg/kg up to 0.08 mg/kg daily</p>	<p>DB, RCT</p> <p>Children and adolescents, aged 8 to 18, with autistic disorder</p>	<p>N=30</p> <p>12 weeks</p>	<p>Primary: CGI-I, Ritvo-Freeman Real Life Rating Scale (RF-RLRS), ABC, Turgay DSM-IV Pervasive Developmental Disorder Rating Scale (TPDDRS), adverse events</p> <p>Secondary: Not reported</p>	<p>Primary: The change in CGI-I scores from baseline was not significantly different between the two study groups at week-12 (<math>P = 0.11</math>).</p> <p>At week-12, there was no statistically significant difference between groups in the change from baseline in any of the RF-RLRS subscale scores (<math>P &gt; 0.05</math>). Risperidone was associated with significant improvement from baseline in all RF-RLRS subtypes; whereas haloperidol was associated with a significant improvement in all but one measure (language subscale).</p> <p>While the change from baseline in ABC scores was significant in both groups (<math>P &lt; 0.005</math>), risperidone therapy was associated with significantly greater improvement compared to haloperidol (<math>P = 0.0062</math>).</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>While the change from baseline in TPDDRS scores was significant in both groups (P&lt;0.005), risperidone therapy was associated with significantly greater improvement compared to haloperidol (P=0.0052).</p> <p>Patients receiving haloperidol experienced significantly more EPS events than at baseline (P=0.0477); whereas there was no significant increase in EPS events in the risperidone group (P value not reported).</p> <p>Haloperidol therapy was associated with increased heart rate, weight, height and prolactin (P&lt;0.05). Risperidone therapy was associated with increased weight, height, HbA<sub>1c</sub> and prolactin (P&lt;0.05). The only statistically significant differences between groups in terms of adverse events were increases in ALT with haloperidol therapy and increases in prolactin with risperidone therapy (P&lt;0.05).</p> <p>Secondary: Not reported</p>
<p>Gencer et al<sup>153</sup></p> <p>Risperidone dosed up to 0.08 mg/kg daily</p> <p>vs</p> <p>haloperidol dosed up to 0.08 mg/kg daily</p>	<p>ES (of Miral et al)</p> <p>Children and adolescents, aged 8 to 18, with autistic disorder</p>	<p>N=28</p> <p>12 weeks DB; 12 weeks OL</p>	<p>Primary: CGI-I, Ritvo-Freeman Real Life Rating Scale (RF-RLRS), ABC, Turgay DSM-IV Pervasive Developmental Disorder Rating Scale (TPDDRS), adverse events</p> <p>Secondary: Not reported</p>	<p>Primary: Risperidone therapy was associated with significantly greater improvement from baseline in CGI-I scores compared to haloperidol (P=0.0186).</p> <p>At week-24, the change from baseline in RF-RLRS sensory-motor subscale scores was statistically significant in the risperidone group (P=0.018), but not in the haloperidol group (P=0.16).</p> <p>Risperidone therapy was associated with significantly greater improvement from baseline in RF-RLRS language subscale scores compared to haloperidol (P=0.0414).</p> <p>There were no statistically significant differences between groups in the change from baseline in the other RF-RLRS subscales (P&gt;0.05).</p> <p>At week-24, the change from baseline in ABC scores was statistically</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>significant in the risperidone group (P=0.0029), but not in the haloperidol group (P=0.53). However, there was no statistically significant difference in the change in ABC scores from baseline between the two groups (P=0.07).</p> <p>Both risperidone and haloperidol groups experienced a statistically significant improvement in TPDDRS scores from baseline at week-24 of therapy (P&lt;0.05).</p> <p>At week-24, both groups experienced statistically significant weight gain from baseline. However, haloperidol was associated with more weight gain than risperidone therapy (P=0.04).</p> <p>At week-24, there was no statistically significant difference between the groups in serum prolactin levels (P=0.55) or EPS adverse events (P value not reported).</p> <p>Secondary: Not reported</p>
<p>Nagaraj et al<sup>154</sup></p> <p>Risperidone 0.5 mg daily for the first week then 1 mg daily</p> <p>vs</p> <p>placebo</p>	<p>DB, PC, RCT</p> <p>Children 2-9 years of age diagnosed with autism according to DSM-IV criteria</p>	<p>N=40</p> <p>6 months</p>	<p>Primary: CARS, CGAS, global impression of parents, analysis of parents questionnaire</p> <p>Secondary: Safety</p>	<p>Primary:</p> <p>In the risperidone group 63% of the patients demonstrated an improvement of at least 20% from baseline in their CARS score compared to none of the patients in the placebo group (P&lt;0.001).</p> <p>In the risperidone group 89% of the patients demonstrated an improvement of at least 20% from baseline in their CGAS score compared to 9% of the patients in the placebo group (P=0.035).</p> <p>There was no significant difference between the treatment groups in the global impression of the parents (P value not reported).</p> <p>In the analysis of the parent questionnaire risperidone significantly improved functioning in the domains of social responsiveness (P=0.014), nonverbal communication (P=0.008), decreased symptoms of hyperactivity (P=0.002), and aggression and irritability (P=0.016). No</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>significant difference was reported with regard to restricted interests, emotional interaction or verbal communication.</p> <p>Secondary: An increased appetite, mild sedation in 20% and transient dyskinesias in 10% were reported (P value not reported).</p> <p>In the risperidone group, the mean weight gain was 2.81 kg, an increase of 17% compared to 1.71 kg, an increase of 9.3% in the placebo group, a difference that was statistically significant (P value not reported).</p>
<p>Malone et al<sup>155</sup></p> <p>Ziprasidone 20 mg to 160 mg daily</p>	<p>OL</p> <p>Adolescents, aged 12.1 to 18.5 years, with autism and a CGI-S score of <math>\geq 4</math></p>	<p>N=12</p> <p>6 weeks</p>	<p>Primary: CGI</p> <p>Secondary: ABC subtypes, Children's Psychiatric Rating Scale (CPRS) subtypes, adverse events</p>	<p>Primary: At week six, 75% of patients experienced a response on the CGI scale. The change from baseline in CGI-S was not statistically significant (P=0.07).</p> <p>Secondary: Statistically significant improvement from baseline was seen in respect to the irritability and hyperactivity subtypes of the ABC (P<math>\leq</math>0.05). However, the other ABC subtypes (lethargy/social withdrawal, stereotypic behavior and inappropriate speech) were not significantly changed from baseline (P&gt;0.05).</p> <p>Statistically significant improvement from baseline was only seen in respect to the autism measure of the CPRS (P=0.009). There were no significant changes from baseline in the anger, hyperactivity, or speech deviance measures of the CPRS (P&gt;0.05).</p> <p>Ziprasidone was weight neutral, significantly increased QTc by a mean of 14.7 msec (P=0.04), significantly decreased baseline total cholesterol levels (P=0.04), was not associated with significant changes in LDL, HDL cholesterol, triglycerides, or prolactin levels.</p>
<b>Schizophrenia</b>				
<p>Findling et al<sup>156</sup></p> <p>Aripiprazole 10 mg daily</p>	<p>DB, MC, PC, RCT</p>	<p>N=302</p> <p>6 weeks</p>	<p>Primary: Mean change from baseline in PANSS</p>	<p>Primary: Compared to placebo, patients randomized to the aripiprazole 10 mg and 30 mg groups experienced a statistically significant improvement in</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
vs aripiprazole 30 mg daily vs placebo	Children and adolescents between the ages of 13 and 17, with a diagnosis of schizophrenia, baseline PANSS score of 70 or higher		total score  Secondary: Mean change in the PANSS positive and negative subscale scores, Clinical Global Impression (CGI) improvement and severity, clinician-rated Children's Global Assessment scale, quality of life and patient satisfaction, adverse effects	the primary endpoint from baseline (P=0.05 and P=0.007, respectively) at week six.  Secondary: Patients randomized to the aripiprazole 10 mg and 30 mg groups experienced a statistically significant improvement in the PANSS positive subscale scores from baseline (P=0.02 and P=0.002, respectively) at week six, compared to placebo.  Only patients randomized to the aripiprazole 10 mg treatment group experienced a statistically significant improvement in the PANSS negative subscale scores from baseline at week six, compared to placebo (P=0.05).  At week six, patients randomized to the aripiprazole 10 mg and 30 mg groups experienced a statistically significant improvement in the CGI severity and improvement scores from baseline compared to placebo (P<0.05).  At week six, patients randomized to the aripiprazole 10 mg and 30 mg groups experienced a statistically significant improvement in the Children's Global Assessment Scale scores from baseline compared to placebo (P=0.006 and P=0.005, respectively).  At week six, patients randomized to the aripiprazole 10 mg and 30 mg groups experienced a statistically significant improvement in the Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire overall scores from baseline compared to placebo (P=0.005 and P=0.003, respectively).  However, there was no statistically significant difference between the two aripiprazole groups and placebo in the change from baseline of the Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire total scores (P>0.05).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>At week six, 53% and 56%, respectively, of patients in the aripiprazole 10 mg and 30 mg treatment groups achieved disease remission, compared to 35% of patients in the placebo group (P=0.02 and P=0.003, respectively).</p> <p>The most frequently reported treatment-emergent adverse effects that occurred at an incidence of at least 5% were EPS disorder (5% with placebo, 13% with aripiprazole 10 mg, 22% with aripiprazole 30 mg), somnolence (6% with placebo, 11% with aripiprazole 10 mg, 22% with aripiprazole 30 mg), and tremor (2% with placebo, 2% with aripiprazole 10 mg, 12% with aripiprazole 30 mg).</p> <p>The most common types of experienced EPS events were parkinsonism (7% with placebo, 15% with aripiprazole 10 mg, 30% with aripiprazole 30 mg) and akathisia (6% with placebo, 6% with aripiprazole 10 mg, 12% with aripiprazole 30 mg).</p> <p>Patients randomized to the aripiprazole 30 mg group gained an average of 0.2 kg from baseline compared to a weight loss of an average of 0.8 kg in the placebo group (P=0.009). The 10 mg aripiprazole group did not exhibit changes in weight.</p> <p>There were no clinically significant differences among treatment groups in glucose or lipid measures.</p> <p>Both aripiprazole treatment groups exhibited statistically significant reductions in prolactin levels compared to placebo (P&lt;0.005).</p> <p>There were no statistically significant differences among groups with respect to time to discontinuation (P&gt;0.05).</p>
<p>Kryzhanovskaya et al<sup>157</sup></p> <p>Olanzapine 2.5mg to 20 mg daily</p>	<p>DB, I, MC, PC, RCT</p> <p>Children and adolescents,</p>	<p>N=107</p> <p>6 weeks (double-blind); 26 weeks</p>	<p>Primary: Change from baseline in the Brief Psychiatric Rating Scale</p>	<p>Primary: Compared to placebo, olanzapine-treated patients exhibited significantly greater improvements in BPRS-C scores from baseline (-19.4 vs -9.3; Effect Size, 0.63; P=0.003). This improvement became significant at week two and remained so for the duration of the study.</p>



Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
vs placebo	aged 13 to 17 years, with schizophrenia of the paranoid, disorganized, catatonic, undifferentiated, and residual types, had a BPRS-C score of at least 35, and a score of at least 3 on any one of the following BPRS-C items: hallucination, delusion, peculiar fantasy	(open label)	(BPRS-C) total score  Secondary: Change from baseline in the Clinical Global Impression (CGI-S), Positive and Negative Syndrome Scale (PANSS), and the Overt Aggression Scale (OAS) scores, patients response rate (30% or greater reduction in the BPRS-C total score from baseline and a CGI-S score of $\leq 3$ at the last measurement), adverse events	<p>Secondary: Compared to placebo, olanzapine-treated patients exhibited significantly greater improvements in CGI-S scores from baseline (-1.1 vs -0.5; P=0.004).</p> <p>Compared to placebo, olanzapine-treated patients exhibited significantly greater improvements in PANSS total scores from baseline (-21.3 vs -8.8; Effect Size, 0.6; P=0.005).</p> <p>Compared to placebo, olanzapine-treated patients exhibited significantly greater improvements in OAS physical aggression toward others subtype scores from baseline (-0.1 vs -0.0; P=0.019). The other components of the OAS total score were not significantly different between groups (P&gt;0.05).</p> <p>The response rate was not significantly different between olanzapine and placebo (37.5 vs 25.7%; P=0.278).</p> <p>Treatment-emergent adverse events occurring at any time during treatment in at least 5% of olanzapine-treated patients included weight gain (30.6 vs 8.6%; P=0.14), somnolence (23.6 vs 2.9%; P=0.006); headache (16.7 vs 8.6%; P=0.138), increased appetite (16.7 vs 8.6%; P=0.376), sedation (15.3 vs 5.7%; P=0.214), dizziness (8.3 vs 2.9%; P=0.423), nasopharyngitis (5.6 vs 5.7%; P=1.00), and pain in extremity (5.6 vs 2.9%; P=1.0).</p> <p>Olanzapine therapy was associated with significantly increased from baseline fasting triglycerides (P=0.029) and uric acid (P&lt;0.001). In addition, olanzapine-treated patients experienced a weight gain of 4.3 kg compared to 0.1 kg in the placebo group (P&lt;0.001). Olanzapine therapy was associated with liver function test elevation compared to placebo (P&lt;0.05), reduction in bilirubin (P=0.001), HbA<sub>1c</sub> (P=0.004), and an increase in prolactin levels (P=0.002).</p>
Cianchetti et al <sup>158</sup>	RETRO	N=47	Primary:	Primary:

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
<p>Antipsychotics (aripiprazole 10 to 20 mg daily, clozapine 200 to 500 mg daily, haloperidol 3 to 8 mg daily, olanzapine 10 to 20 mg daily, quetiapine 250 to 450 mg daily, risperidone 3 to 6 mg daily)</p>	<p>Children and adolescents, 10 to 17 years, with schizophrenia or schizoaffective disorder</p>	<p>3 years to 11 years</p>	<p>Response rate, PANSS, CGI scores, adverse events</p> <p>Secondary: Not reported</p>	<p>At year three of follow-up, clozapine therapy was associated with the highest response rate (81.5%), followed by aripiprazole (75%), quetiapine (50%), risperidone (37.5%), olanzapine (8.3%), and finally haloperidol (10%). Response rates were significantly greater among patients who had received clozapine compared to risperidone (P&lt;0.01) or olanzapine (P&lt;0.001).</p> <p>A comparison of the degree of clinical improvement at the five years of follow-up showed a statistically greater improvement in PANSS and CGI scores in patients treated with clozapine compared to either risperidone or olanzapine treatment (P&lt;0.05).</p> <p>At three-year through 11-year follow-up, clozapine was associated with a significantly greater improvement in GAF scores compared to the other antipsychotics, combined (P&lt;0.05).</p> <p>Excessive weight gain was observed in 60% of patients receiving olanzapine, 35.5% and 28.6% of patients receiving risperidone and clozapine, respectively.</p> <p>After five years of therapy, olanzapine was associated with the greatest rate of discontinuations due to adverse events (33.3%), followed by risperidone (28.1%), clozapine (16%), and aripiprazole (14.3%). Of note all the patients receiving olanzapine discontinued therapy by year-five of follow-up. The reasons for discontinuing olanzapine were weight gain in 25% and amenorrhea in 16.7%. The reasons for discontinuing risperidone were weight gain in 6%, amenorrhea in 6%, neurodysleptic crisis in 6%, and adenoma, parkinsonism, or seizures in 1%, each. The reasons for discontinuing clozapine were weight gain in 3.6%, neutropenia in 7.1% and seizures in 3.6%. Only one patient discontinued aripiprazole therapy and that was due to anorexia.</p> <p>Secondary: Not reported</p>
<p>Fleischhaker et al<sup>159</sup></p>	<p>MC, OL</p>	<p>N=51</p>	<p>Primary:</p>	<p>Primary:</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
<p>Olanzapine average dose 16.6 mg/day</p> <p>vs</p> <p>risperidone average dose 3.9 mg/day</p> <p>vs</p> <p>clozapine average dose 321.9 mg/day</p>	<p>Patients with an average age of 16 years, with various psychiatric disorders, with the majority diagnosed with schizophrenia</p>	<p>Average 7.4 weeks of drug therapy (range 1-34)</p>	<p>Dosage Record Treatment Emergent Symptom Scale (DOTES)</p> <p>Secondary: Adverse events</p>	<p>Significant change in weight was noted between the olanzapine and clozapine groups (<math>P&lt;0.03</math>), and between the olanzapine and risperidone groups (<math>P&lt;0.03</math> for both).</p> <p>Secondary: Risperidone was associated with: reduced motor activity and/or drowsiness (6/19), weight gain (7/19), rigidity (2/19), dystonia (2/19), and depressive effect (3/19).</p> <p>Olanzapine was associated with: weight gain (4.6 kg at week 6) (11/16), reduced motor activity (6/16), drowsiness (9/16), rigidity and tremor (2/16), akathisia (1/16), dry mouth or increase salivation (4/16), and depressive effect (4/16).</p> <p>Clozapine was associated with: reduced motor activity (9/16), drowsiness (9/16), orthostatic hypotension (5/16), depressive effect (4/16), and increased salivation (10/16).</p>
<p>Gothelf et al<sup>160</sup></p> <p>olanzapine average dose 12.9 mg/day</p> <p>vs</p> <p>risperidone 3.3 mg/day</p> <p>vs</p> <p>haloperidol 8.3 mg/day</p>	<p>MC, PRO</p> <p>Patients with a confirmed diagnosis of schizophrenia</p>	<p>N=43</p> <p>risperidone – 17</p> <p>olanzapine – 19</p> <p>haloperidol – 7</p> <p>8 weeks</p>	<p>Primary: Positive and Negative Syndrome Scale (PANSS)</p> <p>Secondary: Adverse events</p>	<p>Primary: A significant change in PANSS scores was seen for positive, negative and total scores from baseline to four weeks and eight weeks (<math>P&lt;0.01</math>).</p> <p>Secondary: Increased fatigue occurred: 11.8% in the risperidone group, 42.1% in the risperidone group and 71.4% in the haloperidol group (<math>P&lt;0.01</math>).</p>
<p>Mozes et al<sup>161</sup></p> <p>Olanzapine 2.5 to 20 mg daily</p> <p>vs</p>	<p>OL, PRO, R</p> <p>Hospitalized children (mean age 10.71)</p>	<p>N=25</p> <p>12 weeks</p>	<p>Primary: Change in the total PANSS score</p> <p>Secondary:</p>	<p>Primary: Both treatment groups were associated with a statistically significant improvement in the total PANSS scores from baseline (<math>P&lt;0.001</math>). However, the difference between risperidone and olanzapine-treated groups was not statistically significant (<math>P=0.236</math>).</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
risperidone 0.25 to 4.5 mg daily  Prior non-antipsychotic therapy was continued.	years), diagnosed with Childhood-Onset Schizophrenia (COS)		PANSS positive and negative subscale scores, Brief Psychiatric Rating Scale (BPRS) scores, Children's Global Assessment Scale (CGAS), drop-out rate, adverse events	<p>Secondary:</p> <p>Both treatment groups were associated with a statistically significant improvement in the PANSS positive subscale scores from baseline (P&lt;0.001). However, the difference between risperidone and olanzapine-treated groups was not statistically significant (P=0.318).</p> <p>Both treatment groups were associated with a statistically significant improvement in scores on the PANSS negative subscale from baseline (P&lt;0.001). However, the difference between risperidone and olanzapine-treated groups was not statistically significant (P=0.144).</p> <p>Both treatment groups exhibited a statistically significant improvement in the BPRS scores from baseline (P&lt;0.001). However, the difference between risperidone and olanzapine-treated groups was not statistically significant (P=0.254).</p> <p>Both treatment groups exhibited a statistically significant improvement in the CGAS scores from baseline (P&lt;0.001). However, the difference between risperidone and olanzapine-treated groups was not statistically significant (P=0.791).</p> <p>Of the olanzapine-treated children, 91.7% completed the 12 weeks of the study as compared to 69.2% in the risperidone-treated group (P=0.161).</p> <p>The two treatment groups were not associated with statistically significant differences in the incidence of EPS side effects or changes in blood pressure and pulse.</p> <p>Olanzapine and risperidone therapies were associated with a weight gain of 5.78 kg and 4.45 kg, respectively (P=0.33). The weight gain was statistically significant from baseline in both treatment groups (P&lt;0.001).</p>
Kumra et al <sup>162</sup>	DB, PG, RCT	N=39	Primary: Responder rate	Primary: A significantly greater responder rate was observed in the clozapine

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
<p>Olanzapine 10 to 30 mg daily vs clozapine 50 to 700 mg daily</p>	<p>Children and adolescents, aged 10 to 18 years, diagnosed with schizophrenia or schizoaffective disorder and treatment-refractory (defined as treatment failure of at least two prior adequate antipsychotic trials), a baseline BPRS total score of at least 35 and a score of at least moderate on at least one psychotic items on the BPRS</p>	<p>12 weeks</p>	<p>(defined as a decrease of 30% or more in total BPRS score from baseline and a CGI-S improvement rating of 1 (very much improved) or 2 (much improved)</p> <p>Secondary: Change in BPRS, CGI, SANS and SGAS, adverse effects</p>	<p>group compared to olanzapine-treated patients (66 vs 33%, P=0.038).</p> <p>Among patients who were previously treated with standard olanzapine doses, a trend of greater response rate was seen in patients who switched to clozapine as opposed to patients who received high olanzapine dose (P=0.093).</p> <p>Secondary: The two treatment groups were associated with comparable changes from baseline in the total BPRS, BPRS-Psychosis Cluster, CGAS, and CGI scores (P&gt;0.05 for all).</p> <p>Patients receiving clozapine exhibited significantly greater reduction (improvement) in the SANS total scores from baseline (P=0.02).</p> <p>Both clozapine and olanzapine were associated with significant weight gain from baseline. Overall, 13% of patients (three clozapine and two olanzapine) gained more than 7% of their baseline weight in 12 weeks of the study.</p> <p>The only statistically significant differences between the two groups were in the incidence of increased salivation and sweating, which were more common with clozapine therapy (P&lt;0.05).</p>
<p>Kumra et al<sup>163</sup> Olanzapine 10 to 30 mg daily vs clozapine 50 to 700 mg daily</p>	<p>OL, ES Children and adolescents, aged 10 to 18 years, diagnosed with schizophrenia or schizoaffective disorder and treatment-</p>	<p>N=33 (of original 39 patients)  12 weeks</p>	<p>Primary: Adverse effects, treatment discontinuation, change in BPRS, CGI, SANS and SGAS, adverse effects</p> <p>Secondary:</p>	<p>Primary: At week-24, a significantly higher proportion of patients who were initially assigned to clozapine therapy remained on their initial assigned drug compared to patients initially randomized to olanzapine therapy (86 vs 42%; P=0.01). Of the patients who changed therapy from olanzapine to clozapine, all but one did so due to inadequate therapeutic effect.</p> <p>At week-24, olanzapine-treated patients had significantly greater body weight compared to clozapine-treated group, though the weight appeared to stabilize after the initial 12 weeks of therapy (P=0.05).</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
	refractory (defined as treatment failure of at least two prior adequate antipsychotic trials), a baseline BPRS total score of at least 35 and a score of at least moderate on at least one psychotic items on the BPRS		Not reported	<p>Prolactin level elevation was significantly greater among olanzapine-treated patients compared to clozapine (P=0.02); though the steep rise in prolactin level in the olanzapine group occurred during the first 12 weeks of therapy and tended to decrease during the open-label extension study.</p> <p>Patients who changed therapy from olanzapine to clozapine due to inadequate response to therapy exhibited statistically significant improvements in the BPRS, SANS, CGI, and CGAS scores at the end of the 12 week extension phase (P&lt;0.05).</p> <p>Secondary: Not reported</p>
<p>Kumra et al<sup>164</sup></p> <p>Olanzapine 10 to 30 mg daily vs clozapine 50 to 700 mg daily</p>	<p>DB, PG, RCT</p> <p>Children and adolescents, aged 10 to 18 years, diagnosed with schizophrenia or schizoaffective disorder and treatment-refractory (defined as treatment failure of at least two prior adequate antipsychotic trials), a baseline BPRS total score of at</p>	<p>N=39</p> <p>12 weeks</p>	<p>Primary: Responder rate (defined as a decrease of 30% or more in total BPRS score from baseline and a CGIS improvement rating of 1 (very much improved) or 2 (much improved)</p> <p>Secondary: Change in BPRS, CGI, SANS and SGAS, adverse effects</p>	<p>Primary: A significantly greater responder rate was observed in the clozapine group compared to olanzapine-treated patients (66 vs 33%, P=0.038).</p> <p>Among patients who were previously treated with standard olanzapine doses, a trend of greater response rate was seen in patients who switched to clozapine as opposed to patients who received high olanzapine dose (P=0.093).</p> <p>Secondary: The two treatment groups were associated with comparable changes from baseline in the total BPRS, BPRS-Psychosis Cluster, CGAS, and CGI scores (P&gt;0.05 for all).</p> <p>Patients receiving clozapine exhibited significantly greater reduction (improvement) in the SANS total scores from baseline (P=0.02).</p> <p>Both clozapine and olanzapine were associated with significant weight gain from baseline. Overall, 13% of patients (three clozapine and two olanzapine) gained more than 7% of their baseline weight in 12 weeks of</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
	least 35 and a score of at least moderate on at least one psychotic items on the BPRS			<p>the study.</p> <p>The only statistically significant differences between the two groups were in the incidence of increased salivation and sweating, which were more common with clozapine therapy (P&lt;0.05).</p>
<p>Sikich et al<sup>165</sup></p> <p>TEOSS Study</p> <p>Olanzapine 2.5 to 20 mg daily</p> <p>vs</p> <p>risperidone 0.5 to 6 mg daily</p> <p>vs</p> <p>molindone 10 to 140 mg daily, in addition to benztropine 1 mg</p>	<p>DB, MC, RCT</p> <p>Children and adolescents, 8 to 19 years of age, diagnosed with schizophrenia, schizophreniform disorder, or schizoaffective disorder and had current positive psychotic symptoms of at least moderate intensity</p>	<p>N=116</p> <p>8 weeks</p>	<p>Primary: Responder status (defined as Clinical Global Impression (CGI) improvement score of 1 (“very much improved”) or 2 (“much improved”), plus ≥20% reduction in baseline PANSS score and the ability to tolerate 8 weeks of treatment)</p> <p>Secondary: PANSS total scores, PANSS positive and negative symptom subscales, the Brief Psychiatric Rating Scale for Children (BPRS-C), and the Child and Adolescent Functional</p>	<p>Primary: No statistically significant differences were found among treatment groups in response rates (molindone: 50%, olanzapine: 34%, risperidone: 46%) or magnitude of symptom reduction.</p> <p>Secondary: The reduction in total PANSS scores from baseline was statistically significant in all three treatment groups (molindone: 27%, olanzapine: 27%, risperidone: 23%; P≤0.001 for all comparisons). There were no statistically significant differences in the total PANSS score reduction from baseline across the three treatment groups (P value not reported).</p> <p>The reduction in PANSS positive subscale scores from baseline was statistically significant in all three treatment groups (molindone: 34%, olanzapine: 34%, risperidone: 32%; P≤0.001 for all comparisons). There were no statistically significant differences in the total PANSS score reduction from baseline across the three treatment groups (P value not reported).</p> <p>The reduction in PANSS negative subscale scores from baseline was statistically significant in all three treatment groups (molindone: 24%, olanzapine: 21%, risperidone: 20%; P≤0.001 for all comparisons). There were no statistically significant differences in the total PANSS score reduction from baseline across the three treatment groups (P value not reported).</p> <p>The reduction in the BPRS-C total scores from baseline was statistically significant in all three treatment groups (molindone: 39%, olanzapine: 41%, risperidone: 34%; P≤0.001 for all comparisons). There were no</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
			Assessment Scale (CAFAS), adverse effects	<p>statistically significant differences in the total PANSS score reduction from baseline across the three treatment groups (P value not reported).</p> <p>The reduction in CAFAS scores from baseline was statistically significant in all three treatment groups (molindone: 32%, olanzapine: 40%, risperidone: 47%; <math>P \leq 0.001</math> for all comparisons). There were no statistically significant differences in the total PANSS score reduction from baseline across the three treatment groups (P value not reported).</p> <p>Olanzapine-treated patients experienced a statistically significant weight gain of 6.1 kg and exhibited a 2.2 kg/m<sub>2</sub> increase of body mass index from baseline (<math>P \leq 0.0001</math>).</p> <p>Risperidone-treated patients experienced a statistically significant weight gain of 3.6 kg and exhibited a 1.3 kg/m<sub>2</sub> increase of body mass index from baseline (<math>P \leq 0.0001</math>). Molindone therapy was not associated with a statistically significant weight gain.</p> <p>Olanzapine-treated patients exhibited a statistically significant increase in their total cholesterol (19.9 mg/dl) and LDL cholesterol (14.7 mg/dl) levels from baseline over the eight week treatment course (<math>P \leq 0.05</math>). Neither molindone nor risperidone therapies were associated with significant changes in cholesterol levels.</p> <p>Molindone was associated with a statistically significant risk of akathisia (<math>P &lt; 0.027</math>); 18% of patients experienced moderate-severe akathisia.</p> <p>Prolactin levels were significantly increased from baseline in the risperidone group, but not in the olanzapine or molindone groups (<math>P \leq 0.0001</math>).</p> <p>Rate-corrected QT intervals increased significantly by 11.2 msec in the olanzapine group, but not in the molindone or risperidone groups (<math>P \leq 0.05</math>).</p>



Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
<p>Findling, et al<sup>166</sup></p> <p>TEOSS Study</p> <p>Olanzapine 2.5 to 20 mg daily</p> <p>vs</p> <p>risperidone 0.5 to 6 mg daily</p> <p>vs</p> <p>molindone 10 to 140 mg daily, in addition to benzotropine 1 mg</p>	<p>DB, ES</p> <p>Children and adolescents, 8 to 19 years of age, diagnosed with schizophrenia, schizophreniform disorder, or schizoaffective disorder and had current positive psychotic symptoms of at least moderate intensity</p>	<p>N=54</p> <p>44 weeks</p>	<p>Primary: PANSS total score</p> <p>Secondary: PANSS positive and negative symptom subscales, the Brief Psychiatric Rating Scale for Children (BPRS-C), CGI severity, and the Child and Adolescent Functional Assessment Scale (CAFAS), adverse effects</p>	<p>Olanzapine, molindone and risperidone therapies were associated with the following discontinuation rates: 51, 38 and 32%, respectively.</p> <p>Primary: There was no statistically significant difference among treatment groups in the PANSS total score over the course of the maintenance study period.</p> <p>Secondary: Over the course of the maintenance phase, risperidone was associated with a statistically significant increase from baseline in the CAFAS 8 total score, indicating worse functioning (29.4; P&lt;0.05). However, when assessing the change from baseline over the overall 52-week treatment course, risperidone led to a reduction in CAFAS total scores (-44.7).</p> <p>There were no statistically significant differences between groups in any of the other clinical outcome measures.</p> <p>There were no statistically significant treatment group differences in the length of maintenance study participation (P=0.467). However, olanzapine was associated with the shortest time until study discontinuation compared to risperidone and molindone (23 weeks, 25.3 weeks and 29.9 weeks, respectively).</p> <p>There were no significant differences among the treatment groups in adverse events at the beginning of the extension study. The most common reason for study discontinuation during maintenance was adverse events. Weight gain (39% of all patients) and anxiety (26% of all patients) were the most common adverse events reported, though the rates did not significantly differ across the treatment groups.</p> <p>Olanzapine, risperidone and molindone experienced the following weight gains during the overall 52 weeks of treatment: 11.1 kg, 11 kg, and 7.6 kg.</p> <p>All olanzapine-treated patients experienced at least one adverse event,</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>compared to 71% and 85% in the risperidone and molindone groups, respectively.</p> <p>Over the 52 weeks of therapy, prolactin level was reduced in the molindone and olanzapine groups, but increased in the risperidone group. However, during the 44 weeks of maintenance therapy, risperidone was associated with a reduction in prolactin level (P&lt;0.05). This suggests an initial steep rise in prolactin with risperidone therapy and subsequent reduction in levels.</p>
<p>Singh et al<sup>167</sup></p> <p>Paliperidone 1.5 mg once daily (low-dose)</p> <p>vs</p> <p>paliperidone 3 mg once daily (medium-dose)</p> <p>vs</p> <p>paliperidone 6 mg once daily (medium dose for patients weighing &lt;51 kg and high-dose for patients weighing ≥51 kg)</p> <p>vs</p> <p>paliperidone 12 mg once daily (high dose for patients weighing ≥51 kg)</p> <p>vs</p> <p>placebo</p>	<p>DB, PG, PC, RCT</p> <p>Adolescents, aged 12 to 17 years of age, diagnosed with schizophrenia for at least 1 year prior to study, with PANSS total score between 60 and 120, with a history of at least 1 adequate antipsychotic trial</p>	<p>N=201</p> <p>6 weeks</p>	<p>Primary: Change from baseline in PANSS total scores</p> <p>Secondary: CGI-S, CGAS, responder rate (at least 20% improvement in PANSS total scores), PANSS Marder factor scores</p>	<p>Primary: Compared to placebo, the mean change in PANSS total score from baseline was statistically significant only in the paliperidone medium-treatment group (P=0.006). There was no significant difference from placebo with the other doses.</p> <p>When evaluated by the actual dose, the mean change in PANSS total score was significant for the 2 mg, 6 mg, and 12 mg doses compared to placebo (P&lt;0.05).</p> <p>Secondary: The CGI-S scores were significantly improved in the paliperidone ER medium- and high-dose treatment groups, compared to placebo (P&lt;0.05).</p> <p>The CGAS scores were significantly improved only in the paliperidone ER medium-dose treatment groups, compared to placebo (P&lt;0.05).</p> <p>The responder rate was significantly higher in the medium-dose (64.6%) and high-dose (51.1%) groups, compared to placebo (P&lt;0.05).</p> <p>Paliperidone medium-dose group was associated with significant improvement in all PANSS Marder factor scores, except for depression/anxiety (P&lt;0.05).</p> <p>Paliperidone high-dose group was associated with significant</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
<p>McConville et al<sup>168</sup></p> <p>Quetiapine 333 mg to 695 mg a day; average dose 600 mg/day</p>	<p>OL</p> <p>Individuals 12-17 years of age with schizoaffective disorder or bipolar disorder with psychotic features</p>	<p>N=10</p> <p>88 weeks</p>	<p>Primary: Brief Psychiatric Rating Scale (BPRS), Clinical Global Severity of Illness (CGI-S), Scale of the Assessment of Negative Symptoms (SANS)</p> <p>Secondary: Tolerability, EPS, Simpson-Angus Scale (SAS), Abnormal Involuntary Movement Scale (AIMS), adverse events</p>	<p>improvement in positive symptoms, uncontrolled hostility and excitement, compared to placebo (P&lt;0.05).</p> <p>Primary: Significant improvement was measured from baseline to week 64 for BPRS and CGI scores and to week 52 for SANS scores (P&lt;0.05 for each).</p> <p>Secondary: No significant change from baseline SAS score or AIMS scores was seen (P value not provided).</p> <p>Change in weight (gain) from baseline was not significant; however, three patients reported it as a mild adverse event.</p>
<p>Schimmelmann et al<sup>169</sup></p> <p>Quetiapine 200 to 800 mg daily</p>	<p>OL</p> <p>Adolescents, aged 12 to 17 years, diagnosed with schizophrenia-spectrum disorder, with a Positive and Negative Syndrome Scale (PANSS) score of at least 60</p>	<p>N=56</p> <p>12 weeks</p>	<p>Primary: Change from baseline in the PANSS total score</p> <p>Secondary: PANSS positive, negative, disorganization, impulsivity/hostility, and anxiety/depression subscales, Clinical</p>	<p>Primary: Quetiapine-treated patients experienced a statistically significant reduction from baseline in the PANSS total score (24.9 points; 95%CI, 17.3 to 32.4; effect size=0.92; P&lt;0.0001).</p> <p>Secondary: At week-12, quetiapine therapy was associated with a statistically significant improvements from baseline in the PANSS positive, negative, disorganization, impulsivity/hostility, and anxiety/depression subscales (P&lt;0.001 for all variables).</p> <p>Quetiapine-treated patients experienced a statistically significant reduction from baseline in the CGI scores and the SWN total score (P&lt;0.0001 for both).</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
	points		Impressions-Severity of Illness Scale (CGI-S), Subjective Wellbeing under Neuroleptic Treatment Scale (SWN), PANSS response (50% reduction in PANSS scores, adverse events	<p>The 50% reduction in baseline PANSS scores was observed in 34.6% of patients (P value not reported).</p> <p>Quetiapine-treated patients experienced a statistically significant weight gain (6.2 kg) and an increase in BMI (2.1 kg/m<sup>2</sup>) from baseline (P&lt;0.001). At week-12, 60.7% of patients had gained more than 7% of their baseline weight.</p> <p>While quetiapine-treated patients experienced a statistically significant decrease in total serum thyroxin and an increase in thyroid-stimulating hormone (TSH), no one exhibited clinical signs of hypothyroidism (P&lt;0.05).</p> <p>Increases in prolactin, total cholesterol, and blood pressure from baseline were not statistically significant (P&gt;0.05).</p>
Jensen et al <sup>170</sup>  Risperidone, mean dose 3.4 mg vs olanzapine, mean dose 14 mg vs quetiapine, mean dose 611 mg	OL, PG, R  Children and adolescents 10 to 18 years of age with schizophrenia, schizoaffective disorder, schizophreniform, or psychotic disorder not otherwise specified	N=30  12 weeks	Primary: Change in the PANSS total score  Secondary: Change in the PANSS positive and negative subscale scores and the Children's Global Assessment Scale (SGAS), response rate (defined as at least a 40% reduction in PANSS total and subscale scores, adverse effects	Primary: There was no statistically significant difference among groups in the change in the primary endpoint (P=0.06), though there was a trend towards a better outcome in patients treated with risperidone compared to quetiapine (d=1.10; 95% Confidence Interval [CI], 0.09 to 2.01).  Secondary: There were no statistically significant differences among groups in respect to the positive and negative PANSS subscale scores as well as the CGAS scores (P>0.05).  Risperidone was associated with a greater improvement on the PANSS general symptoms subscale compared to quetiapine (P=0.04).  A non-significantly greater proportion of patients in the risperidone treatment group (7/10) met the responder criteria compared to patients in the quetiapine (3/10) or olanzapine (5/10) groups (P=0.65).  All three treatment groups were associated with a significant increase in

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
<p>Olfson et al<sup>171</sup></p> <p>Risperidone</p> <p>vs</p> <p>other atypical antipsychotics (olanzapine, aripiprazole, quetiapine, ziprasidone)</p> <p>Note: risperidone was chosen as a reference drug due to high utilization</p>	<p>Matched CC</p> <p>45-state Medicaid data was used to identify children and adolescents, aged 6-17 years, diagnosed with schizophrenia, schizoaffective disorder or schizophreniform disorder, who were free of any antipsychotic drug for at least 180 continuous days before filling the study medication</p>	<p>N=1,745</p> <p>180 days</p>	<p>Primary: Drug discontinuation rate, days to discontinuation, psychiatric hospital admission during the first 180 days, days to admission</p> <p>Secondary: Not reported</p>	<p>weight and body mass index from baseline. Sixty-three percent of patients gained &gt;7% of their baseline weight during the course of the study (risperidone: eight, olanzapine: six, quetiapine: five).</p> <p>Primary: Compared to risperidone, olanzapine, quetiapine, aripiprazole, and ziprasidone were associated with comparable rates of drug discontinuation during the first 180 days (74.69, 74.72, 70.68, 76.47, 73.33%, respectively; P=0.79).</p> <p>Compared to risperidone, olanzapine, quetiapine, aripiprazole, and ziprasidone were associated with comparable number of days prior to drug discontinuation during the first 180 days (56.03, 51.60, 57.70, 57.77, and 51.03 days, respectively; P=0.37).</p> <p>Compared to risperidone, olanzapine, quetiapine, aripiprazole, and ziprasidone were associated with comparable rates of psychiatric hospital admission during the first 180 days (8.42, 7.58, 8.81, 7.19, 9.89%, respectively; P=0.94).</p> <p>Compared to risperidone, olanzapine, quetiapine, aripiprazole, and ziprasidone were associated with comparable number of days prior to psychiatric hospital admission during the first 180 days (37.50, 34.81, 40.59, 38.80, and 35.89 days, respectively; P=0.99).</p> <p>The percentage of patients in each treatment group with a psychiatric hospital admission ranged from 14.21% for the risperidone group to 16.06% for the quetiapine group (P=0.98).</p>
<p>Ardizzone et al<sup>172</sup></p> <p>Atypical antipsychotics (olanzapine, risperidone, aripiprazole)</p>	<p>MA</p> <p>Multicenter, randomized, double-blind clinical trials evaluating the role of atypical</p>	<p>N=not reported</p> <p>Study durations varied</p>	<p>Primary: Change in Positive and Negative Syndrome Scale (PANSS) total score, PANSS positive subscale score, Clinical</p>	<p>Primary: All three atypical antipsychotics were associated with significant improvements in the total PANSS score from baseline (P&lt;0.001).</p> <p>All three atypical antipsychotics were associated with significant improvements in the PANSS positive subscale score from baseline (P&lt;0.001).</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
	antipsychotics in adolescents (13-17 years) diagnosed with Schizophrenia		<p>Global Impression Scale-Severity of Illness (CGIS-SI) score, adverse effects</p> <p>Secondary: Not reported</p>	<p>All three atypical antipsychotics were associated with significant improvements in the CGIS-SI score from baseline (P&lt;0.001).</p> <p>Olanzapine group exhibited the greatest amount of weight gain from baseline (P value not reported).</p> <p>Risperidone therapy was associated with a significantly greater incidence of akathisia, tremor, and dystonic events compared to controls.</p> <p>High aripiprazole dose was associated with a significantly greater incidence of tremor and Parkinsonism compared to control (P&lt;0.01).</p> <p>Aripiprazole 10 mg was associated with the lowest incidence of EPS and was not associated with significant weight gain (P value not reported).</p> <p>Secondary: Not reported</p>
<b>Schizophrenia, Schizoaffective Disorder, or Bipolar Disorder</b>				
<p>DelBello, Versavel et al<sup>173</sup></p> <p>Ziprasidone 20 mg daily initially, titrated to 80 mg daily for three weeks, followed by flexible dosing in the range of 20 mg to 160 mg daily (low-dose group)</p> <p>vs</p> <p>ziprasidone 40 mg daily initially, titrated to 160 mg daily for three weeks, followed by flexible dosing in the range of 20 mg to 160 mg daily (low-dose group)</p>	<p>OL, MC</p> <p>Children and adolescents, aged 10 to 17 years, with a manic or mixed episode of bipolar I disorder or with schizophrenia or schizoaffective disorder</p>	<p>N=63</p> <p>3 weeks fixed dose period/ 24 weeks flexible dose period</p>	<p>Primary: Young Mania Rating Scale (YMRS), Brief Psychiatric Rating Scale-Anchored Version (BPRS-A), CGI-S, adverse events</p> <p>Secondary: Not reported</p>	<p>Primary:</p> <p>The low ziprasidone dose (40 mg twice daily) was associated with a 17.2 (95% CI, 11.7 to 22.7) point reduction on the YMRS scale and a 1.5 (95% CI, 0.6 to 2.3) point reduction on the CGI-S scale in patients with bipolar mania (P value not reported).</p> <p>The high ziprasidone dose (80 mg twice daily) was associated with a 13.1 (95% CI, 8.6 to 17.7) point reduction on the YMRS scale and a 1.3 (95% CI, 0.8 to 1.8) point reduction on the CGI-S scale in patients with bipolar mania (P value not reported).</p> <p>The low ziprasidone dose (40 mg twice daily) was associated with a 9.5 (95% CI, -21.0 to 2.0) point reduction on the BPRS-A scale and a 0.7 (95% CI, -1.5 to 0.2) point reduction on the CGI-S scale in patients with schizophrenia or schizoaffective disorder (P value not reported).</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>The high ziprasidone dose (80 mg twice daily) was associated with a 15 (95% CI, 11.2 to 19.2) point reduction on the BPRS-A scale and a 0.8 (95% CI, 0.2 to 1.4) point reduction on the CGI-S scale in patients with schizophrenia or schizoaffective disorder (P value not reported).</p> <p>The most common adverse events during the fixed-dose phase were sedation (32%), somnolence (30%), and nausea (25%); while, the most common adverse events during the flexible-dosing phase were sedation (30%), somnolence (30%), and headache (25%). Nausea and vomiting were reported during the initial fixed-dose phase and were considerably less frequent in the subsequent flexible-dosing phase.</p> <p>The incidence of movement disorders in the fixed-dose and flexible-dose phases was 22% and 16%, respectively.</p> <p>While 13% and 40% of patients in the low- and high-dose groups, respectively, discontinued from the study due to adverse events during the fixed-dose phase, only 4.5% and 8.8% of patients in the low- and high-dose groups, respectively, discontinued during the flexible-dosing phase. Adverse events tended to occur more frequently during the initial three weeks and there were more adverse events reported in the high-dose group.</p> <p>Overall, 33% of patients gained at least 7% of their baseline weight. More patients experienced weight gain with continued flexible-dose therapy (4/63 patients during fixed-dose phase vs 20/56 patients during the flexible-dose phase). The mean weight gain at week-3 was 1kg; while the mean weight gain at week-27 was 2.8 kg.</p> <p>There were no clinically significant changes in lipid profiles with either of the two dose groups.</p> <p>QT prolongation was not observed during the fixed-dose phase, while one case occurred during the flexible-dosing phase.</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
<p>Stewart et al<sup>174</sup></p> <p>Ziprasidone 20 mg daily initially, titrated to 80 mg daily for three weeks, followed by flexible dosing in the range of 20 mg to 160 mg daily (low-dose group)</p> <p>vs</p> <p>ziprasidone 40 mg daily initially, titrated to 160 mg daily for three weeks, followed by flexible dosing in the range of 20 mg to 160 mg daily (low-dose group)</p>	<p>PH</p> <p>Children and adolescents, aged 10 to 17 years, with a manic or mixed episode of bipolar I disorder or with schizophrenia or schizoaffective disorder</p>	<p>N=63</p> <p>3 weeks fixed dose period/ 24 weeks flexible dose period</p>	<p>Primary: Children's Global Assessment Scale (CGAS)</p> <p>Secondary: Not reported</p>	<p>Secondary: Not reported</p> <p>Primary: At week three, the mean increase in CGAS score from baseline was 14.4 in the low-dose group compared to a 17.4 increase observed in the high-dose group (P value not reported).</p> <p>While there no one scored at the level of normal functioning (SGAS <math>\geq</math>70) at baseline, five patients scored <math>\geq</math>70 on the SCAS scale.</p> <p>Improvements in CGAS scores occurred as early as the first week of therapy.</p> <p>Secondary: Not reported</p>
<b>Tourette Disorder (TD)</b>				
<p>Budman et al<sup>175</sup></p> <p>Aripiprazole 2.5 mg to 40 mg daily</p>	<p>RETRO</p> <p>Children and adolescents, aged 8 to 18, with Tourette Disorder with or without intermittent explosive disorder</p>	<p>N=37</p> <p>6-12 weeks</p>	<p>Primary: Reduction in tic severity on the CGI-Tic scale, reduction in rage on the CGI-Rage scale, adverse events</p> <p>Secondary: Not reported</p>	<p>Primary: Reduction in tic severity on the CGI-Tic scale was noted in 100% of the patients at the end of the study (P value not reported).</p> <p>Reduction in rage on the CGI-Rage scale was noted in 96% of the patients at the end of the study (P value not reported).</p> <p>Among the eight patients who discontinued the study due to adverse events, 16% experienced akathisia, 8% experienced agitation, 8% experienced increased mood lability and/or anxiety, and 3% experienced symptoms of drug-induced Parkinsonism.</p> <p>Weight gain was noted in 87% of patients. Among these patients, there was a mean weight gain of 18 lbs.</p> <p>Secondary: Not reported</p>



Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
<p>Cui et al<sup>176</sup></p> <p>Aripiprazole 1.25 to 2.5 mg (prepubertal age) or 2.5 to 5 mg (children) initially and titrated up to effect</p> <p>Final mean dose was 8.17 mg or 0.19 mg/kg</p>	<p>OL</p> <p>Children and adolescents, aged 6 to 18 years, with TD and a CGI-S of at least 4 (moderately ill)</p>	<p>N=72</p> <p>8 weeks</p>	<p>Primary: Yale Global Tic Severity Scale (YGTSS) subscale scores, Clinical Global Impressions-Tics (CGI-Tics)</p> <p>Secondary: CBCL, adverse events</p>	<p>Primary: Over the course of the study, there was a 50% reduction in tic severity, as assessed by YGTSS. A reduction of 56.5% in YGTSS Global impairment was also noted.</p> <p>A significant reduction from baseline in YGTSS motor tic and phonic tic scores was observed beginning at week two and continued through the end of the study (P=0.000).</p> <p>YGTSS total tic scores were also significantly improved from baseline, beginning at week two of therapy (P=0.000).</p> <p>Aripiprazole therapy was associated with a significant reduction from baseline in mean CGI-Tics severity score (P=0.000).</p> <p>Secondary: Aripiprazole therapy was associated with significant improvements in the following subscales of the CBCL: somatic complaints (P&lt;0.05), anxious/depressed (P&lt;0.01), thought problems (P&lt;0.01), attention problems (P&lt;0.05), aggressive behavior (P&lt;0.05), externalizing (P&lt;0.01), internalizing (P&lt;0.01) and total problem scales (P&lt;0.01).</p> <p>There were no EPS adverse events reported during the study. Nausea and vomiting were the most frequently reported adverse events and occurred at an incidence of 29.2% and 26.4%, respectively.</p> <p>Patients receiving aripiprazole did not experience any clinically significant changes in laboratory parameters, including BMI.</p>
<p>Lyon et al<sup>177</sup></p> <p>Aripiprazole 1.25 mg to 13.75 mg daily</p>	<p>OL, PRO</p> <p>Children and adolescents, aged 7 to 18, with Tourette's Disorder or</p>	<p>N=10</p> <p>10 weeks</p>	<p>Primary: YGTSS subscales, CGI-Tics</p> <p>Secondary: Children's Global Assessment Scale</p>	<p>Primary: Aripiprazole therapy was associated with statistically significant reduction from baseline in YGTSS motor (-6.09; P=0.005) and vocal tic scores (-5.36; P=0.008).</p> <p>Aripiprazole therapy was associated with statistically significant reduction from baseline in YGTSS total tic (-11.45; P=0.003) and global</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
	chronic motor tic disorder, had failed trials with clonidine, guanfacine or neuroleptic medication in the past, tics caused significant distress, and had normal intelligence		(C-GAS), Children's Depression Rating Scale (CDRS-R), Clinical Global Impressions Scale for Obsessive Compulsive Disorder (CGI-OCD), CGI-ADHD, CY-BOCS, Multidimensional Anxiety Scale for Children (MASC), Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS)	<p>severity scores (-28.09; P=0.003).</p> <p>Aripiprazole therapy was associated with statistically significant reduction from baseline in CGI-Tic severity scores (-1.27; P=0.004). On the CGI-Tic improvement scale, 91% of patients had a rating of one ("very much improved") or two ("much improved") at the end of the study.</p> <p>Secondary: Aripiprazole therapy was associated with statistically significant improvements from baseline in the C-GAS scores, both attention and hyperactivity/impulsivity measures of ADHD-RS, CGI-OCD, and the obsession subscale of CY-BOCS (P&lt;0.05).</p> <p>Aripiprazole therapy was not associated with statistically significant improvements from baseline in CDRS-R, CGI-ADHD, MASC total score, and the compulsion subscale of the CY-BOCS (P&gt;0.05).</p> <p>Most frequently reported adverse events were appetite increase and weight gain, mild EPS effects, headaches, and tiredness/fatigue. Patients gained an average of 2.16 lbs over the course of the study, which was not significantly different from baseline (P=0.286).</p> <p>There were no significant changes from baseline in ECGs (P value not reported). Patients experienced a significant reduction in prolactin levels (P=0.03).</p>
Murphy et al <sup>178</sup>  Aripiprazole 1.25 mg to 7.5 mg daily	OL  Children and adolescents, aged 8 to 17 years, with a primary diagnosis of a chronic tic	N=16  6 weeks	Primary: Yale Global Tic Severity Scale (YGTSS), CY-BOCS, CGI-Tic  Secondary: CGI-OCD, Abbreviated	<p>Primary: Aripiprazole therapy was associated with statistically significant reduction from baseline in YGTSS motor (-8.9; P&lt;0.0001), phonic (-8.6; P&lt;0.0001), and total tic scores (-17.5; P&lt;0.0001).</p> <p>Aripiprazole therapy was associated with statistically significant improvement from baseline in CY-BOCS Obsessions, Compulsions, and total OCD subscale scores (P&lt;0.005).</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
	disorder		Symptom Questionnaire for Parents (ASQ-P), CDRS, adverse events	<p>Aripiprazole therapy was associated with statistically significant improvement from baseline in CGI-Tic Severity (-1.75; P&lt;0.0001) and Improvement scores (2.5; P&lt;0.0001).</p> <p>Secondary: Aripiprazole therapy was associated with statistically significant improvement from baseline in CGI-OCD Severity (-1.1; P&lt;0.0001) and Improvement scores (2.0; P&lt;0.0001).</p> <p>Aripiprazole therapy was associated with statistically significant reduction from baseline in ASQ-P scores (P=0.012).</p> <p>Aripiprazole therapy was associated with statistically significant reduction from baseline in CDRS scores (P=0.002).</p> <p>Aripiprazole was associated with an average weight gain of 2.3 kg overall (P&lt;0.003), and 4.1 kg among patients concurrently receiving a selective serotonin reuptake inhibitor (SSRI). There were no statistically significant changes in metabolic test results or ECG (P value not reported).</p>
Seo et al <sup>179</sup>  Aripiprazole 2.5 mg to 15 mg daily	OL, PRO  Children and adolescents, aged 7 to 19 years, with Tourette Disorder or chronic tic disorder	N=15  12 weeks	Primary: Yale Global Tic Severity Scale (YGTSS)  Secondary: CGI-I, CGI-S, adverse events	<p>Primary: Aripiprazole therapy was associated with statistically significant improvement in YGTSS motor tic, phonic tic, and total tic scores compared to baseline (P&lt;0.001 for all).</p> <p>Secondary: At week-12, aripiprazole therapy was associated with statistically significant improvement from baseline in CGI-I and SGI-S scores, beginning at week-3 of the study (P&lt;0.001 for both).</p> <p>Nausea and sedation were the most frequently reported adverse events. There was no statistically significant change from baseline in BMI (P=0.749).</p>
McCracken et al <sup>180</sup>	OL, PRO	N=12	Primary: YGTSS motor tic,	Primary: Aripiprazole was associated with statistically significant improvements in

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
Olanzapine 2.5 mg up to a maximum of 20 mg daily	<p>Children and adolescents, aged 7 to 17 years, with Tourette Disorder, CGI <math>\geq 4</math> (moderately ill)</p> <p>Note: all patients had at least one comorbid condition, most commonly ADHD</p>	6 weeks	<p>YGTSS vocal tic, YGTSS total tic severity scores</p> <p>Secondary: Swanson, Nolan and Pelham Questionnaire (SNAP-IV), Overt Aggression Scale (OAS), Multidimensional Anxiety Scale for Children (MASC) Child, MASC Parent scores, adverse events</p>	<p>all measures of the YGTSS motor tic scale, including the total motor tic severity score (P&lt;0.05 for all).</p> <p>Aripiprazole was associated with a statistically significant improvement in the YGTSS vocal tic interference scores (P&lt;0.05), though the other measures of this category were not significantly changed from baseline.</p> <p>Aripiprazole was associated with statistically significant improvements in most measures of the YGTSS total tic scale, including the total tic severity score (P&lt;0.05 for all). The only measures that were not significantly changed from baseline were YGTSS total tic number and complexity (P&gt;0.05).</p> <p>Secondary: Significant changes from baseline were noted in the YGTSS Overall Impairment and Global Severity scores (P&lt;0.001).</p> <p>Significant changes from baseline were noted in all of the following categories of SNAP IV: ADHD Inattention, ADHD Hyperactivity/Impulsivity, ODD, Inattention/overactivity, Aggression/Defiance, and Conners' Index (P&lt;0.01).</p> <p>Significant changes from baseline were also noted in the OAS number of episodes scores and MASC Child Physical Symptoms scores (P&lt;0.05). No significant changes from baseline were observed in the remaining categories of OAS or MASC-Child, as well as the MASC-Parent scores (P&gt;0.05).</p> <p>Olanzapine therapy was associated with a statistically significant weight gain from baseline (P&lt;0.001). The mean percentage change from baseline to week six was 8.4 (P&lt;0.001). Drowsiness/sedation was also frequently reported.</p>
Stephens et al <sup>181</sup> Olanzapine 2.5 mg up to a	OL, PRO Children and	N=10 10 weeks	Primary: CBCL, Achenbach Teacher Rating	Primary: Olanzapine therapy was associated with a statistically significant improvement in CBCL scores from baseline (P<0.009).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
maximum of 20 mg daily for 8 weeks	adolescents, aged 7 to 13 years, with a primary diagnosis of Tourette Disorder and a history of aggressive behavior		Form (TRF), CGI-Aggression, YGTSS, CGI-Tic, adverse events  Secondary: Not reported	<p>Olanzapine therapy was not associated with a statistically significant improvement in mean TRF scores from baseline (P&gt;0.05).</p> <p>Olanzapine therapy was associated with a statistically significant improvement in CGI-Aggression scores from baseline (P&lt;0.03).</p> <p>Olanzapine therapy was associated with a statistically significant improvement in YGTSS total tic scores from baseline (P&lt;0.007).</p> <p>Olanzapine therapy was associated with a statistically significant improvement in CGI-Tic severity scores from baseline (P&lt;0.04).</p> <p>Patients exhibited an average weight gain of 12 lbs from baseline (P&lt;0.005). Weight gain occurred most rapidly during the first two weeks of therapy. EPS adverse events were not reported during the study.</p> <p>Secondary: Not reported</p>
Copur et al <sup>182</sup>  Quetiapine 25 mg daily and titrated up to effect	RETRO  Children and adolescents, aged 8 to 18 years, with Tourette's syndrome	N=12  8 weeks	Primary: YGTSS scores  Secondary: Adverse events	<p>Primary: At both four and eight weeks after therapy initiation, quetiapine therapy was associated with a statistically significant improvement in YGTSS scores from baseline (P&lt;0.003).</p> <p>Secondary: There were no statistically significant changes in laboratory parameters and serum prolactin levels from baseline (P&gt;0.05). Mild but significant weight gain was noted during the study duration (P value not reported).</p>
Sallee et al <sup>183</sup>  Ziprasidone 5 mg up to a maximum of 40 mg daily	PC, RCT  Children and adolescents, aged 7 to 17 years, with Tourette's	N=28  56 days	Primary: YGTSS Global Severity scores, Total Tic scores, tic frequency, adverse events	<p>Primary: Compared to placebo, ziprasidone was associated with a statistically significant improvement from baseline in the YGTSS Global Severity scores (P=0.016) and Total Tic scores (P=0.008).</p> <p>Compared to placebo, ziprasidone was associated with a statistically significant improvement from baseline in tic frequency, as determined by</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
	syndrome and chronic tic disorders		Secondary: Not reported	blind videotape tic counts (P=0.039).  There were no clinically significant EPS adverse events. Mild transient somnolence was the most common adverse event.  Secondary: Not reported
<b>Miscellaneous Mental Health Disorders/Multiple Conditions</b>				
Capone et al <sup>184</sup>  Risperidone 0.25 mg to 1.5 mg once daily at bedtime	NAT  Children, aged 3 to 13 years, with Down Syndrome, severe intellectual disability, and a comorbid autistic spectrum disorder	N=23  95.8 days on average	Primary: ABC subscales, adverse events  Secondary: Not reported	Primary: Risperidone therapy was associated with a statistically significant improvement in the ABC composite score from baseline (P<0.001).  The greatest improvement from baseline occurred in regard to the following ABC subtypes: lethargy, stereotypy, and hyperactivity (P<0.001). However, the other two ABC subtypes were also significantly improved from baseline (P<0.05). Children with both disruptive behavior and self-injury were associated with the greatest improvement in symptoms with risperidone therapy.  Among patients with pre-existing sleep disturbances, 88% experienced an improvement in sleep quality.  Risperidone therapy was associated with an average weight gain of 2.8 kg.  Secondary: Not reported
Erickson et al <sup>185</sup>  Aripiprazole, 9.8 mg daily on average	OL, PRO  Patients, aged 6 to 25, with Fragile X syndrome (FXS)  Note: FXS is a	N=12  12 weeks	Primary: Treatment response (defined as CGI-I score of much improved or very much improved and a $\geq$ 25% improvement	Primary: Aripiprazole therapy was associated with a treatment response in 87% of patients.  Discontinuations from the study occurred in two of 12 patients and were due to the following adverse events: akathisia, drooling, and tiredness.  There were no significant changes from baseline in weight or laboratory

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
	form of genetic developmental disability and one of the causes of autism		on the ABC-Irritability subscale)  Secondary: Not reported	measures.  Secondary: Not reported
Krieger et al <sup>186</sup>  Risperidone 0.5 to 3 mg daily	OL  Children and adolescents, aged 7 to 17 years, with irritability at least three times weekly, abnormal mood (anger or sadness) for at least half the day on most days, hyperarousal, severe impairment in at least one setting and at least mild impairment in the second setting, symptom onset before the age of 12 and present for at least 12 months without	N=21  8 weeks	Primary: Aberrant Behavior Checklist-Irritability (ABC-Irritability)  Secondary: CGI, Clinical Global Assessment Scale (CGAS), Swanson, Nolan, and Pelham Scale-version IV (SNAP-IV), Young Mania Rating Scale (YMRS), Children Depression Rating Scale (CDRS), Mood Symptom Questionnaire (MSQ), The Screen for Child Anxiety-Related Emotional Disorders (SCARED), adverse events	Primary: At week eight, patients experienced a statistically significant reduction in ABC-irritability scores from baseline (P<0.05).  Secondary: At week eight, patients exhibited a statistically significant reduction in CGI scores from baseline (P<0.05).  At week eight, risperidone therapy was associated with significantly increased CGAS scores from baseline (P<0.05).  At week eight, patients exhibited a statistically significant reduction in SNAP-IVI scores from baseline (P<0.05).  At week eight, patients exhibited a statistically significant reduction in YMRS scores from baseline (P<0.05).  At week eight, patients exhibited a statistically significant reduction in CDRS scores from baseline (P<0.05).  At week eight, patients exhibited a statistically significant reduction in MSQ scores from baseline (P<0.05).  At week eight, patients exhibited a statistically significant reduction in SCARED scores from baseline (P<0.05).  At week eight, risperidone therapy was associated with statistically significant increases in prolactin level, serum glucose, and weight from baseline (P<0.05).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
	symptom-free periods of greater than 2 months, and no psychotropic use within 6 months			
<p>Castro-Fornieles et al<sup>187</sup></p> <p>Antipsychotic agents (risperidone, quetiapine, olanzapine) administered at varying doses</p>	<p>PRO, OL</p> <p>Children and adolescents, aged 9 to 17 years, with a first psychotic episode attributed to a psychotic disorder not otherwise specified, schizophrenia-type disorder, depressive disorder with psychotic symptoms, and bipolar mania with psychotic features</p>	<p>N=110</p> <p>6 months</p>	<p>Primary: PANSS, CGI, Disability Assessment Scale (DAS), Global Assessment Functioning (GAF), adverse events</p> <p>Secondary: Not reported</p>	<p>Primary:</p> <p>At six months of follow-up, PANSS total scores were significantly improved from baseline in patients treated with risperidone, quetiapine or olanzapine (<math>P \leq 0.001</math>). There were no significant differences among the three treatment groups in the reduction of PANSS total scores from baseline (<math>P=0.876</math>).</p> <p>At six months of follow-up, PANSS positive symptom scores were significantly improved from baseline in patients treated with risperidone, quetiapine or olanzapine (<math>P \leq 0.001</math>). There were no significant differences among the three treatment groups in the reduction of PANSS positive symptom scores from baseline (<math>P=0.681</math>).</p> <p>At six months of follow-up, PANSS negative symptom scores were not significantly changed from baseline in the risperidone group (<math>P=0.53</math>), but were significantly improved from baseline in patients treated with quetiapine or olanzapine (<math>P &lt; 0.01</math>). There were no significant differences among the three treatment groups in the reduction of PANSS negative symptom scores from baseline (<math>P=0.195</math>).</p> <p>At six months of follow-up, PANSS general scores were significantly improved from baseline in patients treated with risperidone, quetiapine or olanzapine (<math>P \leq 0.001</math>). There were no significant differences among the three treatment groups in the reduction of PANSS general scores from baseline (<math>P=0.741</math>).</p> <p>At six months of follow-up, CGI scores were significantly improved from baseline in patients treated with risperidone, quetiapine or olanzapine</p>



Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>(<math>P \leq 0.001</math>). There were no significant differences among the three treatment groups in the reduction of CGI scores from baseline (<math>P=0.237</math>).</p> <p>At six months of follow-up, DAS scores were significantly improved from baseline in patients treated with risperidone, quetiapine or olanzapine (<math>P &lt; 0.05</math>). There were no significant differences among the three treatment groups in the reduction of DAS scores from baseline (<math>P=0.075</math>).</p> <p>At six months of follow-up, GAF scores were significantly improved from baseline in patients treated with risperidone, quetiapine or olanzapine (<math>P &lt; 0.05</math>). There were no significant differences among the three treatment groups in the reduction of GAF scores from baseline (<math>P=0.069</math>).</p> <p>Olanzapine therapy was associated with significantly greater weight gain (11.7 kg) from baseline compared to either risperidone (6.1 kg; <math>P=0.02</math>) or quetiapine (6.0 kg; <math>P=0.04</math>).</p> <p>Risperidone was associated with a significantly greater frequently of neurological side effects, compared to olanzapine (<math>P=0.022</math>). Hypokinesia was the most frequent neurological adverse event reported in association with risperidone therapy and occurred at a significantly greater incidence compared to quetiapine and olanzapine (50 vs 13.3 vs 15.4%, respectively; <math>P=0.001</math>).</p>
<p>Sikich et al<sup>188</sup></p> <p>Olanzapine 2.5 mg to 12.5 mg daily, up to a maximum daily dose of 20 mg</p> <p>vs</p> <p>risperidone 0.5 to 3 mg daily, up</p>	<p>DB, PG, RCT</p> <p>Children and adolescents, 8 to 19 years, with psychotic symptoms secondary to either</p>	<p>N=50</p> <p>8 weeks</p>	<p>Primary: BPRS-C,</p> <p>Secondary: CGI-S, CGI-I, CPRS, response (defined as CGI-I score of 1 or 2 and at least a 20%</p>	<p>Primary: All treatment groups experienced a statistically significant improvement in BPRS-C scores from baseline (<math>P &lt; 0.05</math>), though the difference in BPRS-C score change among the three groups was not statistically significant (<math>P=0.2</math>).</p> <p>Secondary: CPRS-total scores were significantly improved from baseline in the risperidone and olanzapine groups (<math>P &lt; 0.005</math>). The change in CPRS-</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
<p>to a maximum daily dose of 6 mg</p> <p>vs</p> <p>haloperidol 1 to 5 mg daily, up to a maximum daily dose of 8 mg</p>	<p>schizophrenia spectrum or affective disorders</p>		<p>reduction in BPRS-C total score), adverse events</p>	<p>total scores did not significantly differ among the groups (P=0.416).</p> <p>CPRS-positive scores were significantly improved from baseline in all three treatment groups (P&lt;0.05), though the difference in CPRS-positive scores was not statistically significant among the three groups (P=0.252).</p> <p>CPRS-negative scores were significantly improved from baseline only in the risperidone group (P=0.005); however, there was no significant difference among the three groups (P=0.47).</p> <p>CGI-S scores were significantly improved from baseline in the risperidone and olanzapine treatment groups (P&lt;0.01), though the difference in CGI-S scores was not statistically significant among the three groups (P=0.064).</p> <p>CGI-I scores were significantly improved from baseline in the risperidone and olanzapine treatment groups (P=0.0018), though the difference in CGI-I scores was not statistically significant among the three groups (P=0.15).</p> <p>Treatment response was achieved by 88% of patients in the olanzapine group, 74% of patients in the risperidone group, and 53% of patients in the haloperidol group. The difference among the three groups was not statistically significant (P=0.12). However, there were differences in the mean time to response among the three antipsychotic groups: 1.6 weeks with olanzapine, 2.3 weeks with risperidone, and 2.4 weeks with haloperidol (P&lt;0.045).</p> <p>While more than 50% of patients treated with either olanzapine or risperidone experienced Parkinsonian symptoms, the incidence of EPS adverse events was significantly greater in the haloperidol group, compared to either of the atypical antipsychotics (P&lt;0.05). A larger percentage of patients in each group required low-dose anticholinergics to control their EPS: 67% with haloperidol, 56% with olanzapine, and</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>53% with risperidone.</p> <p>Significant weight gain from baseline was noted in all treatment groups: 15.7 lbs with olanzapine, 10.9 lbs with risperidone, and 7.8 lbs with haloperidol (P&lt;0.001). The difference in weight gain was statistically significant among groups (P=0.039).</p> <p>Compared to the other treatment groups, patients receiving olanzapine experienced a statistically significant glucose level elevation (P=0.008), although the change from baseline did not reach statistical significance (P=0.06).</p> <p>Haloperidol-treated patients experienced a statistically significant QTc elevation compared to baseline (P=0.031); none of the other treatment groups experienced significant ECG changes from baseline.</p>

\*Agent not available in the United States.

Study abbreviations: AC=active controlled, CC=case-control, CI=confidence interval, DB=double-blind, ES=extension study, I=International, MC=multicenter, OL=open-label, PC=placebo-controlled, PG=parallel-group, PH=post-hoc, PRO=prospective trial, R=randomized, RCT=randomized controlled trial, RETRO=retrospective, SR-systematic review, XO=cross-over

Miscellaneous abbreviations: BAC=Aberrant Behavior Checklist, AD=Alzheimer's Disease, ADHD=Attention Deficit Hyperactivity Disorder, ADHD-RS-IV=ADHD Rating Scale-Version IV, AIMS=Abnormal Involuntary Movement Scale, ASD=Autistic Spectrum Disorder, ASQ-P=Abbreviated Symptom Questionnaire for Parents, BAS=Barnes Akathisia Scale, BIS=Body Image Software, BMI=body mass index, BOCS=Yale-Brown Obsessive Compulsive Scale, BPRS=Brief Psychiatric Rating Scale, BPRS-A=Brief Psychiatric Rating Scale-Anchored Version, BSPS=Brief Social Phobia Scale, CAFAS=Child and Adolescent Functional Assessment Scale, CAPT=Color-A-Person Test, CARS-Childhood Autism Rating Scale, CBCL=Child Behavior Checklist, CDRS=Children's Depression Rating Scale, CGAS=Children's Global Assessment Scale, CGI=Clinical Global Impressions Scale, CGI-BP=Clinical Global Impressions-Bipolar Version Scale CGI-C=Clinical Global Impression of Change, CGAS=Children's Global Assessment Scale, CGI-C=Clinical Global Impression of Change, CGI-I=Clinical Global Impression-Improvement, CGI-S=Clinical Global Impression Severity, CGI-SI=Clinical Global Impression—Severity of Illness, CMAI=Cohen-Mansfield Agitation Inventory, CMRS-P=Child Mania Rating Scale-Parent Version, CPRS-CP=Connors' Parent Rating Scale, CPRS=Children's Psychiatric Rating Scale, CPS= Connors' Parent Scale, CPT=Continuous Performance Test, DRS-R98=Delirium Rating Scale Revised-98, CY-BOCS-PDD=Compulsion subscale of the Children's Yale Brown Obsessive Compulsive Scale Modified for PDD, DAS=Disability Assessment Scale, DOTES=Dosage Record Treatment Emergent Symptom Scale, DSM-IV=Diagnostic and Statistical Manual of Mental Disorders, 4<sup>th</sup> edition, EAT=Eating Attitude Test, EDI-2=Eating Disorder Inventory, ECG=electrocardiogram, EPS=EPS side effects, ESRS=EPS Symptom Rating Scale, GAD=generalized anxiety disorder, GAF=Global Assessment of Functioning Scale, GARS=Gilliam Autism Rating Scale, HALFS=Health and Life Functioning Scale, HAM-A=Hamilton Rating Scale for Anxiety, HAM-D=Hamilton Rating Scale for Depression, HbA<sub>1c</sub>=glycosylated hemoglobin, IBW=Ideal Body Weight, KADS=Kutcher Adolescent Depression Scale, MADRS=Montgomery-Asberg Depression Rating Scale, MASC=Multidimensional Anxiety Scale for Children, MBW=Median Body Weight, MDD=major depressive disorder, MJTS=Mendota Juvenile Treatment Center, MOAS=Modified Overt Aggression Scale, MSQ=Mood Symptom Questionnaire, MVLT-C=Modified Verbal Learning Test-Children's Version, N-CBRF=Nisonger Child Behavior Rating Form, NNH=number needed to harm, NNT=number needed to treat, NOS=Not Otherwise Specified, NPI=Neuropsychiatric Inventory, OAS=Overt Aggression Scale, OCD=Obsessive Compulsive Disorder, OR=Odds Ratio, PANSS=Positive and Negative Syndrome Scale, PAC=Personal Assessment Checklist, PANSS-P=Positive and Negative Syndrome Scale-Positive Subscale, PDD=Pervasive Developmental Disorder, PTSD=Post Traumatic Stress Disorder, PYMRS=Parent Young Mania Rating Scale, RAAPP=Rapid Assessment and Action Planning Process, REE=Resting Energy Expenditure, RF-RLRS=Ritvo-Freeman Real Life Rating Scale, SANS=Scale for the Assessment of Negative Symptoms, SAPS=Scale for the Assessment of Positive Symptoms, SAS=Simpson-Angus Scale, SAS=Riker Sedation Agitation Scale, SCARED=Screen for Child Anxiety-Related Emotional Disorders, SMC=standardized mean changes, SIAB-EX=Structured Inventory for Anorexic and Bulimic Syndromes-Exert Form, SNAP-IV=Swanson, Nolan, Pelham Scale-Version IV, PGDRS=Psychogeriatric Dependency Rating Scales, TPDDRS-Turgay DSM-IV Pervasive Developmental Disorder Rating Scale, TD=Tourette's Disorder, TRF=Teacher's Report Form, TSH=thyroid stimulating hormone, VABS=Vineline Adaptive Behavior Scale, VAS-MS=Visual Analog Scale for Most Troublesome Symptom, YBOCS=Yale-Brown Obsessive Compulsive Scale, YGTSS=Yale Global Tic Severity Scale, YMRS=Young Mania Rating Scale

**Table 7. Strength of Evidence for Off-Label Use of the Atypical Antipsychotics (2011 AHRQ Report)<sup>78,189</sup>**

Disease State	Aripiprazole	Olanzapine	Quetiapine	Risperidone	Ziprasidone
<b>Anxiety Disorder</b>					
General	NA	-	Moderate/High	-	-
Social Phobia	NA	Low	-	NA	NA
<b>ADHD</b>					
No comorbidity	NA	NA	NA	Low	NA
Bipolar	-	NA	NA	NA	NA
Mental Retardation	NA	NA	NA	Low	NA
<b>Dementia</b>					
Overall	Moderate/High	Low	Low	Moderate/High	NA
Psychosis	Low	Mixed	Mixed	Moderate/High	NA
Agitation	Low	Moderate/High	Mixed	Moderate/High	NA
<b>Depression</b>					
Augmentation of SSRI/SNRI	Moderate/High*	Low*	Moderate/High*	Moderate/High	Low
Monotherapy	NA	-	Moderate/High	NA	NA
<b>Eating Disorders</b>					
Insomnia	NA	NA	-	NA	NA
<b>Obsessive Compulsive Disorder</b>					
Augmentation of SSRI	NA	Low	--	Moderate/High	-
Augmentation of citalopram	NA	NA	Low	Low	NA
<b>Personality Disorder</b>					
Borderline	Low	Mixed	Low	NA	-
Schizotypal	NA	NA	NA	Mixed	NA
<b>Post Traumatic Stress Disorder</b>					
	NA	Mixed	Low	Moderate/High	NA
<b>Substance Abuse</b>					
Alcohol	--	-	-	NA	NA
Cocaine	NA	-	NA	-	NA
Methamphetamine	-	NA	NA	NA	NA
Methodone	NA	NA	NA	-	NA
<b>Tourette's Syndrome</b>					
	NA	NA	NA	Low	-

\*FDA-approved for the indication.

-Low or very low evidence of inefficacy.

-- Moderate or high evidence of inefficacy.

NA=No studies analyzed in this patient population or insufficient information.

ADHD=Attention Deficit Hyperactivity Disorder; SSRI=Selective Serotonin Reuptake Inhibitor; SNRI=Serotonin-Norepinephrine Reuptake Inhibitor.

**Table 8. Safety Clinical Trials Using the Antipsychotics in Adults**

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
<b>Mortality/Cardiovascular</b>				
Strom et al <sup>190</sup>  ZODIAC Study  Ziprasidone at varying doses  vs  olanzapine at varying doses	I, MC, OL, R  Patients, 18 years or older, diagnosed with schizophrenia	N=18,154  1 year	Primary: Non-suicide mortality in the year after initiation of assigned treatment  Secondary: All-cause mortality, mortality due to sudden death, mortality due to cardiovascular causes, mortality due to suicide, all-cause hospitalization, hospitalization for cardiovascular causes, diabetic ketoacidosis or psychiatric hospitalization, discontinuation rate	Primary: There was no significant difference between ziprasidone and olanzapine treatment groups with respect to non-suicide mortality (RR, 1.02; 95%CI, 0.76 to 1.39).  Secondary: There was no significant difference between ziprasidone and olanzapine treatment groups with respect to all-cause mortality (RR, 1.01; 95%CI, 0.77 to 1.33).  There was no significant difference between ziprasidone and olanzapine treatment groups with respect to mortality due to sudden death (RR, 0.67; 95%CI, 0.11 to 3.99).  There was no significant difference between ziprasidone and olanzapine treatment groups with respect to cardiovascular mortality, including fatal myocardial infarction and fatal arrhythmia (0.03 vs 0.09%; RR, 0.38; 95%CI, 0.10 to 1.41).  There was no significant difference between ziprasidone and olanzapine treatment groups with respect to mortality due to suicide (RR, 1.19; 95%CI, 0.61 to 2.31).  Significantly more patients were hospitalized for any cause in the ziprasidone group compared to patients receiving olanzapine (15.1 vs 10.9%; RR, 1.39; 95%CI, 1.29 to 1.50).  There was no significant difference between ziprasidone and olanzapine treatment groups with respect to hospitalization for myocardial infarction (RR, 1.18; 95%CI, 0.53 to 2.64).  There was no significant difference between ziprasidone and olanzapine treatment groups with respect to hospitalizations for arrhythmia or

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>arrhythmia reported during hospitalization for other reasons (RR, 1.75; 95%CI, 0.51 to 5.98).</p> <p>There was no significant difference between ziprasidone and olanzapine treatment groups with respect to hospitalization for diabetic ketoacidosis (RR, 1.00; 95%CI, 0.29 to 3.45).</p> <p>Significantly more patients in the ziprasidone group experienced psychiatric hospitalizations compared to patients receiving olanzapine (11.1 vs 7.5%; RR, 1.48; 95%CI, 1.35 to 1.62).</p> <p>At 6 months, 64.6% of ziprasidone-treated patients and 73% of olanzapine-treated patients remained on study medication (<math>P&lt;0.001</math>). At 12 months, 52.7% of ziprasidone-treated patients and 61.5% of olanzapine-treated patients remained on study medication (<math>P&lt;0.001</math>).</p>
<b>Metabolic</b>				
<p>Lamberti et al<sup>191</sup></p> <p>Clozapine</p> <p>vs</p> <p>general population</p>	<p>RETRO, cohort</p> <p>Adult outpatients with DSM-IV diagnosis of schizophrenia or schizoaffective disorder receiving clozapine for &gt;3 months without a documented history of diabetes prior to age 18</p>	<p>N=101</p> <p>1 year</p>	<p>Primary: Diagnosis of diabetes</p> <p>Secondary: Not reported</p>	<p>Primary: Point prevalence of diabetes mellitus was 25.7% compared to 7.9% of the general population (no statistical analysis provided).</p> <p>BMI, percentage of body fat, and gender were not associated with development of diabetes (<math>P=0.23</math> to 0.75). Mean age at time of clozapine initiation was higher in patients with diabetes (<math>P=0.05</math>).</p> <p>Development of diabetes was associated with a positive family history (<math>P=0.002</math>).</p> <p>Secondary: Not reported</p>
<p>Reist et al<sup>192</sup></p> <p>Second generation antipsychotics, (aripiprazole, clozapine, olanzapine, quetiapine, risperidone, or</p>	<p>CC, OS</p> <p>Data was collected from the Nationwide Inpatient Sample</p>	<p>N=exact numbers not reported</p> <p>15 years</p>	<p>Primary: Prevalence of obesity, diabetes, and diabetic ketoacidosis with or</p>	<p>Primary: The prevalence of obesity in controls increased from 1.2% in 1988 to 3.8% in 2002, yielding a 2.6% net increment in obesity prevalence rate.</p> <p>In contrast, there was a net increase of 12.6% in obesity prevalence from 1988 (5.9%), before the adoption of second generation antipsychotics, to</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
<p>ziprasidone)</p> <p>Doses for all regimens not reported.</p>	<p>database which includes 5-8 million inpatient hospital stays/year in order to approximate a 20% sample of United States community hospitals, for both schizophrenia and schizoaffective disorder; data was overlaid with data regarding the market penetration of the second generation antipsychotics in order to examine the prevalence rates of obesity, diabetes mellitus, and diabetic ketoacidosis with or without hyperosmolar coma among inpatients with schizophrenia compared to controls</p>		<p>without hyperosmolar coma in cases and controls for each study year</p> <p>Secondary: Not reported</p>	<p>2002 (18.5%), when second generation antipsychotics accounted for 86.0% of all new and repeat antipsychotic prescriptions.</p> <p>From 1988 to 1991, there was no significant change in obesity rates for cases or controls (<math>P&gt;0.60</math>). However, both groups showed significant increases in prevalence of obesity in the subsequent years, but notably, the increase was markedly larger for the cases (<math>P=0.016</math>).</p> <p>For diabetes mellitus, the prevalence in controls was 7.5% in 1988 and 15.3% in 2002, reflecting a net increase of 7.8% during this period.</p> <p>In cases, the prevalence of diabetes was 6.1% in 1988 and 17.4% in 2002. This represents a net increase of diabetes in cases (11.3%) vs controls (7.8%) during the 15-year study period.</p> <p>Analysis of variance of the data on diabetes from 1988 to 1997 found a significant increase in prevalence in both groups (<math>P=0.001</math>) but no difference in rates of change (<math>P=0.96</math>).</p> <p>For the years after 1997, however, the rate of change accelerated much faster for the cases vs the controls (<math>P&lt;0.0001</math>).</p> <p>For diabetic ketoacidosis with or without hyperosmolar coma, a regression analysis indicated that the diabetic ketoacidosis with or without hyperosmolar coma prevalence vs time curve for the cases started at a significantly lower minimum value (0.20%) vs the controls (0.26%) (<math>P=0.04</math>) and reached a higher maximum value (0.47% in cases vs 0.41% in controls) (<math>P=0.02</math>).</p> <p>Secondary: Not reported</p>
<p>Lambert et al<sup>193</sup></p> <p>Atypical antipsychotics</p>	<p>Matched CC</p> <p>California Medicaid</p>	<p>N=18,186</p> <p>5 years</p>	<p>Primary: Risk of developing diabetes</p>	<p>Primary: At 12 weeks, there was an increased risk of developing diabetes with clozapine (OR, 1.34; 95% CI, 1.16 to 1.55), olanzapine (OR, 1.36; 95%</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
(administered as either a low, medium or high dose)	data was used to identify patients (cases) who developed diabetes subsequent to being diagnosed with schizophrenia, patients were exposed to at least one antipsychotic during the 12 weeks preceding diabetes diagnosis		Secondary: Not reported	<p>CI, 1.20 to 1.53), and combination atypical therapy (OR, 1.58; 95% CI, 1.33 to 1.88). There was no increased risk with risperidone or quetiapine vs conventional antipsychotics.</p> <p>At 24 weeks, an increased risk of developing diabetes was seen with clozapine (OR, 1.32; 95% CI, 1.14 to 1.53), olanzapine (OR, 1.38; 95% CI, 1.22 to 1.56), or combination therapy (OR, 1.54; 95% CI, 1.29 to 1.84).</p> <p>At 52 weeks, increased risk of developing diabetes was seen with clozapine (OR, 1.41; 95% CI, 1.21 to 1.65), olanzapine (OR, 1.41; 95% CI, 1.24 to 1.60), or combination therapy (OR, 1.58; 95% CI, 1.31 to 1.90).</p> <p>Hispanic, African American, and unknown ethnicity were also significant risk factors for development of diabetes (OR, 1.4-1.6) as was exposure to combination therapy (OR, 1.6; 95% CI, 1.3 to 1.9).</p> <p>Secondary: Not reported</p>
<p>Olfson et al<sup>194</sup></p> <p>Antipsychotic medications (aripiprazole, clozapine, olanzapine, quetiapine, risperidone ziprasidone or a first generation agent)</p> <p>vs</p> <p>no antipsychotic agent</p> <p>Doses for all regimens not</p>	<p>CC, Cohort</p> <p>Claims data was collected from California Medicaid, cases included those aged 18-64 years with schizophrenia, major depression, bipolar disorder, or other affective psychoses and incident</p>	<p>N=85,273</p> <p>4 years</p>	<p>Primary: Relative risk of developing hyperlipidemia after treatment with antipsychotics</p> <p>Secondary: Not reported</p>	<p>Primary: There was a significant increase in the risk of incident hyperlipidemia with clozapine (OR, 1.82; 95% CI, 1.61 to 2.05), olanzapine (OR, 1.56; 95% CI, 1.47 to 1.67), quetiapine (OR, 1.52; 95% CI, 1.40 to 1.65), risperidone (OR, 1.53; 95% CI, 1.43 to 1.64), ziprasidone (OR, 1.40; 95% CI, 1.19 to 1.65), and first generation antipsychotics (OR, 1.26; 95% CI, 1.14 to 1.39), but not aripiprazole (OR, 1.19; 95% CI, 0.94 to 1.52).</p> <p>Secondary: Not reported</p>



Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
<p>reported.</p> <p>Gianfrancesco et al<sup>195</sup></p> <p>Olanzapine, risperidone, or high-potency (haloperidol, fluphenazine) or low-potency (chlorpromazine, thioridazine) conventional antipsychotics</p> <p>vs</p> <p>no treatment</p>	<p>hyperlipidemia</p> <p>RETRO</p> <p>Claims data for the period January 1996 through December 1997 were analyzed for patients with mood disorders, patients either received no antipsychotics or received them for at least 60 consecutive days</p>	<p>N=7,933</p> <p>1 year</p>	<p>Primary: Association of antipsychotic use and newly reported diabetes</p> <p>Secondary: Not reported</p>	<p>Primary: The risk of newly reported diabetes in patients who received risperidone was not significantly different compared to untreated patients (OR, 0.88; 95% CI, 0.372 to 2.070).</p> <p>However, there was a much greater risk of diabetes in patients treated with olanzapine (OR, 3.10; 95% CI, 1.620 to 5.934), high-potency conventional antipsychotics (OR, 2.13; 95% CI, 1.097 to 4.134) and low-potency conventional antipsychotics (OR, 3.46; 95% CI, 1.552 to 7.785) compared to untreated patients.</p> <p>There was also a dose dependent increase in risk based on olanzapine dose (OR, 1.161; <i>P</i>&lt;0.01). This correlates to an increased risk of diabetes equal to 16.1% for each 2.6 mg increase in olanzapine dose.</p> <p>Secondary: Not reported</p>
<p>Etminan et al<sup>196</sup></p> <p>Atypical neuroleptics (olanzapine, quetiapine, or risperidone)</p> <p>vs</p> <p>typical neuroleptics (chlorpromazine, chlorprothixene*, clorazepate, fluphenazine, flupenthixol*, haloperidol, loxapine, mesoridazine*, perphenazine, pimozide, prochlorperazine, or trifluoperazine)</p>	<p>RETRO Cohort</p> <p>Residents in long-term care institutions ≥65 years of age</p>	<p>N=11,104</p> <p>Duration not specified</p>	<p>Primary: Development of a diabetic event defined as prescribing of antidiabetic medication</p> <p>Secondary: Not reported</p>	<p>Primary: In comparing diabetes incidence rates per 1,000 patient years, the highest incidence was observed in the corticosteroid group (190) followed by typical neuroleptics (47), benzodiazepines (40) and atypical neuroleptics (31).</p> <p>Increased risk of developing diabetes was not observed in older adults receiving atypical neuroleptic medications vs those receiving benzodiazepines (adjusted HR, 0.89; 95% CI, 0.66 to 1.21; adjusted HR for typical neuroleptic treatment vs benzodiazepine group was 1.27; 95% CI, 0.91 to 1.77).</p> <p>The corticosteroid treatment group was nearly twice as likely to develop diabetes vs the benzodiazepine group (adjusted HR, 2.2; 95% CI, 1.41 to 3.12).</p> <p>The number of diabetic events did not differ between the risperidone,</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
vs control group (benzodiazepines) vs corticosteroids (positive control group)				olanzapine, or quetiapine groups (HR, 2.1%, 1.0%, and 2.1% respectively; <i>P</i> values not provided).  Secondary: Not reported
Simpson et al <sup>197</sup>  Atypical antipsychotics (mean doses listed; clozapine 323.0 mg daily, olanzapine 15.8 mg daily, quetiapine 384.4 mg daily, or risperidone 5.78 mg daily vs typical antipsychotics (mean doses listed; chlorpromazine 100.0 mg daily, fluphenazine 34.2 mg daily, haloperidol 9.0 mg daily, molindone 50.0 mg daily, perphenazine 23.8 mg daily, pimozide 2.5 mg daily, thioridazine 200.0 mg daily, or trifluoperazine 23.3 mg daily vs antipsychotic free period of 2-	NAT, RETRO  Review of all patients admitted to Schizophrenia Research Unit of New York Psychiatric Institute from 1994-1999	N=121  5 years  Specific time per individual patient not specified (range 6.4-12.4 weeks of therapy)	Primary: Weight gain per week, rate of weight gain, weekly change in BMI  Secondary: Not reported	Primary: More weight gain per week was observed in the atypical antipsychotic group compared to antipsychotic free periods ( <i>P</i> =0.031); however, there was no difference in rate of weight gain between antipsychotic free and typical antipsychotic treatment periods ( <i>P</i> value not reported).  Olanzapine treatment resulted in a higher rate of weight gain compared to clozapine and risperidone ( <i>P</i> =0.001) and there was no difference in rates of weight gain between clozapine and risperidone ( <i>P</i> value not reported).  Olanzapine treatment was associated with a higher rate of weight gain compared to the antipsychotic free period, typical antipsychotics and treatment with other atypical antipsychotics ( <i>P</i> =0.001).  Olanzapine and clozapine were associated with significantly higher weekly weight gain compared to the antipsychotic free period treatment group ( <i>P</i> =0.001 and 0.036); no difference in weekly weight gain was observed between risperidone treatment and the antipsychotic free period ( <i>P</i> =0.833).  There was no significant association between length of treatment and weight gain ( <i>P</i> value not reported).  Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
<p>4 weeks</p> <p>Guo et al<sup>198</sup></p> <p>Atypical antipsychotics (clozapine, olanzapine, quetiapine, risperidone, or ziprasidone)</p> <p>vs</p> <p>conventional antipsychotics (chlorpromazine, fluphenazine, haloperidol, loxapine, molindone, perphenazine, pimozide, thioridazine, thiothixene, or trifluoperazine)</p> <p>Doses for all regimens not reported.</p>	<p>CC, RETRO</p> <p>Medicaid claims from 7 states were analyzed for 283 patients with diabetes (cases) and 1,134 controls matched by age, sex, and date when bipolar disorder was diagnosed, all patients had at least a 3-month exposure to either conventional or atypical antipsychotics or three prescriptions related to treatment of bipolar disorder</p>	<p>N=1,417</p> <p>4 years</p>	<p>Primary: Risk of developing diabetes</p> <p>Secondary: Not reported</p>	<p>Primary: Compared to patients receiving conventional antipsychotics, the risk of diabetes was greatest with risperidone (HR, 3.8; 95% CI, 2.7 to 5.3), olanzapine (HR, 3.7; 95% CI, 2.5 to 5.3), and quetiapine (HR, 2.5; 95% CI, 1.4 to 4.3).</p> <p>The risk for developing diabetes was associated with weight gain (HR, 2.5; 95% CI, 1.9 to 3.4), hypertension (HR, 1.6; 95% CI, 1.2 to 2.2), and substance abuse (HR, 1.5; 95% CI, 1.0 to 2.2).</p> <p>Secondary: Not reported</p>
<p>Guo et al<sup>199</sup></p> <p>Atypical antipsychotics (41% of patients received either clozapine, olanzapine, risperidone, or ziprasidone)</p> <p>vs</p> <p>conventional antipsychotics (34% of patients received either chlorpromazine, fluphenazine, haloperidol,</p>	<p>CC, RETRO</p> <p>Patients with diabetes (N=928) were matched with controls (N=5,258) according to age, sex, and bipolar index.</p>	<p>N=6,178</p> <p>5 years</p>	<p>Primary: Risk of diabetes</p> <p>Secondary: Not reported</p>	<p>Primary: The risk of developing diabetes was greatest with clozapine (HR, 7.0; 95% CI, 1.7 to 28.9), olanzapine (HR, 3.2; 95% CI, 2.7 to 3.8), quetiapine (HR, 1.8; 95% CI, 1.4 to 2.4), and risperidone (HR, 3.4; 95% CI, 2.8 to 4.2), compared to conventional antipsychotics (HR, 1.5; 95% CI, 1.3 to 1.8).</p> <p>Secondary: Not reported</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
<p>pimozide, thioridazine, thiothixene, or trifluoperazine)</p> <p>Ostbye et al<sup>200</sup></p> <p>Atypical antipsychotic(s) (clozapine, olanzapine, quetiapine, risperidone, ziprasidone or a combination of two or more of these drugs)</p> <p>vs</p> <p>conventional antipsychotics (acetophenazine*, chlorpromazine, chlorprothixene*, fluphenazine, haloperidol, loxapine, mesoridazine*, molindone, perphenazine, prochlorperazine, promazine*, thioridazine, thiothixene, trifluoperazine, triflupromazine*)</p> <p>vs</p> <p>antidepressants</p> <p>vs</p> <p>antibiotic</p> <p>Doses not reported.</p>	<p>RETRO Cohort</p> <p>A pharmaceutical benefit manager database was used to identify outpatients with at least 1 claim for an atypical antipsychotic (cases; N=10,265) compared to (controls) claims for traditional antipsychotics (N=4,607), antidepressants (N=60,856) or antibiotics (N=59,878)</p>	<p>N=135,606</p> <p>2 years</p>	<p>Primary: Incidence of new onset diabetes</p> <p>Secondary: Not reported</p>	<p>Primary: The annual incidence rates of diabetes (new cases per 1,000 per year) were 7.5 for atypical antipsychotics, 11.3 for traditional antipsychotics, 7.8 for antidepressants and 5.1 for antibiotics (<i>P</i> value not reported).</p> <p>In multivariable analyses, age, male sex and Chronic Disease Score were associated with greater odds of diabetes onset (<i>P</i> value not reported).</p> <p>There were no statistically significant differences in outcome between the atypical antipsychotic, traditional antipsychotic and antidepressant groups (<i>P</i> value not reported).</p> <p>Comparisons among specific agents showed an increased risk of diabetes for clozapine, olanzapine, ziprasidone and thioridazine (relative to risperidone); however, these results were not statistically significant (no <i>P</i> values reported).</p> <p>Secondary: Not reported</p>
<p>Ollendorf et al<sup>201</sup></p>	<p>RETRO</p>	<p>N=2,443</p>	<p>Primary:</p>	<p>Primary:</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
<p>Atypical antipsychotics (clozapine, olanzapine, quetiapine, or risperidone)</p> <p>vs</p> <p>acetophenazine*, chlorpromazine, chlorprothixene*, fluphenazine, haloperidol, loxapine, mesoridazine*, molindone, perphenazine, pimozide, promazine*, thioridazine, thiothixene, trifluoperazine, or triflupromazine*</p> <p>Doses for all regimens not reported.</p>	<p>Analyzed medical and pharmacy claims for patients with schizophrenia who were treated with atypical or conventional antipsychotics between September 1996 and June 2001</p>	<p>4 years</p>	<p>Rate of new-onset diabetes</p> <p>Secondary: Not reported</p>	<p>The incidence of diabetes did not differ for atypical antipsychotics and conventional antipsychotics (2.46 vs 2.76%, respectively; <math>P=0.525</math>). The mean time to event across both groups was <math>62.2 \pm 35.8</math> days.</p> <p>When the overall atypical and conventional antipsychotic cohorts were compared, atypical antipsychotic use was temporally associated with a moderately increased risk of diabetes at one year after therapy initiation compared to conventional antipsychotics (HR, 1.172; 95% CI, 1.061 to 1.300; <math>P=0.0063</math>).</p> <p>Each increase in calendar year of therapy initiation was associated with a more than threefold increase in diabetes risk independent of therapeutic choice (HR, 3.581; 95% CI, 3.492 to 3.659; <math>P&lt;0.0001</math>).</p> <p>When atypical medication cohorts were compared, there were no significant differences with respect to the risk of new-onset diabetes (HR, 1.049; 95% CI, 0.930 to 1.168; <math>P=0.4308</math>; HR, 1.170; 95% CI, 0.967 to 1.372; <math>P=0.1291</math>; and HR, 1.467; 95% CI, 0.967 to 1.968; <math>P=0.1332</math> for olanzapine vs risperidone, quetiapine, and clozapine, respectively).</p> <p>Secondary: Not reported</p>
<p>Huang et al<sup>202</sup></p> <p>Conventional antipsychotics (haloperidol 10-15 mg/day, loxapine 100-150 mg/day, sulpiride* 800-1,200 mg/day)</p> <p>vs</p> <p>atypical antipsychotics (clozapine 100-300 mg daily, olanzapine 10-20 mg daily, risperidone 3-5 mg daily)</p>	<p>PRO</p> <p>Adult patients with schizophrenia as diagnosed by one psychiatrist using semi-structured clinical interview for DSM-IV criteria; &gt;1 week drug free prior to enrollment</p>	<p>N=182</p> <p>1 year</p>	<p>Primary: Relationship between serum lipid profiles and schizophrenia, effects of conventional antipsychotics and atypical antipsychotics on serum lipid profiles</p> <p>Secondary:</p>	<p>Primary: Schizophrenia was associated with increased HDL (<math>P=0.046</math>), VLDL (<math>P=0.004</math>) and decreased ratios of total cholesterol/HDL (<math>P=0.021</math>) and LDL/HDL (<math>P=0.002</math>). No changes in total cholesterol, triglycerides, and LDL levels were associated with schizophrenia (no <math>P</math> value provided).</p> <p>No changes in any lipid profile levels were observed in the haloperidol treatment group (<math>P=0.200</math> to <math>0.521</math>), loxapine was associated with decreased total cholesterol/HDL (<math>P=0.009</math>) and LDL/HDL (<math>P&lt;0.05</math>). Increased total cholesterol (<math>P=0.032</math>) and HDL (<math>P&lt;0.05</math>) and decreased total cholesterol/HDL and LDL/HDL (<math>P=0.006</math>) were observed in the risperidone group.</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
vs  control group, no antipsychotics			Not reported	Olanzapine treatment was associated with increased total cholesterol ( $P=0.049$ ) and VLDL levels ( $P=0.044$ ).  Patients with a positive response to treatment were observed to have increased total cholesterol ( $P=0.040$ ) and VLDL levels ( $P=0.002$ ) and decreased LDL/HDL ( $P=0.005$ ). No difference in total cholesterol/HDL change between responders and nonresponders was noted.  Secondary: Not reported
Wirshing et al <sup>203</sup>  Novel antipsychotics (clozapine, olanzapine, quetiapine, or risperidone)  vs  typical antipsychotics (fluphenazine or haloperidol)	R  Adult patients receiving any one of the listed antipsychotics	N=215  All laboratory values within 2.5 years before or after initiation of antipsychotic included	Primary: Change in glucose and lipid measurements  Secondary: Clinically significant elevations in glucose (fasting blood glucose $\geq 126$ mg/dL) and lipid measurements (total cholesterol $\geq 200$ mg/dL, LDL $\geq 160$ mg/dL, HDL $< 35$ mg/dL)	Primary: Treatment with clozapine, olanzapine, and haloperidol were associated with an increase in glucose levels from baseline (14%, 21%, and 7% respectively; $P=0.05$ , 0.03 and 0.04).  Clozapine and olanzapine treatment groups showed increases in maximum glucose levels (31 and 37% respectively; $P=0.03$ and 0.04).  No difference was observed between mean or maximum glucose between groups ( $P=0.3$ and 0.8).  Risperidone was associated with a decrease in maximum total cholesterol.  In post hoc analysis, clozapine treatment was associated with higher mean total cholesterol levels compared to fluphenazine ( $P=0.03$ ) and higher total cholesterol levels vs risperidone ( $P=0.02$ ).  Initiation of a cholesterol lowering agent was required in 15% of patients treated with clozapine and a dose increase cholesterol lowering agent was required in 13% of patients in the olanzapine treatment group; $P$ value not reported.  Secondary: No differences were found in the percentage of patients with clinically

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>significant changes in glucose levels between groups (<i>P</i> value not reported).</p> <p>Clinically significant elevations in total cholesterol were observed in 48% of clozapine-treated patients, 25% of olanzapine-treated patients, 21% of risperidone-treated patients and 25% of quetiapine-treated patients compared to 25% of patients receiving haloperidol and 28% of patients receiving fluphenazine (<i>P</i>=0.4).</p> <p>Clinically significant elevations in triglycerides were observed in 56% of patients receiving clozapine, 39% of patients receiving olanzapine, and 40% of patients receiving quetiapine compared to 0% of patients in the haloperidol treatment group and 8% of patients in the fluphenazine treatment group (<i>P</i>=0.002).</p> <p>Mean triglyceride levels in the clozapine and olanzapine treatment groups increased from baseline (<i>P</i>=0.01 and 0.02). Maximum triglyceride levels were also increased in the clozapine treatment group (<i>P</i>=0.02).</p> <p>Post hoc comparisons found higher triglyceride levels in patients treated with clozapine and olanzapine in comparison to those treated with haloperidol (clozapine vs haloperidol <i>P</i>=0.008, olanzapine vs haloperidol <i>P</i>=0.02) and fluphenazine (clozapine vs fluphenazine <i>P</i>=0.0003 and olanzapine vs fluphenazine <i>P</i>=0.002). Clozapine and olanzapine use resulted in higher triglyceride levels vs fluphenazine (<i>P</i>=0.004 and 0.02).</p> <p>No difference was observed in the percentage of patients that developed clinically significant decreases in HDL levels between the two treatment groups (<i>P</i>=0.1).</p>
<p>Wirshing et al<sup>204</sup></p> <p>Clozapine, olanzapine, risperidone, and sertindole*</p> <p>vs</p>	<p>RETRO</p> <p>An analysis of 122 clinical records was conducted involving 92 male patients</p>	<p>N=92</p> <p>6 years</p>	<p>Primary: Differences in weight gain</p> <p>Secondary: Not reported</p>	<p>Primary: The most weight gain was seen with clozapine and olanzapine (16.8±13.3 and 17.8±13.3 lb, respectively; <i>P</i>=0.01).</p> <p>Patients treated with clozapine and olanzapine appeared to gain weight over a prolonged period of time, whereas risperidone and sertindole</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
haloperidol	with schizophrenia			demonstrated a more limited period of weight gain ( $P=0.04$ ).  Secondary: Not reported
Hardy et al <sup>205</sup>  Olanzapine 7.5-25 mg daily  vs  risperidone 2-7.5 daily  vs  typical antipsychotics (agents and doses not provided, although fluphenazine and haloperidol described as most frequently used agents in this group)	MC  Adult outpatients with a DMS-IV diagnosis of schizophrenia or schizoaffective disorder for $\geq 5$ years, psychiatrically stable, $\geq 3$ months with no inpatient hospitalizations	N=211  $\geq 1$ year	Primary: Comparison of lipid panel  Secondary: Not reported	Primary: Mean fasting triglyceride levels were higher in the olanzapine group compared to the risperidone group ( $P=0.022$ ).  Median triglyceride levels did not differ between treatment groups ( $P$ value not provided).  No between group differences were observed in mean fasting total cholesterol, direct LDL-C, or HDL-C, or in total cholesterol /HDL-C ratios ( $P$ values not provided).  VLDL-C and ApoB levels were higher in the olanzapine group compared to the risperidone group ( $P=0.43$ and $0.011$ ).  Olanzapine treatment was associated with low HDL-C levels in comparison to typical antipsychotic treatment ( $P=0.03$ ) but not to the risperidone group ( $P$ value not provided).  Calculated VLDL-C and LDL particle concentrations were higher in the olanzapine group in comparison to the risperidone group ( $P=0.043$ , $P=0.44$ ); no differences in VLDL-C and LDL particle concentrations were observed between olanzapine and typical antipsychotic treatment groups ( $P$ value not provided).  No differences were observed between mean LDL, HDL, or VLDL particle size; mean fasting serum glucose, insulin levels, HbA <sub>1c</sub> , leptin, and uric acid values were also comparable ( $P$ values not provided).  Secondary: Not reported
McQuaid et al <sup>206</sup>	AC, DB, MC, R	N=316	Primary:	Primary:



Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
<p>Olanzapine 10-20 mg/day vs aripiprazole 15-30 mg/day</p>	<p>Adult patients with DSM-IV schizophrenia in acute relapse and requiring hospitalization</p>	<p>26 weeks</p>	<p>Change in weight  Secondary: Serum lipids, reduction in symptoms of schizophrenia (CGI and PANSS), incidence of EPS, blood pressure, heart rate, QTc, mean fasting glucose, serum prolactin levels</p>	<p>A greater proportion of patients receiving olanzapine experienced significant (&gt;7%) weight gain compared to those treated with aripiprazole (37 vs 14%; <math>P&lt;0.001</math>).</p> <p>Secondary: Treatment with olanzapine when compared to aripiprazole was associated with increased serum triglycerides and decreased HDL (<math>P&lt;0.05</math>) and increased total cholesterol and LDL levels (not statistically significant; <math>P</math> value not reported).</p> <p>Treatment with olanzapine was associated with increased incidence of new lipidemias, increased total cholesterol, LDL, and triglycerides (<math>P&lt;0.05</math>), as well as decreased HDL (<math>P</math> value not reported).</p> <p>No significant difference was observed between the two agents in reduction of symptoms of schizophrenia, change in serum glucose levels, and rate of EPS (<math>P</math> value not reported).</p> <p>Mean decreases in serum prolactin from elevated baseline levels were observed in both treatment groups (<math>P</math> value not reported).</p> <p>Patients with normal baseline levels treated with olanzapine and aripiprazole were observed to have prolactin levels above the upper limits of normal at some point during the trial (37 vs 8%; <math>P</math> value not reported).</p>
<p>Zipursky et al<sup>207</sup>  Olanzapine 2-20 mg daily vs haloperidol 5-20 mg daily</p>	<p>DB, MC, R  Patients aged 16-40 with first episode DSM-IV diagnosis of schizophrenia, schizophreniform disorder, or schizo-affective disorder</p>	<p>N=263  2 years</p>	<p>Primary: Clinically significant weight gain (&gt;7%)  Secondary: BMI, nonfasting blood glucose, non-fasting cholesterol, clinical improvement defined as PANNS</p>	<p>Primary: Olanzapine was associated with a faster rate of clinically significant weight gain in comparison to haloperidol (<math>P&lt;0.0001</math>).</p> <p>Likelihood of clinically significant weight gain was more than five times greater for the olanzapine treatment group vs the haloperidol treatment group (HR, 5.19; <math>P&lt;0.001</math>).</p> <p>Higher baseline weight was associated with longer time to weight gain (<math>P&lt;0.0001</math>).</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
			reduction of $\geq 10$ points	<p>Secondary: Increase in BMI was not correlated with increases in nonfasting glucose (<i>P</i> value not reported).</p> <p>Increased BMI was associated with increases in nonfasting cholesterol levels (<i>P</i>&lt;0.01 olanzapine, <i>P</i>&lt;0.29 haloperidol).</p> <p>Clinical improvement was associated with the amount of weight gained and increase in BMI at week one and week six (<i>P</i>=0.02 and <i>P</i>&lt;0.001) but not after week 12 (<i>P</i> value not reported for weight, <i>P</i>&lt;0.001 for BMI).</p>
<p>Moisan et al<sup>208</sup></p> <p>Olanzapine vs risperidone</p>	<p>RETRO</p> <p>Ambulatory patients receiving an atypical antipsychotic medication from January 1997 through August 1999</p>	<p>N=19,582</p> <p>44 months</p>	<p>Primary: Initiation of antidiabetic drug therapy, initiation of lipid-lowering drug therapy</p> <p>Secondary: Not reported</p>	<p>Primary: The risk of initiating antidiabetic drug therapy was higher in the olanzapine treatment group in comparison to the risperidone treatment group (IRR, 1.33; 95% CI, 1.03 to 1.73).</p> <p>Olanzapine therapy was associated with a higher risk of initiating a lipid-lowering agent in comparison with risperidone therapy (IRR, 1.49; 95% CI, 1.22 to 1.83).</p> <p>Risk of initiating either an antidiabetic or lipid lowering medication was higher among patients receiving olanzapine when compared to risperidone (IRR, 1.47; 95% CI, 1.23 to 1.76).</p> <p>Secondary: Not reported</p>
<p>Caro et al<sup>209</sup></p> <p>Olanzapine vs risperidone</p>	<p>RETRO</p> <p>Outpatients receiving olanzapine and risperidone</p>	<p>N=32,328</p> <p>2 years</p>	<p>Primary: Primary diagnosis of diabetes identified by ICD-9 code or claim for insulin or oral hypoglycemic agent</p> <p>Secondary:</p>	<p>Primary: Crude hazard ratio of diabetes for all patients was 1.08 (95% CI, 0.89 to 1.31; <i>P</i>=0.43).</p> <p>Proportional hazard analyses adjusting for duration of olanzapine exposure indicated a RR of diabetes with olanzapine of 1.9 during the first three months of therapy (95% CI, 1.40 to 2.57; <i>P</i>&lt;0.0001) when compared to risperidone.</p> <p>Secondary:</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
Brown et al <sup>210</sup>  Olanzapine  vs  ziprasidone	RETRO  Adults with schizophrenia and other psychoses	N=191  Duration not specified	Not reported  Primary: QT <sub>C</sub> interval, weight, metabolic parameters  Secondary: Not reported	Not reported  Primary: No significant differences in QT <sub>C</sub> intervals were found ( <i>P</i> value not reported).  Significant weight gain was seen in the olanzapine group ( <i>P</i> <0.001) but not in the ziprasidone group ( <i>P</i> >0.05).  Significant metabolic changes were seen in the olanzapine group: increased total cholesterol ( <i>P</i> =0.01), increased triglycerides ( <i>P</i> =0.05) and increased HbA <sub>1c</sub> ( <i>P</i> <0.05).  Favorable metabolic changes were observed for the ziprasidone group for total cholesterol ( <i>P</i> <0.05), LDL ( <i>P</i> <0.01), HDL ( <i>P</i> <0.05), and HbA <sub>1c</sub> ( <i>P</i> <0.05).  Secondary: Not reported
Basson et al <sup>211</sup>  Study 1: Olanzapine  vs  haloperidol  Study 2: Olanzapine 10-20 mg daily  vs  risperidone 4-12 mg daily  Doses for Study 1 varied per	DB, MC, R  Study 1: Adult patients with DSM-III-R criteria for schizophrenia, schizoaffective disorder or schizophreniform disorder  Study 2: Adult patients with DSM-IV-R criteria for schizophrenia, schizoaffective disorder or	Study 1: N=1,996 6 weeks  Study 2: N=339 28 weeks	Primary: Change in weight, appetite  Secondary: Change in BPRS	Study 1: Primary: Treatment with olanzapine was associated with significantly greater weight gain than haloperidol ( <i>P</i> <0.001).  Low BBMI (<25) was associated with more weight gain than high BBMI (>25; <i>P</i> <0.001) without regard to treatment group.  Olanzapine was associated with a greater increase in appetite compared to haloperidol ( <i>P</i> <0.001) and this increase in appetite correlated with weight gain ( <i>P</i> <0.001).  Age was not a predictor of weight change ( <i>P</i> =0.573). More weight gain was observed in males vs females with olanzapine ( <i>P</i> <0.001), and nonwhite patients gained more weight than white patients across both treatment groups ( <i>P</i> <0.001).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
patient and ranges were not specified.	schizophreniform disorder			<p>Dose was not correlated with weight gain (<math>P=0.059</math>).</p> <p>Secondary: Better clinical outcome (<math>BPRS \leq 18</math>) was associated with more weight gain (<math>P &lt; 0.003</math>) with no correlation to treatment group.</p> <p>Study 2: Primary: Differences in weight change between olanzapine and risperidone were not significant (<math>P &lt; 0.387</math>).</p> <p>Low BBMI (<math>\leq 25</math>) was associated with more weight gain than high BBMI (<math>&gt; 25</math>; <math>P &lt; 0.001</math>).</p> <p>The effects of both clinical outcome and BBMI on weight change did not differ between the two groups (<math>P</math> value not reported).</p> <p>No significant difference in appetite increase was observed between olanzapine and risperidone (25.6 vs 23.0%; <math>P=0.230</math>).</p> <p>Age <math>&lt; 34.7</math> was associated with more weight gain (<math>P=0.29</math>), but no difference in the effect of age was observed between the two treatment groups (<math>P</math> value not reported).</p> <p>No significant association was observed between gender and weight gain (<math>P=0.057</math>).</p> <p>Race (<math>P=0.154</math>) and dose (no <math>P</math> value reported) were not predictors of weight change.</p> <p>Secondary: Better clinical outcome (<math>BPRS \leq 17</math>) was associated with more weight gain (<math>P=0.001</math>).</p>
Wu et al <sup>212</sup>	PRO	N=112	Primary: Effect on glucose	Primary: Clozapine and olanzapine treatment were associated with increases in

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
<p>Clozapine 200-400 mg once daily</p> <p>vs</p> <p>olanzapine 10-20 mg once daily</p> <p>vs</p> <p>risperidone 2-5 mg once daily</p> <p>vs</p> <p>sulpiride* 600-1,000 mg once daily</p>	<p>Adult patients aged 18-45 with first episode schizophrenia diagnosed in accordance with DSM-IV criteria</p>	<p>≥16 weeks</p>	<p>and lipid metabolism</p> <p>Secondary: Change in BMI, WHR, fasting blood sugar, fasting insulin, C-peptide, cholesterol, triglyceride levels</p>	<p>cholesterol and triglyceride levels (<math>P=0.035</math> to <math>0.040</math>).</p> <p>Mean blood glucose levels were decreased in all treatment groups (<math>P=0.09</math> to <math>0.172</math>).</p> <p>Secondary: A significant increase in mean BMI and WHR were observed in the clozapine, olanzapine and sulpiride groups (<math>P=0.008</math> to <math>0.047</math>) but not in the risperidone group (<math>P=0.07</math> and <math>0.085</math>).</p> <p>Increases in insulin and C-peptide levels were observed in all treatment groups (<math>P=0.009</math> to <math>0.044</math>). A decrease in mean blood glucose was observed in each of the four groups (<math>P=0.09</math> to <math>0.172</math>).</p> <p>Pairwise comparisons revealed a higher change in BMI in those treated with clozapine in comparison to olanzapine (<math>P=0.011</math>) and clozapine and olanzapine were associated with increases in rates of elevated insulin and C-peptide levels in comparison to risperidone and sulpiride (<math>P=0.001</math> to <math>0.043</math>).</p>
<p>Mukundan et al<sup>213</sup></p> <p>Switching to a different antipsychotic depot formulation, switching from olanzapine to another atypical antipsychotic, or switching to aripiprazole from another atypical antipsychotic</p> <p>vs</p> <p>continuation on previous antipsychotic regimen</p>	<p>SR</p> <p>Patients diagnosed with schizophrenia or schizophrenia-like illness, with weight or metabolic problems</p>	<p>N=636</p> <p>≤26 weeks</p>	<p>Primary: Change in weight and physiological measures</p> <p>Secondary: Fasting blood glucose, discontinuation, mental state, global state, adverse events</p>	<p>Primary: Patients who switched to aripiprazole or quetiapine from olanzapine experienced a nonsignificant mean weight loss of 1.94 kg (95% CI, -3.9 to 0.08).</p> <p>BMI decreased when patients were switched from olanzapine to quetiapine (MD, -0.52; 95%CI, -1.26 to 0.22) and aripiprazole (RR, 0.28; 95% CI, 0.13 to 0.57).</p> <p>Secondary: Fasting blood glucose levels were significantly decreased when patients were switched from olanzapine to aripiprazole or quetiapine (MD, -2.53 95% CI, -2.94 to -2.11).</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>Patients were less likely to discontinue from the study early when they remained on olanzapine compared to switching to quetiapine or aripiprazole.</p> <p>There were no significant differences in outcomes of mental state, global state, and adverse events between groups that switched medications and those that remained on previous medication.</p>
<p>Rummel-Kluge et al<sup>214</sup></p> <p>Aripiprazole vs clozapine vs olanzapine vs quetiapine vs risperidone vs ziprasidone</p>	<p>MA</p> <p>Randomized, controlled, head-to-head studies in patients receiving atypical antipsychotics for the treatment of schizophrenia or related disorders</p>	<p>N=not reported (48 studies)</p> <p>Study duration not reported</p>	<p>Primary: Weight change</p> <p>Secondary: Change in cholesterol, glucose level</p>	<p>Primary: Clozapine was associated with significantly more weight gain from baseline compared to risperidone (MD, 2.86 kg).</p> <p>Olanzapine was associated with significantly more weight gain from baseline compared to aripiprazole (MD, 3.9 kg), quetiapine (MD, 2.68 kg), risperidone (MD, 2.44 kg), and ziprasidone (MD, 3.82 kg).</p> <p>No significant differences in weight gain were observed between aripiprazole and risperidone, clozapine and olanzapine, clozapine and quetiapine, quetiapine and risperidone, quetiapine and ziprasidone, and risperidone and ziprasidone (<i>P</i> values not reported).</p> <p>Secondary: Olanzapine was associated with significantly greater cholesterol increase compared to aripiprazole (MD, 15.35 mg/dl), risperidone (MD, 12.92 mg/dl), and ziprasidone (MD, 15.83 mg/dl).</p> <p>Quetiapine was associated with significantly greater cholesterol increase compared to ziprasidone (MD, 16.01 mg/dl) and risperidone (MD, 8.61 mg/dl).</p> <p>Risperidone was associated with significantly greater cholesterol increase compared to aripiprazole (MD, 22.3 mg/dl) and ziprasidone (MD, 8.58 mg/dl).</p> <p>There was no statistically significant difference in cholesterol change from baseline between olanzapine and quetiapine groups (<i>P</i> value not reported).</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>reported).</p> <p>Olanzapine was associated with significantly greater increase in glucose levels from baseline compared to aripiprazole (MD, 4.13 mg/dl), quetiapine (MD, 9.32 mg/dl), risperidone (MD, 5.94 mg/dl), and ziprasidone (MD, 8.25 mg/dl).</p> <p>There were no statistically significant differences in glucose changes from baseline between aripiprazole and risperidone, quetiapine and risperidone, quetiapine and ziprasidone, risperidone and ziprasidone, clozapine and olanzapine, and between clozapine and risperidone.</p>
<b>EPS</b>				
<p>Ghaemi et al<sup>215</sup></p> <p>Chart review of patients with a trial of at least one of the following atypical neuroleptics: aripiprazole, olanzapine, quetiapine, risperidone and ziprasidone</p>	<p>OL, RETRO, descriptive study</p> <p>Patients with bipolar disorder type I and II</p>	<p>N=34 (51 trials)</p> <p>107 weeks</p>	<p>Primary: Assessing the risk of EPS using the AIMS, BAS and SAS scales</p> <p>Secondary: Not reported</p>	<p>Primary: The combined AIMS, BAS, and SAS scores demonstrated that EPS were reported most frequently with risperidone (76.5%) and quetiapine (72.7%), followed by ziprasidone (50.0%), and olanzapine (46.2%), (individual scores and <i>P</i> vales not reported).</p> <p>Less akathisia was observed with low potency agents compared to high potency agents (OR, 0.22; 95% CI, 0.05 to 0.96), and with older age (OR, 0.95; 95% CI, 0.91 to 1.00).</p> <p>Secondary: Not reported</p>
<p>Gharabawi et al<sup>216</sup></p> <p>Risperidone long-acting 25 mg intramuscularly every 2 weeks plus risperidone by mouth unspecified dosage for first 2 to 3 weeks (separate entities)</p> <p>vs</p>	<p>MC, OL</p> <p>Clinically stable patients 18-84 years of age with DSM-IV diagnosis of schizophrenia or schizoaffective disorder</p>	<p>N=662 (530 no dyskinesia at baseline, 132 with dyskinesia at baseline; 25 mg, 114; 50 mg, 192; 75 mg, 224)</p>	<p>Primary: Treatment-emergent persistent tardive dyskinesia, severity of dyskinesia</p> <p>Secondary: ESRS</p>	<p>Primary: For patients with no dyskinesia at baseline, treatment-emergent persistent tardive dyskinesia occurred in 0.94% of patients in all treatment groups, with a calculated one year rate of 1.19% (95% CI, 0.15 to 2.24). Treatment-emergent persistent tardive dyskinesia occurred in 0.88%, 1.04%, and 0.89% of patients receiving 25 mg, 50 mg, and 75 mg of long-acting risperidone, respectively (<i>P</i> values not reported).</p> <p>For patients with dyskinesia at baseline, the mean ESRS physician's exam for dyskinesia score improved by -2.77 points and the mean CGI for dyskinesia score improved by -1.2 points by 50 weeks (<i>P</i>&lt;0.001).</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
<p>risperidone long-acting 50 mg intramuscularly every 2 weeks plus risperidone orally unspecified dosage for first 2 to 3 weeks (separate entities)</p> <p>vs</p> <p>risperidone long-acting 75 mg intramuscularly every 2 weeks plus risperidone orally unspecified dosage for first 2 to 3 weeks (separate entities)</p>		50 weeks		<p>Improvement that lasted the study duration occurred in 27.3% of these patients. There was no significant difference in improvement between patients receiving anticholinergic agents or not (<math>P=0.243</math>).</p> <p>Secondary: For all patients, the mean ESRS physician's exam for Parkinsonism score improved by -5.6 points and the mean CGI for Parkinsonism score improved by -1.7 points by 50 weeks (<math>P&lt;0.001</math>). There was no significant difference in improvement between patients receiving anticholinergic agents or not (<math>P=0.85</math>).</p>
<p>Emsley et al<sup>217</sup></p> <p>Haloperidol 5 mg by mouth per day for 4 days, 10 mg by mouth per day for <math>\geq 3</math> days, then flexible dose adjustments as needed up to 20 mg by mouth per day</p> <p>vs</p> <p>quetiapine 100 mg by mouth per day for 2 days, 200 mg by mouth per day for 2 days, 300 mg by mouth per day for 2 days, 400 mg by mouth per day for <math>\geq 1</math> day, then flexible dose adjustments as needed up to 800 mg by mouth per day</p>	<p>PG, RCT, SB</p> <p>Clinically stable patients 18-65 years of age with DSM-IV diagnosis of tardive dyskinesia and schizophrenia or schizoaffective disorder</p>	<p>N=45</p> <p>52 weeks</p>	<p>Primary: Change in dyskinesia scores over time</p> <p>Secondary: Treatment effect on psychotic symptoms, other EPS, weight change, BMI changes, serum prolactin changes, HbA<sub>1c</sub> changes</p>	<p>Primary: ESRS dyskinesia subscale scores decreased over time for both treatment groups (<math>P&lt;0.001</math>). Patients receiving quetiapine had significantly lower ESRS scores than patients receiving haloperidol at six months (<math>P=0.01</math>) and nine months (<math>P=0.004</math>), but not at 12 months (<math>P=0.1</math>).</p> <p>Patients receiving quetiapine had significantly lower CGI scores than patients receiving haloperidol at six months (<math>P=0.03</math>), nine months (<math>P=0.001</math>) and at 12 months (<math>P=0.03</math>). Response of <math>\geq 50\%</math> reduction in CGI dyskinesia score in patients receiving quetiapine and haloperidol was 64% and 37% at six months, and 55% and 28% at 12 months, respectively (<math>P</math> values not reported).</p> <p>Secondary: PANSS scores were not significantly different between treatment groups (<math>P</math> value not reported).</p> <p>EPS other than dyskinesia decreased more in patients receiving quetiapine than haloperidol at three months (<math>P=0.01</math>), six months (<math>P=0.01</math>), and nine months (<math>P=0.002</math>), but not at 12 months (<math>P=0.3</math>). Anticholinergic medication was needed in 27% and 61% of patients receiving quetiapine and haloperidol, respectively (<math>P</math> value not reported).</p>



Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>There was no significant difference in weight change for either treatment group (<i>P</i> value not reported).</p> <p>In patients receiving haloperidol and quetiapine, mean serum prolactin levels changed +10.3 ng/mL and -16.3 ng/mL, respectively (<i>P</i>=0.005).</p> <p>There was no significant difference in HbA<sub>1c</sub> levels for either treatment group (<i>P</i> value not reported).</p>
<p>Ritchie et al<sup>218</sup></p> <p>Olanzapine 5 mg daily</p> <p>or</p> <p>risperidone 0.5 mg daily</p>	<p>OL, XO</p> <p>Elderly patients over the age of 60 with schizophrenia who were taking conventional neuroleptics</p>	<p>N=66</p> <p>3 years</p>	<p>Primary: Quality of life, efficacy, safety</p> <p>Secondary: Not reported</p>	<p>Primary: Patients switched to risperidone showed no significant change to any aspect of their quality of life. Patients switched to olanzapine demonstrated significant improvement in psychological well being (<i>P</i>=0.002), physical well being (<i>P</i>=0.006), and their perceived health status (<i>P</i>=0.04).</p> <p>Secondary: Not reported</p>
<p>Mullen et al<sup>219</sup></p> <p>Quetiapine 329 mg/day (maximum mean daily dose)</p> <p>vs</p> <p>risperidone 5.0 mg/day (maximum mean daily dose)</p>	<p>MC, OL, RCT</p> <p>Patients older than 18 years of age classified by the DSM-IV criteria as having schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, MDD with psychotic features, dementia of Alzheimer's disease with</p>	<p>N=728</p> <p>4 months</p>	<p>Primary: Comparison of relative safety, tolerability (EPS, adverse events), and efficacy</p> <p>Secondary: Not reported</p>	<p>Primary: After adjusting for baseline differences, patients receiving risperidone were significantly more likely to develop EPS and substantial EPS over long-term treatment (<i>P</i>=0.003 and <i>P</i>&lt;0.001).</p> <p>During initial (one month) treatment there was no difference in the chance of developing EPS amongst the two groups with 41.1% of quetiapine patients and 47.3% of risperidone patients experiencing EPS initially. Anti-EPS medication was required in 51.6% of risperidone-treated patients compared to 31.7% of quetiapine-treated patients (<i>P</i>&lt;0.001).</p> <p>The rate of withdrawal in the quetiapine group was 31.8% and 33.7% in the risperidone group. Risperidone withdrawals were mostly attributed to lack of efficacy and quetiapine withdrawals due to the incidence of side effects.</p> <p>Somnolence occurred more frequently in the quetiapine group (31.1 vs</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
	psychotic symptoms, vascular dementia, or dementia due to substance abuse			<p>15.4%; <math>P &lt; 0.001</math>). Other measured side effects, including dry mouth, dizziness, and agitation were found to be more frequent in the quetiapine group (<math>P &lt; 0.05</math>). Although insomnia and headache were reported more frequently with quetiapine, the difference was not significant.</p> <p>Both groups were found to be efficacious as determined by the CGI-Global Improvement scores (<math>P = 0.087</math>). While there were no changes in PANSS total scores between the two groups, the quetiapine group showed a significant increase in the improvement of depressive symptoms (<math>P = 0.028</math>).</p> <p>Secondary: Not reported</p>
<p>Modestin et al<sup>220</sup></p> <p>Clozapine</p> <p>vs</p> <p>typical neuroleptic</p> <p>vs</p> <p>clozapine in combination with a typical neuroleptic</p>	<p>Cohort</p> <p>200 inpatients with an average age of 45 for men and 53 for women who had received continuous typical neuroleptic treatment for at least 3 days</p>	<p>N=200</p> <p>Duration not reported</p>	<p>Primary: EPS (Parkinson syndrome, akathisia and tardive dyskinesia)</p> <p>Secondary: Not reported</p>	<p>Primary: Tardive dyskinesia was noted significantly more often in the clozapine group compared to the typical neuroleptic group (<math>P = 0.024</math>).</p> <p>Older subjects were found to be more susceptible to EPS than younger subjects in all groups (<math>P = 0.020</math>).</p> <p>There was no significant difference found between the groups in Parkinson syndrome and akathisia (<math>P</math> value was not reported).</p> <p>Secondary: Not reported</p>
<p>Schillevoort et al<sup>221</sup></p> <p>Haloperidol</p> <p>vs</p> <p>risperidone</p> <p>vs</p>	<p>Cohort</p> <p>Patients 15-54 years of age initiating treatment with risperidone, olanzapine, or haloperidol for the first time between January 1, 1994,</p>	<p>N=848</p> <p>Duration not reported</p>	<p>Primary: Antiparkinsonian medications usage</p> <p>Secondary: Not reported</p>	<p>Primary: After cohort, 13.2% of the patients using haloperidol, 11.9% of the patients using risperidone and 5.0% of the patients using olanzapine started antiparkinsonian medications. Compared to haloperidol there was an adjusted relative risk of 0.57 (95% CI, 0.31 to 1.04) for risperidone and 0.19 (95% CI, 0.08 to 0.48) for olanzapine.</p> <p>Prior use of antiparkinsonian medication was significantly more common among the risperidone and olanzapine group when compared to those using haloperidol (<math>P = 0.001</math>).</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
olanzapine	and June 30, 1999			<p>Prior to cohort entry, 12, 11, and five antiparkinsonian medications were received by users of risperidone, olanzapine, and haloperidol, respectively (<math>P&lt;0.05</math>).</p> <p>Secondary: Not reported</p>
<p>Rummel-Kluge et al<sup>222</sup></p> <p>Aripiprazole 10 mg to 30 mg daily</p> <p>vs</p> <p>clozapine 300 mg to 800 mg daily</p> <p>vs</p> <p>olanzapine 10 mg to 20 mg daily</p> <p>vs</p> <p>quetiapine 250 mg to 750 mg daily</p> <p>vs</p> <p>risperidone 4 mg to 6 mg daily</p> <p>vs</p> <p>ziprasidone 120 mg to 160</p>	<p>MA</p> <p>Randomized, blinded, head-to-head studies comparing atypical antipsychotics in patients diagnosed with schizophrenia or related disorders</p>	<p>N=not reported (54 studies)</p> <p>Study duration not reported</p>	<p>Primary: Use of antiparkinson medication</p> <p>Secondary: Barnes Akathisia Scale (BAS), Simpson Angus Scale (SAS)</p>	<p>Primary: Risperidone was associated with significantly more use of antiparkinson medication than all other atypical antipsychotics (vs clozapine: RR, 2.57; <math>P=0.0009</math>, NNH=6; vs olanzapine: RR, 1.28; <math>P=0.01</math>; NNH=17; vs quetiapine: RR, 1.98; <math>P=0.01</math>; NNH=20; vs ziprasidone: RR, 1.42; <math>P=0.03</math>; NNH=17), except for aripiprazole (RR, 1.68; <math>P=0.11</math>) where no significant differences were found.</p> <p>Ziprasidone was associated with significantly more use of antiparkinson medication than olanzapine (RR, 1.43; <math>P=0.03</math>; NNH = 20) and quetiapine (RR, 2.32; <math>P=0.03</math>; NNH=25). No significant difference was found between ziprasidone and clozapine (RR, 1.11; <math>P=0.39</math>).</p> <p>Aripiprazole was associated with significantly more use of antiparkinson medication compared to olanzapine (RR, 1.8; <math>P=0.005</math>; NNH=14). There was no statistically significant difference between aripiprazole and risperidone (<math>P=0.11</math>).</p> <p>Clozapine was associated with significantly less use of antiparkinson medication than risperidone (RR, 0.39; <math>P=0.0009</math>; NNT=6).</p> <p>Olanzapine was associated with significantly less antiparkinson medication compared to aripiprazole (RR, 0.55; <math>P=0.005</math>; NNT=14), risperidone (RR, 0.78; <math>P=0.01</math>; NNT=17), and ziprasidone (RR, 0.7; <math>P=0.03</math>; NNT=20). There was no significant difference compared to clozapine (<math>P=0.69</math>). However, olanzapine was associated with significantly more EPS than quetiapine (RR, 2.05; <math>P=0.004</math>; NNH=25).</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
mg daily				<p>Quetiapine was associated with the least use of antiparkinson medication compared to all three other agents for which comparisons were available (vs olanzapine: RR, 0.49; <math>P=0.004</math>; NNT=25; vs risperidone: RR, 0.5; <math>P=0.01</math>; NNT=20; vs ziprasidone: RR, 0.43; <math>P=0.03</math>; NNT=25).</p> <p>Secondary: Aripiprazole was associated with more akathisia than olanzapine (<math>P=0.04</math>) and clozapine more than ziprasidone (<math>P&lt;0.0001</math>). Risperidone was associated with more akathisia than ziprasidone (<math>P&lt;0.00001</math>).</p> <p>Risperidone was associated with more EPS according to the SAS than quetiapine (<math>P=0.04</math>) and ziprasidone (<math>P&lt;0.00001</math>).</p>
<b>Sexual Dysfunction</b>				
<p>Byerly et al<sup>223</sup></p> <p>Quetiapine 200 mg/day titrated to 300-400 mg/day</p> <p>Patients were previously treated with risperidone 4-5 mg/day or haloperidol 10 mg/day.</p>	<p>Cohort, OL, OS</p> <p>Adult males 24-50 years of age with schizophrenia or schizoaffective disorder; excluded if they were taking clozapine, had medical conditions or medications known to cause sexual dysfunction</p>	<p>N=8</p> <p>6 weeks</p>	<p>Primary: Sexual functioning evaluated using ASEX scores</p> <p>Secondary: Prolactin levels, PANSS</p>	<p>Primary: Quetiapine was associated with a clinically and statistically significant improvement in ASEX total scores at the end of the study when compared to baseline ASEX (<math>P=0.008</math>).</p> <p>Secondary: PANSS total scores decreased significantly from baseline to study end with quetiapine (<math>P=0.03</math>).</p> <p>A nonsignificant change was noted in plasma prolactin levels after transitioning to quetiapine (<math>P=0.09</math>).</p>
<p>Aizenberg et al<sup>224</sup></p> <p>Clozapine 100-400 mg by mouth once daily</p> <p>vs</p> <p>classical antipsychotics, including: fluphenazine</p>	<p>CS, OS</p> <p>Healthy male patients 20 to 60 years of age with DSM-IV criteria diagnosis of chronic schizophrenia in a</p>	<p>N=60</p> <p>Patients completed a one time survey</p> <p>Recruitment period</p>	<p>Primary: Evaluate and compare sexual function and behavior</p> <p>Secondary: PANSS scores, serum prolactin</p>	<p>Primary: Patients receiving clozapine reported a higher incidence in frequency of sexual thoughts (<math>P=0.006</math>), frequency of masturbation (<math>P=0.013</math>), number of orgasms per month (<math>P=0.037</math>), frequency of orgasm during sex (<math>P=0.046</math>), sexual desire (<math>P=0.0073</math>), enjoyment of sex with partner (<math>P=0.013</math>), and satisfaction with own sexual function (<math>P=0.0004</math>) compared to classical antipsychotics. Only frequency of desire for sex was lower for patients receiving clozapine than classical antipsychotics (<math>P=0.025</math>). All other sexual differences were not significant (<math>P</math> values not</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
deaconate 12.5-50 mg intramuscularly every 4 weeks, haloperidol deaconate 100-200 mg intramuscularly every 4 weeks, and perphenazine 24-48 mg by mouth once daily	stable relationship with female partner and no alcohol or drug abuse	unspecified	levels	reported).  Secondary: In patients receiving classical antipsychotics and clozapine, the mean PANSS positive scores were 16.2 and 9.5 ( $P<0.0001$ ), negative scores were 16.5 and 24.6 ( $P<0.001$ ), respectively, and general psychopathology scores were not significantly different ( $P$ value not reported).  There was no significant difference in mean serum prolactin levels.
Knegtering et al <sup>225</sup>  Quetiapine administered daily with the dose ranging from 200-1,200 mg a day  vs  risperidone administered daily with the dose ranging from 1-6 mg a day	OL, R  Patients between the ages of 18 and 40 with schizophrenia and not on other medications with known effects on sexual functioning	N=51  6 weeks	Primary: Clinical response and sexual dysfunction based on PANSS and ASFG scores after 6 weeks of treatment  Secondary: Not reported	Primary: Based on the results of the ASFG, 50% of the patients taking risperidone experienced sexual dysfunction compared to only 16% of patients using quetiapine ( $P<0.01$ ).  No significant differences were found in the PANSS total scores between patients treated with quetiapine and patients treated with risperidone.  Secondary: Not reported
Serretti et al <sup>226</sup>  Atypical antipsychotics (aripiprazole, clozapine, olanzapine, quetiapine, risperidone, ziprasidone) and typical antipsychotics (haloperidol, thioridazine)	MA  Patients receiving antipsychotic therapy and who had experienced sexual dysfunction	N=not reported  Study duration not reported	Primary: Rate of sexual dysfunction  Secondary: Not reported	Primary: Quetiapine, ziprasidone, perphenazine, and aripiprazole were associated with relatively low incidence of sexual dysfunction (16-27%).  Olanzapine, risperidone, haloperidol, clozapine, and thioridazine were associated with higher incidence of sexual dysfunction (40-60%).  Secondary: Not reported
Wirshing et al <sup>227</sup>  Clozapine  vs	MA  Adult males 24 to 58 years of age with DSM-IV	N=25 (3 trials referenced for records)	Primary: Degree of sexual functioning (erectile frequency, enjoyment of	Primary: Decline in sexual functioning was significantly less common in the clozapine group compared to the risperidone group ( $P=0.01$ ) and the haloperidol/fluphenazine group ( $P=0.02$ ).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
risperidone vs haloperidol/fluphenazine	diagnosed schizophrenia, who were participants in one of three different R, DB, clinical studies	Duration not reported	orgasm, interest, erectile maintenance, and ejaculatory volume)  Secondary: Not reported	Decline in the erectile frequency was significantly more common in the risperidone group compared to the clozapine group (93 vs 40%; $P=0.01$ ).  Decline in the erectile frequency was significantly more common in the haloperidol/fluphenazine group compared to the clozapine group (93 vs 50%; $P=0.03$ ).  Fewer subjects in the clozapine group compared to the risperidone group reported a decline in the enjoyment of orgasm and ejaculatory volume (20 vs 86%; $P=0.01$ ).  Risperidone (71%) and haloperidol/fluphenazine (67%) treated subjects but not clozapine (40%) treated subjects reported over-all worsening of sexual functioning ( $P$ value was not reported).  Objective global rating revealed 80% of the clozapine group, 86% of the risperidone group, and 83% of the haloperidol/fluphenazine groups were viewed as having sexual dysfunction ( $P$ value was not reported).  Secondary: Not reported
Byerly et al <sup>228</sup>  Olanzapine administered daily with the dose ranging from 5-40 mg a day  vs  risperidone administered daily with the dose ranging from 1-8 mg a day  vs	QE  Outpatients evaluating the sexual dysfunction in patients over the age of 18 with a DSM-IV diagnosis of schizophrenia or schizoaffective disorder without a general medical condition or history of a surgical	N=238  4 years	Primary: Measuring the severity of sexual dysfunction using ASEX and Likert-type scales in schizophrenic patients  Secondary: Not reported	Primary: The adjusted average ASEX total scores were lower in the quetiapine group compared to the risperidone or olanzapine groups. Individual comparisons of the treatments on adjusted average ASEX total scores indicated a significant difference between olanzapine and quetiapine ( $P<0.04$ ) but no difference between risperidone and quetiapine ( $P>0.17$ ) or olanzapine and risperidone ( $P>0.76$ ).  Secondary: Not reported

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
quetiapine administered daily with the dose ranging from 50-900 mg a day	procedure known to cause sexual dysfunction			
Bobes et al <sup>229</sup>  Haloperidol 1-50 mg orally per day  vs  olanzapine 2.5-30 mg orally per day  vs  quetiapine 100-800 mg orally per day  vs  risperidone 1-15 mg orally per day	CS, MC, OS  Adult patients mean 32.2-41.2 years of age with a DSM-IV diagnosis of schizophrenia receiving ≥4 weeks of single antipsychotic treatment (haloperidol, olanzapine, quetiapine, or risperidone)	N=636 (haloperidol, 131; olanzapine, 228; quetiapine, 43; risperidone, 234)  Patients completed a one time survey  Recruitment period: November 5 to December 7, 2000	Primary: Treatment duration, sexual side effects, other reproductive side effects  Secondary: Not reported	Primary: Mean treatment duration for patients receiving haloperidol, olanzapine, quetiapine and risperidone was 4.5, 1.5, 0.1 and 1.8 years, respectively. Treatment duration was significantly longer for patients receiving haloperidol and significantly shorter for patients receiving quetiapine ( $P<0.05$ ).  Sexual dysfunction reported in patients receiving haloperidol, olanzapine, quetiapine and risperidone was 38.1, 35.3, 18.2, and 43.2%, respectively. For patients receiving quetiapine, the incidence was significantly lower compared to haloperidol and risperidone ( $P$ values $<0.05$ ), but not to olanzapine ( $P=0.55$ ). For patients receiving olanzapine and risperidone, incidence increased significantly with dose ( $P<0.05$ ). The risk of sexual dysfunction for olanzapine (OR, 0.9; 95% CI, 0.5 to 1.5), and quetiapine (OR, 0.4; 95% CI, 0.1 to 0.955) was lower than haloperidol but higher for risperidone (OR, 1.2; 95% CI, 0.7 to 2.0).  There was no significant difference in incidence of other reproductive side effects between treatment groups, except when stratified by sex. For women receiving olanzapine, there was a lower incidence of other reproductive side effects and amenorrhea compared to risperidone ( $P<0.05$ ).  Secondary: Not reported
Dossenbach et al <sup>230</sup>  Olanzapine  vs  risperidone	OS, PRO  Outpatients with diagnosis of schizophrenia who initiated or changed antipsychotic	N=3,828  3 years	Primary: Patient reported sexual side effects, menstrual irregularities  Secondary:	Primary: Patients perceived that the odds of experiencing sexual side effects were significantly lower with olanzapine and quetiapine than with risperidone and haloperidol ( $P\leq 0.001$ ).  Reported menstrual irregularities were as follows: olanzapine 14%, quetiapine 8%, risperidone 23%, and haloperidol 29% ( $P$ value not

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
vs quetiapine  vs haloperidol	treatment		Not reported	reported).  Secondary: Not reported
<b>Suicidal Risk/Behavior</b>				
Hennen et al <sup>231</sup>  Clozapine 12.5-450 mg daily	MA  Published studies with contrasting rates of suicides or attempts by psychotic patients treated with clozapine vs other agents (with the exception of olanzapine no other agents were specified)	N=240,564  104,796 person-years of exposure to clozapine	Primary: Attempted or completed suicide  Secondary: Not reported	Primary: Among chronically psychotic patients, treatment with clozapine was associated with variably lower rates of suicides-plus-attempts (by a computed, pooled value of 3.3-fold) and of completed suicides (by 2.9-fold) compared to other treatments.  Secondary: Not reported
<b>Therapeutic Duplication/Polypharmacy</b>				
Kreyenbuhl et al <sup>232</sup>  Clozapine, olanzapine, quetiapine, risperidone, chlorpromazine, chlorprothixene*, fluphenazine, haloperidol, loxapine, mesoridazine*, molindone, perphenazine, pimozide, thioridazine, thiothixene, and	MA  Veterans Affairs patients with schizophrenia and schizoaffective disorder	N=61,257  1 year	Primary: Prevalence of polypharmacy  Secondary: Not reported	Primary: Rate of overlapping use of two or more antipsychotic agents was 20.0% for ≥30 days, 13.1% for ≥60 days, and 9.5% for ≥90 days.  The rate of prescription fills for two or more antipsychotic agents proximal to hospital discharge (within one week) was 14.0%.  Of the polypharmacy uses, 74.1% were one second generation agent plus one first generation agent, 18.2% was for two second generation agents, 1.3% was for combinations of three antipsychotic agents, and 0.03% was for combinations of four antipsychotic agents.



Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
trifluoperazine of varying doses				Secondary: Not reported
Correll et al <sup>233</sup>  Monotherapy vs polypharmacy with second generation antipsychotic agents (aripiprazole, clozapine, olanzapine, quetiapine, risperidone, ziprasidone) and first generation antipsychotic agents of varying doses	Cross-sectional study  Adult psychiatric inpatients treated with at least one second generation antipsychotics at the time of admission to a psychiatric hospital	N=364  24 hours	Primary: Presence of metabolic syndrome and insulin resistance (defined as triglyceride/HDL ratio>3.5)  Secondary: Not reported	Primary: The overall rate of polypharmacy was 19.2% (71 patients out of 364), of which 70.0% was with combinations of two second generation antipsychotics, 22.9% were with combinations of a first and a second generation antipsychotic, 4.3% was with combinations of three second generation antipsychotics, and 2.9% was with two second generation antipsychotics and one first generation antipsychotic.  Patients on polypharmacy was more likely to have metabolic syndrome (50.0 vs 34.3%; $P=0.015$ ) and insulin resistance (50.7 vs 35.0%; $P=0.016$ ) than patients on monotherapy.  Individual metabolic variables did not significantly differ between patients in the monotherapy group and patients in the polypharmacy group, except for higher waist circumference ( $P=0.028$ ) and lower high-density lipoprotein ( $P=0.026$ ) which was observed with the polypharmacy group.  Polypharmacy was significantly more common with schizophrenic patients, patients with higher body mass index, and patients concurrently on anticholinergic treatment ( $P\leq 0.05$ for all), while monotherapy was significantly more common in patients with bipolar disorder, patients with depressive disorder, and patients concurrently on antihypertensive drug treatment ( $P\leq 0.05$ for all).  Quetiapine, risperidone, ziprasidone, clozapine, and first generation antipsychotic agents had higher rates of polypharmacy ( $P\leq 0.05$ for all).  Secondary: Not reported
Ganguly et al <sup>234</sup>  Conventional antipsychotic	MC, OS, RETRO, cohort study	N=31,435  2 years	Primary: Prevalence, frequency, and	Primary: The prevalence of antipsychotic polypharmacy was 40% (12,549 patients out of 31,435). The mean duration of polypharmacy was 149 days. The

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
agents (chlorpromazine, fluphenazine, haloperidol, loxapine, mesoridazine*, molindone, perphenazine, pimozide, prochlorperazine, promazine*, thioridazine, thiothixene, trifluoperazine, chlorprothixene*) and atypical antipsychotic agents (clozapine, olanzapine, quetiapine, risperidone, ziprasidone) of varying doses	California and Georgia Medicaid recipients ≥16 years of age with schizophrenia		<p>mean duration of antipsychotic polypharmacy</p> <p>Secondary: Not reported</p>	<p>prevalence of long-term polypharmacy (defined as more than two months) was 23%, with the average duration of 236 days.</p> <p>California Medicaid recipients had a higher prevalence of polypharmacy compared to Georgia Medicaid recipients (46 vs 35%; <math>P&lt;0.0001</math>).</p> <p>The odds ratio of long-term antipsychotic polypharmacy was 11.77 with clozapine, 14.45 with olanzapine, 9.18 with risperidone, 18.32 with quetiapine, 6.53 with oral haloperidol, 5.43 with injectable haloperidol, 5.50 with oral fluphenazine, 5.13 with injectable fluphenazine, 18.61 with thioridazine, 28.87 with chlorpromazine, and 8.44 with thiothixene (<math>P&lt;0.0001</math> for all).</p> <p>Secondary: Not reported</p>
Kogut et al <sup>235</sup>  Aripiprazole, clozapine, olanzapine, quetiapine, risperidone, ziprasidone, and conventional antipsychotics at varying doses	<p>Cross-sectional, RETRO study</p> <p>Rhode Island Medicaid enrollees in a fee-for-service program, with ≥3 pharmacy claims for oral solid antipsychotic medications</p>	<p>N=8,616</p> <p>1 year</p>	<p>Primary: Frequency of use of polytherapy with multiple antipsychotic medications, frequency of prescribing of off-label dosages of atypical antipsychotic agents</p> <p>Secondary: Frequency of prescribing of off-label dosages of atypical antipsychotic agents stratified by</p>	<p>Primary: Of the Rhode Island Medicaid fee-for-service program enrollees who have three or more pharmacy claims for oral solid antipsychotic medications, approximately 90.0% (7,748 patients out of 8,616) were receiving monotherapy with an oral antipsychotic medication, 2.1% were receiving polytherapy with an atypical and a conventional antipsychotic medication, and 8.0% were receiving polytherapy with two atypical antipsychotic medications.</p> <p>Approximately 33.0% of the patients, who were prescribed an atypical antipsychotic medication, received a dosage that was not within the recommended range according to the product labeling (27.0% received medication below the recommended range and 6.0% received medication above the recommended range).</p> <p>Secondary: Patients who received dosages above the recommended range were more frequently male (<math>P&lt;0.001</math>) and younger than 65 years of age (<math>P&lt;0.001</math>).</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
			gender and age group	<p>Olanzapine (<math>P&lt;0.05</math>) and quetiapine (<math>P&lt;0.05</math>) were more frequently administered above the recommended range compared to the other atypical antipsychotic medications.</p> <p>Quetiapine was most frequently prescribed below the recommended range compared to the other atypical antipsychotic medications (<math>P</math> value not reported).</p>
<p>Ziegenbein et al<sup>236</sup></p> <p>Clozapine plus ziprasidone of varying doses</p>	<p>Open study</p> <p>Outpatients or inpatients with treatment-resistant schizophrenia, who were unresponsive or partially responsive to a stable dose of clozapine monotherapy for <math>\geq 6</math> months</p>	<p>N=9</p> <p>6 months</p>	<p>Primary: Clinical status assessed with the BPRS</p> <p>Secondary: Side effects</p>	<p>Primary: At six months, the combination of clozapine plus ziprasidone significantly reduced the total BPRS score from baseline (<math>P=0.013</math>), with a mean improvement of 28.0%.</p> <p>Seven out of the nine patients (77.8%) responded to the combination treatment regimen.</p> <p>At six months, the dose of ziprasidone remained unchanged, but the dose of clozapine was reduced by 18.0% (<math>P=0.057</math>).</p> <p>Secondary: At six months, no increase in side effects was observed.</p>
<p>Patrick et al<sup>237</sup></p> <p>Monotherapy of antipsychotics vs combination of antipsychotics</p>	<p>MA (including DB studies, OL studies, and case reports)</p> <p>Demographics not defined</p>	<p>N=not specified</p> <p>Duration not specified</p>	<p>Primary: Efficacy of combination therapy</p> <p>Secondary: Not reported</p>	<p>Primary: Most frequent combination was clozapine and risperidone.</p> <p>Seventy five percent of double-blinded studies and 69% of open-label trials found that combination treatment was effective at reducing symptoms.</p> <p>Thirty seven percent of case reports found that combination treatment produced positive outcomes (<math>P</math> values not reported).</p> <p>Secondary: Not reported</p>
<p>Josiassen et al<sup>238</sup></p>	<p>DB, MC, PC, RCT</p>	<p>N=40</p>	<p>Primary: Clinical status</p>	<p>Primary: More patients in the clozapine/risperidone group (seven of 20 or 35%)</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results																												
<p>Clozapine steady dose plus risperidone up to 6 mg/day</p> <p>vs</p> <p>clozapine steady dose plus placebo</p>	<p>Inpatients or outpatients with schizophrenia who were unresponsive or partially responsive to clozapine monotherapy for ≥3 months of ≥600 mg/day</p>	<p>12 weeks</p>	<p>assessed with the BPRS, CGI, and SANS, movement disorders assessed with SAS</p> <p>Secondary: Adverse events</p>	<p>than in the clozapine/placebo group (two of 20 or 10%) achieved a treatment response (<math>P&lt;0.01</math>).</p> <p>Clozapine/risperidone treatment resulted in a greater reduction in BPRS total scores (<math>P&lt;0.04</math>), BPRS positive symptom subscale scores (<math>P&lt;0.05</math>), and SANS scores (<math>P&lt;0.05</math>) than treatment with clozapine/placebo.</p> <p>The SAS scores were lower with clozapine/risperidone group than clozapine/placebo group throughout the 12 weeks (<math>P</math> value not reported).</p> <p>Secondary: No significant between group differences in weight gain, agranulocytosis, and seizures were observed.</p>																												
<p>Glick et al<sup>239</sup></p> <p>Clozapine 12.5-450 mg daily</p> <p>vs</p> <p>olanzapine 5-20 mg daily</p>	<p>MC, RCT</p> <p>Male and female patients aged 18-65 years with a DSM-IV diagnosis of schizophrenia or schizoaffective disorder considered to be at a high risk for committing suicide</p>	<p>N=956</p> <p>2 years</p>	<p>Primary: Usage patterns of concomitant psychotropic medications</p> <p>Secondary: Not reported</p>	<p>Primary: 92.4% of the clozapine group and 91.8% of the olanzapine group received at least one concomitant psychotropic medications during the study.</p> <p>The mean±SD number of concomitant psychotropic medications per patient was 3.80±2.90 in the clozapine group and 4.20±3.16 in the olanzapine group.</p> <p>For each class of concomitant psychotropic medications, the mean daily dose was lower in the clozapine group vs the olanzapine group:</p> <table border="1" data-bbox="1192 1049 2018 1357"> <thead> <tr> <th rowspan="2">Medication Class</th> <th colspan="2">Clozapine</th> <th colspan="2">Olanzapine</th> <th rowspan="2">P value</th> </tr> <tr> <th>N</th> <th>Mean Daily Dose, mg (SD)</th> <th>N</th> <th>Mean Daily Dose, mg (SD)</th> </tr> </thead> <tbody> <tr> <td>anti-psychotics</td> <td>410</td> <td>2.10 (0.33)</td> <td>390</td> <td>3.80 (0.34)</td> <td>&lt;0.001</td> </tr> <tr> <td>anti-depressants</td> <td>241</td> <td>16.70 (1.05)</td> <td>270</td> <td>20.70 (0.97)</td> <td>&lt;0.01</td> </tr> <tr> <td>sedatives/anxiolytics</td> <td>284</td> <td>6.30 (0.64)</td> <td>315</td> <td>10.10 (0.61)</td> <td>&lt;0.001</td> </tr> </tbody> </table>	Medication Class	Clozapine		Olanzapine		P value	N	Mean Daily Dose, mg (SD)	N	Mean Daily Dose, mg (SD)	anti-psychotics	410	2.10 (0.33)	390	3.80 (0.34)	<0.001	anti-depressants	241	16.70 (1.05)	270	20.70 (0.97)	<0.01	sedatives/anxiolytics	284	6.30 (0.64)	315	10.10 (0.61)	<0.001
Medication Class	Clozapine		Olanzapine			P value																										
	N	Mean Daily Dose, mg (SD)	N	Mean Daily Dose, mg (SD)																												
anti-psychotics	410	2.10 (0.33)	390	3.80 (0.34)	<0.001																											
anti-depressants	241	16.70 (1.05)	270	20.70 (0.97)	<0.01																											
sedatives/anxiolytics	284	6.30 (0.64)	315	10.10 (0.61)	<0.001																											

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results			
				mood stabilizers	120	487.3 (43.2)	144
				Secondary: Not reported			
Faries et al <sup>240</sup>  Olanzapine of varying doses vs quetiapine of varying doses vs risperidone of varying doses	MC, OS, PRO  Inpatient and outpatients with schizophrenia, who were initiated on olanzapine, quetiapine, or risperidone	N=796  1 year	Primary: Rate and duration of antipsychotic monotherapy, rate and duration of antipsychotic polypharmacy  Secondary: Not reported	Primary: More than 300 days of therapy were predominately with monotherapy in 35.7% of the patients, polypharmacy in 26.9% of the patients, mix of monotherapy and polypharmacy in 30.2% of the patients, and no treatment in 0.6% of the patients.  Overall, the average number of days was 195.5 (54.0% of the year) on monotherapy, 155.7 (43.0% of the year) on polypharmacy, and 13.9 (3.0% of the year) on no antipsychotic therapy.  Patients on olanzapine were more likely to be on monotherapy than quetiapine (OR, 2.08; 95% CI, 1.30 to 3.31; <i>P</i> =0.002) and risperidone (OR, 1.36; 95% CI, 1.01 to 1.84; <i>P</i> =0.043).  Secondary: Not reported			
<b>Miscellaneous</b>							
Harrington et al <sup>241</sup>  Paliperidone vs placebo	MA  Adults receiving paliperidone or placebo who had experienced an adverse event	N=3,779  Study duration not reported	Primary: Adverse events  Secondary: Not reported	Primary: Adverse events with the greatest incidence in the paliperidone population were any treatment emergent adverse event (68%), extra-pyramidal symptoms (23%), headache (14%), insomnia (11%), somnolence (9%), tachycardia (9%) and weight gain (8%).  Adverse events with highest risk of being caused by paliperidone and not placebo were EPS, reduction in acute psychosis, any treatment emergent adverse event, tachycardia, and weight gain.  Adverse events entirely attributed to paliperidone included hypersalivation, dysarthria, and sexual dysfunction.			

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>Reported events unrelated to paliperidone included anxiety, asthenia, constipation, depression, dyspepsia, glucose related events, and vomiting.</p> <p>Secondary: Not reported</p>
<p>Harrington et al<sup>242</sup></p> <p>Ziprasidone 10 mg to 200 mg daily</p> <p>vs</p> <p>placebo</p>	<p>MA</p> <p>Adults taking oral ziprasidone or placebo who had experienced an adverse event</p>	<p>N=4,132</p> <p>&lt;3 months (most);</p> <p>1 study was 52 weeks and</p> <p>1 study was 26 weeks</p>	<p>Primary: Adverse events</p> <p>Secondary: Not reported</p>	<p>Primary: Ziprasidone was associated with a significantly greater overall rate of treatment-emergent adverse events compared to placebo (73 vs 60%; <math>P&lt;0.0001</math>).</p> <p>Adverse events with the greatest frequency included somnolence (21%), EPS (13%), headache (13%), insomnia (11%) and respiratory disorders (10%).</p> <p>Adverse events with highest risk of being caused by ziprasidone and not placebo, evaluated by using the risk difference (RD) summary statistic, were sedation/somnolence (RD, 14), EPS (RD, 6), asthenia (RD, 5), weight gain of &gt;7% from baseline (RD, 4), dizziness (RD, 4), and dyspepsia (RD, 4).</p> <p>Adverse events reported but unlikely to be caused by ziprasidone included headache (RD, 0), QTc interval greater than 480 msec (RD, 0), diarrhea (RD, 0), and abdominal pain (RD, 0).</p> <p>Secondary: Not reported</p>

Study abbreviations: AC=active-controlled, CC=case control, CS=cross sectional, DB=double-blind, I=international, MA=meta-analysis, MC=multicenter, NAT=naturalistic, OL=open-label, OS=observational study, PC=placebo-controlled, PG=parallel-group, PRO=prospective, QE=quasi-experimental design, R=randomized, RCT=randomized controlled trial, RETRO=retrospective, SB=single-blind, XO=crossover

Miscellaneous abbreviations: AIMS= Abnormal Involuntary Movement Scale, APO<sub>B</sub>=apolipoprotein B, ASEX=Arizona Sexual Experience Scale, ASFQ=Antipsychotics and Sexual Functioning Questionnaire, BAS=Barnes Akathisia rating Scale, BMI=body mass index, BBMI= baseline body mass index, BPRS= Brief Psychiatric Rating Scale, CGI=Clinical Global Impression Scale, CI=confidence interval, DSM-III R=Diagnostic and Statistical Manual of Mental Disorders 3<sup>rd</sup> revised edition, DSM-IV=Diagnostic and Statistical Manual of Mental Disorders, 4<sup>th</sup> edition, EPS=EPS syndromes, ESRS=EPS Symptom Rating Scale, HbA<sub>1c</sub>=glycosylated hemoglobin, HDL=high-density lipoproteins, HR=hazard ratio, IRR=incidence rate ratio, LDL=low-density lipoprotein, OR=odds ratio, MD=mean difference, NNH=number needed to harm, NNT=number needed to treat, PANSS=Positive and Negative Syndrome Scale, QLS=quality of life scale, RD-Risk Difference, RR=rate ratio, RSSE=Rating Scale for Side Effects, SAS=Simpson-Angus Scale, SANS=Scale for the Assessment of Negative Symptoms, SD=standard deviation, VLDL/VLDL-C=very low density lipoprotein cholesterol, WHR=waist to hip ratio, WMD=weighted mean difference

**Table 9. Safety Clinical Trials Using the Antipsychotics in Children and Adolescents**

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
<b>Diabetes</b>				
<p>Baker et al<sup>243</sup></p> <p>Atypical antipsychotics (olanzapine, risperidone, quetiapine, clozapine, ziprasidone, aripiprazole) or haloperidol</p>	<p>RETRO, SBSDA</p> <p>Data relating to diabetes-related adverse events (DRAEs) was extracted from the FDA Adverse Event Reporting System (AERS), evaluated for patients under 18 years of age, 18 to 64 years of age, and for patients over 65 years of age</p>	<p>N=8,032 cases of DRAEs</p> <p>Duration of therapy not reported</p>	<p>Primary: Cases of DRAEs across age groups</p> <p>Secondary: Not reported</p>	<p>Primary: A total of 258 cases of DRAEs were identified for children and adolescents receiving atypical antipsychotics or haloperidol. Among the study drugs, olanzapine and risperidone were associated with the highest incidence of DRAEs (82 and 56 cases, respectively). Of the DRAEs identified, hyperglycemia was the most frequently reported event (61 cases) in this age group, followed by diabetes (58 cases), and increased blood glucose (37 cases).</p> <p>A total of 5,764 cases of DRAEs were identified for adults, aged 18 to 65 years, who received either an atypical antipsychotic or haloperidol. Olanzapine and clozapine were associated with the highest incidence of DRAEs (2,500 and 1,115 cases, respectively), followed by risperidone. Of the DRAEs, diabetes (1,825 cases) and hyperglycemia (955 cases) were the most frequently reported events in this age group.</p> <p>A total of 529 cases of DRAEs were identified for patients over the age of 65, who received either an atypical antipsychotic or haloperidol. Olanzapine and risperidone were associated with the highest frequency of DRAEs. Of the DRAEs, diabetes (176 cases), followed by hyperglycemia (122 cases) and increased blood glucose (116 cases) were the most frequently reported event in this age group.</p> <p>Across all age groups, the following reporting ratios for diabetes were found with the evaluated atypical antipsychotics: olanzapine (9.6; 95%CI, 9.2 to 10.0; 1306 cases), risperidone (3.8; 95%CI, 3.5 to 4.1; 447 cases), quetiapine (3.5; 95%CI, 3.2 to 3.9; 283 cases), clozapine (3.1; 95%CI, 2.9 to 3.3; 464 cases), ziprasidone (2.4; 95%CI, 2 to 2.9; 74 cases), aripiprazole (2.4; 95%CI, 1.9 to 2.9; 71 cases).</p> <p>Secondary:</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
<p>Guo et al<sup>244</sup></p> <p>Atypical antipsychotics (clozapine, olanzapine, quetiapine, risperidone, or ziprasidone)</p> <p>vs</p> <p>conventional antipsychotics (chlorpromazine, fluphenazine, haloperidol, loxapine, molindone, perphenazine, pimozide, thioridazine, thiothixene, or trifluoperazine)</p> <p>Doses for all regimens not reported</p>	<p>CC, RETRO</p> <p>Medicaid claims from 7 states were analyzed for 283 patients with diabetes (cases) and 1,134 controls matched by age, sex, and date when bipolar disorder was diagnosed, all patients had at least a 3-month exposure to either conventional or atypical antipsychotics or three prescriptions related to treatment of bipolar disorder.</p>	<p>N=1,417</p> <p>4 years</p>	<p>Primary: Risk of developing diabetes</p> <p>Secondary: Not reported</p>	<p>Not reported</p> <p>Primary: Compared to patients receiving conventional antipsychotics, the risk of diabetes was greatest with risperidone (HR 3.8, 95% CI: 2.7 to 5.3), olanzapine (HR 3.7, 95% CI: 2.5 to 5.3), and quetiapine (HR 2.5, 95% CI: 1.4 to 4.3).</p> <p>The risk for developing diabetes was associated with weight gain (HR 2.5, 95% CI: 1.9 to 3.4), hypertension (HR 1.6, 95% CI: 1.2 to 2.2), and substance abuse (HR 1.5, 95% CI: 1.0 to 2.2).</p> <p>Secondary: Not reported</p>
<b>Metabolic</b>				
<p>Calarge et al<sup>245</sup></p> <p>Risperidone</p>	<p>PRO</p> <p>Children and adolescents 7 to 17 years of age receiving risperidone for at least 6 months</p>	<p>N=99</p> <p>2.9 years</p>	<p>Primary: Change in weight and difference in metabolic metrics between obese/overweight and lean patients</p> <p>Secondary: Not reported</p>	<p>Primary: Over the course of the study, patients experienced a mean gain of 0.6 BMI z-score point from baseline.</p> <p>A negative correlation was identified between the patient's baseline BMI z-score and gain in BMI z-score following risperidone initiation (P&lt;0.0001).</p> <p>Concomitant therapy with psychostimulants did not attenuate weight gain secondary to risperidone.</p>



Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>Obese or overweight patients had a 14% lower mean HDL cholesterol concentration compared to lean children (<math>P&lt;0.05</math>).</p> <p>Obese or overweight patients were also more likely than lean patients to have higher insulin and triglyceride levels (<math>P&lt;0.05</math>).</p> <p>The odds of having at least one laboratory metabolic abnormality was approximately 12 times greater in the obese/overweight group (<math>P&lt;0.0001</math>). The odds of meeting at least one metabolic syndrome criteria was seven times higher among obese/overweight patients (<math>P=0.0002</math>). However, the prevalence of metabolic syndrome was low in both groups.</p> <p>Secondary: Not reported</p>
<p>Maayan et al<sup>246</sup></p> <p>Risperidone 0.25 mg to 4.0 mg daily</p>	<p>NAT</p> <p>Children and adolescents between the ages of 11 and 17 years diagnosed with psychotic or mood disorders, initiated on risperidone therapy in the 4 weeks prior to study onset</p>	<p>N=8</p> <p>8 weeks</p>	<p>Primary: Weight gain, BMI, hip and waist circumference, waist-to-height ratio, waist-to-hip ratio, leptin, glucose, insulin, triglycerides, total cholesterol, HDL, LDL, HbA<sub>1c</sub>, and cortisol levels</p> <p>Secondary: Not reported</p>	<p>Primary: At eight weeks, patients gained an average of 4.16 kg from baseline (<math>P=0.03</math>), with 62.5% of patients (6/8) experiencing a clinically significant weight gain, defined as a gain of more than 7% of baseline body weight.</p> <p>An increase in BMI from baseline was also statistically significant among patients taking risperidone for 8 weeks (<math>P=0.03</math>).</p> <p>At eight weeks, patients were observed to have larger waist circumference and hip circumference from baseline (<math>P=0.02</math> and <math>P=0.01</math>, respectively).</p> <p>The waist-to-height ratio was also increased from 0.47 to 0.50 during the eight week treatment course (<math>P=0.01</math>).</p> <p>Risperidone nine week treatment was not associated with significant changes in waist-to-hip ratio, leptin, glucose, insulin, triglycerides, total</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>cholesterol, HDL, LDL, HbA<sub>1c</sub>, and cortisol levels (<math>P&gt;0.05</math>).</p> <p>Secondary: Not reported</p>
<p>Correll et al<sup>247</sup></p> <p>SATIETY Study</p> <p>Aripiprazole</p> <p>vs</p> <p>olanzapine</p> <p>vs</p> <p>quetiapine</p> <p>vs</p> <p>risperidone</p> <p>vs</p> <p>untreated control</p>	<p>PRO, O, CS</p> <p>Children and adolescents between the ages of 4 and 19, with a history of 1 week or less of antipsychotic therapy, psychiatric illness requiring antipsychotic therapy; patients receiving more than one antipsychotic were excluded</p>	<p>N=272</p> <p>Up to 12 weeks</p>	<p>Primary: Absolute and relative weight change</p> <p>Secondary: BMI, waist circumference, plasma glucose, insulin, homeostasis model assessment of insulin resistance (HOMA-IR), ratio of triglycerides to HDL cholesterol, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides</p>	<p>Primary: After a median of 10.8 weeks, weight increased by 8.5 kg with olanzapine (<math>P&lt;0.001</math>), by 6.1 kg with quetiapine (<math>P&lt;0.001</math>), by 5.3 kg with risperidone (<math>P&lt;0.001</math>), and by 4.4 kg with aripiprazole (<math>P&lt;0.001</math>); while the untreated control group experienced a minimal weight change from baseline of 0.2 kg (<math>P=0.77</math>).</p> <p>After a median of 10.8 weeks, weight increased by 15.20% with olanzapine (<math>P&lt;0.001</math>), by 10.42% with quetiapine (<math>P&lt;0.001</math>), by 10.37% with risperidone (<math>P&lt;0.001</math>), and by 8.14% with aripiprazole (<math>P&lt;0.001</math>); while the untreated control group experienced a non-significant weight change from baseline of 0.65% (<math>P=0.39</math>).</p> <p>Secondary: After a median of 10.8 weeks, BMI increased by 14.04% with olanzapine (<math>P&lt;0.001</math>), by 9.29% with quetiapine (<math>P&lt;0.001</math>), by 9.12% with risperidone (<math>P&lt;0.001</math>), and by 7.20% with aripiprazole (<math>P&lt;0.001</math>); while the untreated control group experienced a non-significant change from baseline of 0.05% (<math>P=0.96</math>).</p> <p>After a median of 10.8 weeks, BMI z scores increased by 0.93 with olanzapine (<math>P&lt;0.001</math>), by 0.44 with quetiapine (<math>P&lt;0.001</math>), by 0.60 with risperidone (<math>P&lt;0.001</math>), and by 0.37 with aripiprazole (<math>P&lt;0.001</math>); while the untreated control group experienced a reduction in BMI z scores from baseline of 0.003 (<math>P=0.96</math>).</p> <p>After a median of 10.8 weeks, waist circumference increased by 8.55 cm with olanzapine (<math>P&lt;0.001</math>), by 5.27 cm with quetiapine (<math>P&lt;0.001</math>), by 5.10 with risperidone (<math>P&lt;0.001</math>), and by 5.40 with aripiprazole (<math>P=0.001</math>); while the untreated control group experienced a non-significant change from</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>baseline of 0.70 (<math>P=0.40</math>).</p> <p>After a median of 10.8 weeks, olanzapine-treated patients experienced a statistically significant increase in plasma glucose level (3.14 mg/dl; 95%CI, 0.69 to 5.59; <math>P=0.02</math>). Statistically significant changes in plasma glucose were not observed in association with aripiprazole, quetiapine, and risperidone (<math>P&gt;0.05</math>).</p> <p>After a median of 10.8 weeks, olanzapine-treated patients experienced statistically significant increases in plasma insulin level (2.71 mIU/ml mg/dl; 95%CI, 0.42 to 5.00; <math>P=0.02</math>) and HOMA-IR (0.62; 95%CI, 0.07 to 1.17; <math>P=0.03</math>). Statistically significant changes in plasma insulin level and HOMA-IR were not observed in association with aripiprazole, quetiapine, and risperidone (<math>P&gt;0.05</math>).</p> <p>After a median of 10.8 weeks, statistically significant change in the ratio of triglycerides to HDL cholesterol was observed in association with quetiapine (1.22 mg/dl; <math>P=0.004</math>), olanzapine (0.59 mg/dl; <math>P=0.002</math>), and risperidone (0.20 mg/dl; <math>P=0.05</math>). The ratio of triglycerides to HDL cholesterol decreased in the aripiprazole and untreated control groups (<math>P&gt;0.05</math>).</p> <p>Olanzapine was associated with the greatest increase in total cholesterol from baseline (15.58 mg/dl; <math>P&lt;0.001</math>). Patients receiving quetiapine also experienced a significant increase in total cholesterol levels (9.05 mg/dl; <math>P&lt;0.46</math>). The other groups did not exhibit significant changes from baseline in total cholesterol level (<math>P&gt;0.05</math>).</p> <p>Olanzapine was associated with the greatest increase in LDL cholesterol from baseline (11.54 mg/dl; <math>P=0.004</math>). Patients receiving aripiprazole experienced a marginally significant increase in LDL cholesterol levels (3.75 mg/dl; <math>P=0.05</math>). The other groups did not exhibit significant changes from baseline in LDL cholesterol level (<math>P&gt;0.05</math>).</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>Changes in HDL cholesterol from baseline were not significant in any of the study groups (<math>P&gt;0.05</math>).</p> <p>After a median of 10.8 weeks, triglycerides increased by 36.96 mg/dl with quetiapine (<math>P=0.01</math>), by 24.36 mg/dl with olanzapine (<math>P=0.002</math>) and by 9.74 mg/dl with risperidone (<math>P=0.04</math>). The changes from baseline were non-significant in the aripiprazole and untreated control groups (<math>P&gt;0.05</math>).</p>
<p>Fleischhaker et al<sup>248</sup></p> <p>Olanzapine, average dose 10.2 mg/day</p> <p>vs</p> <p>risperidone, average dose 2.6 mg/day</p> <p>vs</p> <p>clozapine, average dose 311.7 mg/day</p>	<p>OL, PRO</p> <p>Children and adolescents, aged 9 to 21.3 years, treated with olanzapine, risperidone, or clozapine</p>	<p>N=33</p> <p>45 weeks</p>	<p>Primary: Weight gain</p> <p>Secondary: Not reported</p>	<p>Primary: The absolute weight gain from baseline was higher among patients receiving olanzapine compared to clozapine, though the difference did not reach statistical significance (16.2 kg vs 9.5 kg; <math>P=0.10</math>).</p> <p>The percentage average weight gain was significantly higher among patients receiving olanzapine compared to clozapine (30.1 vs 14.8%; <math>P&lt;0.05</math>).</p> <p>The absolute weight gain was higher among patients receiving olanzapine compared to risperidone, though the difference did not reach statistical significance (16.2 kg vs 7.2 kg; <math>P=0.10</math>).</p> <p>The percentage average weight gain was significantly higher among patients receiving olanzapine compared to risperidone (30.1 vs 11.5%; <math>P&lt;0.05</math>).</p> <p>The change in weight from baseline was statistically significant in all three groups (<math>P&lt;0.05</math>).</p> <p>Secondary: Not reported</p>
<p>Fraguas et al<sup>249</sup></p> <p>Risperidone of varying doses</p> <p>vs</p>	<p>NAT</p> <p>Children and adolescents (mean age, 15.2 years),</p>	<p>N=66</p> <p>6 months</p>	<p>Primary: Weight gain, blood pressure, thyroxin level, plasma glucose, LDL</p>	<p>Primary: At six months, there was a statistically significant increase in BMI z scores in patients receiving olanzapine (<math>P&lt;0.001</math>) or risperidone (<math>P=0.008</math>), but not in patients receiving quetiapine (<math>P=0.137</math>). Patients in the olanzapine group had significantly higher BMI z scores at endpoint</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
<p>olanzapine of varying doses vs quetiapine of varying doses</p>	<p>treatment naïve or taking the study antipsychotic for &lt;30 days</p>		<p>cholesterol, HDL cholesterol, triglycerides, and HbA1c, risk for adverse health outcome (defined as at least 1 of the following: 1) <math>\geq 85^{\text{th}}</math> BMI percentile plus presence of at least 1 negative weight-related clinical outcome, or 2) <math>\geq 95^{\text{th}}</math> BMI percentile)</p> <p>Secondary: Not reported</p>	<p>compared to patients in the quetiapine group (<math>P=0.001</math>). There was no statistically significant difference in BMI z scores between risperidone and either olanzapine (<math>P=0.09</math>) or quetiapine (<math>P=0.49</math>).</p> <p>At six months, there was a statistically significant weight gain in patients receiving olanzapine (11.1 kg; <math>P&lt;0.01</math>) or risperidone (5 kg; <math>P=0.01</math>), but not in patients receiving quetiapine (2.5 kg; <math>P&gt;0.05</math>).</p> <p>At six months, there was a statistically significant increase in total cholesterol in patients receiving olanzapine (<math>P=0.047</math>) or quetiapine (<math>P=0.016</math>), but not in patients receiving risperidone (<math>P=0.813</math>).</p> <p>At six months, quetiapine therapy was associated with a statistically significant decrease in free thyroxin level from baseline (<math>P=0.011</math>). The reduction in free thyroxin levels observed in association with quetiapine was significantly greater than that seen with risperidone (<math>P&lt;0.001</math>).</p> <p>At six months, olanzapine group exhibited a greater increase in systolic blood pressure from baseline compared to the risperidone group (7.4 mm Hg vs 1.3 mm Hg; <math>P=0.011</math>).</p> <p>None of the three studied antipsychotics had a significant impact on plasma glucose, LDL cholesterol, HDL cholesterol, triglycerides, and HbA1c within the evaluated time period.</p> <p>At six months, the number of patients at risk for adverse health outcome increased from 16.7% to 37.9% (<math>P=0.001</math>). This increase was significant only in the olanzapine group (<math>P=0.012</math>). The risk of adverse health outcome was significantly greater in patients receiving olanzapine than those using quetiapine (<math>P=0.022</math>) and in patients receiving olanzapine compared to those in the risperidone group (<math>P=0.016</math>).</p> <p>Secondary: Not reported</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
<p>Hrdlicka et al<sup>250</sup></p> <p>Atypical antipsychotics (risperidone, olanzapine, ziprasidone, clozapine)</p> <p>vs</p> <p>typical antipsychotics (haloperidol, perphenazine, sulpiride*)</p>	<p>RETRO</p> <p>Children and adolescents with a mean age of 15.8 years diagnosed with early onset schizophrenia or other related psychotic disorder</p>	<p>N=109</p> <p>6 weeks</p>	<p>Primary: Change in weight at 6 weeks after starting antipsychotic therapy</p> <p>Secondary: Not reported</p>	<p>Primary: Patients receiving atypical antipsychotics and those receiving typical antipsychotics gained an average of 3.4 kg and 2.0 kg, respectively, after six weeks of therapy (<math>P=0.334</math>).</p> <p>At six weeks, patients receiving risperidone experienced a weight gain of 3.6 kg from baseline.</p> <p>At six weeks, patients receiving olanzapine experienced a weight gain of 4.4 kg from baseline.</p> <p>At six weeks, patients receiving clozapine experienced a weight gain of 2.1 kg from baseline.</p> <p>The difference in weight gain among the three atypical antipsychotic groups (with enough patients to allow for a valid comparison) was not statistically significant at study endpoint (<math>P=0.286</math>).</p> <p>Secondary: Not reported</p>
<p>Khan et al<sup>251</sup></p> <p>Olanzapine of varying doses</p> <p>vs</p> <p>risperidone of varying doses</p>	<p>RETRO, CR</p> <p>Hospitalized patients aged &lt;18 years (mean age, 13 years) treated with olanzapine or risperidone</p>	<p>N=49</p> <p>Mean duration of therapy=27 days</p>	<p>Primary:</p> <p>Secondary: Not reported</p>	<p>Primary: Both treatment groups experienced a statistically significant increase in BMI from baseline to endpoint (<math>P&lt;0.001</math>).</p> <p>The difference between the two treatment groups in BMI change from baseline was not statistically significant (<math>P=0.425</math>).</p> <p>While risperidone therapy was associated with 4 (17%) new cases of patients meeting criteria for being overweight or at risk for being overweight, olanzapine therapy was associated with seven (28%) such new cases.</p> <p>Over the course of treatment, olanzapine therapy was associated with a statistically significant increase in risk factors for developing diabetes</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>(<math>P=0.008</math>) and in overall risk factors for metabolic syndrome (<math>P=0.013</math>).</p> <p>Over the course of treatment, risperidone therapy was not associated with a statistically significant change in risk factors for diabetes or metabolic syndrome.</p> <p>Compared to risperidone therapy, olanzapine was associated with a statistically significant increase in mean systolic blood pressure (-3.2 mm Hg vs 5.4 mm Hg; <math>P=0.044</math>). In contrast, there was no statistically significant difference between the groups in the change in diastolic blood pressure from baseline.</p> <p>Secondary: Not reported</p>
<p>Moreno et al<sup>252</sup></p> <p>Atypical antipsychotics (olanzapine, risperidone, quetiapine)</p>	<p>NAT</p> <p>Children and adolescents naïve to antipsychotics or with a maximum exposure of 30 days; patients were divided into the following 3 diagnosis groups: bipolar, other psychotic disorder, and nonpsychotic disorder</p>	<p>N=90</p> <p>3 months</p>	<p>Primary: Changes in weight, BMI, cholesterol, triglycerides, plasma glucose, TSH, T4</p> <p>Secondary: Not reported</p>	<p>Primary: Antipsychotic therapy was associated with a statistically significant 5.5 kg weight gain, assessed at three months of study initiation, in all patients, regardless of the diagnosis (<math>P&lt;0.001</math>). There was no statistically significant difference in weight gain among the three diagnostic groups (<math>P=0.06</math>). Significant weight gain was found in 71.1% of patients after 3 months of therapy.</p> <p>Antipsychotic therapy was associated with a statistically significant increase in BMI z-scores from baseline in all three treatment groups (<math>P&lt;0.001</math>).</p> <p>A statistically significant increase in LDL-cholesterol from baseline was only seen in patients with bipolar disorder (<math>P=0.02</math>). In other diagnostic groups the change was not statistically significant.</p> <p>Total cholesterol increased significantly in patients with bipolar and psychotic disorders (<math>P&lt;0.05</math>).</p> <p>HDL-cholesterol and triglycerides did not change significantly in any of</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>the three diagnostic groups (<math>P&gt;0.05</math>).</p> <p>Plasma glucose, blood pressure, and thyroid-stimulating hormone (TSH) were not significantly changed from baseline at the 3-month follow-up.</p> <p>Free thyroxin (T4) level was significantly decreased in patients with psychotic disorders (other than bipolar) (<math>P=0.05</math>).</p> <p>Secondary: Not reported</p>
<p>Patel et al<sup>253</sup></p> <p>Quetiapine at an average daily dose of 510.9 mg</p> <p>vs</p> <p>olanzapine at an average daily dose of 13.9 mg</p>	<p>RETRO</p> <p>Children and adolescents younger than 18 years of age, hospitalized and receiving either olanzapine or quetiapine at baseline, with at least one measurement of weight and height obtained <math>\geq 14</math> days after baseline</p>	<p>N=100</p> <p><math>\geq 2</math> weeks</p>	<p>Primary: Weight gain, changed in BMI</p> <p>Secondary: Not reported</p>	<p>Primary: Patients receiving quetiapine gained an average of 0.03 kg (<math>P&gt;0.05</math>); while, olanzapine-treated patients gained an average of 3.8 kg from baseline (<math>P&lt;0.001</math>).</p> <p>After controlling for differences in race/ethnicity and baseline weight, the mean weight gain from baseline was significantly greater in the olanzapine group, compared to the quetiapine group (a difference of 3.4 kg; <math>P&lt;0.001</math>).</p> <p>Patients receiving quetiapine experienced a reduction in BMI of 0.2 kg/m<sup>2</sup> (<math>P&gt;0.05</math>); while, olanzapine-treated patients exhibited an increase in BMI of 1.3 kg/m<sup>2</sup> from baseline (<math>P&lt;0.001</math>).</p> <p>After controlling for differences in race/ethnicity and baseline BMI, the increase in BMI from baseline was significantly greater in the olanzapine group, compared to the quetiapine group (a difference of 0.9 kg/m<sup>2</sup>; <math>P=0.008</math>).</p> <p>Secondary: Not reported</p>
<p>Correll et al<sup>254</sup></p> <p>Atypical antipsychotic</p>	<p>SR, MA</p> <p>Children and</p>	<p>N=683</p> <p>(19 studies)</p>	<p>Primary: Change in weight, plasma glucose, lipid</p>	<p>Primary: Patients receiving a mood stabilizer, other than topiramate, exhibited a weight gain of 1.8 kg from baseline.</p>



Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
<p>(olanzapine, aripiprazole, quetiapine, risperidone, clozapine)</p> <p>vs</p> <p>mood stabilizers</p> <p>vs</p> <p>two mood stabilizers</p> <p>vs</p> <p>mood stabilizer with atypical antipsychotic</p>	<p>adolescents (mean age, 12.3 years) with bipolar disorder</p>	<p>up to 48 weeks</p>	<p>levels</p> <p>Secondary: Not reported</p>	<p>Patients receiving a mood stabilizer, including topiramate, exhibited a weight gain of 1.2 kg from baseline.</p> <p>Patients receiving monotherapy with an atypical antipsychotic exhibited a weight gain of 3.4 kg from baseline.</p> <p>Patients receiving combination therapy with two different mood stabilizers exhibited a weight gain of 2.1 kg from baseline.</p> <p>Patients receiving combination therapy with a mood stabilizer and an atypical antipsychotic exhibited the greatest weight gain of 5.5 kg from baseline. The weight gain experienced by this combination treatment group was statistically greater than the weight gain observed in either the mood stabilizer monotherapy group or the two mood stabilizer combination group (<math>P&lt;0.05</math>).</p> <p>Glucose and lipid values were only evaluated in two eight-week, open-label studies. Nonfasting lipid and glucose values did not significantly change from baseline in 16 and 15 preschoolers treated with risperidone and olanzapine, respectively. In the second study, risperidone therapy was not associated with a significant change from baseline in lipid and glucose values in 30 children and adolescents.</p> <p>Secondary: Not reported</p>
<p>Fedorowicz et al<sup>255</sup></p> <p>Atypical antipsychotics (risperidone, olanzapine, clozapine, quetiapine, ziprasidone)</p>	<p>SR</p> <p>Children and adolescents &lt;18 years of age (mean age, 13 years) receiving atypical antipsychotic</p>	<p>N=2,979</p> <p>up to 3.6 years</p>	<p>Primary: Change in weight, blood glucose, LDL cholesterol, prolactin level</p> <p>Secondary: Not reported</p>	<p>Primary: Risperidone was associated with a significantly greater weight gain compared to placebo in two double-blind, randomized controlled trials of five and eight weeks in duration, respectively.</p> <p>Weight gain was more common with atypical antipsychotics compared to typical antipsychotics, with the greatest weight gain associated with clozapine and olanzapine (data from three studies).</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
	therapy			<p>A double-blind, randomized controlled study did not find a statistically significant difference between ziprasidone and placebo at 8 weeks.</p> <p>One double-blind randomized controlled study reported a non-statistically significant increase in blood glucose with olanzapine but not with risperidone or haloperidol, while two case series reported some hyperglycemia with risperidone, quetiapine and olanzapine.</p> <p>One double-blind, randomized controlled study reported a non-statistically significant increase in LDL cholesterol with olanzapine but not with risperidone or haloperidol.</p> <p>Six studies found non-statistically significant increases in prolactin level in association with risperidone. Three open-label comparative studies reported increased prolactin with haloperidol, clozapine, and olanzapine. Two small, open-label studies reported no change in prolactin level with quetiapine use. In contrast, another study reported cases of transient hyperprolactinemia with ziprasidone use.</p> <p>Secondary: Not reported</p>
<p>De Hart et al<sup>256</sup></p> <p>Atypical antipsychotics (aripiprazole, ziprasidone, quetiapine, risperidone, olanzapine)</p>	<p>MA</p> <p>Children and adolescents &lt;18 years of age</p>	<p>N=3,595</p> <p>Study durations varied</p>	<p>Primary: Change in weight from baseline</p> <p>Secondary: Not reported</p>	<p>Primary: Ziprasidone was associated with the lowest weight gain (-0.04 kg; 95% CI, -0.38 to 0.30), followed by aripiprazole (0.79 kg; 95% CI, 0.54 to 1.04), quetiapine (1.43 kg; 95%CI, 1.17 to 1.69) and risperidone (1.76 kg; 95%CI, 1.27 to 2.25).</p> <p>Olanzapine was association with the greatest weight gain compared to the other agents included in the meta-analysis (3.45 kg; 95% CI, 2.93 to 3.97).</p> <p>Significant weight gain was observed in children with autism, who were also younger and less likely to have been previously exposed to</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				antipsychotics.  Secondary: Not reported
Safer et al <sup>257</sup>  Risperidone of varying doses	SR  Studies of youths and adults over the age of 65 with risperidone-induced weight gain data; the treatment and weight gain data were pooled by age group and by duration of therapy	N=2,692 (36 studies)  4 to 56 weeks	Primary: Weight gain for patients aged five to 11 years, 12 to 17 years, 33 to 45 years, and 71 to 83 years  Secondary: Not reported	Primary: Total weight gain for children between the ages of five and 11 years was 2.1 kg, 3.4 kg, and 5.8 kg after the following durations of therapy: six to eight weeks, 11 to 14 weeks, and 46 to 78 weeks, respectively.  Total weight gain for children between the ages of 12 and 17 years was 2.6 kg, 2.6 kg, and 4.2 kg after the following durations of therapy: six to eight weeks, 11 to 14 weeks, and 26 to 28 weeks, respectively.  Total weight gain for adults between the ages of 33 and 45 years was 1.6 kg, 2.1 kg, 2.4 kg, and 3.3 kg after the following durations of therapy: six to eight weeks, 11 to 14 weeks, 26 to 28 weeks, and 46 to 78 weeks, respectively.  Total weight gain for older adults between the ages of 71 and 83 years was 0.30 kg, -0.006 kg, and 0.65 kg after the following durations of therapy: six to eight weeks, 26 to 28 weeks, and 46 to 78 weeks, respectively.  Children between the ages of 5 and 11 years experienced the greatest percentage of weight gain from baseline (5.6, 7.4, and 16.3%), compared to other age groups, when assessed after the following durations of therapy: four to eight weeks, nine to 16 weeks, and 17 to 56 weeks, respectively.  Adolescents between the ages of 12 and 17 years experienced less weight gain compared to pre-adolescents but twice that of adults in their early 30s and 40s. Adolescents experienced an increase in weight of 4.1, 6.3 and 8.1% from baseline, when assessed after the following durations of therapy: four to eight weeks, nine to 16 weeks, and 17 to 56 weeks, respectively.

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>respectively.</p> <p>Adults between the ages of 33 and 44 years experienced a weight gain of 2.1, 2.9 and 3.4% from baseline after four to eight weeks, nine to 16 weeks, and 17 to 56 weeks of therapy, respectively.</p> <p>Older adults between the ages of 71 and 83 years experienced a weight gain of 0.5, 0.2 and 0.3% from baseline after four to eight weeks, nine to 16 weeks, and 17 to 56 weeks of therapy, respectively.</p> <p>The following average mg/kg doses were administered to pre-adolescents, adolescents, adults, and older adults: 0.04 mg/kg, 0.05 mg/kg, 0.08 mg/kg, and 0.03 mg/kg, respectively.</p> <p>Pre-adolescents (children between the ages of five and 11 years) exhibited consistently larger increases in BMI (5.6 to 15%) compared to middle-aged adults (2.7 to 5.9%).</p> <p>In middle-aged adults and youths, risperidone was associated with the greatest weight gain during the first few months of therapy; though, weight gain could persist beyond the first year.</p> <p>Secondary: Not reported</p>
<b>Prolactin Levels</b>				
<p>Saito et al<sup>258</sup></p> <p>Risperidone at a mean daily dose of 2.2 mg</p> <p>vs</p> <p>olanzapine at a mean daily dose of 7.8 mg</p>	<p>PRO</p> <p>Children and adolescents, aged 5 to 18 years, who were initiated on an atypical antipsychotic</p>	<p>N=40</p> <p>4 to 15 weeks</p>	<p>Primary: Prolactin level</p> <p>Secondary: Not reported</p>	<p>Primary:</p> <p>A significantly greater percentage of patients in the risperidone group exhibited hyperprolactinemia compared to patients in the olanzapine and quetiapine groups (71 vs 38 vs 17%; <math>P=0.031</math>).</p> <p>Endpoint prolactin levels were significantly higher among patients receiving risperidone compared to patients in the olanzapine group (46.8 vs 24.5 ng/ml; <math>P=0.027</math>).</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
vs quetiapine at a mean daily dose of 282.3 mg				Endpoint prolactin levels were significantly higher among patients receiving risperidone compared to patients in the quetiapine group (46.8 vs 16.7 ng/ml; $P=0.008$ ).  Secondary: Not reported
Staller et al <sup>259</sup>  Risperidone (median dose 15 mg/day), or olanzapine (median dose 10 mg/day), or quetiapine (median dose 200 mg/day)  vs  control (no antipsychotic medication)	NAT  Children aged 5-17 years receiving one of the specified antipsychotics for at least 6 months	N=50  Not specified	Primary: Average of 2 fasting prolactin levels taken one month apart  Secondary: Side effects associated with sustained prolactin elevation defined as changes in sexual functioning or menstrual or breast problems	Primary: Mean prolactin level among all patients receiving risperidone, olanzapine, and quetiapine were greater than those of the control group ( $P<0.05$ ).  The mean prolactin level for males in the risperidone treatment group was elevated above upper limit of standard normal values ( $P$ value not provided) and risperidone treatment was associated with greater prolactin levels in comparison to the three other treatment groups ( $P=0.05$ ).  Secondary: Side effects possibly associated with sustained prolactin elevation were reported in 12% of patients; two male patients receiving risperidone and one male patient receiving olanzapine indicated breast problems, one male on olanzapine indicated a change in sexual functioning, and two female patients receiving quetiapine reported menstrual or breast problems.
<b>Metabolic and Neurological</b>				
Pringsheim et al <sup>260</sup>  Atypical antipsychotics (risperidone, olanzapine, quetiapine, aripiprazole, clozapine, ziprasidone, paliperidone)	MA  Double blind, randomized-controlled studies in children and adolescents up to 18 years of age on atypical antipsychotics for the treatment of a	35 studies (number of patients not provided)  $\leq 12$ weeks	Primary: Weight gain, cholesterol, blood pressure, prolactin, blood glucose, triglycerides, liver enzymes, ECG changes, neurological adverse events	Primary: Compared to placebo, mean weight gain was highest for olanzapine at 3.47 kg, followed by risperidone at 1.72 kg, quetiapine at 1.41 kg and aripiprazole at 0.85 kg ( $P<0.00001$ ). In one study, olanzapine and clozapine were associated with comparable weight gain and BMI increase from baseline ( $P=0.96$ ; $P=0.76$ , respectively). According to the only pediatric study with ziprasidone, weight gain was comparable to placebo ( $P$ value not reported).  Prolactin levels were significantly increased from baseline by 44.57 ng/mL in association with risperidone therapy ( $P<0.00001$ ). Olanzapine

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
	<p>mental health disorder</p> <p>Note: none of the paliperidone studies met inclusion criteria and were hence excluded from MA</p>		<p>Secondary: Not reported</p>	<p>therapy was likewise associated with a statistically significant prolactin elevation compared to placebo (OR, 30.52; <math>P &lt; 0.00001</math>). In contrast, aripiprazole therapy was associated with a significantly greater decrease in prolactin levels after treatment compared to placebo (-5.03 ng/ml; 95% CI, -7.80 to -2.26). Quetiapine was not associated with a significant change in prolactin levels (<math>P</math> value not reported)/</p> <p>Risperidone-treated children had significantly greater odds of experiencing EPS (EPS) compared to placebo-treated patients (OR, 3.35; <math>P &lt; 0.00001</math>). Aripiprazole therapy was also associated with a statistically significant increase in the odds of EPS compared to placebo (OR, 3.70; <math>P &lt; 0.00001</math>). Risperidone was associated with a higher risk of requiring anti-cholinergic therapy for the treatment of EPS compared to olanzapine, though the difference did not reach statistical significant (<math>P</math> value not reported).</p> <p>Olanzapine and clozapine were associated with the greatest increases in cholesterol and triglycerides compared to placebo. The odds of high triglycerides after receiving olanzapine were higher compared to placebo, with an OR of 5.13. Cholesterol increased by a mean of 3.67 mg/dl (<math>P = 0.001</math>) from baseline. Risperidone was not associated with significant changes in cholesterol, triglycerides, or glucose plasma levels compared to baseline. Quetiapine was associated with a significant increase in triglycerides levels compared to placebo (30 vs -14 mg/dl; <math>P = 0.003</math>). Aripiprazole was not associated with significant changes in cholesterol, triglycerides, blood pressure or blood glucose compared to placebo (<math>P</math> value not reported).</p> <p>Olanzapine, aripiprazole, ziprasidone and quetiapine were not associated with significant changes in QTc interval from baseline.</p> <p>Olanzapine was associated with a statistically significant increase in systolic blood pressure compared to placebo (3.61 vs -2.28 mmHg; <math>P = 0.001</math>). Quetiapine was also associated with significantly higher blood</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>pressure compared to placebo (6 vs -6 mmHg; <i>P</i> value not reported). Heart rate was also significantly higher in the quetiapine-treated patients compared to placebo (11 beats per minute vs -3 bpm; <i>P</i> value not reported).</p> <p>Compared to placebo, olanzapine was associated with a significantly greater risk of ALT elevation from baseline (<i>P</i>=0.0005).</p> <p>Secondary: Not reported</p>
<b>Neurological</b>				
<p>Jerrell et al<sup>261</sup></p> <p>Antipsychotics (aripiprazole 5-30 mg, ziprasidone 20-80 mg, quetiapine 25-300 mg, risperidone 0.25-4 mg, olanzapine 2.5-20 mg, haloperidol [doses not reported], fluphenazine [doses not reported])</p> <p>vs</p> <p>controls (no history of antipsychotic medications)</p>	<p>RETRO</p> <p>Medicaid data was used to identify patients (0-17 years of age) who developed neurological adverse events subsequent to exposure to at least one antipsychotic (aripiprazole, ziprasidone, quetiapine, risperidone, olanzapine, haloperidol, fluphenazine)</p>	<p>N=8,649</p> <p>8 years</p> <p>Treatment duration: 1-5 months (35% of children); 6-90 months (65% of children)</p>	<p>Primary: Involuntary movements/ EPS, convulsions/ seizures, sedation/ somnolence</p> <p>Secondary: Not reported</p>	<p>Primary: The odds of being diagnosed with involuntary movements/ EPS were significantly increased for those taking aripiprazole (OR, 6.04), risperidone (OR, 1.85), and haloperidol (OR, 15.98) as monotherapy, those taking multiple antipsychotics (OR, 3.35), or those with preexisting central nervous system disorders (OR, 3.89), organic brain disorders/mental retardation (OR, 1.56), or cardiovascular disorders (OR, 2.02; <i>P</i>&lt;0.05 for all).</p> <p>The odds of developing convulsions or seizures were increased among patients receiving risperidone (OR, 1.62), multiple antipsychotics (OR, 3.41), serotonin-specific reuptake inhibitors (OR, 1.46), those with preexisting central nervous system (OR, 3.71) or organic brain disorders/mental retardation (OR, 1.39; <i>P</i>&lt;0.05 for all).</p> <p>The odds of experiencing sedation/somnolence were significantly greater among patients receiving ziprasidone (OR, 2.05), risperidone (OR, 1.28), and quetiapine (OR, 1.68) as monotherapy, those requiring multiple antipsychotic use (OR, 2.20), serotonin-specific reuptake inhibitors (OR, 1.78), or those with preexisting central nervous system (OR, 1.99), cardiovascular disorders (OR, 1.52) and obstructive sleep apnea (OR, 1.96; <i>P</i>&lt;0.05 for all). The odds of sedation/ somnolence were lower among males (OR, 0.75) and children 12 years and under (OR, 0.79;</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p><math>P &lt; 0.05</math> for all).</p> <p>Secondary: Not reported</p>
<p>Correll et al<sup>262</sup></p> <p>Atypical antipsychotics (amisulpride*, aripiprazole, clozapine, olanzapine, quetiapine, risperidone, sertindole*, sulpiride, ziprasidone, and zotepine*)</p>	<p>SR</p> <p>Prospective and retrospective studies with a duration of at least 11 months, conducted in children, 4-18 years of age, treated with any atypical antipsychotic and who had developed tardive dyskinesia (TD) or dyskinesia</p>	<p>N=783</p> <p>≥11 months</p> <p>(Treatment duration= mean of 329.6 days)</p>	<p>Primary: 1-year risk of tardive dyskinesia in children with assumed minimal past exposure to first-generation antipsychotics</p> <p>Secondary: Not reported</p>	<p>Primary: Three new cases of TD were associated with during treatment with atypical antipsychotics of up to three years (one with quetiapine and two with risperidone).</p> <p>The crude and annualized TD rates associated with atypical antipsychotics were 0.38% (95% CI, 0.079 to 1.11) and 0.42% (95% CI, 0.087 to 1.24), respectively.</p> <p>The crude and annualized TD rates associated with risperidone use were 0.27% (95% CI, 0.033 to 0.97) and 0.30% (95% CI, 0.037 to 1.10), respectively. TD resolved within a few weeks after risperidone discontinuation.</p> <p>Secondary: Not reported</p>
<b>Cardiovascular</b>				
<p>De Castro et al<sup>263</sup></p> <p>Atypical antipsychotics (olanzapine, quetiapine, risperidone)</p> <p>vs</p> <p>matched healthy controls</p>	<p>RETRO</p> <p>Children and adolescents (mean age, 15.1 years) who received a new prescription for olanzapine, quetiapine, or risperidone and who took the prescribed antipsychotic</p>	<p>N=52</p> <p>6 months</p>	<p>Primary: Change from baseline in QTc</p> <p>Secondary: Not reported</p>	<p>Primary: Mean QTc durations at baseline and at six months were 387.29 msec and 393.63 msec, respectively (<math>P=0.134</math>).</p> <p>QTc interval duration at baseline was inversely related to QTc change in controls at endpoint (<math>P &lt; 0.001</math>).</p> <p>The difference in QTc change from baseline between the two groups was not statistically significant (<math>P=0.364</math>).</p> <p>Secondary: Not reported</p>



Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
	without interruptions for 6 months			
<b>Growth and Development</b>				
Calarge et al <sup>264</sup>  Risperidone 0.03 mg/kg	NAT  Male patients between the ages of 7 and 17, treated with risperidone for at least 6 months	N=83  Average of 2.9 years	Primary: Prolactin level, serum testosterone, BMD	Primary: Hyperprolactinemia was found in 49% of children treated with risperidone for an average of 2.9 years.  Serum testosterone level increased with sexual development ( $P<0.0001$ ) but was not affected by hyperprolactinemia ( $P>0.07$ ).  Volumetric BMD significantly increased with sexual maturity ( $P=.002$ ).  After adjustment for the stage of sexual development, height and BMD z scores, serum prolactin was negatively associated with trabecular volumetric BMD at the ultra-distal radius ( $P<0.03$ ). Prolactin level was also negatively associated with total volumetric BMD ( $P<0.04$ )  Treatment with SSRIs was associated with lower trabecular BMD at the radius ( $P=0.03$ ) and BMD z score at the lumbar spine ( $P<0.05$ ).  Secondary: Not reported
<b>Liver Function Tests</b>				
Erdogan et al <sup>265</sup>  Risperidone 0.25 to 6 mg daily (or 0.01 to 0.32 mg/kg daily)	O, OL  Children and adolescents, aged 2 to 18 years, treated with risperidone (new starts) for any psychiatric problem (diagnoses	N=102  6 months	Primary: Changes from baseline in alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyl transpeptidase (GGT), alkaline	Primary: At six months, patients exhibited statistically significant increases in ALT levels from baseline (17.21 vs 12.34; $P=0.0001$ ).  At six months, patients exhibited statistically significant increases in AST levels from baseline (28.27 vs 17.06; $P=0.0001$ ).  At six months, patients exhibited statistically significant increases in GGT levels from baseline (12.75 vs 9.28; $P=0.0001$ ).

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
	included ADHD, anxiety, tic disorder, psychotic disorder), drug-free for at least two weeks prior to study onset		phosphatase (ALP), direct and indirect bilirubin levels, weight	<p>At six months, patients exhibited statistically significant increases in ALP levels from baseline (310.54 vs 229.83; <math>P=0.0001</math>).</p> <p>At six months, patients exhibited statistically significant increases in direct bilirubin levels from baseline (0.17 vs 0.09; <math>P=0.0001</math>).</p> <p>At six months, patients exhibited statistically significant increases in indirect bilirubin levels from baseline (0.38 vs 0.27; <math>P=0.0001</math>).</p> <p>At six months, patients exhibited statistically significant increases in weight from baseline (37.50 vs 31.98; <math>P=0.002</math>).</p> <p>There was no significant association between weight gain and changes in liver function tests (<math>P</math> value not reported).</p> <p>Secondary: Not reported</p>
<b>Usage and Safety</b>				
<p>Harrison-Woolrych et al<sup>266</sup></p> <p>Atypical antipsychotics (clozapine, olanzapine, risperidone, quetiapine)</p>	<p>I, O, PRO</p> <p>Children and adolescents, aged 2 to 15 years, who were prescribed an atypical antipsychotic, identified through a post-marketing Prescription Event Monitoring system in Australia</p>	<p>N=420</p> <p>641.2 patient-years</p>	<p>Primary: Usage, safety</p> <p>Secondary: Not reported</p>	<p>Primary: During the study period, 93% of patients included in the study received a prescription for risperidone, followed by 8, 2 and 0.2% of patients with a prescription for quetiapine, olanzapine, and clozapine, respectively. Total exposure to atypical antipsychotics was 7694 patient-months, with the majority of exposure (94%) being to risperidone.</p> <p>The most common indications for prescribing an antipsychotic were disruptive disorders (conduct disorder, ADHD) reported in 43% of patients, pervasive developmental disorders (34%), and cognitive impairment (17%). Aggression was the most common target symptom among pediatric patients treated by an antipsychotic, reported in 43% of the study sample. Other common target symptoms for antipsychotic therapy included behavioral difficulties (26%), anxiety (17%), hyperactivity (10%) and mood disturbances (9%). Mood disturbances were identified as a target symptom in 3% of pediatric patients prescribed</p>

Study and Drug Regimen	Study Design and Demographics	Sample Size and Study Duration	End Points	Results
				<p>an atypical antipsychotic.</p> <p>The most commonly reported adverse events in patients receiving risperidone were weight gain, dental caries, dental extractions, and somnolence. Six patients in the risperidone group experienced dystonic reactions.</p> <p>The estimated incidence of new-onset diabetes among risperidone recipients was four cases per 1000 patient-years of therapy.</p> <p>The estimated incidence of depression among risperidone recipients was eight cases per 1000 patient-years of therapy.</p> <p>Secondary: Not reported</p>

Study abbreviations: AC=active-controlled, CC=case control, CR=Chart Review, CS=cross sectional, DB=double-blind, I=international, MA=meta-analysis, MC=multicenter, NAT=naturalistic, OL=open-label, OS=observational study, PC=placebo-controlled, PG=parallel-group, PRO=prospective, R=randomized, RCT=randomized controlled trial, RETRO=retrospective, SB=single-blind, SBSDA=Systematic Bayesian Signal Detection Analysis, SR=systematic review, XO=crossover

Miscellaneous abbreviations: AERS=Adverse Event Reporting System, AIMS= Abnormal Involuntary Movement Scale, ALP=Alkaline phosphatase, ALT=Alanine aminotransferase, AST=aspartate aminotransferase, APO<sub>B</sub>=apolipoprotein B, BAS=Barnes Akathisia rating Scale, BMI=body mass index, BBMI= baseline body mass index, BPRS= Brief Psychiatric Rating Scale, CGI=Clinical Global Impression Scale, CI=confidence interval, DSM-III R=Diagnostic and Statistical Manual of Mental Disorders 3<sup>rd</sup> revised edition, DRAEs=Diabetes Related Adverse Events, DSM-IV=Diagnostic and Statistical Manual of Mental Disorders, 4<sup>th</sup> edition, EPS=EPS syndromes, ESRS=EPS Symptom Rating Scale, GGT=Gamma glutamyl transpeptidase, HOMA-IR=Homeostatic Model Assessment of Insulin Resistance, HDL=high-density lipoproteins, HR=hazard ratio, IRR=incidence rate ratio, LDL=low-density lipoprotein, OR=odds ratio, MD=mean difference, NNH=number needed to harm, NNT=number needed to treat, PANSS=Positive and Negative Syndrome Scale, QLS=quality of life scale, RD-Risk Difference, RR=rate ratio, RSSE=Rating Scale for Side Effects, SAS=Simpson-Angus Scale, SANS=Scale for the Assessment of Negative Symptoms, SD=standard deviation, VLDL/VLDL-C=very low density lipoprotein cholesterol, WHR=waist to hip ratio, WMD=weighted mean difference

**Special Populations**

**Table 11. Special Populations**<sup>1-14</sup>

Generic Name	Population and Precaution				
	Elderly/Children	Renal Dysfunction	Hepatic Dysfunction	Pregnancy Category	Excreted in Breast Milk
Aripiprazole	<p>No dosage adjustment is recommended for elderly patients.</p> <p>The safety and effectiveness in pediatric patients with schizophrenia less than 13 years of age have not been established.</p> <p>The safety and effectiveness in pediatric patients with bipolar mania less than 10 years of age have not been established.</p> <p>The safety and effectiveness in pediatric patients with autism less than six years of age have not been established.</p> <p>Safety and effectiveness in pediatric patients with other conditions have not been established.</p>	No dosage adjustment is required in subjects with renal function impairment.	No dosage adjustment is required in subjects with hepatic function impairment.	C	Excreted in breast milk; women receiving aripiprazole should not breastfeed.
Asenapine	<p>Clinical studies did not include sufficient numbers of patients aged 65 and over to determine whether or not they respond differently than younger patients.</p> <p>Not approved for the treatment of patients with dementia-related psychosis.</p> <p>FDA-approved for the treatment of bipolar</p>	No dosage adjustment is required in subjects with renal function impairment.	Not recommended in patients with severe hepatic impairment.	C	Unknown; women receiving asenapine should not breastfeed.

Generic Name	Population and Precaution				
	Elderly/ Children	Renal Dysfunction	Hepatic Dysfunction	Pregnancy Category	Excreted in Breast Milk
	mania in pediatric patients 10 years of age and older. Safety and effectiveness in pediatric patients for other uses have not been established.				
Brexipiprazole	Safety and efficacy in elderly patients have not been established.  Safety and effectiveness in pediatric patients have not been established.	For patients with moderate, severe, or end-stage renal impairment (creatinine clearance <60 mL/minute), the maximum recommended dosage is 2 mg once daily for patients with MDD and 3 mg once daily for patients with schizophrenia.	For patients with moderate to severe hepatic impairment (Child-Pugh score $\geq 7$ ), the maximum recommended dosage is 2 mg once daily for patients with MDD and 3 mg once daily for patients with schizophrenia.	Not studied; increased risk for extra-pyramidal symptoms in neonates if mother is exposed during the third trimester.	Unknown; women receiving brexipiprazole should not breastfeed.
Clozapine	Dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.  Safety and effectiveness in pediatric patients have not been established.	It may be necessary to reduce the dose in patients with significant renal impairment..	It may be necessary to reduce the dose in patients with significant hepatic impairment.	B	Unknown; women receiving clozapine should not breastfeed.
Iloperidone	Clinical studies did not include sufficient numbers of patients aged 65 and over to determine whether or not they respond differently than younger patients.  Safety and effectiveness in pediatric patients have not been established.	Renal impairment (creatinine clearance <30 mL/min) had minimal effect on maximum plasma concentrations of iloperidone and its metabolites; No dose	Use caution in moderate hepatic impairment; not recommended for patients with severe hepatic impairment.	C	Unknown; women receiving iloperidone should not breastfeed.

Generic Name	Population and Precaution				
	Elderly/ Children	Renal Dysfunction	Hepatic Dysfunction	Pregnancy Category	Excreted in Breast Milk
		adjustments are required.			
Lurasidone	No dosage adjustment is recommended for elderly patients.  The safety and effectiveness in pediatric patients have not been established.	Dosage adjustment is recommended in patients with moderate/severe renal impairment (dose should not exceed 80 mg daily).	Dosage adjustment is recommended in patients with moderate/severe hepatic impairment (dose should not exceed 80 or 40 mg daily based on impairment).	B	Unknown; women receiving lurasidone should not breastfeed.
Olanzapine	Consider a lower starting dose for any elderly patient if factors are present that might decrease pharmacokinetic clearance or increase the pharmacodynamic response.  The safety and effectiveness in pediatric patients with schizophrenia or manic/mixed bipolar I disorder less than 13 years of age have not been established.  Safety and effectiveness in pediatric patients with other conditions have not been established.	Dosage adjustment based upon the degree of renal function impairment is not required.	Exercise caution in patients with signs and symptoms of hepatic function impairment, preexisting conditions associated with limited hepatic functional reserve, or being treated with potentially hepatotoxic drugs.	C	Excreted into breast milk; Women receiving olanzapine should not breastfeed.
Paliperidone	Because elderly patients may have diminished renal function, dose adjustments may be required according to their renal function status.  In general, the recommended dosing for elderly patients with healthy renal	Dose according to the patient's renal function.  For mild renal impairment (creatinine clearance 50 to <80 mL/minute), the recommended initial dosage is 3 mg daily;	For patients with mild to moderate hepatic impairment no dose adjustment is recommended.  Not studied in patients with severe hepatic	C.	Excreted into breast milk; The known benefits of breast-feeding should be weighed against the known risks of infant exposure.

Generic Name	Population and Precaution				
	Elderly/ Children	Renal Dysfunction	Hepatic Dysfunction	Pregnancy Category	Excreted in Breast Milk
	<p>function is the same as for younger adult patients with healthy renal function.</p> <p>The safety and effectiveness in pediatric patients with schizophrenia less than 12 years of age have not been established.</p> <p>Safety and effectiveness in pediatric patients with other conditions have not been established.</p>	<p>dose may then be increased to a maximum recommended dosage of 6 mg once daily based on clinical response and tolerability.</p> <p>For moderate to severe renal impairment (creatinine clearance 10 to &lt;50 mL/minute), the recommended initial dosage is 1.5 mg once daily, which may be increased to a maximum recommended dosage of 3 mg once daily after clinical reassessment.</p>	<p>impairment.</p>		
Quetiapine	<p>For elderly patients, consider a slower rate of dose titration and a lower target dose; when indicated, dose escalation should be performed with caution in these patients.</p> <p>The safety and effectiveness in pediatric patients with schizophrenia less than 13 years of age have not been established.</p> <p>The safety and effectiveness in pediatric patients with bipolar mania less</p>	<p>Dosage adjustment not needed.</p>	<p>Dosage adjustment may be needed.</p>	C	<p>Excreted into breast milk; Women receiving quetiapine should not breastfeed.</p>

Generic Name	Population and Precaution				
	Elderly/ Children	Renal Dysfunction	Hepatic Dysfunction	Pregnancy Category	Excreted in Breast Milk
	<p>than 10 years of age have not been established.</p> <p>Safety and effectiveness in pediatric patients with other conditions have not been established.</p>				
Risperidone	<p>Clinical studies in the treatment of schizophrenia did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger patients. Other reported clinical experience has not identified differences in responses between elderly and younger patients.</p> <p>No dosage adjustment is recommended for elderly patients (injection).</p> <p>The safety and effectiveness in pediatric patients with schizophrenia less than 13 years of age have not been established.</p> <p>The safety and effectiveness in pediatric patients with bipolar disorder less than 10 years of age have not been established.</p> <p>The safety and effectiveness in pediatric patients with autistic disorder less</p>	<p>Reduce dose in patients with renal disease; for patients with severe renal impairment (creatinine clearance &lt; 30 mL/min), the initial dosage is 0.5 mg twice daily; dosage increases should be in increments of no more than 0.5 mg twice daily.</p>	<p>Reduce dose in patients with hepatic /disease; for patients with severe hepatic impairment, the initial dosage is 0.5 mg twice daily; dosage increases should be in increments of no more than 0.5 mg twice daily.</p>	C	<p>Women receiving risperidone should not breastfeed.</p>



Generic Name	Population and Precaution				
	Elderly/ Children	Renal Dysfunction	Hepatic Dysfunction	Pregnancy Category	Excreted in Breast Milk
	<p>than five years of age have not been established.</p> <p>The safety and effectiveness in pediatric patients has not been established (injection)</p>				
Ziprasidone	<p>Consider a lower starting dose, slower titration, and careful monitoring during the initial dosing period for some elderly patients.</p> <p>Safety and effectiveness in pediatric patients have not been established.</p>	<p>Dosage adjustments are generally not required on the basis of renal impairment.</p>	<p>Dosage adjustments are generally not required on the basis of hepatic impairment.</p>	C	<p>Unknown; women receiving ziprasidone should not breastfeed.</p>

FDA=Food and Drug Administration

**Adverse Drug Events**

**Table 12. Adverse Drug Events(%)-Single-Entity Products<sup>1-14</sup>**

Adverse Event	Aripiprazole	Asenapine	Brexipiprazole	Clozapine	Iloperidone	Lurasidone	Olanzapine	Paliperidone	Quetiapine	Risperidone Oral	Risperidone IM	Ziprasidone Oral	Ziprasidone IM
<b>Cardiovascular</b>													
Angina	-	-	-	-	-	a	-	-	-	-	a	-	-
Atrioventricular block	-	-	-	-	a	a	-	>2	-	-	a	-	-
Bradycardia	-	-	-	-	-	a	-	a	-	-	a	-	-
Bundle branch block	-	-	-	-	-	-	-	>2	-	-	a	-	-
Electrocardiogram changes	-	-	-	1	-	-	-	>2	-	-	-	a	a
Hypertension	2	2	-	4	-	a	2	>2	a	0.1-1.0	>2	>1	≤2
Hypotension	>1	a	-	9	1-5	a	3-5*	>2	7*	0.1-1.0	a	1*	≤5
Myocardial infarction	0.1-1.0	-	-	a	-	-	-	-	-	0.1-1.0	-	-	-
Palpitation	0.1-1.0	-	-	-	a	-	0.1-1.0	a	>1	0.1-1.0	a	-	-
Phlebitis	0.1-1.0	-	-	a	-	-	-	-	-	<0.1	-	<0.1	<0.1
Pulmonary embolus	<0.1	-	-	a	-	-	<0.1	-	-	a	-	<0.1	<0.1
Q- and T-wave distortions	-	-	-	-	-	-	-	>2	-	-	-	-	-
QTc interval prolongation	0.1-1.0	a	-	-	a	-	-	>2	0.1-1.0	-	-	a	a
Sinus arrhythmia	-	-	-	-	-	-	-	>2	-	-	-	-	-
T-wave flattening	-	-	-	a	-	-	-	-	0.1-1.0	-	-	-	-
T-wave inversion	-	-	-	a	-	-	-	-	0.1-1.0	<0.1	a	-	-
Tachycardia	>1	-	-	25	3-12	a	3	>2	7	3-5	-	2	2
Thrombophlebitis	<0.1	-	-	a	-	-	-	-	0.1-1.0	-	-	<0.1	<0.1

Adverse Event	Aripiprazole	Asenapine	Brexipiprazole	Clozapine	Iloperidone	Lurasidone	Olanzapine	Paliperidone	Quetiapine	Risperidone Oral	Risperidone IM	Ziprasidone Oral	Ziprasidone IM
Twitch	0.1-1.0	-	-	a	-	-	-	-	0.1-1.0	-	-	-	-
Vasodilation	0.1-1.0	-	-	-	-	-	0.1-1.0	-	0.1-1.0	-	-	-	≤1
<b>Central Nervous System</b>													
Agitation	25	-	-	4	-	6	-	-	-	22-26	a	>1	≤2
Akathisia	15-17	4-6	4 to 9	3	1.7-2.3	15	3	>2	-	-	>5	8	≤2
Akinesia	0.1-1.0	-	-	4	-	-	<0.1	-	-	-	-	>1	>1
Amnesia	0.1-1.0	-	-	a	a	-	0.1-1.0	-	0.1-1.0	0.1-1.0	a	>1	>1
Anxiety	20	4	-	1	-	6	-	>2	-	12-20	a	-	≤2
Apathy	0.1-1.0	-	-	-	-	-	-	-	0.1-1.0	0.1-1.0	a	-	-
Asthenia	8	-	-	-	-	-	10-15	>2	4	-	a	5	≤2
Ataxia	0.1-1.0	-	-	1	-	-	0.1-1.0	-	0.1-1.0	-	a	>1	>1
Catatonic-like states	-	-	-	-	a	-	-	-	0.1-1.0	0.1-1.0	-	-	-
Cerebrovascular accident	-	-	-	-	-	a	-	-	-	-	-	-	-
Confusion	>1	-	-	3	a	-	-	a	0.1-1.0	0.1-1.0	a	>1	>1
Convulsions†	a	a	-	3	-	-	-	-	-	-	a	-	-
Delirium	0.1-1.0	-	-	a	a	-	0.1-1.0	-	<0.1	<0.1	a	>1	>1
Dementia	-	-	-	-	-	-	-	-	-	-	a	-	-
Depersonalization	-	-	-	-	-	-	-	-	-	-	a	-	-
Depression	>1	-	-	1	a	-	-	-	-	0.1-1.0	a	-	-
Dizziness	-	5-11	-	19	10-20	5	11-18	>2	10	4-7	>2	8	3-10
Dreams, abnormal/bizarre/ increased	≥1	-	-	a	-	a	>1	-	0.1-1.0	≥1	>2	-	-
Drowsiness/sedation/somnolence	7.5-15.3	13-24	5	39-46	9-15	22	29-35	>2	12-18	3-8	>5	14	8-20
Dysarthria	0.1-1.0	-	-	a	-	a	0.1-1.0	-	>1	0.1-1.0	-	>1	>1
Dyskinesia	0.1-1.0	-	-	-	1.0-1.7	-	≤2	-	0.1-1.0	-	a	>1	>1

Adverse Event	Aripiprazole	Asenapine	Brexipiprazole	Clozapine	Iloperidone	Lurasidone	Olanzapine	Paliperidone	Quetiapine	Risperidone Oral	Risperidone IM	Ziprasidone Oral	Ziprasidone IM
Dystonia	0.1-1.0	-	-	-	0.8-1.0	5	2-3	>2	-	-	a	4	4
Euphoria	<0.1	-	-	-	-	-	>1	-	<0.1	0.1-1.0	a	-	-
EPS	6	7-10	-	-	4-5	-	-	>2	a	17-34	-	5	≤2
Fatigue	-	3-4	-	2	4-6	4	-	>2	-	>1	>5	-	-
Gait abnormal	>1	-	-	-	-	-	6	a	0.1-1.0	-	a	>1	>1
Hallucinations	≥1	-	-	a	-	-	-	-	0.1-1.0	-	>2	-	-
Headache	31	12	7	7	-	-	-	>2	19	12-14	>2	-	3-13
Hostility	>1	-	-	-	-	-	-	-	a	-	-	>1	>1
Hyperactivity	0.1-1.0	-	-	-	-	-	-	-	-	-	-	-	-
Hyperkinesia	0.1-1.0	-	-	1	-	-	-	-	0.1-1.0	-	-	>1	>1
Hyperreflexia	0.1-1.0	-	-	-	-	-	-	-	-	<0.1	-	<0.1	<0.1
Hypertonia	-	-	-	-	-	-	-	>2	-	-	a	-	-
Hypesthesia	0.1-1.0	-	-	-	-	-	0.1-1.0	-	-	<0.1	-	>1	>1
Hypoesthesia	-	-	-	-	-	-	-	-	-	-	>2	-	-
Hypokinesia	0.1-1.0	-	-	4	-	-	0.1-1.0	-	-	-	a	>1	>1
Impaired concentration	-	-	-	-	-	-	-	-	-	-	a	-	-
Impaired thinking	-	-	-	-	-	-	-	-	-	-	-	-	-
Incoordination	<0.1	-	-	-	-	-	0.1-1.0	-	0.1-1.0	-	-	>1	>1
Insomnia	20	6-15	-	2	-	8	12	-	a	23-26	>2	<3	<3
Lethargy	-	-	-	1	1-3	-	-	-	-	-	-	-	-
Libido increased	0.1-1.0	-	-	a	-	-	0.1-1.0	-	0.1-1.0	0.1-1.0	-	-	-
Libido loss of/decreased	0.1-1.0	-	-	a	a	-	-	-	<0.1	≥5	a	-	-
Light-headedness	11	-	-	-	-	-	-	-	-	-	-	-	-
Malaise	0.1-1.0	-	-	-	-	-	0.1-1.0	-	0.1-1.0	0.1-1.0	a	-	-
Manic reaction	-	-	-	-	a	-	-	-	-	-	a	-	-
Migraine	0.1-1.0	-	-	-	-	-	0.1-1.0	-	0.1-1.0	<0.1	a	-	-

Adverse Event	Aripiprazole	Asenapine	Brexipiprazole	Clozapine	Iloperidone	Lurasidone	Olanzapine	Paliperidone	Quetiapine	Risperidone Oral	Risperidone IM	Ziprasidone Oral	Ziprasidone IM
Nervousness	>1	-	-	-	-	-	-	-	a	≥1	a	-	-
Neuroleptic malignant syndrome	a	a	a	a	a	a	a	a	a	a	a	a	a
Neuropathy	0.1-1.0	-	-	-	-	-	<0.1	-	-	-	-	>1	>1
Panic attack	-	-	-	-	-	a	-	-	-	-	-	-	-
Paranoid reaction	-	-	-	-	-	-	-	-	-	-	a	-	-
Paresthesia	0.1-1.0	-	-	-	a	-	>1	-	a	0.1-1.0	a	>1	≤2
Parkinsonism	-	-	-	-	0.2-0.3	11	-	>2	-	-	>5	-	-
Pseudo-parkinsonism	-	-	-	<1	-	-	a	-	-	a	-	-	-
Psychosis	a	-	-	a	a	-	-	-	0.1-1.0	-	a	-	≤1
Restlessness	-	-	-	4	a	3	-	-	-	-	-	-	-
Seizure	a	a	-	a	a	a	a	a	a	a	a	a	a
Sleep disorder	-	-	-	-	-	a	-	-	-	-	-	-	-
Speech slurred	-	-	-	1	-	-	-	-	-	-	-	-	-
Suicide attempt/ thought	0.1-1.0	a	-	-	a	a	>1	a	0.1-1.0	a	>2	a	a
Stupor	0.1-1.0	-	-	-	-	-	-	-	0.1-1.0	0.1-1.0	-	-	-
Syncope	-	-	-	6	a	a	-	a	-	-	>2	-	-
Tardive dyskinesia	0.1-1.0	a	a	a	a	a	0.1-1.0	a	0.1-1.0	a	a	>1	>1
Tardive dystonia	4-9	-	-	-	-	-	-	-	-	-	-	-	-
Tremor	-	-	-	6	2.5-3.1	-	4-6	>2	a	-	>2	>1	>1
Vertigo	0.1-1.0	-	-	19	-	a	0.1-1.0	-	0.1-1.0	0.1-1.0	a	>1	>1
Weakness	-	-	-	1	-	-	-	-	-	-	-	-	-
<b>Dermatological</b>													
Acne	0.1-1.0	-	-	-	-	-	0.1-1.0	-	0.1-1.0	0.1-1.0	>2	-	-
Alopecia	0.1-1.0	-	-	-	-	-	0.1-1.0	-	-	0.1-1.0	a	0.1-1.0	0.1-1.0

Adverse Event	Aripiprazole	Asenapine	Brexipiprazole	Clozapine	Iloperidone	Lurasidone	Olanzapine	Paliperidone	Quetiapine	Risperidone Oral	Risperidone IM	Ziprasidone Oral	Ziprasidone IM
Angioedema	-	-	-	-	-	a	-	-	-	-	-	-	-
Dermatitis	<0.1†	-	-	a	-	-	0.1-1.0	-	0.1-1.0	0.1-1.0	a	0.1-2.0†‡§	0.1-2.0†‡§
Dry skin	-	-	-	-	-	-	-	-	-	-	>2	-	-
Ecchymosis	>1	-	-	a	-	-	5	-	0.1-1.0	-	-	0.1-1.0	0.1-1.0
Eczema	0.1-1.0	-	-	a	-	-	0.1-1.0	-	0.1-1.0	2-4	a	0.1-1.0	0.1-1.0
Erythema	-	-	-	a	-	-	-	-	-	-	a	-	-
Increased sweating	-	-	-	-	-	-	-	-	-	-	a	-	-
Maculopapular skin reactions	<0.1	-	-	-	-	-	0.1-1.0	-	a	-	-	0.1-1.0	0.1-1.0
Pallor	0.1-1.0	-	-	-	-	-	0.1-1.0	-	-	<0.1	-	-	-
Photosensitivity	0.1-1.0	-	-	a	-	-	0.1-1.0	-	0.1-1.0	>1	a	>1	>1
Pruritus	0.1-1.0	-	-	-	-	a	0.1-1.0	-	0.1-1.0	0.1-1.0	a	-	-
Psoriasis	0.1-1.0	-	-	-	-	-	-	-	<0.1	<0.1	-	-	-
Rash	a	-	-	2	2-3	a	-	-	4	2-5	-	4	4
Rash, vesiculobullous	0.1-1.0	-	-	-	-	-	0.1-1.0	-	-	-	-	0.1-1.0	0.1-1.0
Seborrhea	0.1-1.0	-	-	-	-	-	0.1-1.0	-	0.1-1.0	≤1	a	-	-
Urticaria	<0.1	-	-	a	-	-	<0.1	-	-	<0.1	-	0.1-1.0	0.1-1.0
<b>Gastrointestinal</b>													
Abdominal discomfort/pain	a	2	-	4	1-3	a	-	>2	3	1-4	a	>1	≤2
Abdominal distention/enlargement	0.1-1.0	-	-	-	-	-	0.1-1.0	-	<0.1	<0.1	-	-	-
Anorexia	a	-	-	1	-	-	-	-	>1	>1	a	2	≤2
Appetite decreased	-	-	-	-	-	a	-	-	-	-	-	-	-
Appetite increased	0.1-1.0	2-4	-	a	a	-	3-6	-	0.1-1.0	0.1-1.0	a	-	-

Adverse Event	Aripiprazole	Asenapine	Brexipiprazole	Clozapine	Iloperidone	Lurasidone	Olanzapine	Paliperidone	Quetiapine	Risperidone Oral	Risperidone IM	Ziprasidone Oral	Ziprasidone IM
Colitis	-	-	-	-	-	-	-	-	-	-	a	-	-
Constipation	13	5	-	14	-	-	9-11	-	6-9	7-13	>5	9	≤2
Diarrhea	a	-	-	2	5-7	a	-	-	a	≥5	>2	5	≤3
Diverticulitis	-	-	-	-	-	-	-	-	-	<0.1	-	-	-
Dry mouth	a	2-3	-	6	8-10	-	9-22	>2	7-12	≥5	>5	4	≤1
Dyspepsia	15	4	-	14	-	8	7-11	>2	5-6	5-10	>5	8	1-3
Dysphagia	0.1-1.0	-	-	a	-	a	0.1-1.0	a	0.1-1.0	0.1-1.0	a	0.1-1.0	0.1-1.0
Eructation	0.1-1.0	-	-	a	-	-	0.1-1.0	-	-	<0.1	-	-	-
Esophageal ulcer/ esophagitis	<0.1	-	-	-	-	-	<0.1	-	-	<0.1	-	-	-
Fecal impaction	0.1-1.0	-	-	a	-	-	0.1-1.0	-	-	-	-	<0.1	<0.1
Flatulence	0.1-1.0	-	-	-	-	-	0.1-1.0	-	0.1-1.0	0.1-1.0	a	-	-
Gastric ulcer	-	-	-	-	-	-	-	-	-	-	a	-	-
Gastritis	0.1-1.0	-	-	-	-	a	0.1-1.0	-	0.1-1.0	0.1-1.0	a	-	-
Gastroenteritis	0.1-1.0	-	-	a	-	-	0.1-1.0	-	0.1-1.0	<0.1	-	-	-
Gastro-esophageal reflux	0.1-1.0	-	-	4	-	-	-	-	0.1-1.0	<0.1	a	-	-
Gingivitis	0.1-1.0	-	-	-	-	-	0.1-1.0	-	0.1-1.0	<0.1	a	-	-
Glossitis	<0.1	-	-	-	-	-	<0.1	-	<0.1	-	-	-	-
Gum hemorrhage	<0.1	-	-	-	-	-	-	-	0.1-1.0	-	-	<0.1	<0.1
Hematemesis	<0.1	-	-	a	-	-	-	-	<0.1	<0.1	-	<0.1	<0.1
Hemorrhoids	0.1-1.0	-	-	-	-	-	-	-	0.1-1.0	0.1-1.0	a	-	-
Incontinence, fecal	0.1-1.0	-	-	-	-	-	0.1-1.0	-	0.1-1.0	<0.1	a	-	-
Intestinal obstruction	0.1-1.0	-	-	a	-	-	<0.1	-	<0.1	a	-	-	-
Irritable bowel syndrome	-	-	-	-	-	-	-	-	-	-	a	-	-
Melena	<0.1	-	-	-	-	-	0.1-1.0	-	0.1-1.0	0.1-1.0	a	<0.1	<0.1

Adverse Event	Aripiprazole	Asenapine	Brexipiprazole	Clozapine	Iliperidone	Lurasidone	Olanzapine	Paliperidone	Quetiapine	Risperidone Oral	Risperidone IM	Ziprasidone Oral	Ziprasidone IM
Mouth ulceration	0.1-1.0	-	-	-	-	-	0.1-1.0	-	0.1-1.0	-	-	-	-
Nausea	16	-	-	5	7-10	12	0.1-1.0	>2	a	4-6	a	10	4-12
Paralytic ileus	-	-	-	-	-	-	<0.1	-	-	-	-	-	-
Polydipsia	0.1-1.0	-	-	-	-	-	>1	-	0.1-1.0	>1	-	0.1-1.0	≤2
Rectal hemorrhage	0.1-1.0	-	-	a	-	-	0.1-1.0	-	0.1-1.0	-	a	<2	<2
Salivation	3	2	-	31	-	2	>1	>2	0.1-1.0	≤2	>2	a	a
Stomatitis	0.1-1.0	-	-	-	-	-	0.1-1.0	-	0.1-1.0	0.1-1.0	a	0.1-1.0	0.1-1.0
Taste altered	0.1-1.0	3	-	-	-	-	-	-	0.1-1.0	-	-	-	-
Tongue discoloration	-	-	-	-	-	-	<0.1	-	-	<0.1	-	-	-
Tongue swollen	-	-	-	-	-	-	-	a	-	-	-	-	-
Tooth caries/ toothache	0.1-1.0	-	-	-	-	-	0.1-1.0	-	0.1-1.0	-	>2	-	-
Tooth infection	-	-	-	-	-	-	-	-	-	-	-	-	-
Vomiting	11	5	-	3	-	8	4	-	a	5-7	a	>1	<3
Weight gain	3-8	3-5	4 to 7	4	1-9	-	5-6	-	2	18	>5	10	10
Weight loss	>1	-	-	a	-	-	-	-	0.1-1.0	0.1-1.0	>2	-	-
<b>Genitourinary</b>													
Albuminuria	0.1-1.0	-	-	-	-	-	<0.1	-	-	-	-	0.1-1.0	0.1-1.0
Amenorrhea	0.1-1.0	-	-	-	a	a	>1	-	0.1-1.0	0.1-1.0	-	0.1-1.0	0.1-1.0
Breast enlargement	-	-	-	-	-	a	-	-	-	-	-	-	-
Breast pain	-	-	-	-	a	a	-	-	-	-	a	-	-
Dysmenorrhea	-	-	-	a	-	a	-	-	0.1-1.0	0.1-1.0	a	-	≤2
Dysuria	-	-	-	-	-	a	-	-	-	-	-	-	-
Ejaculation disorders	0.1-1.0	-	-	1	2	a	0.1-1.0	-	0.1-1.0	≥5	-	0.1-1.0	0.1-1.0
Galactorrhea	-	-	-	-	-	a	0.1-1.0	-	0.1-1.0	0.1-1.0	-	0.1-1.0	0.1-1.0
Glycosuria	<0.1	-	-	-	-	-	0.1-1.0	-	<0.1	-	a	0.1-1.0	0.1-1.0



Adverse Event	Aripiprazole	Asenapine	Brexipiprazole	Clozapine	Iloperidone	Lurasidone	Olanzapine	Paliperidone	Quetiapine	Risperidone Oral	Risperidone IM	Ziprasidone Oral	Ziprasidone IM
Gynecomastia	0.1-1.0	-	-	-	a	-	<0.1	-	<0.1	<0.1	-	<0.1	<0.1
Hematuria	0.1-1.0	-	-	-	-	-	>1	-	-	0.1-1.0	a	0.1-1.0	0.1-1.0
Impotence	0.1-1.0	-	-	a	-	-	0.1-1.0	-	0.1-1.0	≥5	a	0.1-1.0	0.1-1.0
Incontinence, urinary	>1	-	-	-	a	-	2	-	0.1-1.0	0.1-1.0	a	-	-
Mastalgia	0.1-1.0	-	-	a	-	-	0.1-1.0	-	-	0.1-1.0	-	-	-
Menorrhagia	<0.1	-	-	-	a	-	0.1-1.0	-	-	≥5	-	0.1-1.0	0.1-1.0
Metrorrhagia	-	-	-	-	-	-	>1	-	0.1-1.0	-	-	0.1-1.0	0.1-1.0
Nocturia	<0.1	-	-	-	-	-	-	-	<0.1	-	-	<0.1	<0.1
Polyuria	<0.1	-	-	-	-	-	0.1-1.0	-	<0.1	>1	-	0.1-1.0	0.1-1.0
Priapism	<0.1	-	-	a	a	-	0.1-1.0	a	-	a	a	a	≤1
Renal failure	-	-	-	-	-	a	-	-	-	-	-	-	-
Urinary frequency/urgency increased	0.1-1.0	-	-	1	-	-	0.1-1.0	-	0.1-1.0	-	a	-	-
Urinary retention	0.1-1.0	-	-	1	a	-	0.1-1.0	-	0.1-1.0	>1	a	0.1-1.0	0.1-1.0
Vaginal discharge	-	-	-	-	-	-	-	-	-	-	-	-	-
Vaginal hemorrhage	0.1-1.0	-	-	-	-	-	0.1-1.0	-	0.1-1.0	0.1-1.0	-	<0.1	<0.1
Vaginitis	-	-	-	-	-	-	-	-	-	-	a	-	-
<b>Hematologic</b>													
Agranulocytosis	-	a	-	1	a	-	-	-	a	-	-	-	-
Anemia	>1	-	-	a	a	a	0.1-1.0	-	0.1-1.0	0.1-1.0	a	0.1-1.0	0.1-1.0
Anemia, hypochromic	0.1-1.0	-	-	-	-	-	-	-	0.1-1.0	0.1-1.0	-	<0.1	<0.1
Edema	0.1-1.0	-	-	a	-	-	-	a	-	0.1-1.0	-	-	-
Edema, facial	0.1-1.0	-	-	-	-	-	0.1-1.0	-	0.1-1.0	-	-	>1	>1
Edema, peripheral	2	-	-	-	-	-	3	-	>1	-	>2	0.1-1.0	0.1-1.0
Eosinophilia	<0.1	-	-	1	-	-	-	-	0.1-1.0	-	-	0.1-1.0	0.1-1.0

Adverse Event	Aripiprazole	Asenapine	Brexipiprazole	Clozapine	Iloperidone	Lurasidone	Olanzapine	Paliperidone	Quetiapine	Risperidone Oral	Risperidone IM	Ziprasidone Oral	Ziprasidone IM
Hemorrhage	0.1-1.0	-	-	-	-	-	0.1-1.0	-	-	<0.1	-	-	-
Hypo-proteinemia	-	-	-	-	-	-	<0.1	-	-	<0.1	-	<0.1	<0.1
Leukocytosis	0.1-1.0	-	-	a	-	-	0.1-1.0	-	0.1-1.0	<0.1	a	0.1-1.0	0.1-1.0
Leukopenia	0.1-1.0	a	-	3	a	a	>1	-	>1	<0.1	a	0.1-1.0	0.1-1.0
Lymphadenopathy	0.1-1.0	-	-	-	-	-	0.1-1.0	-	0.1-1.0	-	a	0.1-1.0	0.1-1.0
Neutropenia	-	-	-	-	a	a	-	-	a	-	-	-	-
Pancytopenia	-	-	-	-	-	-	-	-	-	-	-	<0.1	<0.1
Thrombocythemia	<0.1	-	-	a	-	-	0.1-1.0	-	-	-	-	<0.1	<0.1
Thrombocytopenia	<0.1	-	-	a	-	-	0.1-1.0	a	<0.1	a	a	<0.1	<0.1
<b>Laboratory Test Abnormalities</b>													
Alanine amino-transferase /aspartate amino-transferase elevation	0.1-1.0	-	-	-	-	-	-	-	a	0.1-1.0	a	0.1-1.0	0.1-1.0
Alkaline phosphatase increased	0.1-1.0	-	-	-	-	-	0.1-1.0	-	0.1-1.0	-	a	0.1-1.0	0.1-1.0
Cholecystitis	0.1-1.0	-	-	-	-	-	-	-	-	<0.1	-	-	-
Cholelithiasis	0.1-1.0	-	-	a	-	-	-	-	-	<0.1	-	-	-
Creatine phosphokinase elevated	>1	-	-	a	-	a	-	-	-	-	-	0.1-1.0	0.1-1.0
Creatinine increased	0.1-1.0	-	-	-	-	-	-	-	0.1-1.0	0.1-1.0	a	<0.1	<0.1
Hepatitis	<0.1	-	-	a	-	-	0.1-1.0	-	-	<0.1	a	<0.1	<0.1
Hyper-cholesterolemia	0.1-1.0	-	-	-	-	-	0.1-1.0	-	a	-	a	0.1-1.0	0.1-1.0
Hyperglycemia	0.1-1.0	a	-	a	a	-	0.1-1.0	>2	0.1-1.0	a	a	0.1-1.0	0.1-1.0

Adverse Event	Aripiprazole	Asenapine	Brexipiprazole	Clozapine	Iloperidone	Lurasidone	Olanzapine	Paliperidone	Quetiapine	Risperidone Oral	Risperidone IM	Ziprasidone Oral	Ziprasidone IM
Hyperkalemia	0.1-1.0	-	-	-	-	-	<0.1	-	-	-	-	<0.1	<0.1
Hyperlipemia	0.1-1.0	-	-	-	-	-	0.1-1.0	-	0.1-1.0	-	a	<0.1	<0.1
Hyperprolactinemia	-	-	-	-	-	-	a	a	a	a	a	a	a
Hyperthyroidism	<0.1	-	-	-	-	-	-	-	<0.1	-	-	<0.1	<0.1
Hypertonia	a	-	-	-	-	-	3	-	>1	-	-	3	3
Hyperuricemia	0.1-1.0	-	-	a	-	-	-	-	-	-	a	<0.1	<0.1
Hypoglycemia	0.1-1.0	-	-	-	-	-	0.1-1.0	-	0.1-1.0	<0.1	-	<0.1	<0.1
Hypokalemia	0.1-1.0	-	-	-	-	-	0.1-1.0	-	<0.1	<0.1	a	0.1-1.0	0.1-1.0
Hyponatremia	0.1-1.0	-	-	a	-	-	0.1-1.0	-	-	0.1-1.0	a	<0.1	<0.1
Hypothyroidism	0.1-1.0	-	-	-	a	-	-	-	0.1-1.0	-	-	<0.1	<0.1
Liver function impaired	-	-	-	1	-	-	-	-	-	-	a	-	-
Renal failure, acute	0.1-1.0	-	-	-	-	-	-	-	<0.1	-	-	-	-
<b>Musculoskeletal</b>													
Arthralgia/joint pain	0.1-1.0	3	-	a	3	-	5	-	0.1-1.0	2-3	a	a	a
Arthritis	0.1-1.0	-	-	-	-	-	0.1-1.0	-	0.1-1.0	<0.1	a	-	-
Bone pain	0.1-1.0	-	-	-	-	-	<0.1	-	0.1-1.0	-	a	-	-
Bursitis	0.1-1.0	-	-	-	-	-	0.1-1.0	-	-	<0.1	-	-	-
Leg cramps	-	-	-	-	-	-	-	-	-	-	a	-	-
Injection site pain	-	-	-	-	-	-	-	-	-	-	-	-	-
Injection site reactions	-	-	-	-	-	-	-	-	-	-	a	-	-
Muscle rigidity	-	-	-	a	1-3	-	-	-	-	-	a	-	-
Muscle spasms	-	-	-	-	-	-	-	-	-	-	-	-	-
Muscle stiffness	-	-	-	-	-	-	-	-	-	-	-	-	-
Muscle weakness	0.1-1.0	-	-	1	-	-	-	-	0.1-1.0	-	a	-	-
Myalgia	4	-	-	1	-	-	-	-	a	0.1-1.0	>2	1	1

Adverse Event	Aripiprazole	Asenapine	Brexipiprazole	Clozapine	Iloperidone	Lurasidone	Olanzapine	Paliperidone	Quetiapine	Risperidone Oral	Risperidone IM	Ziprasidone Oral	Ziprasidone IM
Myoclonus	0.1-1.0	-	-	1	-	-	-	-	0.1-1.0	-	-	<0.1	<0.1
Myopathy	0.1-1.0	-	-	-	-	-	<0.1	-	-	-	-	<0.1	<0.1
Opisthotonos	-	-	-	-	-	-	-	-	-	-	-	<0.1	<0.1
Rhabdomyolysis	-	-	-	-	-	a	-	-	-	-	-	-	-
Rigidity	-	-	-	5	-	-	-	-	-	0.1-1.0	-	-	-
Tendinitis	-	-	-	-	-	-	-	-	-	-	a	-	-
Tetany	-	-	-	-	-	-	-	-	-	-	a	-	-
Torticollis	-	-	-	-	-	-	-	-	-	<0.1	a	<0.1	<0.1
<b>Respiratory</b>													
Apnea	<0.1	-	-	-	-	-	0.1-1.0	-	-	a	a	-	-
Aspiration	-	-	-	a	-	-	-	-	-	<0.1	-	-	-
Asthma	≥1	-	-	-	a	-	0.1-1.0	-	0.1-1.0	<0.1	-	-	-
Cough, increased	3	-	-	a	-	-	6	>2	>1	3	>2	3	3
Dyspnea	>1	-	-	1	2	-	>1	a	>1	≤1	-	>1	>1
Epistaxis	0.1-1.0	-	-	a	a	-	0.1-1.0	-	0.1-1.0	0.1-1.0	-	0.1-1.0	0.1-1.0
Hemoptysis	<0.1	-	-	-	-	-	0.1-1.0	-	-	-	a	<0.1	<0.1
Hyperventilation	-	-	-	a	-	-	-	-	<0.1	0.1-1.0	-	-	-
Nasal congestion	-	-	-	1	5-8	-	-	-	-	-	-	-	-
Pharyngitis	4	-	-	-	3-4	-	4	-	>1	2-3	-	-	-
Pharyngo-laryngeal pain	-	-	-	-	-	-	-	-	-	-	-	-	-
Pneumonia	>1	-	-	a	-	-	0.1-1.0	-	0.1-1.0	0.1-1.0	a	0.1-1.0	0.1-1.0
Pulmonary edema/ embolus	-	-	-	a	-	-	-	a	-	-	a	-	-
Rhinitis	4	-	-	-	a	-	7	-	3	8-10	>2	4	≤1
Sinusitis	-	-	-	-	a	-	-	-	-	-	>2	-	-
Stridor	-	-	-	-	-	-	-	-	-	-	a	-	-
Upper respiratory	-	-	-	-	2-3	-	-	-	a	-	>2	-	-

Adverse Event	Aripiprazole	Asenapine	Brexipiprazole	Clozapine	Iloperidone	Lurasidone	Olanzapine	Paliperidone	Quetiapine	Risperidone Oral	Risperidone IM	Ziprasidone Oral	Ziprasidone IM
tract infection													
<b>Other</b>													
Accidental injury	6	-	-	-	-	-	12	-	a	-	-	4	4
Allergic reaction	a	-	-	a	-	-	a	a	-	<0.1	a	-	-
Anaphylactoid reactions	-	-	-	-	-	-	a	a	-	a	a	-	-
Back pain	a	-	-	1	-	4	5	>2	2	≤2	a	-	≤1
Blepharitis	0.1-1.0	-	-	-	a	-	0.1-1.0	-	0.1-1.0	<0.1	-	0.1-1.0	0.1-1.0
Cataracts	0.1-1.0	-	-	-	-	-	0.1-1.0	-	a	-	-	0.1-1.0	0.1-1.0
Chest pain	>1	-	-	1	-	-	3	-	a	2-3	a	-	-
Chills	0.1-1.0	-	-	a	-	-	0.1-1.0	-	0.1-1.0	-	-	>1	>1
Choreoathetosis	-	-	-	-	-	-	-	-	<0.1	<0.1	-	>1	>1
Cogwheel rigidity	0.1-1.0	-	-	-	-	-	0.1-1.0	-	-	-	-	>1	≤1
Conjunctivitis	>1	-	-	a	a	-	>1	-	0.1-1.0	-	a	0.1-1.0	0.1-1.0
Death, sudden	-	-	-	-	-	a	-	-	-	-	-	-	-
Dehydration	≥1	-	-	-	-	-	0.1-1.0	-	0.1-1.0	<0.1	a	0.1-1.0	0.1-1.0
Diabetes	a	a	-	a	a	-	a	a	a	a	a	a	a
Diaphoresis	>1	-	-	6	-	-	>1	-	>1	0.1-1.0	-	-	≤2
Diplopia	<0.1	-	-	-	-	-	0.1-1.0	-	-	<0.1	-	>1	>1
Dry eyes	0.1-1.0	-	-	-	a	-	0.1-1.0	-	0.1-1.0	-	-	0.1-1.0	0.1-1.0
Ear disorder	-	-	-	-	a	-	-	-	-	-	>2	-	-
Ear pain	-	-	-	-	-	-	-	-	-	-	-	-	-
Edema, tongue	0.1-1.0	-	-	-	-	-	0.1-1.0	-	0.1-1.0	<0.1	-	0.1-1.0	0.1-1.0
Eye hemorrhage	0.1-1.0	-	-	-	-	-	0.1-1.0	-	-	-	-	<0.1	<0.1
Eye pain	-	-	-	-	-	-	-	-	-	-	a	-	-
Fever	≥1	-	-	5	-	-	6	-	2	2-3	>2	>1	>1
Flu syndrome	>1	-	-	-	-	-	>1	-	>1	0.1-1.0	-	>1	≤1
Glaucoma	-	-	-	a	-	-	<0.1	-	<0.1	-	-	-	-

Adverse Event	Aripiprazole	Asenapine	Brexpiprazole	Clozapine	Iloperidone	Lurasidone	Olanzapine	Paliperidone	Quetiapine	Risperidone Oral	Risperidone IM	Ziprasidone Oral	Ziprasidone IM
Gout	<0.1	-	-	-	-	-	<0.1	-	<0.1	-	-	<0.1	<0.1
Hypertonia	<sup>a</sup>	-	-	-	-	-	3	-	>1	-	-	3	3
Hypotonia	<0.1	-	-	-	-	-	0.1-1.0	-	-	<0.1	-	>1	>1
Moniliasis	-	-	-	-	-	-	0.1-1.0	-	0.1-1.0	-	-	-	-
Mydriasis	-	-	-	-	-	-	<0.1	-	-	-	-	-	-
Nasopharyngitis	-	-	-	-	-	-	-	-	-	-	-	-	-
Neck pain/rigidity	>1	-	-	1	-	-	0.1-1.0	-	0.1-1.0	-	-	-	-
Obesity	-	-	-	-	-	-	-	-	-	-	<sup>a</sup>	-	-
Oculogyric crisis	<0.1	-	-	-	-	-	-	-	-	-	-	>1	>1
Pain	≥1	2	-	-	-	-	0.1-1.0	>2	0.1-1.0	-	>2	-	-
Parotid swelling	-	-	-	<sup>a</sup>	-	-	-	-	-	-	-	-	-
Photophobia	<0.1	-	-	-	-	-	-	-	-	<0.1	-	0.1-1.0	0.1-1.0
Pyrexia	-	-	-	-	-	-	-	-	-	-	-	-	-
Tinnitus	0.1-1.0	-	-	-	<sup>a</sup>	-	0.1-1.0	-	0.1-1.0	-	-	0.1-1.0	0.1-1.0
Viral infection	-	-	-	-	-	-	-	-	-	-	-	-	-
Vision abnormal	-	-	-	-	-	-	-	-	0.1-1.0	1-2	>2	3	3
Vision blurred	3	-	-	-	1-3	<sup>a</sup>	-	>2	-	-	-	-	-
Visual disturbances	-	-	-	5	-	-	-	-	-	-	-	-	-
Withdrawal syndrome	-	-	-	-	-	-	1	-	-	<0.1	-	>1	>1

<sup>a</sup> Percent not specified.

- Event not reported or incidence <1%.

\*Includes orthostatic.

†Includes petit and grand mal seizures.

‡Exfoliative dermatitis included.

§Contact dermatitis included.

|| Fungal dermatitis.

¶Gained at least 7% body weight.

#Narrow-angle glaucoma.

**Contraindications**

**Table 13. Contraindications-Single Entity Products**<sup>1-14</sup>

Contraindication(s)	Aripiprazole	Asenapine	Brexipiprazole	Clozapine	Iloperidone	Lurasidone	Olanzapine	Paliperidone	Quetiapine	Risperidone	Ziprasidone
Concurrent use with dofetilide, sotalol, quinidine, Class 1a and III antiarrhythmics, mesoridazine, thioridazine, chlorpromazine, droperidol, pimozide, sparfloxacin, gatifloxacin, moxifloxacin, halofantrine, mefloquine, pentamidine, arsenic trioxide, levomethadyl acetate, dolasetron mesylate, probucol, or tacrolimus	-	-	-	-	-	-	-	-	-	-	a
Concurrent use with other agents that have demonstrated QT prolongation as a pharmacodynamic effect and have this effect described in the full prescribing information as a contraindication or as a boxed or bolded warning	-	-	-	-	-	-	-	-	-	-	a
Concurrent use with other agents with well-known potential to cause agranulocytosis or suppress bone marrow function	-	-	-	a	-	-	-	-	-	-	-
Concurrent use with strong CYP3A4 inducers	-	-	-	-	-	a	-	-	-	-	-
Concurrent use with strong CYP3A4 inhibitors	-	-	-	-	-	a	-	-	-	-	-
History of clozapine-induced agranulocytosis or severe granulocytopenia	-	-	-	a	-	-	-	-	-	-	-
History of QT prolongation including congenital long QT syndrome	-	-	-	-	-	-	-	-	-	-	a
Hypersensitivity to the drug or its ingredients	a	a	a	a	a	a	a	a	a	a	a
Recent acute myocardial infarction	-	-	-	-	-	-	-	-	-	-	a
Uncompensated heart failure	-	-	-	-	-	-	-	-	-	-	a

## **Boxed Warnings**

### **Black Box Warning for Antipsychotics<sup>1-14</sup>**

#### **WARNING**

Increased mortality in elderly patients with dementia-related psychosis: Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in the drug-treated patients of between 1.6 to 1.7 times that seen in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear.

### **Black Box Warning for Aripiprazole<sup>1</sup>**

#### **WARNING**

Suicidality and antidepressant drugs: Antidepressants increased the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder and other psychiatric disorders. Anyone considering the use of adjunctive aripiprazole or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults older than 24 years of age; there was a reduction in risk with antidepressants compared to placebo in adults 65 years of age and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Aripiprazole is not approved for use in children with depression.

### **Black Box Warning for Brexpiprazole<sup>3</sup>**

#### **WARNING**

Suicidality thoughts and behaviors: Antidepressants increased the risk of suicidal thoughts and behaviors in patients aged 24 years and younger in short-term studies. Monitor closely for clinical worsening and for emergence of suicidal thoughts and behaviors. The safety and efficacy of **brexpiprazole** have not been established in pediatric patients.

### **Black Box Warnings for Clozapine<sup>4-6</sup>**

#### **WARNING**

Agranulocytosis: Because of a significant risk of agranulocytosis, a potentially life-threatening adverse reaction, reserve clozapine for use in the treatment of severely ill patients with schizophrenia who fail to show an acceptable response to adequate courses of standard antipsychotic drug treatment or for use in reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder who are judged to be at risk of reexperiencing suicidal behavior.

Patients being treated with clozapine must have a baseline white blood cell count and absolute neutrophil count before initiation of treatment, as well as regular white blood cell counts and absolute neutrophil counts during treatment and for at least four weeks after discontinuation of treatment.

Clozapine is available only through a distribution system that ensures monitoring of white blood cell count



**WARNING**

counts and absolute neutrophil counts according to the following schedule prior to delivery of the next supply of medication.

**Seizures:** Seizures have been associated with the use of clozapine. Dose appears to be an important predictor of seizure, with a greater likelihood at higher clozapine doses. Use caution when administering clozapine to patients who have a history of seizures or other predisposing factors. Advise patients not to engage in any activity in which sudden loss of consciousness could cause serious risk to themselves or others.

**Myocarditis:** Analyses of postmarketing safety databases suggest that clozapine is associated with an increased risk of fatal myocarditis, especially during, but not limited to, the first month of therapy. In patients in whom myocarditis is suspected, promptly discontinue clozapine treatment.

**Other adverse cardiovascular and respiratory reactions:** Orthostatic hypotension, with or without syncope, can occur with clozapine treatment. Rarely, collapse can be profound and be accompanied by respiratory and/or cardiac arrest. Orthostatic hypotension is more likely to occur during initial titration in association with rapid dose escalation. In patients who have had even a brief interval off clozapine (two or more days since the last dose), start treatment with 12.5 mg once or twice daily.

Because collapse, respiratory arrest, and cardiac arrest during initial treatment have occurred in patients who were being administered benzodiazepines or other psychotropic drugs, caution is advised when clozapine is initiated in patients taking a benzodiazepine or any other psychotropic drug. (See group monograph.) Antipsychotic Agents.

**Black Box Warning for Lurasidone<sup>8</sup>**

**WARNING**

Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; however, there was a reduction in risk with antidepressant use in patients aged 65 and older. In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber.

**Black Box Warning for Quetiapine and Quetiapine Fumarate<sup>11,12</sup>**

**WARNING**

**Suicidality and antidepressant drugs:** Antidepressants increased the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder and other psychiatric disorders. Anyone considering the use of Seroquel XR<sup>®</sup> or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults older than 24 years of age; there was a reduction in risk with antidepressants compared to placebo in adults 65 years of age and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Seroquel XR<sup>®</sup> is not approved for use in pediatric patients.

**Warnings/Precautions**

**Table 14. Warnings and Precautions-Single Entity Products**<sup>1-14</sup>

Warning(s)/Precaution(s)	Aripiprazole	Asenapine	Brexipiprazole	Clozapine	Iloperidone	Lurasidone	Olanzapine	Paliperidone	Quetiapine	Risperidone	Ziprasidone
Agranulocytosis, significant risk	-	-	-	a	-	-	-	-	-	-	-
Anticholinergic toxicity may occur	-	-	-	a	-	-	-	-	-	-	-
Antiemetic effects have been observed which may mask signs of drug overdose or conditions such as intestinal obstruction, Reye's syndrome and brain tumor	-	-	-	-	-	-	-	a	-	a	-
Blood pressure increased, children and adolescents	-	-	-	-	-	-	-	-	a	-	-
Cardiomyopathy has been reported	-	-	-	a	-	-	-	-	-	-	-
Cataract development has been observed in dogs, lenticular changes cannot be ruled out	-	-	-	-	-	-	-	-	a	-	-
Caution is advised in patients undergoing anesthesia	-	-	-	a	-	-	-	-	-	-	-
Clinical experience with use in patients with concomitant illness is limited	a	a	-	-	-	-	a	a	a	a	a
Clinical worsening of depression and suicide risk may occur	a	a	a	-	a	a	a	a	a	a	a
Cognitive and motor impairment may occur	a	a	a	a	a	a	a	a	a	a	a
Disruption in the body's ability to reduce core body temperature has been associated with antipsychotic drugs	a	a	a	-	a	a	a	a	a	a	a
Electrocardiogram repolarization changes have been reported	-	-	-	a	-	-	-	-	-	-	-
Eosinophilia has been reported	-	-	-	a	-	-	-	-	-	-	a
Esophageal dysmotility and aspiration have been associated with antipsychotic drugs	a	a	a	-	a	a	a	a	a	a	a
Fever has been reported, with temperature >100.4°F	-	-	-	a	-	-	-	-	-	-	-
Gradual withdrawal is advised when discontinuation medication due to acute withdrawal symptoms, such as insomnia, nausea, and vomiting	-	-	-	-	-	-	-	-	a	-	-
Hepatitis has been reported	-	-	-	a	-	-	-	-	-	-	-
Hyperprolactinemia has been associated with antipsychotic drugs	-	a	-	-	a	a	a	a	a	a	a
Hypersensitivity reactions, including angioedema and anaphylaxis, have been reported	-	a	-	-	-	-	-	-	-	-	-
Hypothyroidism has been reported, dose-related	-	-	-	-	-	-	-	-	a	-	-
Increased mortality and cerebrovascular adverse events including stroke have been observed in elderly patient with dementia-related psychosis	a	a	a	a	a	a	a	a	a	a	a
Leukopenia, neutropenia and agranulocytosis have been reported temporally related to antipsychotic drugs	a	a	a	-	a	a	a	a	a	a	a

Warning(s)/Precaution(s)	Aripiprazole	Asenapine	Brexipiprazole	Clozapine	Iloperidone	Lurasidone	Olanzapine	Paliperidone	Quetiapine	Risperidone	Ziprasidone
Metabolic changes including hyperglycemia/diabetes mellitus, hyperlipidemia, and weight gain have been observed	a	a	a	a	a	a	a	a	a	a	a
Myocarditis has been reported	-	-	-	a	-	-	-	-	-	-	-
Neurological adverse reactions in patients with Parkinson's Disease or Dementia with Lewy Bodies including confusion, obtundation, postural instability with frequent falls, extrapyramidal symptoms	-	-	-	-	-	a	-	-	-	-	-
Neuroleptic malignant syndrome may occur with antipsychotic drugs	a	a	a	a	a	a	a	a	a	a	a
Orthostatic hypotension may occur	a	a	a	a	a	a	a	a	a	a	a
Phenylketonuric patients should be informed that the product contains phenylalanine	-	-	-	a*	-	-	-	-	-	-	-
Potential for gastrointestinal obstruction, avoid in patients with severe gastric narrowing	-	-	-	-	-	-	-	a	-	-	-
Priapism has been reported	-	-	-	a	a	-	-	a	a	a	a
Pulmonary embolism has been reported	-	-	-	a	-	-	-	-	-	-	-
QT prolongation has been reported	-	a	-	a	a	-	-	a	a	-	a
Rash and/or urticaria has been reported	-	-	-	-	-	-	-	-	-	-	a
Recurrence of psychosis and cholinergic rebound after abrupt discontinuation has been reported	-	-	-	a	-	-	-	-	-	-	-
Restricted access program; due to risk of agranulocytosis, only available through a restricted access program			-	a							
Seizures and/or convulsions have been reported	a	a	a	a	a	a	a	a	a	a	a
Serum transaminase increases, transient	-	-	-	-	-	-	-	-	a	-	-
Tachycardia has been reported	-	-	-	a	-	-	-	-	-	-	-
Tardive dyskinesia may develop in patients treated with antipsychotic drugs	a	a	a	a	a	a	a	a	a	a	a
Thrombotic thrombocytopenic purpura has been reported	-	-	-	-	-	-	-	-	-	a	-
Use should be avoided in combination with drugs known to prolong the QT interval and in patients with cardiac arrhythmias and other circumstances which may increase the risk of torsades des pointes	-	a	-	a	a	-	-	a	a	a	a
Withdrawal symptoms after abrupt cessation of therapy	-	-	-	-	-	-	-	-	a	-	-

\*Fazaclo®

**Frequency of Monitoring Based on Stage of Clozapine Therapy or Results from White Blood Cell Count and Absolute Neutrophil Count Monitoring Tests<sup>4,6</sup>**

Situation	Hematological Values for Monitoring	Frequency of White Blood Cell and Absolute Neutrophil Count Monitoring
Initiation of therapy	WBC $\geq 3,500/\text{mm}^3$ ANC $\geq 2,000/\text{mm}^3$ Do not initiate in patients with history of myeloproliferative disorder or clozapine-induced agranulocytosis or granulocytopenia	Weekly for 6 months
6 to 12 months of therapy	All results for WBC $\geq 3,500/\text{mm}^3$ and ANC $\geq 2,000/\text{mm}^3$	Every 2 weeks for 6 months
12 months of therapy	All results for WBC $\geq 3,500/\text{mm}^3$ and ANC $\geq 2,000/\text{mm}^3$	Every 4 weeks ad infinitum
Immature forms present	N/A	Repeat WBC and ANC
Discontinuation of therapy	N/A	Weekly for at least 4 weeks from day of discontinuation or until WBC $\geq 3,500/\text{mm}^3$ and ANC $> 2,000/\text{mm}^3$
Substantial drop in WBC or ANC	Single drop or cumulative drop within 3 weeks of WBC $\geq 3,000/\text{mm}^3$ and ANC $\geq 1,500/\text{mm}^3$	1. Repeat WBC and ANC 2. If repeat values are WBC $\leq 3,000/\text{mm}^3$ and ANC $> 2,000/\text{mm}^3$ , then monitor twice weekly
Mild leukopenia Mild granulocytopenia	3,500/ $\text{mm}^3$ > WBC $\geq 3,000/\text{mm}^3$ and/or 2,000/ $\text{mm}^3$ > ANC $\geq 1,500/\text{mm}^3$	Twice weekly until WBC $> 3,500/\text{mm}^3$ and ANC $> 2,000/\text{mm}^3$ , then return to previous monitoring frequency
Moderate leukopenia Moderate granulocytopenia	3,000/ $\text{mm}^3$ > WBC $\geq 2,000/\text{mm}^3$ and/or 1,500/ $\text{mm}^3$ > ANC $\geq 1,000/\text{mm}^3$	1. Interrupt therapy 2. Daily until WBC $> 3,000/\text{mm}^3$ and ANC $> 1,500/\text{mm}^3$ 3. Twice weekly until WBC $> 3,500/\text{mm}^3$ and ANC $> 2,000/\text{mm}^3$ 4. May rechallenge when WBC $> 3,500/\text{mm}^3$ and ANC $> 2,000/\text{mm}^3$ 5. If rechallenged, monitor weekly for 1 year before returning to the usual monitoring schedule of every 2 weeks for 6 months and then every 4 weeks ad infinitum
Severe leukopenia Severe granulocytopenia	WBC $< 2,000/\text{mm}^3$ and/or ANC $< 1,000/\text{mm}^3$	1. Discontinue treatment and do not rechallenge patient 2. Monitor until normal and for at least 4 weeks from day of discontinuation as follows: <ul style="list-style-type: none"> <li>• Daily until WBC <math>&gt; 3,000/\text{mm}^3</math> and ANC <math>&gt; 1,500/\text{mm}^3</math></li> <li>• Twice weekly until WBC <math>&gt; 3,500/\text{mm}^3</math> and ANC <math>&gt; 2,000/\text{mm}^3</math></li> <li>• Weekly after WBC <math>&gt; 3,500/\text{mm}^3</math></li> </ul>

Situation	Hematological Values for Monitoring	Frequency of White Blood Cell and Absolute Neutrophil Count Monitoring
Agranulocytosis	ANC $\leq 500/\text{mm}^3$	<ol style="list-style-type: none"> <li>Discontinue treatment and do not rechallenge patient</li> <li>Monitor until normal and for at least 4 weeks from day of discontinuation as follows: <ul style="list-style-type: none"> <li>Daily until WBC <math>&gt;3,000/\text{mm}^3</math> and ANC <math>&gt;1,500/\text{mm}^3</math></li> <li>Twice weekly until WBC <math>&gt;3,500/\text{mm}^3</math> and ANC <math>&gt;2,000/\text{mm}^3</math></li> <li>Weekly after WBC <math>&gt;3,500/\text{mm}^3</math></li> </ul> </li> </ol>

ANC=absolute neutrophil count, N/A=not applicable, WBC=white blood cell count

### Resuming Monitoring Frequency for Clozapine Treatment after an Interruption in Therapy<sup>4-6</sup>



**Drug Interactions****Table 15. Significant Drug-Drug Interactions<sup>1-14</sup>**

<b>Drug(s)</b>	<b>Interacting Medication or Disease</b>	<b>Mechanism</b>
Aripiprazole, iloperidone, quetiapine, risperidone	Azole antifungals	Inhibition of metabolism through CYP3A4 by azole antifungals may result in increased concentrations. When the azole antifungal is discontinued, adjust the dose.
Aripiprazole, quetiapine, risperidone	Carbamazepine	Induction of metabolism through CYP3A4 by carbamazepine may result in decreased concentrations, decreasing the pharmacologic effects. When carbamazepine is discontinued, adjust the dose.
Clozapine, iloperidone, risperidone	Serotonin-reuptake inhibitors	Serum levels may be elevated, resulting in increased pharmacologic and toxic effects. Monitor serum levels, observe clinical response and adjust the dose as needed.
Aripiprazole	Quinidine	Inhibition of aripiprazole metabolism through CYP2D6 by quinidine may result in increased aripiprazole concentrations, increasing the pharmacologic and adverse effects. When quinidine is discontinued, adjust the dose of aripiprazole.
Brexpiprazole	Strong CYP2D6 and CYP3A4 inhibitors	Increased exposure to brexpiprazole. Reduce the dose of brexpiprazole by one-half with concurrent use of a strong CYP2D6 or CYP3A4 inhibitor. No dose adjustment is required for concurrent use of a strong CYP2D6 inhibitor in patients treated for major depressive disorder
Brexpiprazole	CYP3A4 inducers AND CYP2D6 inhibitor	Increased exposure to brexpiprazole. Reduce the dose to one-quarter the normal dose if the patient is concurrently using any strong/moderate CYP3A4 inhibitor and a strong/moderate CYP2D6 inhibitor.
Brexpiprazole	CYP3A4 inducers	Decreased exposure of brexpiprazole. Double the usual dose with concurrent use of a CYP3A4 inhibitor. Additional dose-adjustment may be required.
Clozapine	Barbiturates	Induction of clozapine metabolism by barbiturates may result in decreased clozapine concentrations, decreasing the pharmacologic effects of clozapine. Observe the patient for clozapine toxicity when phenobarbital is stopped.
Clozapine	Benzodiazepines	The pharmacologic or toxic effects of certain benzodiazepines may be increased with concomitant administration. Consider monitoring vital signs and observing patients for excessive adverse reactions.
Clozapine	Quinolones	Clozapine plasma concentrations may be elevated due to inhibition of metabolism (CYP1A2) by certain quinolone antibiotics, increasing the risk of adverse reactions. Observe the clinical response of the patient and adjust the dose of clozapine as needed.
Clozapine	Ritonavir	Inhibition of clozapine metabolism through CYP2D6 by ritonavir may result in increased clozapine concentrations, increasing risk of toxicity. Coadministration is contraindicated.
Iloperidone	Agents that prolong the QT interval	Concomitant administration may increase the risk of life-threatening cardiac arrhythmias, torsades de pointes or QT prolongation. Coadministration is contraindicated.
Lurasidone	Strong CYP3A4	Concomitant administration is contraindicated. Coadministration

Drug(s)	Interacting Medication or Disease	Mechanism
	inhibitors (i.e. ketoconazole)	has resulted in significant increases in lurasidone Cmax and AUC, via inhibition of CYP3A4-mediated lurasidone metabolism.
Lurasidone	Strong CYP3A4 inducers (i.e. rifampin)	Concomitant administration is contraindicated. Coadministration has resulted in significant increases in lurasidone Cmax and AUC, via induction of CYP3A4-mediated lurasidone metabolism.
Lurasidone	Moderate CYP3A4 inhibitor (diltiazem)	Concomitant use of diltiazem and lurasidone has resulted in significant increases in lurasidone Cmax and AUC, via inhibition of CYP3A4-mediated lurasidone metabolism. Therefore, the lurasidone dose should not exceed 40 mg/day when coadministered with diltiazem.
Lurasidone	Lithium	Concomitant use of lithium and lurasidone has resulted in increases in lurasidone Cmax and AUC. However, no lurasidone dose adjustments are required with concomitant use.
Olanzapine	Protease inhibitors	Increased metabolism of olanzapine through CYP1A2 by protease inhibitors may result in decreased olanzapine concentrations, decreasing the therapeutic effects. Adjust the dose of olanzapine as needed.
Quetiapine	Hydantoins	Increased metabolism of quetiapine through CYP3A4 by hydantoins may result in decreased quetiapine concentrations, decreasing pharmacologic effects.
Quetiapine	Valproic acid	Quetiapine plasma concentrations may be elevated due to inhibition of metabolism (CYP3A4) by valproic acid, increasing the pharmacologic and adverse effects. Closely monitor patients and be prepared to change the quetiapine dose as needed.
Ziprasidone	Antiarrhythmics	Concomitant administration may increase the risk of life-threatening cardiac arrhythmias, torsades de pointes or QT prolongation. Coadministration is contraindicated.
Ziprasidone	Cisapride	Concomitant administration may increase the risk of life-threatening cardiac arrhythmias, torsades de pointes or QT prolongation. Coadministration is contraindicated.
Ziprasidone	Dofetilide	Concomitant administration may increase the risk of life-threatening cardiac arrhythmias, torsades de pointes or QT prolongation. Coadministration is contraindicated.
Ziprasidone	Dolasetron	Concomitant administration may increase the risk of life-threatening cardiac arrhythmias, torsades de pointes or QT prolongation. Coadministration is contraindicated.
Ziprasidone	Droperidol	Concomitant administration may increase the risk of life-threatening cardiac arrhythmias, torsades de pointes or QT prolongation. Coadministration is contraindicated.
Ziprasidone	Halofantrine	Concomitant administration may increase the risk of life-threatening cardiac arrhythmias, torsades de pointes or QT prolongation. Coadministration is contraindicated.
Ziprasidone	Mefloquine	Concomitant administration may increase the risk of life-threatening cardiac arrhythmias, torsades de pointes or QT prolongation. Coadministration is contraindicated.
Ziprasidone	Pentamidine	Concomitant administration may increase the risk of life-threatening cardiac arrhythmias, torsades de pointes or QT prolongation. Coadministration is contraindicated.
Ziprasidone	Phenothiazines	Concomitant administration may increase the risk of life-threatening cardiac arrhythmias, torsades de pointes or QT

Drug(s)	Interacting Medication or Disease	Mechanism
		prolongation. Coadministration is contraindicated.
Ziprasidone	Pimozide	Concomitant administration may increase the risk of life-threatening cardiac arrhythmias, torsades de pointes or QT prolongation. Coadministration is contraindicated.
Ziprasidone	Quinolones	Concomitant administration may increase the risk of life-threatening cardiac arrhythmias, torsades de pointes or QT prolongation. Coadministration is contraindicated.
Ziprasidone	Tacrolimus	Concomitant administration may increase the risk of life-threatening cardiac arrhythmias, torsades de pointes or QT prolongation. Coadministration is contraindicated.

### Dosage and Administration

**Table 16. Dosing and Administration**<sup>1-14</sup>

Drug	Usual Adult Dose	Usual Pediatric Dose	Availability
Aripiprazole	<p><u>Adjunctive treatment of major depressive disorder:</u> Orally disintegrating tablet, oral solution, tablet: initial, 2-5 mg PO daily; target dose, 5-10 mg PO daily; maximum, 15 mg PO daily</p> <p><u>Agitation associated with schizophrenia or bipolar mania:</u> Injection: initial, 5.25 mg IM up to every 2 hours; recommended dose, 9.75 mg IM daily; maximum, 30 mg IM daily; 15 mg IM daily was not shown to be more efficacious than 9.75 mg IM daily</p> <p><u>Bipolar disorder:</u> Orally disintegrating tablet, tablet: initial, 15 mg PO daily; recommended dose, 15 mg PO daily; maximum, 30 mg PO daily; if used in adjunction with lithium or valproate, initial dose may range from 10 mg to 15 mg PO daily</p> <p>Oral solution: initial, 15 mg PO daily; maintenance, 15 mg PO daily, maximum, 25 mg PO daily</p> <p><u>Schizophrenia:</u> Orally disintegrating tablet, tablet: initial, 10-15 mg PO daily; maintenance, 10-15 mg PO daily; maximum, 30 mg PO daily</p>	<p><u>Schizophrenia, adolescents (13 to 17 years):</u> Orally disintegrating tablet, oral solution, tablet: initial, 2 mg PO daily; target dose, 10 mg PO daily; maximum, 30 mg PO daily tablet or 25 mg PO daily solution; 30 mg PO daily was not shown to be more efficacious than 10 mg PO daily</p> <p><u>Bipolar mania, children and adolescents (10 to 17 years):</u> Orally disintegrating tablet, oral solution, tablet: initial, 2 mg PO daily; target dose, 10 mg PO daily; maximum, 30 mg PO daily tablet or 25 mg PO daily solution</p> <p><u>Autistic disorder with irritability, children and adolescents (6 to 17 years):</u> Orally disintegrating tablet, oral solution, tablet: initial, 2 mg PO daily; target dose, 5 to 10 mg PO daily; maximum, 15 mg PO daily</p> <p>The safety and effectiveness in pediatric patients with schizophrenia less than 13 years of age or in pediatric</p>	<p><u>Injection:</u> 7.5 mg/mL (9.75 mg/1.3 mL vial)</p> <p><u>Orally disintegrating tablet:</u> 10 mg 15 mg</p> <p><u>Oral solution:</u> 1 mg/mL</p> <p><u>Tablet:</u> 2 mg 5 mg 10 mg 15 mg 20 mg 30 mg</p>



Drug	Usual Adult Dose	Usual Pediatric Dose	Availability
	<p>Oral solution: initial, 15-25 mg PO daily; maintenance, 15-25 mg PO daily; maximum, 25 mg PO daily</p> <p><u>Long-acting Injection:</u> Initial: 400 mg IM monthly Maintenance: 400 mg IM monthly Maximum: 400 mg/month</p>	<p>patients with bipolar mania less than 10 years of age have not been established.</p> <p>Safety and effectiveness in pediatric patients with other conditions have not been established.</p>	
Asenapine	<p><u>Bipolar disorder:</u> Acute treatment: initial, 10 mg PO twice daily; dose can be decreased to 5 mg PO twice daily if adverse effects occur; target dose, 5 to 10 mg PO twice daily; maximum dose, 10 mg PO twice daily</p> <p><u>Adjunctive treatment (when used in combination with lithium or valproate):</u> initial, 5 mg PO twice daily; maintenance, 5 to 10 mg PO twice daily</p> <p><u>Schizophrenia:</u> Acute treatment: initial, 5 mg PO twice daily; target dose, 5 to 10 mg PO twice daily; maximum dose, 10 mg PO twice daily; safety of doses above 10 mg PO twice daily have not been evaluated</p>	<p><u>Bipolar disorder</u> (10 to 17 years of age): Acute treatment: initial, 2.5 mg PO twice daily; maintenance, 2.5 to 10 mg PO twice daily</p>	<p><u>Sublingual tablet:</u> 5 mg 10 mg</p>
Brexipiprazole	<p><u>Major Depressive Disorder</u> (Adjunctive): Tablet: initial, 0.5 mg PO once daily; Maintenance, 2 mg PO daily</p> <p><u>Schizophrenia:</u> Tablet: initial, maintenance, 1 mg PO daily on days one to four then 2 mg PO daily on days five through seven then 4 mg PO daily starting on day 8</p>	<p>Safety and effectiveness in pediatric patients have not been established.</p>	<p><u>Tablet:</u> 0.25 mg 0.5 mg 1 mg 2 mg 3 mg 4 mg</p>
Clozapine	<p><u>Treatment-resistant schizophrenia:</u> Orally disintegrating tablet, tablet, oral suspension: initial, 12.5 mg PO every 12 to 24 hours;* maximum, 900 mg PO daily</p>	<p>Safety and effectiveness in pediatric patients have not been established.</p>	<p><u>Orally disintegrating tablet:</u> 12.5 mg 25 mg 100 mg 150 mg 200 mg</p> <p><u>Tablet:</u> 25 mg 50 mg 100 mg</p>

Drug	Usual Adult Dose	Usual Pediatric Dose	Availability
			<u>Suspension:</u> 50 mg/mL
lloperidone	<p><u>Schizophrenia:</u> Tablet: initial, 1 mg PO twice daily; increases to reach the target dose range of 6-12 mg PO twice daily with daily dosage adjustments; maximum, 12 mg PO twice daily</p> <p>Dose should be reduced by one-half when administered concomitantly with strong CYP2D6 inhibitors.</p>	Safety and effectiveness in pediatric patients have not been established.	<u>Tablet:</u> 1 mg 2 mg 4 mg 6 mg 8 mg 10 mg 12 mg
Lurasidone	<p><u>Schizophrenia:</u> Tablet: initial, 40 mg PO once daily<sup>†</sup>; maximum, 80 mg PO once daily</p> <p>Dose should not exceed 40 mg daily if administered concomitantly with a moderate CYP3A4 inhibitor (i.e. diltiazem). Use with strong CYP3A4 inhibitors/inducers is contraindicated.</p> <p><u>Depressive episodes associated with bipolar disorder:</u> Tablet: initial, 20 mg PO once daily; maintenance 20 to 120 mg once daily; maximum, 120 mg once daily</p>	Safety and effectiveness in pediatric patients have not been established.	<u>Tablet:</u> 20 mg 40 mg 80 mg 60 mg 120 mg
Olanzapine	<p><u>Agitation associated with schizophrenia and bipolar I mania:</u> Injection: initial, 2.5-10 mg IM up to every 2 hours; target dose, 10 mg IM; maximum, 30 mg IM daily</p> <p><u>Bipolar disorder:</u> Orally disintegrating tablet, tablet: initial, 10 mg or 15 mg PO daily; maintenance, 5-20 mg PO daily; maximum, 20 mg PO daily</p> <p><u>Depressive episodes associated with bipolar disorder:</u> Tablet: initial, 5 mg PO daily in combination with fluoxetine 20 mg PO daily; maintenance, 5-12.5 mg PO daily in combination with fluoxetine 20-50 mg PO daily</p> <p><u>Schizophrenia:</u> Orally disintegrating tablet, tablet: initial, 5-10 mg PO daily; maintenance, 10-15 mg PO daily; maximum, 20 mg</p>	<p><u>Bipolar disorder, adolescents (13 to 17 years):</u> Orally disintegrating tablet, tablet: initial, 2.5mg or 5mg PO daily; target, 10 mg PO daily; maximum, 20 mg PO daily</p> <p><u>Schizophrenia, adolescents (13 to 17 years):</u> Orally disintegrating tablet, tablet: initial, 2.5mg or 5mg PO daily; target, 10 mg PO daily; maximum, 20 mg PO daily</p> <p><u>Depressive episodes associated with bipolar disorder in children and adolescents (10 to 17 years):</u> Tablet: initial, 2.5 mg PO daily in combination with fluoxetine 20 mg PO daily; maintenance, 2.5-12 mg PO</p>	<p><u>Injection:</u> 10 mg vial</p> <p><u>Orally disintegrating tablet:</u> 5 mg 10 mg 15 mg 20 mg</p> <p><u>Tablet:</u> 2.5 mg 5 mg 7.5 mg 10 mg 15 mg 20 mg</p>

Drug	Usual Adult Dose	Usual Pediatric Dose	Availability
	<p>PO daily</p> <p><u>Treatment resistant depression:</u> Tablet: initial, 5 mg PO daily in combination with fluoxetine 20 mg PO daily; maintenance, 5-20 mg PO daily in combination with fluoxetine 20-50 mg PO daily</p>	<p>daily in combination with fluoxetine 20-50 mg PO daily</p> <p>The safety and effectiveness in pediatric patients with schizophrenia or bipolar disorder less than 13 years of age have not been established.</p> <p>Safety and effectiveness in pediatric patients with other conditions have not been established.</p>	
Olanzapine pamoate	<p><u>Schizophrenia:</u> Long-acting IM injection: 150 mg, 210 mg or 300 mg administered every 2 weeks or 405 mg administered every 4 weeks via deep IM gluteal injection</p>	<p>Safety and effectiveness in pediatric patients have not been established.</p>	<p><u>Long-acting Injection:</u> 210 mg vial 300 mg vial 405 mg vial</p>
Paliperidone	<p><u>Schizophrenia:</u> Extended-release tablet†: initial, 6 mg PO daily; maintenance, 3-12 mg PO daily*; maximum, 12 mg PO daily</p> <p>Long acting IM injection: initial, 234 mg administered on treatment day one, followed by 156 mg one week later; maintenance, 117 mg administered once monthly; however, some patients may benefit from higher maintenance doses</p> <p><u>Schizoaffective disorder:</u> Extended-release tablet†: initial, 6 mg PO daily; maintenance, 3-12 mg PO daily*; maximum, 12 mg PO daily</p>	<p><u>Schizophrenia, adolescents (13 to 17 years) weighing &lt;51 kg:</u> Extended-release tablet†: initial, 3 mg PO daily; maintenance, 3-6 mg PO daily; maximum, 6 mg PO daily</p> <p><u>Schizophrenia, adolescents (13 to 17 years) weighing ≥/51 kg:</u> Extended-release tablet†: initial, 3 mg PO daily; maintenance, 3-12 mg PO daily; maximum, 12 mg PO daily</p> <p>The safety and effectiveness in pediatric patients with schizophrenia less than 12 years of age have not been established.</p> <p>Safety and effectiveness in pediatric patients with other conditions have not been established.</p>	<p><u>Extended-release tablet:</u> 1.5 mg 3 mg 6 mg 9 mg</p>
Quetiapine	<p><u>Bipolar disorder (depression):</u> Tablet: initial, 50 mg PO once daily at bedtime; maintenance, 300-600 mg PO daily*; maximum, 600 mg PO daily</p>	<p><u>Bipolar mania, children and adolescents (10 to 17 years):</u> Tablet: initial, 25 mg PO twice daily; maintenance, 200-300 mg PO twice daily*</p>	<p><u>Extended-release tablet:</u> 50 mg 150 mg</p>

Drug	Usual Adult Dose	Usual Pediatric Dose	Availability
	<p>Extended-release tablet: initial, 50 mg PO once daily; maintenance, 300 mg once PO daily*</p> <p><u>Bipolar disorder (mania):</u> Tablet: initial, 50 mg PO every 12 hours; maintenance, 400-800 mg PO daily*; maximum, 800 mg PO daily</p> <p>Extended-release tablet: initial, 300 mg PO once daily; maintenance, 400-800 mg PO once daily*</p> <p><u>Major depressive disorder:</u> Extended-release tablet: initial, 50 mg PO once daily; maintenance, 150-300 mg PO once daily*</p> <p><u>Schizophrenia:</u> Tablet: initial, 25 mg PO every 12 hours; maintenance, 150-750 mg PO daily*; maximum, 800 mg PO daily</p> <p>Extended-release tablet: initial, 300 mg PO once daily; maintenance, 400-800 mg PO once daily*</p>	<p><u>Schizophrenia, adolescents (13 to 17 years):</u> Tablet: initial, 25 mg PO twice daily; maintenance, 200-400 mg PO twice daily*</p> <p>The safety and effectiveness in pediatric patients with bipolar disorder less than 10 years of age or schizophrenia less than 13 years of age have not been established.</p> <p>Safety and effectiveness in pediatric patients with other conditions have not been established.</p>	<p>200 mg 300 mg 400 mg</p> <p><u>Tablet:</u> 25 mg 50 mg 100 mg 200 mg 300 mg 400 mg</p>
Risperidone	<p><u>Bipolar mania†:</u> Orally disintegrating tablet, oral solution, tablet: initial, 2-3 mg PO daily; maximum, 6 mg PO daily</p> <p>Injection: 25 mg IM every 2 weeks; maintenance, maintenance, 25-50 mg IM every 2 weeks; maximum, 50 mg IM every 2 weeks</p> <p><u>Schizophrenia:</u> Injection: initial, 25 mg IM every 2 weeks; maintenance, 25-50 mg IM every 2 weeks; maximum, 50 mg IM every 2 weeks</p> <p>Orally disintegrating tablet, oral solution, tablet: initial, 1 mg PO every 12 hours; maintenance, 4-16 mg PO daily dosed every 12-24 hours; maximum, 16 mg PO daily</p>	<p><u>Bipolar mania, children and adolescents aged 10 to 17 years:</u> Orally disintegrating tablet, oral solution, tablet: initial, 0.5 mg PO once daily; dosage adjustments, if indicated, at intervals not less than 24 hours, in increments of 0.5 mg or 1 mg PO daily, as tolerated, to a recommended dose of 2.5 mg PO daily; no additional benefit was seen above 2.5 mg PO daily; doses higher than 6 mg PO daily were not studied</p> <p><u>Irritability associated with autistic disorder, children and adolescents aged 5 to 16 years§:</u> Orally disintegrating tablet, oral solution, tablet: initial, 0.25 mg PO daily for patients &lt;20 kg and 0.5 mg daily for patients ≥20 kg; maximum, 1 mg PO daily in patients &lt;20</p>	<p><u>Orally disintegrating tablet:</u> 0.25 0.5 mg 1 mg 2 mg 3 mg 4 mg</p> <p><u>Oral solution:</u> 1 mg/mL</p> <p><u>Tablet:</u> 0.25 mg 0.5 mg 1 mg 2 mg 3 mg 4 mg</p>

Drug	Usual Adult Dose	Usual Pediatric Dose	Availability
		kg, 2.5 mg in patients $\geq$ 20 kg  <u>Schizophrenia, adolescents aged 13 to 17 years:</u> Orally disintegrating tablet, oral solution, tablet: initial, 0.5 mg PO once daily; dosage adjustments, if indicated, at intervals not less than 24 hours, in increments of 0.5 mg or 1 mg PO daily, as tolerated, to a recommended dose of 3 mg PO daily; maximum, 6 mg PO daily	
Ziprasidone	<u>Acute agitation in schizophrenia:</u> Injection: initial, 10 mg IM every 2 hours or 20 mg IM every 4 hours; maximum, 40 mg IM daily†  <u>Bipolar mania:</u> Capsule: initial, 40 mg PO every 12 hours; maintenance, 40-80 mg PO every 12 hours  <u>Schizophrenia:</u> Capsule: initial, 20 mg PO every 12 hours; maintenance, 20-80 mg PO every 12 hours; maximum, 100 mg PO every 12 hours; no additional benefit was demonstrated for doses above 20 mg twice daily	Safety and effectiveness in pediatric patients have not been established.	<u>Capsule:</u> 20 mg 40 mg 60 mg 80 mg  <u>Injection:</u> 20 mg/mL

IM=intramuscular, PO=by mouth

\*Please refer to individual package insert for titration of dose information.

†Initial dose titration is not required.

‡There is no clinical data supporting maintenance dosing.

§No dosing data is available for children who weighed less than 15 kg.

¶Administration for more than three consecutive days has not been studied.

\*\*In combination with fluoxetine 20 mg (adults and children)

## Clinical Guidelines

Table 14. Clinical Guidelines in Adults

Guideline	Recommendations
<b>Anxiety Disorder</b>	
National Collaborating Centre for Mental Health, National Institute for Health and Clinical Excellence: <b>Generalised Anxiety Disorder and Panic Disorder (with or without agoraphobia) in Adults: Management in Primary</b>	<u>High-intensity psychological interventions</u> <ul style="list-style-type: none"> <li>If a patient with generalized anxiety disorder (GAD) chooses a high-intensity psychological intervention, cognitive behavioral therapy (CBT) or applied relaxation may be offered.</li> </ul> <u>Pharmacotherapy</u> <ul style="list-style-type: none"> <li>If pharmacotherapy is chosen, selective serotonin reuptake inhibitors (SSRIs) are preferred. Sertraline is the most cost-effective treatment option and may be used first-line.</li> <li>If sertraline is ineffective, either an alternative SSRI or a serotonin-</li> </ul>

Guideline	Recommendations
<p><b>Secondary and Community Care (update) (2011)</b><sup>291</sup></p>	<p>norepinephrine reuptake inhibitor (SNRI) may be offered.</p> <ul style="list-style-type: none"> <li>• If a patient cannot tolerate either a SSRI or a SNRI, pregabalin may be tried.</li> <li>• Benzodiazepines or antipsychotics should not be used for the treatment of GAD in primary care.</li> <li>• Efficacy and safety should be evaluated every 2-4 weeks during the first 3 months of therapy and every 3 months subsequently.</li> <li>• If a drug is effective, therapy should continue for at least one year as the risk of relapse is high.</li> </ul> <p><u>Complex, treatment-refractory GAD</u></p> <ul style="list-style-type: none"> <li>• Combination of psychological and pharmacotherapy may be offered. Alternatively, combinations of antidepressants or augmentation of antidepressants with other drugs may be tried. However, the evidence for the effectiveness of combination treatments is lacking and side effects and interactions are more likely when combining and augmenting antidepressants.</li> <li>• Combination therapy should only be initiated by practitioners with expertise in the psychological and drug treatment of complex, treatment-refractory anxiety disorders and after full discussion with the patients about the benefits and risks of therapy.</li> </ul>
<p>American Psychiatric Association: <b>Practice guideline for the treatment of patients with panic disorder (2009)</b><sup>292</sup></p>	<p><u>Initial therapy</u></p> <ul style="list-style-type: none"> <li>• The use of a selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), tricyclic antidepressant (TCA), benzodiazepine (appropriate as monotherapy only in the absence of a co-occurring mood disorder), or CBT as the initial treatment for panic disorder is strongly supported by demonstrated efficacy in numerous randomized controlled trials.</li> <li>• There is insufficient evidence to recommend any of these pharmacological or psychosocial interventions as superior to the others, or to routinely recommend a combination of treatments over monotherapy.</li> <li>• Considerations that guide the choice of an initial treatment modality include patient preference, the risks and benefits for the particular patient, the patient's past treatment history, the presence of co-occurring general medical and other psychiatric conditions, cost, and treatment availability.</li> <li>• Psychosocial treatment (i.e.CBT) is recommended for patients who prefer non-pharmacological treatment and are able to commit to weekly sessions and complete between-session practices.</li> <li>• Pharmacotherapy (SSRI or SNRI) is recommended for patients who prefer this modality or who do not have sufficient time or other resources to engage in psychosocial treatment.</li> <li>• Adding psychosocial treatment to pharmacotherapy either from the start, or at some later point in treatment, may enhance long-term outcomes by reducing the likelihood of relapse when pharmacological treatment is stopped.</li> </ul> <p><u>Treatment of Refractory Patients</u></p> <ul style="list-style-type: none"> <li>• Patients who have failed first-line therapy may either augment the current treatment by adding another agent or another modality (i.e.CBT), or add pharmacotherapy if the patient is already receiving</li> </ul>

Guideline	Recommendations
	<p>CBT, or they can switch to a different medication or treatment modality.</p> <ul style="list-style-type: none"> <li>• If one first-line treatment (e.g., CBT, SSRI, or SNRI) has failed, adding or switching to another first-line treatment is recommended].</li> <li>• Adding a benzodiazepine to an antidepressant is a common augmentation strategy to target residual symptoms.</li> <li>• After first- and second-line treatments and augmentation approaches have failed (either due to lack of efficacy or intolerance), less well-supported treatment approaches may be considered. These include monotherapy or augmentation with gabapentin or a second-generation antipsychotic or with a psychotherapeutic intervention other than CBT or panic-focused psychodynamic psychotherapy.</li> </ul>
<p><b><i>Bipolar Disorder</i></b></p> <p>Veterans Affairs/Department of Defense: <b>Clinical Practice Guideline for Management of Bipolar Disorder in Adults (2010)</b><sup>293</sup></p>	<p><u>Bipolar mania or mixed bipolar disorder</u></p> <ul style="list-style-type: none"> <li>• Pharmacotherapy for bipolar mania or mixed episode should start with initiation or optimization of a medication that has been shown to be the most effective in treating bipolar manic episodes while minimizing the potential risks. Agents that are most likely to be beneficial for mania are the following: lithium, valproate, carbamazepine, aripiprazole, olanzapine, quetiapine, risperidone, or ziprasidone. In addition, lithium or valproate may be combined with an atypical antipsychotic.</li> <li>• Agents most likely to be beneficial for the treatment of a mixed bipolar episode are valproate, carbamazepine, aripiprazole, olanzapine, risperidone, or ziprasidone.</li> <li>• Agents that are unlikely to be beneficial either for bipolar mania or mixed bipolar are lamotrigine, topiramate, or gabapentin.</li> <li>• Clozapine, haloperidol and oxcarbazepine may be considered in patients with mania or mixed episode. [I] Lithium or quetiapine may be considered in patients with mixed episode.</li> <li>• Treatment response should be evaluated at 4 to 8 weeks after initiation of treatment, after each change in treatment, and periodically until full remission is achieved. In patients who reach full remission, assessment of symptoms should be continued periodically to monitor for relapse or recurrence.</li> <li>• Patients who have failed monotherapy may consider switching to another monotherapy, combining a non-antipsychotic mood stabilizer (lithium or valproate) with a second generation antipsychotic.</li> <li>• Clozapine, with its more serious side effect profile, may be combined with valproate or lithium as a treatment of severe mania or mixed episode, if it has been successful in the past or if other antipsychotics have failed.</li> </ul> <p><u>Pharmacotherapy for bipolar depression</u></p> <ul style="list-style-type: none"> <li>• Pharmacotherapy for bipolar depression should start with initiation or optimization of a medication that has been shown to be the most effective in treating bipolar depressive episodes, while minimizing the potential risks.</li> <li>• Quetiapine, lamotrigine, or lithium monotherapy should be considered as first-line treatment for adult patients with bipolar depression.</li> <li>• Olanzapine/fluoxetine combination should be considered for treatment of bipolar depression, but its adverse effects (weight gain,</li> </ul>

Guideline	Recommendations
	<p>risk of diabetes, hypertriglyceridemia) places this combination as a second-line treatment. Olanzapine alone may also be considered for bipolar depression, but adverse effects require caution.</p> <ul style="list-style-type: none"> <li>• Agents that had been effective in treating prior episodes of depression should be considered.</li> <li>• There is insufficient evidence to recommend for or against the use of valproate, carbamazepine, topiramate, risperidone, ziprasidone, or clozapine for BD depression.</li> <li>• Aripiprazole is not recommended for monotherapy in the treatment of acute bipolar depression, unless there is a history of previous good response during depression without switch to mania or a history of treatment refractory depression.</li> <li>• Combining lithium with lamotrigine can be considered for patients with bipolar depression who do not respond to monotherapy.</li> <li>• When patients do not respond to treatment options that have shown better efficacy, antidepressant augmentation with SSRI, SNRI, bupropion, and monoamine oxidase inhibitor (MAOI) can be considered for short-term treatment, monitoring closely for triggering of manic symptoms.</li> <li>• Clozapine may be considered for augmentation, using caution regarding metabolic or other adverse effects.</li> <li>• There is insufficient evidence to recommend for or against use of augmentation with aripiprazole, olanzapine, risperidone, haloperidol, oxcarbazepine, topiramate, ziprasidone, valproate, or carbamazepine for the treatment of bipolar depression.</li> <li>• Gabapentin and the tricyclic antidepressants (TCAs) are not recommended for monotherapy or augmentation in the treatment of acute bipolar depression, unless there is a history of previous good response during depression without switch to mania or a history of treatment refractory depression.</li> <li>• If there is no response within 2 to 4 weeks on an adequate dose of medication, therapy should be adjusted by either augmenting with additional agents, discontinuing switching to another effective medication or electroconvulsive therapy if multiple medication trials have been ineffective.</li> </ul>
<p>National Institute for Health and Clinical Excellence:  <b>Bipolar Disorder: The Assessment and Management of Bipolar Disorder in Adults, Children and Adolescents, in Primary And Secondary Care (2014)</b><sup>294</sup></p>	<p><b>Acute manic episode in adults</b></p> <ul style="list-style-type: none"> <li>• If a person develops mania or hypomania and is taking an antidepressant: <ul style="list-style-type: none"> <li>○ Consider stopping the antidepressant and</li> <li>○ Offer an antipsychotic regardless of whether the antidepressant is stopped.</li> </ul> </li> <li>• If a person develops mania or hypomania and is not taking an antipsychotic or mood stabilizer, offer haloperidol, olanzapine, quetiapine or risperidone.</li> <li>• If the first antipsychotic is poorly tolerated at any dose (including rapid weight gain) or ineffective at the maximum licensed dose, offer an alternative antipsychotic</li> <li>• If an alternative antipsychotic is not sufficiently effective at the maximum licensed dose, consider adding lithium, and if lithium is ineffective or not suitable, consider valproate instead.</li> <li>• If a person develops mania or hypomania and is taking an antidepressant in combination with a mood stabilizer, consider</li> </ul>



Guideline	Recommendations
	<p>stopping the antidepressant.</p> <ul style="list-style-type: none"> <li>• If already taking lithium, consider adding haloperidol, olanzapine, quetiapine or risperidone.</li> <li>• If the person is already taking valproate or another mood stabilizer as prophylactic treatment, consider increasing the dose, up to the maximum level.               <ul style="list-style-type: none"> <li>○ Consider adding haloperidol, olanzapine, quetiapine or risperidone</li> </ul> </li> <li>• Do not offer lamotrigine to treat mania.</li> </ul> <p><u>Acute depressive episode in adults</u></p> <ul style="list-style-type: none"> <li>• If a person develops moderate or severe bipolar depression and is not taking a drug to treat their bipolar disorder, offer fluoxetine combined with olanzapine, or quetiapine on its own.               <ul style="list-style-type: none"> <li>○ Olanzapine or lamotrigine monotherapy may be considered.</li> <li>○ If no response from combination olanzapine/fluoxetine or quetiapine alone, consider lamotrigine</li> </ul> </li> <li>• If a person develops moderate or severe bipolar depression and is already taking lithium or valproate, check their plasma lithium or valproate level. If it is inadequate, increase the dose of lithium; if it is at maximum level, add either fluoxetine/olanzapine combination or quetiapine alone</li> <li>• Patients with concurrent depressive and psychotic symptoms may be managed with olanzapine, quetiapine, or risperidone if the depressive illness is severe.</li> </ul> <p><u>Long-term management</u></p> <ul style="list-style-type: none"> <li>• Lithium is first line for long-term therapy.               <ul style="list-style-type: none"> <li>○ Consider valproate or olanzapine if lithium is ineffective or cannot be taken.</li> </ul> </li> <li>• Quetiapine or lamotrigine can be considered for the management of patients with chronic and recurrent depressive symptoms.</li> <li>• Long-acting intramuscular antipsychotic injections should not be used routinely.</li> <li>• Stop treatment gradually and monitor the person for signs of relapse.</li> </ul>
<p>The Texas Medication Algorithm Project:  <b>Texas Implementation of Medication Algorithms Procedural Manual: Bipolar Disorder Algorithms (2007)</b><sup>295</sup></p>	<p><u>Treatment of hypomanic or manic episodes</u></p> <ul style="list-style-type: none"> <li>• Stage 1 treatment options for euphoric symptoms include: lithium, valproate, aripiprazole, quetiapine, risperidone, and ziprasidone.</li> <li>• Stage 1 treatment options for mixed symptoms include: valproate, aripiprazole, risperidone, and ziprasidone.</li> <li>• Stage 1b, olanzapine and carbamazepine are potential alternatives to stage 1 agents.</li> <li>• Stage 2 treatment options include a combination with two of the following: lithium, valproate, olanzapine, quetiapine, risperidone, or ziprasidone (not 2 antipsychotics).</li> <li>• Stage 3 treatment options include a different combination than that tried in Stage 2, with additional options including carbamazepine, oxcarbazepine, aripiprazole, and a typical antipsychotic.</li> <li>• Stage 4 treatment options include clozapine or 3-drug combinations (include lithium, an anticonvulsant mood stabilizer [valproate, carbamazepine, or oxcarbazepine], plus an atypical antipsychotic).</li> </ul>

Guideline	Recommendations
	<p><u>Treatment of depression</u></p> <ul style="list-style-type: none"> <li>• Stage 1 recommended treatment is lamotrigine monotherapy for those patients without a recent and/or severe history of manic symptoms. Others should receive lamotrigine plus a mood stabilizer.</li> <li>• Stage 2 treatment options include quetiapine monotherapy or the olanzapine/fluoxetine combination treatment.</li> <li>• For Stage 3 and beyond, evidence-based medicine is limited to case series, open-label studies and expert clinical consensus. A variety of treatment options are suggested.</li> <li>• For intolerance or unresponsiveness to agents used in a particular Stage, it is recommended to try an alternative mood stabilizer within that Stage.</li> </ul>
<p>American Psychiatric Association: <b>Practice Guideline for the Treatment of Patients with Bipolar Disorder (2002)</b><sup>296</sup></p>	<p><u>Treatment of acute manic or mixed episodes</u></p> <ul style="list-style-type: none"> <li>• Adjunctive antipsychotic treatment is recommended for manic or mixed manic episodes with psychotic features.</li> <li>• Second generation antipsychotics are preferable over first generation antipsychotics because of their side effect profile.</li> </ul> <p><u>Treatment of acute depressive episodes</u></p> <ul style="list-style-type: none"> <li>• Patients presenting with psychotic features would require adjunctive treatment with an antipsychotic medication or electroconvulsive therapy.</li> </ul> <p><u>Treatment of acute rapid cycling</u></p> <ul style="list-style-type: none"> <li>• A combination regimen containing a second generation antipsychotic may also be used.</li> </ul> <p><u>Maintenance treatment for manic/depressive episode</u></p> <ul style="list-style-type: none"> <li>• Ongoing adjunctive antipsychotic therapy should be reassessed, and slowly tapered, unless required for control of persistent psychosis or prophylaxis against recurrence.</li> </ul>
<b>Dementia</b>	
<p>American Psychiatric Association: <b>Practice Guideline for the Treatment of Patients with Alzheimer's Disease and Other Dementias (2007)</b><sup>297</sup></p>	<p><u>Treatment of cognitive symptoms</u></p> <ul style="list-style-type: none"> <li>• Cholinesterase inhibitors should be offered to patients with mild to moderate Alzheimer's disease after a thorough discussion of their potential risks and benefits, and they may be helpful for patients with severe Alzheimer's disease.</li> <li>• Cholinesterase inhibitors should be considered for patients with mild to moderate dementia associated with Parkinson's disease.</li> <li>• Cholinesterase inhibitors can be considered for patients with dementia with Lewy bodies.</li> <li>• Memantine, a noncompetitive N-methyl-D-aspartate (NMDA) antagonist, may provide modest benefits and has few adverse effects; thus, it may be considered. There is some evidence of its benefit in mild Alzheimer's disease and very limited evidence of its benefit in vascular dementia.</li> </ul> <p><u>Treatment of psychosis and agitation</u></p> <ul style="list-style-type: none"> <li>• Psychosis, aggression, and agitation are common in patients with dementia and may respond to similar therapies.</li> <li>• On the basis of good evidence, antipsychotic medications are recommended for the treatment of psychosis in patients with</li> </ul>

Guideline	Recommendations
	<p>dementia and for the treatment of agitation.</p> <ul style="list-style-type: none"> <li>• These medications have also been shown to provide modest improvement in behavioral symptoms in general.</li> <li>• Evidence for a difference in efficacy and safety among antipsychotic medications is limited.</li> <li>• Antipsychotic medications as a group are associated with a number of severe adverse events, including increased risks for death, cerebrovascular accidents, tardive dyskinesia, neuroleptic malignant syndrome, hyperlipidemia, weight gain, diabetes mellitus, sedation, parkinsonism, and worsening of cognition. Thus, they must be used with caution and at the lowest effective dosage, after considering the risks of not treating the psychiatric symptoms.</li> <li>• Data demonstrating benefit from benzodiazepines are modest, but benzodiazepines occasionally have a role in treating patients with prominent anxiety or on an as-needed basis for patients with infrequent episodes of agitation or for those who require sedation for a procedure. Lorazepam and oxazepam, which have no active metabolites, are preferable to agents with a longer half-life such as diazepam or clonazepam.</li> <li>• There is minimal evidence for the efficacy of anticonvulsants, lithium, and beta-blockers for the treatment of psychosis or agitation in dementia, and these medications have significant adverse effects; therefore, they are generally not recommended except for patients for whom other treatments have failed.</li> <li>• The antidepressant trazodone and the SSRIs are not well studied but may be appropriate for nonpsychotic patients with agitation.</li> </ul> <p><u>Treatment of depression:</u></p> <ul style="list-style-type: none"> <li>• Clinical consensus supports a trial of an antidepressant to treat clinically significant, persistent depressed mood.</li> <li>• SSRIs may be preferred because they appear to be better tolerated than other antidepressants. Bupropion, venlafaxine, and mirtazapine may also be effective.</li> <li>• Agents with substantial anticholinergic effects (e.g., amitriptyline, imipramine) should be avoided.</li> <li>• Psychostimulants, bupropion, bromocriptine, and amantadine may be helpful for apathy. Psychostimulants are also sometimes useful in the treatment of depression in patients with significant general medical illness.</li> </ul> <p><u>Treatment of sleep disturbances:</u></p> <ul style="list-style-type: none"> <li>• If a patient requires medication for another psychiatric condition, an agent with sedating properties, given at bedtime, is preferred.</li> <li>• For primarily sleep disturbance, medications with possible effectiveness include trazodone, zolpidem, or zaleplon, but there are few data on the efficacy of specific agents.</li> <li>• Benzodiazepines are not recommended for other than brief use because of risks of daytime sedation, tolerance, rebound insomnia, worsening cognition, falls, disinhibition, and delirium.</li> <li>• Diphenhydramine is not recommended because of its anticholinergic properties.</li> <li>• Antipsychotic medications should not be used solely for the purpose</li> </ul>

Guideline	Recommendations
	of treating sleep disturbances.
<b>Eating Disorder</b>	
<p>World Federation of Societies of Biological Psychiatry:  <b>Guidelines for the Pharmacological Treatment of Eating Disorders (2011)</b><sup>298</sup></p>	<p><u>Anorexia Nervosa</u></p> <ul style="list-style-type: none"> <li>• Zinc supplementation may be used.</li> <li>• Olanzapine may be used for weight gain.</li> <li>• The other atypical antipsychotics have an less evidence supporting their use compared to olanzapine.</li> <li>• Antidepressants are not associated with weight gain, but can improve depressive symptoms.</li> </ul> <p><u>Bulimia Nervosa</u></p> <ul style="list-style-type: none"> <li>• Imipramine, desipramine, fluoxetine, and topiramate may be used to reduce bulimic behavior.</li> <li>• Fluvoxamine and sertraline may reduce bulimic behavior.</li> </ul> <p><u>Binge Eating Disorder</u></p> <ul style="list-style-type: none"> <li>• Imipramine, citalopram, escitalopram, sertraline, topiramate, and sibutramine may be used to reduce binge eating behavior.</li> <li>• Zonisamide may reduce binge eating behavior.</li> </ul>
<p>American Psychiatric Association:  <b>Practice Guideline for the Treatment of Patients with Eating Disorders (2012)</b><sup>299</sup></p>	<p><u>Anorexia nervosa</u></p> <ul style="list-style-type: none"> <li>• The limited empirical data on SSRIs do not suggest a role in weight gain.</li> <li>• Atypical antipsychotics, especially olanzapine, risperidone, and quetiapine, have been studied in small case series and case studies. These agents may be useful in patients with severe, unremitting resistance to gaining weight, severe obsessional thinking, and denial that assumes delusional proportions. Ziprasidone has not been studied in patients with anorexia nervosa; hence, patients who are using this agent should be monitored for ECG changes and serum potassium abnormalities.</li> </ul> <p><u>Bulimia nervosa</u></p> <ul style="list-style-type: none"> <li>• Antidepressants are effective as one component of an initial treatment program for most patients, with SSRIs having the most evidence for efficacy and the fewest difficulties with adverse effects. Of the SSRIs, fluoxetine is the best studied agent.</li> <li>• Lithium is ineffective and should not be used.</li> </ul> <p><u>Binge eating disorder</u></p> <ul style="list-style-type: none"> <li>• Antidepressants, particularly SSRIs, are associated with a short-term reduction in binge eating behavior, but not with substantial weight loss.</li> <li>• Topiramate is effective in binge reduction and weight loss, although adverse effects may limit its use.</li> <li>• Zonisamide is another option for patients with binge eating disorder.</li> </ul>
<b>Major Depressive Disorder (MDD)</b>	
<p>Institute for Clinical Systems Improvement:  <b>Major Depression in Adults in Primary Care (2013)</b><sup>300</sup></p>	<p><u>Pharmacotherapy</u></p> <ul style="list-style-type: none"> <li>• SSRIs, venlafaxine, duloxetine, desvenlafaxine, mirtazapine and bupropion are recommended as first-line antidepressant treatment options. Side effects may include headache, nervousness, insomnia, and sexual side effects.</li> </ul>

Guideline	Recommendations
	<ul style="list-style-type: none"> <li>• Secondary Amine Tricyclics (TCAs) are effective for the treatment of MDD; however, they are used less frequently as first-line agents due to their safety profile. Secondary amine tricyclics cause less orthostatic hypotension and sedation than do tertiary amine tricyclics. Monitoring blood levels and electrocardiogram (EKG) may be advised.</li> <li>• Monoamine Oxidase Inhibitors (MAOIs) should only be used in patients who do not respond to other treatments because of their potential for serious side effects and the necessity of dietary restrictions.</li> <li>• Augmentation therapy is used in patients whose depression is either treatment-resistant or partially responsive to treatment. Consultation with a behavioral health specialist is advised. The following agents may be added to antidepressant therapy: bupropion, buspirone, mirtazapine, triiodothyronine, stimulants, TCA-SSRI combination, lithium, and atypical antipsychotics.</li> </ul>
<p>American Psychiatric Association:  <b>Practice Guideline for the Treatment of Patients With Major Depressive Disorder (2010)</b><sup>301</sup></p>	<p><u>Acute phase</u></p> <ul style="list-style-type: none"> <li>• Pharmacotherapy:             <ul style="list-style-type: none"> <li>○ An antidepressant medication is recommended as an initial treatment choice for patients with mild to moderate major depressive disorder (MDD) and definitely should be provided for those with severe MDD.</li> <li>○ Due to the fact that the effectiveness of antidepressant medications is generally comparable between classes and within classes of medications, the initial selection of an antidepressant medication will largely be based on the anticipated side effects; the safety or tolerability of these side effects; pharmacological properties of the medication and additional factors such as medication response in prior episodes, cost and patient preference.</li> <li>○ For the majority of patients, a selective serotonin reuptake inhibitor (SSRI), serotonin norepinephrine reuptake inhibitor (SNRI), bupropion or mirtazapine is optimal.</li> <li>○ In general, the use of nonselective monoamine oxidase inhibitors (MAOIs) should be restricted to patients who do not respond to other treatments.</li> <li>○ In patients who prefer complementary and alternative therapies, S-adenosyl methionine or St John's Wort might be considered.</li> <li>○ Once an antidepressant has been initiated, the rate at which it is titrated to a full therapeutic dose should depend upon the patient's age, the treatment setting and the presence of co-occurring illnesses, concomitant pharmacotherapy or medication side effects.</li> <li>○ During the acute phase of treatment, patients should be carefully and systematically monitored on a regular basis to assess their response to pharmacotherapy.</li> <li>○ Determine the frequency of patient monitoring based upon the patient's symptom severity, co-occurring disorders, cooperation with treatment, availability of social supports and the frequency and severity of side effects with the chosen treatment.</li> </ul> </li> </ul>

Guideline	Recommendations
	<ul style="list-style-type: none"> <li>○ If side effects do occur, an initial strategy is to lower the dose of the antidepressants or to change to an antidepressant that is not associated with those side effects.</li> <li>· Assessing the adequacy of treatment response:             <ul style="list-style-type: none"> <li>○ It is important to establish that treatment has been administered for a sufficient duration and at a sufficient frequency or, in the case of medication, dose.</li> <li>○ Generally, four to eight weeks of treatment are needed before concluding that a patient is partially responsive or unresponsive to a specific intervention.</li> </ul> </li> <li>· Strategies to address non-response:             <ul style="list-style-type: none"> <li>○ For individuals who have not responded fully to treatment, the acute phase of treatment should not be concluded prematurely, as an incomplete response to treatment is often associated with poor functional outcomes.</li> <li>○ If at least a moderate improvement in symptoms is not observed within four to eight weeks of treatment initiation, the diagnosis should be reappraised, side effects assessed, complicating co-occurring conditions and psychosocial factors reviewed and the treatment plan adjusted.</li> <li>○ It is important to assess the quality of the therapeutic alliance and treatment adherence.</li> <li>○ If medications are prescribed, the psychiatrist should determine whether pharmacokinetic or pharmacodynamic factors suggest a need to adjust medication dose.</li> <li>○ After an additional four to eight weeks of treatment, if the patient continues to show minimal or no improvement in symptoms, the psychiatrist should conduct another thorough review of possible contributory factors and make additional changes in the treatment plan.</li> <li>○ There are a number of strategies available when a change in treatment seems necessary.                 <ul style="list-style-type: none"> <li>§ For patients treated with an antidepressant, optimizing the medication dose is a reasonable first step if the side effect burden is tolerable and the upper limit of a medication dose has not been reached.</li> <li>§ In patients who have shown minimal improvement or experienced significant medication side effects, other options include augmenting the antidepressant with a depression-focused psychotherapy or with other agents or with changing to another non-MAOI antidepressant.</li> <li>§ Patients may be changed to an antidepressant from the same pharmacological class or to one from a different class.</li> <li>§ Patients who have not responded to an SSRI, may respond to SNRI.</li> <li>§ Augmentation of antidepressant medications can utilize another non-MAOI antidepressant, generally from a different pharmacological class, or a non-antidepressant medication, such as lithium, thyroid hormone or a second generation antipsychotic.</li> </ul> </li> </ul> </li> </ul>

Guideline	Recommendations
	<p><u>Continuation phase</u></p> <ul style="list-style-type: none"> <li>• During the continuation phase of treatment, the patient should be carefully monitored for signs of possible relapse.</li> <li>• Systematic assessment of symptoms, side effects, adherence and functional status is essential and may be facilitated through the use of clinician- and/or patient-administered rating scales.</li> <li>• To reduce the risk of relapse, patients who have been treated successfully with antidepressant medications in the acute phase should continue treatment with these agents for four to nine months.</li> <li>• In general, the dose used in the acute phase should be used in the continuation phase.</li> <li>• To prevent a relapse of depression in the continuation phase, depression-focused psychotherapy is recommended, with the best evidence available for CBT.</li> </ul> <p><u>Maintenance phase</u></p> <ul style="list-style-type: none"> <li>• In order to reduce the risk of a recurrent depressive episode, patients who have had three or more prior MDD episodes or who have chronic MDD should proceed to the maintenance phase of treatment after completing the continuation phase.</li> <li>• Maintenance therapy should also be considered for patients with additional risk factors for recurrence.</li> <li>• Additional considerations that may play a role in the decision to use maintenance therapy include patient preference, the type of treatment received, the presence of side effects during continuation therapy, the probability of recurrence, the frequency and severity of prior depressive episodes, the persistence of depressive symptoms after recovery and the presence of co-occurring disorders. Such factors also contribute to decisions about the duration of the maintenance phase.</li> <li>• For many patients, some form of maintenance treatment will be required indefinitely.</li> <li>• An antidepressant medication that produced symptom remission during the acute phase and maintained remission during the continuation phase should be continued at a full therapeutic dose.</li> <li>• For patients whose depressive episodes have not previously responded to acute or continuation treatment with medications or a depression-focused psychotherapy but who have shown a response to electroconvulsive therapy (ECT), maintenance ECT may be considered.</li> <li>• Due to the risk of recurrence, patients should be monitored systematically and at regular intervals during the maintenance phase.</li> </ul> <p><u>Discontinuation of treatment</u></p> <ul style="list-style-type: none"> <li>• When pharmacotherapy is being discontinued, it is best to taper the medication over the course of at least several weeks.</li> <li>• To minimize the likelihood of discontinuation symptoms, patients should be advised not to stop medications abruptly and to take medications with them when they travel or are away from home.</li> <li>• A slow taper or temporary change to a longer half-life antidepressant may reduce the risk of discontinuation syndrome when discontinuing</li> </ul>

Guideline	Recommendations
	<p>antidepressants or reducing antidepressant doses.</p> <ul style="list-style-type: none"> <li>• Before the discontinuation of active treatment, patients should be informed of the potential for a depressive relapse and a plan should be established for seeking treatment in the event of recurrent symptoms.</li> <li>• After discontinuation of medications, patients should continue to be monitored over the next several months and should receive another course of adequate acute phase treatment if symptoms recur.</li> </ul> <p><u>Clinical factors influencing treatment</u></p> <ul style="list-style-type: none"> <li>• Psychiatric factors:               <ul style="list-style-type: none"> <li>○ For suicidal patients, an increase in the intensity of treatment should be considered and may include hospitalization when warranted and/or combined treatment with pharmacotherapy and psychotherapy.</li> <li>○ For patients who exhibit psychotic symptoms during an episode of MDD, treatment should include a combination of antipsychotic and antidepressant medications or ECT.</li> <li>○ Catatonic features should be treated with a benzodiazepine or barbiturate, typically in conjunction with an antidepressant. If an antipsychotic medication is needed, it is important to monitor for signs of neuroleptic malignant syndrome, to which patients with catatonia may have a heightened sensitivity.</li> <li>○ Benzodiazepines may be used adjunctively in MDD and co-occurring anxiety, although they do not treat depressive symptoms.</li> <li>○ In patients who smoke, bupropion or nortriptyline may be options to simultaneously treat depression and assist with smoking cessation.</li> </ul> </li> </ul>
<p>National Institute for Health and Clinical Excellence:  <b>The Treatment and Management of Depression in Adults (2009)</b><sup>302</sup></p>	<p><u>Persistent subthreshold depressive symptoms or mild to moderate depression with inadequate response to initial interventions, and moderate and severe depression</u></p> <ul style="list-style-type: none"> <li>• For patients with persistent subthreshold depressive symptoms or mild to moderate depression who have not benefited from a low-intensity psychosocial intervention, discuss the relative merits of different interventions with the person and provide:               <ul style="list-style-type: none"> <li>○ An antidepressant (normally an SSRI) or a high intensity psychosocial intervention.</li> </ul> </li> <li>• For people with moderate or severe depression, provide a combination of an antidepressant medication and a high intensity psychological intervention.</li> <li>• The choice of intervention should be influenced by the duration of the episodes of depression and the trajectory of symptoms, previous course of depression and response to treatment, likelihood of adherence to treatment and any potential adverse effects and the patient's treatment preference and priorities.</li> <li>• For people with depression who decline an antidepressant, CBT, interpersonal therapy, behavioral activation and behavioral couples therapy; consider counseling for people with persistent subthreshold depressive symptoms or mild to moderate depression, short term psychodynamic psychotherapy for people with mild to moderate depression or discussing with the patient the uncertainty of the</li> </ul>



Guideline	Recommendations
	<p>effectiveness of counseling and psychodynamic psychotherapy in treating depression.</p> <p><u>Antidepressant drugs</u></p> <ul style="list-style-type: none"> <li>• Choice of antidepressant:               <ul style="list-style-type: none"> <li>○ Discuss the choice of antidepressant with the patient, including any anticipated adverse events and potential drug interactions, and their perception of the efficacy and tolerability of any antidepressant they have previously taken.</li> <li>○ When an antidepressant is used, it should normally be an SSRI in a generic form. The SSRIs are equally effective as other antidepressants and have a favorable risk-benefit ratio. Fluoxetine, fluvoxamine and paroxetine are associated with a higher propensity for drug interactions than other SSRIs, and paroxetine is associated with a higher incidence of discontinuation symptoms than other SSRIs.</li> <li>○ Take into account toxicity in overdose when choosing an antidepressant for people at significant risk for suicide. Be aware that compared to other equally effective antidepressants routinely used in primary care, venlafaxine is associated with a greater risk of death from overdose, and tri-cyclic antidepressants (TCAs), except lofepramine, are associated with the greatest risk in overdose.</li> <li>○ When prescribing drugs other than SSRIs, take the following into account: the increased likelihood of the person stopping treatment because of side effects with duloxetine, venlafaxine and TCAs, the specific cautions, contraindications and monitoring requirements for some drugs, that non-reversible MAOIs should normally be prescribed only by specialists and dosulepin should not be prescribed.</li> </ul> </li> <li>• Starting and initial phase of treatment:               <ul style="list-style-type: none"> <li>○ When prescribing antidepressants, explore any concerns the patient has. Explain the gradual development of the full antidepressant effect, the importance of taking the medication as prescribed, the need to continue treatment after remission, potential side effects, the potential for interactions with other medications, the risk and nature of discontinuation symptoms with all antidepressants and how these symptoms can be minimized and the fact that addiction does not occur with antidepressants.</li> <li>○ If side effects develop early in antidepressant treatment, provide appropriate information and consider one of the following strategies: monitor symptoms closely where side effects are mild and acceptable to the patient, stop the antidepressant, change to a different antidepressant if the person prefers or consider short term concomitant treatment with a benzodiazepine if anxiety, agitation and/or insomnia are problematic (this should usually be for no longer than two weeks in order to prevent the development of dependence).</li> <li>○ Patients who start on low dose TCAs and who have clear clinical response can be maintained on that dose with careful monitoring.</li> <li>○ If the patient's depression shows no improvement after two to</li> </ul> </li> </ul>

Guideline	Recommendations
	<p>four weeks with the first antidepressant, check that the drug has been taken regularly and in the prescribed dose.</p> <ul style="list-style-type: none"> <li>○ If response is absent or minimal after three to four weeks of treatment with a therapeutic dose of an antidepressant, increase the level of support and consider increasing the dose in line with the summary of product characteristics if there are no significant side effects or switching to another antidepressant.</li> <li>○ If the patient's depression shows some improvement by four weeks, continue treatment for another two to four weeks. Consider switching to another antidepressant if response is still not adequate, there are side effects or the person prefers to change treatment.</li> </ul>
<b>Obsessive Compulsive Disorder (OCD)</b>	
<p>American Psychiatric Association: <b>Practice Guideline for the Treatment of Patients with Obsessive-Compulsive Disorder (2007)</b><sup>303</sup></p>	<ul style="list-style-type: none"> <li>· In choosing a treatment approach, the clinician should consider the patient's motivation and ability to comply with pharmacotherapy and psychotherapy.</li> <li>· CBT and SSRIs are recommended as safe and effective first-line treatments for OCD. Combined treatment should be considered for patients with an unsatisfactory response to monotherapy, for those with co-occurring psychiatric conditions for which SSRIs are effective, and for those who wish to limit the duration of SSRI treatment.</li> <li>· Clomipramine, fluoxetine, fluvoxamine, paroxetine, and sertraline are recommended first-line pharmacological agents. Because the SSRIs have a less troublesome side-effect profile than clomipramine, an SSRI is preferred for a first medication trial.</li> <li>· CBT that relies primarily on behavioral techniques such as exposure and response prevention is recommended because it has the best evidentiary support.</li> <li>· Most patients will not experience substantial improvement until 4 to 6 weeks after starting medication, and some who will ultimately respond will experience little improvement for as many as 10 to 12 weeks.</li> <li>· Medication doses may be increased weekly or biweekly to the maximum dose comfortably tolerated and indicated. This maximum dose may exceed the manufacturer's recommended maximum dose in some cases. Higher doses may be appropriate for patients who have had little response to treatment and are tolerating a medication well.</li> <li>· When initial therapy is inadequate, augmentation strategies may be preferred to switching strategies in patients who have a partial response to the initial treatment.</li> <li>· The psychiatrist should first consider augmentation of SSRIs with trials of different antipsychotic medications or with CBT.</li> <li>· Patients who do not respond to one SSRI may be switched to a different SSRI. A switch to venlafaxine is less likely to produce an adequate response. For patients who have not benefitted from their first SSRI trial, a switch to mirtazapine can also be considered.</li> <li>· SSRI nonresponders and partial responders may try augmentation with antipsychotic medications. Available evidence does not support the use of antipsychotic monotherapy.</li> <li>· After first- and second-line treatments and well-supported</li> </ul>

Guideline	Recommendations
	<p>augmentation strategies have been exhausted, less well-supported treatment strategies may be considered. These include augmenting SSRIs with clomipramine, buspirone, pindolol, riluzole, or once-weekly oral morphine sulfate.</p>
<b>Post-Traumatic Stress Disorder (PTSD)</b>	
<p>Veterans Affairs/Department of Defense: <b>Clinical Practice Guideline for the Management of Post-Traumatic Stress (2010)</b><sup>304</sup></p>	<p><u>Pharmacotherapy</u></p> <ul style="list-style-type: none"> <li>• There is no evidence to support a recommendation for use of a pharmacological agent to prevent the development of ASD or PTSD.</li> <li>• Benzodiazepines are not recommended for the prevention of ASD or PTSD.</li> <li>• Monotherapy should be optimized before proceeding to subsequent strategies by monitoring outcomes, maximizing dosage (medication or psychotherapy), and allowing sufficient response time (for at least 8 weeks). If there is some response and patient is tolerating the drug, therapy should be continued for at least another 4 weeks.</li> <li>• If there is no improvement at 8 weeks consider increasing the dose of the initial drug to maximum tolerated, discontinuing the current agent and switching to another effective medication or augmenting with additional agents.</li> <li>• Patients diagnosed with PTSD should be offered selective serotonin reuptake inhibitors (SSRIs), for which fluoxetine, paroxetine, or sertraline have the strongest support, or serotonin norepinephrine reuptake inhibitors (SNRIs), for which venlafaxine has the strongest support, for the treatment of PTSD.</li> <li>• Mirtazapine, nefazodone, tricyclic antidepressants (TCAs) (amitriptyline and imipramine), or monoamine oxidase inhibitors (phenelzine) may also be used for the treatments for PTSD.</li> <li>• Guanfacine and anticonvulsants (tiagabine, topiramate, or valproate) are not recommended to be used as monotherapy in the management of PTSD.</li> <li>• The existing evidence does not support the use of bupropion, buspirone, trazodone, anticonvulsants (lamotrigine or gabapentin), or atypical antipsychotics as monotherapy in the management of PTSD.</li> <li>• There is evidence against the use of benzodiazepines in the management of PTSD.</li> <li>• There is insufficient evidence to support the use of prazosin as monotherapy in the management of PTSD.</li> <li>• Atypical antipsychotics (risperidone or olanzapine or, quetiapine) are recommended as adjunctive therapy for the management of PTSD.</li> <li>• Prazosin is recommended as adjunctive therapy for sleep/nightmares.</li> <li>• There is insufficient evidence to recommend a sympatholytic or an anticonvulsant as an adjunctive therapy for the treatment of PTSD.</li> </ul>
<p>American Psychiatric Association: <b>Practice Guideline for the Treatment of Patients with Acute Stress Disorder and Posttraumatic Stress Disorder (2004)</b><sup>305</sup></p>	<p><u>Pharmacotherapy</u></p> <ul style="list-style-type: none"> <li>• SSRIs are recommended as first-line pharmacotherapy option for PTSD.</li> <li>• Other antidepressants, including tricyclic antidepressants and monoamine oxidase inhibitors (MAOIs), may also be beneficial in the treatment of PTSD.</li> <li>• Benzodiazepines may be useful in reducing anxiety and improving sleep. Although their efficacy in treating the core symptoms of PTSD has not been established, benzodiazepines are often used in trauma-</li> </ul>

Guideline	Recommendations
	<p>exposed individuals and patients with PTSD. However, due to the risk of dependence, increased incidence of PTSD after early treatment with these medications, or worsening of PTSD symptoms after withdrawal of these medications, benzodiazepines cannot be recommended as monotherapy in PTSD.</p> <ul style="list-style-type: none"> <li>• Second generation antipsychotic medications (e.g., olanzapine, quetiapine, risperidone) may be helpful in individual patients with PTSD.</li> <li>• Anticonvulsant medications (e.g., divalproex, carbamazepine, topiramate, lamotrigine), alpha-2-adrenergic agonists, and beta-adrenergic blockers may also be helpful in treating specific symptom clusters in individual patients.</li> </ul> <p><u>Psychotherapy</u></p> <ul style="list-style-type: none"> <li>• Cognitive behavior therapies may speed recovery and prevent PTSD when therapy is given over a few sessions beginning 2-3 weeks after trauma exposure.</li> <li>• Early supportive interventions, psychoeducation, and case management appear to be helpful in acutely traumatized individuals, because these approaches promote engagement in ongoing care and may facilitate entry into evidence-based psychotherapeutic and psychopharmacological treatments. Encouraging acutely traumatized persons to first rely on their inherent strengths, their existing support networks, and their own judgment may also reduce the need for further intervention.</li> <li>• Patients with ASD may be helped by cognitive behavior therapy and other exposure-based therapies. In addition, cognitive behavior therapy is an effective treatment for core symptoms of acute and chronic PTSD.</li> </ul>
<b>Schizophrenia</b>	
<p>National Institute for Health and Clinical Excellence: Psychosis and <b>Schizophrenia in Adults: Treatment and Management (2014)</b><sup>306</sup></p>	<ul style="list-style-type: none"> <li>• If a person is considered to be at increased risk of developing psychosis:             <ul style="list-style-type: none"> <li>○ Offer individual cognitive behavioral therapy (CBT) with or without family intervention and</li> <li>○ Offer interventions recommended in National Institute for Health and Clinical Excellence guidance for people with any of the anxiety disorders, depression, emerging personality disorder or substance misuse.</li> </ul> </li> <li>• Do not offer antipsychotic medication:             <ul style="list-style-type: none"> <li>○ To people considered to be at increased risk of developing psychosis or</li> <li>○ With the aim of decreasing the risk of or preventing psychosis.</li> </ul> </li> </ul> <p><u>First episode psychosis</u></p> <ul style="list-style-type: none"> <li>• Oral antipsychotic medication in conjunction with psychological interventions</li> <li>• Psychological interventions are more effective when delivered in conjunction with antipsychotic medication.</li> <li>• The choice of antipsychotic medication should take into account:             <ul style="list-style-type: none"> <li>○ Metabolic (weight gain and diabetes)</li> </ul> </li> </ul>

Guideline	Recommendations
	<ul style="list-style-type: none"> <li>○ extrapyramidal (akathisia, dyskinesia and dystonia)</li> <li>○ cardiovascular (QT prolongation)</li> <li>○ hormonal (increased prolactin)</li> <li>○ other (unpleasant subjective experience)</li> </ul> <ul style="list-style-type: none"> <li>· Do not initiate regular combined antipsychotic medication, except for short periods (for example, when changing medication)</li> </ul> <p><u>Acute episode</u></p> <ul style="list-style-type: none"> <li>· For people with an acute exacerbation or recurrence of psychosis or schizophrenia, offer oral antipsychotic medication in conjunction with psychological interventions</li> <li>· For people with an acute exacerbation or recurrence of psychosis or schizophrenia, offer oral antipsychotic medication or review existing medication. The choice of drug should be influenced by the same criteria recommended for starting treatment                             <ul style="list-style-type: none"> <li>○ A single antipsychotic agent is first line. Regular use of combination therapy should not be initiated except when changing agents.</li> </ul> </li> <li>· If withdrawing antipsychotic medication, undertake gradually and monitor regularly for signs and symptoms of relapse.</li> <li>· Clinical response and side effects should be routinely monitored.</li> <li>· Large loading doses should not be used with antipsychotics.</li> <li>· Combination antipsychotic therapy should not be prescribed except for a short duration while transitioning to a different antipsychotic agent.</li> <li>· Due to the high risk of relapse following an acute episode, it is recommended to continue antipsychotic medications for up to one to two years.</li> </ul> <p><u>Recovery/relapse prevention</u></p> <ul style="list-style-type: none"> <li>· The goal of pharmacologic treatment is to prevent relapse and maintain the patient's quality of life.</li> <li>· The same considerations for drug treatment should be given as in acute episodes: potential side effects, patient characteristics and preferences.</li> <li>· Depot preparations should be considered when adherence to oral medication is in question.</li> </ul> <p><u>Inadequate response to treatment</u></p> <ul style="list-style-type: none"> <li>· Factors for inadequate response should be evaluated including diagnosis, adherence to treatment, and comorbid conditions.</li> <li>· Consider clozapine for patients who have tried two antipsychotic agents (including one second generation antipsychotic) without significant improvement.</li> <li>· Adding a second antipsychotic to clozapine may be considered for patients who are unresponsive to clozapine alone at standard doses; however, the use of more than 1 antipsychotic is not recommended in other situations except during the conversion from one agent to another.</li> </ul>
<p>The Texas Medication Algorithm Project:</p>	<p><u>Stage 1</u></p> <ul style="list-style-type: none"> <li>· Second generation antipsychotics such as aripiprazole, olanzapine,</li> </ul>

Guideline	Recommendations
<p><b>Texas Implementation of Medication Algorithms Procedural Manual: Schizophrenia Module (2008)</b><sup>307</sup></p>	<p>quetiapine, risperidone, and ziprasidone are considered first-line and can be used short-term for agitation and excitement.</p> <ul style="list-style-type: none"> <li>• A lower dose of an antipsychotic medication is required for patients during a first episode.</li> </ul> <p><u>Stage 2</u></p> <ul style="list-style-type: none"> <li>• A trial of a single second generation antipsychotic not tried in Stage 1 or first generation antipsychotics is an appropriate treatment option.</li> <li>• A first generation antipsychotic may be worth trying if the patient has never tried one.</li> </ul> <p><u>Stage 3</u></p> <ul style="list-style-type: none"> <li>• A trial of clozapine is recommended.</li> <li>• Clozapine should be considered earlier if there is a history of suicidal ideation, violence, or comorbid substance abuse.</li> </ul> <p><u>Stage 4</u></p> <ul style="list-style-type: none"> <li>• A trial of clozapine and a first generation antipsychotic, second generation antipsychotic or electroconvulsive therapy are considered appropriate treatment options.</li> <li>• Monotherapy should be exhausted before using combination therapy.</li> </ul> <p><u>Stage 5</u></p> <ul style="list-style-type: none"> <li>• A trial of a single first or second generation antipsychotic not tried in Stages 1 or 2 is recommended.</li> </ul> <p><u>Stage 6</u></p> <ul style="list-style-type: none"> <li>• Combination therapy (first and second generation antipsychotics, combination of second generation antipsychotics, first or second generation antipsychotics and electroconvulsive therapy, first or second generation antipsychotic and other agent-mood stabilizer) is recommended.</li> <li>• Little evidence supports combination therapy due to increased risk of drug interactions, side effects and decreased safety and compliance.</li> </ul>
<p>American Psychiatric Association: <b>Practice Guideline for the Treatment of Patients with Schizophrenia (2004)</b><sup>†308</sup></p>	<p><u>Acute phase</u></p> <ul style="list-style-type: none"> <li>• Pharmacological treatment with aripiprazole, olanzapine, quetiapine, risperidone, or ziprasidone should begin at once with the first episode.</li> <li>• Patients with persistent suicidal behavior or persistent hostility and aggressive behavior should be treated with clozapine.</li> <li>• Patients with tardive dyskinesia should be treated with clozapine or second generation antipsychotics.</li> <li>• Patients sensitive to EPS side effects should be treated with a second generation antipsychotics (except clozapine); if risperidone is used, high doses are not recommended.</li> <li>• Patients sensitive to prolactin elevations should be treated with a second generation antipsychotics (except clozapine and risperidone).</li> <li>• Patients sensitive to weight gain, hyperglycemia, or hyperlipidemia should be treated with either aripiprazole or ziprasidone.</li> <li>• Patient's nonadherent to pharmacological treatment should be treated with long-acting injectable antipsychotic agents.</li> <li>• Agent should be chosen based on clinical circumstances and side</li> </ul>

Guideline	Recommendations
	<p>effects.</p> <ul style="list-style-type: none"> <li>• For intolerable side effects, one of the following should be chosen: aripiprazole, a first generation antipsychotic, olanzapine, quetiapine, risperidone or ziprasidone.</li> <li>• For an inadequate response, a different agent should be chosen: aripiprazole, clozapine, a first generation antipsychotic, olanzapine, quetiapine, risperidone or ziprasidone.</li> <li>• For an inadequate response to a second agent, a different agent should be chosen; aripiprazole, clozapine, a first generation antipsychotic, olanzapine, quetiapine, risperidone or ziprasidone.</li> <li>• Clozapine should be used to treat persistent psychotic symptoms. Consider electroconvulsive therapy for persistent severe psychosis, catatonia, and/or suicidal behavior in patients who failed prior treatments (including clozapine).</li> <li>• Clozapine has the greatest efficacy on suicidal behavior and it should be considered in patients with suicidal ideation.</li> <li>• Electroconvulsive therapy is used when a schizophrenic patient has not responded to antipsychotic treatment. When electroconvulsive therapy is administered in conjunction with an antipsychotic agent (either a first or second generation antipsychotic, it provides the largest benefit; however electroconvulsive therapy should not be used prior to a trial of clozapine.</li> </ul> <p><u>Stabilization or maintenance phase</u></p> <ul style="list-style-type: none"> <li>• The goal of medication in the stable phase is to minimize the risk of relapse, severity of side effects and possible residual symptoms.</li> <li>• Continue with acute phase treatment. Electroconvulsive therapy should be considered for maintenance therapy for patients who have used electroconvulsive therapy in acute treatment with good response and who were not controlled with medication alone.</li> <li>• Maintenance electroconvulsive therapy may help patients who have responded to acute electroconvulsive therapy and pharmacological prophylaxis is ineffective or intolerable. Evidence shows that antipsychotics should be used with electroconvulsive therapy maintenance.</li> <li>• For intolerable side effects, another agent should be chosen; aripiprazole, a first generation antipsychotic, olanzapine, quetiapine, risperidone or ziprasidone.</li> </ul>
<p><b>Metabolic Side Effects</b></p> <p>American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity: <b>Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes (2004)</b><sup>309</sup></p>	<ul style="list-style-type: none"> <li>• Second-generation antipsychotics are more effective than first-generation antipsychotics in the treatment of negative symptoms and have fewer or no EPS side effects at clinically effective doses.</li> <li>• The second generation antipsychotics are a widely used and they have important public health ramifications.</li> <li>• Whether the prevalence of metabolic disorders is increased in psychiatric patient populations independent of drug therapy is difficult to determine.</li> <li>• Study data suggests that the prevalence of both diabetes and obesity among individuals with schizophrenia and affective disorders is 1.5-2.0 times higher than in the general population.</li> <li>• Whether a function of the illness itself or from the pharmacologic treatment, the limited amount of epidemiological data suggests an</li> </ul>

Guideline	Recommendations
	<p>increased prevalence of obesity, impaired glucose tolerance and type 2 diabetes in patients with psychiatric illness.</p> <ul style="list-style-type: none"> <li>• Treatment with a second generation antipsychotic particularly in patients with schizophrenia can cause a rapid increase in body weight that may not reach a plateau even after 1 year of treatment.</li> <li>• There have been numerous reports of the onset or exacerbation of diabetes following the initiation of therapy with many of the second generation antipsychotics and in some cases, hyperglycemia promptly resolved after the medication was discontinued.</li> <li>• According to current evidence, changes in serum lipids correspond with changes in body weight.</li> <li>• The benefits of first and second generation antipsychotics in certain patients could outweigh the potential risks.</li> <li>• Patients taking second generation antipsychotics should receive appropriate baseline screening and ongoing monitoring due to the health risks associated with these medications.</li> <li>• Further research is needed to better understand the relationship between first and second generation antipsychotics and significant weight gain, dyslipidemia and diabetes.</li> </ul>

† This guideline can no longer be assumed to be current.

**Table 15. Clinical Guidelines in Children and Adolescents**

Guideline	Recommendations
<b>Anxiety Disorders</b>	
<p>American Academy of Child and Adolescent Psychiatry:  <b>Practice Parameter for the Assessment and Treatment of Children and Adolescents with Anxiety Disorders (2007)</b><sup>†,310</sup></p>	<ul style="list-style-type: none"> <li>• The psychiatric assessment should consider differential diagnosis of other physical conditions and psychiatric disorders that may mimic anxiety symptoms.</li> <li>• Treatment planning should consider a multimodal treatment approach.</li> <li>• Psychotherapy should be considered as part of the treatment of children and adolescents with anxiety disorders.                         <ul style="list-style-type: none"> <li>○ Cognitive behavioral therapy (CBT) has the most empirical support for the treatment of anxiety disorders in youths.</li> </ul> </li> <li>• SSRIs should be considered for the treatment of youths with anxiety disorders.</li> <li>• There is no empirical evidence that any one SSRI is more effective than another for the treatment of childhood anxiety disorders.</li> <li>• Medications other than SSRIs may be considered for the treatment of youths with anxiety disorders. These include venlafaxine, tricyclic antidepressants, buspirone, and benzodiazepines.</li> </ul>
<b>Bipolar Disorder</b>	
<p>American Academy of Child and Adolescent Psychiatry:  <b>Practice Parameter for the Assessment and Treatment of Children and Adolescents with Bipolar Disorder (2007)</b><sup>†,311</sup></p>	<ul style="list-style-type: none"> <li>• Youth with suspected bipolar disorder must also be carefully evaluated for other associated problems, including suicidality, comorbid disorders (including substance abuse), psychosocial stressors, and medical problems.</li> <li>• The diagnostic validity of bipolar disorder in young children has yet to be established. Caution must be taken before applying this diagnosis in preschool children.</li> <li>• For mania in well-defined DSM-IV-TR bipolar I disorder, pharmacotherapy is the primary treatment.                         <ul style="list-style-type: none"> <li>○ Standard therapy, based on adult literature, includes lithium,</li> </ul> </li> </ul>



Guideline	Recommendations
	<p>valproate, and/or atypical antipsychotic agents, with other adjunctive medications used as indicated.</p> <ul style="list-style-type: none"> <li>○ The choice of medication should be based on 1) evidence of efficacy, 2) illness phase, 3) presence of confounding symptoms, 4) side effects, 5) patient’s medication response history, 6) patient and family preferences.</li> <li>○ Clozapine is reserved for treatment-refractory cases because of its side effect profile.</li> <li>○ Antidepressants may be used as adjunctive therapy for bipolar depression.</li> </ul> <ul style="list-style-type: none"> <li>· Most youths with bipolar I disorder will require ongoing medication therapy to prevent relapse; some individuals will need lifelong treatment.</li> <li>· Psychopharmacological interventions require baseline and follow-up symptoms, side effect (including patient’s weight), and laboratory monitoring as indicated. <ul style="list-style-type: none"> <li>○ A 6-8 week trial of a mood-stabilizing agent is recommended, using adequate doses, before adding or substituting other mood stabilizers.</li> </ul> </li> <li>· For severely impaired adolescents with manic or depressive episodes in bipolar I disorder, electroconvulsive therapy (ECT) may be used if medications either are not helpful or cannot be tolerated.</li> <li>· Psychotherapeutic interventions are an important component of a comprehensive treatment plan for early-onset bipolar disorder.</li> <li>· The treatment of bipolar disorder not otherwise specified (NOS) generally involves the combination of psychopharmacology with behavioral/psychosocial interventions.</li> </ul>
<p>American Academy of Pediatrics:  <b>Collaborative Role of the Pediatrician in the Diagnosis and Management of Bipolar Disorder in Adolescents (2012)</b><sup>312</sup></p>	<p><u>Psychopharmacology</u></p> <ul style="list-style-type: none"> <li>· Medication management is an important component of treatment of youth with bipolar disorder and is the primary treatment in cases of well-defined mania.</li> <li>· Mood stabilizers are the primary medications used to treat patients with bipolar disorder (e.g., lithium, divalproex, lamotrigine, carbamazepine, oxcarbazepine, gabapentin, and topiramate; and atypical antipsychotics, including aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, paliperidone, clozapine, asenapine, and iloperidone).</li> <li>· Adjunctive medications include antidepressant medications and “typical” antipsychotics, as well as medications for ADHD, anxiety, and insomnia.</li> <li>· Medication selection should be based on efficacy, phase of illness, type of presentation (e.g., with psychotic symptoms), safety and adverse effect profile, history of medication response, and patient or family preference.</li> <li>· Medication combinations are common, with some patients on five or more drugs.</li> </ul> <p><u>Adverse events</u></p> <ul style="list-style-type: none"> <li>· Mood stabilizer and atypical antipsychotic medications have a variety of adverse effects, interactions, and safety concerns.</li> <li>· Weight gain and metabolic effects are common with the atypical antipsychotics, although weight gain is also commonly associated</li> </ul>

Guideline	Recommendations
	<p>with valproate and, to a lesser extent, lithium.</p> <ul style="list-style-type: none"> <li>• Children and adolescents may be more vulnerable than adults to weight gain from these medications and, thus, likely to be at higher risk of glucose and lipid abnormalities.</li> <li>• Weight management potentially can be addressed with suggestions of diet and exercise as well as changing the dose and/or type of medication. Use of metformin may be of some help.</li> <li>• Stable patients should be seen by their pediatrician every four to six months, with more frequent visits when there are active adverse effects, interactions, or safety issues.</li> </ul>
<p>National Institute for Health and Clinical Excellence:  <b>Bipolar Disorder: The Assessment and Management of Bipolar Disorder in Adults, Children and Adolescents, in Primary And Secondary Care (2014)</b><sup>294</sup></p>	<p><u>Mania</u></p> <ul style="list-style-type: none"> <li>• Consider the recommendations for adults (see above)</li> <li>• Aripiprazole is recommended as an option for treating moderate to severe manic episodes in adolescents with bipolar I disorder, within its marketing authorization (that is, up to 12 weeks of treatment for moderate to severe manic episodes in bipolar I disorder in adolescents aged 13 and older).</li> <li>• Aripiprazole was as effective as other antipsychotics for treating acute mania and had a comparable and acceptable adverse reaction profile.</li> </ul> <p><u>Acute depressive episode in children and adolescents</u></p> <ul style="list-style-type: none"> <li>• Patients with mild depressive symptoms, not requiring immediate treatment should be monitored.</li> <li>• Children and adolescents with depressive symptoms needing treatment should be treated by specialists.</li> <li>• A structured psychological therapy aimed at treating depression should be considered in addition to prophylactic medication.</li> <li>• When prescribing an antidepressant, an antimanic agent should also be prescribed.</li> <li>• Recombinations are limited to due to marketing authorization for antipsychotics and antidepressants in the UK.</li> </ul>
<p><b>Depressive Disorder</b></p> <p>American Academy of Child and Adolescent Psychiatry:  <b>Practice Parameter for the Assessment and Treatment of Children and Adolescents With Depressive Disorders (2007)</b><sup>†,313</sup></p>	<ul style="list-style-type: none"> <li>• The clinician should maintain a confidential relationship with the child or adolescent while developing collaborative relationships with parents, medical providers, other mental health professionals, and appropriate school personnel.</li> <li>• The psychiatric assessment of children and adolescents should routinely include screening questions about depressive symptomatology.</li> <li>• If the screening indicates significant depressive symptomatology, the clinician should perform a thorough evaluation to determine the presence of depressive and other comorbid psychiatric and medical disorders.</li> <li>• The evaluation must include assessment for the presence of harm to self or others.</li> <li>• The evaluation should assess for the presence of ongoing or past exposure to negative events, the environment in which depression is developing, support and family psychiatric history.</li> <li>• The treatment of depressive disorders should always include an acute and continuation phase; some children may also require maintenance treatment.</li> </ul>

Guideline	Recommendations
	<ul style="list-style-type: none"> <li>• Each phase of treatment should include psychoeducation, supportive management, and family and school involvement.</li> <li>• Education, support, and case management appear to be sufficient treatment for the management of depressed children and adolescents with an uncomplicated or brief depression or with mild psychosocial impairment.</li> <li>• For children and adolescents who do not respond to supportive psychotherapy or who have more complicated depressions, a trial with specific types of psychotherapy and/or antidepressants is indicated.</li> <li>• Selective serotonin reuptake inhibitors (SSRIs) is the most commonly used pharmacotherapy for depression in youths. Clinical response should be assessed at 4-week intervals, and if the response is inadequate, the dose may be increased.</li> <li>• To consolidate the response to the acute treatment and avoid relapses, treatment should always be continued for 6 to 12 months (MS).</li> <li>• To avoid recurrences, some depressed children and adolescents should be maintained on treatment for longer periods of time.</li> <li>• Depressed patients with psychosis, seasonal depression, and bipolar disorder may require specific somatic treatment.                         <ul style="list-style-type: none"> <li>○ Atypical antipsychotics, combined with SSRIs, are recommended as the treatment of choice for depressed psychotic youths.</li> </ul> </li> <li>• Treatment should include the management of comorbid conditions.</li> <li>• During all treatment phases, clinicians should arrange frequent follow-up contacts that allow sufficient time to monitor the subject's clinical status, environmental conditions, and if appropriate, medication side effects.</li> </ul>
<p><b>Obsessive Compulsive Disorder (OCD)</b></p> <p>American Academy of Child and Adolescent Psychiatry:  <b>Practice Parameter for the Assessment and Treatment of Children and Adolescents Obsessive-Compulsive Disorders (2012)</b><sup>314</sup></p>	<ul style="list-style-type: none"> <li>• The psychiatric assessment of children and adolescents should routinely screen for the presence of obsessions and/or compulsions or repetitive behaviors.</li> <li>• A complete psychiatric evaluation should be performed, including information from all available sources and comprising standard elements of history and a mental state examination, with attention to the presence of commonly occurring comorbid psychiatric disorders.</li> <li>• A full medical, developmental, family, and school history should be included with the psychiatric history and examination.</li> <li>• When possible, CBT is the first-line treatment for mild to moderate cases of OCD in children.</li> <li>• For moderate-severe OCD, medication is indicated in addition to CBT.</li> <li>• SSRIs are the first-line medications recommended for OCD in children.</li> <li>• Multimodal treatment is recommended if CBT fails to achieve a clinical response after several months or in more severe cases.</li> <li>• For greatest efficacy, the combination of CBT and medication is the treatment of choice and should be considered the default option for first-line treatment in moderate to severe OCD.</li> <li>• Medication augmentation strategies are reserved for treatment-resistant cases in which impairments are deemed moderate in at</li> </ul>

Guideline	Recommendations
	<p>least one important domain of function despite adequate monotherapy.</p> <ul style="list-style-type: none"> <li>○ Treatment resistance is defined as failure of adequate trials of at least two SSRIs or one SSRI and a clomipramine trial (as monotherapy) AND a failure of adequately delivered CBT (no improvement or substantial residual OCD symptoms after 8-10 total sessions). Children should have a minimum of 10 weeks of each SSRI or clomipramine at maximum recommended or maximum tolerated doses, with no change in dose for the preceding 3 weeks.</li> <li>· The most commonly used augmentation strategy is the addition of atypical antipsychotics; though, there is no controlled data for the use of these agents in children with OCD.</li> <li>· According to expert consensus, some children with treatment-resistant OCD may benefit from judicious antipsychotic augmentation, particularly children with tic disorders, poor insight, pervasive developmental disorder symptoms, and mood instability. Clinical experience indicates a minimum of two different adequate SSRI trials or an SSRI and clomipramine before antipsychotic augmentation.</li> <li>· When atypical antipsychotics are used, at a minimum, there should be regular weight, fasting lipid profile, serum glucose and adverse event monitoring.</li> <li>· Other augmentation strategies include addition of clomipramine to an SSRI or addition of either venlafaxine or duloxetine to an SSRI.</li> </ul>
<b>Oppositional Defiant Disorder (ODD)</b>	
<p>American Academy of Child and Adolescent Psychiatry  <b>Practice Parameter for the Assessment and Treatment of Children and Adolescents with Oppositional Defiant Disorder (2007)</b><sup>†,315</sup></p>	<ul style="list-style-type: none"> <li>· Successful assessment and treatment of oppositional defiant disorder (ODD) requires the establishment of therapeutic alliances with the child and family.</li> <li>· Cultural issues need to be actively considered in diagnosis and treatment.</li> <li>· The assessment of ODD includes information obtained directly from the child as well as from the parents regarding the core symptoms of ODD, age at onset, duration of symptoms, and degree of functional impairment.</li> <li>· Clinicians should carefully consider significant comorbid psychiatric conditions when diagnosing and treating ODD.</li> <li>· Clinicians may find it helpful to include information obtained independently from multiple outside informants.</li> <li>· The use of specific questionnaires and rating scales may be useful in evaluating children for ODD and in tracking progress.</li> <li>· The clinician should develop an individualized treatment plan based on the specific clinical situation. Multimodal treatment is often indicated.</li> <li>· The clinician should consider parent intervention based on one of the empirically tested interventions.</li> <li>· Medications may be helpful as adjuncts to treatment packages, for symptomatic treatment and to treat comorbid conditions. <ul style="list-style-type: none"> <li>○ Medication should not be the sole intervention in ODD.</li> <li>○ Nonresponsiveness to a specific compound should lead to a trial of another class of medication rather than the rapid addition of other medications.</li> <li>○ Treatment options include mood stabilizers, such as</li> </ul> </li> </ul>

Guideline	Recommendations
	<p>divalproex sodium, lithium, antipsychotics, and stimulants. Atypical antipsychotics are the most commonly prescribed medication class for the treatment of acute and chronic maladaptive aggression, regardless of diagnosis.</p> <ul style="list-style-type: none"> <li>Intensive and prolonged treatment may be required if ODD is unusually severe and persistent.</li> </ul>
<b>Post-Traumatic Stress Disorder (PTSD)</b>	
<p>American Academy of Child and Adolescent Psychiatry: <b>Practice Parameter for the Assessment and Treatment of Children and Adolescents with Posttraumatic Stress Disorder (2010)</b><sup>316</sup></p>	<ul style="list-style-type: none"> <li>The psychiatric assessment should consider differential diagnoses of other psychiatric disorders and Physical conditions that may mimic posttraumatic stress disorder (PTSD).</li> <li>Treatment planning should consider a comprehensive treatment approach which includes consideration of the severity and degree of impairment of the child's PTSD symptoms.</li> <li>Treatment planning should incorporate appropriate interventions for comorbid psychiatric disorders.</li> <li>Trauma-focused psychotherapies should be considered first-line treatment for children and adolescents with PTSD.</li> <li>SSRIs can be considered for the treatment of children and adolescents with PTSD. <ul style="list-style-type: none"> <li>There is insufficient data to support the use of SSRIs in the absence of psychotherapy for the treatment of childhood PTSD.</li> </ul> </li> <li>Medications other than SSRIs may be considered for children and adolescents with PTSD. <ul style="list-style-type: none"> <li>These include alpha- and beta-adrenergic blockers, atypical antipsychotics, non-SSRI antidepressants, mood-stabilizing agents, and opiates.</li> </ul> </li> </ul>
<b>Schizophrenia</b>	
<p>American Academy of Child and Adolescent Psychiatry: <b>Practice Parameter for the Assessment and Treatment of Children and Adolescents with Schizophrenia (2001)</b><sup>317</sup></p>	<ul style="list-style-type: none"> <li>Adequate treatment requires the combination of psychopharmacological agents and psychosocial interventions.</li> </ul> <p><u>Pharmacotherapy</u></p> <ul style="list-style-type: none"> <li>Antipsychotic agents are recommended for the treatment of the psychotic symptoms associated with schizophrenia.</li> <li>First-line agents include traditional neuroleptic medications (block dopamine receptors) and the atypical antipsychotic agents (that have a variety of effects, including antagonism of serotonergic receptors). Compared to traditional agents, the atypical antipsychotics are at least as effective for positive symptoms and they may be more helpful for negative symptoms.</li> <li>The use of antipsychotic drugs requires the following: adequate informed consent, documentation of target symptoms, baseline and follow-up laboratory monitoring, documentation of treatment response, monitoring for known side effects adequate therapeutic trials (appropriate dose for 4-6 weeks),</li> <li>In general, first-episode patients should receive some maintenance psychopharmacological treatment for 1 to 2 years after the initial episode, given the risk for relapse.</li> <li>Some patients may benefit from the use of adjunctive agents, including antiparkinsonian agents, mood stabilizers, antidepressants, or benzodiazepines.</li> </ul>

Guideline	Recommendations
	<p><u>Psychosocial Interventions</u></p> <ul style="list-style-type: none"> <li>• Psychoeducational therapy for the patient, including ongoing education about the illness, treatment options, social skills training, relapse prevention, basic life skills training, problem-solving skills and strategies, is recommended.</li> <li>• Psychoeducational therapy for the family, to increase their understanding of the illness, treatment options, prognosis and for developing strategies to cope with the patient's symptoms, is recommended.</li> </ul>
<p>National Collaborating Centre for Mental Health, National Institute for Health and Clinical Excellence:  <b>Psychosis and Schizophrenia in Children and Young People, Recognition and Management (2013)</b><sup>318</sup></p>	<p><u>Treatment options for first episode psychosis</u></p> <ul style="list-style-type: none"> <li>• If the child or young person and their parents or carers wish to try psychological interventions (family intervention with individual CBT) alone without antipsychotic medication, advise that psychological interventions are more effective when delivered in conjunction with antipsychotic medication.</li> <li>• If the child or young person and their parents or carers still wish to try psychological interventions alone, offer family intervention with individual CBT. Agree a time limit (one month or less) for reviewing treatment options, including introducing antipsychotic medication.</li> <li>• The choice of antipsychotic medication should be made by the parents or carers of younger children, or jointly with the young person and their parents or carers, and healthcare professionals.</li> <li>• Aripiprazole is recommended as an option for the treatment of schizophrenia in people aged 15 to 17 years who are intolerant of risperidone, or for whom risperidone is contraindicated, or whose schizophrenia has not been adequately controlled with risperidone.</li> <li>• Continue to monitor symptoms, level of distress, impairment and level of functioning, including educational engagement and achievement, regularly.</li> <li>• Before starting antipsychotic medication and throughout treatment, record baseline parameters, including weight and height, waist and hip circumference, pulse and blood pressure, fasting blood glucose, HbA<sub>1c</sub>, blood lipid profile and prolactin levels, assessment of any movement disorders and assessment of nutritional status, diet and level of physical activity.</li> <li>• Before starting antipsychotic medication, offer the child or young person an electrocardiogram if: specified for adults and/or children, a physical examination has identified specific cardiovascular risk (such as diagnosis of high blood pressure), there is a personal history of cardiovascular disease, family history of cardiovascular disease such as premature sudden cardiac death or prolonged QT interval, or the child or young person is being admitted as an inpatient.</li> <li>• Do not use a loading dose of antipsychotic medication (often referred to as 'rapid neuroleptization').</li> <li>• Do not initiate regular combined antipsychotic medication, except for short periods (for example, when changing medication).</li> <li>• If prescribing chlorpromazine, warn of its potential to cause skin photosensitivity.</li> <li>• Advise using sunscreen if necessary.</li> <li>• Review antipsychotic medication annually, including observed benefits and any side effects.</li> </ul>

Guideline	Recommendations
	<p><u>Interventions for children and young people whose illness has not responded adequately to treatment</u></p> <ul style="list-style-type: none"> <li>• For illness that has not responded adequately to pharmacological or psychological interventions: review the diagnosis, confirm adherence to antipsychotic medication, prescribed at an adequate dose and for the correct duration, review engagement with and use of psychological interventions and ensure that these have been offered.</li> <li>• If family intervention has been undertaken suggest CBT; if CBT has been undertaken suggest family intervention for children and young people in close contact with their families consider other causes of non-response, such as comorbid substance misuse (including alcohol), the concurrent use of other prescribed medication or physical illness.</li> <li>• Offer clozapine to children and young people with schizophrenia that has not responded adequately to treatment despite the sequential use of adequate doses of at least two different antipsychotic drugs each used for six to eight weeks.</li> <li>• For illness that has not responded adequately to clozapine at an optimized dose, consider a multidisciplinary review and recommendation (including measuring therapeutic drug levels) before adding a second antipsychotic to augment treatment with clozapine.</li> <li>• An adequate trial of such an augmentation may need to be up to eight to 10 weeks.</li> <li>• Choose a drug that does not compound the common side effects of clozapine.</li> </ul>
<b>Tourette's Syndrome</b>	
<p>European Society for the Study of Tourette Syndrome: <b>European Clinical Guidelines for Tourette Syndrome and other Tic Disorders. Part II: Pharmacological Treatment (2011)</b><sup>319</sup></p>	<ul style="list-style-type: none"> <li>• Based on the available evidence, experience with the drug, and experts' preference, risperidone is recommended as a first line agent for the treatment of tics. Weight gain and sedation are common side effects of risperidone therapy.</li> <li>• Aripiprazole has a role in treatment refractory cases and is associated with a smaller risk of severe weight gain.</li> <li>• Clonidine may be used, especially in the presence of comorbid ADHD.</li> </ul>
<b>General Guidance</b>	
<p>American Academy of Child and Adolescent Psychiatry: <b>Practice Parameter for the Use of Atypical Antipsychotic Medications in Children and Adolescents (2011)</b><sup>320</sup></p>	<ul style="list-style-type: none"> <li>• Clozapine-in children and adolescents, the strongest empirical evidence is in patients with refractory schizophrenia or those who require antipsychotic treatment but who have a history of severe EPS with other agents.</li> <li>• Risperidone-of the atypical antipsychotics, it has the most substantial amount of methodologically stringent evidence for use in children and adolescents.</li> <li>• Olanzapine-of the atypical antipsychotics, its receptor binding profile most closely matches that of clozapine. Limited long-term data exists. Olanzapine is associated with substantial weight gain.</li> <li>• Quetiapine, ziprasidone and aripiprazole have clinical trial evidence for use in children and adolescents.</li> <li>• Prior to the initiation of and during treatment with an atypical antipsychotic, the general guidelines that pertain to the prescription of psychotropic medications should be followed.             <ul style="list-style-type: none"> <li>○ These include diagnostic assessment, attention to comorbid</li> </ul> </li> </ul>

Guideline	Recommendations																																				
	<p>medical conditions, review of concomitant drugs, multi-disciplinary plan, including education and psychotherapy, and a thorough discussion of the risks and benefits of psychotropic treatment.</p> <ul style="list-style-type: none"> <li>• When selecting any atypical antipsychotic for use in a child or adolescent, the clinician should follow the most current available evidence in the scientific literature.</li> <li>• Table 16 provides a summary of the literature supporting the use of atypical antipsychotics in specific clinical populations.</li> <li>• There is almost no data to support the use of atypical antipsychotics in pre-school aged children. A marked amount of caution is advised before using these agents in preschoolers.</li> <li>• Due to the specific risks associated with the use of atypical antipsychotics, additional factors to address, prior to the initiation of treatment with the atypical antipsychotics, include obtaining a personal and family history of diabetes and hyperlipidemia, seizures and cardiac abnormalities, as well as any family history of previous response or adverse events associated with atypical antipsychotics.</li> <li>• Dosing of atypical antipsychotics should follow the “start low and go slow” approach and seek to find the lowest effective dose, recognizing that dosing may differ based on the targeted symptoms and patient diagnosis.</li> <li>• If side-effects do occur, a trial at a lower dose should be considered; however, certain side effects may preclude further treatment with the specific atypical antipsychotic .</li> <li>• The use of multiple psychotropic medications in refractory patients may, at times, be necessary but has not been studied rigorously and clinicians should proceed with caution.</li> <li>• The simultaneous use of multiple atypical antipsychotics has not been studied rigorously and generally should be avoided. <ul style="list-style-type: none"> <li>○ Consideration of medication combinations should only begin after patients are refractory to medication trials of each atypical antipsychotic and, perhaps, older antipsychotic agents or other evidence-supported agents (such as mood stabilizers) at the appropriate target dose(s) and length of treatment.</li> </ul> </li> <li>• After the failure of one atypical antipsychotic (after 4–6 week therapy), the selection of an alternative agent may include consideration of another atypical antipsychotic and/or a medication from a different class of drugs.</li> <li>• The acute and long-term safety in children and adolescents has not been fully evaluated and therefore careful and frequent monitoring of side effects is indicated. See table below.</li> </ul> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="background-color: #cccccc;">Monitoring parameters</th> <th style="background-color: #cccccc;">Baseline</th> <th style="background-color: #cccccc;">4 weeks</th> <th style="background-color: #cccccc;">8 weeks</th> <th style="background-color: #cccccc;">12 weeks</th> <th style="background-color: #cccccc;">Annually</th> </tr> </thead> <tbody> <tr> <td>Personal/family history</td> <td style="text-align: center;">X</td> <td></td> <td></td> <td></td> <td style="text-align: center;">X</td> </tr> <tr> <td>Weight (BMI)</td> <td style="text-align: center;">X</td> <td style="text-align: center;">X</td> <td style="text-align: center;">X</td> <td style="text-align: center;">X</td> <td></td> </tr> <tr> <td>Waist circumference</td> <td style="text-align: center;">X</td> <td></td> <td></td> <td></td> <td style="text-align: center;">X</td> </tr> <tr> <td>Blood pressure</td> <td style="text-align: center;">X</td> <td></td> <td style="text-align: center;">X</td> <td style="text-align: center;">X</td> <td style="text-align: center;">X</td> </tr> <tr> <td>Fasting plasma</td> <td style="text-align: center;">X</td> <td></td> <td style="text-align: center;">X</td> <td style="text-align: center;">X</td> <td style="text-align: center;">X</td> </tr> </tbody> </table>	Monitoring parameters	Baseline	4 weeks	8 weeks	12 weeks	Annually	Personal/family history	X				X	Weight (BMI)	X	X	X	X		Waist circumference	X				X	Blood pressure	X		X	X	X	Fasting plasma	X		X	X	X
Monitoring parameters	Baseline	4 weeks	8 weeks	12 weeks	Annually																																
Personal/family history	X				X																																
Weight (BMI)	X	X	X	X																																	
Waist circumference	X				X																																
Blood pressure	X		X	X	X																																
Fasting plasma	X		X	X	X																																



Guideline	Recommendations					
	glucose					
	Fasting lipid profile (LDL, HDL, TG, total chol.)	<b>X</b>		<b>X</b>	<b>X</b>	
	<ul style="list-style-type: none"> <li>• BMI should be obtained at baseline and monitored at regular intervals throughout treatment with an atypical antipsychotic. Careful attention should be given to the increased risk of developing diabetes with the use of atypical antipsychotics, and blood glucose levels and other parameters should be obtained at baseline and monitored at regular intervals.</li> <li>• In those patients with significant weight changes and/or a family history indicating high risk, lipid profiles should be obtained at baseline and monitored at regular intervals.</li> <li>• Measurements of movement disorders utilizing structured measures, such as the abnormal involuntary movement scale, should be done at baseline and at regular intervals during treatment and during tapering of the atypical antipsychotic.</li> <li>• Due to limited data surrounding the impact of atypical antipsychotics on the cardiovascular system, regular monitoring of heart rate, blood pressure and EKG changes should be performed. Due to the increased risk of QTc changes with ziprasidone, obtaining an ECG at baseline and once a stable dose is achieved is recommended.</li> <li>• Although there is a relationship between atypical antipsychotics and elevation in prolactin, the current state of evidence does not support the need for routine monitoring of prolactin levels in asymptomatic youths.</li> <li>• The limited long-term safety and efficacy data warrants careful consideration, before the initiation of medication, of the planned duration of the medication trial.</li> <li>• Abrupt discontinuation of a medication is not recommended.</li> </ul>					

† This guideline can no longer be assumed to be current.

**Table 16. Evidence for the Use of Atypical Antipsychotics (adopted from the AACAP guideline)<sup>308</sup>**

	Clozapine	Risperidone	Olanzapine	Quetiapine	Ziprasidone	Aripiprazole
Schizophrenia/ Psychosis	+++	+++*	++++*	++++*	+	++++*
Bipolar Disorder	++	+++*	+++*	++++*	+++	+++*
Disruptive behavior disorders/ Aggression	++	+++	+++	++	+	+
Autism/ PDD irritability	+	++++*	+++	+	+	++++*
Tourette's/tics		++++	+		+++	
PTSD	+					
Eating Disorder			+			
Long-term safety studies		+		+		

PDD=pervasive developmental disorder; PTSD=post-traumatic stress disorder

++++ Multiple randomized controlled studies.

+++ One randomized controlled study.

++ Uncontrolled study.

+ Case studies.

\* FDA-approved in children and/or adolescents.

### **Conclusions**

The antipsychotics are divided into two distinct classes: typical antipsychotics, also called first-generation antipsychotics (FGAs), and the atypical antipsychotics, which collectively are also referred to as second-generation antipsychotics (SGAs).<sup>15</sup> These agents are available in various dosage forms including capsules, tablets, injections, oral solutions, sublingual tablets, and orally disintegrating tablets.

The FGAs are effective in the treatment of positive symptoms of schizophrenia (agitation, aggression, delusions and hallucinations), but are thought to be less effective against the negative symptoms (avolition, anhedonia, alogia, affective flattening and social withdrawal).<sup>17</sup> FGAs are also approved for the management of various manifestations of other psychotic disorders and the suppression of motor and phonic tics in patients with Tourette's disorder. Adverse events are common with the FGAs, potentially resulting in these agents being used in a more limited capacity.<sup>15,17</sup>

Each of the SGAs has a distinctive neuropharmacologic and adverse event profile, mechanism of action and chemical structure. It should be noted that paliperidone is an active metabolite of risperidone and therefore carries some similarity in chemical structure and pharmacologic effects with the parent drug. When compared to the FGAs, the SGAs are associated with a lower risk of extrapyramidal symptoms (EPS) and tardive dyskinesia, making them a generally better-tolerated treatment option. The SGAs are approved for the treatment of bipolar disorder and/or schizophrenia and are often a preferred treatment over the FGAs since they are thought to have a more favorable outcome in the treatment of the negative symptoms of schizophrenia.<sup>15</sup> Moreover, several agents have recently been approved for the treatment of schizoaffective disorder, irritability associated with autistic disorder and for the adjunctive treatment of major depressive disorder.<sup>1-14</sup> While the use of atypical antipsychotics in pediatric patients is in many instances off-label, aripiprazole, asenapine, olanzapine, paliperidone, quetiapine, and risperidone have been Food and Drug Administration (FDA)-approved for children and/or adolescents with bipolar disorder and/or schizophrenia. Aripiprazole and risperidone are also FDA-approved for use in children and adolescents suffering from irritability secondary to autistic disorder.<sup>1-14</sup>

Meta-analyses evaluating the roles of available atypical antipsychotics in the treatment of schizophrenia suggest that all agents are significantly more effective than placebo.<sup>46-58,68-72</sup> The trends for respective efficacy suggest that clozapine is the most effective agent in the class, followed by olanzapine and risperidone. In clinical trials, aripiprazole tended to exhibit lower efficacy than the other agents.<sup>46-58,68-72</sup> A meta-analysis in adult patients with bipolar disorder found risperidone to be the most effective treatment option (taking into account both efficacy and tolerability).<sup>68</sup> The next best treatment options, in order of decreased efficacy were olanzapine, haloperidol, quetiapine, carbamazepine, aripiprazole, valproate, lithium, and ziprasidone. Lamotrigine, topiramate and gabapentin were found to be less effective than placebo. In the management of major depressive disorder, aripiprazole, quetiapine, and risperidone augmentation therapies were associated with improved outcomes.<sup>77</sup>

Augmentation with atypical antipsychotics for the treatment of patients with anxiety disorders was associated with mixed results.<sup>79,80</sup> Atypical antipsychotics were associated with a moderate effect on anger associated with borderline personality disorder, with no effect on depressive symptoms.<sup>81,82</sup> Mood stabilizers were found to offer greater benefit in these patients.<sup>82</sup> All evaluated atypical antipsychotics were found to improve symptoms of agitation/aggression secondary to dementia.<sup>83-91</sup> When used as a part of multimodal therapy, SGAs have some limited evidence for use in patients with anorexia.<sup>97-99</sup> However, the Agency for Healthcare Research and Quality's review does not recommend the use of these agents for eating disorders.<sup>189</sup> Available evidence in pediatric patients with clinically significant aggression suggests a potential benefit in the short-term use of SGAs (majority of evidence is with risperidone).<sup>112-130</sup> Aripiprazole and risperidone are supported by evidence-based medicine for use in patients with irritability/agitation or aggression secondary to an autistic spectrum disorder.<sup>134-154</sup> Atypical

antipsychotics (aripiprazole, quetiapine, risperidone, olanzapine and ziprasidone) were also shown to reduce tic severity in patients with Tourette's syndrome.<sup>175-183,189</sup>

Available evidence suggests that, except for clozapine, olanzapine is associated with greater weight gain compared to all other atypical antipsychotic agents. In contrast, ziprasidone is associated with a low incidence of weight gain.<sup>214</sup> A systematic review by Safer et al suggests that weight gain is greater in children and adolescents than in adults.<sup>257</sup> In addition, olanzapine is associated with a greater risk of other metabolic side-effects, such as hyperglycemia and hypercholesterolemia, vs other atypical antipsychotics. Likewise, data from the FDA Adverse Reporting System (AERS) indicates that the risk of experiencing a diabetes-related adverse event is greatest with olanzapine, followed by risperidone, and least with ziprasidone and aripiprazole, across all age groups.<sup>243</sup> Of note, despite the increased metabolic risk with olanzapine, the Zodiac study failed to find a significant difference in non-suicide mortality between patients exposed to olanzapine and ziprasidone.<sup>190</sup> Risperidone is associated with the greatest risk of prolactin elevation-related adverse events.<sup>46-58,68-72,260</sup> In addition, risperidone, aripiprazole and ziprasidone are associated with a high incidence of EPS adverse events.<sup>222</sup> Quetiapine is associated with the least risk of EPS adverse events.<sup>222</sup> The incidence of sexual dysfunction was noted to be higher with the use of olanzapine, risperidone, and clozapine than with quetiapine, ziprasidone or aripiprazole.<sup>236</sup>

As mentioned previously, available clinical consensus guidelines do not differentiate among the different SGAs; however, they provide guidance on the place in therapy of antipsychotics as a class in various disease states, both FDA-approved and off-label. The use of these agents for the treatment of schizophrenia is recognized by national and international guidelines as a mainstay in therapy.<sup>306-308</sup> Lithium, valproate and/or antipsychotics are recommended as initial therapy of bipolar disorder.<sup>293-296</sup> Furthermore, the American Psychiatric Association guideline recommends the use of antipsychotics for the management of psychosis or agitation in patients with dementia.<sup>297</sup> For the treatment of anxiety disorders, sertraline is recommended as a first-line pharmacotherapeutic agent.<sup>291,292</sup> Second-line treatment options include serotonin norepinephrine reuptake inhibitors (SNRIs) or switching to alternative selective serotonin reuptake inhibitors (SSRIs). Augmentation therapy with antipsychotics is an option in treatment-refractory patients but the guidelines recommend that initiation of combination therapy be limited to specialists. In major depressive disorder, first-line treatment options include SSRIs, SNRIs, bupropion or mirtazapine.<sup>300-302</sup> Antipsychotic augmentation therapy is an option for patients who have failed antidepressant monotherapy. In obsessive-compulsive disorder, SSRIs and cognitive behavioral therapy are recommended as first-line treatment options.<sup>303</sup> Patients who have failed an SSRI trial may be offered augmentation therapy with an antipsychotic or cognitive behavioral therapy. Similarly, SSRIs and SNRIs are considered to be first-line treatment options for the treatment of post-traumatic stress disorder (PTSD).<sup>304,305</sup> Atypical antipsychotics may be used as adjunctive therapy for the management of treatment-refractory PTSD. Furthermore, the European Society for the Study of Tourette Syndrome guideline recommends risperidone as a first-line agent for the treatment of tics.<sup>319</sup> Aripiprazole has a role in treatment-refractory patients. Moreover, the American Academy of Child and Adolescent Psychiatry (AACAP) guideline acknowledges that atypical antipsychotics are the most commonly prescribed class of drugs for the treatment of maladaptive aggression, regardless of diagnosis; yet emphasize that pharmacotherapy should not be used as the only intervention in children with oppositional defiant disorder.<sup>314</sup> Although the antipsychotics are not addressed in national and international insomnia treatment guidelines, the National Institute of Health (NIH) Consensus and State-of-the-Science Statement on Manifestations and Management of Chronic Insomnia in Adults state that due to the lack of evidence supporting the short and long term efficacy of antipsychotics, in addition to their significant risks, their use in the treatment of chronic insomnia cannot be recommended.<sup>321</sup>

In a practice guideline on the use of atypical antipsychotics in children and adolescents, issued by the AACAP in 2011, the panel recommends that prior to initiation of antipsychotic therapy patients should undergo a thorough diagnostic assessment, evaluation for comorbid medical conditions and concomitant medications.<sup>319</sup> Furthermore, a multidisciplinary plan that includes education and psychotherapy should be established. The prescriber should also have a thorough discussion of the risks and benefits of psychotropic medication. Of the atypical antipsychotics, risperidone is recognized as an agent with the

most substantial amount of methodologically stringent evidence for use in pediatric patients. Of note, combination antipsychotic therapy has not been well studied and should be avoided, unless the patient has failed trials of all antipsychotic agents, used as monotherapy. In addition, there is almost no data to support the use of atypical antipsychotics in pre-school aged children. The guideline recommends a marked amount of caution before using these agents in pre-schoolers. Given the risk of metabolic side-effects, pediatric patients receiving atypical antipsychotic therapy should be closely monitored for changes in weight, blood pressure, fasting plasma glucose and lipid profile.

Therapeutic duplication with the atypical antipsychotics is also of concern in adults due to the inherent risks of polypharmacy (eg, adverse events, drug interactions, decreased adherence) and lack of sufficient evidence and guidelines supporting clinical value with such practice. This risk is exemplified by results of clinical trials demonstrating that combination antipsychotic therapy results in a greater risk of metabolic adverse events.<sup>232-240</sup>

**Appendix Ia: Summary of the Strength of Evidence for Off-Label Efficacy Outcomes (adopted from 2011 AHRQ systematic review)<sup>189</sup>**

Indication	Strength of Evidence	Findings	Conclusions
<b>Dementia</b>	<b>High</b>	<p>The 2011 meta-analysis of PCTs, aripiprazole, olanzapine, and risperidone were superior to placebo as treatment of behavioral symptoms as measured by total scores on BEHAVE-AD, BPRS, and NPI. Effect sizes were generally considered to be “small” in magnitude.</p> <p>Psychosis –risperidone was superior to placebo, as measured by the psychosis subscales of the BEHAVE-AD, BPRS, and NPI. Results for aripiprazole did not meet conventional levels of statistical significance.</p> <p>Agitation – Aripiprazole, olanzapine and risperidone were superior to placebo, as measured by the agitation subscales of the BEHAVE-AD, BPRS, NPI, and CMAI.</p> <p>Three head to head trials compared atypicals; none was found superior.</p>	Aripiprazole, olanzapine, and risperidone <b>have efficacy</b> as treatment for behavioral symptoms of dementia.
<b>Depression</b>			
<b>Augmentation of SSRI/SNRI</b>	<p><b>Moderate</b> (risperidone, aripiprazole, quetiapine)</p> <p><b>Low</b> (olanzapine,</p>	The meta-analysis used “response” to treatment and remission as outcome. Pooling trials that reported the HAM-D as outcome, the relative risk of responding for participants taking quetiapine or risperidone was	Aripiprazole, quetiapine, and risperidone <b>have efficacy</b> as augmentation to SSRIs/SNRIs for major depressive disorder.  Olanzapine and

Indication	Strength of Evidence	Findings	Conclusions
	ziprasidone)	<p>significantly higher than for placebo. Other trials reported MADRS scores; the relative risk of responding for participants taking aripiprazole was significantly higher than those taking placebo. Risperidone was included in two trials. These reported the drug superior to placebo. The relative risk of responding for participants taking aripiprazole was significantly higher than those taking placebo.</p> <p>Olanzapine had only two trials, so pooling was not performed; the trials reported olanzapine superior to placebo.</p> <p>In one available ziprasidone trial, the drug was superior to placebo in terms of MADRS scores. One trial compared ziprasidone at differing levels augmenting sertraline to sertraline alone. This trial found a greater improvement in CGI-S and MADRS scores augmenting with ziprasidone at 160mg than either augmentation with ziprasidone at 80mg or sertraline alone. However, there was no significant difference in HAMD-17, CGI-I or HAM-A scores.</p>	ziprasidone <b>may also have efficacy.</b>
<b>Monotherapy</b>	<b>Moderate</b>	<p>Olanzapine alone was no better than placebo in improving symptoms at six or 12 weeks in three trials. Outcomes were too heterogeneous to allow pooling.</p> <p>In five PCTs, quetiapine was superior according to relative risk of both responding and remitted as measured by MADRS.</p>	<p>Olanzapine <b>does not have efficacy</b> as monotherapy for major depressive disorder.</p> <p>Quetiapine <b>has efficacy</b> as monotherapy for major depressive disorder</p>
<b>Obsessive Compulsive Disorder (OCD)</b>			
<b>Augmentation of SSRIs</b>	<p><b>Moderate</b> (risperidone)</p> <p><b>Low</b> (olanzapine)</p>	The 2006 meta-analysis pooled results of nine trials of risperidone, olanzapine, or quetiapine as augmentation therapy in patients who were resistant to treatment with SSRI. Atypical antipsychotics had a clinically important benefit,	Risperidone <b>has efficacy</b> in improving OCD symptoms when used as an adjunct to SSRI in treatment refractory patients.

Indication	Strength of Evidence	Findings	Conclusions
		<p>(measured by the Yale-Brown Obsessive-Compulsive Scale (YBOCS), when used as augmentation therapy. Relative risk of “responding” significant for augmentation with quetiapine and risperidone.</p> <p>The updated 2011 meta-analysis found risperidone superior to placebo, as measured by changes in the Y-BOCS.</p> <p>There were too few studies (two) of olanzapine augmentation to permit separate pooling of this drug. Both trials reported olanzapine superior to placebo.</p> <p>One new head to head trial found no difference in effect between olanzapine and risperidone as SSRI augmentation. One new head to head trial found quetiapine more effective than ziprasidone as SSRI augmentation. In one new trial, quetiapine produced a significant reduction in Y-BOCS score, while clomipramine did not.</p>	<p>Olanzapine <b>may have efficacy</b>.</p> <p>Quetiapine is more <b>efficacious</b> than ziprasidone and clomipramine.</p>
<b>Augmentation of citalopram</b>	<p><b>Low</b> (quetiapine)</p> <p><b>Very low</b> (risperidone)</p>	<p>One trial of risperidone reported no differences between groups in achieving a response to therapy, but patients maintained on risperidone had a significantly longer period of time to relapse compared to placebo (102 vs 85 days).</p> <p>Two trials found quetiapine superior to placebo as augmentation for citalopram, according to Y-BOCS and CGI-I scores.</p>	<p>Quetiapine and risperidone <b>may be efficacious</b> as augmentation to citalopram in OCD patients.</p>
<b>Post-Traumatic Stress Disorder</b>	<p><b>Moderate</b> (risperidone)</p> <p><b>Low</b> (Olanzapine)</p> <p><b>Very Low</b> (Quetiapine)</p>	<p>Three trials enrolled men with combat-related PTSD; these showed a benefit in sleep quality, depression, anxiety, and overall symptoms when risperidone or olanzapine was used to augment therapy with antidepressants or other psychotropic medication.</p>	<p>Risperidone is <b>efficacious</b> in reducing combat-related PTSD symptoms when used as an adjunct to primary medication.</p>

Indication	Strength of Evidence	Findings	Conclusions
		<p>Three trials of olanzapine or risperidone as monotherapy for abused women with PTSD were inconclusive regarding efficacy.</p> <p>One trial found a three-fold decline in PTSD Scale (CAPS) scores in patients treated with quetiapine monotherapy compared to placebo.</p> <p>There were too few olanzapine studies (two) to pool; one reported olanzapine superior to placebo, while one did not.</p> <p>A meta-analysis of risperidone, using CAPS scores as outcome, found risperidone to be superior to placebo.</p> <p>In a meta-analysis by condition, atypical antipsychotics were efficacious for combat-related PTSD but not PTSD in abused women.</p>	
<b>Personality Disorders</b>			
<b>Borderline</b>	<p><b>Low</b> (aripiprazole)</p> <p><b>Very low</b> (quetiapine, olanzapine)</p>	<p>Four trials provide evidence that olanzapine is superior to placebo and may be superior to fluoxetine. The benefit of adding olanzapine to dialectical therapy in one trial was small. Two trials of olanzapine found no difference from placebo in any outcomes compared to placebo.</p> <p>Aripiprazole was superior to placebo in one small trial. Another trial found aripiprazole superior to placebo in improving SCL-90, HAM-D, and HAM-A scores at 8 months and less self-injury at 18 months.</p> <p>A trial of ziprasidone found no significant difference in CGI-BPD, depressive, anxiety, psychotic or impulsive symptoms compared to placebo at 12 weeks.</p>	<p>Olanzapine had <b>mixed results</b> in seven trials, aripiprazole was found <b>efficacious</b> in two trials, quetiapine was found <b>efficacious</b> in one trial, and ziprasidone was found <b>not efficacious</b> in one trial.</p>

Indication	Strength of Evidence	Findings	Conclusions
		One trial found quetiapine to be superior to placebo on BPRS and PANSS scales.  Due to heterogeneity of outcomes, a meta-analysis could not be performed.	
<b>Schizotypal</b>	<b>Low</b>	Risperidone was superior to placebo in one small trial. In another trial risperidone was found to be no different from placebo on a cognitive assessment battery.	Risperidone had <b>mixed results</b> when used to treat schizotypal personality disorder in two small trials.
<b>Tourette's Syndrome</b>	<b>Low</b>	Risperidone was superior to placebo in one small trial, and it was at least as effective as pimozide or clonidine for eight to 12 weeks of therapy in the three other trials. One trial of ziprasidone showed variable efficacy compared to placebo.	Risperidone <b>is at least as efficacious as pimozide or clonidine</b> for Tourette's syndrome.
<b>Anxiety</b>	<b>Moderate</b>	Three placebo-controlled trials of quetiapine as monotherapy for Generalized Anxiety Disorder (GAD) could be pooled; relative risk of responding on HAM-A favored the quetiapine group.  One head to head trial showed no difference between risperidone and paroxetine on HAM-A score improvement. One trial each found quetiapine equally effective as paroxetine and escitalopram.	Quetiapine <b>has efficacy</b> as treatment for Generalized Anxiety Disorder.
<b>Attention Deficit/Hyperactivity Disorder</b>			
<b>No comorbidity</b>	<b>Low</b>	One trial showed risperidone superior to placebo in reducing scores on the Children's Aggression Scale-Parent version (CAS-P).	Risperidone <b>may be efficacious</b> in treating children with ADHD with no serious co-occurring disorders.
<b>Mental retardation</b>	<b>Low</b>	One trial showed risperidone led to greater reduction in SNAP-IV (Swanson, Nolan, and Pelham teacher & parent rating scale) scores than methylphenidate.	Risperidone <b>may be superior to methylphenidate</b> in treating ADHD symptoms in mentally retarded children.
<b>Bipolar</b>	<b>Low</b>	Two trials of aripiprazole showed no effect on SNAP-IV (Swanson, Nolan, and Pelham teacher & parent rating scale) scores than placebo.	Aripiprazole is <b>inefficacious</b> in reducing ADHD symptoms in children with bipolar disorder.
<b>Eating Disorders</b>	<b>Moderate</b>	In a pooled analysis of three trials,	Olanzapine and quetiapine



Indication	Strength of Evidence	Findings	Conclusions
	(olanzapine)  <b>Low</b> (quetiapine)	there was no difference in change in BMI at either one or three months with olanzapine compared to placebo.  One trial of quetiapine reported no statistical difference from placebo in BMI increase at three months.	<b>have no efficacy</b> in increasing body mass in eating disorder patients.
<b>Insomnia</b>	<b>Very Low</b>	In one small trial (N=13) of quetiapine, sleep outcomes were not statistically different from placebo.	Quetiapine may be <b>inefficacious</b> in treating insomnia.
<b>Substance Abuse</b>			
<b>Alcohol</b>	<b>Moderate</b> (aripiprazole)  <b>Low</b> (quetiapine)	Two trials of aripiprazole and one of quetiapine reported percentage of patients completely abstinent during follow-up. In a pooled analysis, the effect vs placebo was insignificant.	Aripiprazole is <b>inefficacious</b> in treating alcohol abuse/dependence. Quetiapine may also be <b>inefficacious</b> .
<b>Cocaine</b>	<b>Low</b>	Two trials of olanzapine and one of risperidone reported there was no difference in efficacy vs placebo as measured by the Addiction Severity Index (ASI).	Olanzapine is <b>inefficacious</b> in treating cocaine abuse /dependence. Risperidone may also be <b>inefficacious</b> .
<b>Meth-amphetamine</b>	<b>Low</b>	One trial found aripiprazole inefficacious in reducing use of intravenous amphetamine, as measured by urinalysis. Another trial found aripiprazole inefficacious in reducing craving for methamphetamine.	Aripiprazole is <b>inefficacious</b> in treating methamphetamine abuse/dependence.
<b>Methadone</b>	<b>Low</b>	One trial of methadone-treated patients found no difference between risperidone and placebo in reduction of cocaine or heroin use.	Risperidone is an <b>inefficacious</b> adjunct to methadone maintenance

ADHD=attention-deficit hyperactivity disorder; BEHAVE-AD=Behavioral Pathology in Alzheimer's Disease Scale; BPRS=Brief Psychiatric Rating Scale; CGI-BPD=Clinical Global Impression Scale for Borderline Personality Disorder; CGI-I=Clinical Global Impression Improvement; CGI-S=Clinical Global Impression-Severity; CMAI =Cohen-Mansfield Agitation Inventory; HAM-A = Hamilton Anxiety Scale; HAM-D=Hamilton Depression Rating Scale; MADRS=Montgomery-Asberg Depression Rating Scale; MDD=major depressive disorder; NPI=Neuropsychiatric Inventory; OCD=obsessive-compulsive disorder; PANSS=Positive and Negative Syndrome Scale; PCT=placebo-controlled trial; PTSD=post-traumatic stress disorder; SSRI=selective serotonin reuptake inhibitor; SNRI=serotonin-norepinephrine reuptake inhibitors; ZAN-BPD=Zanarini Rating Scale for Borderline Personality Disorder

**Appendix Ib: Summary of Adverse Events of Atypical Antipsychotics for Off-Label Use (adopted from 2011 AHRQ systematic review)<sup>189</sup>**

Adverse Event	Head-to-Head Studies	Active Comparator Studies	Placebo-Controlled Studies
<b>Weight Gain</b>			
<b>Elderly</b>	In one large trial (CATIE-AD) patients who were treated with olanzapine,	More common in patients taking olanzapine than risperidone or	According to the meta-analysis, more common in patients taking olanzapine and risperidone than

Adverse Event	Head-to-Head Studies	Active Comparator Studies	Placebo-Controlled Studies
	quetiapine, or risperidone averaged a monthly gain of 1.0, 0.7, and 0.4 lbs respectively, compared to a monthly weight loss of 0.9 lbs for placebo patients.	conventional antipsychotics, particularly if their BMI was less than 25 at baseline, according to a large cohort study.	placebo.
<b>Adults</b>	More common in olanzapine patients than ziprasidone patients in one trial.	More common among patients taking olanzapine than patients taking conventional antipsychotics in three trials. More common in patients taking aripiprazole than patients taking conventional antipsychotics in one trial. More common among patients taking olanzapine than patients taking mood stabilizers in two trials.	According to the meta-analysis, more common in patients taking aripiprazole, olanzapine, quetiapine, and risperidone than placebo.
<b>Children/Adolescents</b>	No head to head studies	No difference between clonidine and risperidone in one trial.	More common in patients taking risperidone in two PCTs. No difference in one small PCT of ziprasidone.
<b>Mortality-in the elderly</b>	No difference between olanzapine and risperidone according to a meta-analysis of six trials of olanzapine published in 2006.	Six large cohort studies compared mortality in elderly patients taking atypical and conventional antipsychotics. Four of these studies found a significantly higher rate of death with conventional antipsychotics, while two found no statistical difference in mortality between the drug classes.	The difference in risk for death was small but statistically significant for atypicals, according to a 2006 meta-analysis which remains the best available estimate. Sensitivity analyses found no difference between drugs in the class. Patients taking atypicals had higher odds of mortality than those taking no antipsychotics in the two cohort studies that made that comparison. There are no trials or large observational studies of ziprasidone in this population.
<b>Endocrine</b>			

Adverse Event	Head-to-Head Studies	Active Comparator Studies	Placebo-Controlled Studies
<b>Elderly</b>	No evidence reported	No evidence reported	No difference in endocrine events in risperidone patients in one PCT. Regarding diabetes, risk was elevated but not statistically significant in one industry-sponsored cohort study of olanzapine patients.
<b>Adults</b>	Diabetes more common in patients taking olanzapine than patients taking risperidone in one trial.	No evidence reported	Endocrine events more common in patients taking quetiapine, risperidone, and ziprasidone in one PCT each. More common in olanzapine in two pooled PCTs.  Diabetes more common in patients taking quetiapine in six pooled PCTs; however, the pooled odds ratio was elevated at 1.47 but not statistically significant. More common in olanzapine patients in one PCT; the odds ratio of 5.14 was not statistically significant, with very wide confidence intervals (0.6 to 244). Lower odds of diabetes in risperidone patients in one large observational study.
<b>Cerebrovascular Accident (CVA)</b>	No evidence reported	Hospitalization for CVA was increased in the first week after initiation of typical antipsychotics, but not for initiation of atypicals in a large cohort study.	More common in risperidone patients than placebo according to four PCTs pooled by the manufacturer. In a meta-analysis of PCTs, risperidone was the only drug associated with an increase. More common in olanzapine than placebo according to five PCTs pooled by the manufacturer.
<b>Extrapyramidal Symptoms (EPS)</b>			
<b>Elderly</b>	More common in patients taking aripiprazole and risperidone patients than patients taking	No evidence reported	More common in patients taking risperidone, according to the meta-analysis. Quetiapine and aripiprazole were not

Adverse Event	Head-to-Head Studies	Active Comparator Studies	Placebo-Controlled Studies
	quetiapine in one large trial (CATIE-AD).		associated with an increase.  More common in olanzapine in one PCT.
<b>Adults</b>	No evidence reported	Less likely in patients taking quetiapine than mood stabilizers in one small trial. Less likely in patients taking olanzapine or aripiprazole than patients taking conventional antipsychotics in one trial each.	More common in patients taking aripiprazole, quetiapine, and ziprasidone than placebo according to the meta-analysis.
<b>Sedation</b>			
<b>Elderly</b>	More common in elderly patients taking olanzapine or quetiapine than risperidone according to the meta-analysis, but not statistically significant.	No difference in one trial of olanzapine vs benzodiazepines. No difference in three trials of olanzapine and three of risperidone vs conventional antipsychotics.	More common in patients taking aripiprazole, olanzapine, quetiapine, and risperidone than placebo according to the meta-analysis.
<b>Adults</b>	More common in patients taking quetiapine than risperidone in two trials.  No difference in one trial of risperidone vs olanzapine.	Olanzapine patients had higher odds than mood stabilizer patients in two trials.  More common in olanzapine and quetiapine patients than SSRIs patients in three and two trials respectively.  Olanzapine patients had lower odds than patients taking conventional antipsychotics in the pooled analysis of three trials.	More common in patients taking aripiprazole, olanzapine, quetiapine, risperidone, and ziprasidone than placebo in the meta-analysis.
<b>Children/Adolescents</b>	No head-to-head trials	No difference in one small trial of clonidine vs risperidone. More patients on haloperidol than risperidone reported sleep problems in one trial.	Less common in aripiprazole patients than placebo patients in one PCT. No difference from placebo in one small PCT of ziprasidone.

BMI=body mass index; CATIE-AD=Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer's Disease; CVA=cerebrovascular accident; EPS=EPS symptoms; PCT=placebo-controlled trial; SSRI=serotonin selective reuptake inhibitor

**Appendix IIa: Summary of the Strength of Evidence for Efficacy Outcomes in Children and Adolescents (adopted from the 2012 AHRQ systematic review)<sup>96</sup>**

Outcome	Comparison (# of studies)	Strength of Evidence	Summary
<b><i>Pervasive developmental disorder</i></b>			
Autistic symptoms	FGA vs SGA (2 RCTs)	Low	No significant difference
	SGA vs placebo (7 RCTs)	Low	Significant effect in favor of SGA on ABC (MD, 218.3; 95% CI, 227.1 to 29.5; I2, 79.6%); CARS (MD, 24.9; 95% CI, 28.5 to 21.4; I2, 64%).
CGI	SGA vs placebo (3 RCTs)	Low	No significant difference
OC symptoms	SGA vs placebo (3 RCTs)	Low	Significant effect in favor of SGA (MD, 21.7; 95% CI, 23.2 to 20.3; I2, 49%).
Medication adherence	SGA vs placebo (2 RCTs)	Low	No significant difference
<b><i>Disruptive behavior disorder</i></b>			
Aggression	SGA vs placebo (5 RCTs)	Low	No significant difference
Anxiety	SGA vs placebo (4 RCTs)	Low	No significant difference
Behavior symptoms	SGA vs placebo (7 RCTs)	Moderate	Significant effect in favor of SGA for ABC (MD, 221.0; 95% CI, 231.1 to 210.8; I2, 62%); BPI (MD, 23.8; 95% CI, 26.2 to 21.4; I2, 0%); NCBRF (MD, 26.9; 95% CI, 210.4 to 23.5; I2, 62%).
CGI	SGA vs placebo (7 RCTs)	Moderate	Significant effect in favor of SGA for CGI-I (MD, 21.0; 95% CI, 21.7 to 20.3; I2, 45%); CGI-S (MD, 21.3; 95% CI, 22.2 to 20.5; I2, 78%).
Medication adherence	SGA vs placebo (5 RCTs)	Low	No significant difference
<b><i>Bipolar Disorder</i></b>			
CGI	SGA vs placebo (7 RCTs)	Moderate	Significant effect in favor of SGA (MD, 20.7; 95% CI, 20.8 to 20.5; I2, 36%).
Depression	SGA vs placebo (7 RCTs)	Low	No significant difference
Manic Symptoms	SGA vs placebo (7 RCTs)	Low	All except one study significantly favored SGA (studies not pooled due to high heterogeneity).
Medication adherence	SGA vs placebo (7 RCTs)	Low	Significant effect in favor of placebo (RR, 2.0; 95% CI, 1.0 to 4.0; I2, 0%).

Outcome	Comparison (# of studies)	Strength of Evidence	Summary
	RCTs)		
Suicide-related behavior	SGA vs placebo (7 RCTs)	Moderate	No significant difference for suicide-related deaths, attempts, or ideation.
<b>Schizophrenia</b>			
CGI	FGA vs SGA (3 RCTs)	Low	Significant effect in favor of SGA (MD, 20.8; 95% CI, 21.3 to 20.3; I2, 0%).
	Clozapine vs olanzapine (2 RCTs)	Low	No significant difference
	Olanzapine vs risperidone (3 RCTs)	Low	No significant difference
	SGA vs placebo (6 RCTs)	Moderate	Significant effect in favor of SGA (MD, 20.5; 95% CI, 20.7 to 20.3; I2, 28%).
Positive and negative symptoms	FGA vs SGA (3 RCTs)	Low	No significant difference
	Clozapine vs olanzapine (2 RCTs, 1 PCS)	Low	No significant difference
	Olanzapine vs risperidone (3 RCTs, 1 PCS)	Low	No significant difference
	SGA vs placebo (6 RCTs)	Moderate	Significant effect in favor of SGA (MD, 28.7; 95% CI, 211.8 to 25.6; I2, 38%).
Medication adherence	FGA vs SGA (2 RCTs, 1 PCS)	Low	No significant difference
	Clozapine vs quetiapine (2 RCTs)	Low	No significant difference
	Olanzapine vs risperidone (4 RCTs, 1 PCS)	Low	No significant difference
	SGA vs placebo (2 RCTs)	Low	No significant difference
Suicide-related behaviors	SGA vs placebo (5 RCTs)	Low	No significant difference
<b>Tourette syndrome</b>			
Tics	SGA vs	Moderate	Significant effect in favor of SGA (MD, 27.0; 95%

Outcome	Comparison (# of studies)	Strength of Evidence	Summary
	placebo (2 RCTs)		CI, 210.3 to 23.6; I2, 0%)
<b>Behavioral symptoms</b>			
Autistic symptoms	Risperidone vs placebo (2RCTs)	Low	Significant effect in favor of risperidone in one study; NR in second study.

ABC=Aberrant Behavior Checklist, BPI=Behavior Problem Inventory, CARS=Childhood Autism Rating Scale, CGI-I=Clinical Global Impressions-Improvement, CGI-S=Clinical Global Impressions-Severity, NCBRF=Nisonger Child Behavior Rating Scale, NR=not reported, OC=obsessive-compulsive, PCS=prospective cohort study, RR=relative risk

**Appendix IIb: Summary of Evidence for Adverse Events in Children and Adolescents (adopted from 2012 AHRQ systematic review)<sup>96</sup>**

Outcome	Strength of Evidence	SGA vs SGA	Placebo-Controlled Studies
<b>Dyslipidemia</b>	Low	Aripiprazole was significantly favored over olanzapine (RR, 0.25; 95% CI, 0.08 to 0.8) <sup>a</sup> and 95% CI, 271.3 to 27.4). <sup>a</sup> No significant differences were observed for clozapine vs olanzapine, olanzapine vs quetiapine and quetiapine vs risperidone.	Significant effect in favor of placebo over aripiprazole (RR, 2.5; 95% CI, 1.4, 4.4) <sup>a</sup> , olanzapine (RR, 2.4; 95% CI, 1.2 to 4.9; I <sup>2</sup> , 45%), and quetiapine (RR, 2.4; 95% CI, 1.1 to 5.4; I2, 0%).
	Moderate	Significant effect in favor of risperidone compared with olanzapine for cholesterol (MD, 10.2 mg/dL; 95% CI, 3.1 to 17.2; I <sup>2</sup> , 0%) and triglycerides (MD, 17.3 mg/dL; 95% CI, 3.5 to 31.1; I2, 0%).	NA
<b>EPS</b>	Low	No significant difference for clozapine vs olanzapine, clozapine vs risperidone, olanzapine vs quetiapine, olanzapine vs risperidone, quetiapine vs risperidone.	No significant differences for placebo compared to olanzapine or quetiapine.
	Moderate	NA	Significant effect in favor of placebo over aripiprazole (RR, 4.2; 95% CI, 2.4 to 7.2; I <sup>2</sup> , 0%) and risperidone (RR, 2.7; 95% CI, 1.4 to 4.9; I <sup>2</sup> , 0%).
<b>Insulin Resistance</b>	Low	No significant difference for olanzapine vs quetiapine, olanzapine vs risperidone or quetiapine vs risperidone.	No significant difference between aripiprazole and placebo or olanzapine and placebo.
<b>Prolactin-related sexual side effects</b>	Low	Significant effect in favor of clozapine over olanzapine (MD, 210.8 ng/dL; 95% CI, 216.7 to 24.8; I <sup>2</sup> , 21%). No significant difference for quetiapine vs	Significant effect in favor of placebo over risperidone in seven or eight studies (not pooled due to heterogeneity). No

Outcome	Strength of Evidence	SGA vs SGA	Placebo-Controlled Studies
		risperidone.	significant difference for quetiapine compared to placebo.
	Moderate	Significant effect in favor of olanzapine over risperidone (RR, 0.4; 95% CI, 0.2 to 0.6; I <sup>2</sup> , 0%).	Significant effect in favor of aripiprazole over placebo (MD, 24.1 ng/mL; 95% CI, 26.3 to 21.8; I <sup>2</sup> , 0%). Significant effect in favor of placebo over olanzapine (MD, 11.5 ng/mL; 95% CI, 8.8 to 14.1; I <sup>2</sup> , 0%).
<b>Sedation</b>	Low	No significant differences for clozapine vs olanzapine, olanzapine vs quetiapine, olanzapine vs risperidone, quetiapine vs risperidone.	Significant effect in favor of placebo over aripiprazole (RR, 2.7; 95% CI, 1.1 to 6.5; I <sup>2</sup> , 76%). No significant difference in placebo comparisons with olanzapine and quetiapine.
	Moderate	NA	Significant effect in favor of placebo over risperidone (RR, 2.9; 95% CI, 1.5 to 5.5; I <sup>2</sup> , 32%) and ziprasidone (RR, 3.0; 95% CI, 1.7 to 5.2; I <sup>2</sup> , 0%).
<b>Weight gain</b>	Low	Significant effect in favor of aripiprazole over olanzapine (MD, 24.1 kg; 95% CI, 25.5 to 22.7), a quetiapine (MD, 21.6 kg; 95% CI, 23.0 to 20.3) <sup>a</sup> and risperidone (MD, 22.3 kg; 95% CI, 23.9 to 20.7). a No significant difference for clozapine vs olanzapine, clozapine vs risperidone, and quetiapine vs risperidone.	No significant difference for ziprasidone compared to placebo.
	Moderate	Significant effect in favor of quetiapine over olanzapine (RR, 1.5; 95% CI, 1.1 to 2.0; I <sup>2</sup> , 0%) and risperidone over olanzapine (MD, 2.4 kg; 95% CI, 1.5 to 3.3; I <sup>2</sup> , 72%).	Significant effect in favor of placebo over aripiprazole (MD, 0.8 kg; 95% CI, 0.4 to 1.2; I <sup>2</sup> , 13%), olanzapine (MD, 4.6 kg; 95% CI, 3.1 to 6.1; I <sup>2</sup> , 70%), quetiapine (MD, 1.8 kg; 95% CI, 1.1 to 2.5; I <sup>2</sup> , 49%), and risperidone (MD, 1.8 kg; 95% CI, 1.5 to 2.1; I <sup>2</sup> , 0%).

AE=adverse event; EPS=EPS symptom; RR=relative risk.

a=Only 1 study contributed to this estimate; therefore, an I<sup>2</sup> value could not be calculated.



## References

1. Abilify<sup>®</sup> and Abilify Discmelt<sup>®</sup> [package insert]. Princeton (NJ): Bristol-Myers Squibb Company; 2014 Jul.
2. Saphris<sup>®</sup> [package insert]. Kenilworth (NJ): Schering-Plough Corp.; 2015 Mar.
3. Rexulti<sup>®</sup> [package insert]. Rockville (MD): Otsuka America Pharmaceutical, Inc.; 2015 Jul.
4. Clozaril<sup>®</sup> [package insert]. East Hanover (NJ): Novartis Pharmaceuticals Corporation; 2013 Mar.
5. Fazaclo<sup>®</sup> [package insert]. New York (NY): Azur Pharma International III Limited; 2013 July.
6. Versacloz<sup>®</sup> [package insert]. Palo Alto (CA): Jazz Pharmaceuticals, Inc., 2013 Jul.
7. Fanapt<sup>®</sup> [package insert]. Rockville (MD): Vanda Pharmaceuticals, Inc; 2014 Apr.
8. Latuda<sup>®</sup> [package insert]. Marlborough (MA): Sunovion Pharmaceuticals, Inc.; 2013 Jul.
9. Zyprexa<sup>®</sup> [package insert]. Indianapolis (IN): Eli Lilly and Company; 2015 Jul.
10. Invega<sup>®</sup> [package insert]. Titusville (NJ): Janssen, L.P.; 2011 Jun.
11. Seroquel<sup>®</sup> [package insert]. Wilmington (DE): AstraZeneca Pharmaceuticals LP; 2013 Oct.
12. Seroquel XR<sup>®</sup> [package insert]. Wilmington (DE): AstraZeneca Pharmaceuticals LP; 2013 Oct.
13. Risperdal<sup>®</sup> [package insert]. Titusville (NJ): Janssen, LP; 2014 Apr.
14. Geodon<sup>®</sup> [package insert]. New York (NY): Pfizer Inc; 2015 Aug.
15. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. *Molecular Psychiatry*. 2005; 10:79-104.
16. Farah A. Atypicality of atypical antipsychotics. *Prim Care Companion J Clin Psychiatry*. 2005;7:268-74.
17. Arana GW. An overview of side effects caused by typical antipsychotics. *J Clin Psychiatry*. 2000;6 {suppl8}:5-11.
18. Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: a critical overview. *CMAJ*. 2005;172(3):1703-11.
19. Citome L. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. *Int J Clin Pract*. 2010 Dec: 3(10):1-22.
20. Kane J, Canas F, Kramer M, Ford L, Gassmann-Mayer C, Lim P, et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. *Schizophr Res*. 2007 Feb;90(1-3):147-61.
21. FDA Public Health Advisory. Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances. Rockville (MD): Food and Drug Administration (US); 2005 Apr 11 [cited 2013 Jul 30]. Available from: <http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm053171.htm>.
22. Olfson M, Blanco C, Liu L, Moreno C, Laje G. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. *Arch Gen Psychiatry*. 2006 Jun;63(6):679-85.
23. Hatta K, Kawabata T, Yoshida K, Hamakawa H, Wakejima T, Furuta K, Nakamura M, Hirata T, Usui C, Nakamura H, Sawa Y. Olanzapine orally disintegrating tablet vs risperidone oral solution in the treatment of acutely agitated psychotic patients. *Gen Hosp Psychiatry*. 2008 Jul-Aug;30(4):367-71.
24. Verma S, Oregno C, Kunik M, et al. Tolerability and effectiveness of atypical antipsychotics in male geriatric inpatients. *Int J Geriatr Psychiatry*. 2001 Feb;16(2):223-7.
25. Currier GW, Simpson GM. Risperidone liquid concentrate and oral lorazepam vs intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. *J Clin Psychiatry*. 2001 Mar;62(3):153-7.
26. Marshall M, Rathbone J. Early intervention for psychosis. *Cochrane Database Syst Rev*. 2011 Jun 15; (6):CD004718.
27. Correll CU, Skuban A, Ouyang J, Hobart M, Pfister S, McQuade RD, Nyilas M, Carson WH, Sanchez R, Eriksson H. Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial. *Am J Psychiatry*. 2015 Apr 16:appiajp201514101275. [Epub ahead of print].
28. Kane JM, Skuban A, Ouyang J, Hobart M, Pfister S, McQuade RD, Nyilas M, Carson WH, Sanchez R, Eriksson H. A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. *Schizophr Res*. 2015 May;164(1-3):127-35. doi: 10.1016/j.schres.2015.01.038. Epub 2015 Feb 12.

29. Potkin SG, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. *J Clin Psychiatry*. 2007;68:1492-1500.
30. Kane JM, Mackle M, Snow-Adami L, et al. A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment. *J Clin Psychiatry*. 2011; 72(3):349-55.
31. Kane JM, Cohen M, Zhao J, et al. Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. *J Clin Psychopharmacol*. 2010; 30:106-115.
32. Schoemaker J, Naber D, Vrijland P, et al. Long-term assessment of asenapine vs olanzapine in patients with schizophrenia or schizoaffective disorder. *Pharmacopsychiatry*. 2010; 43:e1-e10.
33. Cutler AJ, Kalali AH, Weiden PJ, Hamilton J, Wolfgang CD. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. *J Clin Psychopharmacol*. 2008;28:S20-S28.
34. Potkin SG, Litman RE, Torres R, Wolfgang CD. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. *J Clin Psychopharm*. 2008;28:S4-S11.
35. Citrome L, Meng X, Hochfeld M. Efficacy of iloperidone in schizophrenia: a PANSS five-factor analysis. *Schizophrenia Research*. 2011; 131:75-81.
36. Citrome L, Meng X, Hochfeld M. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials. *Hum Psychopharmacol Clin Exp*. 2012; 27:24-32.
37. Kane JM, Lauriello J, Laska E, DiMarino M, Wolfgang CD. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia. *J Clin Psychopharmacol*. 2008;28:S29-S35.
38. Weiden PJ, Cutler AJ, Polymeropoulos MH, Wolfgang CD. A pooled analysis of 6-week acute-phase pivotal trials. *J Clin Psychopharmacol*. 2008;28:S12-S19.
39. Nakamura M, Ogasa MS, Guarino J, Phillips AS, Severs J, Cucchiaro J, et. al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. *J Clin Psychiatry*. 2009 Jun; 70(6):829-36.
40. Harvey PD, Ogasa M, Cucchiaro, et al. Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs ziprasidone. *Schizophrenia Research*. 2011; 127:188-194.
41. Potkin SG, Ogasa M, Cucchiaro J, et al. Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder. *Schizophrenia Research*. 2011; 132:101-107.
42. Meltzer HY, Cucchiaro J, Silva R, et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. *Am J Psychiatry*. 2011; 168:957-67.
43. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. *N Engl J Med*. 2005 Sep 22;353(12):1209-23.
44. Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK; CATIE Investigators. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. *Am J Psychiatry*. 2006 Apr;163(4):611-22.
45. Stroup TS, Lieberman JA, McEvoy JP, Davis SM, Swartz MS, Keefe RS, Miller AL, Rosenheck RA, Hsiao JK; CATIE Investigators. Results of phase 3 of the CATIE schizophrenia trial. *Schizophr Res*. 2009 Jan;107(1):1-12.
46. Citrome L. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. *Int J Clin Pract*. 2009; 63(12):1762-1784.
47. Glick ID, Correll CU, Altamura AC, et al. Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data driven, personalized clinical approach. *J Clin Psychiatry*. 2011; 72(12):1616-27.

48. Jones MP, Nicholl D, Trakas K, et al. Efficacy and tolerability of paliperidone ER and other oral atypical antipsychotics in schizophrenia. *Int J Clin Pharmacol Ther.* 2010 Jun;48(6):383-99.
49. Klemp M, Tsvete IF, Skomedal T, et al. A review and Bayesian meta-analysis of clinical efficacy and adverse effects of 4 atypical neuroleptic drugs compared to haloperidol and placebo. *J Clin Psychopharmacol.* 2011; 31:698-704.
50. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation vs first-generation drugs for schizophrenia: a meta-analysis. *Lancet.* 2009; 373:31-41.
51. Khanna P, Komossa K, Rummel-Kluge C, Hunger H, Schwarz S, El-Sayeh HG, et al. Aripiprazole vs other atypical antipsychotics for schizophrenia. *Cochrane Database Syst Rev.* 2013 Feb 28;2:CD006569.
52. Komossa K, Rummel-Kluge C, Hunger H, et al. Olanzapine vs other atypical antipsychotics for schizophrenia. *Cochrane Database Syst Rev.* 2010 Mar 17;(3):CD006654.
53. Komossa K, Rummel-Kluge C, Schmid F, et al. Quetiapine vs other atypical antipsychotics for schizophrenia. *Cochrane Database Syst Rev.* 2010 Jan 20;(1):CD006625.
54. Komossa K, Rummel-Kluge C, Schmid F, et al. Risperidone vs other atypical antipsychotics for schizophrenia. *Cochrane Database Syst Rev.* 2011 Jan 19;(1):CD006626.
55. Komossa K, Rummel-Kluge C, Hunger H, et al. Ziprasidone vs other atypical antipsychotics for schizophrenia. *Cochrane Database of Systematic Reviews.* 2009, Issue 4. Art. No.: CD006627.
56. Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, Asenjo Lobos C, Schwarz S, Davis JM. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. *Am J Psychiatry.* 2009;166:152-63.
57. Asenjo Lobos C, Komossa K, Rummel-Kluge C, et al. Clozapine vs other atypical antipsychotics for schizophrenia. *Cochrane Database Syst Rev.* 2010 Nov 10;(11):CD006633.
58. Riedel M, Schennach-Wolff R, Dehning MS, et al. Neurocognition and its influencing factors in the treatment of schizophrenia-effects of aripiprazole, olanzapine, quetiapine and risperidone. *Hum Psychopharmacol Clin Exp.* 2010; 25:116-25.
59. McIntyre RS, Cohen M, Zhao J, et al. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. *Bipolar Disorders.* 2009; 11:673-86.
60. McIntyre RS, Cohen M, Zhao J, et al. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. *Journal of Affective Disorders.* 2010; 122:27-38.
61. Szegedi A, Zhao J, van Willigenburg A, et al. Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials. *BMC Psychiatry.* 2011; 11:101.
62. McIntyre RS, Cohen M, Zhao J, et al. Asenapine versus olanzapine in acute mania: a double-blind extension study. *Bipolar Disorders.* 2009; 11:815-26.
63. McIntyre RS, Cohen M, Zhao J, et al. Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study. *Journal of Affective Disorders.* 2010; 126:358-65.
64. Calabrese JR, Keck PE Jr, Macfadden W, Minkwitz M, Ketter TA, Weisler RH, Cutler AJ, McCoy R, Wilson E, Mullen J. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. *Am J Psychiatry.* 2005 Jul;162(7):1351-60.
65. Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Mitchell PB, Centorrino F, Risser R, Baker RW, Evans AR, Beymer K, Dube S, Tollefson GD, Breier A. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. *Arch Gen Psychiatry.* 2003 Nov;60(11):1079-88.
66. Perlis RH, Baker RW, Zarate CA, Brown EB, Schuh LM, Jamal HH, Tohen M. Olanzapine vs risperidone in the treatment of manic or mixed states in bipolar I disorder: a randomized, double-blind trial. *J Clin Psychiatry.* 2006;67:1747-53.
67. Yatham LN, Fallu A, Binder CE. A 6-month randomized open-label comparison of continuation of oral atypical antipsychotic therapy or switch to long acting injectable risperidone in patients with bipolar disorder. *Acta Psychiatr Scand Suppl.* 2007;(434):50-6.
68. Cipriani A, Barbui C, Salanti G, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. *Lancet.* 2011 Oct 8;378(9799):1306-15.

69. Perlis RH, Welge JA, Vornik LA, Hirschfeld RMA, Keck PE Jr. Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. *J Clin Psychiatry*. 2006;76:509-16.
70. Tarr GP, Glue P, Herbison P. Comparative efficacy and acceptability of mood stabilizer and second generation antipsychotic monotherapy for acute mania-a systematic review and meta-analysis. *Journal of Affective Disorders*.2011; 134:14-19.
71. Yildiz A, Vieta E, Leucht S, et al. Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. *Neuropsychopharmacology*.2011; 36:375-389.
72. Vieta E, Locklear J, Gunther O, et al. Treatment options for bipolar depression: a systematic review of randomized, controlled trials. *J Clin Psychopharmacol*.2010; 30:579-90.
73. Papakostas GI, Petersen TJ, Kinrys G, Burns AM, Worthington JJ, Alpert JE, Fava M, Nierenberg AA. Aripiprazole augmentation of selective serotonin-reuptake inhibitors for treatment-resistant major depressive disorder. *J Clin Psychiatry*. 2005 Oct; 66(10):1326-30.
74. Papakostas GI, Petersen TJ, Nierenberg AA, Murakami JL, Alpert JE, Rosenbaum JF, Fava M. Ziprasidone augmentation of selective serotonin-reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. *J Clin Psychiatry*. 2004 Feb; 65(2):217-21.
75. Barbee JG, Conrad EJ, Jamhour NJ. The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder. *J Clin Psychiatry*. 2004 Jul; 65(7):975-81.
76. Bauer M, El-Khalili N, Datto C, et al. A pooled analysis of two randomized, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder. *Journal of Affective Disorders*.2010; 127:19-30.
77. Komossa K, Depping AM, Gaudchau A, et al. Second-generation antipsychotics for major depressive disorder and dysthymia. *Cochrane Database of Systematic Reviews*.2010, Issue 12.Art.No.:CD008121.
78. Maher AR, Maglione M, Bagley S, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. *JAMA*.2011; 306(12):1359-69.
79. Depping AM, Komossa K, Kissling W, et al. Second generation antipsychotics for anxiety disorders. *Cochrane Database Syst Rev*. 2010 Dec 8;(12):CD008120.
80. Lalonde CD, Lieshout RJV. Treating generalized anxiety disorder with second generation antipsychotics: a systematic review and meta-analysis. *J Clin Psychopharmacol*. 2011; 31:326-33.
81. Lieb K, Völm B, Rücker G, Timmer A, Stoffers JM. Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. *Br J Psychiatry*. 2010 Jan;196(1):4-12.
82. Mercer D, Douglass AB, Links PS, et al. Meta-analyses of mood stabilizers, antidepressants, and antipsychotics in the treatment of borderline personality disorder: effectiveness for depression and anger symptoms. *Journal of Personality Disorders*.2009; 23(2):156-74.
83. Cheung G, Stapelberg J. Quetiapine for the treatment of behavioral and psychological symptoms of dementia (BPSD): a meta-analysis of randomized placebo-controlled trials. *NZMJ*.2011; 124(1336):39-50.
84. Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. *J Clin Psychiatry*. 2003;64:134-43.
85. Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, et al. Risperidone for psychosis of Alzheimer's disease and mixed dementia: results of a double-blind, placebo-controlled trial. *Int J Geriatr Psychiatry*. 2005;20:1153-7.
86. De Deyn PP, Katz IR, Brodaty H, Lyons B, Greenspan A, Burns A. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone. *Clin Neurol Neurosurg*. 2005 Oct;107(6):497-508.
87. Rocha FL, Hara C, Ramos MG, Kascher GG, Santos MA, de Oloveira Lança G. An exploratory open-label trial of ziprasidone for the treatment of behavioral and psychological symptoms of dementia. *Dement Geriatr Cogn Disord*. 2006;22:445-8.

88. Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's Disease. *N Engl J Med.* 2006;355(15):1525-38.
89. Verhy FRJ, Verkaaik M, Lousberg R. Olanzapine vs haloperidol in the treatment of agitation in elderly patients with dementia: results of a randomized controlled double-blind trial. *Dement Geriatr Cogn Disord.* 2006;21:1-8.
90. Suh GH, Greenspan AJ, Choi SK. Comparative efficacy of risperidone vs haloperidol on behavioral and psychological symptoms of dementia. *Int J Geriatr Psychiatry.* 2006;21:654-60.
91. Fontaine CS, Hynan LS, Koch K, Martin-cook K, Svetlik D, Weiner MF. A double-blind comparison of olanzapine vs risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities. *J Clin Psychiatry.* 2003;64(4):726-30.
92. Komossa K, Depping AM, Meyer M, et al. Second-generation antipsychotics for obsessive compulsive disorder. *Cochrane Database Syst Rev.* 2010 Dec 8;(12):CD008141.
93. Padala PR, Madison J, Monnahan M, Marcil W, Price P, Ramaswamy S, Din AU, et al. Risperidone monotherapy for post-traumatic stress disorder related to sexual assault and domestic abuse in women. *Int Clin Psychopharmacol.* 2006 Sep;21(5):275-80.
94. Pivac N, Kozaric-Kovacic D, Muck-Seler D. Olanzapine vs fluphenazine in an open trial in patients with psychotic combat-related post-traumatic stress disorder. *Psychopharmacology (Berl).* 2004 Oct; 175(4):451-6.
95. Seida JC, Schouten JR, Boylan K, et al. Antipsychotics for children and young adults: a comparative effectiveness review. *Pediatrics.*2012; 129:e771-e784.
96. Seida JC, Schouten JR, Mousavi SS, Hamm M, et al. First- and second-generation antipsychotics for children and young adults. Comparative Effectiveness Review No. 39. (Prepared by the University of Alberta Evidence-based Practice Center under Contract No. 290-2007-10021). [Monograph on the internet]. Rockville (MD): Agency for Healthcare Research and Quality; 2012 Feb [cited 2013 Jul 30]. Available from: [http://www.effectivehealthcare.ahrq.gov/ehc/products/147/918/CER39\\_First-and-Second-Generation-Antipsychotics\\_execsumm\\_20120104.pdf](http://www.effectivehealthcare.ahrq.gov/ehc/products/147/918/CER39_First-and-Second-Generation-Antipsychotics_execsumm_20120104.pdf)
97. Leggero C, Masi G, Brunori E, et al. Low-dose olanzapine monotherapy in girls with anorexia nervosa, restricting subtype: focus on hyperactivity. *Journal of Child and Adolescent Psychopharmacology.* 2010; 20(2):127-33.
98. Kafantaris V, Leigh E, Hertz S, et al. A placebo-controlled pilot study of adjunctive olanzapine for adolescents with anorexia nervosa. *Journal of Child and Adolescent Psychopharmacology.* 2011; 21(3):207-12.
99. Findling RL, Nyilas M, Forbes RA, et al. Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study. *J Clin Psychiatry.* 2009; 70(10):1441-51.
100. Tramontina S, Zeni CP, Ketzer CR, et al. Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder: a pilot randomized clinical trial. *J Clin Psychiatry.*2009; 70(5):756-64.
101. Biederman J, McDonnell MA, Wozniak J, et al. Aripiprazole in the treatment of pediatric bipolar disorder: a systematic chart review. *CNS Spectrums.*2005; 10(2):141-8.
102. Frazier JA, Biederman J, Tohen M, Feldman PD, Jacobs TG, Toma V, et al. A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. *J Child Adolesc Psychopharmacol.* 2001 Fall;11(3):239-50.
103. Shaw JA, Lewis JE, Pascal S, Sharma RK, Rodriguez RA, Guillen R, et al. A study of quetiapine: efficacy and tolerability in psychotic adolescents. *J Child Adolesc Psychopharmacol.* 2001 Winter;11(4):415-24.
104. Marchand WR, Wirth L, Simon C. Quetiapine adjunctive and monotherapy for pediatric bipolar disorder: a retrospective chart review. *J Child Adolesc Psychopharmacol.* 2004 Fall;14(3):405-11.
105. DelBello MP, Schwiers ML, Rosenberg HL, et al. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. *J Am Acad Child Adolesc Psychiatry.* 2002; 41(10):1216-23.
106. DelBello MP, Chang K, Welge JA, et al. A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder. *Bipolar Disorders.*2009; 11:483-93.

107. Delbello MP, Kowatch RA, Adler CM, et al. A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. *J Am Acad Child Adolesc Psychiatry.* 2006; 45(3):305-13.
108. Haas M, DelBello MP, Pandina G, et al. Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study. *Bipolar Disorders.*2009; 11:687-700.
109. Biederman J, Mick E, Hammerness P, Harpold T, Aleardi M, Dougherty M, Wozniak J. Open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children. *Biol Psychiatry.* 2005 Oct 1;58(7):589-94.
110. Pavuluri MN, Henry DB, Findling RL, et al. Double-blind randomized trial of risperidone vs divalproex in pediatric bipolar disorder. *Bipolar Disord.*2010; 12 (6):593-605.
111. Biederman J, Mick E, Spencer T, et al. A prospective open-label treatment trial of ziprasidone monotherapy in children and adolescents with bipolar disorder. *Bipolar Disorders.*2007; 9:888-94.
112. Ercan ES, Uystal T, Ercan E, et al. Aripiprazole in children and adolescents with conduct disorder: a single-center, open-label study. *Pharmacopsychiatry.*2012; 45(1):13-9.
113. Findling RL, Kauffman R, Sallee FR, et al. An open-label study of aripiprazole: pharmacokinetics, tolerability, and effectiveness in children and adolescents with conduct disorder. *Journal of Child and Adolescent Psychopharmacology.* 2009; 19(4):431-8.
114. Bastiaens L. A non-randomized, open label study with aripiprazole and ziprasidone for the treatment of aggressive behavior in youth in a community clinic. *Community Ment Health J.* 2009; 45:73-77.
115. Masi G, Milone A, Canepa G, et al. Olanzapine treatment in adolescents with severe conduct disorder. *Eur Psychiatry.* 2006; 21(1):51-7.
116. Khan SS, Mican LM. A naturalistic evaluation of intramuscular ziprasidone vs intramuscular olanzapine for the management of acute agitation and aggression in children and adolescents. *Journal of Child and Adolescent Psychopharmacology.* 2006; 16(6):671-77.
117. Kronenberger WG, Giauque AL, Lafata DE, et al. Quetiapine addition in methylphenidate treatment-resistant adolescents with comorbid Attention-Deficit/Hyperactivity Disorder, Conduct/Oppositional-Defiant Disorder, and aggression: a prospective, open-label study. *Journal of Child and Adolescent Psychopharmacology.* 2007; 17(3):334-47.
118. Connor DF, McLaughlin TJ, Jeffers-Terry M et al. Randomized controlled pilot study of quetiapine in the treatment of adolescent conduct disorder. *Journal of Child and Adolescent Psychopharmacology.*2008; 18(2):140-56.
119. Ercan ES, Basay BK, Basay O, et al. Risperidone in the treatment of conduct disorder in preschool children without intellectual disability. *Child and Adolescent Psychiatry and Mental Health.*2011; 5:10.
120. Caldwell MF, Malterer M, Umstead D, et al. A retrospective evaluation of adjunctive risperidone treatment in severely behaviorally disordered boys receiving psychosocial treatment. *Journal of Child and Adolescent Psychopharmacology.* 2008; 18(1):34-43.
121. Croonenberghs J, Fegert JM, Findling RL, et al. Risperidone in children with disruptive behavior disorders and subaverage intelligence: a 1-year, open-label study of 504 patients. *J Am Acad Child Adolesc Psychiatry.* 2005 Jan;44(1):64-72.
122. Reyes M, Olah R, Csaba K, et al. Long-term safety and efficacy of risperidone in children with disruptive behaviour disorders. Results of a 2-year extension study. *Eur Child Adolesc Psychiatry.* 2006 Mar;15(2):97-104.
123. Pandina GJ, Zhu Y, Cornblatt B. Cognitive function with long-term risperidone in children and adolescents with disruptive behavior disorder. *Journal of Child and Adolescent Psychopharmacology.*2009; 19(6):749-56.
124. Reyes M, Buitelaar J, Toren P, Augustyns I, Eerdeken M. A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. *Am J Psychiatry.* 2006 Mar;163(3):402-10.
125. Haas M, Karcher K, Pandina GJ. Treating disruptive behavior disorders with risperidone: a 1-year, open-label safety study in children and adolescents. *Journal of Child and Adolescent Psychopharmacology.* 2008; 18(4):337-46.

126. Van Bellinghen M, De Troch C. Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled pilot trial. *J Child Adolesc Psychopharmacol*. 2001 Spring;11(1):5-13.
127. Aman M, Buitelaar J, DeSmedt G, et al. Pharmacotherapy of a disruptive behavior and item changes on a standardized rating scale: pooled analysis of risperidone effects in children with subaverage IQ. *Journal of Child and Adolescent Psychopharmacology*.2005; 15(2):220-32.
128. LeBlank JC, Binder CE, Armenteros JL, et al. Risperidone reduces aggression in boys with a disruptive behavior disorder and below average intelligence quotient: analysis of two placebo-controlled randomized trials. *Int Clin Psychopharmacol*. 2005; 20(5):275-83.
129. Biederman J, Mick E, Faraone SV, et al. Risperidone for the treatment of affective symptoms in children with disruptive behavior disorder: a post hoc analysis of data from a 6-week, multicenter, randomized, double-blind, parallel-arm study. *Clinical Therapeutics*. 2006; 28(5):794-800.
130. Scott LK, Green R, McCarthy PJ, et al. Agitation and/or aggression after traumatic brain injury in the pediatric population treated with ziprasidone. *J Neurosurg Pediatrics*.2009; 3:484-7.
131. Turkel SB, Jacobson J, Munzig E, et al. Atypical antipsychotic medications to control symptoms of delirium in children and adolescents. *Journal of Child and Adolescent Psychopharmacology*.2012; 22(2):1-6.
132. Pathak S, Johns ES, Kowatch RA. Adjunctive quetiapine for treatment-resistant adolescent major depressive disorder: a case series. *Journal of child and adolescent psychopharmacology*. 2005; 15(4):696-702.
133. Masi G, Pfanner C, Millepiedi S, et al. Aripiprazole in 39 adolescents with medication-resistant obsessive-compulsive disorder. *J Clin Psychopharmacol*.2010; 30:688-93.
134. Masi G, Cosenza A, Millepiedi S, et al. Aripiprazole monotherapy in children and young adolescents with pervasive developmental disorders: a retrospective study. *CNS Drugs*.2009; 23(6):511-21.
135. Stigler KA, Diener JT, Kohn AE, et al. Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study. *Journal of Child and Adolescent Psychopharmacology*.2009; 19(3):265-74.
136. Marcus RN, Owen R, Kamen L, et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. *J Am Acad Child Adolesc Psychiatry*. 2009; 48(11):1110-19.
137. Owen R, Sikich L, Marcus RN, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. *Pediatrics*.2009; 124:1533-40.
138. Aman MG, Kasper W, Manos G, et al. Line-item analysis of the aberrant behavior checklist: results from two studies of aripiprazole in the treatment of irritability associated with autistic disorder. *Journal of Child and Adolescent Psychopharmacology*.2010; 20(5):415-22.
139. Marcus RN, Owen R, Manos G, et al. Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter study. *J Clin Psychiatry*. 2011 Sep;72(9):1270-6.
140. Hollander E, Wasserman S, Swanson EN, et al. A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. *Journal of Child and Adolescent Psychopharmacology*.2006; 16(5):541-8.
141. Corson AH, Barkenbus JE, Posey DJ, et al. A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders. *J Clin Psychiatry*.2004; 65:1531-6.
142. Hardan AY, Jou RJ, Handen BL. Retrospective study of quetiapine in children and adolescents with pervasive developmental disorders. *Journal of Autism and Developmental Disorders*.2005; 35(3):387-92.
143. Golubchik P, Sever J, Weizman A. Low-dose quetiapine for adolescents with autistic spectrum disorder and aggressive behavior: open-label trial. *Clin Neuropharm*.2011; 34:216-9.
144. Martin A, Koenig K, Scahill L, et al. Open-label quetiapine in the treatment of children and adolescents with autistic disorder. *Journal of Child and Adolescent Psychopharmacology*.1999; 9(2):99-107.
145. Gagliano A, Germano E, Pustorino G, Impallomeni C, D'Arrigo C, Calamoneri F, Spina E. Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications. *J Child Adolesc Psychopharmacol*. 2004 Spring;14(1):39-47.

146. Lemmon ME, Gregas M, Jeste SD. Risperidone use in autism spectrum disorders: a retrospective review of a clinic-referred patient population. *Journal of Child Neurology*. 2011; 26(4):428-32.
147. Aman MG, Arnold LE, McDougle CJ, Vitiello B, Scahill L, Davies M, et al. Acute and long-term safety and tolerability of risperidone in children with autism. *J Child Adolesc Psychopharmacol*. 2005 ec;15(6):869-84.
148. Aman MG, Hollway JA, McDougle CJ, et al. Cognitive effects of risperidone in children with autism and irritable behavior. *J Child Adolesc Psychopharmacol*. 2008; 18(3):227-36.
149. Aman MG, McDougle CJ, Scahill L, et al. Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial. *J Am Acad Child Adolesc Psychiatry*. 2009 Dec;48(12):1143-54.
150. Luby J, Mrakotsky C, Stalets MM, Belden A, Heffelfinger A, Williams M, Spitznagel E. Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. *J Child Adolesc Psychopharmacol*. 2006 Oct;16(5):575-87.
151. McCracken JT, McGough J, Shah J, et al. Risperidone in children with autism and serious behavioral problems. *N Engl J Med*. 2002; 347:314-21.
152. Miral S, Gencer O, Inal-Emiroglu FN, et al. Risperidone vs haloperidol in children and adolescents with AD: a randomized, controlled, double-blind trial. *Eur Child Adolesc Psychiatry*. 2008; 17:1-8.
153. Gencer O, Emiroglu FNI, Miral S, et al. Comparison of long-term efficacy and safety of risperidone and haloperidol in children and adolescents with autistic disorder: an open-label maintenance study. *Eur Child Adolesc Psychiatry*. 2008; 217-25.
154. Nagaraj R, Singhi P, Malhi P. Risperidone in children with autism: randomized, placebo-controlled, double-blind study. *J Child Neurol*. 2006 Jun;21(6):450-5.
155. Malone RP, Delaney MA, Hyman SB, et al. Ziprasidone in adolescents with autism: an open-label pilot study. 2007; 17(6):779-90.
156. Findling RL, Robb A, Nyilas M, et al. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. *Am J Psychiatry*. 2008; 165:1432-41.
157. Kryzhanovskaya L, Schulz SC, McDougle C, et al. Olanzapine vs placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial. *J Am Acad Child Adolesc Psychiatry*. 2009; 48(1):60-70.
158. Cianchetti C, Ledda MG. Effectiveness and safety of antipsychotics in early onset psychoses: a long-term comparison. *Psychiatry Research*. 2011; 189:349-56.
159. Fleischhaker C, Heiser P, Hennighausen K, Herpertz-Dahlmann B, Holtkamp K, et al. Clinical drug monitoring in child and adolescent psychiatry: side effects of atypical neuroleptics. *J Child Adolesc Psychopharmacol*. 2006 Jun;16(3):308-16.
160. Gothelf D, Apter A, Reidman J, Brand-Gothelf A, Bloch Y, Gal G, Kikinzon L, Tyano S, Weizman R, Ratzoni G. Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia. *J Neural Transm*. 2003 May;110(5):545-60.
161. Mozes T, Ebert T, Sabbagh-Etun M, et al. An open-label randomized comparison of olanzapine vs risperidone in the treatment of childhood-onset Schizophrenia. *J Child Adolesc Psychopharmacology*. 2006; 16(4):393-403.
162. Kumra S, Kranzler H, Gerbino-Rosen G, et al. Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. *Biol Psychiatry*. 2008 Mar 1;63(5):524-9.
163. Kumra S, Kranzler H, Gerbino-Rosen G, et al. Clozapine vs high-dose olanzapine in refractory early-onset schizophrenia: an open-label extension study. *Journal of Child and Adolescent Psychopharmacology*. 2008; 18(4):307-16.
164. Kumra S, Kranzler H, Gerbino-Rosen G, et al. Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. *Biol Psychiatry*. 2008 Mar 1;63(5):524-9.
165. Sikich L, Frazier JA, McClellan J, et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. *Am J Psychiatry*. 2008 Nov;165(11):1420-31.



166. Findling RL, Johnson JL, McClellan J, et al. Double-blind maintenance safety and effectiveness findings from the treatment of Early-Onset Schizophrenia Spectrum Study (TEOSS). *J Am Acad Child Adolesc Psychiatry*.2010; 49(6):583-94.
167. Singh J, Robb A, Vijapurkar U, et al. A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents. *Biol Psychiatry*.2011; 70:1179-1187.
168. McConville B, Carrero L, Sweitzer D, Potter L, Chaney R, Foster K, et al. Long-term safety, tolerability, and clinical efficacy of quetiapine in adolescents: an open-label extension trial. *J Child Adolesc Psychopharmacol*. 2003 Spring;13(1):75-82.
169. Schimmelmann BG, Mehler-Wex C, Lambert M, et al. A prospective 12-week study of quetiapine in adolescents with schizophrenia spectrum disorders. *Journal of Child and Adolescent Psychopharmacology*.2006; 17(6):768-78.
170. Jensen JB, Kumra S, Leitten W, et al. A comparative pilot study of second-generation antipsychotics in children and adolescents with Schizophrenia-Spectrum disorders. *Journal of Child and Adolescent Psychopharmacology*.2008; 18(4):317-26.
171. Olfson M, Gerhard T, Huang C, et al. Comparative effectiveness of second generation antipsychotic medications in early-onset schizophrenia. *Schizophrenia Bulletin*. 2011 Feb 9.
172. Ardizzone I, Nardecchia F, Marconi A, et al. Antipsychotic medication in adolescents suffering from schizophrenia: a meta-analysis of randomized controlled trials. *Psychopharmacol Bull*.2010; 43(2):45-66.
173. DelBello MP, Versavel M, Ice K, et al. Tolerability of oral ziprasidone in children and adolescents with bipolar mania, schizophrenia, or schizoaffective disorder. *Journal of Child and Adolescent Psychopharmacology*.2008; 18(5):491-9.
174. Stewart M, DelBello MP, Versavel M, et al. Psychosocial functioning and health-related quality of life in children and adolescents treated with open-label ziprasidone for bipolar mania, schizophrenia, or schizoaffective disorder. *Journal of Child and Adolescent Psychopharmacology*. 2009; 19(6):635-40.
175. Budman C, Coffey BJ, Shechter R, Schrock M, et al. Aripiprazole in children and adolescents with Tourette Disorder with and without explosive outbursts. *Journal of Child and Adolescent Psychopharmacology*.2008; 18(5):509-15.
176. Cui YH, Zheng Y, Yang YP, et al. Effectiveness and tolerability of aripiprazole in children and adolescents with Tourette's Disorder: a pilot study in China.*Journal of Child and Adolescent Psychopharmacology*.2010; 20(4):291-8.
177. Lyon GL, Samar S, Jummani R, et al. Aripiprazole in children and adolescents with Tourette's Disorder: an open-label safety and tolerability study. *Journal of Child and Adolescent Psychopharmacology*.2009; 19(6):623-33.
178. Murphy TK, Mutch J, Reid JM, et al. Open-label aripiprazole in the treatment of youth with tic disorders. *Journal of Child and Adolescent Psychopharmacology*. 2009; 19(4):441-47.
179. Seo WS, Sung HM, Sea HS, et al. Aripiprazole treatment of children and adolescents with Tourette Disorder or chronic tic disorder. *Journal of Child and Adolescent Psychopharmacology*. 2008; 18(2):197-205.
180. McCracken JT, Suddath R, Chang S, et al. Effectiveness and tolerability of open-label olanzapine in children and adolescents with Tourette syndrome. *Journal of Child and Adolescent Psychopharmacology*.2008; 18(5):501-508.
181. Stephens RJ, Bassel C, Sandor P. Olanzapine in the treatment of aggression and tics in children with Tourette's Syndrome-a pilot study. *Journal of Child and Adolescent Psychopharmacology*.2004; 14(2):255-66.
182. Copur M, Arpacı B, Demir T, et al. Clinical effectiveness of quetiapine in children and adolescents with Tourette's syndrome: a retrospective case-note survey.*Clin Drug Investig*.2007; 27(2):123-30.
183. Sallee FR, Kurlan R, Goetz CG, et al. Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study. *J Am Acad Child Adolesc Psychiatry*.2000; 39(3):292-9.
184. Capone GT, Goyal P, Grados M, et al. Risperidone use in children with down syndrome, severe intellectual disability, and comorbid autistic spectrum disorders: a naturalistic study. *J Dev Behav Pediatr*.2008; 29:106-16.
185. Erickson CA, Stigler KA, Wink LK, et al. A prospective open-label study of aripiprazole in fragile X syndrome. *Psychopharmacology (Berl)*.2001; 216(1):85-90.

186. Krieger FV, Pheula GF, Coelho R, et al. An open-label trial of risperidone in children and adolescents with severe mood dysregulation. *Journal of Child and Adolescent Psychopharmacology*.2011; 21(3):237-43.
187. Castro-Fornieles J, Parellada M, Soutullo CA, et al. Antipsychotic treatment in child and adolescent first-episode psychosis: a longitudinal naturalistic approach. *Journal of Child and Adolescent Psychopharmacology*.2008; 18(4):327-36.
188. Sikich L, Hamer RM, Bashford RA, et al. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. *Neuropsychopharmacology*.2004; 29:133-145.
189. Maglione M, Ruelaz Maher A, Hu J, Wang Z, Shanman R, Shekelle PG, Roth B, Hilton L, Suttorp MJ, Ewing BA, Motala A, Perry T. Off-Label Use of Atypical Antipsychotics: An Update. Comparative Effectiveness Review No. 43. (Prepared by the Southern California Evidence-based Practice Center under Contract No. HHS290-2007-10062-1.) Rockville, MD: Agency for Healthcare Research and Quality. September 2011 [cited 2013 Jul 30]. Available at: [www.effectivehealthcare.ahrq.gov/reports/final.cfm](http://www.effectivehealthcare.ahrq.gov/reports/final.cfm).
190. Strom BL, Eng SM, Faich G, et al. Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: the Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC). *Am J Psychiatry*.2011; 168:193-201.
191. Lamberti SJ, Costea O, Olson D, Crilly JF. Diabetes mellitus among outpatients receiving clozapine: Prevalence and clinical-demographic correlates. *J Clin Psychiatry*. 2005;66:900-6.
192. Reist C, Minta J, Albers LJ, et al. Second generation antipsychotic exposure and metabolic-related disorders in patients with schizophrenia. *J Clin Psychopharmacol*. 2007;27:46-51.
193. Lambert BL, Chia-Hung C, Chang KU, et al. Antipsychotic Exposure and Type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims. *Pharmacoepidemiology and Drug Safety*. 2005;14: 417-25.
194. Olfson M, Marcus SC, Corey-Lisle, P et al. Hyperlipidemia Following Treatment with Antipsychotic Medications. *Am J Psychiatry*. 2006; 163: 1821-5.
195. Gianfrancesco FD, Grogg AL, Mahmoud RA, et al. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. *J Clin Psychiatry*. 2002;63:920-30.
196. Etminan M, Streiner DL, Rochon PA. Exploring the association between atypical neuroleptic agents and diabetes mellitus in older adults. *Pharmacotherapy*. 2003;23(11):1411-5.
197. Simpson MM, Goetz RR, Devlin MH, Goetz AB, et al. Weight gain and antipsychotic medication: Differences between antipsychotic-free and treatment periods. *J Clin Psychiatry*. 2001;62:694-700.
198. Guo JJ, Keck PE Jr, Corey-Lisle PK, Li H, Jiang D, Jang R, et al. Risk of diabetes mellitus associated with atypical antipsychotic use among Medicaid patients with bipolar disorder: a nested case-control study. *Pharmacotherapy*. 2007 Jan;27(1):27-35.
199. Guo JJ, Keck PE Jr, Corey-Lisle PK, Li H, Jiang D, Jang R, L'Italien GJ. Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: A retrospective, population-based, case-control study. *J Clin Psychiatry*. 2006 Jul;67(7):1055-61.
200. Ostbye T, Curtis LH, Masselink LE et al. Atypical antipsychotic drugs and diabetes mellitus in a large outpatient population: a retrospective cohort study. *Pharmacoepidemiol Drug Saf*. 2005;14: 407-15.
201. Ollendorf DA, Joyce AT, Rucker M et al. Rate of new-onset diabetes among patients treated with atypical or conventional antipsychotic medications for schizophrenia. *MedGenMed*. 2005;6(1); 1-12.
202. Huang TL, Chen, JF. Serum lipid profiles and schizophrenia: effects of conventional or atypical antipsychotics in Taiwan. *Schizophr Res*. 2005;80:55-9.
203. Wirshing DA, Boyd JA, Meng LR, Ballon JS et al. The effects of novel antipsychotics on glucose and lipid levels. *J Clin Psychiatry*. 2002;63: 856-65.
204. Wirshing DA, Wirshing WC, Kysar L et al. Novel antipsychotics: comparison of weight gain liabilities. *J Clin Psychiatry*. 1999;60:358-63.
205. Hardy TA, Marquez E, Krzyhanovskaya L, Taylor CC, Cavazzoni P. Cross-sectional comparison of fasting lipids in normoglycemic patients with schizophrenia during chronic treatment with olanzapine, risperidone, or typical antipsychotics. *J Clin Psychopharmacology*. 2006;26:405-8.

206. McQuade RD, Stock E, Marcus R, Jody D et al. A comparison of weight change during treatment with olanzapine or aripiprazole: Results from a randomized, double-blind study. *J Clin Psychiatry*. 2004; 65[suppl 18]: 47-56.
207. Zipursky RB, GU H, Green AI, Perkins DO, Tohen MF et al. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. *British J Psychiatry*. 2005;187: 937-43.
208. Moisan J, Gregoire JP, Gaudet M, Cooper D. Exploring the risk of diabetes mellitus and dyslipidemia among ambulatory users of atypical antipsychotics: a population-based comparison of risperidone and olanzapine. *Pharmacoepidemiol Drug Saf*. 2005;14:427-36.
209. Caro, JJ, Ward A, Levington C, Robinson K. The risk of diabetes during olanzapine use compared to risperidone use: A retrospective database analysis. *J Clin Psychiatry*. 2002;63:1135-9.
210. Brown RR and Estoup MW. Comparison of the metabolic effects observed in patients treated with ziprasidone vs olanzapine. *International Clinical Psychopharmacology*. 2005;20(2):105-15.
211. Basson BR, Kinon BJ, Taylor CC, Srymanski KA et al. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. *J Clin Psychiatry*. 2001;62:231-8.
212. Wu RR, Zhao, JP, Liu ZN, Zhai JG et al. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. *Psychopharmacology (Berl)*. 2006 Jul;186(4):572-8.
213. Mukundan A, Faulkner G, Cohn T, Remington G. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems. *Cochrane Database Syst Rev*. 2010 Dec 8;(12):CD006629.
214. Rummel-Kluge C, Komossa K, Schwarz S, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. *Schizophr Res*. 2010; 123(2-3):225-33.
215. Ghaemi SN, Hsu DJ, Rosenquist KJ, Pardo TB, Goodwin FK. EPS side effects with atypical neuroleptics in bipolar disorder. *Prog Neuropsychopharmacol Biol Psychiatry*. 2006 Mar; 30(2):209-13.
216. Gharabawi GM, Bossie CA, Zhu Y, Mao L, Lasser RA. An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study. *Schizophr Res*. 2005 Sep 15;77(2-3):129-39.
217. Emsley R, Turner HJ, Schronen J, Botha K, Smit R, Oosthuizen PP. A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. *J Clin Psychiatry*. 2004 May;65(5):696-701.
218. Ritchie CW, Chiu E, Harrigan S, Hall K, Hassett A, Macfarlane S, Mastwyk M, O'Connor DW, Opie J, Ames D. The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia. *Int J Geriatr Psychiatry*. 2003 May; 18(5):432-40.
219. Mullen J, Jibson M, Sweitzer D, et al. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: The quetiapine experience with safety and tolerability (QUEST) study. *Clin Ther*. 2001;23(11):1839-54.
220. Modestin J, Stephan PL, Erni T, Umari T; Prevalence of EPS syndromes in psychiatric inpatients and the relationship of clozapine treatment to tardive dyskinesia. *Schizophr Res*. 2000 May 5; 42(3):223-30.
221. Schillevoort I, de Boer A, Herings RM, Roos RA, Jansen PA, Leufkens HG. Risk of EPS syndromes with haloperidol, risperidone, or olanzapine. *Ann Pharmacother*. 2001 Dec;35(12):1517-22.
222. Rummel-Kluge C, Komossa K, Schwarz S, et al. Second-generation antipsychotic drugs and EPS side effects: a systematic review and meta-analysis of head-to-head comparisons. *Schizophr Bull*. 2012 Jan;38(1):167-77.
223. Byerly MJ, Lescouffair E, Weber MT, Bugno RM, Fisher R, Carmody T, Varghese F, Rush AJ; An open-label trial of quetiapine for antipsychotic-induced sexual dysfunction. *J Sex Marital Ther*. 2004 Oct-Dec; 30(5):325-32.

224. Aizenberg D, Modai I, Landa A, Gil-Ad I, Weizman A. Comparison of sexual dysfunction in male schizophrenic patients maintained on treatment with classical antipsychotics vs clozapine. *J Clin Psychiatry*. 2001 Jul;62(7):541-4.
225. Knegtering H, Boks M, Blijd C, Castelein S, van den Bosch RJ, Wiersma D. A randomized open-label comparison of the impact of olanzapine vs risperidone on sexual functioning. *J Sex Marital Ther*. 2006 Jul-Sep; 32(4):315-26.
226. Serretti A, Chiesa A. A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics. *Int Clin Psychopharmacol*. 2011 May; 26(3):130-40.
227. Wirshing DA, Pierre JM, Marder SR, Saunders CS, Wirshing WC; Sexual side effects of novel antipsychotic medications. *Schizophr Res*. 2002 Jul 1; 56(1-2):25-30.
228. Byerly MJ, Nakonezny PA, Bettcher BM, Carmody T, Fisher R, Rush AJ. Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of olanzapine, risperidone, and quetiapine. *Schizophr Res*. 2006 Sep; 86(1-3):244-50.
229. Bobes J, Garc A-Portilla MP, Rejas J, Hern Ndez G, Garcia-Garcia M, Rico-Villademoros F, Porras A. Frequency of sexual dysfunction and other reproductive side effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study. *J Sex Marital Ther*. 2003 Mar-Apr;29(2):125-47.
230. Dossenbach M, Dyachkova Y, Pirildar S et al. Effects of atypical and typical antipsychotic treatments of sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. *Journal of the Association of European Psychiatrists*. 2006;21(4):251-8.
231. Hennen J and Baldessarini RJ. Suicidal risk during treatment with clozapine: a meta-analysis. *Schizophr Res*. 2005;73:139-45.
232. Kreyenbuhl J, Valenstein M, McCarthy JF, et al. Long-term combination antipsychotic treatment in VA patients with schizophrenia. *Schizophr Res*. 2006;84:90-9.
233. Correll CU, Frederickson AM, Kane JM, et al. Does antipsychotic polypharmacy increase the risk for metabolic syndrome? *Schizophr Res*. 2007;89:91-100.
234. Ganguly R, Kotzan JA, Miller S, et al. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. *J Clin Psychiatry*. 2004;65:1377-88.
235. Kogut SJ, Dufresne R. Prescribing of antipsychotic medication in a Medicaid population. *J Manag Care Pharm*. 2005;11(1):17-24.
236. Ziegenbein M, Kropp S, Kuenzel HE. Combination of clozapine and ziprasidone in treatment-resistant schizophrenia: an open clinical study. *Clin Neuropharmacol*. 2005;28:220-4.
237. Patrick V, Levin E and Schleifer S. Antipsychotic polypharmacy is there evidence for its use? *Journal of Psychiatric Practice*. 2005;11(4):248-57.
238. Josiassen RC, Joseph A, Kohegyi E, et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blinded, placebo-controlled trial. *Am J Psychiatry*. 2005;162:130-6.
239. Glick ID, Zaninelli R, Hsu C, et al. Patterns of concomitant psychotropic medication use during a 2-year study comparing clozapine and olanzapine for the prevention of suicidal behavior. *J Clin Psychiatry*. 2004;65:679-85.
240. Faries D, Ascher-Svanum H, Zhu B, et al. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. *BMC Psychiatry*. 2005;5:26-37.
241. Harrington CA, English C. Tolerability of paliperidone: a meta-analysis of randomized, controlled trials. *Int Clin Psychopharmacol*.2010; 25(6):334-41.
242. Harrington CA, English C. Adverse drug events related to ziprasidone: a meta-analysis of randomized, placebo-controlled trials. *Pharmacotherapy*.2011; 31(9):840-49.
243. Baker RA, Pikalov A, Tran QV, et al. Atypical antipsychotic drugs and diabetes mellitus in the US Food and Drug Administration adverse event database: a systematic Bayesian signal detection analysis. *Psychopharmacol Bull*.2009; 42(1):1-21.

244. Guo JJ, Keck PE Jr, Corey-Lisle PK, Li H, Jiang D, Jang R, et al. Risk of diabetes mellitus associated with atypical antipsychotic use among Medicaid patients with bipolar disorder: a nested case-control study. *Pharmacotherapy*. 2007 Jan;27(1):27-35.
245. Calarge CA, Acion L, Kuperman S, et al. Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents. *J Child Adolesc Psychopharmacol*. 2009; 19(2):101-109.
246. Maayan LA, Vakhrusheva J. Risperidone associated weight, leptin, and anthropometric changes in children and adolescents with psychotic disorders in early treatment. *Hum Psychopharmacol Clin Exp*.2010; 25:133-38.
247. Correll CU, Manu P, Olshanskiy V, et al. Cardiovascular risk of second-generation antipsychotic medications during first-time use in children and adolescents. *JAMA*.2009; 302(16):1765-1773.
248. Fleischhaker C, Heiser P, Hennighausen K, et al. Weight gain in children and adolescents during 45 weeks treatment with clozapine, olanzapine and risperidone. *J Neural Transm*.2008; 115:1599-1608.
249. Fraguas D, Merchan-Naranjo J, Laita P, et al. Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. *J Clin Psychiatry*.2008; 69:1166-1175.
250. Hrdlicka M, Zedkova L, Blatny M, et al. Weight gain associated with atypical and typical antipsychotics during treatment of adolescent schizophrenic psychoses: a retrospective study. *Neuro Endocrinol Lett*.2009; 30(2):256-61.
251. Khan RA, Mican LM, Suehs BT. Effects of olanzapine and risperidone on metabolic factors in children and adolescents: a retrospective evaluation. *J Psychiatr Pract*.2009; 15(4):320-8.
252. Moreno C, Merchan-Naranjo J, Alvarez M, et al. Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses. *Bipolar Disorders*.2010; 12:172-84.
253. Patel NC, Kistler JS, James EB, et al. A retrospective analysis of the short-term effects of olanzapine and quetiapine on weight and body mass index in children and adolescents. *Pharmacotherapy*. 2004 Jul;24(7):824-30.
254. Correll CU. Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials. *J Am Acad Child Adolesc Psychiatry*. 2007; 46(6):687-700.
255. Fedorowicz VJ, Fombonne E. Metabolic side effects of atypical antipsychotics in children: a literature review. *Journal of Psychopharmacology*.2005; 19(5):533-550.
256. De Hart M, Dobbelaere M, Sheridan EM, Cohen D, et al. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. *Eur Psychiatry*.2011; 26(3):144-58.
257. Safer DJ. A comparison of risperidone-induced weight gain across the age span. *J Clin Psychopharmacol*.2004; 24:429-36.
258. Saito E, Correll CU, Gallelli K, et al. A prospective study of hyperprolactinemia in children and adolescents treated with atypical antipsychotic agents. *Journal of Child and Adolescent Psychopharmacology*.2004; 14(3):350-58.
259. Staller J. The effect of long-term antipsychotic treatment on prolactin. *J Child and Adolescent Psychopharmacology*. 2006;16:317-26.
260. Pringsheim T, Lam D, Ching H, et al. Metabolic and neurological complications of second-generation antipsychotic use in children. *Drug Saf*.2011; 34(8):651-68.
261. Jerrell JM, Hwang TL, Livingston TS. Neurological adverse events associated with antipsychotic treatment in children and adolescents. *J Child Neurology*.2008; 23(12):1392-99.
262. Correll CU, Kane JM. One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review. *Journal of Child and adolescent psychopharmacology*. 2007; 17(5):647-55.
263. De Castro MJ, Fraguas D, Laita P, et al. QTc changes after 6 months of second-generation antipsychotic treatment in children and adolescents. *Journal of child and adolescent psychopharmacology*. 2008; 18(4):381-3.
264. Calarge CA, Zimmerman B, Xie D, et al. A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys. *J Clin Psychiatry*.2010; 71(3):338-47.

265. Erdogan A, Karaman MG, Ozdemir E, et al. Six months of treatment with risperidone may be associated with nonsignificant abnormalities of liver function tests in children and adolescents: a longitudinal, observational study from Turkey. *Journal of Child and Adolescent Psychopharmacology*. 2010; 20(5):407-13.
266. Harrison-Woolrych M, Garcia-Quiroga J, Ashton J, et al. Safety and usage of atypical antipsychotic medicines in children. *Drug Safety*. 2007; 30(7):569-79.
267. San L, Arranz B, Perez V, Safont G, Corripio I, Ramirez N, et al. One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychotic-naive patients with a first-episode psychosis. *Psychiatry Res*. 2012 Dec 30;200(2-3):693-701.
268. Cutler AJ, Kalali AH, Mattingly GW, Kunovac J, Meng X. Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial. *CNS Spectr*. 2013 Feb;18(1):43-54.
269. Nasrallah HA, Silva R, Phillips D, Cucchiari J, Hsu J, Xu J, et al. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study. *J Psychiatr Res*. 2013 May;47(5):670-7.
270. Ogasa M, Kimura T, Nakamura M, Guarino J. Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study. *Psychopharmacology (Berl)*. 2013 Feb;225(3):519-30.
271. Souza JS, Kayo M, Tassell I, Martins CB, Elkis H. Efficacy of olanzapine in comparison with clozapine for treatment-resistant schizophrenia: evidence from a systematic review and meta-analyses. *CNS Spectr*. 2013 Apr;18(2):82-9.
272. Soares-Weiser K, Bécharde-Evans L, Lawson AH, Davis J, Ascher-Svanum H. Time to all-cause treatment discontinuation of olanzapine compared to other antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. *Eur Neuropsychopharmacol*. 2013 Feb;23(2):118-25.
273. Suttajit S, Srisurapanont M, Xia J, Suttajit S, Maneeton B, Maneeton N. Quetiapine vs typical antipsychotic medications for schizophrenia. *Cochrane Database Syst Rev*. 2013 May 31;5:CD007815.
274. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. *Lancet*. 2013 Jun 26. pii: S0140-6736(13)60733-3. doi: 10.1016/S0140-6736(13)60733-3. [Epub ahead of print].
275. Muralidharan K, Ali M, Silveira LE, Bond DJ, Fountoulakis KN, Lam RW, et al. Efficacy of second generation antipsychotics in treating acute mixed episodes in bipolar disorder: A meta-analysis of placebo-controlled trials. *J Affect Disord*. 2013 Jun 1. pii: S0165-0327(13)00333-9. doi: 10.1016/j.jad.2013.04.032. [Epub ahead of print].
276. Maneeton N, Maneeton B, Srisurapanont M, Martin SD. Quetiapine monotherapy in acute phase for major depressive disorder: a meta-analysis of randomized, placebo-controlled trials. *BMC Psychiatry*. 2012 Sep 27;12:160.
277. Pathak S, Findling RL, Earley WR, Acevedo LD, Stankowski J, Delbello MP. Efficacy and safety of quetiapine in children and adolescents with mania associated with bipolar I disorder: a 3-week, double-blind, placebo-controlled trial. *J Clin Psychiatry*. 2013 Jan;74(1):e100-9.
278. Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A, Tsai AC. Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. *PLoS Med*. 2013;10(3):e1001403. doi: 10.1371/journal.pmed.1001403. Epub 2013 Mar 12.
279. Crespo-Facorro B, Ortiz-García de la Foz V, Mata I, Ayesa-Arriola R, Suarez-Pinilla P, Valdizan EM, et al. Aripiprazole, Ziprasidone and Quetiapine in the treatment of first-episode nonaffective psychosis: a 12-week randomized, flexible-dose, open-label trial. *Schizophr Res*. 2013 Jul;147(2-3):375-82. doi: 10.1016/j.schres.2013.04.014. Epub 2013 May 1.
280. Sanz-Fuentenebro J, Taboada D, Palomo T, Aragües M, Ovejero S, Del Alamo C, et al. Randomized trial of clozapine vs. risperidone in treatment-naïve first-episode schizophrenia: results after one year. *Schizophr Res*. 2013 Sep;149(1-3):156-61. doi: 10.1016/j.schres.2013.07.003. Epub 2013 Jul 18.
281. Naber D, Peuskens J, Schwarzmann N, Goltz M, Krüger H, Lambert M, et al. Subjective well-being in schizophrenia: a randomised controlled open-label 12-month non-inferiority study comparing

- quetiapine XR with risperidone (RECOVER). *Eur Neuropsychopharmacol*. 2013 Oct;23(10):1257-69. doi: 10.1016/j.euroneuro.2013.07.006. Epub 2013 Jul 29.
282. Asmal L, Flegar SJ, Wang J, Rummel-Kluge C, Komossa K, Leucht S. Quetiapine versus other atypical antipsychotics for schizophrenia. *Cochrane Database Syst Rev*. 2013 Nov 18;11:CD006625. doi: 10.1002/14651858.CD006625.pub3.
283. Leucht S, Cipriani A, Spinelli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. *Lancet*. 2013 Sep 14;382(9896):951-62. doi: 10.1016/S0140-6736(13)60733-3. Epub 2013 Jun 27.
284. Kumar A, Datta SS, Wright SD, Furtado VA, Russell PS. Atypical antipsychotics for psychosis in adolescents. *Cochrane Database Syst Rev*. 2013 Oct 15;10:CD009582. doi: 10.1002/14651858.CD009582.pub2.
285. Loebel A, Cucchiari J, Silva R, Kroger H, Sarma K, Xu J, et al. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. *Am J Psychiatry*. 2014 Feb 1;171(2):169-77. doi: 10.1176/appi.ajp.2013.13070985.
286. Loebel A, Cucchiari J, Silva R, Kroger H, Hsu J, Sarma K, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. *Am J Psychiatry*. 2014 Feb 1;171(2):160-8. doi: 10.1176/appi.ajp.2013.13070984.
287. Kent JM, Kushner S, Ning X, Karcher K, Ness S, Aman M, et al. Risperidone dosing in children and adolescents with autistic disorder: a double-blind, placebo-controlled study. *J Autism Dev Disord*. 2013 Aug;43(8):1773-83. doi: 10.1007/s10803-012-1723-5.
288. Findling RL, Mankoski R, Timko K, Lears K, McCartney T, McQuade RD, et al. A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder. *J Clin Psychiatry*. 2014 Jan;75(1):22-30. doi: 10.4088/JCP.13m8500.
289. Fleischhacker WW, Sanchez R, Johnson B, Jin N, Forbes RA, McQuade R, et al. Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia. *Int Clin Psychopharmacol*. 2013 Jul;28(4):171-6. doi: 10.1097/YIC.0b013e3283615dba.
290. Rexulti® (brexipiprazole) formulary dossier. Otsuka Pharmaceutical, Data on file.
291. National Collaborating Centre for Mental Health, National Institute for Clinical Excellence. Generalised Anxiety Disorder and Panic Disorder (with or without agoraphobia) in Adults: Management in Primary Secondary and Community Care [monograph on the internet]. London (UK): The Royal College of Psychiatrists & The British Psychological Society; 2011 [cited 2013 Jul 30]. Available from: <http://www.nice.org.uk/nicemedia/live/13314/52599/52599.pdf>
292. American Psychiatric Association (APA Practice guideline for the treatment of patients with panic disorder. Arlington (VA): American Psychiatric Association (APA); 2009. [cited 2013 Jul 30]. Available from: <http://psychiatryonline.org/pdfaccess.ashx?ResourceID=243182&PDFSource=6>
293. Management of Bipolar Disorder Working Group. VA/DoD clinical practice guideline for management of bipolar disorder in adults. Washington (DC): Department of Veterans Affairs, Department of Defense; 2010 May. 176 p. Available from: [http://www.healthquality.va.gov/bipolar/bd\\_305\\_full.pdf](http://www.healthquality.va.gov/bipolar/bd_305_full.pdf)
294. National Institute for Health and Clinical Excellence. Bipolar disorder: the assessment and management of bipolar disorder in adults, children and adolescents, in primary and secondary care. National clinical practice guideline number 185 [monograph on the internet]. London (UK): National Institute for Health Care Excellence; 2014 [cited 2014 Sep 24]. Available from: <http://guidance.nice.org.uk/cg185>.
295. Suppes T, Dennehy EB, Hirschfeld RMA, et al. The Texas Implementation of Medication Algorithm: update to the algorithm for treatment of bipolar I disorder. *J Clin Psychiatry*. 2005; 66(7):870-86. [cited 2013 Jul 30]. Available from: <http://www.dshs.state.tx.us/mhprograms/tima.shtm>.
296. Hirschfeld RMA, Bowden CL, Gitlin MJ, Keck PE, Suppes T, Thase ME, et al. Practice guideline for the treatment of patients with bipolar disorder [monograph on the internet]. 2nd ed. Arlington (VA): American Psychiatric Association; 2002 Apr [cited 2013 Jul 30]. Available from: [http://www.psych.org/psych\\_pract/treatg/pg/prac\\_guide.cfm](http://www.psych.org/psych_pract/treatg/pg/prac_guide.cfm).
297. Rabins PV, Blacker D, Rovner BW, et al. Practice guideline for the treatment of patients with Alzheimer's disease and other dementias [monograph on the internet]. Arlington (VA): American

- Psychiatric Association; 2007 Oct. 85 p. [cited 2013 Jul 30]. Available from: <http://psychiatryonline.org/data/Books/prac/AlzPG101007.pdf>
298. Aigner M, Treasure J, Kaye W, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of eating disorders. *The World Journal of Biological Psychiatry*.2011; 12:400-43.
299. Yager J, Devlin MJ, Halmi KA, et al. Practice guideline for the treatment of patients with eating disorders (Third Edition). American Psychiatric Association: Arlington (VA). Accessed on March 7, 2012. Available from: [http://www.psych.org/MainMenu/PsychiatricPractice/PracticeGuidelines\\_1.aspx](http://www.psych.org/MainMenu/PsychiatricPractice/PracticeGuidelines_1.aspx)
300. Institute for Clinical Systems Improvement (ICSI). Major depression in adults in primary care. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2012 May. 106 p. [cited 2013 Jul 30] Available from: [http://www.icsi.org/depression\\_5/depression\\_\\_major\\_\\_in\\_adults\\_in\\_primary\\_care\\_3.html](http://www.icsi.org/depression_5/depression__major__in_adults_in_primary_care_3.html)
301. American Psychiatric Association (APA). Practice guideline for the treatment of patients with major depressive disorder [guideline on the Internet]. Arlington (PA): APA; 2010 [cited 2013 Jul 30]. Available from: [http://www.psychiatryonline.com/pracGuide/pracGuideTopic\\_7.aspx](http://www.psychiatryonline.com/pracGuide/pracGuideTopic_7.aspx).
302. National Institute for Health and Clinical Excellence (NICE). The treatment of management of depression in adults [guideline on the Internet]. London: The British Psychological Society & the Royal College of Psychiatrists; 2009 [cited 2013 Jul 30]. Available from: <http://guidance.nice.org.uk/CG90>.
303. American Psychiatric Association (APA). Practice guideline for the treatment of patients with obsessive-compulsive disorder. Arlington (VA): American Psychiatric Association (APA); 2007. [cited 2013 Jul 30]. Available from: <http://psychiatryonline.org/data/Books/prac/OCDPracticeGuidelineFinal05-04-07.pdf>
304. Management of Post-Traumatic Stress Working Group. VA/DoD clinical practice guideline for management of post-traumatic stress. Washington (DC): Veterans Health Administration, Department of Defense; 2010. 251 p. Available from: <http://www.healthquality.va.gov/PTSD-FULL-2010c.pdf>
305. American Psychiatric Association. Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. Arlington (VA): American Psychiatric Association; 2004 Nov. 57 p. [cited 2013 Jul 30]. Available from: [http://psychiatryonline.org/data/Books/prac/ASD\\_PTSD\\_Inactivated\\_04-16-09.pdf](http://psychiatryonline.org/data/Books/prac/ASD_PTSD_Inactivated_04-16-09.pdf)
306. National Institute for Clinical Excellence. Psychosis and Schizophrenia: treatment and management [monograph on the internet]. London (UK): National Institute for Clinical Excellence; 2014 [cited 2014 Sep 24]. Available from: <http://guidance.nice.org.uk/CG82>.
307. Miller AL, Hall CS, Crismon ML, Chiles J; The Texas Medication Algorithm Project (TMAP), Texas Implementation of Medication Algorithms (TIMA). TIMA procedural manual: schizophrenia module [monograph on the internet]. Austin (TX): Texas Department of Mental Health and Mental Retardation; 2008 [cited 2013 Jul 30]. Available from: <http://www.dshs.state.tx.us/mhprograms/tima.shtm>.
308. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al. Practice guideline for the treatment of patients with schizophrenia [monograph on the internet]. 2nd ed. Arlington (VA): American Psychiatric Association; 2004 [cited 2013 Jul 30]. Available from: [http://www.psych.org/psych\\_pract/treatg/pg/prac\\_guide.cfm](http://www.psych.org/psych_pract/treatg/pg/prac_guide.cfm).
309. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. *Diabetes Care*.2004 Feb; 27(2):596-601.
310. Connolly SD, Bernstein G, et al. Practice parameter for the assessment and treatment of children and adolescents with anxiety disorders. *J Am Acad Child Adolesc Psychiatry*.2007; 46(2):267-83.
311. McClellan J, Kowatch R, Findling RL, et al. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. *J Am Acad Child Adolesc Psychiatry*.2007 ; 46(1):107-125.



312. Shain BN; COMMITTEE ON ADOLESCENCE. Collaborative role of the pediatrician in the diagnosis and management of bipolar disorder in adolescents. *Pediatrics*. 2012 Dec;130(6):e1725-42.
313. Birmaher B, Brent D, et al. Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. *J Am Acad Child Adolesc Psychiatry*. 2007 Nov; 46(11):1503-1526.
314. Geller DA, March J, et al. Practice parameter for the assessment and treatment of children and adolescents with obsessive-compulsive disorder. *J Am Acad Child Adolesc Psychiatry*. 2012; 51(1):98-113.
315. Steiner H, Remsing L, et al. Practice parameter for the assessment and treatment of children and adolescents with oppositional defiant disorder. *J Am Acad Child Adolesc Psychiatry*. 2007 Jan; 46(1):126-140.
316. Cohen JA, et al. Practice parameter for the assessment and treatment of children and adolescents with posttraumatic stress disorder. *J Am Acad Child Adolesc Psychiatry*. 2010; 49(4):414-30.
317. McClellan J, Werry J, et al. Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. *J Am Acad Child Adolesc Psychiatry*. 2001; 40(7 Supplement):4S–23S. Available from: <http://www.aacap.org/galleries/PracticeParameters/JAACAP%20Schizophrenia%202001.pdf>
318. National Collaborating Centre for Mental Health, National Institute for Clinical Excellence. Psychosis and Schizophrenia in Children and Young People: Recognition and Management [monograph on the internet]. London (UK): 2013 [cited 2013 Jul 30]. Available from: <http://www.nice.org.uk/nicemedia/live/14021/62389/62389.pdf>
319. Roessner V, Plessen KJ, Rothenberger A, et al. European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. *Eur Child Adolesc Psychiatry*. 2011; 20:173-196.
320. Findling RL, Drury SS, Jensen PS, et al. Practice parameter for the use of atypical antipsychotic medications in children and adolescents. *American Academy of Child and Adolescent Psychiatry*. Accessed on March 7, 2012. Available from: [http://www.aacap.org/galleries/PracticeParameters/Atypical\\_Antipsychotic\\_Medications\\_Web.pdf](http://www.aacap.org/galleries/PracticeParameters/Atypical_Antipsychotic_Medications_Web.pdf).
321. NIH State-of-the-Science Conference Statement on manifestations and management of chronic insomnia in adults. *NIH Consens State Sci Statements* 2005 Jun 13-15;22(2):1-30.